PMID,NCTID,CombnID,DLT_Name,Grade,Duration,DLT_Exculsion,Comments
27853996,NCT01451632,4,a drug-related toxicity â‰¥ Grade 3 thatoccurred during cycle 1,>=3,cycle 1,TRUE,NA
27853996,NCT01451632,5,"neutropenia was onlyconsidered a DLT in cases of Grade 4 neutropenia unresponsive to GCSF treatment for >7 days duration,",4,>7 days,NA,NA
27853996,NCT01451632,5,"Grade 3 neutropeniathat was complicated by infection,",3,NA,NA,NA
27853996,NCT01451632,5,Grade 3 febrile neutropenia.,3,NA,NA,NA
27853996,NCT01451632,5,Grade 4 thrombocytopenia,4,NA,NA,NA
27853996,NCT01451632,5,Grade 3 thrombocytopenia associated with bleeding,3,NA,NA,NA
30278378,NCT02020577,7,decrease in cardiac left ventricular function,>=2,NA,NA,NA
30278378,NCT02020577,7,diarrhoea,2,>= 7 days despite supportive treatment,NA,NA
30278378,NCT02020577,7,"diarrhoea, nausea and/or vomitingdespite supportive treatment",>=3,NA,NA,NA
30278378,NCT02020577,7,rash despitestandard medical management,>=3,NA,NA,NA
30278378,NCT02020577,7,fatigue,>=3,>7 days,NA,NA
30278378,NCT02020577,7,hypomagnesaemia,4,NA,NA,NA
30278378,NCT02020577,7,hypomagnesaemia with clinically significant sequelae,3,NA,NA,NA
30278378,NCT02020577,7,all other grade 3 AEs (exceptalopecia and allergic reaction) leading to an interruptionof afatinib and/or cetuximab for >14 days until recoveryto baseline or grade 1,3,> 14 days,TRUE,NA
28280091,NCT00501410,25,NA,NA,NA,NA,Not clearly defined.
32053229,NCT01962792,26,NA,NA,NA,NA,not provided
32053229,NCT01962792,26,NA,NA,NA,NA,NA
28422758,NCT02095054,28,"DLTs were defined as adverse events related to the study agents and included any grade 3 or 4 nonhematologic toxicity (except nausea and vomiting responsive to appropriate regimens, alopecia, or correctable electrolyte imbalances),",>=3,NA,FALSE,NA
28422758,NCT02095054,28,"any grade 4 hematologic toxicity lasting 2 weeks or longer despite supportive care, or any severe or life-threatening complication or abnormality",4,NA,NA,NA
28422758,NCT02095054,28,NA,4,NA,NA,NA
30327312,NCT02350712,30,any patritumab-relatedgrade >=3 hematologic or nonhematologic toxicity,>=3,NA,TRUE,NA
30941307,NCT02429089,31,grade 4 neutropenia lasting more than seven consecutive days,4,NA,NA,NA
30941307,NCT02429089,31,grade 4 thrombocytopenia,4,NA,NA,NA
30941307,NCT02429089,31,grade 3â€“4 neutropenia with fever,>=3,NA,NA,NA
30941307,NCT02429089,31,"any ribociclib-related grade 3â€“4 toxicities with the exception of sub-optimally treated nausea/vomiting/diarrhea, or brief (<72 h) grade three fatigue and grade three electrolyte disturbance resolving to grade 1 with 7 days of drug interruption",>=3,NA,FALSE,NA
32545260,NCT02277197,38,"any â>= Grade 3 non-hematologic toxicity (except rash, infusion reaction, nausea, vomiting ordiarrhea lasting < 48 hours, isolated AST or ALT elevation, or asymptomatic electrolyte abnormality)",>=3,NA,NA,NA
32545260,NCT02277197,38,Grade 3 neutropenia with fever,3,NA,NA,NA
32545260,NCT02277197,38,Grade 3 thrombocytopenia with bleeding,3,NA,NA,NA
32545260,NCT02277197,38,Grade 4 neutropenia orthrombocytopenia,4,NA,NA,NA
32545260,NCT02277197,38,AST or ALT elevation â‰¥ 3-fold the upper limit of normal (ULN) with concurrentelevation of bilirubin â‰¥ 2-fold ULN,NA,NA,NA,NA
32545260,NCT02277197,38,ficlatuzumab-related toxicity requiring a dose reduction or resultingin â‰¥ 2 missed doses.,NA,NA,NA,NA
32545260,NCT02277197,38,NA,NA,NA,NA,NA
27311401,NA,42,grade 4 neutropenia,4,NA,NA,NA
27311401,NA,42,grade 4infection with grade 3/4 neutropenia,4,NA,NA,NA
27311401,NA,42,grade 4 thrombocytopenia with bleeding,4,NA,NA,NA
27311401,NA,42,Non-hematologic DLT was defined as palbociclibrelated grade 3/4 toxicity except: sub-optimally treated nausea/vomiting/diarrhea or grade 3 metabolic abnormalities.,>=3,NA,NA,NA
27311401,NA,42,NA,4,NA,NA,NA
28600476,NCT01482377,43,"grade 4 neutropenia (i.e., absolute neutrophil count <0.5  109 cells/L for a minimal duration of 7 days);",4,NA,NA,NA
28600476,NCT01482377,43,febrile neutropenia grade 3/4,>=3,NA,NA,NA
28600476,NCT01482377,43,; grade 4 thrombocytopenia;,4,NA,NA,NA
28600476,NCT01482377,43,grade 3 thrombocytopenia associated with bleeding episodes,3,NA,NA,NA
28600476,NCT01482377,43,grade >= 3nonhematologic toxicity,>=3,NA,NA,NA
27729313,NCT01787500,45,NA,4,NA,NA,Did not find in the paper
27729313,NCT01787500,45,NA,4,NA,NA,NA
34251048,NCT01755975,48,>=grade 3 non-hematologic toxicities,>=3,NA,NA,NA
34251048,NCT01755975,48,grade four hematologic toxicities,4,NA,NA,NA
34251048,NCT01755975,48,"grade three thrombocytopenia orneutropenia that resulted in a >3 day delay in romidepsin dosing,",3,NA,NA,NA
34251048,NCT01755975,48,greater than 1 week delay in initiating cycle two day 1 due to continued drug related toxicity,4,NA,NA,NA
34251048,NCT01755975,48,NA,4,NA,NA,NA
31005227,NA,49,NA,4,NA,NA,NA
31005227,NA,49,"any toxicity-related treatment break greater thantwo weeks during CRT,",NA,NA,NA,NA
32335709,NA,50,NA,4,NA,NA,DLT is not defined in the paper
32335709,NA,50,NA,4,NA,NA,NA
28054329,NA,51,"Grade 3 or 4 nonhematologic toxicity (except for nausea or vomiting, anorexia,and allergic reactions or hypersensitivity symptoms),",>=3,NA,NA,NA
28054329,NA,51,Grade 4hematologic toxicity,4,NA,NA,NA
28054329,NA,51,Grade 4 decreased neutrophil counts(<500/mm3) lasting for five or more days,4,NA,NA,NA
28054329,NA,51,Grade 3 decreased neutrophil counts (<1000 to 500/mm3) with a fever of38.0 Â°C or greater,3,NA,NA,NA
28054329,NA,51,NA,4,NA,NA,NA
32122924,NCT02889523,52,"ADLT was defined as an AE or clinically significant abnormal laboratoryvalue attributable to tazemetostat or to the combination of tazemetostat and R-CHOP and unrelated to disease progression, intercurrentillness, or concomitant medication.",4,NA,NA,NA
32122924,NCT02889523,52,NA,4,NA,NA,NA
32381487, NCT03168061,53,grade 2 increase in serumaspartate aminotransferase or alanine aminotransferase in combination with a grade 2 increase in serum bilirub,2,NA,NA,NA
32381487, NCT03168061,53,febrile neutropenia;,NA,NA,NA,NA
32381487, NCT03168061,53,grade 4 neutropenia lasting more than 7 days and unresponsive togrowth factor administration,4,NA,NA,NA
32381487, NCT03168061,53,grade 4 thrombocytopenia;,4,NA,NA,NA
32381487, NCT03168061,53,"grade 3thrombocytopenia, with clinically significant bleeding or requiring aplatelet transfusion",3,NA,NA,NA
32381487, NCT03168061,53,"grade 3 or grade 4 nonhematological toxicity(excluding alopecia and grade 3 nausea, vomiting, diarrhea, andelectrolyte imbalances lasting less than 48 hours or with suboptimalprophylactic);",>=3,NA,NA,NA
32381487, NCT03168061,53,"grade 3 nausea, vomiting, diarrhea, or electrolyteimbalances lasting >48 hours despite optimal prophylactic;",3,NA,NA,NA
32381487, NCT03168061,53,"grade 4vomiting, diarrhea, or electrolyte imbalances of any duration despiteoptimal prophylactic",4,NA,NA,NA
32381487, NCT03168061,53,â‰¥grade 3 hypersensitivity reaction and dosingdelay >21 days due to toxicity,>=3,NA,NA,NA
31675535,NCT00856037,54,grade 4 neutropenia lasting more than 7 days or febrile neutropenia,4,NA,NA,NA
31675535,NCT00856037,54,grade 4thrombocytopenia or grade 3 thrombocytopenia requiring platelettransfusion,>=3,NA,NA,NA
31675535,NCT00856037,54,"World Health Organization (WHO) grade 3/4 non-hematological toxicity, excluding nausea and alopecia.",>=3,NA,NA,NA
31675535,NCT00856037,54,NA,4,NA,NA,NA
26903311,NCT00878904,55,grade 3 or 4 non-hematological toxicity,>=3,NA,NA,NA
26903311,NCT00878904,55,"grade 4 hematological toxicity other than grade 4 neutropenia <8days,",4,NA,NA,NA
26903311,NCT00878904,55,toxicities reducing dose delivery in cycle 1 to <75% of planned dose,NA,NA,NA,NA
26903311,NCT00878904,55,NA,4,NA,NA,NA
33219014,NCT02779855,56,any treatment-related grade 3 or higher adverse event occurringduring the first 5 weeks of study treatment leading to treatmentdelays greater than 14 days or any systemic herpetic infection.,>=3,NA,NA,NA
29856514,NA,57,anygrade 3 or 4 nonhematological toxicity determined probably or definitely related to metformin,>=3,NA,TRUE,NA
29856514,NA,57,Persistent marrow aplasia at Day 44,NA,NA,NA,NA
29856514,NA,57,Grade 3 or4 lactic acidosis,>=3,NA,NA,NA
29856514,NA,57,grade 3 or 4 hypoglycemia,>=3,NA,NA,NA
29856514,NA,57,NA,4,NA,NA,NA
27403082,NCT00878800,58,absoluteneutrophil count <0.5 âˆ— 109/L lasting for â‰¥7 days,NA,NA,NA,NA
27403082,NCT00878800,58,absoluteneutrophil count <0.5 âˆ— 109/L with fever >39âˆ˜C,NA,NA,NA,NA
27403082,NCT00878800,58,platelet count<25 âˆ— 109/L,NA,NA,NA,NA
27403082,NCT00878800,58,"any other drug-related grade 3 or 4nonhaematological toxicity (with the exception of alopecia,brief nausea and vomiting, diarrhoea, rash, arthralgia, andmyalgia).",>=3,NA,NA,"grade 3 nausea and/or
vomiting persisted or if grade 4 diarrhoea in spite of standard
therapeutic measures persisted or there was inability to tolerate a full 5-day dosing cycle due to toxicity or any drug-related
adverse events resulting in more than a 14-day treatment
delay, these were included in the DLT definition"
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,59,Grade 2 or greater haemorrhagic event requiring medical intervention or any intracranial haemorrhage,>=2,NA,NA,NA
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,59,"Grade 3 or greater non-haematological toxicity at least possibly related to acalabrutinib (including grade 3 or 4 biochemical AEs). The following will be excluded; Grade 3 or 4 nausea in participants who have not received optimal treatment with anti-emetics, Grade 3 or 4 diarrhoea in participants who have not received optimal treatment with anti-diarrhoeal therapy, alopecia and those participants experiencing grade 3 or 4 administration reactions from rituximab.",>=3,NA,NA,NA
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,59,Grade 4 thrombocytopenia or neutropenia for more than 7 days despite GCSF use,4,NA,NA,NA
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,59,"Any complete, continuous dose interruption more than 7 days for acalabrutinib related toxicities of grade 2 or greater within cycle 2",NA,NA,NA,NA
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,59,NA,NA,NA,NA,NA
33602316,NCT01839097,60,Anyâ‰¥Grade 3 nonhematological toxicity,>=3,NA,NA,NA
33602316,NCT01839097,60,Platelet count of 25Ã—109/L forâ‰¥7  days or platelet nadir 10Ã—109/L at any time,4,NA,NA,NA
33602316,NCT01839097,60,Failure to recover platelet countâ‰¥75Ã—109/L and/or ANCâ‰¥1.5Ã—109/L by Day 28,4,NA,NA,NA
33602316,NCT01839097,60,ANC<0.5Ã—109/L lasting forâ‰¥7 days despite G-CSF administration,4,NA,NA,NA
33602316,NCT01839097,60,Treatment toxicity requiring dose reduction in Cycle 2.,4,NA,NA,NA
33602316,NCT01839097,60,Nonhematological toxicity requiring a delay in Cycle 2 for>7 days,4,NA,NA,NA
33602316,NCT01839097,60,NA,4,NA,NA,NA
29055839,NA,61,NA,4,NA,NA,Not defined in the paper
29055839,NA,61,NA,4,NA,NA,NA
33474828,NCT02677116,62,"grade â‰¥3 non-hematologic toxicity (exceptions were made for the following grade 3 AEs: uncomplicated febrile neutropenia; nausea; vomiting; diarrhea; transient electrolyte abnormalities; constipation that could be controlled within 48 hours; transient elevations of alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] lasting fewer than 8 days, without evidence of other hepatic injury)",>=3,NA,NA,NA
33474828,NCT02677116,62,grade 4 neutropenia lasting longer than 2 weeks,4,NA,NA,NA
33474828,NCT02677116,62,grade â‰¥3 thrombocytopenia complicated by hemorrhage,>=3,NA,NA,NA
33474828,NCT02677116,62,any hematologic toxicity causing a cycle delay of >14 days,NA,NA,NA,NA
33474828,NCT02677116,62,any other significant toxicity deemed by the primary investigator and sponsor to be dose limiting,NA,NA,NA,NA
32055930,NCT01145430,63,Any CTCAE grade 3 or 4 non-hematologic toxicity (see exceptions below),>=3,NA,NA,"Exceptions: The following grade 3 or 4 non-hematologic toxicities will not be classified as a 
DLT: 
â€¢ Electrolyte abnormalities that could be corrected within 24 hours
â€¢ Nausea and vomiting that responds to symptomatic therapy 
â€¢ Afebrile neutropenia, defined as grade 3 - 4 neutropenia without fever (however, a 
temperature > 38.5 ÂºC and/or infection requiring antibiotic or antifungal treatment OR 
any grade 4 neutropenia lasting 5 days or more WILL BE considered a DLT);
â€¢ Nausea, vomiting, or diarrhea that is not optimally treated
â€¢ Fatigue 
â€¢ Lymphopenia"
32055930,NCT01145430,63,Any grade > 2 mucocutaneous toxicity (such as those commonly encountered during treatment with PLD) that persists for over 10 days without resolution to at least a grade 1 level;,>2,NA,NA,NA
32055930,NCT01145430,63,Any grade 4 hematologic toxicity (see exceptions below),4,NA,NA,NA
32055930,NCT01145430,63,platelet count < 25000/muL of any duration,4,NA,NA,NA
32055930,NCT01145430,63,"Failure of ANC to recover to >1000/muL or platelets to recover to >100,000/muL after 28days from last PLD treatment",4,NA,NA,NA
32055930,NCT01145430,63,"Regardless of grade or nature of toxicity, inability to complete at least ten consecutive days of oral veliparib dosing or need for veliparib dose reduction in cycle 1.",4,NA,NA,NA
32055930,NCT01145430,63,NA,4,NA,NA,NA
27255289,NA,64,"nonhematological toxicity (excluding nausea/vomiting,diarrhea)",>=3,NA,NA,NA
27255289,NA,64,nausea/vomiting uncontrolled by aggressive antiemetic support,>=3,NA,NA,NA
27255289,NA,64,diarrhea lastingmore than 24 h despite antidiarrheal treatment,>=3,NA,NA,NA
27255289,NA,64,febrileneutropenia (absolute neutrophil count \1.0 9 109/L witha single temperature of [38.3 C or a sustained temperature of [38 C for more than 1 h),NA,NA,NA,NA
27255289,NA,64,neutropenialasting >=5 days,4,NA,NA,NA
27255289,NA,64,"thrombocytopenia associated withdose interruption or hemorrhage,",4,NA,NA,NA
27255289,NA,64,any drug-related toxicitythat resulted in a[1 week delay in the initiation of cycle 2,NA,NA,NA,NA
27255289,NA,64,any drug-related toxicity that resulted in the administrationof \80 % of the total planned S-1 dose.,NA,NA,NA,NA
29174203,NA,65,NA,4,NA,NA,NA
27577069,NCT01176799,66,NA,4,NA,NA,NA
31772119,NCT01902225,67,hematologic toxicity,>=4,NA,TRUE,NA
31772119,NCT01902225,67,"grade 3 thrombocytopenia lasting more than7 days, requiring dose modifications in cycle 1 or associated withbleeding",3,NA,NA,NA
31772119,NCT01902225,67,"any other grade 3 or greater nonhematologic toxicity withthe exception of grade 3 nausea, vomiting, anorexia, or diarrheaadequately managed with supportive care",>=3,NA,TRUE,NA
31772119,NCT01902225,67,grade 3 or greater left ventricular systolic dysfunction or QTcprolongation,>=3,NA,NA,NA
31772119,NCT01902225,67,NA,NA,NA,NA,NA
29104762,NCT01655693,68,NA,4,NA,NA,Not defined in the paper
29104762,NCT01655693,68,NA,4,NA,NA,NA
32601796,NA,69,"grade â‰¥ 3 non hematological toxicity for more than 10 days (except forGrade 3 fatigue, Grade 3 nausea, and Grade 3 infusion reaction)",>=3,more than 10 days,TRUE,NA
32601796,NA,69,grade â‰¥ 3 hematological toxicity lasting more than10 days or leading to a treatment delay of more than 2 weeks(as defined in retreatment requirements),>=3,"more than
10 days or leading to a treatment delay of more than 2 weeks",NA,NA
32601796,NA,69,NA,4,NA,NA,NA
33095287,NCT01606878,75,neutropenia or thrombocytopenia that precluded the initiation of the next cycle of therapy within 7Â days of the scheduled start date,NA,NA,NA,NA
33095287,NCT01606878,75,as any grade 3 or 4 non-hematologic toxicity attributed to the investigational agent with the exception of grade 3 nausea and vomiting of < 3Â days duration,>=3,NA,NA,NA
33095287,NCT01606878,75,"grade 3 liver enzyme elevation that resolved to levels that met initial eligibility criteria within 7Â days of study drug interruption,",3,NA,NA,NA
33095287,NCT01606878,75,grade 3 or 4 fever < 5Â days duration,>=3,NA,NA,NA
33095287,NCT01606878,75,grade 3 infection < 5Â days duration,3,NA,NA,NA
33095287,NCT01606878,75,"grade 3 hypophosphatemia, hypokalemia, hypocalcemia, or hypomagnesemia responsive to oral supplementation",3,NA,NA,NA
33095287,NCT01606878,75,QTc prolongation > 500Â ms that persisted despite correction of serum electrolytes or any grade 2 non-hematologic toxicity that persisted for â‰¥ 7Â days and was considered sufficiently medically significant or intolerable by patients that it required treatment interruption,NA,NA,NA,NA
33095287,NCT01606878,75,NA,NA,NA,NA,NA
33095287,NCT01606878,75,any grade 3 or 4 non-hematologic toxicity attributed to the investigational agent with the exception of grade 3 nausea and vomiting of < 3Â days duration,>=3,NA,NA,NA
33095287,NCT01606878,75,grade 3 liver enzyme elevation that resolved to levels that met initial eligibility criteria within 7Â days of study drug interruption,3,NA,NA,NA
33095287,NCT01606878,75,QTc prolongation > 500Â ms that persisted despite correction of serum electrolytes or any grade 2 non-hematologic toxicity that persisted for â‰¥ 7Â days and was considered sufficiently medically significant or intolerable by patients that it required treatment interruption was considered dose limiting,NA,NA,NA,NA
28718812,NCT02562378,79,Grade 4 neutropenia (i.e. absolute neutrophil count (ANC) < 0.5 x 109cells/L for minimal duration of 7 days).,4,NA,NA,NA
28718812,NCT02562378,79,Grades 3 and 4 febrile neutropenia (i.e. ANC < 1.0 x 109 cells/L with a single temperature of >38.3Â°C or a sustained temperature of â‰¥ 38Â°C for more than one hour).,>=3,NA,NA,NA
28718812,NCT02562378,79,Uncomplicated Grade 4 thrombocytopenia (< 25.0 x 109 cells/L) which does not recover to â‰¥ 75.0 x 109 cells/L before next planned dose administration.,NA,NA,NA,NA
28718812,NCT02562378,79,"Thrombocytopenia (any grade) complicated with clinically significant bleeding requiring medical intervention, such as platelet transfusion or cauterization",NA,NA,NA,NA
28718812,NCT02562378,79,Sudden death (defined as within 24 hours; unexplained),NA,NA,NA,NA
28718812,NCT02562378,79,Heart failure NYHA criteria class III-IV and LVEF decline defined as an absolute drop â‰¥10% resulting in a final LVEF <50%,NA,NA,NA,NA
28718812,NCT02562378,79,Increase in AST (SGOT)/ALT (SGPT) values to >5x ULN,NA,NA,NA,NA
28718812,NCT02562378,79,Increase in total bilirubin value to > 3xULN,NA,NA,NA,NA
28718812,NCT02562378,79,Abnormalities meeting the Hyâ€™s Law,NA,NA,NA,NA
28718812,NCT02562378,79,Grade â‰¥ 3 non-hematological toxicities c.,>=3,NA,NA,NA
28718812,NCT02562378,79,Any treatment-related non-hematological toxicity grade â‰¥ 3 preventing the start of the 3rd cycle on Day 42 (6 weeks cycle length),>=3,NA,NA,NA
28718812,NCT02562378,79,- Grade 2 non-hematological toxicity requiring interruption of treatment for > 21 days,2,NA,NA,NA
28718812,NCT02562378,79,"Patient not able to receive 100% of the dose level going into Cycle 3, Day 1",NA,NA,NA,NA
29903707,NCT01622439,80,NA,4,NA,NA,NA
29903707,NCT01622439,80,NA,4,NA,NA,Not find in the paper
30850381,NCT02055820,81,any grade >=3 AEs attributed to venetoclax plus R-CHOP or G-CHOP,>=3,NA,NA,NA
30850381,NCT02055820,81,"grade 3/4 neutropenia or thrombocytopenia, identified on day 1 of cycle 2 or 3, resulting in delay of that cycle.",>=3,NA,NA,NA
16870542,NA,83,non hematological toxicity,>=3,NA,FALSE,NA
16870542,NA,83,NA,4,NA,NA,NA
16179099,NA,84,nonhematologic toxicity,>=3,NA,FALSE,NA
16179099,NA,84,NA,4,NA,NA,NA
12655441,NA,85,neutropenia,4,more than 7 days,NA,NA
12655441,NA,85,febrile neutropenia,NA,NA,NA,NA
12655441,NA,85,thrombocytopenia,4,NA,NA,NA
12655441,NA,85,nonhematologic toxicity,3,NA,FALSE,NA
12649112,NA,86,"haematological toxicity consisting of nadir neutrophils <0.5 Ã— 109/l for at least 7 days or <0.1 Ã— 109/l for at least 3 days, thrombocytopenia <25 Ã— 109/l or thrombocytopenia with bleeding or requiring platelet transfusion;",4,NA,NA,NA
12649112,NA,86,febrile neutropenia defined as absolute neutrophil count <0.5 Ã— 109/l and fever (three measured temperatures >38Â°C in 24 h or one >38.5Â°C),4,NA,NA,NA
12649112,NA,86,any grade 3/4 major organ toxicity except alopecia or unpremedicated nausea/vomiting,>=3,NA,NA,NA
12649112,NA,86,NA,4,NA,NA,NA
15809877,NA,87,"an absolute granulocyte count of <0.5Â·109 l1 for 7 days or more,",NA,NA,NA,NA
15809877,NA,87,"febrile neutropenia,",NA,NA,NA,NA
15809877,NA,87,"platelets <10Â·109 l1, thrombocytopenic bleeding requiring transfusion,",NA,NA,NA,NA
15809877,NA,87,any grade 3 or worse nonhaematologic toxicity excluding nausea and vomiting as defined,>=3,NA,FALSE,NA
15809877,NA,87,NA,4,NA,NA,NA
16211365,NA,88,Haematological toxicity consisting of nadir absolute neutrophil count < 0.5 Ã— 109/L (Grade IV) for at least 7 days or < 0.1 Ã— 109/L for at least 3 days,NA,NA,NA,NA
16211365,NA,88,febrile neutropenia defined as absolute neutrophil count < 0.5 Ã— 109/L and fever (three measured temperatures >38â—¦C in 24 hours or 1 > 38.5â—¦C),4,NA,NA,NA
16211365,NA,88,thrombocytopenia < 25 Ã— 109/L (Grade IV) or thrombocytopenia with bleeding or requiring platelet transfusion,4,NA,NA,NA
16211365,NA,88,grade III/IV major organ toxicity except alopecia or un-premedicated nausea/vomiting.,>=3,NA,NA,NA
16211365,NA,88,NA,4,NA,NA,NA
16937306,NA,89,leukocyte count less than 1000/Î¼l,NA,NA,NA,NA
16937306,NA,89,neutrophil count less than 500/Î¼l,NA,NA,NA,NA
16937306,NA,89,febrile neutropenia (<1000/Î¼l),NA,NA,NA,NA
16937306,NA,89,platelet count less than 10 000/Î¼l,NA,NA,NA,NA
16937306,NA,89,thrombopenia requiring platelet transfusion,NA,NA,NA,NA
16937306,NA,89,nonhematological toxicity of grade 3 or more (except for nausea and vomiting),>=3,NA,NA,NA
16937306,NA,89,any toxicity that required treatment interruption lasting more than 2 weeks,NA,NA,NA,NA
16937306,NA,89,NA,NA,NA,NA,NA
14984944,NA,90,"non-hematologic toxicity (dermatitis, diarrhea, nausea, etc.)",>=3,NA,NA,NA
14984944,NA,90,hematologic toxicity,4,NA,NA,NA
14984944,NA,90,any toxicity which requires 1 week or greater delay of radiotherapy or an omission of more than one dose of chemotherapy.,NA,NA,NA,NA
14984944,NA,90,NA,NA,NA,NA,NA
15122074,NA,91,any Grade 3 or worse toxicity,>=3,NA,NA,NA
31959492,NA,1,failure to recover blood counts,1,Dose delay of >3 weeks ,NA,NA
31959492,NA,1,febrile neutropenia,1,NA,NA,NA
31959492,NA,1,neutropenia,4,> 7 Days,NA,NA
31959492,NA,1,thrombocytopenia ,4,NA,NA,NA
31959492,NA,1,Bleeding associated with grade 3 thrombocytopenia,4,NA,NA,NA
31959492,NA,1,Study treatment-related non-hematologic toxicity,3 or 4,NA,FALSE,NA
31959492,NA,1,Death,5,NA,NA,NA
31959492,NA,1,NA,4,NA,NA,NA
7664282,NA,2,hypotension,4,NA,NA,dose-limiting hypotension as a >25% decrease in systolic or diastolic pressure that did not improve with adminis tration of an i.v. fluid bolus or did not resolve (<25% decrease in systolic or diastolic pressure from baseline) by the time of melphalan administration.
7664282,NA,3,mvelosuppression,4,>7 days,NA,"an absolute granulocyte count <15000 cells/mm3 or a platelet count of <100,000/mm3 28 days"
29500276,NCT01696032,4,thrombocytopenia or neutropenia,4,> 7 days,NA,NA
29500276,NCT01696032,4,febrile neutropenia,3 or 4,NA,NA,NA
29500276,NCT01696032,4,non-hematologic toxicity,>=3,NA,NA,NA
29500276,NCT01696032,4,"failure to recover absolute neutrophil count (ANC) to 1,000 cells/mm3 and/or platelets to > 75,000 cells/mm3 by Cycle 1, Day 42",1,NA,NA,NA
29500276,NCT01696032,4,Any other clinically significant AE placing patients at undue safety risk or resulting in discontinuation of treatment.,4,NA,NA,NA
29348128,NCT01814826,5, toxicity related to study drug,>=3,NA,FALSE,NA
28881739,NCT00748553,6,nonhematologic toxicities,>=3,NA,FALSE,NA
28881739,NCT00748553,6,thrombocytopenia,3,more than 7 days,NA,NA
28881739,NCT00748553,6,hematologic toxicity,4,NA,FALSE,NA
28881728,ACTRN12610001031055,7,non-hematologic toxicity ,3 or 4,NA,NA,NA
28881728,ACTRN12610001031055,7,neutropenia,4,NA,NA,NA
28881728,ACTRN12610001031055,7,thrombocytopenia,4,NA,NA,NA
28555084,NCT01729845,8,non-hematologic toxicity,3,asting >48 hours that resulted in a > 7-day delay of the subsequent treatment cycle,FALSE,NA
28555084,NCT01729845,8,non-hematologic toxicity,4,recovery to grade â‰¤2 within 14 days,NA,NA
27542211,NCT01193517,10,non-hematological toxicity,>=3,NA,FALSE,NA
27542211,NCT01193517,10,anemia,4,NA,NA,NA
27542211,NCT01193517,10, thrombocytopenia,4,NA,NA,NA
27542211,NCT01193517,10,neutropenia,4,> 5 days,NA,NA
27542211,NCT01193517,10,febrile neutropenia,>=3,NA,NA,NA
27542211,NCT01193517,10,a treatment delay,4,> 14 days,NA,NA
26055299,NCT00986804,11,"ANC <500/ÂµL and/or platelet count <30,000/ÂµL",4,two consecutive weeks,NA,NA
26055299,NCT00986804,11,"inability to achieve ANC â‰¥1000/ÂµL and platelet count â‰¥50,000/Âµl after a delay of the second cycle",4,2 weeks,NA,NA
26055299,NCT00986804,11,non-hematological toxicities,3 or 4,NA,NA,NA
25806091,NCT01039155,12,nausea/vomiting and diarrhea,>=3,> 3 days,NA,NA
25806091,NCT01039155,12, any toxicityâ€‰,>=3,NA,FALSE,NA
25062770,NCT00925132,14,hematologic toxicity,4,NA,NA,NA
25062770,NCT00925132,14,nonhematologic toxicity,>=3,NA,FALSE,NA
25062770,NCT00925132,14,nonhematologic toxicity requiring a dose reduction or treatment interruption for more than 7 days,2,NA,NA,NA
25062770,NCT00925132,14,hematologic toxicity requiring a dose reduction or treatment interruption for more than 7 days,3,NA,NA,NA
24493831,NA,16,hematologic toxicity,>=3,NA,NA,NA
24493831,NA,16,nonhepatic major organ toxicity,>=3,NA,NA,NA
24493831,NA,16,hepatic toxicity,>=3,NA,NA,NA
24649202,NA,17,hematological toxicity,4,NA,NA,NA
24649202,NA,17,neutropenia,3,NA,NA,with fever
24649202,NA,17,thrombocytopenia,>=3,NA,NA,NA
24649202,NA,17,nonâ€‘hematological toxicity,>=3,NA,NA,NA
24649202,NA,17,any single interruption of radiation therapy,NA,>= 7days,NA,NA
24649202,NA,17,>2 interruptions per radiation course,NA,NA,NA,NA
24649202,NA,17,any delay in the completion of radiation therapy,NA,> 14 days,NA,NA
24649202,NA,17,any treatmentâ€‘related hospitalization or death,NA,NA,NA,NA
24770667,NCT00633529,18,neutropenia,4,NA,NA,NA
24770667,NCT00633529,18,anemia,4,NA,NA,NA
24770667,NCT00633529,18,thrombocytopenia,4,lasting 5 or more days,NA,NA
24770667,NCT00633529,18,nausea,>=3,NA,NA,NA
24770667,NCT00633529,18,diarrhea,>=3,NA,NA,NA
24770667,NCT00633529,18,vomiting,>=3,NA,NA,NA
24770667,NCT00633529,18,non-hematologic toxicity,>=3,NA,NA,NA
24770667,NCT00633529,18,treatment delay,>=2,>= 14 days,NA,NA
24535315,NA,19,neutropenia,4,lasting >7 days,NA,NA
24535315,NA,19,febrile neutropenia,NA,NA,NA,NA
24535315,NA,19,neutropenic infection,NA,NA,NA,NA
24535315,NA,19,thrombocytopenia,4,NA,NA,NA
24535315,NA,19,ALT or AST increase,>=3,lasting >7 days,NA,NA
24535315,NA,19,treatment-related nonhematological toxicity,>=3,NA,FALSE,NA
24535315,NA,19,dosing delay,4,> 2weeks,NA,NA
24535315,NA,19,troponin I increase â‰¥0.1 ng/ml,NA,NA,NA,NA
24535315,NA,19,LVEF decrease >20 %,NA,NA,NA,NA
24535315,NA,20,neutropenia,4,lasting >7 days,NA,NA
24535315,NA,20,febrile neutropenia,NA,NA,NA,NA
24535315,NA,20,neutropenic infection,NA,NA,NA,NA
24535315,NA,20,thrombocytopenia,4,NA,NA,NA
24535315,NA,20,ALT or AST increase,>=3,lasting >7 days,NA,NA
24535315,NA,20,treatment-related nonhematological toxicity,>=3,NA,FALSE,NA
24535315,NA,20,dosing delay,4,> 2weeks,NA,NA
24535315,NA,20,troponin I increase â‰¥0.1 ng/ml,NA,NA,NA,NA
24535315,NA,20,LVEF decrease >20 %,NA,NA,NA,NA
24752867,NA,21,any drug-related toxicity,>=3,NA,FALSE,NA
32847973,NCT00572078,22,any possible treatment related grade â‰¥3 toxicities,>=3,NA,FALSE,NA
32847973,NCT00572078,22,malignant HTN,NA,NA,NA,NA
32847973,NCT00572078,22,any treatment-related toxicity that resulted in >7 days of missed sorafenib dosing,NA,>7 days,NA,NA
32847973,NCT00572078,22,any missed paclitaxel or bevacizumab doses in C1,NA,NA,NA,NA
33159605,UMIN000006254,23,blood transfusion,3,NA,NA,NA
33159605,UMIN000006254,23,thrombocytopenia,4,NA,NA,NA
33159605,UMIN000006254,23,neutropenia,4,> 7days,NA,NA
33159605,UMIN000006254,23,febrile neutropeni,>=3,NA,NA,NA
33159605,UMIN000006254,23,hypertension uncontrolled by antihypertensive drugs,4,NA,NA,NA
33159605,UMIN000006254,23,nonhematological toxicity,>=3,NA,FALSE,NA
32522887,NCT02030561,24,Not available,NA,NA,NA,NA
32490554,UMIN000016094,25,not available,NA,NA,NA,NA
31932108,NCT02055690,28,any adverse events,>=2,NA,NA,A DLT was defined as an adverse event for which a causal link with fosbretabulin and/or pazopanib could not be excluded.
31924737,NCT01916447,29,neutropenia,4,> 7 days,NA,NA
31924737,NCT01916447,29,febrile neutropenia,NA,NA,NA,NA
31924737,NCT01916447,29,thrombocytopenia,4,NA,NA,NA
31924737,NCT01916447,29,thrombocytopenia,3,NA,NA,with bleeding
31924737,NCT01916447,29,nonhematologic toxicity,>=3,NA,NA,NA
31924737,NCT01916447,29,nausea,>=3,> 48 hours,NA,NA
31924737,NCT01916447,29,diarrhea,>=3,> 48 hours,NA,NA
31924737,NCT01916447,29,vomiting,>=3,> 48 hours,NA,NA
31924737,NCT01916447,29,any study drug-related toxicity resulting in a >2-week delay in initiation of cycle 3,NA,NA,NA,NA
31924737,NCT01916447,29,any study drug-related toxicity preventing the administration of 80% of the planned cumulative dose for cycles 1 or 2,NA,NA,NA,NA
31375879,NCT02354131,31,> 10 missed doses,NA,NA,NA,NA
31375879,NCT02354131,31,> 14-day delay in initiating cycle 2,NA,NA,NA,NA
31375879,NCT02354131,31,study drug discontinuation during cycle 1,NA,NA,NA,NA
31375879,NCT02354131,31,nausea,>=3,> 3 days,NA,NA
31375879,NCT02354131,31,vomiting,>=3,> 3 days,NA,NA
31375879,NCT02354131,31,diarrhea,>=3,> 3 days,NA,NA
31375879,NCT02354131,31,non-hematologic toxicity,>=3,NA,NA,NA
31375879,NCT02354131,31,neutropenia,4,>= 7 days,NA,absolute neutrophil count [ANC] < 500/mm3
31375879,NCT02354131,31,febrile neutropenia,NA,NA,NA,ANC < 500/mm3 with a fever â‰¥ 38.5Â Â°C
31375879,NCT02354131,31,thrombocytopenia,>=3,> 5 days,NA,"platelet count < 50,000/mm3"
31194228,NCT02657889,32, treatment-related nonhematologic adverse events ,>=3,NA,NA,NA
31194228,NCT02657889,32,treatment-related hematologic adverse event,>=3,> 7 days,NA,"or associated with bleeding (thrombocytopenia), infection or febrile illness (neutropenia) or requiring blood transfusion (thrombocytopenia or anemia)"
30302599,NCT01047293,33,Any grade â‰¥ 3 non-hematologic toxicity,>=3,NA,FALSE,NA
30302599,NCT01047293,33,thrombocytopenia,3,NA,NA,NA
30302599,NCT01047293,33,anemia,4,NA,NA,NA
30302599,NCT01047293,33,thrombocytopenia,4,NA,NA,NA
30302599,NCT01047293,33,neutropenia,4,NA,NA,with fever
30185228,NCT00960960,34,"nonhematologic, nonhepatic major organ AE",>=3,NA,FALSE,NA
30185228,NCT00960960,34,thrombocytopenia,>=4,lasting > 48 hrs,NA,associated with clinically significant bleeding
30185228,NCT00960960,34,fasting hyperglycemia,>=3,NA,NA,NA
30185228,NCT00960960,34,neutropenia,>=4,lasting >= 7 days,NA,NA
30185228,NCT00960960,34,febrile neutropenia,>=3,NA,NA,NA
30185228,NCT00960960,34,"total bilirubin, alkaline phosphatase (ALP), or hepatic transaminases (alanine aminotransferase or aspartate aminotransferase);",>=3,NA,NA,NA
30185228,NCT00960960,34,lung diffusing capacity concomitant with a decrease of â‰¥ 20% from baseline,>=2,NA,NA,NA
30603797,NCT02835833,38,non-hematologic toxicity,3 or 4,NA,FALSE,NA
30603797,NCT02835833,38,hematologic toxicity,4,last >= 7 days,NA,associated with bleeding or requiring transfusions.
29695765,NCT01113476,40,non-haematologic toxicity,3 or 4,NA,FALSE,NA
29695765,NCT01113476,40,haematologic toxicity,4,lasting >= 2 weeks,NA,"unless complicated by fever or infection, bleeding symptomatic anaemia, or other symptoms concerning to the treating physician,"
29695765,NCT01113476,40,nausea,4,> 5 days,NA,NA
29695765,NCT01113476,40,vomiting,4,> 5 days,NA,NA
29290249,NA,41,hematological toxicity,4,NA,NA,NA
29290249,NA,41,hypertension,4,NA,NA,NA
29290249,NA,41,non-hematological toxicity,>=3,NA,FALSE,NA
29290249,NA,41,non-hematological toxicity,2,lasting >= 7 days,NA,despite supportive care
29290249,NA,41,left ventricular function,>=2,NA,NA,NA
29290249,NA,41,renal function,>=2,NA,NA,NA
29290249,NA,41,pneumonitis,>=1,NA,NA,NA
29290249,NA,41,inability to receive the second course of bevacizumab due to bevacizumab toxicity,NA,NA,NA,NA
29264836,NA,42,"an adverse event or laboratory abnormality that was either assessed as unrelated to disease progression, inter-current illness, or concomitant medications, occurred following the first dose of VOR, BEV and daily TMZ during cycle 1",NA,NA,NA,NA
29264836,NA,42,neutropenia,4,lasting > 5 days,NA,NA
29264836,NA,42,thrombocytopenia,3,NA,NA,NA
29264836,NA,42,any hematologic toxicity,NA,NA,NA,> 14-day delay to re-treat due to failure to resolve
29264836,NA,42,the occurrence of Grade 3 or greater drug-related adverse events,>=3,NA,FALSE,NA
29264836,NA,42,diarrhea,>=3,NA,NA,NA
29559563,NCT01248949,43,al AEs,>=3,NA,NA,NA
28810837,NCT01202032,49,any AEs,4,NA,NA,NA
28810837,NCT01202032,49,thrombotic,NA,NA,NA,NA
28810837,NCT01202032,49,cardiac failure,3,NA,NA,NA
28810837,NCT01202032,49,non-controlled hypertension,NA,NA,NA,NA
28810837,NCT01202032,49,thrombocytopenia,4,NA,NA,NA
28810837,NCT01202032,49,"AST, ALT, or bilirubin level increase",NA,NA,NA,NA
28810837,NCT01202032,49,any other grade 3 AE,3,last > 7 days,FALSE,NA
29101518,UMIN000012536,50,leukopenia,4,NA,NA,NA
29101518,UMIN000012536,50,febrile neutropenia,NA,NA,NA,NA
29101518,UMIN000012536,50,thrombocytopenia,4,NA,NA,NA
29101518,UMIN000012536,50,non-hematological toxicity,3,did not resolve within 43 days,FALSE,NA
28992562,NCT00974584,51,non-haematological,>=3,NA,NA,NA
28992562,NCT00974584,51,non-hepatic organ toxicity,NA,NA,FALSE,NA
28992562,NCT00974584,51,thrombocytopenia,>=4,lasting. > 7 days,NA,or associated with clinically significant bleeding
28992562,NCT00974584,51,neutropenia,>=4,lasting. > 7 days,NA,NA
28992562,NCT00974584,51,febrile neutropenia,>=4,NA,NA,NA
28992562,NCT00974584,51,febrile neutropenia,>=3,NA,NA,NA
28992562,NCT00974584,51,hepatic transaminases,>=3,NA,NA,"for patients with grade I hepatic transaminase at baseline as a result of metastases, hepatic transaminase >7.5  the upper limit of normal was considered a DLT"
28992562,NCT00974584,51,DLCO with a decrease of 20%,NA,NA,NA,NA
28760399,NA,55,non-haematological toxicity,>=3,NA,FALSE,NA
28760399,NA,55,neutropenia,4,lasting  > 7 days,NA,NA
28760399,NA,55,febrile neutropenia,>=3,NA,NA,NA
28760399,NA,55,thrombocytopenia,4,NA,NA,NA
28760399,NA,55,unresolved toxicities causing longer than a 2-week delay of initiation of the next cycle,4,NA,NA,NA
28391576,NCT01660360,56,thrombocytopenia,4,NA,NA,NA
28391576,NCT01660360,56,neutropenia,4,lasting > 7 days,NA,NA
28391576,NCT01660360,56,neutropenia,3 or 4,NA,NA,accompanied by temperature â‰¥ 38 Â°C
28391576,NCT01660360,56,non-hematologic toxicity,3 or 4,NA,FALSE,NA
27943153,NCT00867321,57,adverse event,>=3,NA,NA,NA
27765756,NA,58,neutrophil count decreased,4,lasting >7 days,NA,NA
27765756,NA,58,febrile neutropenia,4,NA,NA,NA
27765756,NA,58,febrile neutropenia,3,> 24 hrs,NA,NA
27765756,NA,58,thrombocytopenia,4,NA,NA,NA
27765756,NA,58,thrombocytopenia,3,NA,NA,requiring platelet transfusion
27765756,NA,58,non-hematological toxicities,>=3,NA,NA,NA
27765756,NA,58,uveitis,>=2,NA,NA,uncontrollable 
27765756,NA,58,eye pain,>=2,NA,NA,uncontrollable 
27765756,NA,58,visual acuity reduced,>=2,NA,NA,uncontrollable 
27765756,NA,58,vomiting,>=3,NA,NA,uncontrollable 
27765756,NA,58,anorexia,>=3,NA,NA,uncontrollable 
27765756,NA,58,diarrhea,>=3,NA,NA,uncontrollable 
27765756,NA,58,intolerable skin toxicities,>=3,NA,NA,NA
27765756,NA,58,aminotransferase increased,NA,NA,NA,"â‰¥10Ã— the upper limit of normal (ULN), or â‰¥5Ã— ULN and continuing for >7 days;"
27765756,NA,58,blood bilirubin increased,NA,NA,NA,â‰¥5Ã— ULN
27765756,NA,58,aminotransferase increased,NA,NA,NA,â‰¥3Ã— ULN
27765756,NA,58,blood bilirubin increased,NA,NA,NA,â‰¥2Ã— ULN
27765756,NA,58,laboratory abnormalities,4,NA,NA,NA
27765756,NA,58,laboratory abnormalities,3,> 7 days,NA,NA
27872953,NA,62,uncomplicated neutropenia,4,> 7 days,NA,fever <= 38.3 C
27872953,NA,62,neutropenia,NA,NA,NA,fever > 38.5 C
27872953,NA,62,thrombocytopenia,3,NA,NA,associated with bleeding requiring transfusion
27872953,NA,62,fall in cardiac left ventricular function,>=2,NA,NA,NA
27872953,NA,62,uncontrolled hypertension,NA,NA,NA,NA
27872953,NA,62,renal function,>=2,NA,NA,NA
27872953,NA,62,diarrhea,>=2,NA,NA,NA
27872953,NA,62,diarrhea,>=2,> 7 days,NA,NA
27872953,NA,62,nausea,>=2,NA,NA,NA
27872953,NA,62,vomitting,>=2,NA,NA,NA
27872953,NA,62,vomitting,>=2,> 7 days,NA,NA
27872953,NA,62,all other drug-related non-hematological,>=3,NA,FALSE,NA
27507617,NCT01183494,64,hematologic grade 4 toxicity,4,NA,NA,NA
27507617,NCT01183494,64,nonhematologic grade 3â€“4 toxicity,3 or 4,NA,NA,NA
27565810,NA,66,non-hematologic toxicity,>=3,NA,FALSE,NA
27565810,NA,66,neutropenia,4,NA,NA,accompanied by fever lasting more than 5 days or of â‰¥38 Â°C
27565810,NA,66,thrombocytopenia,4,NA,NA,NA
27565810,NA,66,reduction in the diffusing capacity of the lungs for carbon monoxide,3,NA,NA,NA
27565810,NA,66,interstitial lung disease,>=2,NA,NA,NA
27565810,NA,66,requiring cessation,NA,>= 14 days,NA,NA
27457310,NA,68,nausea,>=3,NA,NA,NA
27457310,NA,68,vomiting,>=3,NA,NA,NA
27457310,NA,68,diarrhea,>=3,NA,NA,NA
27457310,NA,68,despite maximal prophylaxis,>=3,NA,NA,NA
27457310,NA,68,any grade 3 or 4 non-hematologic toxicity not easily corrected with medical management,3 or 4,NA,NA,NA
27457310,NA,68,neutropenia,4,>= 5 days,NA,NA
27457310,NA,68,febrile neutropenia,>=3,NA,NA,NA
27457310,NA,68,hematologic adverse events,4,NA,NA,NA
27457310,NA,68,a study treatment delay of â‰¥7 days due to an AE or inability to commence cycle 2 within 14 days of the planned start date due to an AE;,NA,>= 7 days,NA,NA
27457310,NA,68,a treatment-emergent AE warranting a dose reduction,NA,NA,NA,NA
27085994,NCT01183663,71,nonhematologic toxicity,3 or 4,NA,FALSE,NA
27085994,NCT01183663,71,hematologic toxicity,4,lasting >= 7 days,NA,NA
27085994,NCT01183663,71,nausea,4,lasting >  5 days,NA,NA
27085994,NCT01183663,71,vomiting,4,lasting >  5 days,NA,NA
27085994,NCT01183663,71,vascular leakage,3,NA,NA,NA
27085994,NCT01183663,71,cytokine release syndrome,3,NA,FALSE,NA
27085994,NCT01183663,71,any severe or life-threatening complication or abnormality not covered in the NCI CTCAE.,NA,NA,NA,NA
27198170,NCT01283048,73,neutropenia,>=3,persistent,NA,NA
27198170,NCT01283048,73,thrombocytopenia,>=3,persistent,NA,NA
27198170,NCT01283048,73,febrile neutropenia,NA,NA,NA,NA
27198170,NCT01283048,73,thrombocytopenia,4,NA,NA,NA
27198170,NCT01283048,73,neurocognitive disorder,>=1,NA,NA,NA
27198170,NCT01283048,73,mood alteration,2,persistent,NA,NA
27198170,NCT01283048,73,mood alteration,>=3,NA,NA,NA
27198170,NCT01283048,73,phototoxicity,>=2,persistent,NA,NA
27198170,NCT01283048,73,skin toxicity,>=2,persistent,NA,NA
27198170,NCT01283048,73,elevations in creatinine,NA,persistent,NA,NA
27198170,NCT01283048,73,elevations in creatinine,>=3,NA,NA,NA
27198170,NCT01283048,73,elevations in bilirubin,NA,persistent,NA,NA
27198170,NCT01283048,73,elevations in bilirubin,>=3,NA,NA,NA
27198170,NCT01283048,73,AST or ALT elevations,3 or 4,persistent,NA,NA
27198170,NCT01283048,73,hyperglycemia,2,persistent,NA,NA
27198170,NCT01283048,73,hyperglycemia,>=3,NA,NA,NA
27198170,NCT01283048,73,pancreatitis,>=2,NA,NA,NA
27198170,NCT01283048,73,amylase and/or lipase elevations,3,persistent,NA,NA
27198170,NCT01283048,73,amylase and/or lipase elevations,4,NA,NA,NA
27198170,NCT01283048,73,Any other grade 3 toxicity,>=3,NA,FALSE,NA
26933802,NA,74,any grade three or four non-hematologic toxicity t,3 or 4,NA,FALSE,NA
26933802,NA,74,hematologic toxicity,4,lasting >= 2 days,NA,NA
26933802,NA,74,nausea,4,> 5 days,NA,NA
26933802,NA,74,vomiting,4,> 5 days,NA,NA
26933802,NA,74,symptoms/signs of vascular leak,3,NA,NA,NA
26933802,NA,74,cytokine release syndrome,3,NA,NA,NA
26933802,NA,74,any severe or life-threatening complication/abnormality not defined in the CTCAEv3.0,4,NA,NA,NA
26616225,NA,76,dose delay,NA,>3 weeks,NA,NA
26616225,NA,76,febrile neutropenia,NA,NA,NA,NA
26616225,NA,76,neutropenia,4,> 7 days,NA,NA
26616225,NA,76,thrombocytopenia,4,NA,NA,NA
26616225,NA,76,thrombocytopenia,3,NA,NA,with clinically significant bleeding
26616225,NA,76,grade 3 or 4 adverse event,3 or 4,NA,FALSE,NA
26616225,NA,76,drug-related death,4,NA,NA,NA
26581401,NA,78,anemia,>=4,NA,NA,NA
26581401,NA,78,neutrophil count decrease,4,NA,NA,NA
26581401,NA,78,platelet count decrease,4,NA,NA,NA
26581401,NA,78,serum creatinine â‰¥2 times baseline,NA,NA,NA,â‰¥2 times the upper limit of normal if baseline is < the upper limit of normal
26581401,NA,78,nonhematologic event,>=3,NA,NA,NA
26581401,NA,78,nausea,>=3,NA,NA,was considered dose-limiting if maximal supportive treatment was utilized.
26581401,NA,78,vomiting,>=3,NA,NA,was considered dose-limiting if maximal supportive treatment was utilized.
26581401,NA,78,diarrhea,>=3,NA,NA,was considered dose-limiting if maximal supportive treatment was utilized.
26272806,NCT00904839,79,vomiting,>=3,NA,NA,despite optimal supportive care/intervention
26272806,NCT00904839,79,diarrhoea,>=3,NA,NA,despite optimal supportive care/intervention
26272806,NCT00904839,79,hypertension,>=3,NA,NA,despite optimal supportive care/intervention
26272806,NCT00904839,79,Non-haematological toxicity,>=3,NA,FALSE,NA
26272806,NCT00904839,79,neutropenia,4,> 7 days,NA,NA
26272806,NCT00904839,79,Neutropenia,>=3,any duration ,NA,with fever â‰¥38.5ÂºC
26272806,NCT00904839,79,thrombocytopenia,3,NA,NA,thrombocytopenia
26272806,NCT00904839,79,"Platelets <25,000/Î¼L",NA,NA,NA,NA
26272806,NCT00904839,79,Inability to resume nintedanib dosing within 14 days,NA,NA,NA,NA
26272806,NCT00904839,79,ALT and/or AST elevation,>=3,NA,NA,NA
26272806,NCT00904839,79,ALT and/or AST elevation,>=2,NA,NA,in conjunction with bilirubin CTCAE grade >1
26272806,NCT00904839,79,Inability to recover from increase ALT/AST in conjunction with increase of bilirubin to ALT/AST to CTCAE grade â‰¤1 and bilirubin to normal or baseline within 14 days,NA,NA,NA,NA
25990659,NA,80,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25990659,NA,80,hematologic toxicity,4,lasting >= 3 weeks,NA,NA
25990659,NA,80,hematologic toxicity,4,NA,NA,associated with bleeding and/or sepsis
25990659,NA,80,nausea,4,lasting>5 days,NA,NA
25990659,NA,80,vomiting,4,lasting>5 days,NA,NA
25990659,NA,80,any other severe or life-threatening complication,NA,NA,NA,NA
25525888,NA,84,haematologic toxicity,>=3,NA,FALSE,NA
25525888,NA,84,nonhaematologic toxicity,>= 3,NA,FALSE,NA
25363205,NA,86,No DLT definition,NA,NA,NA,NA
25080061,UMIN000006937,87,hematological toxicity,4,NA,NA,NA
25080061,UMIN000006937,87,neutropenia,3,NA,NA,with fever > 38 C
25080061,UMIN000006937,87,thrombocytopenia,>=3,NA,NA,NA
25080061,UMIN000006937,87,nonhematological toxicity,>=3,NA,NA,NA
29764853,NCT01478685,88,Any nonhematologic adverse event,>=3,NA,FALSE,NA
29764853,NCT01478685,88,neutropenia,4,lasting >7 days,NA,or with fever
29764853,NCT01478685,88,thrombocytopenia,3,NA,NA,withj bleeding
29764853,NCT01478685,88,neutrophil count [ANC] >= 1.5*10^9/L and platelets>=75*10^9/L,4,NA,NA,NA
28546581,NCT00946647,95,NA,4,NA,NA,NA
24875133,NA,99,non-hematologic toxicity,3 or 4,NA,FALSE,NA
24875133,NA,99,thrombocytopenia,4,NA,NA,NA
24875133,NA,99,neutropenia,4,lasting > 2 weeks,NA,NA
24875133,NA,99,neutropenia,4,NA,NA,or associated infection
24875133,NA,99,any toxicity that results in treatment delay of >4 weeks,4,NA,NA,NA
25483416,NA,101,non-hematologic toxicity,>=3,NA,FALSE,NA
25483416,NA,101,hematologic toxicity,4,persisting beyond Day 42 in the absence of bone marrow involvement with disease.,NA,NA
24413064,ACTRN12610000924055,103,Nonhematologic grade 3 or 4 toxicity,3 or 4,NA,NA,NA
24413064,ACTRN12610000924055,103,febrile neutropenia,4,NA,NA,NA
24413064,ACTRN12610000924055,103,ailure to achieve an absolute neutrophil count > 0.5*10^9/ liter,NA,NA,NA,in patients whose bone marrow biopsy at the end of cycle 1 (days 25â€“28) showed persistent marrow hypoplasia (o10%) and blasts less than 5%.
24413064,ACTRN12610000924055,103,platelet count > 20*10^9/liter by day 42,NA,NA,NA,in patients whose bone marrow biopsy at the end of cycle 1 (days 25â€“28) showed persistent marrow hypoplasia (o10%) and blasts less than 5%.
24138944,NCT00861874,104,non-hematologic toxicity,3 or 4,NA,FALSE,NA
23798029,NCT01130662,106,nonhematologic toxicity,3 or 4,NA,NA,NA
23798029,NCT01130662,106,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
23798029,NCT01130662,106,prolonged myelosuppression,NA,> 41 days,NA,NA
23798029,NCT01130662,106,an inability to deliver at least 80% of the planned dose due to study drugrelated toxicities,NA,NA,NA,NA
23789936,NA,107,any grade â‰¥3 serious adverse event,>=3,NA,NA,NA
21901396,NA,108,hematologic toxicity,4,NA,NA,NA
21901396,NA,108,nonhematologic toxicity,4,NA,NA,NA
21901396,NA,108,Non-hematologic toxicities necessitating dose reduction,NA,NA,NA,NA
21576646,NA,109,nausea,>=3,NA,NA,despite adequate/maximal medical intervention
21576646,NA,109,diarrhea,>=3,NA,NA,despite adequate/maximal medical intervention
21576646,NA,109,vomiting,>=3,NA,NA,despite adequate/maximal medical intervention
21576646,NA,109,clinically significant nonhematologic toxicity,>=3,NA,NA,NA
21576646,NA,109,failure to recover to an absolute neutrophil count (ANC) of higher than 500/L,NA,NA,NA,NA
21576646,NA,109,"platelet count of higher than 25,000/L with hypocellular bone marrow",NA,NA,NA,NA
21576646,NA,109,any treatment-related effect resulting in missing  3 oral azacitidine doses in the 7-day treatment period,NA,NA,NA,NA
21576646,NA,109,any treatment-related nonhematologic toxicity delaying initiation of the second oral azacitidine cycle by longer than 14 days,NA,NA,NA,NA
21278245,NA,110,ANC < 0.5*10^9/L,NA,lasting 7 or more days,NA,NA
21278245,NA,110,febrile neutropenia,NA,NA,NA,NA
21278245,NA,110,platelets less than 25*10^9/L,NA,NA,NA,NA
21278245,NA,110,thrombocytopenia,3,NA,NA,ssociated with bleeding
21278245,NA,110,nonhematologic toxicity,>=3,NA,FALSE,NA
21278245,NA,110,intolerable grade 2 nonhematologic toxicity,2,NA,FALSE,NA
21278245,NA,110,any toxicity resulting in treatment delay of more than 2 weeks,4,NA,NA,NA
23172636,NCT00715793,112,neutropenia,4,lasts >7 days,NA,NA
23172636,NCT00715793,112,thrombocytopenia,4,lasts >7 days,NA,NA
23172636,NCT00715793,112,febrile neutropenia,3 or 4,NA,NA,NA
23172636,NCT00715793,112,non-hematological toxic effects,>=3,NA,NA,NA
22033493,NCT00890929,113,toxicity-related dose delays 28 days,NA,NA,NA,NA
22033493,NCT00890929,113,non-hematologic toxicity.,4,NA,NA,NA
22033493,NCT00890929,113,selected non-hematologic toxicity,2 or 3,NA,NA,NA
20456354,NA,114,non-haematological toxicity,>=3,NA,NA,NA
20456354,NA,114,neutropenia,4,NA,NA,NA
20456354,NA,114,thrombocytopenia,4,> 7days,NA,in patients with NHL
20456354,NA,114,ANC,NA,NA,NA,NA
14604977,NA,116,No info provided,4,NA,NA,NA
10830142,NA,117,ANC of <500/uL,NA,> 7days,NA,NA
10830142,NA,117,ANC of <500/uL,NA,NA,NA,associated with fever > 38 C
10830142,NA,117,"platelet count of < 25,000/uL",NA,NA,NA,NA
10830142,NA,117,mucositis,3 or 4,NA,NA,NA
10830142,NA,117,nausea,3 or 4,NA,NA,NA
10830142,NA,117,vomiting,3 or 4,NA,NA,NA
10830142,NA,117,diarrhea,3 or 4,NA,NA,NA
10492074,NA,118,marrow hypoplasia,NA,6 weeks,NA,NA
20564122,NA,119,thrombocytopenia,4,NA,NA,NA
20564122,NA,119,neutropenic fever,3 or 4,NA,NA,NA
20564122,NA,119,neutropenia,4,lasting  >  5 days,NA,NA
20564122,NA,119,nonhematologic toxicity,3 or 4,NA,NA,NA
20564122,NA,119,failure to recover blood counts by Day 42.,NA,NA,NA,NA
17679729,NA,120,DLT Not Defined,4,NA,NA,NA
33963476,"EudraCT 2009-016080-11, Dutch Trial Register NTR2391",122,any adverse event,>=3,NA,FALSE,NA
33777754,ChiCTR1900021555,123,death,5,NA,NA,NA
33777754,ChiCTR1900021555,123,"digestive, hepatobiliary or pancreatic perforation or fissure requiring surgery",NA,NA,NA,NA
33777754,ChiCTR1900021555,123,hemorrhage requiring transfusion or surgery,NA,NA,NA,NA
33777754,ChiCTR1900021555,123,life-threatening or irreversible disability,NA,NA,NA,NA
33777754,ChiCTR1900021555,123,adverse events,>=3,NA,FALSE,NA
33616416,NCT01852409,124,Any adverse event,>=3,NA,NA,NA
34164713,NCT01749384,125,non-hematologic toxicity,>=3,NA,NA,with additional specified criteria of nausea/vomiting or diarrhea
34164713,NCT01749384,125,hypomagnesemia,3,NA,NA,NA
34164713,NCT01749384,125,hypokalemia,3,NA,NA,NA
34164713,NCT01749384,125,hyperkalemia,3,NA,NA,NA
34164713,NCT01749384,125,neutropenia,4,NA,NA,NA
34164713,NCT01749384,125,febrile neutropenia,4,NA,NA,NA
34164713,NCT01749384,125,thrombocytopenia,4,NA,NA,NA
33215270,NA,128,any nonhematologic toxicity,>=3,> 3 days in spite of supportive care,NA,NA
33215270,NA,128,thrombocytopenia,4,NA,NA,"< 25,000 cells/mm^3"
33215270,NA,128,anemia,4,NA,NA,Hgb < 6.5Â g/dL on the following scheduled dosing day
33215270,NA,128,neutropenia,4,> 5 days,NA,ANC < 500 cells/mm3
33215270,NA,128,febrile neutropenia,NA,NA,NA,temperature > 101Â ÂºF with an absolute neutrophil count < 1000 cells/Î¼L (grade 3 or 4)
33215270,NA,128,inability to receive all standard doses of PG-11047 during the first dosing cycle due to any unexpected toxicity thought to be related to the combination therapy,NA,NA,NA,NA
15205668,NA,135,DLT not clearly defined,NA,NA,NA,NA
8855989,NA,136,haematological toxicity,4,lasting more than 4 days,NA,NA
8855989,NA,136,thrombocytopenia,4,NA,NA,with bleeding
8855989,NA,136,anaemia,4,NA,NA,with cardiac failure
8855989,NA,136,non-haematological toxicity,4,NA,FALSE,NA
8855989,NA,136,granulocytopenic fever,NA,NA,NA,granulocytes <0.5 x 10^9 /l or WBC< 1.0 x 10^9 /l with at least one episode of fever> 38.2Â°C)
8855989,NA,136,clinically or microbiologically documented infection requiring anti-microbial parenteral therapy,NA,NA,NA,NA
8855989,NA,136,fever (>38.2 C) of unknown origin,NA,NA,NA,NA
8855989,NA,136,no haematological recovery by day 21,1,NA,NA,NA
8519675,NA,137,neutropenia,3,NA,NA,NA
8519675,NA,137,thrombocytopenia,2,NA,NA,on day 8
8519675,NA,137,neutropenia,4,lasting longer than 7 days,NA,NA
8519675,NA,137,febrile neutropenia,NA,NA,NA,NA
8519675,NA,137,thrombocytopenia,4,NA,NA,NA
8519675,NA,137,any toxicity exceeding WHO grade II,>2,NA,FALSE,NA
8519675,NA,137,nausea,>3,NA,NA,NA
8519675,NA,137,vomiting,>3,NA,NA,NA
8652277,NA,138,lNot defined,NA,NA,NA,NA
8261569,NA,139,Not defined,4,NA,NA,NA
2313718,NA,140,Not defined,4,NA,NA,NA
7691117,NA,141,Not defined,NA,NA,NA,NA
8612318,NA,143,any toxicity,3  or 4,NA,FALSE,NA
7529516,NA,144,any toxicity,4,NA,NA,NA
8392903,NA,145,hematologic toxicity,4,> 3 days,NA,NA
8392903,NA,145,nonhematologic toxicity,3 or 4,NA,NA,NA
7954234,NA,147,a PR interval of more than 0.24 seconds,NA,NA,NA,NA
7954234,NA,147,pulse of less than 50 bpm,NA,NA,NA,NA
7954234,NA,147,atrioventricular block,>=2,NA,NA,NA
7954234,NA,147,congestive heart failure,NA,NA,NA,NA
7954234,NA,147,systolic blood pressure < 80 mmHg,NA,NA,FALSE,NA
8070013,NA,148,stomatitis,3,NA,NA,NA
8070013,NA,148,leukopenia,4,NA,NA,WBC of <0.4 x 10^9/l lasting for >3 days
8453681,NA,149,somnolence for >50% of waking hours,NA,NA,NA,NA
8453681,NA,149,"coma, extrapyramidal reactions",NA,last for > 6 hrs,NA,NA
8453681,NA,149,severe intolerable extrapyramidal reaction,NA,NA,NA,NA
8453681,NA,149,symptomatic hypotension,NA,NA,NA,NA
8453681,NA,149,a fall of >_30 mmHg in systolic blood pressure,NA,NA,NA,NA
8453681,NA,149,multifocal premature ventricular contractions,NA,NA,NA,NA
8453681,NA,149,ventricular tachycardia,NA,NA,NA,NA
8453681,NA,149,symptomaticcardiac dysfunction,NA,NA,NA,NA
8453681,NA,149,a decrease of >15% inthe left ventricular ejection fraction,NA,NA,NA,NA
8453681,NA,149,alanine aminotransferase/aspartateaminotransferase/alkalinephosphatase values of >= 5.1 times normal,NA,NA,NA,NA
8453681,NA,149,bilimbin levels of >= 2.6 times normal,NA,NA,NA,NA
8453681,NA,149,bronchospasm requiring parental therapy,NA,NA,NA,NA
8453681,NA,149,anaphylaxis,NA,NA,NA,NA
7987997,NA,150,toxicity ECOG,3 or 4,NA,FALSE,NA
7987997,NA,150,toxicity that caused postponement of planned treatment course for more than two weeks,NA,NA,NA,NA
7987997,NA,150,a decrease of LVEF by more than 10% from the patient's baseline value and/or a value lower than 50%,NA,NA,NA,NA
1768677,NA,151,any toxicity,3 or 4,NA,NA,NA
7636539,NA,152,nonhematologic toxicity,>=3,NA,NA,NA
7636539,NA,152,congestive heart failure,NA,NA,NA,NA
7636539,NA,152,persistent asymptomatic systolic hypotension less than 80 mm Hg,NA,NA,NA,NA
7636539,NA,152,any symptomatic hypotension with a greater than 20-mm Hg decrease in baseline systolic blood pressure,NA,NA,NA,NA
7636539,NA,152,heart rate less than 45 beats per minute,NA,NA,NA,NA
7636539,NA,152,second or third degree heart block,NA,NA,NA,NA
7913721,NA,153,granulocytopenia.,NA,NA,NA,NA
8622073,NA,154,any grade 3 and 4 toxicities,3 or 4,NA,FALSE,NA
8622073,NA,154,an AGC nadir of less than 500 cells/uL,NA,for >= 5 days,NA,NA
8622073,NA,154,"a platelet count of less than 25,000/uL",1,>=  7 days,NA,NA
8622080,NA,155,febrile neutropenia,NA,NA,NA,NA
8622080,NA,155,absolute neutrophil count less than 500 cells/uL,NA,> 4 days,NA,NA
8622080,NA,155,"platelet count less than 25,000/ uL",NA,NA,NA,NA
8622080,NA,155,any other grade 4 toxicity,4,NA,NA,NA
8523055,NA,157,Grade 3 toxicity,3,NA,FALSE,NA
8523055,NA,157,hematologic toxicity,4,NA,NA,"ANC less than 2,000/pL and/or platelet count less than 90,000/yL on day 28 after the first cycle of therapy."
7680373,NA,158,ANC <= 500 cells/uL,NA,for 5 days,NA,NA
7680373,NA,158,ANC <= 500 cells/uL,NA,on Day 14,NA,NA
7680373,NA,158,"any platelet count â€¢ 25,000 cells/uL",NA,NA,NA,NA
7680373,NA,158,nonmyelosuppressive toxicity,3 or 4,NA,NA,NA
7680373,NA,158,full doses of chemotherapy not administered on day 14 or 21 due to toxicity,NA,NA,NA,NA
7689093,NA,159,AGC less than 500/uL,NA,for 7 days or longer,NA,NA
7689093,NA,159,"a single platelet count less than 20,000/uL",NA,NA,NA,NA
7689093,NA,159,"lack of hematologic recovery (AGC > 1,500/uL and platelets > 90,000/uL) by day 21",NA,NA,NA,NA
7689093,NA,159,any toxicities,>=2,NA,FALSE,NA
8664188,NA,161,neutrophils <0.5* 10 ^ 9/L,NA,for  >  4 days,NA,NA
8664188,NA,161,febrile neutropenic,NA,NA,NA,NA
8664188,NA,161,absence of recovery of neutrophils (>1.5 * 10^ 9/L) and/or platelets (>75 x 10^9),NA,NA,NA,NA
8664188,NA,161,non-hematological toxicity,3 or 4,NA,FALSE,NA
29850984,NA,162,Any toxicities,>=3,occurred â‰¤ 21 days following the first dose of alpelisib,NA,NA
29850984,NA,162,Any toxicities,<3,last > 7 days or t led to dose interruption of alpelis,NA,NA
1453205,NA,163,Not provided,4,NA,NA,NA
1310105,NA,165,nadir granulocyte counts <=0.2 x 10^9/L,NA,NA,NA,NA
1310105,NA,165,WBC counts <= 1.0 x 10^9/L,NA,NA,NA,NA
1310105,NA,165,platelets <= 40 x 10^9/L,NA,NA,NA,NA
1310105,NA,165,Febrile neutropenia,>=3,NA,NA,NA
1310105,NA,165,nonhematologic toxicity,>=3,NA,NA,NA
8622023,NA,166,any grade 3 or 4 nonhematologic toxicity,3 or 4,NA,FALSE,NA
8622023,NA,166,ANC less than 500/uL,NA,>= 5 days,NA,NA
8622023,NA,166,"a single platelet count less than 20,000/uL",NA,NA,NA,NA
8622023,NA,166,failure of the blood counts to recover by day 22,NA,NA,NA,NA
7595726,NA,167,ANC less than 500/uL,NA,>= 7 days,NA,NA
7595726,NA,167,ANC less than 100/uL,NA,>= 3 days,NA,NA
7595726,NA,167,febrile neutropenia,NA,NA,NA,ANC < 500/uL and fever > 38 C
7595726,NA,167,mucositis,3,NA,NA,WHO
7595726,NA,167,peripheral neuropathy,3,NA,NA,WHO
7595726,NA,167,major organ toxicity,>= 2,NA,NA,WHO
8620409,NA,168,any hematotoxicity,4,NA,NA,in at least five of eight patients
8620409,NA,168,any toxicity,3 or 4,NA,FALSE,NA
8246030,NA,169,not defined,4,NA,NA,NA
1525387,NA,170,Confluent buccal ulceration,NA,NA,NA,NA
1525387,NA,170,myelosuppression to less than 2 x 10^9 /I total white cells,NA,NA,NA,NA
1525387,NA,170,myelosuppression to less than 100 x 10^9/l platelets,NA,NA,NA,NA
12056705,NA,172,neutropenia,4,NA,NA,NA
12056705,NA,172,thrombocytopenia,4,NA,NA,NA
12056705,NA,172,serum creatinine â‰¥2 times baseline or upper limit of normal,NA,NA,NA,NA
12056705,NA,172,nausea,4,NA,NA,despite maximal antiemetic treatment;
12056705,NA,172,vomiting,4,NA,NA,despite maximal antiemetic treatment;
12056705,NA,172,diarrhea,4,NA,NA,in spite of intensive loperamide therapy
12056705,NA,172,other non-hematological toxicity,>=3,NA,NA,NA
12056705,NA,172,failure to recover to grade 1 or lower toxicity by day 43,NA,NA,NA,NA
15937714,NA,173,neutropenia,3 or 4,NA,NA,NA
15937714,NA,173,thrombocytopenia,NA,on day 15,NA,NA
15937714,NA,173,febrile neutropenia,NA,NA,NA,NA
15937714,NA,173,nonhematologic toxicity,>=3,NA,FALSE,NA
32147669,NCT02039336,174,neutropenia,4,>= 5 days,NA,NA
32147669,NCT02039336,174,febrile neutropenia,>=3,NA,NA,NA
32147669,NCT02039336,174,anemia,4,NA,NA,NA
32147669,NCT02039336,174,thrombocytopenia,4,NA,NA,NA
32147669,NCT02039336,174,"AST > 5X ULN OR, ALT > 3X ULN AND bilirubin > 2X ULN",NA,NA,FALSE,NA
32147669,NCT02039336,174,rash,>=4,NA,NA,hand-foot syndrome or photosensitivity
32147669,NCT02039336,174,rash,3,> 7 days,NA,hand-foot syndrome or photosensitivity
32147669,NCT02039336,174,nausea,>=3,NA,NA,NA
32147669,NCT02039336,174,vomiting,>=3,NA,NA,NA
32147669,NCT02039336,174,diarrhea,>=3,NA,NA,NA
32147669,NCT02039336,174,peripheral sensory ,>=2,NA,NA,NA
32147669,NCT02039336,174,motor neuropathy,>=2,NA,NA,NA
32147669,NCT02039336,174,clinically significant non-hematologic toxicity ,>=3,NA,FALSE,NA
32147669,NCT02039336,174,Ejection fraction < lower limit of normal (LLN) with an absolute decrease of >10% from baseline with confirmation within 14 days,NA,NA,NA,NA
32147669,NCT02039336,174,Inability to receive â‰¥75% of scheduled doses,NA,NA,NA,NA
32147669,NCT02039336,174,Treatment delay of > 7 days due to study treatment-related toxicity,NA,NA,NA,NA
32147669,NCT02039336,174,toxicity that occurs beyond 28 days which in the judgment of the investigator is a DLT,>=2,NA,NA,NA
29067643,NCT01347866,175,neutropenia,4,> 7 days,NA,NA
29067643,NCT01347866,175,febrile neutropenia,4,NA,NA,NA
29067643,NCT01347866,175,neutropenic infection,>=3,NA,NA,NA
29067643,NCT01347866,175,thrombocytopenia,3,NA,NA,with bleeding
29067643,NCT01347866,175,thrombocytopenia,4,NA,NA,NA
29067643,NCT01347866,175,any toxicities,>=3,NA,FALSE,NA
29067643,NCT01347866,175, corrected QT prolongation >500 msec,3,NA,NA,persisting after correction of any reversible causes 
29067643,NCT01347866,175,"persistent, intolerable toxicities ",NA,NA,NA,NA
20215549,NA,179,hematologic toxicity,4,NA,NA,NA
20215549,NA,179,nonhematologic treatment-related toxicity,>=3,NA,NA,NA
11937310,NA,182,neutropenia,4,lasting 7 days or longer,NA,NA
11937310,NA,182,thrombocytopenia,4,NA,NA,NA
11937310,NA,182,complicated haematological toxicity,3 or 4,NA,NA,NA
11937310,NA,182,non-haematological toxicity,3 or 4,NA,FALSE,NA
14739041,NA,183,any G3 non-haematological toxicity,3,NA,NA,in three or more patients at any dose level
14739041,NA,183,neutropenia,NA,>= 7 days,NA,with ANC of â‰¤ 0.5 Ã— 10^9
14739041,NA,183,ANC â‰¤ 1.0 Ã— 10^9/l with fever (temperature â‰¥38 C),NA,>=  3 days,NA,NA
14739041,NA,183,thrombocytopenia,NA,NA,NA,<= 25 * 10 ^ 9/l
14739041,NA,183,infections,3,NA,NA,requiring hospitalization
11728688,NA,184,any Grade 4 toxicity,4,NA,NA,observed in one of the initial 3 patients
11728688,NA,184,any Grade 3 toxicity,3,NA,NA,observed in two patients
14758140,NA,185,neutropenia,4,> 7 days,NA,NA
14758140,NA,185,febrile neutropenia,NA,NA,NA,NA
14758140,NA,185,thrombocytopenia,4,NA,NA,NA
14758140,NA,185,thrombocytopenia,3,NA,NA,with bleeding
14758140,NA,185,nonhematologic toxicity,>=3,NA,FALSE,NA
12504047,NA,186,hematologic toxicity,4,NA,NA,NA
12504047,NA,186,nonhematologic toxicities,>=3,NA,NA,NA
15484216,NA,187,platelet toxicity,4,NA,NA,NA
15484216,NA,187,hemoglobin toxicity,4,NA,NA,NA
15484216,NA,187,leukocytopenia,4,NA,NA,NA
15484216,NA,187,granulocytopenia,4,> 5 days,NA,NA
15484216,NA,187,ebrile neutropenia,NA,NA,NA,NA
15484216,NA,187,nonhematologic toxicity,3 or 4,NA,NA,NA
15484216,NA,187,any side effect that required  2 weeks to regress to Grade 1,4,NA,NA,NA
12702534,NA,188,non-hematological toxicity,3 or 4,NA,FALSE,NA
12702534,NA,188,ANC of <0.5 Ã— 10^9 cells/l,NA,lasting >5 days,NA,NA
12702534,NA,188,ANC of <0.5 Ã— 10^9 cells/l,NA,NA,NA,associated with fever or infection
12702534,NA,188,a platelet count of <25 Ã— 10^9 cells/l,NA,any duration,NA,NA
12140144,NA,189,Not Given,4,NA,NA,NA
16150481,NA,190,an absolute neutrophil count (ANC) of <500/mm^3,NA,> 5 days,NA,NA
16150481,NA,190,an absolute neutrophil count (ANC) of <500/mm^3,NA,NA,NA,a neutropenic fever
16150481,NA,190,"a platelet count <40,000/mm^3",NA,> 5 days,NA,NA
16150481,NA,190,"bleeding with a count <40,000/mm^3",NA,NA,NA,NA
16150481,NA,190,a delay of more than 7 days in initiation of subsequent treatment,NA,NA,NA,NA
16150481,NA,190,any grade 3 â€“ 4 (and selected grade 2) events occurring in two patients,3 or 4,NA,NA,NA
16150481,NA,190,Unresolved non-hematologic toxicity resulting in treatment delay of more than 7 days,NA,NA,NA,NA
12540024,NA,191,reversible hematologic or nonhematologic toxicity,4,NA,NA,NA
14533441,NA,192,an absolute neutrophil count (ANC) <500/ul,NA,NA,NA,NA
14533441,NA,192,"febrile neutropenia fever >38 C with ANC <500/ul,",NA,NA,NA,NA
14533441,NA,192,"platelet count < 25,000/ul",NA,NA,NA,NA
14533441,NA,192,diarrhea,>=2,NA,NA,NA
14533441,NA,192,nonhematologic toxicity,>=3,NA,NA,NA
11157033,NA,193,radiation-related mucosal toxicity,>=4,NA,NA,RTOG scale
11157033,NA,193,radiation-related oropharyngeal toxicity,>=4,NA,NA,RTOG scale
11157033,NA,193,radiation-related skin toxicity,>=4,NA,NA,RTOG scale
11157033,NA,193,Any toxicity,>= 3,NA,NA,WHO scale
12003196,NA,194,non-hematologic toxicity,3 or 4,NA,FALSE,WHO scale
12003196,NA,194,neutropenia,4,NA,NA,NA
12003196,NA,194,thrombocytopenia,4,NA,NA,NA
12003196,NA,194,febrile neutropenia,4,NA,NA,NA
12003196,NA,194,A delay >1 week between the first and second cycles due to toxicity,4,NA,NA,NA
12201494,NA,195,neutropenia,3 or 4,NA,NA,NA
12201494,NA,195,thrombocytopenia,3 or 4,NA,NA,NA
12201494,NA,195,febrile neutropenia,NA,NA,NA,NA
12201494,NA,195,non hematological toxicity,3 or 4,NA,FALSE,NA
12201494,NA,195,delay longer than 1 week due to toxicity between the first and the second cycles,4,> 1 week,NA,NA
12419757,NA,196,neutropenia,4,> 7 days,NA,NA
12419757,NA,196,neutropenia,4,NA,NA,any episode of febrile neutropenia
12419757,NA,196,thrombocytopenia,3 or 4,NA,NA,NA
12419757,NA,196,a â‰¥14 day delay in the start of the subsequent cycle due to any toxicity,NA,NA,NA,NA
12419757,NA,196,non-hematological toxicity,3 or 4,NA,FALSE,NA
11810040,NA,197,thrombocytopenia,4,NA,NA,NA
11810040,NA,197,neutropenia,4,NA,NA,NA
11810040,NA,197,anemia,3 or 4,NA,NA,NA
11810040,NA,197,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11810040,NA,197,neutropenic fever,NA,NA,NA,>38.5 C
11810040,NA,197,bleeding,NA,NA,NA,NA
11810040,NA,197,omission of chemotherapy administation on day 8,NA,NA,NA,NA
11810040,NA,197,the delay of recycling on day 22,NA,NA,NA,NA
33052756,2018-000482-36,198,Any grade 4 toxicity adverse event,4,in the first cycle of treatment,NA,NA
33052756,2018-000482-36,198,neutropenia,4,NA,NA,AVC<500/L
33052756,2018-000482-36,198,anemia,4,NA,NA,Hb<80g/L
33052756,2018-000482-36,198,thrombocytopenia,4,NA,NA,platelet count <10x109/L with hypocellular bone marrow (<5%) after 35 thday of treatment
33052756,2018-000482-36,198,Any grade 3 adverse event,3,NA,NA,NA
33052756,2018-000482-36,198,Any treatment related effect resulting in missing 3 oral ORY-1001 doses in the 28-day treatment period,NA,NA,NA,NA
33052756,2018-000482-36,198,any treatment-related non haematologic toxicity delaying initiation of the second oral ORY-1001 cycle by longer than 14 days,4,NA,NA,NA
25977344,NCT01295827,199,nonhematologic toxicity,4,NA,NA,NA
25977344,NCT01295827,199,nonhematologic toxicity,3,lasting > 3 days,NA,despite optimal supportive care
25977344,NCT01295827,199,nonhematologic laboratory value,3,persisted for > 1 weeks,NA,NA
25977344,NCT01295827,199,nonhematologic laboratory value,3,NA,NA,required medical intervention or hospitalization
25977344,NCT01295827,199,febrile neutropenia,>=3,NA,NA,NA
25977344,NCT01295827,199,thrombocytopenia,4,NA,NA,requiring platelet transfusion or leading to a life-threatening bleeding event
12562660,NA,200,neutropenia with fever >38.2Â°C,3 or 4,NA,NA,NA
12562660,NA,200,non-hematological toxicity,3 or 4,NA,FALSE,NA
12562660,NA,200,any treatment delay because of toxicity,4,NA,NA,NA
15125746,NA,201,hematologic toxicity,4,NA,NA,NA
15125746,NA,201,nonhematologic toxicity,3,NA,FALSE,NA
15125746,NA,201,dermatitis,3,NA,NA,NA
15125746,NA,201,desquamation appearing within the first 3 weeks of radiation,3,NA,NA,NA
14533444,NA,202,neutropenia,4,lasting >= 4 days with fever >= grade 2 or infection >= grade 3,NA,ANC <0.5 *10^9/L
14533444,NA,202,thrombocytopenia,4,NA,NA,nadir platelets < 25 *10^9/L
14533444,NA,202,nonhematologic toxicity,3 or 4,NA,FALSE,NA
14533444,NA,202,vomiting,3 or 4,NA,NA,in patients who have received prophylaxis and treatment with an optimal antiemetic regimen.
14533444,NA,202,diarrhea,3 or 4,NA,NA,in patients who have received an optimal antidiarrheal regimen.
14533444,NA,202,"Treatment delay . 2 weeks due to unresolved toxicity in patients who experienced at least grade 3 thrombocytopenia, grade 4 neutropenia, or any grade 2 nonhematologic toxicity",NA,NA,FALSE,NA
15349753,NA,203,nonhematologic toxicity,>=3,NA,FALSE,NA
15349753,NA,203,neurologic or pulmonary toxicity,>=2,NA,NA,NA
15349753,NA,203,neutropenia,4,persisting beyond 28 days,NA,NA
15349753,NA,203,thrombocytopenia,4,persisting beyond 28 days,NA,NA
15349753,NA,204,nonhematologic toxicity,>=3,NA,FALSE,NA
15349753,NA,204,neurologic or pulmonary toxicity,>=2,NA,NA,NA
12881394,NA,205,hematological toxicity,4,NA,NA,NA
12881394,NA,205,neutropenia with fever,3,NA,NA,NA
12881394,NA,205,diarrhea,4,NA,NA,NA
12881394,NA,205,cystitis,4,NA,NA,NA
12881394,NA,205,rectitis,4,NA,NA,NA
12881394,NA,205,skin toxicity inside the radiotherapy field,4,NA,NA,NA
12881394,NA,205,non-hematological toxicity,>=3,NA,NA,NA
12881394,NA,205,any toxicity,NA,lasting >2 weeks,FALSE,NA
11458814,NA,206,neutropenia,4,> 5 days,NA,NA
11458814,NA,206,neutropenia with fever,4,NA,NA,NA
11458814,NA,206,thrombocytopenia,4,NA,NA,NA
11458814,NA,206,nonhematologic,3,NA,FALSE,NA
16327288,NA,207,"white blood cell count <1,000/mm3",NA,NA,NA,NA
16327288,NA,207,neutrophil count <500/ mm3,NA,NA,NA,NA
16327288,NA,207,"platelet count <30,000/mm3",NA,NA,NA,NA
16327288,NA,207,prolonged nonhematologic toxicity,3,NA,FALSE,NA
16327288,NA,207,appetite loss and general malaise over 1 week,1,NA,NA,NA
11172947,NA,208,hematotoxicity,4,NA,NA,NA
11172947,NA,208,other organ toxicity,>=3,NA,FALSE,NA
15226322,NA,209,neutropenia,4,NA,NA,NA
15226322,NA,209,thrombocytopenia,4,NA,NA,NA
15226322,NA,209,febrile neutropenia,4,NA,NA,NA
15226322,NA,209,nonhematologic toxicity,>=3,NA,FALSE,NA
12394252,NA,210,leukopenia,4,NA,NA,NA
12394252,NA,210,thrombocytopenia,4,NA,NA,NA
12394252,NA,210,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16012794,NA,211,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16012794,NA,211,neutropenia,4,NA,NA,NA
16012794,NA,211,febrile neutropenia,NA,NA,NA,ANC <1.0 Ã— 10^9/l concurrent with fever (defined as one oral temperature measurement of â‰¥38.5 C or three oral temperature measurements of â‰¥38.0 C in a24-hour period)
16012794,NA,211,thrombocytopenia,3 or 4,NA,NA,NA
16012794,NA,211,thrombocytopenia,NA,NA,NA,any grade associated with bleeding
16012794,NA,211,absence of recovery of neutrophils (ANC < 1.0Ã—10^9/l) and/or platelets (platelets <100Ã—10^9/l),4,at Day 28,NA,NA
16012794,NA,211,any grade 2 and more toxicity,>2,NA,FALSE,NA
15714201,NA,212,Haematological toxicities,4,NA,NA,WHO scale
15714201,NA,212,All other toxicities,>=3,NA,NA,WHO scale
12182983,NA,213,hematologic toxicity,4,NA,NA,NA
12182983,NA,213,Grade 3 nonhematologic toxicity,3,NA,NA,NA
16251868,NA,214,nonhaematological toxicity,>=3,NA,FALSE,NA
16251868,NA,214,granulocytopenia,4,lasting >5 days,NA,associated with fever/infection
16251868,NA,214,thrombocytopenia,4,NA,NA,NA
16251868,NA,214,interruption of tipifarnib dosing,NA,> 4 days,NA,NA
16251868,NA,214,neurotoxicity,>=2,NA,NA,did not improve to grade 1 or less within 3 weeks
16251868,NA,214,ototoxicity,>=2,NA,NA,did not improve to grade 1 or less within 3 weeks
12481889,NA,215,Any toxicity,4,NA,NA,NA
12481889,NA,215,toxicities that did not resolve within 2 weeks,3,NA,NA,NA
12481889,NA,215,Resolved life-threatening grade III toxicities,3,NA,NA,NA
15165093,NA,216,non-hematologic toxicity,3 or 4,NA,NA,NA
15165093,NA,216,hematologic toxicity,4,NA,NA,NA
12394268,NA,217,hematological WHO toxicity,>=3,lasting for more than 5 days,NA,NA
12394268,NA,217,febrile neutropenia,NA,NA,NA,NA
12394268,NA,217,non-hematological toxicity WHO toxicity,>=3,NA,NA,NA
14760128,NA,218,neutropenia,4,lasting at least 7 days,NA,NA
14760128,NA,218,febrile neutropenia,4,NA,NA,NA
14760128,NA,218,thrombocytopenia,4,NA,NA,NA
14760128,NA,218,nephrotoxicity,>=2,NA,NA,NA
14760128,NA,218,non-hematological toxicity,3 or 4,NA,FALSE,NA
14760128,NA,218,Prolonged nausea/vomiting,NA,"persisted for >1 week despite an adapted anti-emetic regimen, and any other oxicity that required dose reduction or treatment discontinuation",NA,NA
12499100,NA,219,a WBC count less than 1000/ul or neutrophil count less than 500/ul,NA,lasting more than 3 days,NA,NA
12499100,NA,219,a platelet count less than 25000/ul,NA,NA,NA,NA
12499100,NA,219,febrile neutropenia,3,NA,NA,NA
12499100,NA,219,any grade 3 nonhematologic toxicity,3,NA,FALSE,NA
12499100,NA,219,a serum creatinine level greater than 2.0 mg/dl,NA,NA,NA,NA
12643004,NA,220,an absolute granulocyte nadir of < 500/uL,NA,> 5 days,NA,NA
12643004,NA,220,febrile neutropenia,NA,NA,NA,NA
12643004,NA,220,platelet nadir </25000/uL,1,NA,NA,NA
12643004,NA,220,nonhematological toxicity,>=3,NA,NA,NA
12393998,NA,221,neutropenia,4,> 5 days,NA,NA
12393998,NA,221,neutropenia,4,NA,NA,with fever
12393998,NA,221,thrombocytopenia,4,NA,NA,NA
12393998,NA,221,nonhematologic toxicity,3,NA,NA,NA
15493356,NA,222,neutropenia,4,lasting > 5 days,NA,AGC < 0.5*10^9/L
15493356,NA,222,neutropenia,4,NA,NA,with fever (T > 100.5) or infection
15493356,NA,222,Thrombocytopenia,NA,NA,NA,nadir < 25*10^9/L
15493356,NA,222,nonhematologic toxicity,3 or 4,NA,FALSE,NA
15493356,NA,222,nausea/vomiting,3 or 4,NA,NA,who have received prophylaxis and treatment with an optimal antiemetic regimen not controllable by treatment with antiemetics
15493356,NA,222,Treatment delay >2 weeks due to unresolved toxicity,NA,NA,NA,"who experienced at least Grade 3 thrombocytopenia, Grade 4 neutropenia, or any Grade 3 nonhematologic toxicity"
11821464,NA,223,nonhematologic toxicity if observed in one patient,3,NA,NA,NA
11821464,NA,223,hematologic toxicity if observed in one patient,4,NA,NA,NA
11821464,NA,223,nonhematologic toxicity if observed at least in two patients at the same dose level,2,NA,NA,NA
11821464,NA,223,hematologic toxicity if observed at least in two patients at the same dose level,3,NA,NA,NA
11593051,NA,224,thrombocytopenia,4,NA,NA,NA
11593051,NA,224,neutropenia,4,NA,NA,NA
11593051,NA,224,non-hematologic toxicity,>=3,NA,NA,NA
16222156,NA,225,Not defined,4,NA,NA,NA
15380578,NA,226,WHO Grade 4 hematologic toxicity,4,NA,NA,NA
15380578,NA,226,Grade 3 nonhematologic toxicity,3,NA,NA,NA
15380578,NA,226,neutropenia associated with >Grade 2 infection,3,NA,NA,NA
15380578,NA,226,neutropenia associated with>Grade 2 diarrhea,3,NA,NA,NA
11804180,NA,227,granulocytopenia,4,>. 1 week,NA,NA
11804180,NA,227,thrombocytopenia,4,NA,NA,NA
11804180,NA,227,febrile neutropenia,NA,NA,NA,NA
11804180,NA,227,diarrhea,3 or 4,NA,NA,NA
11804180,NA,227,constipation,3 or 4,NA,NA,NA
11804180,NA,227,fever,3 or 4,NA,NA,NA
11804180,NA,227,myalgia/arthralgia,3 or 4,NA,NA,NA
11804180,NA,227,fatigue,3 or 4,NA,NA,NA
11804180,NA,227,other toxicity,3 or 4,NA,FALSE,NA
11804180,NA,227,persistence of grade 2 or higher nonhematological toxicity on day 21,2,NA,FALSE,NA
11899362,NA,228,absolute neutrophil count (ANC) nadir < 500/Î¼L,NA,NA,NA,NA
11899362,NA,228,"platelet nadir < 50,000/Î¼L",NA,NA,NA,NA
11899362,NA,228,nonhematological toxicity,>=2,NA,NA,for the accelerated escalation portion of the study
11899362,NA,228,nonhematologic toxicity,3 or 4,NA,NA,during the standard dose escalation portion of the study
15245938,NA,229,neutropenia,>=4,NA,NA,NA
15245938,NA,229,thrombocytopenia,>=4,NA,NA,NA
15245938,NA,229,nonhematologic toxicity,>=3,NA,FALSE,NA
11704320,NA,230,toxicities,3 or 4,NA,NA,NA
27544076,NCT01451437,237,non-hematological toxicity,>=3,NA,FALSE,NA
27544076,NCT01451437,237,neutropenia,NA,"by Day 42 or Day 35 for the 7 on/7 off and 7 on/14 off schedules, respectively, and lasting >6 weeks in the context of no morphological evidence of recurrent or residual acute leukemia at Day 28",NA,NA
27544076,NCT01451437,237,thrombocytopenia,NA,"by Day 42 or Day 35 for the 7 on/7 off and 7 on/14 off schedules, respectively, and lasting >6 weeks in the context of no morphological evidence of recurrent or residual acute leukemia at Day 28",NA,NA
25854284,NCT00839982,241,non-haematological and non-infectious toxicities,>=3,NA,FALSE,NA
25854284,NCT00839982,241,"Prolonged haematopoietic recovery (absolute neutrophil count <15 9 109/l for >49 d not due to residual leukaemia, recurrent leukaemia, or additional cytotoxic therapy)",NA,NA,NA,NA
32009149,NCT01514201,242,any interruption of irradiation related to protocol therapy for 5 consecutive or 10 cumulative days,NA,NA,NA,NA
32009149,NCT01514201,242,any grade 4 non-hematologic toxicity,4,NA,NA,NA
32009149,NCT01514201,242,nonhematologic toxicity,2,persisting for >7Â  days,NA,NA
32009149,NCT01514201,242,non-hematologic toxicity,3,NA,FALSE,NA
32009149,NCT01514201,242,neutropenia,4,NA,NA,NA
32009149,NCT01514201,242,thrombocytopenia,3,NA,NA,NA
32002547,NCT01120639,243,CNS toxicity,>=3,NA,NA,NA
26333381,NCT00993239,246,neutropenia,4,>7 days,NA,ANC < 500/mm3
26333381,NCT00993239,246,neutropenia with fever,3 or 4,NA,NA,NA
26333381,NCT00993239,246,thrombocytopenia,4,NA,NA,"<25,000/mm3"
26333381,NCT00993239,246,nausea,>=3,NA,NA,despite maximal anti-emetic treatment
26333381,NCT00993239,246,vomiting,>=3,NA,NA,despite maximal anti-emetic treatment
26333381,NCT00993239,246,diarrhea,>=3,NA,NA,despite maximal antidiarrheal treatment
26333381,NCT00993239,246,any other non-hematologic or laboratory AE,>=3,NA,FALSE,NA
28434648,NCT01658878,247,Dose-limiting toxicities were determined on the basis of the incidence and intensity of adverse events occurring up to 2 weeks after the third nivolumab dose.,NA,NA,NA,NA
28434648,NCT01658878,248,Dose-limiting toxicities were determined on the basis of the incidence and intensity of adverse events occurring up to 2 weeks after the third nivolumab dose.,NA,NA,NA,NA
28434648,NCT01658878,249,Dose-limiting toxicities were determined on the basis of the incidence and intensity of adverse events occurring up to 2 weeks after the third nivolumab dose.,NA,NA,NA,NA
22648179,NCT00932373,250,"nonhematologic, nonhepatic major organ AE",>=3,NA,NA,NA
22648179,NCT00932373,250,"thrombocytopenia, neutropenia",>=4,NA,NA,NA
22648179,NCT00932373,250, anemia,>=4,NA,NA,NA
22648179,NCT00932373,250,increases in serum bilirubin,>=3,NA,NA,NA
22648179,NCT00932373,250,increases in hepatic enzymes,>=3,NA,NA,NA
22648179,NCT00932373,250,"an AE that led the investigator to hold treatment at either cycle 1, day 8, or both days 15 and 22.",NA,NA,NA,NA
27932068,NCT01901653,251,neutropenia,4,lasting â‰¥ 7 days,NA,NA
27932068,NCT01901653,251,febrile neutropenia,4,NA,NA,NA
27932068,NCT01901653,251,abnormal laboratory values ,3,NA,FALSE,NA
27932068,NCT01901653,251,thrombocytopenia ,4,NA,NA,NA
27932068,NCT01901653,251,anemia,4,NA,NA,NA
27932068,NCT01901653,251,AST/ALT > 3x ULN AND concomitant Bilirubin > 2x UNL,NA,NA,NA,NA
27932068,NCT01901653,251,non-laboratory toxicity;,>=3,NA,FALSE,NA
25924991,NCT01165216,1,ANC decrease,4,NA,NA,NA
25924991,NCT01165216,1,febrile neutropenia lasting,3,NA,NA,NA
25924991,NCT01165216,1,platelet count decrease,4,NA,NA,NA
25924991,NCT01165216,1,platelet count decrease,3,NA,NA,NA
25924991,NCT01165216,1,"higher nausea, vomiting, and/or diarrhea",>=3,NA,NA,NA
25924991,NCT01165216,1,AST/ALT levels not resolved,2,NA,NA,not resolved to grade 2 or less within 2 weeks of onset;
25924991,NCT01165216,1,rash,>=3,NA,NA,not resolved to grade 2 or less within 2 weeks of onset
25924991,NCT01165216,1,nonhematological toxicity,>=3,NA,NA,"except grade 3 fatigue, grade 3 asthenia, grade 3 transient arthralgia/myalgia, and grade 3 transient abnormal electrolyte"
25924991,NCT01165216,2,ANC decrease,4,NA,NA,NA
25924991,NCT01165216,2,febrile neutropenia lasting,3,NA,NA,NA
25924991,NCT01165216,2,platelet count decrease,4,NA,NA,NA
25924991,NCT01165216,2,platelet count decrease,3,NA,NA,NA
25924991,NCT01165216,2,"higher nausea, vomiting, and/or diarrhea",>=3,NA,NA,NA
25924991,NCT01165216,2,AST/ALT levels not resolved,2,NA,NA,not resolved to grade 2 or less within 2 weeks of onset;
25924991,NCT01165216,2,rash,>=3,NA,NA,not resolved to grade 2 or less within 2 weeks of onset
25924991,NCT01165216,2,nonhematological toxicity,>=3,NA,NA,"except grade 3 fatigue, grade 3 asthenia, grade 3 transient arthralgia/myalgia, and grade 3 transient abnormal electrolyte"
25794535,NCT00969761,1,nonhematologic toxicity,>=3,NA,NA,Apply to Combination ID2
25794535,NCT00969761,1,"hematologic toxicityï¼ˆdecreased white blood cells, platelets, neutrophils, or lymphocytes, other blood and lymphatic system disorders, anemia, febrile neutropenia, coagulation, and hemorrhageï¼‰",>=4,NA,NA,Apply to Combination ID2
21069335,NCT00684099,1,neutropenia,4,NA,NA,NA
21069335,NCT00684099,1,thrombocytopenia,4,NA,NA,NA
21069335,NCT00684099,1,neutropenia,>=3,NA,NA,with fever >38.3Â°C or sustained temperature >38Â°C for more than 1 h
21069335,NCT00684099,1,non-hematologic toxicity,>=3,NA,NA,NA
21481618,NA,1,neutropenia,>=3,lasting for 5 days,NA,NA
21481618,NA,1,neutropenia associated withfever,4,NA,NA,NA
21481618,NA,1,thrombocytopenia,>=3,>5days,NA,NA
21481618,NA,1,non-hematologic,>3,NA,TRUE,NA
21481618,NA,1,toxicity(ANC<500/mm3),4,NA,NA,phase 1b
21481618,NA,1,febrile neutropenia,4,NA,NA,phase 1b
21481618,NA,1,"platelet count <=25,000/mm3",NA,>=7days,NA,phase 1b
21481618,NA,1,"platelet count<=50,000/mm3 with associated severe and lifethreatening (or intracranial) bleeding,",NA,NA,NA,phase 1b
21481618,NA,1,non-hematologic,>=3,NA,TRUE,phase 1b
23942080,NA,1,events,>=3,NA,TRUE,NA
23942080,NA,1,PX-866-related toxicity,NA,">2-week delay in the start
of cycle 2 or 3",NA,NA
23942080,NA,1,neutropenia with fever,>=3,NA,NA,platelets<25 000 per ul; absolute neutrophil count <500 per ul for >7 days
23942080,NA,1,transaminitis,3,>7 days,NA,NA
23942080,NA,1, increase in serum glucose,>3,NA,NA,despite optimal therapy
22828917,NA,1,nonhematologic toxicity,>=3,NA,NA,NA
22828917,NA,1,neutropenia,4,lasting >7 days,NA,NA
22828917,NA,1,febrile neutropenia,>=3,NA,NA,NA
22828917,NA,1,infection neutropenia,>=3,NA,NA,NA
22828917,NA,1,thrombocytopenia,4,NA,NA,NA
22828917,NA,1,allergicreaction/hypersensitivity,>=3,NA,NA,NA
22828917,NA,1,cytokine release syndrome/acuteinfusion reaction,>=3,NA,NA,NA
22828917,NA,2,neutropenia,4,lasting >7 days,NA,NA
22828917,NA,2,febrile neutropenia,>=3,NA,NA,NA
22828917,NA,2,infection neutropenia,>=3,NA,NA,NA
22828917,NA,2,thrombocytopenia,4,NA,NA,NA
22828917,NA,2,allergicreaction/hypersensitivity,>=3,NA,NA,NA
22828917,NA,2,cytokine release syndrome/acuteinfusion reaction,>=3,NA,NA,NA
21792569,NA,1,toxicity,4,lasting more than 7 days,NA,NA
21792569,NA,1,toxicity,3,NA,NA,did not recover within 10 days
23553066,NCT00732745,1,diarrhea,4,NA,NA,DLT in combination1 is same as in Combination2
23553066,NCT00732745,1,diarrhea,3,NA,NA,despite treatment with optimal anti-diarrheal therapy
23553066,NCT00732745,1,nausea/vomiting,4,NA,NA,NA
23553066,NCT00732745,1,nausea/vomiting,3,NA,NA,"despite optimal
antinausea management"
23553066,NCT00732745,1,skin rash,>=3,NA,NA,NA
23553066,NCT00732745,1,neutropenia,4,NA,NA,lasting more than 5 days
23553066,NCT00732745,1,thrombocytopenia,4,NA,NA,NA
23553066,NCT00732745,1,greater neurotoxicity,2,NA,NA,"which did not recover before the next
cycle of therapy"
22124669,NCT00058253,1,neutropenia,4,lasting greater than 7 days,NA,"(defined
as 2 or more consecutive CBC with diVerentials documenting grade 4 neutropenia drawn Â¸8 days apart)"
22124669,NCT00058253,1,Febrile neutropenia,NA,NA,NA,"(ANC < 1,000/mm3
 and temperature Â¸38.5Â°C)"
22124669,NCT00058253,1,thrombocytopenia,>=3,NA,NA,NA
22124669,NCT00058253,1,"higher neurologic, gastrointestinal, or cardiovasculartoxicities",>=3,NA,NA,NA
22124669,NCT00058253,1,QTc interval prolongation,>=3,NA,NA,(QTc > 0.50 s)
23712328,NA,1,non-hematologic toxicity,3,NA,NA,"not resolving to grade 2 or less
within 96 h"
23712328,NA,1,any  toxicity,4,NA,NA,NA
22042372,NA,1,treatment-related toxicity  otherthan hematologic toxicity,>=3,NA,NA,NA
22042372,NA,1,hematologic toxicity,4,NA,NA,"during the phase I portion, any interstitial lung disease
that was considered treatment-related."
22999386,NA,1,non-haematological toxicity,>=3,NA,NA,"defined by the NCI CTCAE version 3 (with the exclusion of alopecia, nausea, vomiting or infusion-related
reaction);clinical heart failure"
22999386,NA,1,neutropenia,NA,"lasting for
P7 days",NA,"absolute neutrophil count (ANC) < 0.5*10^9
/L"""
22999386,NA,1,febrile neutropenia,NA,NA,NA,"ANC < 1.0  109
/L and fever P38.5 C"
22999386,NA,1,thrombocytopenia,NA,NA,NA,"thrombocytopenia 625,000/ll;thrombocytopenic bleeding requiring transfusion."
20087171,NA,1,nonhaematological toxicity,>=3,NA,FALSE,NA
20087171,NA,1,neutropenia,4,more than 7 days,NA,NA
20087171,NA,1,febrile neutropenia,NA,NA,NA,"(fever > 38.5 and absolute neutrophil count < 0.5*10^9
/l
requiring hospitalization)"
20087171,NA,1,thrombocytopenia,4,NA,NA,NA
20087171,NA,1, bleeding episode requiring platelet transfusion,NA,NA,NA,NA
22989664,NA,1,neutropenia,4,"lasting for more
than 7 consecutive days",NA,NA
22989664,NA,1,febrile neutropenia,NA,NA,NA,NA
22989664,NA,1,thrombocytopenia,4,NA,NA,NA
22989664,NA,1,non-hematological toxicity,>=3,NA,TRUE,NA
20530449,NA,1,hematological toxicity,4,NA,NA,NA
20530449,NA,1,nonhematological toxicity,3,NA,NA,NA
21892109,NA,1,thrombocytopenia,4,NA,NA,NA
21892109,NA,1,thrombocytopenia,3,lasting greater than 7 days,NA,"associated with bleeding, transfusion requirement"
21892109,NA,1,febrileneutropenia,NA,NA,NA,NA
21892109,NA,1,neutropenia,4,"greater than 7 days
duration",NA,NA
21892109,NA,1,peripheral neuropathy,>=3,NA,NA,NA
21892109,NA,1,nonhematological toxicity,>=3,NA,TRUE,NA
21075438,NA,1,neutropenia,4,without fever of N7 days,NA,NA
21075438,NA,1,neutropenia,>=3,NA,NA,"associated
with feverr (â‰¥38.5 Â°C)"
21075438,NA,1,thrombocytopenia,4,NA,NA,"(plateletsâ‰¤10,000/Î¼m)"
21075438,NA,1,thrombocytopenia,>=3,NA,NA,"(plateletsâ‰¤50,000/Î¼m) associated with bleeding requiring platelet
transfusion"
21075438,NA,1,non-hematological toxicity,>=3,NA,TRUE,NA
21075438,NA,1,any treatment-related toxicity,NA,NA,NA,"causing a delay of
N14 days."
20564143,NA,1,neutropenia associated with fever,4,NA,NA,NA
20564143,NA,1,neutropenia,4,"lasting
>7 days",NA,NA
20564143,NA,1,thrombocytopenia,4,NA,NA,NA
20564143,NA,1,nonhematological toxicity,>=3,NA,NA,NA
20564143,NA,1,toxicity-related delay of >2 weeksto initiate Cycle 2,NA,NA,NA,NA
21327495,NA,1,hematologic,4,duration >7 days,NA,NA
21327495,NA,1,non-hematologic,>=3,NA,TRUE,NA
21327495,NA,1,"nausea, vomiting,or diarrhea",>=3,NA,NA,"if not controlled
with optimal supportive care and/or prophylaxis"
21327495,NA,1,anytreatment delay >14 days secondary to recovery from drugrelated adverse events,NA,NA,NA,NA
22872523,NA,1,hematologic,3 or 4,NA,NA,combination ID2 has the same with all DLTs below
22872523,NA,1,nonhematologic toxicity,>=3,NA,FALSE,NA
22872523,NA,1,fatigue,3,>7 days,NA,NA
22872523,NA,1,fatigue,4,NA,NA,NA
22872523,NA,1,nausea,3 or 4,NA,NA,"despite
maximum supportive care"
22872523,NA,1,diarrhea,3 or 4,NA,NA,"despite
maximum supportive care"
22872523,NA,1,neutropenia withfever,3 or 4,NA,NA,NA
22872523,NA,1,neutropenia,4,NA,NA,NA
22872523,NA,1,thrombocytopenia,4,>7 days,NA,"platelet count<25*10^9
/L"
22872523,NA,1,anemia,4,NA,NA,NA
22872523,NA,1,hypertension,4,NA,NA,NA
22872523,NA,1,aspartateaminotransferase (AST) or alanine aminotransferase (ALT),NA,">10 times
the upper limit of normal.",NA,NA
20142723,NA,1,any nonhematologic toxicity,3,NA,NA,not reversible to grade 2 or less within 96 hours
20142723,NA,1,nonhematological toxicity,4,lasting more than 7 days,NA,NA
20142723,NA,1,neutropenia,4,lasting more than 7 days,NA,NA
20142723,NA,1,thrombocytopenia,4,lasting more than 7 days,NA,NA
21439816,NA,1,febrile neutropenia,NA,NA,NA,NA
21439816,NA,1,neutropenia,4,lasting for >=7 days,NA,NA
21439816,NA,1,thrombocytopenia,NA,lasting >=7 days,NA,NA
21439816,NA,1,thrombocytopenia with bleeding,NA,NA,NA,NA
21439816,NA,1,non-haematological toxicities,3 or 4,lasting >=7 days,TRUE,NA
21439816,NA,1,hypertension,>=3,NA,NA,"despite optimal treatment (i.e. combination
of 2 anti-hypertensives)"
21439816,NA,1,treatment discontinuation forP2 weeks because of drug related toxicity,NA,NA,NA,NA
23016517,NCT00225420,1,non-haematological,3 or 4,NA,NA,NA
23016517,NCT00225420,1,haematological toxicity,3 or 4,NA,NA,NA
22870147,NA,1,neutropenia,4,during administration of S-1,NA,NA
22870147,NA,1,neutropenia,4,"lasting longer
than 4 days following S-1 administration",NA,NA
22870147,NA,1,neutropenia with fever,3,NA,NA,NA
22870147,NA,1,thrombocytopenia,4,NA,NA,NA
22870147,NA,1,non-hematological toxicity,3 or 4,"other than nausea, vomiting or
fatigue",NA,NA
22870147,NA,1,delay of second cycle within 2 weeks,NA,NA,NA,NA
20407240,NA,1,hematologic,3 or 4,NA,NA,NA
20407240,NA,1,nonhematologic toxicity,3 or 4,NA,NA,NA
24018362,NA,1,non-hematologic toxicity,3 or 4,NA,NA,"(including
nausea and vomiting that could not be controlled with oral
medication)"
24018362,NA,1,hematologic toxicity,4,NA,NA,NA
22752248,NA,1,neutropenia,4,lasting >7 days,NA,NA
22752248,NA,1,neutropenia,>=3,NA,NA,"with sepsis or oral
temperature of C38.5 C"
22752248,NA,1,thrombocytopenia withbleeding,3,NA,NA,NA
22752248,NA,1,thrombocytopenia,4,NA,NA,NA
22752248,NA,1,non-hematological toxicities,4,NA,NA,NA
22752248,NA,1,non-hematological toxicities,3,NA,FALSE,"related to the study regimen and requiring sorafenib or
docetaxel dose modification"
20686817,NA,1,non-hematological toxicity,3,NA,TRUE,NA
20686817,NA,1,neutropenia,4,lasted >7 days,NA,NA
20686817,NA,1,neutropenia,>=3,NA,NA,associated with sepsis or fever >38Â°C
20686817,NA,1,thrombocytopenia,NA,NA,NA,"in starting cycle 2 (or
subsequent cycles)"
20686817,NA,1,toxicity-related delay more than 2 weeks in starting cycle 2 (orsubsequent cycles),NA,NA,NA,NA
20686817,NA,1,abnormal non-hematological,>=3,NA,NA,"clinically significant and
drug-related."
23482452,NA,1,non-hematologic toxicity,3,NA,NA,NA
23482452,NA,1,persistent vomiting despite the use of antiemetics,4,NA,NA,NA
23482452,NA,1,neutropenia,4,persisting for 4 days,NA,NA
23482452,NA,1,neutropenic fever,4,NA,NA,NA
23482452,NA,1,thrombocytopenia,3,NA,NA,NA
23482452,NA,1,thrombocytopenia witheither a bleeding tendency or requirement for transfusionof platelets.,3,NA,NA,NA
20530200,NA,1,febrile neutropenia,NA,lasting >4 days,NA,NA
20530200,NA,1,thrombocytopenia,4,"(<10 000/mm3
)",NA,NA
20530200,NA,1,vomiting,4,NA,NA,NA
20530200,NA,1,nonhematological toxic effect,3 or 4,NA,TRUE,NA
20530200,NA,1,cessation of treatment due to an adverse event,NA,NA,NA,NA
20530200,NA,1,treatment-related death.,NA,NA,NA,NA
21157450,NA,1,neutropaenia,4,NA,NA,"(neutrophil count <0.5 *10^9 per l)
of any duration"
21157450,NA,1,neutropaenia,3,NA,NA,NA
21157450,NA,1,thrombocytopaenia,4,NA,NA,"(platelet count
<10 *10^9 per l) of any duration"
21157450,NA,1,thrombocytopaenia with bleeding,3,NA,NA,(10 â€“49*10^9 per l)
21157450,NA,1,febrile neutropaenia,NA,NA,NA,NA
21157450,NA,1,radiation oesophagitis,4,NA,NA,NA
21157450,NA,1,any non-oesophagitis radiotherapy toxicity,3 or 4,NA,NA,NA
21157450,NA,1,any clinically significanttreatment-related toxicity outside the radiotherapyfield,3 or 4,NA,FALSE,NA
21157450,NA,1,interruption of radiotherapy for,NA,>1 week,NA,NA
21157450,NA,1,omission of chemotherapy,NA,>=1 week,NA,NA
21157450,NA,1,toxicity requiring >=2 chemotherapy dose reductions,NA,NA,NA,NA
20107799,NA,1,neutropenia,4,lasting more than 5 days,NA,accompanied by grade>=2 fever
20107799,NA,1,thrombocytopenia,4,NA,NA,NA
20107799,NA,1,non-hematologic toxicity,3,NA,NA,"resulting in
treatment interruption for more than 2 weeks"
20107799,NA,1,non-hematologic toxicity,4,NA,NA,NA
21493186,NA,1,neutropenia,4,>=5 days,NA,NA
21493186,NA,1,neutropenia,4,NA,NA,"associated with
fever >38Â°C"
21493186,NA,1,neutropenia,4,NA,NA,associated with >=grade 3 infection
21493186,NA,1,febrile neutropenia,NA,NA,NA,fever >=38.1Â°C with grade 3 or 4 neutropenia
21493186,NA,1,thrombocytopenia,4,NA,NA,NA
21493186,NA,1,symptomatic thrombocytopenia (bleeding),NA,NA,NA,NA
21493186,NA,1,mucositis,4,NA,NA,"causing a suspension of the radiotherapy >2
weeks;"
21493186,NA,1,mucositis,3 or 4,NA,NA,associated with grade 3 fatigue (with deterioration of performance status >=2
21493186,NA,1,mucositis,3 or 4,NA,NA,a decrease of 40% in the Karnofsky Index
21493186,NA,1,mucositis,3 or 4,NA,NA,grade 3 weight loss >=20% from baseline weight)
21493186,NA,1,vomiting regardless of appropriate treatmen,3 or 4,NA,NA,NA
21493186,NA,1,non-haematological toxicities,>=3,NA,TRUE,NA
21493186,NA,1,delayof treatment >2 weeks,NA,NA,NA,"due to non-resolved toxicity such
as grade 3 thrombocytopenia, grade 3 neutropenia or any
other grade 2 non-haematological toxicity (non-haematological, non-mucositis toxicity needed to have recovered to
<grade 2)"
23423490,NA,1,hematological toxicity,4,NA,NA,NA
23423490,NA,1,"transfusion of platelets for thrombocytopenia,",NA,NA,NA,NA
23423490,NA,1,neutropenia with infection,3,NA,NA,NA
23423490,NA,1,neutropenia with fever,3,NA,NA,NA
23423490,NA,1,non-hematological toxicity,3 or 4,NA,TRUE,NA
23423490,NA,1,treatment delay of more than 2 weeksfollowing the last administration of docetaxel,NA,NA,NA,NA
23033004,NA,1,non-haematological toxicities,3 or 4,NA,TRUE,NA
23033004,NA,1,haematological toxicities,4,NA,NA,NA
23033004,NA,1,"any adverse event requiring a break in administration of S-1 formore than 4 days during two courses,",NA,NA,NA,NA
23033004,NA,1,any adverse eventrequiring delayed administration of docetaxel for more than 8 daysduring the first three courses,NA,NA,NA,NA
23098625,NA,1,thrombocytopenia,4,NA,NA,"(platelets < 25 x 10^9
/L"
23098625,NA,1,haematological toxicity,4,lasted for five days or more,NA,"(haemoglobin < 65 g/L, neutrophils < 0.5 x 10^9
/L)"
23098625,NA,1,non-haematological toxicity,>=3,NA,NA,despite appropriate treatment
23098625,NA,1,neutropenicfever,NA,NA,NA,NA
23098625,NA,1,neurotoxicity,>=2,"that lasted one
week or more",NA,NA
23098625,NA,1,any toxicity thathad not resolved within two weeks of the end of cycleone,>=2,NA,NA,NA
23394629,NCT00374985,1,non-haematological toxicity,>=3,NA,FALSE,NA
23394629,NCT00374985,1,haematological toxicity,NA,during the RCT.,NA,"neutrophils < 0.5 Ã—
10^9
/l for a minimum of 7 days or temperature > 38.5Â°C,
thrombocytes < 25 Ã— 10^9
/l"
20628389,NA,1,gastrointestinal toxicity,>=3,NA,NA,"despite the use of adequate
medical intervention and/or prophylaxis;"
20628389,NA,1,toxicity not classified under CTCAE blood/bone marrow,>=3,NA,TRUE,NA
20628389,NA,1,g-glutamyl transpeptidase,4,NA,NA,NA
20628389,NA,1,neutropaenia,4,"persisting for >=7
consecutive days",NA,"(absolute neutrophil count<500 cells mm^(â€“3)); complicated by fever (body temperature
>38.0 â„ƒ or 100 â„‰) and requiring hospitalisation"
20628389,NA,1,asymptomatic mitral thickening (>5 mm) with mitral regurgitation greaterthan mild or valve gradient >5 mm Hg on echocardiogram,NA,NA,NA,"minor granulocytic and lymphocytic infiltration, oedema, and
deposition of myxomatous material was observed in the mitral
valve and subvalvular endocardium in preclinical testing"
20628389,NA,1,thrombocytopaenia,4,NA,NA,platelets <25 000 cells mm^(â€“ 3)
34070561,2604784,1,as any severechemotherapy-related,>=3,NA,NA,NA
33755379,2987244,1,non-hematological toxicity,>=3,NA,NA,NA
33755379,2987244,1,agranulocytosis with granulocyte colony-stimulating factorsuppor,4,NA,NA,NA
33755379,2987244,1,thrombocytopenia,4,lasting > 7 days,NA,NA
11051260,NA,1,neutropenia,4,"for 7 days or
more",NA,NA
11051260,NA,1,neutropenia,4,for 3 days,NA,associated with infection;accompanied by fever (>38Â°C)
11051260,NA,1, toxicity,>=3,NA,TRUE,NA
11408509,NA,1,febrile neutropenia,NA,NA,NA,NA
11408509,NA,1,prolonged neutropenia,NA,NA,NA,NA
11408509,NA,1,nonhematologic toxicity,3 or 4,NA,NA,NA
9053501,NA,1,neutropenia,4,NA,NA,fever > 38Â°C
9053501,NA,1,neutropenia,4,lasting greater than 7 days,NA,NA
9053501,NA,1,thrombocytopenia,4,NA,NA,nonrecovery of neutrophils to >=1.5 x 10^9/L or platelets to >= 50 x 10^9/L by day 21
9053501,NA,1,emesis/nausea,4,NA,NA,NA
9053501,NA,1,creatinine,2,NA,NA,"(1.6 to 3.0
times normal)"
9053501,NA,1,nonhematologic toxicity,3,NA,FALSE,NA
9440738,NA,1,neutropenia,3 or 4,NA,NA,NA
9440738,NA,1,thrombocytopenia,NA,NA,FALSE,NA
9440738,NA,1,neutropenic fever,NA,NA,NA,NA
9440738,NA,1,the need for a platelet transfusion,NA,NA,NA,NA
9440738,NA,1,nonhematologic toxicity,>=3,NA,NA,NA
9440738,NA,2,neutropenia,3 or 4,NA,NA,NA
9440738,NA,2,thrombocytopenia,NA,NA,FALSE,NA
9440738,NA,2,neutropenic fever,NA,NA,NA,NA
9440738,NA,2,the need for a platelet transfusion,NA,NA,NA,NA
9440738,NA,2,nonhematologic toxicity,>=3,NA,NA,NA
9440738,NA,3,neutropenia,3 or 4,NA,NA,NA
9440738,NA,3,thrombocytopenia,NA,NA,FALSE,NA
9440738,NA,3,neutropenic fever,NA,NA,NA,NA
9440738,NA,3,the need for a platelet transfusion,NA,NA,NA,NA
9440738,NA,3,nonhematologic toxicity,>=3,NA,NA,NA
9459161,NA,1,Common Toxicity Criteria (CTC),>=3,NA,FALSE,>= three patients at a given dose level.
9459161,NA,1,granulocytes< 0.5 x 1^09 1^(-1),NA,> 7 days,NA,NA
9459161,NA,1,granulocytes < 1.0 x 10^9 1^(-1) with fever>=38Â°C,NA,lasting > 3 days;,NA,NA
9459161,NA,1,platelets < 25 x 10^9 1^(-1),NA,NA,NA,NA
9459161,NA,1,infections,>=3,NA,NA,requiring hospitalization
9193350,NA,1,nonhematologictoxicity,3 or 4,NA,TRUE,NA
9193350,NA,1,neutropenia,4,NA,NA,<500/uL
9193350,NA,1,anemia,4,NA,NA,hemoglobin level < 6.5 g/dL
9193350,NA,1,thrombocytopenia,4,NA,FALSE,NA
9850032,NA,1,febrile neutropenia,NA,NA,NA,ANC <500/1 uL with fever >=38.2Â°C
9850032,NA,1,prolonged neutropenia,NA,NA,NA,"ANC < 500/uL
for > 5 days"
9850032,NA,1,severe thrombocytopenia,NA,NA,NA,"platelet nadir < 20,000/uL"
9850032,NA,1,delayed recovery from myelosuppression,NA,NA,NA,"day-l ANC < 1,500/uL,platelet count <100,000/uL"
9850032,NA,1,nonhematologic toxicity,4,NA,FALSE,NA
9850032,NA,1,nonhematologictoxicity,3,NA,FALSE,NA
9850032,NA,2,febrile neutropenia,NA,NA,NA,ANC <500/1 uL with fever >=38.2Â°C
9850032,NA,2,prolonged neutropenia,NA,NA,NA,"ANC < 500/uL
for > 5 days"
9850032,NA,2,severe thrombocytopenia,NA,NA,NA,"platelet nadir < 20,000/uL"
9850032,NA,2,delayed recovery from myelosuppression,NA,NA,NA,"day-l ANC < 1,500/uL,platelet count <100,000/uL"
9850032,NA,2,nonhematologic toxicity,4,NA,FALSE,NA
9850032,NA,2,nonhematologictoxicity,3,NA,FALSE,NA
10678557,NA,1,febrileneutropenia,4,NA,NA,fever >38.0 Â°C
10678557,NA,1,leukocytopenia,4,NA,NA,fever >38.0 Â°C
10678557,NA,1,neutropenia,4,NA,NA,NA
10678557,NA,1,leukocytopenia,4,lasting more than 5 days,NA,NA
10678557,NA,1,thrombocytopenia,4,NA,NA,NA
10811508,NA,1,neutropenia,4,lasting longer than seven days,NA,or ANC < 100 lasting longer than three
10811508,NA,1,febrile neutropenia,NA,NA,NA,NA
10811508,NA,1,thrombocytopenia,4,lasting,NA,NA
10811508,NA,1,non-hematologic toxicity,>=3,NA,FALSE,NA
10811508,NA,1,omission of day 8 chemotherapy administration,NA,NA,NA,NA
10811508,NA,1,any delay in recycling,NA,NA,NA,NA
10811508,NA,2,neutropenia,4,lasting longer than seven days,NA,or ANC < 100 lasting longer than three
10811508,NA,2,febrile neutropenia,NA,NA,NA,NA
10811508,NA,2,thrombocytopenia,4,lasting,NA,NA
10811508,NA,2,non-hematologic toxicity,>=3,NA,FALSE,NA
10811508,NA,2,omission of day 8 chemotherapy administration,NA,NA,NA,NA
10811508,NA,2,any delay in recycling,NA,NA,NA,NA
11051260,NA,1,neutropenia,4,NA,NA,"associated with infection for 3 days
accompanied by fever (.38Â°C)"
11051260,NA,1,higher toxicity,>=3,NA,TRUE,NA
11051260,NA,2,neutropenia,4,"for 7 days or
more",NA,NA
11051260,NA,2,neutropenia,4,NA,NA,"associated with infection for 3 days
accompanied by fever (.38Â°C)"
11051260,NA,2,higher toxicity,>=3,NA,TRUE,NA
10944133,NA,1,an absolute neutrophil count (ANC) less than 500/mL,NA,for>=3 days,NA,NA
10944133,NA,1,"leukocyte count<=1,000/mL",NA,for>=3 days,NA,NA
10944133,NA,1,febrile neutropenia ,NA,NA,NA,fever>38Â°C with ANC<500/mL
10944133,NA,1,"platelet count<=25,000/mL",NA,NA,NA,NA
10944133,NA,1,nonhematologic toxicity,>=3,NA,TRUE,NA
9060547,NA,1,toxicity,>=2,NA,FALSE,NA
9060547,NA,1,granulocyte count less than 0.5 x 10^9/L,NA,more than 7 days,NA,NA
9060547,NA,1,granulocyte count less than 0.5 x 10^9/L,NA,NA,NA,"fever>=38.5Â°C requiring IV antibiotics,
and no recovery to 1.5 x 10^9
/L on day 21 of treatment;"
9060547,NA,1,platelet count less than 25 x 10^9/L,NA,NA,NA,"without recovery to > 50 x 10^9/
L on day 21 of treatment occurring in more than 25% of courses at
a given dose level"
11032597,NA,1,neutropenia,NA,for 7 days or more,NA,absolute neutrophil count <=500/mL
11032597,NA,1,febrile neutropenia,4,NA,NA,"fever >= grade 2 with grade 4 neutropenia and
requiring IV antibiotics"
11032597,NA,1,thrombocytopenia,4,NA,NA,NA
11032597,NA,1,diarrhea,3 or 4,whatever duration,NA,"despite curative treatment (with loperamide and antibiotics), or patient required hospitalization for rehydration;"
11032597,NA,1,diarrhea,NA, lasting more than 7 days;,NA,any grade
11032597,NA,1,any othertoxicity,3 or 4,NA,FALSE,NA
10963645,NA,1,neutropenia,4,lasting at least 3 days,NA,NA
10963645,NA,1,neutropenia,4,NA,NA,"associated
with fever"
10963645,NA,1,thrombocytopenia,4,NA,NA,NA
10963645,NA,1,elevation of totalbilirubin,4,NA,NA,NA
10963645,NA,1,other nonhematologic toxicity,3,NA,TRUE,NA
11181674,NA,1,neutropenia,4,"more than 7
days despite G-CSF",NA,NA
11181674,NA,1,neutropenia,3 or 4,"with grade 2 fever lasting
more than 3 days",NA,NA
11181674,NA,1,a platelet count of less than 25*10^9/L,NA,NA,NA,NA
11181674,NA,1,infection,3 or 4,NA,NA,NA
11181674,NA,1,"elevation ofbilirubin, AST, ALT, or alkaline phosphatase",3 or 4,NA,NA,NA
11181674,NA,1,vomiting,4,NA,NA,NA
11181674,NA,1,diarrhea with prophylactic treatment,3 or 4,NA,NA,NA
11181674,NA,1,dermatitis,3,NA,NA,NA
11181674,NA,1,sensory or motor neuropathy,3,NA,NA,NA
9552034,NA,1,absolute neutrophil count (ANC) less than 500 cell/pL,NA,greater than 7 days,NA,NA
9552034,NA,1,"thrombocytopenia less than 20,000 cells/gL",NA,greater than 7 days,NA,NA
9552034,NA,1,"ANC less than 1,500 cells/pL or platelet count lessthan 100,000 cells/pL on day 28 of each cycle",NA,NA,NA,NA
9552034,NA,1,mucositis after 5-FU dose reduction,4,NA,NA,NA
9552034,NA,1,any other greater toxicity,>=3,NA,NA,NA
10416004,NA,1,neutropenia,4,"lasting longer than
two days",NA,NA
10416004,NA,1,thrombocytopenia,4,"""lasting longer than
two days""",NA,NA
10416004,NA,1,"neutropenia and fever > 38.2 ""C",NA,for more than 24 hours,NA,NA
10416004,NA,1,any non-hematologic toxicity,NA,"except nausea/vomiting or
alopecia",NA,NA
10416003,NA,1,ANC less than0.5 x 1O^9/1,NA,for more than seven days,NA,NA
10416003,NA,1,ANC less than 0.1 x 10^9/,NA,for more than seven days,NA,NA
10416003,NA,1,ANC less than 0.1 x 10^9/l,NA,more than three days,NA,NA
10416003,NA,1,febrile neutropenia,NA,NA,NA,"ANC <0.5 x 10^9
/l;and
single elevation in oral temperature to > 38.58 Â°C during a 24-hour
period)"
10416003,NA,1,mucositis,>=3,NA,NA,"failure of ANC recovery at day
of retreatment."
10416005,NA,1,neutropenia (ANC <500/ul),4,NA,FALSE,NA
10416005,NA,1,febrileneutropenia,NA,NA,FALSE,(grade 4 neutropenia + grade 2 fever requiring i.v. antibiotics and/or hospitalization)
10416005,NA,1,thrombocytopenia;,4,NA,NA,NA
10416005,NA,1,bleeding,3 or 4,NA,NA,NA
10416005,NA,1, infections,3 or 4,NA,NA,NA
10416005,NA,1,neurotoxicity,2,NA,NA,NA
10416005,NA,1,non-hematologic toxicity,3 or 4,NA,NA,NA
11137204,NA,1,thrombocytopenia,4,NA,NA,NA
11137204,NA,1,neutropenia,NA,"lasting
5 days or more",NA,NA
11137204,NA,1,febrile neutropenia,NA,NA,NA,NA
11137204,NA,1,any non-hematologic toxicity,>=3,NA,TRUE,NA
11137204,NA,2,thrombocytopenia,4,NA,NA,NA
11137204,NA,2,neutropenia,NA,"lasting
5 days or more",NA,NA
11137204,NA,2,febrile neutropenia,NA,NA,NA,NA
11137204,NA,2,any non-hematologic toxicity,>=3,NA,TRUE,NA
9989521,NA,1,any toxicity that enforced more than 1 week delay of radiotherapy in more than 50% of patients (in a cohort of 6 patients),NA,NA,NA,NA
9989521,NA,1,severe nonhematological toxicity,4-Feb,NA,NA,NA
9989521,NA,2,any toxicity that enforced more than 1 week delay of radiotherapy in more than 50% of patients (in a cohort of 6 patients),NA,NA,NA,NA
9989521,NA,3,severe nonhematological toxicity,4-Feb,NA,NA,NA
9989521,NA,3,any toxicity that enforced more than 1 week delay of radiotherapy in more than 50% of patients (in a cohort of 6 patients),NA,NA,NA,NA
9989521,NA,2,severe nonhematological toxicity,4-Feb,NA,NA,NA
11429197,NA,1,grade 3â€“4 leukopenia,NA,NA,NA,NA
11429197,NA,1,thrombocytopenia,NA,NA,NA,NA
11429197,NA,1,neutropenia with anemiaand neutropenic fever,4,NA,NA,NA
11429197,NA,1,non-hematologic toxicity,>=2,NA,TRUE,NA
11429197,NA,1,Omission ofchemotherapy on day 8 and/or 15,NA,NA,NA,NA
34669023,NA,1,clinically signifcant non-hematologic toxicity,>=3,NA,NA,NA
34669023,NA,1,neutropenia,4,lastingâ‰¥7 days,NA,NA
34669023,NA,1,neutropenia,4,NA,NA,"fever
ofâ‰¥38.5 Â°C"
34669023,NA,1,neutropenia,>=3,NA,NA,withâ‰¥grade 3 infection
34669023,NA,1,thrombocytopenia,4,NA,NA,NA
12954580,NA,1,thrombocytopenia,4,NA,NA,NA
12954580,NA,1,febrile neutropenia,NA,lasting >4 days,NA,fever >38Â°C with neutrophils â‰¤13000/mm3
12954580,NA,1,non-hematological toxicity,3 or 4,NA,FALSE,NA
15292922,NA,1,haematological toxicity,4,NA,NA,NA
15292922,NA,1,Nonhaematologicaltoxicity,>=3,NA,FALSE,NA
11557123,NA,1,neutropenia,4,"lasting for at
least 3 days",NA,NA
11557123,NA,1,thrombocytopenia,NA,"lasting for at
least 3 days",NA,NA
11557123,NA,1,febrile neutropenia,3 or 4,NA,NA,NA
11557123,NA,1,non-hematologic toxicity,3 or 4,NA,TRUE,NA
11557123,NA,1,any treatment delay due to toxicity,NA,NA,NA,NA
12452452,NA,1,mucositis,>=3,NA,NA,NA
12452452,NA,1,diarrhea,>=3,NA,NA,NA
12452452,NA,1,hand-foot syndrome,>=3,NA,NA,NA
11350887,NA,2,toxicity,3 or 4,NA,FALSE,NA
11350887,NA,3,toxicity,3 or 4,NA,FALSE,NA
11466671,NA,1,neutropenia,4,NA,NA,NA
11466671,NA,1,thrombocytopenia,NA,lasting 7 days or more,NA,NA
11466671,NA,1,hemorrhage,>=3,NA,NA,NA
11466671,NA,1,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11466671,NA,1,were prevented from receiving 100% of drug forthe next cycle on Day 22,NA,NA,NA,NA
11466671,NA,2,neutropenia,4,NA,NA,NA
11466671,NA,2,thrombocytopenia,NA,lasting 7 days or more,NA,NA
11466671,NA,2,hemorrhage,>=3,NA,NA,NA
11466671,NA,2,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11466671,NA,2,were prevented from receiving 100% of drug forthe next cycle on Day 22,NA,NA,NA,NA
12782942,NA,1,non-hematological toxicity,3 or 4,NA,FALSE,NA
12782942,NA,1,febrile leukopenia,3 or 4,NA,NA,NA
12782942,NA,1,absolute neutrophil count >500 cells/ml,3 or 4,"more than 5
days",NA,NA
12782942,NA,1,thrombocytopenia,3 or 4,NA,NA,NA
12782942,NA,1,any persistent grader 2 side-effect that caused treatment delay of 1 week intwo out of three patients enrolled at a single dose levelsince delay of recycling could cause a significantreduction in planned dose intensity,NA,NA,NA,NA
12419750,NA,1,hematological toxicity,4,for >7 days,NA,NA
12419750,NA,1,non-hematological toxicity,3 or 4,NA,NA,NA
12419750,NA,1,neutropenia with sepsis,3,NA,NA,NA
12621462,NA,1,stomatitis,3,"lasting
more than 1 week",NA,NA
12621462,NA,1,stomatitis,4,NA,NA,NA
12621462,NA,1,cardiotoxicity,2,NA,NA,(decrease of L-VEF >15%)
15218308,NA,1,ANC<500 cells/ul,NA,"for more than 7
days",NA,NA
15218308,NA,1,febrile neutropenia,NA,NA,NA,(ANC <500 cells/ÃŒl and fever >= 38.5Â°C)
15218308,NA,1,infection,NA,NA,NA,NA
15218308,NA,1,"ANC <1,500 cells/ul or platelets <100,000 cells/ul by day35",NA,NA,NA,NA
15218308,NA,1,thrombocytopenia,4,NA,NA,NA
15218308,NA,1,mucositis,3 or 4,"for more than 5
days",NA,NA
15218308,NA,1,nonhematologic toxicity,3 or 4,NA,NA,NA
15218308,NA,1,persistent toxicity,2,NA,FALSE,NA
15218308,NA,1,neuropathy,>=2,NA,NA,NA
12196358,NA,1,neutropenia,4,lasting >7 days,NA,"(absolute neutrophil count <500/mm3
)"
12196358,NA,1,thrombocytopenia,3,lasting at least 7 days,NA,"(platelet count <50000/
mm3"
12196358,NA,1,non-hematological toxicity,4,NA,FALSE,NA
11870176,NA,1,nonhematologic toxicity,4,NA,NA,NA
11870176,NA,1,neutropenia,4,NA,NA,NA
11870176,NA,1,nonhematologic toxicity,NA,"lasting for more than
7 days",NA,NA
11870176,NA,1,neutropenia,NA,"lasting for more than
7 days",NA,NA
11870176,NA,1,nonhematologic toxicity,NA,NA,NA,complicated with fever in half of the treated patients
11870176,NA,1,neutropenia,NA,NA,NA,complicated with fever in half of the treated patients
11900234,NA,1,locoregional toxicity,4,NA,NA,NA
15166622,NA,1,neutropenia,4,NA,NA,NA
15166622,NA,1,thrombocytopenia,4,NA,NA,NA
15166622,NA,1,febrile neutropenia,NA,NA,NA,NA
15166622,NA,1,thrombocytopenia,3,NA,NA,"associated with a bleeding
episode"
15166622,NA,1,any non-hematologic toxicity,3 or 4,NA,NA,NA
15138468,NA,1,leucopenia/neutropenia,4,NA,NA,NA
15138468,NA,1,thrombocytopenia,4,NA,NA,NA
15138468,NA,1,symptomatic thrombocytopenia (haemorrhage),NA,NA,NA,NA
15138468,NA,1,febrile neutropenia,3 or 4,NA,NA,NA
15138468,NA,1,nonhaematological toxicity,>=3,NA,FALSE,NA
11335910,NA,1,An absoluteneutrophil count (ANC) <500/mL or a white blood cellcount (WBC) <1000/mL for more than 5 days;,NA,NA,NA,NA
11335910,NA,1,febrile neutropenia,NA,NA,NA,NA
11335910,NA,1,failure to recover ANC (>1500/mm3) or WBC (>3000/mm3) in time after 4 weeks,NA,NA,NA,NA
11335910,NA,1,nonhematologic toxicities,3 or 4,NA,NA,NA
14998859,NA,1,neutrophil count of<500/Âµl,NA,for >5 days,NA,NA
14998859,NA,1,neutrophil count of<500/Âµl associated neutropenic fever of >38.5Â°C with infection,NA,NA,NA,NA
14998859,NA,1,platelet count of <25 000/Âµl;,NA,NA,NA,NA
14998859,NA,1,non-hematological toxicities,NA,NA,TRUE,NA
11387367,NA,1,any nonhematologic toxicity,>=3,NA,NA,"including >= grade 3  nausea or
vomiting despite optimal antiemetics"
11387367,NA,1,"thrombocytopenia (<25,000/uL)",NA,NA,NA,NA
11387367,NA,1,neutropenia (ANC <500/uL),4,"lasting for at
least 4 days",NA,NA
11387367,NA,1,neutropenia (ANC <500/uL),4,NA,NA, accompanied by fever
11408511,NA,1,absoluteneutrophil count <500 cells/uL,4,at least 5 daysâ€™ duration,NA,NA
11408511,NA,1,hemoglobin <6.5 g/dL;,4,at least 5 daysâ€™ duration,NA,NA
11408511,NA,1,"plateletcount < 25,000 cells/uL",4,at least 5 daysâ€™ duration,NA,NA
11408511,NA,1,anyduration associated with fever,4,NA,NA,NA
15150584,NA,1,two out of six (or>=30%) patients experienced Grade 4 neutropenia,4,lasting >5 days,NA,or if associated with fever
15150584,NA,1,two out of six (or >=30%) patientsexperienced Grade 4 thrombocytopenia,4,NA,NA,NA
15150584,NA,1,two out of six (or>=30%) patients nonhaematologicaltoxicity,3 or 4,NA,TRUE,NA
15150584,NA,1,drugrelated death,NA,NA,NA,NA
11432625,NA,1,any  toxicity,4,NA,FALSE,NA
11432625,NA,1,hematological toxicity,3,"lasting longer than one
week",NA,NA
11432625,NA,1,"hepato, cardiac, pulmonary or renal toxicity",3,NA,NA,NA
11914595,NA,1,neutropenia,NA,NA,NA,NA
11914595,NA,1,thrombocytopenia,NA,persisting for more than 5 days,NA,NA
11914595,NA,1,complicated by fever/infection,NA,NA,NA,NA
11914595,NA,1,hemorrhagic symptoms,NA,NA,NA,NA
11914595,NA,1,non-hematological toxicity,3,NA,FALSE,NA
14501385,NA,1,neutropenia,4,"persisting for more than 7
days",NA, first cycle 
14501385,NA,1,thrombocytopenia,4,NA,NA, first cycle 
14501385,NA,1,nonhematological toxicity ,4,NA,FALSE, first cycle 
14501385,NA,1,Adelay longer than 1 week,NA,NA,NA,"second
cycle"
11996468,NA,1,neutropenia,4,NA,NA,NA
11996468,NA,1,febrileneutropenia,NA,NA,NA,fever >38Â°C and neutrophils <500/mm3ï¼›requiring hospitalisation
11996468,NA,1,thrombocytopenia,4,NA,NA,NA
11996468,NA,1,a bleeding episode requiring platelet infusions for haematological toxicity,NA,NA,NA,NA
11996468,NA,1,nonhaematological toxicity ,3 or 4,NA,FALSE,NA
11996468,NA,1,Cardiac toxicity ,NA,NA,NA,NA
12065868,NA,1,hematologic toxicity lasting more than 3 days,4,NA,NA,NA
12065868,NA,1,neutropeniawith fever 138.2Â°C,4-Feb,NA,NA,NA
12065868,NA,1,non-hematologic toxicity,4-Mar,NA,TRUE,NA
12065868,NA,1,any treatment delay in the first 4weeks of treatment due to unresolved toxicity grade >1,NA,NA,NA,NA
22918789,NA,1,hematologic toxicity,4,NA,NA,NA
22918789,NA,1,nonhematologic  toxicity,3,NA,TRUE,"The toxicities of rash and diarrhea were
considered DLTs only if they remained at grade III or
greater despite maximal medical treatments and required
more than 21 days of dose interruption or dose reduction."
22918789,NA,1,failure torecover from toxicities within 3 weeks from the last doseof study drug,NA,NA,NA,NA
11251001,NA,1,nonhematologic toxicity,4,NA,FALSE,NA
11251001,NA,1,vomiting,4,NA,NA,"despite the use
of antiemetic"
11251001,NA,1,nonhematologic toxicity,>=2,NA,NA,"including
palmar-plantar erythrodysesthesia; which did not resolve by day 21"
11251001,NA,1,neutropenia,4,greater than 7 days,NA,NA
11251001,NA,1,neutropenia at day 21,3 or 4,NA,NA,NA
11251001,NA,1,neutropenia,4,NA,NA,"accompanied by either a
documented infection and/or fever which required parenteral antibiotics;"
11251001,NA,1, thrombocytopenia,4,NA,NA,NA
11251001,NA,1,thrombocytopenia,3,NA,NA,associated with bleedin
15196868,NA,1, neutropenia,4,">4
days",NA,"(ANC < 500/mm3
)"
15196868,NA,1,fever andneutropenia,NA,NA,NA,"temperature >101F and ANC <
500/mm3
)"
15196868,NA,1,thrombocytopenia,4,NA,NA,"(Pl < 10,000/mm3
)"
15196868,NA,1,non-hematological toxicity,>=3,NA,TRUE,NA
15196868,NA,1,mucositis,2,NA,NA,NA
15196868,NA,1,palmer-planter erythrodysesthesia,2,NA,NA,NA
15196868,NA,1,failure to resolvemucositis or palmer-planter erythrodysesthesia to VGr 1 byday 35 of cycle 2,NA,NA,NA,NA
11408493,NA,1,neutropenia,4,lasting more than 8 days,NA,NA
11408493,NA,1,any nonhematologic toxicity,>=3,NA,NA,NA
14962724,NA,1,neutropenia,4,lasting >5 days,NA,NA
14962724,NA,1,febrile neutropenia,NA,NA,NA,NA
14962724,NA,1,platelets <25*10^9 cells/l or bleeding requiring transfusions,NA,NA,NA,NA
14962724,NA,1,uncontrolled nausea andvomiting,NA,NA,NA,NA
14962724,NA,1,"diarrhoea, stomatitis, peripheralneuropathy and hepatic toxicity",>=2,NA,NA,NA
14962724,NA,1,"Failure to meet criteriafor retreatment on day 8 of the first cycle, or for 2 weeksafter day 22",NA,NA,NA,NA
23099006,NA,1,neutropenia,4,for >=7 consecutive days,NA,NA
23099006,NA,1,febrile neutropenia,NA,NA,NA,NA
23099006,NA,1,clinically or microbiologically documented infection,>=3,NA,NA,with Pgrade 3 neutropenia
23099006,NA,1,thrombocytopenia (platelets <25*10^9/L or <50*10^9/L with bleeding requiring transfusion),NA,NA,NA,NA
23099006,NA,1,non-haematologic toxicity,>=3,NA,TRUE,NA
23099006,NA,1,gamma-glutamyltransferase elevation,3,NA,NA,NA
23099006,NA,1,"nausea, vomiting and/or diarrhoea (unless optimallytreated)",3,NA,NA,NA
23099006,NA,1,hypertension unless adequately treated,3,NA,NA,NA
23099006,NA,1,rash (provided this was tolerated by thepatient),3,NA,NA,NA
23099006,NA,1,Interruption of oral dosing for P5 continuousdays within the first 28 d,NA,NA,NA,NA
23099006,NA,1,an inability to begin a second treatment period by day 43 (if due to drug-relatedtoxicity),NA,NA,NA,NA
26886016,NA,1,non-hematologic toxicity,>=3,NA,TRUE,NA
26886016,NA,1,treatment-related febrile neutropenia,NA,NA,NA,"(ANC â‰¤ 1000 cells/ÂµL
and fever â‰¥38.5 Â°C)"
26886016,NA,1,documented infection,>=3,NA,NA,"with
ANC â‰¤1000 cells/ÂµL for >24 h with growth factor support"
26886016,NA,1,thrombocytopenia requiring transfusion or associated with bleeding,>=3,NA,NA,NA
26886016,NA,1,missing two or more doses of eithergemcitabine and/or nab-paclitaxel,NA,NA,NA,NA
26886016,NA,1,missing more than five doses oferlotinib because of toxicity,NA,NA,NA,NA
29801474,NA,1,non-hematological toxicity,>=3,NA,NA,NA
29801474,NA,1,febrile neutropenia,NA,NA,NA,NA
29801474,NA,1,thrombocytopenia requiring transfusion,NA,NA,NA,NA
28424891,NCT00600496,1,neutropenia,4,>5 days,NA,NA
28424891,NCT00600496,1,neutropenia associated with fever,4,NA,NA,NA
28424891,NCT00600496,1, thrombocytopenia,4,NA,NA,NA
28424891,NCT00600496,1,AEs  for >7 days that could not be controlled to grade â‰¤ 2 with appropriate treatment,>=3,NA,NA,NA
28798270,NCT00975182,1,nonhematologic,>=3,NA,TRUE,NA
28798270,NCT00975182,1,nonhepatic organ toxicity,>=3,NA,TRUE,NA
28798270,NCT00975182,1,febrile neutropenia,>=3,NA,NA,NA
28798270,NCT00975182,1,neutropenia,>=4,"lasting
>5 days",NA,NA
28798270,NCT00975182,1,thrombocytopenia,>=4,lasting >48 hours,NA,NA
28798270,NCT00975182,1,anemia,>=4,NA,NA,NA
28798270,NCT00975182,1,elevations in total bilirubin,>=3,NA,NA,NA
28798270,NCT00975182,1,hepatic transaminase(alanine aminotransferase [ALT] or aspartate aminotransferase [AST]),>=3,NA,NA,NA
28798270,NCT00975182,1, amylase,NA,NA,NA,NA
28798270,NCT00975182,1,lipase,NA,"lasting >72
hours",NA,"for patients with grade 1 hepatic transaminase at baseline as a result of metastases, hepatic transaminase 7.5 3
the upper limit of normal was considered a DLT"
28798270,NCT00975182,1,DLCO concomitant with a decrease of 20% from baseline.,>=2,NA,NA,NA
29050231,NA,1,non-hematologic toxicity,>=3,NA,TRUE,NA
29050231,NA,1,reatment delay of more than 14 daysfor cycle 2,NA,NA,NA,NA
29050231,NA,1,"toxicities of concern to investigators orthe NCIC CTG that occurred within cycle 1 and wereconsidered possibly, probably or definitely related to eitheror both study drugs.",NA,NA,NA,NA
27036206,NCT00966472,1,non-hematological toxicity,>=3,NA,TRUE,NA
27036206,NCT00966472,1,neutropenia,4,NA,NA,NA
27036206,NCT00966472,1,neutropenia with fever,NA,NA,NA,NA
27036206,NCT00966472,1,thromocytopenia,4,NA,NA,NA
27036206,NCT00966472,1,dose delay of >2 weeks due to drugrelated toxicity,NA,NA,NA,NA
27853997,NCT00987766,1,anemia,4,NA,NA,NA
27853997,NCT00987766,1,anytreatment-related toxicity,>=3,NA,FALSE,NA
27853997,NCT00987766,1,neutropenia,4,lasting for more than five days,NA,NA
27853997,NCT00987766,1,neutropenia of any duration associated with a feverâ‰¥38.5 Â°C or infection,4,NA,NA,NA
27853997,NCT00987766,1,thrombocytopenia,4,NA,NA,NA
27853997,NCT00987766,1,Treatment on hold due to toxicity for longer than three weeks,NA,NA,NA,NA
22271880,NA,1,neutropenia associated with fever,3 or 4,NA,NA,NA
22271880,NA,1,neutropenia,3 or 4,lasting longer than 5 days,NA,NA
22271880,NA,1,thrombocytopenia,3 or 4,NA,NA,NA
22271880,NA,1,nonhematologic toxicity perNCI/CTC criteria,3 or 4,NA,TRUE,NA
22271880,NA,1,diarrhea,3,NA,NA,"only if
persistent after the initiation of pharmacologic antidiarrheal therapy"
33159216,NCT00770263,1,neutropenia,4,"with
greater than 7 days duration during the frst cycle",NA,NA
33159216,NCT00770263,1,febrileneutropenia,NA,of any duration,NA,NA
33159216,NCT00770263,1,anemia,4,NA,NA,NA
33159216,NCT00770263,1,thrombocytopenia,4,"which required transfusion therapy on more than
two occasions in 7 days during the frst cycle",NA,NA
33159216,NCT00770263,1,non-hematologic toxicity,3 or 4,during the frst cycle,TRUE,NA
33159216,NCT00770263,1,triglyceride elevation,3,NA,NA,"despite appropriate lipid-lowering
drug therapy"
33159216,NCT00770263,1,rash,3,NA,NA,"with no improvement after
2 weeks of supportive therapy"
33159216,NCT00770263,1,Any treatment-related toxicity requiring a delay of 14 daysprior to beginning cycle 2,NA,NA,NA,NA
24429877,NCT00738751,1,rash,4,within cycle 1,NA,NA
24429877,NCT00738751,1,nausea/vomiting refractory to anti-emetics,3 or 4,within cycle 1,NA,NA
24429877,NCT00738751,1,diarrhea refractory to anti-diarrhea medications,3 or 4,within cycle 1,NA,NA
24429877,NCT00738751,1,QTc prolongation >=500 milliseconds or >480 milliseconds on >=2 occasions,NA,within cycle 1,NA,NA
24429877,NCT00738751,1,nonhematologic toxicit,3 or 4,within cycle 1,NA,NA
24429877,NCT00738751,1,hematologic toxicity,4,within cycle 1,NA,NA
24429877,NCT00738751,1,treatment-related death occurring,NA,within cycle 1,NA,NA
22237261,NA,1,any treatment delay of 7 daysbecause of any drug-related toxicity,NA,NA,NA,NA
22237261,NA,1,anynonhematological toxicity,>=3,NA,TRUE,NA
22547007,NCT00266097,1,toxicity,4,NA,NA,NA
22547007,NCT00266097,1,toxicity causing a delay in treatment for morethan a week,3,NA,NA,NA
21791058,NCT01235416,1,fatigue,3,for â‰¥ 7 days,NA,NA
21791058,NCT01235416,1,fatigue,4,NA,NA,NA
21791058,NCT01235416,1,nausea/vomiting,3 or 4,NA,NA,"despite
maximum supportive care"
21791058,NCT01235416,1,neutropenia withfever > 38.5Â°C,3,NA,NA,NA
21791058,NCT01235416,1,neutropenia,4,NA,NA,NA
21791058,NCT01235416,1,thrombocytopenia,4,for â‰¥ 7 days,NA,NA
21791058,NCT01235416,1,anemia,4,NA,NA,NA
21791058,NCT01235416,1,hypertension,4,NA,NA,NA
21791058,NCT01235416,1,alanine aminotransferase or aspartateaminotransferase > 10 times the upper limit of normal,1,NA,NA,NA
21791058,NCT01235416,1,rash for â‰¥ 7 days despite maximum supportivecare,3,NA,NA,NA
21791058,NCT01235416,1,rash,4,NA,NA,NA
21791058,NCT01235416,1,diarrhea for â‰¥ 7 daysdespite maximum supportive care,3,NA,NA,NA
21791058,NCT01235416,1,diarrhea,4,NA,NA,NA
21791058,NCT01235416,1,any other treatment-related hematologic or nonhematologic,3 or 4,NA,FALSE,NA
25521398,NA,1,nonhematologic toxicity,>=3,NA,NA,"including
grade 3 or 4 nausea, vomiting, or diarrhea despite adequate/
maximal medical intervention and/or prophylaxis"
25521398,NA,1,treatmentrelated toxicity that delayed dacomitinib dosing by more than14 days,NA,NA,NA,NA
25521398,NA,1,neutropenia,4,"for more than
or equal to 5 days",NA,NA
25521398,NA,1,febrile neutropenia,NA,NA,NA,NA
25521398,NA,1,thrombocytopenia,4,NA,NA,NA
25521398,NA,1,bleeding requiring platelet transfusion,NA,NA,NA,NA
28761738,NA,1,non haematological toxicity,>=3,NA,NA,NA
28761738,NA,1,haematological toxicity,>=3,NA,NA,NA
28761738,NA,1,anytreatment delay for more than 2 weeks due to trial treatment-related adverse effects.,NA,NA,NA,NA
29843755,NCT00769483,1,neutropenia,4,for â‰¥ 7 days,NA,NA
29843755,NCT00769483,1,febrile neutropenia,>=3,NA,NA,any duration with fever â‰¥ 38.5 Â°C
29843755,NCT00769483,1,thrombocytopenia,4,NA,NA,NA
29843755,NCT00769483,1,non-hematological toxicity,>=3,NA,TRUE,NA
29843755,NCT00769483,1,Any dose interruption for > 14 days because ofTEAE(treatmentemergent adverse events),NA,NA,NA,NA
23135778,NCT00619424,1,clinicalnonhematologic toxicity,>=3,NA,TRUE,NA
23135778,NCT00619424,1,hypertension,4,NA,NA,NA
23135778,NCT00619424,1,uncontrolled hypertension,3,NA,NA,NA
23135778,NCT00619424,1,proteinuria,4,NA,NA,NA
23135778,NCT00619424,1,proteinuria without improvement to Grade <2 upon interruption ofpazopanib in a patient without hypertension and/or renalimpairment,3,NA,NA,NA
23135778,NCT00619424,1,proteinuria in the setting of uncontrolled hypertension and/or renal impairment,3,NA,NA,NA
23135778,NCT00619424,1,neutropenia continuing more than 7 days after discontinuation ofstudy drug;,4,NA,NA,NA
23135778,NCT00619424,1,thrombocytopenia,4,NA,NA,NA
23135778,NCT00619424,1,febrile neutropenia,NA,NA,NA,NA
28971268,NCT01839955,1,neutropenia,4,NA,NA,NA
28971268,NCT01839955,1,thrombocytopenia,4,NA,NA,NA
28971268,NCT01839955,1,febrile neutropenia,NA,NA,NA,NA
28971268,NCT01839955,1,thrombocytopeniain the presence of bleeding,3,NA,NA,NA
28971268,NCT01839955,1,"any toxicity that resulted in scheduled doses to be delayed for 3 weeks or long, anaphylacticreaction",NA,NA,NA,NA
28971268,NCT01839955,1,non-hematological toxicity of any durationor intolerable non hematological grade 2,3,NA,NA,NA
28971268,NCT01839955,1,nausea/vomiting or diarrhea,3,NA,NA,"despite
optimal medical management and symptomatic grade 3 electrolyte imbalance despite supplementation"
24496004,NCT00777699,1,nausea,3 or 4,NA,NA,despite maximal prophylaxis and/or treatment
24496004,NCT00777699,1,vomiting,3 or 4,NA,NA,despite maximal prophylaxis and/or treatment
24496004,NCT00777699,1,diarrhea,3 or 4,NA,NA,despite maximal prophylaxis and/or treatment
24496004,NCT00777699,1,hyperglycemia despite appropriate treatment with an oral hypoglycemic agent (e.g. metformin) at standard doses to control hyperglycemia,2 or 3,NA,NA,NA
24496004,NCT00777699,1,all other non-hematologic toxicities were not easily managed or corrected by medical intervention excluding elevated alkaline phosphatase,3 or 4,NA,NA,NA
24496004,NCT00777699,1,aminotransferase elevations,3,lasting < 3 days,NA,"for patients with Grade 2 aspartate aminotransferase or alanine aminotransferase > 2.5â€“5.0 x upper limit of normal at baseline due to liver metastasis, the DLT criterion was a doubling of the aminotransferase for â‰¥ 3 days"
24496004,NCT00777699,1,neutropenia,4,lasting â‰¥ 5 days,NA,NA
24496004,NCT00777699,1,febrile neutropenia,3 or 4,NA,NA,NA
24496004,NCT00777699,1,hematologic adverse events (AEs),4,NA,NA,NA
24496004,NCT00777699,1,inability to take 75% or more of the planned study treatment in Cycle 1 due to AEs,NA,NA,NA,NA
24496004,NCT00777699,1,a study treatment delay within Cycle 1 of â‰¥ 7 days due to an AE,NA,NA,NA,NA
24496004,NCT00777699,1,an inability to start Cycle 2 within 14 days of planned start date due to an AE,NA,NA,NA,NA
27697581,NCT00965731,1,treatment-related  hematologic toxicities,>=4,NA,TRUE,NA
27697581,NCT00965731,1,treatment-related febrileneutropenia,>=3,NA,NA,NA
27697581,NCT00965731,1,treatment-related nonhematologic toxicities,>=3,NA,NA,NA
27697581,NCT00965731,1,diagnosis of interstitial lung disease,NA,NA,NA,NA
27697581,NCT00965731,1,inability to receive at least 80% of the planned crizotinib,NA,NA,NA,NA
27697581,NCT00965731,1,erlotinib doses during cycle 1 on account of possible treatment-related adverse events(AEs),NA,NA,NA,NA
24901237,NCT00725634,1,toxicity that resulted in dosereduction or interruption of treatment for >2 weeks;,NA,NA,NA,NA
24901237,NCT00725634,1,pertinenthaematologic or nonhaematologic toxicity,3,NA,NA,NA
24901237,NCT00725634,1,neutropaenia,3,lasting >=5 days;,NA,NA
24901237,NCT00725634,1,thrombocytopenia associated with bleeding,4,NA,NA,NA
24901237,NCT00725634,1,haematologic,4,any duration,NA,NA
24901237,NCT00725634,1, nonhaematologic toxicity,4,any duration,NA,NA
21778302,NA,1,diarrhea,3 or 4,NA,NA,NA
21778302,NA,1,mucositis,4,"resulting in >2 weeks interruption of radiation
therapy or that that occurred in the first 3 weeks of treatment",NA,NA
21778302,NA,1,mucositis,3 or 4,NA,NA,"complicated with decrease in performance status (ECOGâ€¡ 2 or >40% decrement
in Karnofsky scale, pain > 7 in visual analgesic scale, weight loss > 20% or needing
parenteral nutrition)"
21778302,NA,1,skin rash,3 or 4,NA,NA,NA
21778302,NA,1,skin rash,2,NA,NA,"clinically unacceptable (cosmetically
unacceptable to the patient)"
21778302,NA,1,any clinically relevant toxicitythat results in discontinuation of treatment for >2 weeks,NA,NA,NA,NA
25441058,NCT00761345,1,non-hematologic toxicity,>=3,NA,TRUE,NA
25441058,NCT00761345,1,thrombocytopenia,3,NA,NA,NA
25441058,NCT00761345,1,granulocytopenia,4,lasting >5 days,NA,NA
25441058,NCT00761345,1,thrombocytopenia,4,NA,NA,NA
25441058,NCT00761345,1,granulocytopenia associated with fever orinfection,4,NA,NA,NA
25441058,NCT00761345,1,interruption of therapy for greater than 14 days dueto toxicity,NA,NA,NA,NA
31570268,NCT01650506,1,nonhematologic toxicity that the patient did not recoverfrom or was not reversed with supportive care within 4 days,3,NA,NA,NA
31570268,NCT01650506,1,"hematologic or nonhematologic toxicity deemedpossibly, probably, or definitely related to study drugs.",>=4,NA,NA,NA
21220471,NCT00225121,1,"nausea, vomiting, or diarrhea despite the use of adequate/maximal medical intervention and/or prophylaxis;",3 or 4,NA,NA,NA
21220471,NCT00225121,1,nonhematologic toxicity,>=3,NA,NA,NA
21220471,NCT00225121,1,delayed recovery from toxicity related to PF299804 treatment which delays scheduled retreatment for >14 days;,NA,NA,NA,NA
21220471,NCT00225121,1,neutropenia,4,5 or more consecutive days,NA,"absolute neutrophil count (ANC)
<500 cells/mm"
21220471,NCT00225121,1,febrile neutropenia,NA,NA,NA,"(i.e., fever >38.5C with ANC <
1,000 cells/mm3"
21220471,NCT00225121,1,"thrombocytopenia (<25,000platelets/mm3)",4,NA,NA,NA
21220471,NCT00225121,1,bleeding requiring a platelet transfusion. Intrapatient dose escalation was permitted if themaximum toxicity experienced during prior cycles oftherapy was grade 2 and 3 patients receiving the nexthigher dose had completed 3 weeks of therapy withoutexperiencing DLT.,NA,NA,NA,NA
19786667,NCT00153933,1,thrombocytopenia,4,NA,NA,NA
19786667,NCT00153933,1,neutropenia,4,>5 days,NA,NA
19786667,NCT00153933,1,neutropenic fever (temperature >= 101Â°F),4,NA,NA,NA
20150632,NA,2,non-hematological of toxicity not reversible to grade 2 or less within 96 hour,3,NA,NA,NA
20150632,NA,2,non-hematological toxicity,4,NA,FALSE,NA
20150632,NA,2,thrombocytopenia,4,NA,NA,NA
20150632,NA,2,"thrombocytopenia (platelet count â‰¤50,000/mm3) associated with any bleeding",3,NA,NA,NA
20150632,NA,2,thrombocytopenia,3,>7 days,NA,NA
20150632,NA,2,febrile neutropenia,>=3,NA,NA,NA
20150632,NA,2,neutropenia,4,>=7 days,NA,NA
20150632,NA,2,NA,4,NA,NA,NA
20378507,NA,3,non-hematologic toxicity,>=3,NA,NA,NA
20378507,NA,3,hematologic toxicity that did not resolve to grade â‰¤ 2 within 1 week and thereby led to more than a weekâ€™s delay in treatment,4,NA,NA,NA
19774377,NA,4,non-hematologic toxicity,>=3,NA,NA,NA
19774377,NA,4,hematologic toxicity,4,NA,FALSE,NA
19774377,NA,4,failure to complete one cycle for reasons other than disease progression was also considered a DLT,NA,NA,NA,NA
21447728,NA,5,non-hematologic toxicities,>=3,NA,NA,NA
21447728,NA,5,hematologic toxicity,4,NA,NA,NA
21596852,NCT00724568,6,nonhematologic toxicity attributed toone or more of the study drugs,>=3,NA,NA,NA
21596852,NCT00724568,6,thrombocytopenia with platelet count of < 25 000 on more than one occasion,4,NA,NA,NA
21596852,NCT00724568,6,neutropenia resulting in neutropenic fever withelevated temperature [defined as >= 100.5Â°F on one occasion],4,NA,NA,NA
21596852,NCT00724568,6,neutropenia without fever with confirmation within 5 days,4,NA,NA,NA
21596852,NCT00724568,6,inability toreceive the day 1 dose for cycle 2 because of continued drug-related toxicityfrom cycle 1 or drug-related toxicity newly encountered on day 1 of cycle 2.,NA,NA,NA,NA
21680752,NA,7,treatment-related nonhematologic toxicity,>=3,NA,FALSE,NA
21680752,NA,7,hematologic toxicity,4,>7 days,NA,NA
21680752,NA,7,hematologic toxicity resulting in omission or delay of 2 or more drug doses in a cycle because of toxicity,4,NA,NA,NA
21680752,NA,7,hematologic toxicity resulting in toxicity-associated cycle initiation delay beyond 2 weeks.,4,NA,NA,NA
21911830, NCT00431990,8,platelet count < 25 X 109/L,NA,NA,NA,NA
21911830, NCT00431990,8,neutropenia,>2,NA,NA,on day 1 of cycle 2 despite G-CSF support for 5 days or more
21911830, NCT00431990,8,febrile neutropenia,NA,NA,NA,NA
21911830, NCT00431990,8,nonhematologic toxicity,>2,NA,NA,"considered of adequate
clinical significance by the treating physician enough to warrant a dose
reduction of bortezomib and/or romidepsin"
21812533,NA,9,hematologic toxicity,4,>3 weeks,NA,NA
21812533,NA,9,hematologic toxicity serious or life threatening bleeding,4,NA,NA,NA
21812533,NA,9,non-hematologic toxicity,>=3,NA,TRUE,NA
22479278,NCT00379574,10,neutropenia associated with fever,4,>3 days,NA,NA
22479278,NCT00379574,10,thrombocytopenia with grade 2 hemorrhage,>=3,NA,NA,NA
22479278,NCT00379574,10,non-hematologic toxicity,>=3,NA,NA,NA
22534815,NA,11,neutropenia,4,NA,NA,NA
22534815,NA,11,thrombocytopenia,4,NA,NA,NA
22534815,NA,11,any nonhematologic toxicity,>=3,NA,FALSE,NA
22534815,NA,11,any neurotoxicity,>=2,NA,NA,NA
22534815,NA,11,neurosensory toxicity of grade 2 with pain,NA,NA,NA,NA
22291084,NCT00726869,12,nonhematologic toxicity,>=3,NA,TRUE,NA
22291084,NCT00726869,12,thrombocytopenia,NA,NA,NA,NA
22291084,NCT00726869,12,neutropenia,4,> 7 days,NA,NA
22291084,NCT00726869,12,febrile neutropenia (temperature > 101Â°F),>=3,NA,NA,NA
22677155, NCT00294632,13,non-haematological event,>=3,NA,NA,NA
22677155, NCT00294632,13,haematological adverse event,4,NA,NA,NA
22535574,NA,14,neurotoxicity,NA,NA,NA,only the NCI CTCAE neurotoxicity assessment was used in determinng DLT.
23150919,NA,15,haematological toxicity,4,NA,NA,NA
23150919,NA,15,thrombocytopenia with grade 3/4 haemorrhage,3,NA,NA,NA
23150919,NA,15,febrile neutropenia,3,NA,NA,NA
23150919,NA,15,nauseaand vomiting refractory to antiemetic therapy,4,NA,NA,NA
23150919,NA,15,drug-related nonhaematological toxicity,>=3,NA,NA,NA
23150919,NA,15,drug-related death,NA,NA,NA,NA
22906230,NA,16,"nausea, vomiting, diarrhea or ileus",3,>96h,NA,NA
22906230,NA,16,"nausea, vomiting, diarrhea or ileus",4,NA,NA,NA
22906230,NA,16,neuropathic pain and/or peripheral sensory neuropathy.,4,NA,NA,NA
22906230,NA,16,neutropenia,4,NA,NA,NA
22906230,NA,16,thrombocytopenia,4,>10 days,NA,NA
23322195,NCT00720148,17,neutropenia,4,NA,NA,NA
23322195,NCT00720148,17,anaemia,4,NA,NA,NA
23322195,NCT00720148,17,thrombocytopenia,4,NA,NA,NA
23322195,NCT00720148,17,fatigue,4,NA,NA,NA
23322195,NCT00720148,17,a two-point decline in ECOG performance status unrelated to underlying malignancy,NA,NA,NA,NA
23322195,NCT00720148,17,gastrointestinal toxicity,>=3,NA,NA,NA
23322195,NCT00720148,17,any other clinically significant toxicity,>=3,NA,NA,NA
23243282,NCT00833833,18,neutropenia (ANC < 500/mL),4,NA,NA,NA
23243282,NCT00833833,18,"febrile neutropenia (fever >38.5Â°C and ANC ,1000/mL)",NA,NA,NA,NA
23243282,NCT00833833,18,"thrombocytopenia (platelet count ,25 000/mL)",4,NA,NA,NA
23243282,NCT00833833,18,pomalidomide-relatednonhematologic toxicity,>=3,NA,NA,NA
23243282,NCT00833833,18,"nausea, vomiting, or diarrhea thatcould not be controlled using symptomatic treatment",>=3,NA,NA,NA
23243282,NCT00833833,18,transaminitis (serum transaminase>20 X ULN),4,NA,NA,NA
23243282,NCT00833833,18,transaminitis (serum transaminase >.5 X ULN),3,>= 7 days,NA,NA
23256542, NCT00103272,19,Non-hematologic toxicity,>=3,NA,TRUE,NA
23256542, NCT00103272,19,failure to recover neutrophil and/or platelet counts by day 42 in patients with < 5% blasts in the bone marrow,NA,NA,NA,NA
23256542, NCT00103272,19,absence of myelodysplastic changes and/or absence of evidence of disease by flow cytometry in the bone marrow,NA,NA,NA,NA
23887852,NCT00303797,20,ANC,4,>= 5 days,NA,NA
23887852,NCT00303797,20,anemia,4,NA,NA,NA
23887852,NCT00303797,20,"PLT<25,000",NA,NA,NA,NA
23887852,NCT00303797,20,serum creatinine â‰¥2 times baseline or>2Ã—ULNif baseline levels are within normal range,NA,NA,NA,NA
23887852,NCT00303797,20,any other adverse event,>=3,NA,NA,NA
23887852,NCT00303797,20,toxicities that caused dose delay of >2 weeks of the intendednext dose,NA,NA,NA,NA
23887852,NCT00303797,20,"nausea, vomiting, or diarrhea with maximal supportive treatment (s)",3,NA,NA,NA
23543109,NA,21,neutropenia,4,NA,NA,NA
23543109,NA,21,thrombocytopenia,3,NA,NA,NA
23543109,NA,21,serum creatinine â‰¥ 2 times baseline or ULN,NA,NA,NA,NA
23543109,NA,21,QTc prolongation,>=3,NA,NA,NA
23543109,NA,21,day 8 dose omitted during cycle 1,NA,NA,NA,NA
23543109,NA,21,Any other non-hematologic toxicity,>=3,NA,NA,NA
23543109,NA,21,"nausea, vomiting, ordiarrhea with maximal supportive treatments",3,NA,FALSE,NA
24019544,NCT00532389,22,febrile neutropenia,3,NA,NA,NA
24019544,NCT00532389,22,neutropenia,4,>= 5 days,NA,NA
24019544,NCT00532389,22,thrombocytopenia,4,NA,NA,NA
24019544,NCT00532389,22,vomiting,>=3,NA,NA,NA
24019544,NCT00532389,22,nausea despite the use of standard antiemetics,>=3,NA,NA,NA
24019544,NCT00532389,22,diarrhea despite the use of optimal antidiarrheal treatments,>=3,NA,NA,NA
24019544,NCT00532389,22,> 5-10Ã— ULN AST or ALT,NA,NA,NA,first occurrence for > 5 days or second occurrence for â‰¤ 5 days
24075534,NCT00382954,23,hematologic toxicity attributable to treatment,4,>28 days after the last day of therapy,NA,NA
24075534,NCT00382954,23,any non-hematologic toxicity attributable to treatment,>=4,NA,FALSE,NA
24114121,NA,24,absolute neutrophil count â‰¤ 500,NA,>= 7 days,NA,NA
24114121,NA,24,febrile neutropenia,NA,NA,NA,NA
24114121,NA,24,neutropenic infection,>=3,NA,NA,NA
24114121,NA,24,"platelets â‰¤ 25,000",NA,NA,NA,NA
24114121,NA,24,thrombocytopenicbleeding,NA,NA,NA,NA
24114121,NA,24,nonhematologic toxicity,>=3,NA,TRUE,NA
24114121,NA,24,AST/ALT elevations,>=3,>7 days,NA,NA
24114121,NA,24,toxicity leading to two or more missed doses percycle,NA,NA,NA,NA
24114121,NA,24,toxicity resulting in the delay of the subsequent cycleby > 7 days,NA,NA,NA,NA
24114123,NA,25,absolute neutrophilcountâ‰¤500,NA,>7 days,NA,NA
24114123,NA,25,febrile neutropenia,NA,NA,NA,NA
24114123,NA,25,neutropenic infection,>=3,NA,NA,NA
24114123,NA,25,"plateletsâ‰¤25,000",NA,NA,NA,NA
24114123,NA,25,thrombocytopenic bleeding,NA,NA,NA,NA
24114123,NA,25,any nonhematologic toxicity,>=3,NA,TRUE,NA
24114123,NA,25,AST/ALT elevations,>=3,>7 days,NA,NA
24114123,NA,25,any toxic effect leadingto missing two or more doses per cycle,4,NA,NA,NA
24114123,NA,25,and any toxiceffect resulting in the delay of the subsequent cycle by>7 days,NA,NA,NA,NA
23665866,NA,26,neutropenia,4,>= 7 days,NA,NA
23665866,NA,26,platelet count â‰¤25Ã—109 per liter,NA,>= 7 days,NA,NA
23665866,NA,26,febrile neutropenia,>=3,NA,NA,NA
23665866,NA,26,non-haematologic toxicity,>=3,NA,TRUE,NA
24434781,NA,27,Any nonhematological ASCT-related toxicity,>2,NA,NA,on the Bearman scale
24429497,NCT01365559,28,hematologictoxicity,>=3,NA,FALSE,NA
24429497,NCT01365559,28,thrombocytopenia with grade 3or 4 hemorrhage,3,NA,NA,NA
24429497,NCT01365559,28,nausea or vomiting refractory to antiemetic therapy,>=3,NA,NA,NA
24429497,NCT01365559,28,diarrhea or constipation refractory toantidiarrheal or constipation therapy,>=3,NA,NA,NA
24429497,NCT01365559,28,any other study treatment related nonhematologic toxicity,>=2,NA,FALSE,NA
24429497,NCT01365559,28,anytreatment-related death,NA,NA,NA,NA
24904120,NCT00963820,29,neutropenia,4,>7 days,NA,NA
24904120,NCT00963820,29,neutropenia with fever (>= 38.5Â°C) and/or infection,3,NA,NA,NA
24904120,NCT00963820,29,thrombocytopenia,4,> 7 days,NA,NA
24904120,NCT00963820,29,thrombocytopenia with clinicallysignificant bleeding,3,NA,NA,NA
24904120,NCT00963820,29,"platelets ,10 000/mm3",NA,NA,NA,NA
24904120,NCT00963820,29,nonhematologic toxicity,>=3,NA,FALSE,NA
24904120,NCT00963820,29,delay of >=2 weeks in starting cycle 2 becauseof lack of recovery from ixazomib-related toxicities in cycle 1,4,NA,NA,NA
24904120,NCT00963820,29,PN with pain,2,NA,NA,NA
24904120,NCT00963820,29,other ixazomib-related nonhematologic toxicitiesrequiring drug discontinuation,>=2,NA,NA,NA
25248382,NCT00082784,30,anemia,4,NA,NA,NA
25248382,NCT00082784,30,absolute neutrophil count or platelet toxicity of greater than one weekduration,4,NA,NA,NA
25248382,NCT00082784,30,febrile neutropenia,>=3,NA,NA,NA
25248382,NCT00082784,30,nonhematologic adverse events,>=3,NA,TRUE,NA
25373733,NA,31,NA,NA,NA,NA,DLT not defined
25247339,NA,32,radiation dermatitis,4,NA,NA,NA
25247339,NA,32,neutropenia,4,>= 8 days,NA,NA
25247339,NA,32,thrombocytopenia,4,>= 8 days,NA,NA
25247339,NA,32,febrile neutropenia,4,NA,NA,NA
25247339,NA,32,esophagitis requiring hospitalization,>=3,NA,NA,NA
25247339,NA,32,pneumonitis requiring oxygen,>=3,NA,NA,NA
25247339,NA,32,dyspnea at rest,4,NA,NA,NA
25247339,NA,32,other nonhematologic toxicities,4,NA,NA,not manageable with medical interventions
24730538,NCT00777114,33,non-hematologic toxicity,3,NA,NA,NA
24730538,NCT00777114,33,hematologic toxicity,4,NA,NA,NA
25655379,NCT01309412,34,any nonhematologic toxicity,>=3,NA,TRUE,NA
25655379,NCT01309412,34,neutropenia,4,>7 days,NA,NA
25655379,NCT01309412,34,febrile neutropenia,NA,NA,NA,NA
25655379,NCT01309412,34,thrombocytopenia,4,>7 days,NA,NA
25655379,NCT01309412,34,thrombocytopenia associated with hemorrhage,4,NA,NA,NA
25655379,NCT01309412,34,Thrombocytopenia with platelet transfusion,NA,NA,NA,NA
25986244,NCT01078961,35,NA,NA,NA,NA,Not reported
25749662,NCT01371227,36,hematological toxicity,4,NA,TRUE,NA
25749662,NCT01371227,36,non-hematological toxicity,>=3,NA,FALSE,NA
25809731,NCT00708292,37,NA,NA,NA,NA,Not reported
26298823,UMIN000001347,38,neutropenia (<500/mm3),NA,>5 days,NA,NA
26298823,UMIN000001347,38,"thrombocytopenia (<25,000/mm3)",NA,>5 days,NA,NA
26298823,UMIN000001347,38,non-hematologic toxicities,>=3,NA,FALSE,NA
26331432,NCT01049945,39,neutropenia,4,>= 7 days,NA,NA
26331432,NCT01049945,39,febrile neutropenia,NA,NA,NA,NA
26331432,NCT01049945,39,thrombocytopenia,4,>= 7 days,NA,NA
26331432,NCT01049945,39,thrombocytopenia associatedwith bleeding,>=3,NA,NA,NA
26331432,NCT01049945,39,neuropathy with pain,>=2,NA,NA,NA
26331432,NCT01049945,39,any toxicity,>=3,NA,FALSE,NA
26331432,NCT01049945,39,nausea,>=3,NA,NA,NA
26331432,NCT01049945,39,vomiting,>=3,NA,NA,NA
26331432,NCT01049945,39,diarrhea,>=3,NA,NA,NA
26331432,NCT01049945,39,fatigue,>=4,>= 7 days,NA,NA
26331432,NCT01049945,39,Any nonhematologic toxicity requiring a dose reduction within Cycle 1 or a delay of subsequent cycle of treatment >= 14 daystreatment >= 14 days because toxicit,NA,NA,NA,NA
26619834,NCT00858234,41,non-hematologic event,>=3,NA,TRUE,NA
26619834,NCT00858234,41,hematologic toxicity,4,NA,TRUE,NA
26619834,NCT00858234,41,Neutropenia accompanied by a fever of â‰¥38.5 Â°C,>=3,NA,NA,NA
26619834,NCT00858234,41,Neutropenia accompanied by  infection requiring antibiotic or antifungal treatment,>=3,NA,NA,NA
26619834,NCT00858234,41,neutropenia,4,>5 days,NA,NA
26588925,UMIN000006604,42,hematologic toxicity,4,NA,NA,NA
26588925,UMIN000006604,42,non-hematologic toxicity,>=3,NA,NA,NA
26494130,NCT00532389,43,NA,NA,NA,NA,Not mentioned
26871714, NCT01531998,44,non-hematological toxicity,>=3,NA,TRUE,NA
26871714, NCT01531998,44,neutropenia,4,>5 days,NA,NA
26871714, NCT01531998,44,febrile neutropenia,NA,NA,NA,NA
26871714, NCT01531998,44,thrombocytopenia,4,NA,NA,NA
26871714, NCT01531998,44,thrombocytopeniawith bleeding,3,NA,NA,NA
27009059,NCT00461045,45,neutropenia,4,NA,NA,NA
27009059,NCT00461045,45,anemia,4,NA,NA,NA
27009059,NCT00461045,45,thrombocytopenia,4,NA,NA,NA
27009059,NCT00461045,45,febrile neutropenia,NA,NA,NA,NA
27009059,NCT00461045,45,shift frombaseline in either pancreatic or neurotoxicity,>=2,NA,NA,NA
27009059,NCT00461045,45,nausea in spite of maximal supportive care,3,NA,NA,NA
27009059,NCT00461045,45,diarrhea in spite of maximal supportive care,3,NA,NA,NA
27009059,NCT00461045,45,vomiting in spite of maximal supportive care,3,NA,NA,NA
27009059,NCT00461045,45,nonhematologic toxicity,>=3,NA,NA,NA
27009059,NCT00461045,45,treatment delay >= 2 weeks due to prolongedtoxicity,NA,NA,NA,NA
27207788,NCT01677858,46,neutropenia,4,>7 days,NA,NA
27207788,NCT01677858,46,febrile neutropenia,NA,NA,NA,NA
27207788,NCT01677858,46,thrombocytopenia,4,>14 days,NA,NA
27207788,NCT01677858,46,thrombocytopeniaassociated with grade .1 bleeding,>=3,NA,NA,NA
27207788,NCT01677858,46,nonhematologic toxicity,>=3,NA,FALSE,NA
27207788,NCT01677858,46,acute kidney injury,>=3,>72 hours,NA,NA
27207788,NCT01677858,46,"nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal medication",>=3,NA,NA,NA
26758913,NA,47,treatment interruption of >7 d for toxicities,>=2,NA,NA,NA
26758913,NA,47,non-hematologicaltoxicities,4,NA,TRUE,NA
26758913,NA,47,hematologicaltoxicities,4,NA,NA,NA
27502784,NA,48,nonhematologic toxicities,>=3,NA,TRUE,temozolomide related DLT
27502784,NA,48,ANC â‰¤500/mm3,NA,NA,NA,temozolomide related DLT
27502784,NA,48,"platelets â‰¤25,000/mm3",NA,NA,NA,temozolomide related DLT
27502784,NA,48,febrile neutropenia,NA,NA,NA,temozolomide related DLT
27502784,NA,48,Failure to recover from toxicity within 2 weeks,NA,NA,NA,temozolomide related DLT
27502784,NA,48,hematologic toxicity,4,NA,NA,bortezomib related DLT
27502784,NA,48,non-hematologic toxicity,>=3,NA,NA,bortezomib related DLT
27502784,NA,48,pulmonary or CNS hemorrhage,1,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,non-pulmonary non-CNS hemorrhage in patients not on anticoagulation,3,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,venous thrombosis,>=3,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,congestive heart failure,3,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,proteinuria,3,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,bowel obstruction,>=2,NA,NA,Bevacizumabrelated DLT
27502784,NA,48,event considered to be related to bevacizumab,3,NA,NA,Bevacizumabrelated DLT
27647864,NCT01352338,49,thrombocytopenia,4,NA,NA,NA
27647864,NCT01352338,49,neutropenia,4,>5 days,NA,NA
27647864,NCT01352338,49,febrile neutropenia,NA,NA,NA,NA
27647864,NCT01352338,49,non-hematologic toxicity,>=3,NA,TRUE,NA
27647864,NCT01352338,49,death,NA,NA,NA,NA
28341300,NCT01074411,50,dose delay of >3 weeks due to persistent low blood counts,NA,NA,NA,NA
28341300,NCT01074411,50,febrile neutropenia,NA,NA,NA,NA
28341300,NCT01074411,50,neutropenia,4,>7 days,NA,NA
28341300,NCT01074411,50,thrombocytopenia,4,NA,NA,NA
28341300,NCT01074411,50,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
28341300,NCT01074411,50,drug-related death,NA,NA,NA,NA
28341300,NCT01074411,50,non-hematologic adverse evnet,>=3,NA,TRUE,NA
28103725,NCT00963274,51,any toxicity,>=3,NA,TRUE,NA
28103725,NCT00963274,51,neutropenia,4,NA,NA,NA
28103725,NCT00963274,51,thrombocytopenia,4,>=3 days,NA,NA
28103725,NCT00963274,51,thrombocytopenia accompanied bybleeding or sepsis,4,NA,FALSE,NA
28103725,NCT00963274,51,inability to administerchemotherapy on 2 of 3 dosing days due to dosemodification for toxicity,4,NA,NA,NA
28550039,NCT01659658,52,thrombocytopenia,4,>= 7 days,NA,NA
28550039,NCT01659658,52,neutropenia,4,>= 7 days,NA,NA
28550039,NCT01659658,52,platelet count below 10 000/mm3,NA,NA,NA,NA
28550039,NCT01659658,52,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
28550039,NCT01659658,52,febrile neutropenia with fever and/or infection,3,NA,NA,NA
28550039,NCT01659658,52,nonhematologic toxicity,>=3,NA,FALSE,NA
28550039,NCT01659658,52,nausea and/or emesis despite the use of antiemetic prophylaxis,>=3,NA,NA,NA
28550039,NCT01659658,52,peripheral neuropathy with pain,2,NA,NA,NA
28550039,NCT01659658,52,peripheral toxicity,>=3,NA,NA,NA
28550039,NCT01659658,52,"a delay ofmore than 2 weeks in the initiation of treatment cycle 2 because of a lack ofadequate recovery from ixazomib-related toxicities, or other grade 2 or worseixazomib-related nonhematologic toxicities that, in the opinion of the investigator, required discontinuation of ixazomib therapy.",NA,NA,NA,NA
28873084,NCT01063907,53,any non-haematologic toxicity,>=3,NA,FALSE,NA
28873084,NCT01063907,53,haematologic toxicity,4,NA,FALSE,NA
28436582,NA,54,"platelets less than 10,000 per ðœ‡l on two consecutive blood draws and/or more than one platelet transfusion required per week",NA,NA,NA,NA
28436582,NA,54,neutropenia,4,>7 days,NA,NA
28436582,NA,54,"neutropenia or thrombocytopenia, which causes a delay of 14 days or more beyond the planned interval between treatment cycles",NA,NA,NA,NA
28436582,NA,54,nonhematologic toxicity,>=3,NA,TRUE,NA
28642620,NCT01497093,55,neutropenia,4,>7 days,NA,NA
28642620,NCT01497093,55,febrile neutropenia,NA,NA,NA,NA
28642620,NCT01497093,55,thrombocytopenia with significant bleeding,3,NA,NA,NA
28642620,NCT01497093,55,thrombocytopenia with a â©¾30% decrease in platelet countfrom baseline and requiring 41 platelet transfusion,4,NA,NA,NA
28642620,NCT01497093,55,infection,4,NA,NA,NA
28642620,NCT01497093,55,"toxicities related to pomalidomide (nausea, vomiting, constipation and/or diarrhea with optimal symptomatic treatment or fatigue lastingfor 47 days)",>=3,NA,NA,NA
29076150,NA,56,infection,4,NA,NA,NA
29076150,NA,56,neutropenia,4,NA,NA,NA
29076150,NA,56,febrile neutropenia,NA,NA,NA,NA
29076150,NA,56,thrombocytopenia,4,NA,NA,NA
29076150,NA,56,thrombocytopeniawith significant bleeding,3,NA,NA,NA
29076150,NA,56,"nausea, vomiting, constipation and/or diarrhoea with optimal antiemetic/antidiarrheal therapy",>=3,NA,NA,NA
29076150,NA,56,fatigue,>=3,>7 days,NA,NA
28696812, NCT00671112,57,NA,NA,NA,NA,Not mentioned
30061664, NCT01864018.,58,NA,NA,NA,NA,Not mentioned
30058108,JapicCTIâ€122020,59,NA,NA,NA,NA,Not mentioned
30400780,NCT02993094,60,non-hematologic toxicities,>=3,NA,FALSE,NA
30400780,NCT02993094,60,nausea and/or emesis despite the use of optimal anti-emeticprophylaxis,>=3,NA,NA,NA
30400780,NCT02993094,60,diarrhea that occurs despite maximal supportive therapy,>=3,NA,NA,NA
30400780,NCT02993094,60,peripheral neuropathy with pain,2,NA,NA,NA
30400780,NCT02993094,60,polyneuropathy,3,NA,NA,NA
30400780,NCT02993094,60,neutropenia,4,>7 days,NA,NA
30400780,NCT02993094,60,febrile neutropenia,3,NA,NA,NA
30400780,NCT02993094,60,thrombocytopenia,4,NA,NA,NA
30400780,NCT02993094,60,thrombocytopenia with bleeding,3,NA,NA,NA
30352784,NCT02343042,61,"missing >= 25% of scheduled doses, a dose-reduction, or discontinuation due to treatment-related adverse events",NA,NA,NA,NA
30352784,NCT02343042,61,"nausea, vomiting, dehydration, diarrhea, or fatigue  despite optimal supportive care medications",>=3,>3 days,NA,NA
30352784,NCT02343042,61,nonhematologictoxicity,>=3,NA,NA,NA
30352784,NCT02343042,61,febrile neutropenia,NA,NA,NA,NA
30352784,NCT02343042,61,neutropenia,4,>7 days,NA,NA
30352784,NCT02343042,61,"thrombocytopenia with clinically significantbleeding, petechiae, or purpura",>=3,NA,NA,NA
30297385,NCT00923247,62,neutrophil count below 1000/ ÂµL,3,NA,NA,NA
30297385,NCT00923247,62,a single neutrophil count below 500/ÂµL,NA,NA,NA,NA
30297385,NCT00923247,62,"Platelet count below 50,000 ÂµL",3,NA,NA,NA
30297385,NCT00923247,62,"a singe platelet count below 25,000/ÂµL",NA,NA,NA,NA
30610196, NCT01549431,63,cardiac toxicity involving either QTc prolongation or congestive heartfailure,>=2,NA,NA,NA
30610196, NCT01549431,63,non-hematologic toxicity,>=3,NA,NA,NA
30610196, NCT01549431,63,any non-hematologic toxicity requiring a dose reduction or dose interruption incycle 1,NA,NA,NA,NA
30610196, NCT01549431,63,neutropenia,4,>= 7 days,NA,NA
30610196, NCT01549431,63,febrile neutropenia,NA,NA,NA,NA
30610196, NCT01549431,63,thrombocytopenia associated with bleeding,4,NA,NA,NA
30610196, NCT01549431,63,a > 7-day delay inreceiving the day-1 dose of cycle 2 due to inadequaterecovery of platelets ( < 75 Ã— 109/L) or other drug-related toxicity persisting from cycle 1,NA,NA,NA,NA
30279233,NCT01522872,64,"thrombocytopenia with platelets <10,000 on more than oneoccasion",NA,NA,NA,NA
30279233,NCT01522872,64,neutropenia assicuated with fever,4,>5 days,NA,NA
30279233,NCT01522872,64,nonhematologic toxicity,>=3,NA,TRUE,NA
30279233,NCT01522872,64,inability to receive day 1 dose for cycle 2 by more than 3 weeks due to prolonged recovery from a drug-relatedtoxicity,NA,NA,NA,NA
30952640,NCT01246063,65,neutropenia,4,NA,NA,NA
30952640,NCT01246063,65,thrombocytopenia,4,NA,NA,NA
30952640,NCT01246063,65,febrile neutropenia,NA,NA,NA,NA
30952640,NCT01246063,65,neuropathy with associated pain,2,NA,NA,NA
30952640,NCT01246063,65,nonhematologic toxicity,>=3,NA,NA,NA
30952640,NCT01246063,65,any other toxicity requiring dose reduction during cycle 1 or precluding cycle 2 of treatment on schedule,NA,NA,NA,NA
31053600,NCT02302495,66,hematologic toxicity,4,NA,NA,NA
31053600,NCT02302495,66,febrileneutropenia,3,NA,NA,NA
31053600,NCT02302495,66,gastrointestinal toxicities,>=3,NA,NA,NA
31053600,NCT02302495,66,nonhematologic toxicity considered related to KMP by theprincipal investigator,>=3,NA,NA,NA
31053600,NCT02302495,66,peripheral neuropathy persisting for more than 3 weeks after discontinuation of study drugs,>=3,NA,NA,NA
31124580,NCT02199665,67,febrile neutropenia,NA,NA,NA,NA
31124580,NCT02199665,67,neutropenia,4,>7 days,NA,NA
31124580,NCT02199665,67,thrombocytopenia,4,>7 days,NA,NA
31124580,NCT02199665,67,thrombocytopenia associated withbleeding,>=3,NA,NA,NA
31124580,NCT02199665,67,neuropathy,>=2,NA,NA,NA
31124580,NCT02199665,67,toxicity for gastrointestinal events,>=3,>=3 days,NA,NA
31124580,NCT02199665,67,fatigue or anorexia,>=3,>7 days,NA,NA
31120355,NCT01111188,68,non-hematologic toxicity,>=3,NA,NA,NA
31120355,NCT01111188,68,neutropenia,4,NA,NA,NA
31120355,NCT01111188,68,thrombocytopenia,4,NA,NA,NA
10531568,NA,69,reversible toxicity,>=3,NA,NA,NA
11025470,NA,70,NA,NA,NA,NA,Not mentioned
12420202,NA,71,non-haematological toxicity,>=3,NA,NA,NA
12431963,NA,72,hematologictoxicity,4,NA,NA,NA
12431963,NA,72,hyperbilirubinemia,4,NA,NA,NA
12431963,NA,72,toxicity,3,NA,FALSE,NA
15286694,NA,73,nephrotoxicity,>=2,NA,NA,NA
15286694,NA,73,neurotoxicity,>=2,NA,NA,NA
15286694,NA,73,othernonhematological toxicity,>=3,NA,TRUE,NA
15570082,NA,75,adverse event attributable to thestudy drug,>=3,NA,FALSE,NA
15570082,NA,75,"hepatic transaminase (AST and/or ALT) elevationreturning to <= grade 1 before the next treatment course,",3,NA,NA,NA
15570082,NA,75,fever or infection,3,NA,NA,NA
15570082,NA,75,neutropenia,4,NA,NA,NA
15570082,NA,75,thrombocytopenia,4,>7 days,NA,NA
15570082,NA,75,Hematologic toxicity resulting in a delay of more than 14 days beyond the planned interval between treatment courses,NA,NA,NA,NA
15626743,NA,76,hematologic toxicity,4,NA,NA,NA
15626743,NA,76,toxicity,3,NA,FALSE,NA
15626743,NA,76,neutropenia associated withfever,4,NA,NA,NA
15626743,NA,76,neutropenia,4,>5 days,NA,NA
16135477,NA,77,hematologic toxicity,4,NA,NA,NA
16135477,NA,77,febrile neutropenia,NA,NA,NA,NA
16135477,NA,77,nonhematologictoxicity,>=3,NA,NA,NA
17409841,NA,78,"platelet count <=25,000 cells/mm3",NA,NA,NA,NA
17409841,NA,78,febrile neutropenia,NA,NA,NA,NA
17409841,NA,78,neutropenia,4,NA,NA,NA
17409841,NA,78,anemia,4,NA,NA,NA
17409841,NA,78,peripheral neuropathy,>=2,NA,NA,NA
17409841,NA,78,any other toxicity,>=3,NA,TRUE,NA
16489083,NA,79,thrombocytopenia,3,NA,NA,NA
16489083,NA,79,neutropenia,4,>= 7 days,NA,NA
16489083,NA,79,febrile neutropenia,NA,NA,NA,NA
16489083,NA,79,anemia,4,NA,NA,NA
16489083,NA,79,nonhematologic toxicity,>=3,NA,FALSE,NA
16489083,NA,79,"thedelivered dose of docetaxel was <75% planned in the first two cycles, or similarly <80% of planned bortezomib during cycles 1 and 2",NA,NA,NA,NA
16418495,NA,80,neutropenia,4,NA,NA,NA
16418495,NA,80,thrombocytopenia,4,NA,NA,NA
16418495,NA,80,anemia,4,NA,NA,NA
16418495,NA,80,thrombocytopenia with grade 3 or 4 hemorrhage,3,NA,NA,NA
16418495,NA,80,nausea and vomiting refractory to antiemetic therapy,>=3,NA,NA,NA
16418495,NA,80,any other nonhematologic toxicity,>=3,NA,NA,NA
16533779,PBTC-004,81,toxicity,>=3,NA,NA,NA
16533779,PBTC-004,81,central nervous system toxicity,>=1,NA,NA,NA
17036355,NA,82,neutropenia,4,NA,NA,NA
17036355,NA,82,any other type of toxicity,>=3,NA,NA,NA
16763792,NA,83,non-hematologic toxicity,>=3,NA,FALSE,NA
16763792,NA,83,nausea and vomiting with maximal anti-emetic treatment,>=3,NA,NA,NA
16763792,NA,83,diarrhea in spite of maximal antidiarrheal therapy,>=3,NA,NA,NA
16763792,NA,83,neutropenia associated with fever,4,NA,NA,NA
16763792,NA,83,neutropenia,4,>= 5 days,NA,NA
16763792,NA,83,anemia,4,NA,NA,NA
16763792,NA,83,platelet counts <= 25 X 109/l,NA,NA,NA,NA
16763792,NA,83,a treatment delay of a week or more with bortezomib during treatm,NA,NA,NA,NA
17575229,NA,84,any drug-related nonhematologictoxicity,>=3,NA,FALSE,NA
17575229,NA,84,neutropenia,4,>5 days,NA,NA
17575229,NA,84,febrile neutropenia,>=3,NA,NA,NA
17575229,NA,84,thrombocytopenia,4,NA,NA,NA
17575229,NA,84,toxicity causing a delay in the start of the next cycle of>2 weeks,NA,NA,NA,NA
17905421,NA,85,hematologic toxicity,4,NA,NA,NA
17905421,NA,85,non-hematologic toxicity related to bortezomib,>=3,NA,NA,NA
18432260,NA,86,neuropathy,>=3,NA,NA,NA
18432260,NA,86,other non-hematologictoxicity,>=3,NA,NA,NA
18432260,NA,86,hematologic toxicity,4,NA,NA,NA
18640031,NA,87,ANC < 500 X 109/L,NA,>7 days,NA,NA
18640031,NA,87,febrile neutropenia,NA,NA,NA,NA
18640031,NA,87,thrombocytopenia,4,NA,NA,NA
18640031,NA,87,thrombocytopenia requiring platelet transfusions,3,NA,NA,NA
18640031,NA,87,neuropathy,>=2,NA,NA,NA
18640031,NA,87,diarrhoea,>=3,NA,NA,NA
18640031,NA,87,any other non haematological toxicity,>=3,NA,FALSE,NA
18640031,NA,87,persisting non haematological toxicities caused a > 2 week delay before starting a new cycle,>=2,NA,NA,NA
18640031,NA,87,failure to deliver P 2 doses of Bortezomib in the first cycledue to toxicity,NA,NA,NA,NA
18645194,NA,88,nonhematologic toxicity,>=3,NA,NA,NA
18645194,NA,88,platelets <= 10 X 109/L on more than one occasion,4,NA,NA,NA
18645194,NA,88,neutropenia,4,>5 days,NA,NA
18645194,NA,88,neutropenia associated with fever,4,NA,NA,NA
18689866,NA,89,hematologic toxic effects,4,NA,NA,NA
18689866,NA,89,non-hematologic toxic effects,>=3,NA,TRUE,NA
18689866,NA,89,thrombocytopenia with grade 2 hemorrhage,3,NA,NA,NA
18327587,NA,90,non-hematological toxicity,>=3,NA,NA,NA
18327587,NA,90,hematologicaltoxicity,>=4,NA,TRUE,NA
18327587,NA,90,handâ€“foot syndrome,>=2,NA,NA,NA
18327587,NA,90,neutropenia accompanied byfever,4,NA,NA,NA
18327587,NA,90,neutropenia,4,>5 days,NA,NA
18327587,NA,90,a 2 week or greater dose delay,NA,NA,NA,NA
18322686,NA,91,any toxicity thought to be probably or deWnitely related totreatment,>=3,NA,NA,NA
18322686,NA,91,neutrophils,>=3,> 5 days,NA,NA
18322686,NA,91,neutrophils accompanied by fever,>=3,NA,NA,NA
18322686,NA,91,hemoglobin,4,NA,NA,NA
18322686,NA,91,"platelets <= 25,000/mm3",NA,NA,NA,NA
18322686,NA,91,Nausea,>=3,NA,NA,NA
18322686,NA,91,vomiting,>=3,NA,NA,NA
18322686,NA,91,diarrhea,>=3,NA,NA,NA
18809314,NA,92,non-haematologic toxicity,>=3,NA,FALSE,NA
18809314,NA,92,haematologic toxicities,>=3,NA,NA,NA
18809314,NA,92,ANC <0.5 X 109/l,>=3,>=5 days,NA,NA
18809314,NA,92,febrile neutropaenia,NA,NA,NA,NA
18809314,NA,92,Any toxicity which prevented the combination from being given according to the planned schedule at cycle 1,NA,NA,NA,NA
19183191,NA,93,non-hematological toxicity,>=3,NA,FALSE,NA
19183191,NA,93,neutropenia,4,>7 days,NA,NA
19183191,NA,93,thrombocytopenia,4,>7 days,NA,NA
19401697, NCT00622674,94,treatment related haematological toxicity,>=4,NA,NA,NA
19401697, NCT00622674,94,treatment related nonhematological toxicity,>=3,NA,NA,NA
19401697, NCT00622674,94,the delay of the start of cycle 2 treatment by more than 3 weeks because of incomplete haematological recovery (ANC <=1500 mm3 or platelets <=100 000 mm3) or unresolved nonhematological >=2 toxicity,NA,NA,NA,NA
21252987, NCT00477542,95,non-hematologictoxicity,>=3,>day +30,TRUE,NA
22080439,NA,96,nonhematologic adverse events,>=3,NA,NA,NA
22080439,NA,96,laboratory abnormalities that did not resolve to grade I or baseline within 14days,>=3,NA,NA,NA
22080439,NA,96,hematologic events that did not improve tograde III or less within 14 days,4,NA,NA,NA
22080439,NA,96,Febrile neutropenia requiring hospitalization or intravenous antibiotics and grade IIIinfusion reactions that did not resolve to grade I or baselinewithin 24 hours,>=3,NA,NA,NA
22179664,NCT00195260,97,non-hematologic toxicity,>=3,NA,NA,NA
22179664,NCT00195260,97,neutropenia,4,>7 days,NA,NA
22179664,NCT00195260,97,neutropenia with fever of at least 38.5*C,4,NA,NA,NA
22179664,NCT00195260,97,thrombocytopenia,4,>2 days,NA,NA
22179664,NCT00195260,97,thrombocytopenia with bleeding that required platelet transfusion,4,NA,NA,NA
22179664,NCT00195260,97,clinically significant toxicity,>=2,>14 days,NA,NA
22198540,NA,98,mortality within 100 days posttransplantation withoutevidence of persistent or recurrent malignancy,NA,NA,NA,NA
22198540,NA,98,seizure occurring within 72 hours of busulfan administration,NA,NA,NA,NA
22198540,NA,98,severe VOD/SOS,NA,NA,NA,NA
22198540,NA,98,"toxicity in the followingcategories: cardiac, gastrointestinal, hepatobiliary, hyperbilirubinemia on at least two consecutive measurements at least 24 hours",4,within the first 100 days posttransplantation,FALSE,NA
24239220,NCT01060904,99,any adverse event requiring a delay of 7 days or greater of ABVD or AVD therapy during cycle 1 only,NA,NA,NA,NA
25776193,NA,101,NA,NA,NA,NA,not mentioned
26210442,NCT00448357,102,NA,1,NA,NA,not mentioned
28473406,NCT01940796,103,any nonhematologic drug-related event,>=3,NA,NA,"either did not resolve to grade 0-1 or baseline within 7 days or resolved but then recurred
after resumingBV"
28473406,NCT01940796,103,peripheral neuropathy,>=2,NA,NA,NA
28473406,NCT01940796,103,infusion reaction that did not resolve to grade 1 or baseline within 24 hours,>=3,NA,NA,NA
31619057,NA,104,nonhematological toxicity,>=4,NA,NA,NA
33991360,NCT02311998,105,NA,1,NA,NA,Not defined
34614506,NCT03613532,106,any treatment-related death,NA,NA,NA,NA
34614506,NCT03613532,106,primary graft failure,NA,NA,NA,NA
34614506,NCT03613532,106,delay in neutrophil engraftment,NA,NA,NA,defined as failure to achieve an ANC >= 0.5 x 109/L by day +28 on at least two separate occasions >2 days apart by day +28
34614506,NCT03613532,106,TLS,>=4,NA,NA,NA
34614506,NCT03613532,106,non-hematologic organ toxicity,>=4,NA,FALSE,NA
34614506,NCT03613532,106,veno-occlusive disease,>=3,NA,NA,NA
9537208,NA,107,"renal, pulmonary, cardiac, or neurologic toxicity",>=2,NA,NA,NA
9537208,NA,107,other nonhematologic toxicity,>=3,NA,NA,NA
9537208,NA,107,hematologic toxicity that resulted in more than a 1-week delay in initiation of a subsequent cycle,4,NA,NA,NA
9537208,NA,107,Neutropenic fevers,NA,NA,NA,NA
9537208,NA,107,thrombocytopenia requiring transfusion,4,NA,NA,NA
17317832,NA,108,toxicity,>=3,NA,FALSE,NA
17317832,NA,108,hypercalcemia that is associated withserious hypercalcemic symptoms,>=2,NA,NA,NA
17317832,NA,108,any treatment interruption that lasts for >2 weeks that is related to treatment toxicity,4,NA,NA,NA
17317832,NA,108,sustained increase (>72 h) in creatinine to >2X baseline and >2 g/dL,NA,NA,NA,NA
17317832,NA,108,clinical or radiological evidence of new genitourinary stones,NA,NA,NA,NA
17066293,NA,109,hypercalcemia,>=2,NA,NA,NA
17066293,NA,109,toxicities that were deemed treatment related and resulted in discontinuation ofthe study drug or were deemed persistent by the investigator.,>=3,NA,NA,NA
19396601,NA,110,toxicity,>=3,NA,FALSE,NA
19396601,NA,110,hypercalcemia (corrected calcium >11.5 mg/dL),>=2,NA,NA,NA
19396601,NA,110,hypercalcemia that is associated with serious hypercalcemic symptoms,>=2,NA,NA,NA
19396601,NA,110,any treatment interruption that lasts for >2 weeks that is related to treatment toxicity,NA,NA,NA,NA
19396601,NA,110,sustained increase (>72 h) in creatinine to>2x baseline and >2 g/dL,NA,NA,NA,NA
19396601,NA,110,clinical or radiological evidence of new genitourinary stones,NA,NA,NA,NA
21606412,NCT00215605,112,cabozantinib-related nonhematologic toxicity,>=3,NA,NA,NA
21606412,NCT00215605,112,nausea and/or vomiting,3,NA,NA,NA
21606412,NCT00215605,112,diarrhea despite prophylaxis and/ortreatment,3,NA,NA,NA
21606412,NCT00215605,112,thrombocytopenia,4,NA,NA,NA
21606412,NCT00215605,112,neutropenia,4,>5 days,NA,NA
21606412,NCT00215605,112,neutropenia with fever or documented infection,4,NA,NA,NA
22975213,NA,113,neutropenia,4,>5 days,NA,NA
22975213,NA,113,thrombocytopenia,4,NA,NA,NA
22975213,NA,113,febrile neutropenia,NA,NA,NA,NA
22975213,NA,113,non-haematologic toxicity,>=3,NA,TRUE,NA
23435876,NA,114,Hypophosphatemia with phosphate < 1.5 mg/dL,NA,>10 days,NA,NA
23435876,NA,114,"Hypophosphatemia  associated with symptoms unequivocally related to hypophosphatemia: profound weakness, ventilatory compromise or serum phosphate < 0.75 mg/dL",NA,NA,NA,NA
23435876,NA,114,Hypercalcemia with an increase in corrected serum calcium >=12 mg/dL,NA,>7 days,NA,NA
23435876,NA,114,"Hypercalcemia with an increase in corrected serum calcium >=12 mg/dL  if symptomatic, any corrected calcium C13 mg/dL (symptomatic or asymptomatic) or development of nephrolithiasis, symptomatic or radiographic",NA,NA,NA,NA
23435876,NA,114,Sustained increases (>72 h) in creatinine of more thandouble the baseline and >2.5 mg/dL,NA,NA,NA,NA
23435876,NA,114,non-hematological toxicity that could beattributed to cisplatin/docetaxel alone,>=3,NA,NA,NA
23435876,NA,114,dose delays ofgreater than 2 weeks,NA,NA,NA,NA
23435876,NA,114,hematological toxicity,4,>7 days,NA,NA
23435876,NA,114,any hospitalization/removal from studyrelated to toxicities or adverse events from the study drugs,NA,NA,NA,included at the start of dose level 3
23435876,NA,114,non-hematological toxicity,>=3,NA,TRUE,included at the start of dose level 3
24099585, NCT01755390,115,neutropenia,4,>5 days,NA,NA
24099585, NCT01755390,115,thrombocytopenia,4,NA,NA,NA
24099585, NCT01755390,115,febrileneutropenia,NA,NA,NA,NA
24099585, NCT01755390,115,non-haematological toxicity,>=3,NA,TRUE,NA
24488323,NA,116,neutropenia,4,>7 days,NA,NA
24488323,NA,116,thrombocytopenia,4,NA,NA,NA
24488323,NA,116,febrile neutropenia,4,NA,TRUE,NA
25013124,NA,117,hypercalcemia,>=3,NA,NA,NA
25013124,NA,117,persistent treatment related toxicities,>=3,NA,NA,NA
25117475,NCT00925743,118,non-hematologic toxicity,>=3,NA,TRUE,NA
25117475,NCT00925743,118,febrile neutropenia,NA,NA,NA,"fever â‰¥38.5 Â°C
of unknown origin without clinically or microbiologically
documented infection combined with Grade 3/4 neutropenia"
25117475,NCT00925743,118,neutropenia,4,>7 days,NA,NA
25117475,NCT00925743,118,thrombocytopenia,4,NA,NA,NA
25117475,NCT00925743,118,any other life-threatening toxicity,NA,NA,NA,NA
25486878,NCT01497964,119,neutropenia,4,> 7days,NA,NA
25486878,NCT01497964,119,neutropenia  complicated by documented infection,>=3,NA,NA,NA
25486878,NCT01497964,119,febrile neutropenia (FN) with neutropenia not improving to Grade <3 within 7 days,3,NA,NA,NA
25486878,NCT01497964,119,febrile neutropenia,4,NA,NA,NA
25486878,NCT01497964,119,thrombocytopenia complicated by serious bleeding,3,NA,NA,NA
25486878,NCT01497964,119,non-hematologic toxicity,>=3,NA,FALSE,NA
25486878,NCT01497964,119,A treatment delay of >2 weeks at Cycle 2 due to delayed recovery of toxicities,NA,NA,NA,NA
26020806,NCT01001221,120,any non-hematologic event,>=3,NA,TRUE,NA
26020806,NCT01001221,120,peripheral neuropathy that had not resolved before the initiation of the next treatment cycle,2,NA,NA,NA
26020806,NCT01001221,120,febrile neutropenia,NA,NA,NA,NA
26020806,NCT01001221,120,neutropenia,4,>7 days,NA,NA
26020806,NCT01001221,120,thrombocytopenia,4,NA,NA,NA
26020806,NCT01001221,120,Any life-threatening toxicity that was thought to be drug related,NA,NA,NA,NA
27439894,NCT01663272,121,thrombocytopenia,>=3,NA,NA,NA
27439894,NCT01663272,121,neutropenia,4,>7 days,NA,NA
27439894,NCT01663272,121,neutropenic fever,>=3,NA,NA,NA
27439894,NCT01663272,121,"non-hematologic toxicity attributable to cabozantinib and/orgemcitabine, with toxicity intolerable to the patient and requiring a dose interruption for â‰¥7 days",>=2,NA,NA,NA
27439894,NCT01663272,121,"non-hematologic toxicities that were possibly, probably, or definitely related to cabozantinib and/or gemcitabine",>=3,NA,FALSE,NA
28039155,NCT01511536,122,non-hematologic AE,>=3,NA,NA,NA
28039155,NCT01511536,122,febrile neutropenia,NA,NA,NA,"fever>= 38.5  C of unknown origin, without infection, with
grade 3â€“4 neutropenia"
28039155,NCT01511536,122,neutropenia,4,>7 days,NA,NA
28039155,NCT01511536,122,thrombocytopenia,4,NA,NA,NA
28039155,NCT01511536,122,thrombocytopenia complicated by hemorrhage,3,NA,NA,NA
28039155,NCT01511536,122,Treatment delay of > 2 weeks due to delayed recovery,NA,NA,NA,NA
28058445,NCT01140607,123,increases in bilirubin and/or transaminase levels to three times the baseline value,NA,NA,NA,NA
28058445,NCT01140607,123,non-hematologic AEs,>=3,NA,FALSE,NA
28058445,NCT01140607,123,febrile neutropenia,NA,NA,NA,NA
28058445,NCT01140607,123,neutropenia,4,>7 days,NA,NA
28058445,NCT01140607,123,thrombocytopenia,4,NA,NA,NA
27862097,NCT01513733,124,febrile neutropenia,4,NA,NA,NA
27862097,NCT01513733,124,thrombocytopenia,4,NA,NA,NA
27862097,NCT01513733,124,thrombocytopenia associated with a clinicallysignificant bleeding event,3,NA,NA,NA
27862097,NCT01513733,124,persistent nausea or vomiting despite maximumsupportive care,>=3,NA,NA,NA
27862097,NCT01513733,124,non-hematologic toxicity,>=3,NA,NA,NA
28352985,NCT00596648,125,a treatment-emergent AE that warranted dose reduction or was of signifcant risk,NA,NA,NA,NA
28352985,NCT00596648,125,non-hematologic significant toxicity,>=3,NA,NA,NA
28352985,NCT00596648,125,diarrhea despite prophylaxis and other optimal treatment,3,NA,NA,NA
28352985,NCT00596648,125,intolerable rash,>=3,NA,NA,NA
28352985,NCT00596648,125,thrombocytopenia,4,NA,NA,NA
28352985,NCT00596648,125,neutropenia,4,>5 days,NA,NA
28352985,NCT00596648,125,neutropenia with fever and documented infection,>=3,NA,NA,NA
28352985,NCT00596648,125,inability to take >75% of planned study dose owing to an AE,NA,NA,NA,NA
28352985,NCT00596648,125,inability to start Cycle 2 within 28 days of planned start date because of an AE,NA,NA,NA,NA
28263212,NA,126,neutropenia,4,>7 days,NA,NA
28263212,NA,126,neutropenia when there was failure of count recovery to allow for the next treatment cycleon time,3,NA,NA,NA
28263212,NA,126,thrombocytopenia,4,NA,NA,NA
28263212,NA,126,thrombocytopenia when failure of count recovery to allow for the next treatment cycle on time,3,NA,NA,NA
28263212,NA,126,anemia,4,NA,NA,NA
28263212,NA,126,nonhematologic toxicities,4,NA,NA,NA
28263212,NA,126,nonhematologic toxicity,3,NA,FALSE,NA
28688700,NA,127,toxicity,>=4,NA,NA,NA
28688700,NA,127,toxicity,3,>7 days,NA,NA
28960265,NCT01961765,128,nonhematologic toxicity,>=3,NA,FALSE,NA
28960265,NCT01961765,128,oral mucositis,4,NA,NA,NA
28960265,NCT01961765,128,nonhematologic toxicity that was intolerable or renderedpatients unable to take 75% or more of the assigned doses,>=2,NA,NA,NA
28960265,NCT01961765,128,"hematologic toxicity with a nonleukemic marrow cellularity <= 5%, and death",4,>42 days,NA,NA
29750396,NCT01751308,131,hematologic toxicity,4,NA,TRUE,NA
29750396,NCT01751308,131,febrile neutropenia,>=3,NA,FALSE,NA
29750396,NCT01751308,131,thrombocytopenia,4,NA,TRUE,NA
29750396,NCT01751308,131,non-hematologic toxicity,>=3,NA,TRUE,NA
29750396,NCT01751308,131,"dehydration that, in the investigator's opinion, occurred in the settingof inadequate treatment of other toxicities",>=3,NA,NA,NA
29750396,NCT01751308,131,fatigue,3,<=7 days,NA,NA
29750396,NCT01751308,131,retreatment delay of >2 weeks due to delayed recovery from a toxicityrelated to the study treatment to baseline grade or â‰¤Grade 1,NA,NA,FALSE,NA
29750396,NCT01751308,131,Platelet transfusions during cycle 1 and treatment delays of >2 weeksbefore cycle 2 due to a treatment-related toxicity,NA,NA,NA,NA
31765988,NA,133,neutropenia with sepsis or with fever > 38.5 Â°C,>=3,NA,NA,NA
31765988,NA,133,thrombocytopenia,4,NA,NA,NA
31765988,NA,133,diarrhoea,4,NA,NA,NA
31765988,NA,133,Symptomatic ophthalmic toxicity (epitheliopathy or erosion) which does not recover within 3 days of detection,4,NA,NA,NA
31765988,NA,133,rash despite optimal treatment,>=3,>5 days,NA,NA
31765988,NA,133,QTc prolongation > 500 msec or QTc increase > 60 msec above screening value,NA,NA,NA,NA
31765988,NA,133,other non-haematological toxicities,>=3,NA,FALSE,NA
31765988,NA,133,Delay of > 2 weeks in administration of cycle 2 of treatment due to haematological or non-haematological toxicities,NA,NA,NA,NA
31765988,NA,133,Failure to deliver 100% of the planned dose of Xelox due to toxicity attributable to AZD8931 or the AZD8931/Xelox combination,NA,NA,NA,NA
32175106,NA,134,NA,NA,NA,NA,DLT not defined
33206291,NCT01588522,135,toxicities attributed to the topical BPM31543,>=3,NA,NA,NA
33469991,NCT02008383,136,NA,NA,NA,NA,Not defined
32969563,NCT01683994,137,non-haematological laboratory findings,>=3,NA,NA,NA
32969563,NCT01683994,137,febrile neutropenia,NA,NA,NA,NA
32969563,NCT01683994,137,neutropenia,4,>5 days,NA,NA
32969563,NCT01683994,137,thrombocytopenia,3,>7 days,NA,NA
32969563,NCT01683994,137,adverse events (AEs) that led to a >2 week delay in treatmentor dose reduction,NA,NA,NA,NA
34019214, NCT04097444,138,neutropenia,4,>8 days,NA,NA
34019214, NCT04097444,138,febrile neutropenia,NA,NA,NA,NA
34019214, NCT04097444,138,thrombocytopenia,4,NA,NA,NA
34019214, NCT04097444,138,thrombocytopeniarequiring platelet transfusion,3,NA,NA,NA
34019214, NCT04097444,138,digestive symptoms that did not improve after â‰¥ 5 days despite optimaltreatment,3,NA,NA,NA
32584367,NCT01702558,139,thrombocytopenia that does not recover before Day 21,4,NA,NA,NA
32584367,NCT01702558,139,thrombocytopenia complicated with clinically significant bleeding requiring medical intervention,NA,NA,NA,NA
32584367,NCT01702558,139,neutropenia,4,>7 days,NA,NA
32584367,NCT01702558,139,febrile neutropenia with absolute neutrophil count (ANC) less than (<) 1000 cells/millimeter cube (mm^3),NA,NA,NA,NA
32584367,NCT01702558,139,diarrhea,>=3,NA,NA,NA
32584367,NCT01702558,139,hand-foot syndrome,3,NA,NA,NA
32584367,NCT01702558,139,toxicity prohibiting start of Cycle 2,>=3,NA,NA,NA
32584367,NCT01702558,139,toxicity requiring treatment interruption for >14 days (>7 days for DL 1),2,NA,NA,NA
32584367,NCT01702558,139,<14 full doses of capecitabine,NA,NA,NA,for DL-1 only
32584367,NCT01702558,139,Cycle 2 dose level <100 percent (%),NA,NA,NA,NA
32253554,NA,140,neutropenia with ANC < 500/mm3,4,>7 days,NA,NA
32253554,NA,140,febrile neutropenia,>=3,NA,NA,NA
32253554,NA,140,thrombocytopenia,4,NA,NA,NA
32253554,NA,140,thrombocytopenia with associated bleeding,3,NA,NA,NA
32253554,NA,140,treatment related non-hematologic toxicities,4,NA,FALSE,NA
32253554,NA,140,any study drug-related toxicity resulting in >2 weeks delayin the initiation of the next cycle,NA,NA,NA,NA
32253554,NA,140,any study drug-related toxicity that prevents completion of cycle 1,NA,NA,NA,NA
32382808,NTR4639,141,non-hematologic toxicity,>=3,NA,FALSE,NA
32382808,NTR4639,141,thrombocytopenia associated with bleeding events,>=3,NA,NA,NA
32382808,NTR4639,141,neutropenia,4,NA,NA,NA
32382808,NTR4639,141,febrile neutropenia,3,NA,NA,NA
32382808,NTR4639,141,anaemia,>=3,NA,NA,NA
32382808,NTR4639,141,a dose interruption of more than 7 days due to toxicity,NA,NA,NA,NA
32915679,NCT02496208,143,adverse event (AE) potentially attributable to any of thestudy drugs or the combination that required permanentdiscontinuation of protocol therapy,NA,NA,NA,NA
32915679,NCT02496208,143,adverse event (AE) potentially attributable to any of thestudy drugs or the combination,>=3,NA,NA,NA
32915679,NCT02496208,143,dose reduction or interruption of cabozantinib led to a patienttaking <= 75% of the planned dose,NA,NA,NA,NA
33452614,NA,144,neutropenia,4,>7 days,NA,NA
33452614,NA,144,febrile neutropenia,>=3,NA,NA,NA
33452614,NA,144,anemia,4,NA,NA,NA
33452614,NA,144,thrombocytopenia,4,NA,NA,NA
33452614,NA,144,thrombocytopenia,>=3,>7 days,NA,NA
33452614,NA,144,thrombocytopenia associated with bleeding,>=3,NA,NA,NA
33452614,NA,144,AST or ALT elevations,4,NA,NA,NA
33452614,NA,144,AST or ALT elevations > 5 Ã— upper limit of normal (ULN) without liver metastases,NA,>3 days,NA,NA
33452614,NA,144,AST or ALT elevations > 5 Ã— ULN plus â‰¥ grade 2 elevation in bilirubin,NA,NA,NA,NA
33452614,NA,144,AST or ALT elevations > 5 Ã— ULN if the baseline level was â‰¤ 3 Ã— ULN in subjects with liver metastases,NA,>3 days,NA,NA
33452614,NA,144,AST or ALT elevations > 8 Ã— ULN if the baseline level was > 3 Ã— ULN in subjects with liver metastases,NA,>3 days,NA,NA
29882250,NA,145,NA,NA,NA,NA,not defined
29693796, NCT01709435,147,decrease in ANC or platelet count,4,NA,NA,NA
29693796, NCT01709435,147,any myelosuppression that caused adelay of>14 days between treatment cycles,NA,NA,NA,NA
29693796, NCT01709435,147,"more than one platelet transfusion administered for a plateletcount â‰¤50,000/ðœ‡l",NA,NA,NA,"for patients with CNS
tumors"
29693796, NCT01709435,147,nonhematological toxicity,>=3,NA,TRUE,NA
29693796, NCT01709435,147,"a blood pressure > 10 mm Hg but â‰¤25 mm Hg above the 95th percentile for age, height, and gender",NA,>14 days,NA,In patients who began antihypertensive therapy
29693796, NCT01709435,147,non-hematological toxicity s considered sufficiently medically significant or intolerable by patients that it required treatment interruption,2,>= 7 days,NA,NA
29693796, NCT01709435,147,any toxicity requiring interruption of study drug during a cycle of therapy for â‰¥7 days or which recurs upon drug challenge,NA,NA,NA,NA
25577134, UMIN000005440,148,neutropenia,4,>4 days,NA,NA
25577134, UMIN000005440,148,febrile neutropenia,NA,NA,NA,NA
25577134, UMIN000005440,148,thrombocytopenia,4,NA,NA,NA
25577134, UMIN000005440,148,non-hematological toxicity,>=3,NA,FALSE,NA
25577134, UMIN000005440,148,any event resulting in treatment discontinuation for longer than 2 weeks,1,NA,NA,NA
25318436,NA,149,absolute neutrophil countless than500,NA,>7 days,NA,NA
25318436,NA,149,febrile neutropenia,NA,NA,NA,NA
25318436,NA,149,neutropenic infection,>=3,NA,NA,NA
25318436,NA,149,"platelets less than 25,000",NA,NA,NA,NA
25318436,NA,149,thrombocytopenic bleeding,NA,NA,NA,NA
25318436,NA,149,nonhematologic toxicity,>=3,NA,FALSE,NA
25318436,NA,149,aspartate transaminase/alanine transaminase elevations,>=3,> 7 days,NA,NA
25318436,NA,149,toxicity leading to two or moremissed doses per cycle,NA,NA,NA,NA
25318436,NA,149,toxicity resulting in the delay ofthe subsequent cycle by 14 days or greater,NA,NA,NA,NA
29725881,NA,150,any non-hematological toxicity,>=3,NA,TRUE,NA
29725881,NA,150,neutropenia,4,> 5 days,NA,NA
29725881,NA,150,neutropenia associated with fever>100.5 Â°F (38.5 Â°C),4,NA,NA,NA
29725881,NA,150,anemia,4,NA,NA,NA
29725881,NA,150,thrombocytopenia,4,NA,NA,NA
29725881,NA,150,any treatment delay of >14 days due to drugrelated toxicity,NA,NA,NA,NA
28973403,NCT01791374,151,hematologic adverse events related to rilotumumab or the combination of rilotumumab and CX,>=3,NA,FALSE,NA
28973403,NCT01791374,151,nonhematologic adverse events related to rilotumumab or the combination of rilotumumab and CX,>=3,NA,FALSE,NA
28973403,NCT01791374,151,pulmonary embolism requiring anticoagulation therapy,>=3,NA,NA,NA
28973403,NCT01791374,151,"ALT or AST >8 Ã— upper limit of normal [ULN], or >5 Ã— ULN for >2 weeks for patients with baseline levels â‰¤2.5 ULN, or >2 Ã— ULN for >2 weeks for patients with baseline levels >2.5â€“â‰¤4 Ã— ULN, or >3 Ã— ULN and total bilirubin >2 Ã— ULN or international normalized ratio >1.5 ULN",NA,NA,NA,NA
28973403,NCT01791374,151,thrombocytopenia with Grade >1 bleeding,>=3,NA,NA,NA
28973403,NCT01791374,151,neutropenia with fever >38.5Â°C or infection,>=3,NA,NA,NA
28973403,NCT01791374,151,neutropenia,4,>7 days,NA,NA
28973403,NCT01791374,151,diarrhea despite maximum supportive care,>=3,NA,NA,NA
28973403,NCT01791374,151,fatigue,3,>7 days,NA,NA
28973403,NCT01791374,151,fatigue,4,NA,NA,NA
26706729,NA,152,"any drug-induced toxicity that resultedin a dose interruption or dose delay during the first 2 cyclesof treatment, where causality was ascribed to the studydrug.",>=2,NA,NA,NA
30783204, NCT01323530,153,neutropenia complicated by fever(â‰¥38.5 Â°C),>=3,NA,NA,NA
30783204, NCT01323530,153,neutropenia,4,>7 days,NA,NA
30783204, NCT01323530,153,thrombocytopenia complicated by bleeding and/or requiring ablood transfusion,3,NA,NA,NA
30783204, NCT01323530,153,thrombocytopenia,4,NA,NA,NA
30783204, NCT01323530,153,non-haematologic toxicities,>=3,NA,FALSE,NA
30783204, NCT01323530,153,delayed recovery from treatment-related toxicity resulting in a dose delay â‰¥14 days,NA,NA,NA,NA
30783204, NCT01323530,153,failure to administer at least 75% of the planned study drugsduring cycle 1 as a result of a grade â‰¥2 treatment-related toxicity that constituted an increase of at least 2 grades from baseline,NA,NA,NA,NA
24820348,NA,154,neutropenia,4,NA,NA,NA
24820348,NA,154,febrile neutropenia,>=3,NA,NA,NA
24820348,NA,154,nonhematological toxicities,>=3,NA,FALSE,NA
29330005,NA,155,an absolute neutrophil count <0.5 X 109/L,NA,>7 days,NA,NA
29330005,NA,155,febrile neutropenia,NA,NA,NA,NA
29330005,NA,155,platelet count < 50 X 109/L,NA,NA,NA,NA
29330005,NA,155,thrombocytopenic bleeding,3,NA,NA,NA
29330005,NA,155,any event,3 or 4,NA,TRUE,NA
29330005,NA,155,creatinine clearance < 40 mL/min,NA,NA,NA,NA
29330005,NA,155,neurotoxicity,>=2,>5 days,NA,NA
31266024,NA,156,anemia,4,NA,NA,NA
31266024,NA,156,thrombocytopenia,4,NA,NA,NA
31266024,NA,156,neutropenia,4,>7 days,NA,NA
31266024,NA,156,neutropenia associated with a fever of 38Â°C,3,NA,NA,NA
31266024,NA,156,nonhematological toxicity,3 or 4,NA,FALSE,NA
26460795,NCT01226732,157,absolute neutrophil count (ANC) <500/Î¼L,NA,NA,NA,NA
26460795,NCT01226732,157,"platelets <25,000/Î¼L",NA,>5 days,NA,NA
26460795,NCT01226732,157,ANC <1000/Î¼L with fever,NA,NA,NA,NA
26460795,NCT01226732,157,thrombocytopenia with â‰¥ grade 2 bleeding,3,NA,NA,NA
26460795,NCT01226732,157,"nausea, vomiting, or diarrhea (NVD)",>=3,>= 72 hours,NA,NA
26460795,NCT01226732,157,"nausea, vomiting, or diarrhea (NVD)",4,NA,NA,NA
26460795,NCT01226732,157,electrolyte imbalance that does not correct within 24 hours to < grade 2 despite maximal medical intervention,>=3,NA,NA,NA
26460795,NCT01226732,157,non-hematological drugrelated toxicity,>=3,NA,NA,NA
26460795,NCT01226732,157,inability to receive 80%of required doses of both agents secondary to toxicity,NA,NA,NA,NA
29153866,NCT01300962,158,nonhematologic toxicity that required withholding a dose for > 7 days or required adose reduction,>=2,NA,NA,NA
29153866,NCT01300962,158,hematologic toxicity that required withholding a dose for > 7 days or required adose reduction,3,NA,NA,NA
29153866,NCT01300962,158,hematologic toxicity,>=4,NA,NA,NA
29153866,NCT01300962,158,nonhematologic toxicity,>=3,NA,FALSE,NA
29153866,NCT01300962,158,photosensitivity,>=2,NA,NA,NA
29153866,NCT01300962,158,level increase in neurotoxicity,>=1,NA,NA,NA
31675952,NCT01661972,159,neutropenia,4,NA,NA,NA
31675952,NCT01661972,159,thrombocytopenia,4,NA,NA,NA
31675952,NCT01661972,159,anemia,4,NA,NA,NA
31675952,NCT01661972,159,neutropenia,3,>7 days,NA,NA
31675952,NCT01661972,159,thrombocytopenia,3,>7 days,NA,NA
31675952,NCT01661972,159,thrombocytopeniaassociated with bleeding,3,NA,NA,NA
31675952,NCT01661972,159,neutropenic fever,NA,NA,NA,NA
31675952,NCT01661972,159,"nausea, vomiting or diarrhea despite supportive measures",>=3,>= 4 days,NA,NA
31675952,NCT01661972,159,bilirubin elevation,>=3,>7 days,NA,NA
31675952,NCT01661972,159,ALT elevation,>=3,>7 days,NA,NA
31675952,NCT01661972,159,AST elevation,>=3,>7 days,NA,NA
31675952,NCT01661972,159,other non-hematologictoxicity,>=3,NA,NA,NA
31675952,NCT01661972,159,"alopecia, anorexia, fatigue, hypertension, isolated lab abnormalities (not clinicallysignificant) and rare, idiosyncratic reactions to any of the study drugs",NA,NA,NA,NA
31675952,NCT01661972,159,inability to receive at least 80% of scheduled doses of each study drug due to treatmentrelated toxicity,NA,NA,NA,NA
31675952,NCT01661972,159,any treatment-related death or treatment-related hospitalization,NA,NA,NA,NA
31675952,NCT01661972,159,Anorexia,>=4,NA,NA,NA
31675952,NCT01661972,159,fatigue,>=4,NA,NA,NA
31675952,NCT01661972,159,hypertension,>=4,NA,NA,NA
30418178,NA,160,neutropenia,4,>7 days,NA,not reversible to â‰¤ grade 3 within 7 days without the use of growth factors
30418178,NA,160,febrile neutropenia,NA,NA,NA,NA
30418178,NA,160,neutropenia associated with bacteremia or sepsis,NA,NA,NA,NA
30418178,NA,160,neutropenia associated withtreatment related fever or infection,>=3,NA,NA,NA
30418178,NA,160,thrombocytopenia,4,NA,NA,NA
30418178,NA,160,thrombocytopeniaaccompanied by clinically significant bleeding,3,NA,NA,NA
30418178,NA,160,non-hematologic toxicity despite maximal supportive care,>=3,NA,FALSE,NA
30418178,NA,160,"nausea, vomiting or diarrhea that persists despite optimal supportive care",>=3,NA,NA,NA
27390847,NCT00845884,161,hematologic toxicity,>=4,NA,NA,NA
27390847,NCT00845884,161,r non-hematologic toxicity,>=3,NA,NA,NA
27390847,NCT00845884,161,any delay in treatment due to toxicity of more than one week,NA,NA,NA,NA
29573846,NA,162,thrombocytopenia,4,NA,NA,NA
29573846,NA,162,neutropenia,4,>7 days,NA,NA
29573846,NA,162,febrile neutropenia,>=3,NA,NA,NA
29573846,NA,162,infection with or withoutneutropenia,4,NA,NA,NA
29573846,NA,162,nausea/vomiting despite full antiemetic treatment,4,NA,NA,NA
29573846,NA,162,diarrhoea despite full-doseloperamide,4,NA,NA,NA
29573846,NA,162,non-haematological toxicity,4,NA,FALSE,NA
29573846,NA,162,dose delay of >2 weeks because drug-related toxicity,NA,NA,NA,NA
29038850,UMIN 000009144,163,neutropenia lasting,4,>4 days,NA,NA
29038850,UMIN 000009144,163,febrile neutropenia,NA,NA,NA,NA
29038850,UMIN 000009144,163,thrombocytopenia,4,NA,NA,NA
29038850,UMIN 000009144,163,acne-like rash,4,NA,NA,NA
29038850,UMIN 000009144,163,other non-hematological  toxicities,3 or 4,NA,FALSE,NA
29038850,UMIN 000009144,163,any event resulting in treatment discontinuation for longer than 2 weeks,NA,NA,NA,NA
30949758,NCT03295084,164,neutropenia,4,NA,NA,NA
30949758,NCT03295084,164,thrombocytopenia,4,NA,NA,NA
30949758,NCT03295084,164,bleeding due to thrombocytopenia,NA,NA,NA,NA
30949758,NCT03295084,164,adverse event thought tobe treatment related,3 or 4,NA,NA,NA
30949758,NCT03295084,164,"diarrhea, vomiting or nauseadespite optimal treatment",>=3,NA,NA,NA
30949758,NCT03295084,164,moderate-to-severe symptoms of early cholinergic syndrome,NA,NA,NA,NA
30949758,NCT03295084,164,other adverse reactions leading to treatment delay for more than 2 weeks,NA,NA,NA,NA
25290090,NCT00959946,165,nausea,3 or 4,>3 days,NA,NA
25290090,NCT00959946,165,vomiting,3 or 4,>3 days,NA,NA
25290090,NCT00959946,165,diarrhoea despite optimal medical therapy,3 or 4,>3 days,NA,NA
25290090,NCT00959946,165,asthenia,3 or 4,>3 days,NA,NA
25290090,NCT00959946,165,haematologic AE,4,NA,NA,NA
25290090,NCT00959946,165,"delayed recovery from one of the above AEs, causing delay of treatment by at least 3 weeks.",NA,NA,NA,NA
29707156,NA,166,non-haematological toxicity,3 or 4,NA,NA,"(mainly represented by diarrhea, mucositis, neurotoxicity, hand-foot syndrome, asthenia"
29707156,NA,166,hematologic toxicity,4,NA,NA,NA
29707156,NA,166,febrile neutropenia,NA,NA,NA,NA
29707156,NA,166,thrombocytopenia,3 or 4,NA,NA,NA
29707156,NA,166,any toxicity determining > 2 weeks treatment delay,NA,NA,NA,NA
28894576,NA,167,neutropenia,4,>4 days,NA,NA
28894576,NA,167,thrombocytopenia,4,NA,NA,NA
28894576,NA,167,febrile neutropenia,NA,NA,NA,NA
28894576,NA,167,non-hematological toxicities,3 or 4,NA,NA,NA
28894576,NA,167,treatment discontinuation due to adverse events,NA,NA,NA,NA
28894576,NA,167,treatment-related death,NA,NA,NA,NA
29273261,NCT01474187,168,hematologic  toxicities,4,NA,NA,NA
29273261,NCT01474187,168,non-hematologic toxicities,3,NA,FALSE,NA
26632033,NA,169,neutropenia,4,>= 5 days,NA,NA
26632033,NA,169,neutropenia with fever,3 or 4,NA,NA,NA
26632033,NA,169,thrombocytopenia,4,NA,NA,NA
26632033,NA,169,nonhematological toxicity,3 or 4,NA,FALSE,NA
26632033,NA,169,symptomatic toxicity despite appropriatesupportive treatment,2,>7 days,NA,NA
26632033,NA,169,delay of treatment 3 weeksdue to toxicity,NA,NA,NA,NA
27473815,NCT01781403,170,neutropenia,4,NA,NA,NA
27473815,NCT01781403,170,febrile neutropenia,>=3,NA,NA,NA
27473815,NCT01781403,170,thrombocytopenia,>=3,NA,NA,NA
27473815,NCT01781403,170,"nonhematologic toxicity, including nausea, vomiting, and diarrhea, that did not improve within2 days after the commencement of appropriate management",>=3,NA,NA,NA
27473815,NCT01781403,170,a treatment interruption lasting longer than 2 weeks,NA,NA,NA,NA
27473815,NCT01781403,170,"an inability, for any reason, to administer more than 50% ofthe scheduled doses of study medications.",NA,NA,NA,NA
26499900,NA,171,nausea or vomiting,>=2,NA,NA,NA
26499900,NA,171,neutropenia,4,> 5 days,NA,NA
26499900,NA,171,thrombocytopenia,>=4,NA,NA,NA
26499900,NA,171,thrombocytopenia with bleeding,3,NA,NA,NA
26499900,NA,171,any other toxicity all despite best supportive care,>=3,NA,FALSE,NA
27404453,NCT01730222,172,neutropenia,4,>=7 days,NA,NA
27404453,NCT01730222,172,febrile neutropenia,>=3,NA,NA,NA
27404453,NCT01730222,172,fever of unknown origin >=38.5 C,NA,NA,NA,NA
27404453,NCT01730222,172,thrombocytopenia,4,NA,NA,NA
27404453,NCT01730222,172,thrombocytopenia which required transfusions,3,NA,NA,NA
27404453,NCT01730222,172,nausea or vomiting,>=3,NA,NA,NA
27404453,NCT01730222,172,diarrhoea,>=3,NA,NA,NA
27404453,NCT01730222,172,neurologicaltoxicity,>=2,NA,NA,NA
27404453,NCT01730222,172,toxicities or representing a shift by twogrades from baseline,>=3,NA,NA,NA
27404453,NCT01730222,172,failure to recover to grade p1 toxicity (except alopecia) or to baseline valuesafter delaying the initiation of next cycle by >2 weeks,NA,NA,NA,NA
31207904,NCT02273713,173,non-hematological toxicity,3 or 4,NA,NA,NA
31207904,NCT02273713,173,febrile neutropenia,NA,>5 days,NA,NA
31207904,NCT02273713,173,neutropenia,4,>7 days,NA,NA
31207904,NCT02273713,173,thrombocytopenia (platelet count < 25 Ã— 109/L),NA,NA,NA,NA
31207904,NCT02273713,173,infection,>=2,NA,NA,NA
31207904,NCT02273713,173,delay of treatment for more than two weeks due toside effects,NA,NA,NA,NA
25687867,NCT00842244,174,Miss > 3 consecutive days of capecitabine and/or > 5 consecutive days of axitinib per cycle due to treatment-related toxicity,NA,NA,NA,NA
25687867,NCT00842244,174,Delay > 2 weeks in administration of cycle 2 due to inadequate recovery from toxicity in cycle 1,NA,NA,NA,NA
25687867,NCT00842244,174,neutropenia,4,>=7 days,NA,NA
25687867,NCT00842244,174,febrile neutropenia,>=3,NA,NA,NA
25687867,NCT00842244,174,neutropenic infection,>=3,NA,NA,NA
25687867,NCT00842244,174,thrombocytopenia,4,NA,NA,NA
25687867,NCT00842244,174,thrombocytopenia with active bleeding,3,NA,NA,NA
25687867,NCT00842244,174,>= 0.5 teaspoon/day hemoptysis without resolution to baseline within 7 days,NA,NA,NA,NA
25687867,NCT00842244,174,proteinuria,2,NA,NA,NA
25687867,NCT00842244,174,nausea/vomiting and/or diarrhea despite optimal use of antiemetics and antidiarrheals,3 or 4,NA,NA,NA
25687867,NCT00842244,174,toxicity,3,>=7 days,NA,NA
25687867,NCT00842244,174,toxicity,4,NA,NA,NA
24983373,NCT00604409,175,non-haematologic toxicity,>=3,NA,TRUE,NA
24983373,NCT00604409,175,thrombocytopenia,3,>5 days,NA,NA
24983373,NCT00604409,175,thrombocytopenia,4,NA,NA,NA
24983373,NCT00604409,175,granulocytopenia,4,>5 days,NA,NA
24983373,NCT00604409,175,granulocytopenia associated with fever or infection,4,NA,NA,NA
24983373,NCT00604409,175,any interruption of therapy for >14 days due to toxicity,NA,NA,NA,NA
24711126,NCT00849550,176,neutropenia,4,> 7 days,NA,NA
24711126,NCT00849550,176,thrombocytopenia,4,> 7 days,NA,NA
24711126,NCT00849550,176,ausea/vomiting or diarrhea,>=3,NA,NA,NA
24711126,NCT00849550,176,ausea/vomiting or diarrhea despite adequate supportive measures,>=3,>= 4 days,NA,NA
24711126,NCT00849550,176,febrile neutropenia where ANC <500/Î¼l and temperature>101 Â°F,NA,NA,NA,NA
24711126,NCT00849550,176,hand foot syndrome,>=3,>=7 days,NA,NA
24711126,NCT00849550,176,neuropathy,>=3,NA,NA,NA
24711126,NCT00849550,176,hypophosphatemia despite adequate supportive measures,>=3,>24h,NA,NA
24711126,NCT00849550,176,hyperglycemia despiteadequate supportive measures,>=3,>7 days,NA,NA
24711126,NCT00849550,176,hypertriglyceridemia or hyperlipidemia  despite adequate supportive measures,>=3,>28 days,NA,NA
24711126,NCT00849550,176,other non-hematologic treatment related toxicity,>=3,NA,FALSE,NA
24711126,NCT00849550,176,"rare, allergic and/or idiosyncratic reactions to any of the study agents ofany severity",NA,NA,NA,NA
24711126,NCT00849550,176,any treatment-related death or hospitalization,NA,NA,NA,NA
24711126,NCT00849550,176,receiving less than 85 % of any of the planned study medication due to treatment-related toxicity,NA,NA,NA,NA
25750312,NCT00478634,177,noninfectious pneumonitis,3 or 4,NA,NA,NA
25750312,NCT00478634,177,febrile neutropenia,NA,NA,NA,NA
25750312,NCT00478634,177,thrombocytopenia,4,NA,NA,NA
25750312,NCT00478634,177,neutropenia,3 or 4,NA,NA,NA
25750312,NCT00478634,177,thrombocytopenia,3,>7 days,NA,NA
25750312,NCT00478634,177,thrombocytopenia recurring in the samecycle,3,NA,NA,NA
25750312,NCT00478634,177,nonhematological adverse event (AE) despiteappropriate prophylactic treatment occurring at any time,4,NA,NA,NA
25750312,NCT00478634,177,non-hematological AE despite appropriate prophylactic treatment lasting 7 days or recurring in the same cycle,3,NA,FALSE,NA
25750312,NCT00478634,177,any AE resulting in more than 2 week interruption or delay in any study treatment,NA,NA,NA,NA
30988080,NCT02650752,178,nonhematologic toxicity,>=3,NA,FALSE,NA
30988080,NCT02650752,178,"nausea, vomiting, or dehydration",3,NA,FALSE,NA
30988080,NCT02650752,178,diarrhea not responsive to supportive care measureswithin 72 hours,3,NA,NA,NA
30988080,NCT02650752,178,neutropenia,4,>= 5 days,NA,NA
30988080,NCT02650752,178,neutropenia with fever >38.5 and/or infection requiring antibiotic orantifungal therapy,4,NA,NA,NA
30988080,NCT02650752,178,thrombocytopenia,4,NA,NA,NA
30988080,NCT02650752,178,anemia,4,NA,NA,NA
30988080,NCT02650752,178,Any unresolved drug-related toxicity requiring drug interruption for >14 days in the first cycle and any drug-related toxicity leading to a dose modification of lapatinib in the first cycle,NA,NA,NA,NA
25142843,EudraCT: 2007-001021-10,179,NA,NA,NA,NA,not defined
27336466,NA,180,NA,NA,NA,NA,not defined
26715573,NCT00551096,181,neutropenia,4,NA,NA,NA
26715573,NCT00551096,181,febrile neutropenia,4,NA,NA,NA
26715573,NCT00551096,181,thrombocytopenia,4,NA,NA,NA
26715573,NCT00551096,181,thrombocytopenia withbleeding requiring transfusion,3,NA,NA,NA
26715573,NCT00551096,181,Any non-hematologic toxicity,>=3,NA,NA,NA
26715573,NCT00551096,181,"Diarrhea, nausea, or vomiting if all anti-emetic and anti-diarrheal treatments were maximally utilized",>=3,NA,NA,NA
27106554,NA,182,non-hematologic adverse event,>=3,NA,FALSE,NA
27106554,NA,182,nausea and/or vomiting despite optimal medical management,>=3,>=48 h,NA,NA
27106554,NA,182,neutropenia,4,>= 7 days,NA,NA
27106554,NA,182,febrile neutropenia,>=3,NA,NA,NA
27106554,NA,182,thrombocytopenia,4,NA,NA,NA
27106554,NA,182,hematologictoxicity,5,NA,NA,NA
27106554,NA,182,any study-related toxicity that required a hold ofchemotherapy and/or radiation of >14 days,NA,NA,NA,NA
27106554,NA,182,inability to deliver >75% of planned chemotherapy and/or radiation therapy in the two-week period,NA,NA,NA,NA
27542211,NCT01193517,183,drug related non-hematological toxicity,>=3,NA,TRUE,NA
27542211,NCT01193517,183,anemia,4,NA,NA,NA
27542211,NCT01193517,183,thrombocytopenia,4,NA,NA,NA
27542211,NCT01193517,183,neutropenia,4,>5 days,NA,NA
27542211,NCT01193517,183,febrile neutropenia,>=3,NA,NA,NA
27542211,NCT01193517,183,a treatment delay of > 14 days,NA,NA,NA,NA
25267761,NA,184,nonhematological drug-related toxicity unamenable to supportive care within 72 hours,3 or 4,NA,NA,NA
25267761,NA,184,neutropenia,4,> 5 days,NA,NA
25267761,NA,184,neutropenia associated with fever more than 100.5Â°F,4,NA,NA,NA
25267761,NA,184,thrombocytopenia,4,NA,NA,NA
25267761,NA,184,peripheral sensory neuropathy not resolving within 4 weeks of study drug discontinuation,>=2,NA,NA,NA
30858085,NCT02010567,185,toxicities,3 or 4,NA,NA,NA
30858085,NCT02010567,185,toxicities requiring a dose reduction of CRLX101 or capecitabine,NA,NA,NA,NA
30858085,NCT02010567,185,toxicities requiring RT interruption â‰¥5 days,1,NA,NA,NA
29998365,NCT 00925769,186,toxicity,3 or 4,NA,NA,NA
29998365,NCT 00925769,186,stopping of C and/or E intake â‰¥7 days and/or cancellation of one or more B infusions due to AEs,NA,NA,NA,NA
25287822,NCT00741260,187,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25287822,NCT00741260,187,diarrhea,3,>2 days,NA,NA
25287822,NCT00741260,187,neutropenia,4,>=3 days,NA,NA
25287822,NCT00741260,187,febrile neutropenia,4,NA,NA,NA
25287822,NCT00741260,187,thrombocytopenia,4,>=3 days,NA,NA
25287822,NCT00741260,187,thrombocytopenia associated with bleeding or requiring platelet transfusion,4,NA,NA,NA
25287822,NCT00741260,187,Delayed recovery from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks,NA,NA,NA,NA
31138588,NCT02361112,188,any treatment-related hematologic adverse events,4,NA,NA,NA
31138588,NCT02361112,188,heart failure,2,NA,NA,NA
31138588,NCT02361112,188,other nonhematologic AEs,3 or 4,NA,TRUE,NA
28413680,"ChiCTRâ€‘ONRCâ€‘13,004,023",189,hematological toxicity,4,NA,NA,NA
28413680,"ChiCTRâ€‘ONRCâ€‘13,004,023",189,any nonâ€‘hematological toxicity over the 2â€‘week delay prior tothe next cycle,3 or 4,NA,FALSE,NA
28413680,"ChiCTRâ€‘ONRCâ€‘13,004,023",189,Skin toxicity despiteoptimal treatment,>=3,NA,NA,NA
28413680,"ChiCTRâ€‘ONRCâ€‘13,004,023",189,vomiting despiteoptimal treatment,>=3,NA,NA,NA
28413680,"ChiCTRâ€‘ONRCâ€‘13,004,023",189,diarrhea despiteoptimal treatment,>=3,NA,NA,NA
30893699,UMIN000018383,190,long-lasting thrombocytopenia which did not recover to grade 1 within 21 days,4,NA,NA,NA
30893699,UMIN000018383,190,thrombocytopenia associated with severe bleeding,3,NA,NA,NA
30893699,UMIN000018383,190,neutropenia,4,>7 days,NA,NA
30893699,UMIN000018383,190,febrile neutropenia,NA,NA,NA,NA
30893699,UMIN000018383,190,non-hematological toxicity,4,NA,FALSE,NA
30893699,UMIN000018383,190,non-hematologic adverse events lasting until day 22 andcausing delay in starting the second cycle,>=3,NA,NA,NA
30893699,UMIN000018383,190,any adverse event requiring a rest of S-1 for longer than 7 days,NA,NA,NA,NA
19319526,NA,191,neutropaenic infection (ANC < 1.0Ã—109/l) with fever > 38.3Â°C,3 or 4,NA,NA,NA
19319526,NA,191,neutropaenia,4,>7 days,NA,NA
19319526,NA,191,thrombocytopaenia,4,NA,NA,NA
19319526,NA,191,thrombocytopaenia,3,>7 days,NA,NA
19319526,NA,191,any non-haematological toxicity possibly related to study medication,3 or 4,NA,NA,NA
19319526,NA,191,nausea,>=3,NA,NA,NA
19319526,NA,191,vomiting,>=3,NA,NA,NA
19319526,NA,191,mucositis,>=3,NA,NA,NA
19319526,NA,191,fatigue,>=3,NA,NA,NA
19319526,NA,191,tearing,>=3,NA,NA,NA
19319526,NA,191,nail disturbance,>=3,NA,NA,NA
19319526,NA,191,alopecia,>=3,NA,NA,NA
19319526,NA,191,diarrhoea,>=3,NA,NA,NA
19319526,NA,191,any life-threatening eventpossibly related to the study drug,NA,NA,NA,NA
19839918,NA,192,neutropenia,4,>5 days,NA,NA
19839918,NA,192,thrombocytopenia,4,>5 days,NA,NA
19839918,NA,192,febrile neutropenia,3 or 4,NA,NA,NA
19839918,NA,192,non-hematologic toxicity,>=3,NA,TRUE,NA
19839918,NA,192,any treatment delay lasting more than one week at day 1 of the 2 nd treatment cycle because of unresolved toxicity,NA,NA,NA,NA
21339064,NA,193,NA,NA,NA,NA,Not defined
19657639,NA,194,neutropenia,4,>5 days,NA,NA
19657639,NA,194,neutropenia accompanied by >= grade 2fever,4,NA,NA,NA
19657639,NA,194,thrombocytopenia,4,NA,NA,NA
19657639,NA,194,nonhematologic toxicity that results in an interruption of capecitabine for more than 5 days,3 or 4,NA,NA,NA
19657639,NA,194,non-hematologic toxicity,3 or 4,NA,FALSE,NA
19657639,NA,194,clinical inability (due to toxicity) to start the next cycle of treatment within 2 weeks of planned start date,NA,NA,NA,NA
19657639,NA,194,Toxicitiesshould be considered drug-related by the investigator,NA,NA,NA,NA
20839949,NA,195,hematologic toxicity,>=4,NA,NA,NA
20839949,NA,195,neutropenia with fever (T > 38â—¦C),>2,NA,NA,NA
20839949,NA,195,non-hematologic toxicity in patients who had not received appropriate antiemetic therapy,3 or 4,NA,FALSE,NA
23263993,NA,196,neutropenia,4,>= 5 days,NA,NA
23263993,NA,196,febrile neutropenia,NA,NA,NA,NA
23263993,NA,196,anemia,4,NA,NA,NA
23263993,NA,196,thrombocytopenia,4,NA,NA,NA
23263993,NA,196,sensoryneuropathy,4,NA,NA,NA
23263993,NA,196,nausea/vomiting with maximal antiemetic treatment,3,NA,NA,NA
23263993,NA,196,diarrhea with maximal antidiarrhealtherapy,3,NA,NA,NA
23263993,NA,196,non-hematologic toxicity,>=3,NA,NA,NA
20837944,NCT 00618124,197,nonhematologictoxicities,3 or 4,>= 7 days,NA,NA
20837944,NCT 00618124,197,"nausea, vomiting, and diarrhea despite maximal supportive care",3 or 4,NA,NA,NA
20837944,NCT 00618124,197,neutropenia,4,NA,NA,NA
20837944,NCT 00618124,197,thrombocytopenia,4,>= 7 days,NA,NA
20837944,NCT 00618124,197,febrile neutropenia,4,>= 24 h,NA,NA
20837944,NCT 00618124,197,neutropenic infection,3 or 4,NA,NA,NA
20461379,NCT00320749,198,neutropenia,4,>5 days,NA,NA
20461379,NCT00320749,198,neutropenia accompanied by >= grade 2fever,4,NA,NA,NA
20461379,NCT00320749,198,thrombocytopenia,4,NA,NA,NA
20461379,NCT00320749,198,non-hematologic toxicity that results in interruption of capecitabine for more than 5 days,3 or 4,NA,NA,NA
20461379,NCT00320749,198,clinical inability (due to toxicity) to start the next cycle of treatment within 2 weeks of planned start date,NA,NA,NA,NA
21184645,NA,199,>= 3/5 S or >= 4/14 C doses missed,NA,NA,NA,NA
21184645,NA,199,> two weeks delay in the startof second cycle,NA,NA,NA,NA
21184645,NA,199,neutropenia,>=4,>5 days,NA,NA
21184645,NA,199,neutropenia complicated by febrile neutropenia,4,NA,NA,NA
21184645,NA,199,thrombocytopenia,4,NA,NA,NA
21184645,NA,199,thrombocytopenia with signs ofbleeding,3,NA,NA,NA
21184645,NA,199,persisting neuropathy between cycles,2,NA,NA,NA
21184645,NA,199,renal/gastrointestinal/other non-hematological toxicity,>=3,NA,NA,NA
22045498,NA,200,neutropenia,4,>= 7 days,NA,NA
22045498,NA,200,febrile neutropenia,NA,NA,NA,NA
22045498,NA,200,neutropenic infection,NA,NA,NA,grade 3 or 4 infection concomitant with grade >=3 neutropenia
22045498,NA,200,thrombocytopenia,4,NA,NA,NA
22045498,NA,200,thrombocytopenia with bleeding or requiring platelet transfusion,4,NA,NA,NA
22045498,NA,200,non-haematological toxicity,>=3,NA,FALSE,NA
22045498,NA,200,delay of more than 3 weeks in starting the second cycle because of toxicity,NA,NA,NA,NA
23053263,NA,201,neutropenia at the scheduled start of a new treatment cycle,3 or 4,NA,NA,NA
23053263,NA,201,neutropenia with fever(T >= 38.5),3 or 4,NA,NA,NA
23053263,NA,201,"a platelet count < 100,000/mm3 at the scheduled start of a new treatment cycle",NA,NA,NA,NA
23053263,NA,201,thrombocytopenia,4,NA,NA,NA
23053263,NA,201,diarrhea despite optimal medical management,>=2,NA,NA,NA
23053263,NA,201,handâ€“foot syndrome,>=2,NA,NA,NA
23053263,NA,201,peripheral neuropathy,>=2,NA,NA,NA
23053263,NA,201,"any other clinically relevant non-hematologic toxicity, including laboratoryabnormalities",3 or 4,>3 days,NA,NA
23053263,NA,201,treatment delay of all agents for > 2 weeks,NA,NA,NA,NA
23053263,NA,201,of any one agent for >4 weeks due to delayed recovery from treatment-related toxicity,NA,NA,NA,NA
21590447,NCT00705375,202,hematologic toxicity,4,NA,NA,NA
21590447,NCT00705375,202,febrile neutropenia,NA,NA,NA,NA
21590447,NCT00705375,202,non-hematologic toxicity,3 or 4,NA,NA,NA
21590447,NCT00705375,202,any adverse event causing delay of treatment on day 21,NA,NA,NA,NA
20881475,NCT00121251,203,treatment emergent hypertension [grade(Gr) 2 resulting in treatment delay >2 weeks,NA,NA,NA,NA
20881475,NCT00121251,203,treatment emergent hypertension,3 or 4,NA,NA,NA
20881475,NCT00121251,203,neutropenia,>=3,NA,NA,NA
20881475,NCT00121251,203,thrombocytopenia,>=3,NA,NA,NA
20881475,NCT00121251,203,dermatitis,>=3,NA,NA,NA
20881475,NCT00121251,203,hand-foot syndrome,>=3,NA,NA,NA
20881475,NCT00121251,203,nonhematologic toxicity probably or possibly or related to any of the study drugs,>=3,NA,NA,NA
21404105,NA,204,neutropenia with fever,4,NA,NA,NA
21404105,NA,204,neutropenia,4,>=7 days,NA,NA
21404105,NA,204,neutropeniawith fever,3,NA,NA,NA
21404105,NA,204,neutropenia,3,>=14 days,NA,NA
21404105,NA,204,thrombocytopenia,3,>=7 days,NA,NA
21404105,NA,204,non hematological toxicity,3 or 4,NA,TRUE,NA
21404105,NA,204,diarrhea despite optimal medical management,>=3,NA,NA,NA
21404105,NA,204,delay of >2 consecutiveweeks of treatment due to persistent toxicity,NA,NA,NA,NA
20670085,NCT00350961,205,treatment-related non hematological toxicity,3 or 4,NA,FALSE,NA
20670085,NCT00350961,205,treatment-related hematological toxicity,4,NA,NA,NA
20670085,NCT00350961,205,treatment-related hematological toxicity requiring a treatment delay of more than two weeks,3,NA,NA,NA
22367239,NCT01077986,206,neutropenia,4,>5 days,NA,NA
22367239,NCT01077986,206,febrile neutropenia,3,NA,NA,NA
22367239,NCT01077986,206,thrombocytopenia,4,NA,NA,NA
22367239,NCT01077986,206,red cell count,>=3,NA,NA,NA
22367239,NCT01077986,206,vomiting,>=2,NA,NA,NA
22367239,NCT01077986,206,any other toxicity despite supportive treatment,>=3,NA,NA,NA
22367239,NCT01077986,206,rash,4,NA,NA,NA
19693503,NA,207,neutropenia,4,>5 days,NA,NA
19693503,NA,207,febrile neutropenia,4,NA,NA,NA
19693503,NA,207,thrombocytopenia,4,NA,NA,NA
19693503,NA,207,thrombocytopenia with bleeding requiring platelet transfusion,3,NA,NA,NA
19693503,NA,207,nausea/vomiting notwithstanding adequate medication,>=3,NA,NA,NA
19693503,NA,207,nonhematologicaltoxicity,>=3,NA,FALSE,NA
19693503,NA,207,failure to re-administer treatment within 14 days of the last expected day of administration due to delayed recovery from treatment related toxicity,NA,NA,NA,NA
22977524,NA,208,febrile neutropenia,NA,>3 days,NA,NA
22977524,NA,208,neutropenia,4,>7 days,NA,NA
22977524,NA,208,thrombocytopenia,4,NA,NA,NA
22977524,NA,208,any drug-related non-hematologicaltoxicity,>=3,NA,FALSE,NA
22977524,EudraCT 2005005548-21,209,febrile neutropenia,NA,>3 days,NA,NA
22977524,EudraCT 2005005548-21,209,neutropenia,4,>7 days,NA,NA
22977524,EudraCT 2005005548-21,209,thrombocytopenia,4,NA,NA,NA
22977524,EudraCT 2005005548-21,209,any drug-related non-hematological toxicity,>=3,NA,FALSE,NA
20397772,NA,210,hematologic toxicity,>=3,NA,NA,NA
20397772,NA,210,"liver, renal, neurologic, gastrointestinal, or skin toxicity",>=2,NA,NA,NA
20397772,NA,210,any toxicity producing prolonged(10 days) radiotherapy interruption,NA,NA,NA,NA
24661655,NCT00858429,211,"toxicity attributable to hepatic radiation treatment, specifically hepatobiliary toxicities, fatigue, abdominalpain, nausea/vomiting, and leukopenia.",>=3,NA,NA,NA
22681700,NA,1,toxicity,3 or 4,NA,FALSE,NA
23403636,NCT00452673,2,any adverse event possibly related to dasatinib and/orcapecitabine,>=3,NA,NA,NA
23403636,NCT00452673,2,adverse event requiring interruption,4,>=7 days,NA,NA
23403636,NCT00452673,2,nonhematologic laboratory abnormalit,>=3,NA,NA,NA
23403636,NCT00452673,2,hematologic adverse event,4,>=7 days,NA,NA
23403636,NCT00452673,2,any toxicity requiring dose reduction or discontinuation,NA,NA,NA,NA
19858399,NA,3,neutropenia,4,>=7 days,NA,NA
19858399,NA,3,neutropenic fever,NA,NA,NA,NA
19858399,NA,3,thrombocytopenia,4,NA,NA,NA
19858399,NA,3,diarrhea despite optimal supportive care,3 or 4,NA,NA,NA
19858399,NA,3,any nonhematologic toxicity,>=3,>=7 days,FALSE,NA
19858399,NA,3,hemorrhage or GI perforation,3 or 4,NA,NA,NA
19858399,NA,3,treatment delay of more than 4 weeks as a resultof toxicity,NA,NA,NA,NA
24551455,NA,4,toxicity,3 or 4,NA,NA,NA
22037922,NCT 00544063,5,toxicity,4,NA,FALSE,NA
22037922,NCT 00544063,5,toxicity requiring a cycle delay of more than 15 days,NA,NA,NA,NA
22037922,NCT 00544063,5,febrile neutropenia,3,NA,NA,NA
22037922,NCT 00544063,5,neutropenia withinfection,3,NA,NA,NA
22037922,NCT 00544063,5,any symptomatic thrombocytopenia,NA,NA,NA,NA
22037922,NCT 00544063,5,diarrhea associated with grade 4 neutropenia,>=2,NA,NA,NA
22037922,NCT 00544063,5,anyperipheral neuropathy at the dose level of 60 mg/m2 for oxaliplatin,3,NA,NA,NA
20215798,NA,7,ANC < 500/ul associated with fever,NA,NA,NA,NA
20215798,NA,7,ANC < 500/ul,NA,>7 days,NA,NA
20215798,NA,7,"platelet count < 25,000/ul",NA,NA,NA,NA
20215798,NA,7,hepatic or renal toxicity,2,NA,FALSE,NA
20215798,NA,7,diarrhea despite aggressive antidiarrheal therapy,>=3,NA,NA,NA
20215798,NA,7,nonhematological toxicity,>=3,NA,FALSE,NA
20215798,NA,7,treatment delay > 2 weeks due to toxicity,NA,NA,NA,NA
19443364,NA,8,neutropenia,4,NA,NA,NA
19443364,NA,8,thrombocytopenia,4,NA,NA,NA
19443364,NA,8,nonhematologic toxic effect,3 or 4,NA,NA,NA
21552099,NA,9,neutropenia,4,NA,FALSE,NA
21552099,NA,9,neutropenia with fever (temperature >38.5),3,NA,NA,NA
21552099,NA,9,more than 1 episode of neutropenia,3 or 4,NA,NA,NA
21552099,NA,9,thrombocytopenia,4,NA,NA,NA
21552099,NA,9,any clinically relevant nonhematologictoxicity,3 or 4,NA,NA,NA
21552099,NA,9,treatment delay of both agents for more than 2weeks,NA,NA,NA,NA
21552099,NA,9,treatment delay r of either agent for more than 4 weeks due to delayed recovery from treatment-related toxicity,NA,NA,NA,NA
20216541,NA,10,neutropenia,4,>7 days,NA,NA
20216541,NA,10,neutropenia associated with fever >38C,3 or 4,NA,NA,NA
20216541,NA,10,thrombocytopenia,4,NA,NA,NA
20216541,NA,10,symptomatic thrombocytopenia (haemorrhage),NA,NA,NA,NA
20216541,NA,10,non-haematological toxicity,3 or 4,NA,TRUE,NA
21931969,NA,11,absolute neutrophil count (ANC) <500/Î¼l,NA,>5 days,NA,NA
21931969,NA,11,ANC <500/Î¼l with fever (temperature â‰¥38.5Â°C) orsepsis,NA,NA,NA,NA
21931969,NA,11,"platelets <25,000/Î¼l",NA,NA,NA,NA
21931969,NA,11,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21931969,NA,11,any delay in continuation of therapy of >3 weeks,NA,NA,NA,NA
20839031,NA,12,neutropenia,4,>5 days,NA,NA
20839031,NA,12,neutropenia with fever â‰¥38.5Â°C,3 or 4,NA,NA,NA
20839031,NA,12,thrombocytopenia of any duration,4,NA,NA,NA
20839031,NA,12,nonhematologic toxicities not improving to at least grade 1within 2 days after institution of appropriate therapy,3 or 4,NA,TRUE,NA
20839031,NA,12,a toxicity causing discontinuation of capecitabine or sorafenib for more than 25% of the scheduled dosage within a cycle (3 weeks),NA,NA,NA,NA
20839031,NA,12,a delay of >14 days in initiating the second cycle of therapy due to the persistent toxicity of grade 2 or higher in cycle 1,NA,NA,NA,NA
22648745,NA,13,neutropenia,4,>7 days,NA,NA
22648745,NA,13,febrileneutropenia,NA,NA,NA,NA
22648745,NA,13,thrombocytopenia,4,NA,NA,NA
22648745,NA,13,non-hematologic toxicity,3 or 4,NA,FALSE,NA
19936751,NA,14,neutropenia,4,>5 days,NA,NA
19936751,NA,14,neutropenia with fever,3 or 4,NA,NA,NA
19936751,NA,14,thrombocytopenia,4,NA,NA,NA
19936751,NA,14,non-hematological toxicity,3,NA,FALSE,NA
19936751,NA,14,treatment delay of more than 2 weeks following the time of planned treatment.,NA,NA,NA,NA
21853311,NCT00960349,16,hypertension or diarrhoea that required cessation of cediranib treatment,NA,NA,NA,NA
21853311,NCT00960349,16,an absolute neutrophil count<500/mm3,NA,>=5 days,NA,NA
21853311,NCT00960349,16,"a platelet count <50,000/mm3",NA,>=5 days,NA,NA
21853311,NCT00960349,16,a dose delay to starting any chemotherapy agentin cycle 2 for longer than 14 days,NA,NA,NA,NA
21853311,NCT00960349,16,dose reductions of cediranib due to cediranib-related toxicity,NA,NA,NA,NA
21853311,NCT00960349,16,a single increase from baseline in the QT interval corrected for heart rate (QTc) of 60 ms that results in a QTc of at least 460 ms,NA,NA,NA,NA
21853311,NCT00960349,16,two QTc measurements[490 ms taken at least 24 h apart,NA,NA,NA,NA
21853311,NCT00960349,16,"any other that was, in the opinion of theinvestigator and the SRC, not clearly related to diseaseprogression, clinically significant and related to the studydrug",>=3,NA,NA,NA
24173967,NCT00920868,17,neutropenia,4,>7 days,NA,NA
24173967,NCT00920868,17,thrombocytopenia,4,>7 days,NA,NA
24173967,NCT00920868,17,neutropenic fever,>=3,NA,NA,NA
24173967,NCT00920868,17,"nausea, vomiting ordiarrhea",>=3,>=4 days,NA,NA
24173967,NCT00920868,17,inability to receive at least 85 % of scheduled doses of each study drug due to treatment-related toxicity,NA,NA,NA,NA
24173967,NCT00920868,17,other non-hematologic toxicity,>=3,NA,NA,NA
24173967,NCT00920868,17,any treatment-related death or treatment-related hospitalization,NA,NA,NA,NA
24173967,NCT00920868,17,"Anorexia, hand-foot syndrome, hypertension, and neuropathy",4,NA,NA,NA
20429725,NA,18,non-haematologicaltoxicity,3 or 4,NA,NA,NA
20429725,NA,18,febrile neutropenia,NA,>5 days,NA,NA
20429725,NA,18,neutropenia,4,>7 days,NA,NA
20429725,NA,18,thrombocytopenia,NA,NA,NA,NA
20429725,NA,18,infection,>=2,NA,NA,NA
20429725,NA,18,delay of treatment for more than two weeks due to sideeffects,NA,NA,NA,NA
20857171,NA,19,nonhematologic toxicity,>=3,NA,TRUE,NA
20857171,NA,19,neutropenia,4,NA,NA,"during the
5 days of treatment for stage 1 subjects or during the
14 days of treatment for stage 2 and 3 subjects"
20857171,NA,19,neutropenia,3,NA,NA,before day 7
20857171,NA,19,neutropenia,4,â‰¥5 days during the rest period,NA,NA
20857171,NA,19,neutropenic infection,NA,NA,NA,NA
20857171,NA,19,thrombocytopenia,NA,NA,NA,NA
20857171,NA,19,failure to complete a full treatment course due todrug-related toxicity,NA,NA,NA,NA
20857171,NA,19,failure to recover to gradeâ‰¤1toxicity (except alopecia) and initiate the next cycle oftherapy within 35 days from the start of the current cycle,NA,NA,NA,NA
24574780,NA,20,leukopenia,4,NA,NA,NA
24574780,NA,20,neutropenia,4,NA,NA,NA
24574780,NA,20,thrombocytopenia,3 or 4,NA,NA,NA
24574780,NA,20,anemia,3 or 4,NA,NA,NA
24574780,NA,20,non-hematological toxicity,3 or 4,NA,NA,NA
20421151,NA,21,nonhematologic or hematologic toxicity requiring >7-day interruptionin therapy,3,NA,FALSE,NA
20421151,NA,21,nonhematologic toxicity,4,NA,NA,NA
20421151,NA,21,neutropenia,4,NA,NA,NA
20421151,NA,21,thrombocytopenia,4,NA,NA,NA
24091982,NCT00555620,22,neutropenia,4,>=7 days,NA,NA
24091982,NCT00555620,22,febrile neutropenia,>=3,NA,NA,NA
24091982,NCT00555620,22,neutropenic infection,>=3,NA,NA,NA
24091982,NCT00555620,22,thrombocytopenia,4,NA,NA,NA
24091982,NCT00555620,22,thrombocytopenia,3,>=7 days,NA,NA
24091982,NCT00555620,22,toxicities,3,>=7 days,NA,NA
24091982,NCT00555620,22,non-hematologic toxicity,4,NA,NA,NA
24091982,NCT00555620,22,"nausea, vomiting or diarrhea persistingdespite maximum supportive therapy",3 or 4,NA,NA,NA
24091982,NCT00555620,22,Missing >3 consecutive days of capecitabineand/or sunitinib dosing per cycle,NA,NA,NA,NA
24091982,NCT00555620,22,Delay of >2 weeks in starting the next treatmentcycle,NA,NA,NA,NA
20092990,NA,23,neutropenia complicated byfever,3 or 4,NA,NA,NA
20092990,NA,23,neutropenia,4,>5 days,NA,NA
20092990,NA,23,thrombocytopenia,4,NA,NA,NA
20092990,NA,23,non-hematologic toxicity,3 or 4,NA,FALSE,NA
20092990,NA,23,delay of recovery from treatment-relatedtoxicity for more than 2 weeks,NA,NA,NA,NA
22669361,NA,24,hematological toxicity,4,NA,NA,NA
22669361,NA,24,neuropathy,3,NA,NA,NA
22669361,NA,24,non-hematological toxicity,3,NA,NA,NA
23235319,NA,25,hematological toxicities,4,>=7 days,NA,NA
23235319,NA,25,febrile neutropenia,NA,NA,NA,NA
23235319,NA,25,leukopenia with fever,3 or 4,NA,NA,NA
23235319,NA,25,diarrhea despite optimal supportive care,3 or 4,>=3 days,NA,NA
23235319,NA,25,vomiting despite optimal supportive care,3 or 4,NA,NA,NA
23235319,NA,25,hand-foot syndrome,3,>=7 days,NA,NA
23235319,NA,25,skin toxicity,4,NA,NA,NA
23235319,NA,25,severe infection,NA,NA,NA,NA
23235319,NA,25,performance status deterioration to grade 3 or 4 or mono- or multitoxicity judged as unacceptable by the investigator,NA,NA,NA,NA
23647753,NA,26,non-hematologic toxicity,>=3,NA,NA,NA
23647753,NA,26,hematologic toxicity,>=4,NA,NA,NA
23647753,NA,26,post-operative toxicity within 30 days post-surgery,>=4,NA,NA,NA
24315563,NA,27,acute toxicity,>=3,NA,NA,NA
23517808,NA,28,dermatitis within >= 50% of the high dose irradiation area,4,NA,NA,NA
23517808,NA,28,dermatitis in all other parts of the skin,3,NA,NA,NA
23517808,NA,28,nausea,>=2,NA,NA,NA
23517808,NA,28,vomiting,>=2,NA,NA,NA
23517808,NA,28,neutropenia,4,.5 days,NA,NA
23517808,NA,28,platelets,>=4,NA,NA,NA
23517808,NA,28,platelets withbleeding,3,NA,NA,NA
23517808,NA,28,any other toxicity,>=3,NA,FALSE,NA
21547572,NA,29,febrile neutropenia,NA,NA,NA,NA
21547572,NA,29,neutropenia,4,>5 days,NA,NA
21547572,NA,29,thrombocytopenia,NA,NA,NA,NA
21547572,NA,29,vomiting despite maximum supportive care,>=3,NA,NA,NA
21547572,NA,29,neurotoxicity,>=3,NA,NA,NA
21547572,NA,29,nonhematologic toxicity,>=3,NA,FALSE,NA
21547572,NA,29,inability to start a second treatment cycle after a 1-week delay,NA,NA,NA,NA
19294501,NA,30,toxicity,3 or 4,NA,NA,NA
19294501,NA,30,a delay > 3 weeks due tounresolved toxicity,NA,NA,NA,NA
19294501,NA,30,acneiform rash not resolving to grade 1 after 5 days off therapy or recurring with rechallenge,3,NA,NA,NA
24114122,NCT00433550,31,absolute neutrophil count,4,>5 days,NA,NA
24114122,NCT00433550,31,hemoglobin,4,NA,NA,NA
24114122,NCT00433550,31,"platelet count less than 25,000/Î¼L",NA,NA,NA,NA
24114122,NCT00433550,31,serum creatinine â‰¥ two times baseline,NA,NA,NA,NA
24114122,NCT00433550,31,treatment delay more than 14 days,NA,NA,NA,NA
24114122,NCT00433550,31,sensory neuropathy,>=3,NA,NA,NA
24114122,NCT00433550,31,non-hematologic toxicity,3 or 4,NA,FALSE,NA
24114122,NCT00433550,31,"nausea, vomiting, or diarrhea in patients who had received prophylaxis and treatment with an optimal antiemetic or antidiarrheal regimen",NA,NA,NA,NA
24114122,NCT00433550,31,Inability to complete 10 days of prescribed doseof capecitabine,NA,NA,NA,NA
17998790,NA,32,hematologic toxicity,4,NA,NA,NA
17998790,NA,32,febrile neutropenia,NA,NA,NA,NA
17998790,NA,32,any nonhematologic toxicity,3 or 4,NA,NA,NA
17998790,NA,32,any adverse event causing a treatment delay on days 15 and/or 28,NA,NA,NA,NA
17628744,NA,33,febrile neutropenia,NA,NA,NA,NA
17628744,NA,33,hypothermia without documented infection,NA,NA,NA,NA
17628744,NA,33,neutropenia,4,>7 days,NA,NA
17628744,NA,33,thrombocytopenia,4,NA,NA,NA
17628744,NA,33,thrombocytopenia with bleeding requiring platelet transfusion,3,NA,NA,NA
17628744,NA,33,"treatment-related non-hematological toxicity that did not improve to at least grade 1 within 2 days after starting appropriate symptomatic treatment, led to interruption of capecitabine treatment or delayed irofulven treatment for more than 1 week",3 or 4,NA,FALSE,NA
17628744,NA,33,dosing omission or delay greater than 1 weekwithin the first four dosings due to toxicity,NA,NA,NA,NA
17426973,NA,34,hematologic toxicity,4,NA,NA,NA
17426973,NA,34,non-hematologic toxicity,3,NA,TRUE,NA
18765554,NA,36,neutropenia,4,>=7 d,NA,NA
18765554,NA,36,thrombocytopenia,4,>=7 d,NA,NA
18765554,NA,36,febrileneutropenia,NA,NA,NA,NA
18765554,NA,36,nonhematologic toxicity,3 or 4,NA,FALSE,NA
18765554,NA,36,diarrhea associated with fever,3,NA,NA,NA
18765554,NA,36,diarrhea despite medicaltreatment,3,>2 days,NA,NA
19074845,NA,37,nonhematologic toxicity,>=3,NA,FALSE,NA
19074845,NA,37,thrombocytopenia,4,NA,NA,NA
19074845,NA,37,neutropenia,4,>5 days,NA,NA
19074845,NA,37,neutropenia complicated by fever,4,NA,NA,NA
19074845,NA,37,skin rash occurring after the second exposure to gefitinib,>=3,NA,NA,NA
19074845,NA,37,treatment delay due to toxicity lasting >2 weeks,NA,NA,NA,NA
17582215,NA,38,TCT-related hematologic toxicity,4,NA,NA,NA
17582215,NA,38,nonhematologic toxicity,3 or 4,NA,TRUE,NA
16750332,NA,39,neutropenia,4,NA,NA,NA
16750332,NA,39,thrombocytopenia,3 or 4,NA,NA,NA
16750332,NA,39,nonhematologic toxicity,>=3,NA,FALSE,NA
16750332,NA,39,nausea/vomiting that did not resolve within 24 hours with appropriateantiemetic therapy,3,NA,NA,NA
16750332,NA,39,diarrhea that did not resolve toGrade 0 to 2 within 48 hours,3,NA,NA,NA
16750332,NA,39,any dose delay 7 days,NA,NA,NA,NA
16750332,NA,39,inability to administer >=4 or more weeks of the intended oxaliplatin and capecitabine,NA,NA,NA,NA
17158771,NA,40,neutropenia,4,>=7 days,NA,NA
17158771,NA,40,neutropenia associated with fever >= 38.1C,3 or 4,NA,NA,NA
17158771,NA,40,thrombocytopenia,4,>=7 days,NA,NA
17158771,NA,40,anemia,4,NA,NA,NA
17158771,NA,40,non-hematologic toxicity,3 or 4,NA,FALSE,NA
17158771,NA,40,"nausea, vomiting,or mucositis",3 or 4,NA,NA,NA
17158771,NA,40,diarrhea,3 or 4,NA,NA,NA
17158771,NA,40,a second occurrence of grade 2diarrhea,NA,NA,NA,NA
17158771,NA,40,hand-foot syndrome not reduced to grade 1 beforethe start of cycle 2,2,NA,NA,NA
17158771,NA,40,hand-foot syndrome not reduced to grade 1 beforethe start of cycle 2,3,NA,NA,NA
17158771,NA,40,delay of â€¡14 days in initiating the second or the third cycle of therapy because of persistent toxicity of grade 2 or higher,NA,NA,NA,NA
18209010,NA,41,non-haematologic toxicity,3 or 4,NA,FALSE,NA
18209010,NA,41,febrile neutropenia,NA,NA,NA,NA
18209010,NA,41,neutropenia,4,>4 days,NA,NA
18209010,NA,41,thrombocytopaenia,4,NA,NA,NA
18209010,NA,41,thrombocytopaenia associated with bleeding,NA,NA,NA,NA
18209010,NA,41,toxicity that persisted over day 35 of thefirst cycle,>=2,NA,NA,NA
17641893,NA,42,"leukopenia(<1,000/mm3)",4,>4 days,NA,NA
17641893,NA,42,neutropenia (<500/mm3),4,>4 days,NA,NA
17641893,NA,42,toxicity resulting in omission of two or morepaclitaxel doses,NA,NA,NA,NA
17641893,NA,42,"fever (>38.0Â°C) associated with grade3 or 4 neutropenia (<1,000/mm3) or clinical infection",NA,NA,NA,NA
17641893,NA,42,thrombocytopenia,4,NA,NA,NA
17641893,NA,42,handâ€“foot syndrome,3,NA,NA,NA
17641893,NA,42,non-hematologic toxicity,4,NA,FALSE,NA
17641893,NA,42,toxicity resulting in a delay of >7 days beforeadministration of the second or third cycle,NA,NA,NA,NA
18000507,NA,43,leucocytopenia,4,NA,NA,NA
18000507,NA,43,neutropenia,4,NA,NA,NA
18000507,NA,43,thrombocytopenia,4,NA,NA,NA
18000507,NA,43,symptomatic thrombocytopenia (haemorrhage),NA,NA,NA,NA
18000507,NA,43,febrile neutropenia,3 or 4,NA,NA,NA
18000507,NA,43,non-haematological toxicity,>=3,NA,FALSE,NA
17465235,NA,44,neutropenia,4,>=7 days,NA,NA
17465235,NA,44,"platelet count <25,000/mm3",NA,NA,NA,NA
17465235,NA,44,fever â‰¥38C,NA,>=72 hours,NA,NA
17465235,NA,44,neutropenia with mucositis or diarrhoea grade â‰¥2,3,NA,NA,NA
17465235,NA,44,non-haematological toxicity,3 or 4,NA,TRUE,NA
17465235,NA,44,any event leading to a >7-day delay in administration of the next cycle,NA,NA,NA,NA
18936940,NA,45,Absolute Neutrophyl Count (ANC) <0.5 x 109/L,NA,>=7 days,NA,NA
18936940,NA,45,ANC < 0.1 x 109/L,NA,.3 days,NA,NA
18936940,NA,45,neutropenic fever defined as ANC < 0.5 x 109/L with fever >= 38.5Â°C,NA,NA,NA,NA
18936940,NA,45,neutropenic fever defined as ANC < 0.5 x 109/L with fever >38Â°C in two evaluations lasting 12 h each other,NA,NA,NA,NA
18936940,NA,45,platelets count <25 x 109/L,NA,>=7 days,NA,NA
18936940,NA,45,platelets count <25 x 109/L with bleeding requiring transfusions,NA,NA,NA,NA
18841362,NA,46,neutropenia,>=3,>=7 days,NA,NA
18841362,NA,46,neutropenia associated with fever (>= 38.1Â°C),>=3,NA,NA,NA
18841362,NA,46,neutropenia associated with  infection,>=3,NA,NA,NA
18841362,NA,46,thrombocytopenia,>=3,.>=7 days,NA,NA
18841362,NA,46,mucositis,>=3,NA,NA,NA
18841362,NA,46,nausea,>=3,NA,NA,NA
18841362,NA,46,vomiting,>=3,NA,NA,NA
18841362,NA,46,handâ€“foot syndrome,>=3,NA,NA,NA
18841362,NA,46,diarrhea,>=3,NA,NA,NA
18841362,NA,46,non-hematologic toxicity,>=3,NA,NA,NA
18187954,NA,47,leukopenia or neutropenia,4,>=7 days,NA,NA
18187954,NA,47,neutropenia with fever,3,>=3 days,NA,NA
18187954,NA,47,thrombocytopenia,4,NA,NA,NA
18187954,NA,47,nonhematological toxicity,3 or 4,NA,FALSE,NA
18187954,NA,47,treatment interruption for >2 weeks,NA,NA,NA,NA
16778105,NA,48,neutropenia before day 7,3,NA,NA,NA
16778105,NA,48,neutropenia,4,>5 days,NA,NA
16778105,NA,48,febrile neutropenia,NA,NA,NA,NA
16778105,NA,48,neutropenic infection,NA,NA,NA,NA
16778105,NA,48,thrombocytopenia,4,NA,NA,NA
16778105,NA,48,diarrhea despite maximal intensive loperamide support,3 or 4,NA,NA,NA
16778105,NA,48,nausea,>=2,NA,NA,NA
16778105,NA,48,vomiting despite maximal oral antiemetic therapy,>=2,NA,NA,NA
16778105,NA,48,vomiting leading to discontinue the study treatment for 3 days,NA,NA,NA,NA
16778105,NA,48,stomatitis,3 or 4,NA,NA,NA
16778105,NA,48,palmar-plantar erythrodysesthesia,3,NA,NA,NA
16778105,NA,48,failure to complete the 14 days of full-dose irinotecan therapy,NA,NA,NA,NA
16778105,NA,48,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17600871,NA,49,neutropenia,4,>7 days,NA,NA
17600871,NA,49,febrile neutropenia,NA,NA,NA,NA
17600871,NA,49,thrombocytopenia,4,NA,NA,NA
17600871,NA,49,hemorrhagic syndromedue to thrombocytopenia,4,NA,NA,NA
17600871,NA,49,diarrhea,4,NA,NA,NA
17600871,NA,49,nausea,4,NA,NA,NA
17600871,NA,49,vomiting,4,NA,NA,NA
17600871,NA,49,neurotoxicity,4,NA,NA,NA
17600871,NA,49,constipation,4,NA,NA,NA
17600871,NA,49,stomatitis,3,NA,NA,NA
16821609,NA,50,febrile neutropenia with an absolute neutrophil count <1.0x109/l,NA,NA,NA,NA
16821609,NA,50,neutropenia,4,>7 days,NA,NA
16821609,NA,50,thrombocytopenia,4,NA,NA,NA
16821609,NA,50,non-hematological toxicity,4,NA,FALSE,NA
16821609,NA,50,mucositis or stomatitis,3,>3 days,NA,NA
16821609,NA,50,non-hematological toxicity that did notregress to grade 1 or less within 35 days,3,NA,NA,NA
18249110,NA,51,non-haematologic toxicity,>=3,NA,NA,NA
18249110,NA,51,thrombocytopaenia,NA,NA,NA,NA
18249110,NA,51,neutropaenia,4,>=5 days,NA,NA
18249110,NA,51,febrile neutropaenia,NA,NA,NA,NA
18249110,NA,51,any toxicity necessitating the interruption of erlotinib administration during cycle 1,NA,NA,NA,NA
18249110,NA,51,any other laboratory abnormality occurring during cycle 1 requiring adose reduction,NA,NA,NA,NA
18539404,NA,52,leukocytopenia,4,NA,NA,NA
18539404,NA,52,neutropenia,4,NA,NA,NA
18539404,NA,52,thrombocytopenia,4,NA,NA,NA
18539404,NA,52,symptomatic thrombocytopenia(hemorrhage),NA,NA,NA,NA
18539404,NA,52,febrile neutropenia,3 or 4,NA,NA,NA
18539404,NA,52,any nonhematologic toxicity,>=3,NA,FALSE,NA
18539404,NA,52,renal toxicity,2,NA,NA,NA
17195945,NA,53,neutropenia,4,>5 days,NA,NA
17195945,NA,53,neutropenia associated with grade â‰¥ 2 fever,4,NA,NA,NA
17195945,NA,53,thrombocytopenia,>=3,>=5 days,NA,NA
17195945,NA,53,neutropenia on treatment day,>=3,NA,NA,NA
17195945,NA,53,thrombocytopenia on treatment day,>=3,NA,NA,NA
17195945,NA,53,"nausea, vomiting, or diarrhea despite maximal supportive therapy",>=3,NA,NA,NA
17195945,NA,53,non-hematologic toxicity,>=3,NA,NA,NA
18414865,NA,54,treatment-related non-hematological toxicity,3,NA,FALSE,NA
18414865,NA,54,treatment-related hematological toxicity,4,NA,NA,NA
18525298,NA,55,febrile neutropenia,NA,NA,NA,NA
18525298,NA,55,hematological toxicity,4,NA,NA,NA
18525298,NA,55,nonhematological toxicity withouttumor progression,>=3,NA,NA,NA
18398145,NA,56,nonhematologic toxicity,3 or 4,NA,NA,NA
18398145,NA,56,hematologic toxicity despite growth factor support,3 or 4,>2 weeks,NA,NA
18534963,NA,57,neutropenia,4,>=7 days,NA,NA
18534963,NA,57,neutropenia associatedwith fever or infection,3,NA,NA,NA
18534963,NA,57,anemia,4,NA,NA,NA
18534963,NA,57,thrombocytopenia,4,NA,NA,NA
18534963,NA,57,non-hematologic toxic effects,3 or 4,NA,TRUE,NA
18534963,NA,57,Any toxicity requiring a 2-week delay betweencycles,NA,NA,NA,NA
18773144,NA,58,the dose of capecitabine that produced hematologic adverse events,3 or 4,>7 days,NA,NA
18773144,NA,58,non-hematologic adverse events,>=3,NA,NA,NA
18773144,NA,58,neurotoxicity,2,>7 days,NA,NA
16909414,NA,59,"nonhematologic toxicity, includingpalmar-plantar erythrodysesthesia",>=3,NA,FALSE,NA
16909414,NA,59,neutropenia,4,>7 days,NA,NA
16909414,NA,59,neutropenia at Day 21,3 or 4,NA,NA,NA
16909414,NA,59,neutropenia accompanied by infection and/or fever requiring parenteral antibiotics,4,NA,NA,NA
16909414,NA,59,thrombocytopenia,4,NA,NA,NA
16909414,NA,59,thrombocytopenia associated with bleeding,3,NA,NA,NA
19238629,NA,60,non-haematological toxicities related to matuzumab,3 or 4,NA,FALSE,NA
19238629,NA,60,nausea,4,NA,NA,NA
19238629,NA,60,vomiting,4,NA,NA,NA
19238629,NA,60,skin reactions,4,NA,NA,NA
19238629,NA,60,toxicity related discontinuation of treatment for more than 1 week,1,NA,NA,NA
18455328,NA,61,any nonhematologic toxicity,3,NA,NA,NA
18455328,NA,61,hematologic toxicity,4,NA,NA,NA
17450468,NA,62,non-hematological toxicity,3 or 4,NA,FALSE,NA
17450468,NA,62,febrile neutropenia,NA,NA,NA,NA
17450468,NA,62,thrombocytopenia,4,NA,NA,NA
17450468,NA,62,neutropenia,4,NA,NA,NA
19219674,NA,63,"hematologic toxicity (ANC < 500/Î¼L or platelets <25,000/Î¼L)",4,>1 week,NA,NA
19219674,NA,63,neutropenic fever with temperature â‰¥38.1â—¦C,NA,NA,NA,NA
19219674,NA,63,"ANC â‰¤1,000/Î¼L",NA,NA,NA,NA
19219674,NA,63,dose delay of >2 weeks,NA,NA,NA,NA
19219674,NA,63,serum creatinine >1.8 mg/dl,NA,>2 weeks,NA,NA
19219674,NA,63,diarrhea despite aggressive loperamide therapy,3,>2 days,NA,NA
19219674,NA,63,diarrhea,4,NA,NA,NA
19219674,NA,63,stomatitis despite intensiveviscous lidocaine therapy,3,.1 week,NA,NA
19219674,NA,63,stomatitis,4,NA,NA,NA
19219674,NA,63,fatigue,3 or 4,>1 week,NA,NA
19219674,NA,63,peripheral neuropathy,3 or 4,.2 weeks,NA,NA
18208793,NA,64,thrombocytopenia,4,NA,NA,NA
18208793,NA,64,neutropenia,4,>5 days,NA,NA
18208793,NA,64,febrile neutropenia,NA,NA,NA,NA
18208793,NA,64,non-haematological toxicity,3 or 4,NA,FALSE,NA
18208793,NA,64,diarrhoea associated with fever or lasting more than 2 days despitemedical treatment,3,NA,NA,NA
18650153,NA,65,any treatment-related toxicity requiring permanent discontinuation in â‰¥ 2 patients duringthe first 2 treatment cycles at a specific dose,NA,NA,NA,NA
17848909,NA,66,any event,>=3,NA,NA,NA
17848909,NA,66,neutropaenia,4,NA,NA,NA
17848909,NA,66,neutropaenia with neutropaenic fever,>=3,NA,NA,NA
17848909,NA,66,neutropaenia with neutropaenicinfection,>=3,NA,NA,NA
17848909,NA,66,neutropaenia occurred in the first 14 days,>=3,NA,NA,NA
17653805,NA,67,"white blood cell (WBC) and platelets < 3.0 and < 100 x 109/L, respectively, before start of the next treatment cycle with oxaliplatin after amaximum delay of one week",NA,NA,NA,NA
17653805,NA,67,diarrhea,>2,NA,NA,NA
17653805,NA,67,oral mucositis,>1,NA,NA,NA
17653805,NA,67,"skin toxicity before start of next treatment cycle with capecitabine, despite a delay of dosing for 1 week",>2,NA,NA,NA
17653805,NA,67,neurosensory toxicity despite a delay in dosingfor 1 week,>2,NA,NA,NA
17653805,NA,67,occurrence of any grade 4 toxicity,NA,NA,NA,NA
17653805,NA,67,any event that would compromise the administration of radiotherapy,NA,NA,NA,NA
17415843,NA,68,neutropenia,4,NA,NA,NA
17415843,NA,68,hyperbilirubinemia,4,NA,NA,NA
17415843,NA,68,nausea/vomiting,4,NA,NA,NA
17415843,NA,68,neutropenic fever,3,NA,NA,NA
17415843,NA,68,thrombocytopenia,3,NA,NA,NA
17415843,NA,68,haemorrhage,NA,NA,NA,NA
17415843,NA,68,anaemia,NA,NA,NA,NA
17415843,NA,68,severe infection requiring hospitalization,NA,NA,NA,NA
17415843,NA,68,shift in liver transaminases,3,NA,NA,NA
17415843,NA,68,stomatitis,3,NA,NA,NA
17415843,NA,68,diarrhea,3,NA,NA,NA
17415843,NA,68,hand-foot syndrome,3,NA,NA,NA
17415843,NA,68,gastrointestinal toxicities including severe proctitis orcolitis,3,NA,NA,NA
17333194,NA,69,side-effects,3 or 4,NA,FALSE,NA
17333194,NA,69,Any side effect causing treatment delay for more than 2 weeks,NA,NA,NA,NA
16374040,NA,70,neutropenia,4,>5 days,NA,NA
16374040,NA,70,thrombocytopenia,4,>5 days,NA,NA
16374040,NA,70,febrile neutropenia (fever > 38.5 Â° C persisting for > 48 h),3 or 4,NA,NA,NA
16374040,NA,70,nonhematologic toxicity,>=3,NA,FALSE,NA
16374040,NA,70,any treatment delay lasting more than 7 days at day 1 of the 2nd treatment cycle because of unresolved toxicity,NA,NA,NA,NA
15729602,NA,71,clinical adverse events,3 or 4,NA,NA,NA
14739668,NA,72,febrile neutropenia,NA,NA,NA,NA
14739668,NA,72,neutropenia,4,>5 days,NA,NA
14739668,NA,72,thrombocytopenia,4,NA,NA,NA
14739668,NA,72,thrombocytopenia with bleeding,3,NA,NA,NA
14739668,NA,72,nonhematological toxicity,3 or 4,NA,FALSE,NA
14739668,NA,72,second cycle delay of 2 or more weeks,NA,NA,NA,NA
14739668,NA,72,toxicity requiring one or more 25% dose reductions,NA,NA,NA,NA
16622464,NA,73,any non-haematological toxicity,>=3,NA,FALSE,NA
16622464,NA,73,haematological toxicity causing a chemotherapy delay of more than 5 days,4,NA,NA,NA
12196374,NA,74,myelosuppression with neutropenia,4,>=5 days,NA,NA
12196374,NA,74,neutropenia with fever,4,NA,NA,NA
12196374,NA,74,thrombocytopenia,4,NA,NA,NA
12196374,NA,74,neutropenia with fever,3,NA,NA,NA
12196374,NA,74,thrombocytopenia with bleeding requiring platelet transfusion,3,NA,NA,NA
12196374,NA,74,non-haematological toxicity,3 or 4,NA,FALSE,NA
12196374,NA,74,stomatitis,>=2,NA,NA,NA
10883663,NA,75,granulocytes < 0.5 Ã— 109 lâ€“1,NA,>7 days,NA,NA
10883663,NA,75,granulocytopenia with complications such as fever orother non-haematological toxicities,4,NA,NA,NA
10883663,NA,75,gastrointestinal toxicity,>2,NA,NA,NA
10883663,NA,75,skin toxicity,>2,NA,NA,NA
11432617,NA,76,an ANC <500/ul,NA,>5 days,NA,NA
11432617,NA,76,an ANC < 1000/ul associated with fever (temperature >38.5Â°C),NA,NA,NA,NA
11432617,NA,76,"a platelet count <25,00O/ul",NA,NA,NA,NA
11432617,NA,76,non-hematologic toxicity that did not resolve to at least grade 1 severity within two days following the institution ofappropriate supportive therapy,>=3,NA,NA,NA
11432617,NA,76,palmar-plantar erythrodysesthesia of sufficient severity to alter routine daily function,NA,NA,NA,NA
16284060,NA,77,non-haematological or clinical adverseevent,3 or 4,NA,FALSE,NA
16284060,NA,77,neutropenia,4,NA,NA,NA
16284060,NA,77,neutropenia with fever requiring supportive therapy,3 or 4,NA,NA,NA
16284060,NA,77,hyperbilirubinaemia,NA,NA,NA,NA
16284060,NA,77,Any adverse event requiring capecitabine interruption for more than seven doses or more than 10% of the planned dose,NA,NA,NA,NA
12491516,NA,78,neutropenia,4,NA,NA,"during the 2 weeks of
chemotherapy administration"
12491516,NA,78,neutropenia,4,>=5 days,NA,during the week off treatment
12491516,NA,78,febrile neutropenia requiring hospitalization,NA,NA,NA,NA
12491516,NA,78,thrombocytopenia,4,NA,NA,NA
12491516,NA,78,nonhematologic toxicity related to the study drugs,>=3,NA,FALSE,NA
12864942,NA,79,neutropenia,4,>5 days,NA,NA
12864942,NA,79,thrombocytopenia,4,>5 days,NA,NA
12864942,NA,79,febrile neutropenia,3 or 4,NA,NA,NA
12864942,NA,79,nonhematologic toxicity,>=3,NA,FALSE,NA
12864942,NA,79,any treatment delay at day 8 of the first treatment cycle or at day 1 of the second treatmentcycle because of unresolved toxicity,NA,NA,NA,NA
16242260,NA,80,any nonhematologic toxicities,3,NA,NA,"Grade 3 vomiting, nausea, stomatitis, diarrhea, or handâ€“foot syndrome"
16242260,NA,80,hematologic toxicities,3,NA,NA,"more than Grade 3 neutropenia, neutropenic fever, thrombocytopenia,
anemia, infection, or Grade 3 liver dysfunction"
15827767,NA,81,neutropenia,4,>4 days,NA,NA
15827767,NA,81,neutropenia with fever,3 or 4,NA,NA,NA
15827767,NA,81,thrombocytopenia,4,NA,NA,NA
15827767,NA,81,non-hematologicaltoxicity,3,NA,NA,NA
15827767,NA,81,treatment delay of more than 2 weeks following the last administration of doxifluridine,NA,NA,NA,NA
15520075,NA,82,platelet nadir < 25 000/ul,NA,NA,NA,NA
15520075,NA,82,absolute neutrophil count < 500/ul,NA,>=5 days,NA,NA
15520075,NA,82,absolute neutrophil count < 500/ul associated withinfection or fever,NA,NA,NA,NA
15520075,NA,82,treatment-related central nervous system toxicities,>=2,>24h,NA,NA
15520075,NA,82,non-hematologic toxicity of any type,>=3,NA,NA,NA
15520075,NA,82,failure to recover from treatment-related toxicity with 21 days of discontinuation of therapy,NA,NA,NA,NA
15520075,NA,82,a terminated or non-compliant treatment cycle with < 80% of planned capecitabine or CI-994 doses administered due to treatment-related toxicity,NA,NA,NA,NA
15612026,NA,83,neutropenia,4,>=7 days,NA,NA
15612026,NA,83,neutropenia associated with fever >= 38.1 Â°C,3 or 4,NA,NA,NA
15612026,NA,83,thrombocytopenia,4,>=7 days,NA,NA
15612026,NA,83,nonhematologic toxicity,3 or 4,NA,TRUE,NA
15612026,NA,83,"nausea, emesis, or mucositis not reduced to Grade 1 within 2 weeks with maximal supportive therapy",3 or 4,NA,NA,NA
15612026,NA,83,diarrhea ora second occurrence of Grade 2 diarrhea not reduced to Grade 1 within 2 weeks with maximal supportive therapy,3 or 4,NA,NA,NA
15612026,NA,83,hand-foot syndrome not reducedto Grade 1 before the start of Cycle 2,>=2,NA,NA,NA
15612026,NA,83,the inability to administer 2 successive doses of gemcitabine within the first treatment cycle,1,NA,NA,NA
15612026,NA,83,a delay of  14 days in initiating the second cycle of therapy due to persistent toxicity of  Grade 2,NA,NA,NA,NA
15305186,NA,84,lower gastrointestinal or genitourinary toxicity,3 or 4,NA,NA,NA
15305186,NA,84,perineal skin toxicity,3 or 4,NA,NA,NA
15305186,NA,84,any other toxicity,4,NA,NA,NA
15305186,NA,84,A delay of 48 weeks before surgery for toxicity reasons after completing concurrent therapy,NA,NA,NA,NA
15939714,NA,85,neutropenia,4,>7 days,NA,NA
15939714,NA,85,neutropenic fever,NA,NA,NA,NA
15939714,NA,85,thrombocytopenia,4,NA,NA,NA
15939714,NA,85,diarrhoea,3,>8 days,NA,NA
15939714,NA,85,diarrhoea,2,>8 days,NA,NA
15939714,NA,85,vomiting,4,NA,NA,NA
15939714,NA,85,handâ€“foot syndrome,3,>=2 days,NA,NA
15939714,NA,85,other toxicity,>=3,NA,NA,NA
15939714,NA,85,inability to administer treatment on schedule,NA,NA,NA,NA
16601432,NA,86,neutropenia,4,>=3 days,NA,NA
16601432,NA,86,neutropenia associated with fever>= 38.5Â°C,3 or 4,NA,NA,NA
16601432,NA,86,thrombocytopenia,4,>=3 days,NA,NA
16601432,NA,86,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16601432,NA,86,"nausea, vomiting, or mucositis not reduced to grade 1with maximal supportive therapy",3 or 4,NA,NA,NA
16601432,NA,86,diarrhea or a second occurrence of grade 2 diarrhea,3 or 4,NA,NA,NA
16601432,NA,86,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,2,NA,NA,NA
16601432,NA,86,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,3,NA,NA,NA
16601432,NA,86,a delay of >=14 days in initiating the second cycle of therapybecause of persistent toxicity of >= grade 2,NA,NA,NA,NA
16601432,NA,86,the omission of day 8 chemotherapy administration because of toxicity in the first cycle,NA,NA,FALSE,NA
12763217,NA,87,febrile neutropenia,NA,NA,NA,NA
12763217,NA,87,neutropenia,4,NA,FALSE,NA
12763217,NA,87,thrombocytopenia,4,NA,NA,NA
12763217,NA,87,nonhaematological toxicity,3 or 4,NA,TRUE,NA
12763217,NA,87,discontinuation of capecitabine for morethan eight doses due to toxicity,NA,NA,FALSE,NA
11768362,NA,88,febrile neutropenia,NA,NA,NA,NA
11768362,NA,88,neutropenia,4,>=7 days,NA,NA
11768362,NA,88,thrombocytopenia,4,NA,NA,NA
11768362,NA,88,any non-hematological toxicity,>=3,NA,FALSE,NA
12954586,NA,89,neutropenia associated with complications (e.g. neutropenic fever),3 or 4,NA,NA,NA
12954586,NA,89,thrombocytopenia,>=3,NA,NA,NA
12954586,NA,89,non-hematological toxicity,>=3,NA,FALSE,NA
12954586,NA,89,a toxicity-related discontinuation of capecitabine treatment for >1 week and/or a delay in the administration of irinotecan for>2 weeks,NA,NA,NA,NA
11843252,NA,90,leuko/neutropenia,4,NA,NA,NA
11843252,NA,90,thrombocytopenia,4,NA,NA,NA
11843252,NA,90,non hematologic toxicity,>=3,NA,FALSE,NA
15550580,NA,91,ANC <0.5 x 109/l,NA,>=4 days,NA,NA
15550580,NA,91,platelet count <25 x 109/l,NA,>=4 days,NA,NA
15550580,NA,91,non-hematological toxicity,3 or 4,NA,TRUE,NA
15550580,NA,91,dose reduction of vinorelbine on day 8,NA,NA,NA,NA
15550580,NA,91,treatment interruption due to chemotherapy-related toxicity grade >_2 and lasting >1 week,NA,NA,NA,NA
15238990,NA,92,leucopenia/neutropenia,4,NA,NA,NA
15238990,NA,92,thrombocytopenia,4,NA,NA,NA
15238990,NA,92,symptomatic thrombocytopenia,NA,NA,NA,NA
15238990,NA,92,febrile neutropenia,3 or 4,NA,NA,NA
15238990,NA,92,nonhaematological toxicity,>=3,NA,FALSE,NA
16462509,NA,93,febrile neutropenia,NA,>3 days,NA,NA
16462509,NA,93,ANC < 500/mmc,NA,>7 days,NA,NA
16462509,NA,93,leukocytes count < 1000/mmc,NA,>7 days,NA,NA
16462509,NA,93,"platelet count < 10,000/mmc",NA,NA,NA,NA
16462509,NA,93,organ toxicity,3 or 4,NA,NA,NA
15539915,NA,94,absolute neutrophil count < 0.5 x 109/l in two consecutive blood counts at least 72 h apart,NA,NA,NA,NA
15539915,NA,94,neutropenicfever,NA,NA,NA,NA
15539915,NA,94,platelet count < 25 x 109/l in two consecutive blood counts atleast 72 h apart,NA,NA,NA,NA
15539915,NA,94,nonhematological toxicity,3 or 4,NA,FALSE,NA
15539915,NA,94,any dose reduction of paclitaxel on day 8 or 15 of the first cycle,NA,NA,NA,NA
15539915,NA,94,treatment interruption due to chemotherapy-related toxicity of grade 62 or lasting 61 week,NA,NA,NA,NA
34301752,NCT02264678,95,neutropenia,4,>4 days,NA,NA
34301752,NCT02264678,95,neutropenia accompanied by fever of â‰¥38.5Â°C and/or systemic infection,3,NA,NA,NA
34301752,NCT02264678,95,"thrombocytopenia (25,000â€“<50,000 cells/mm3) with bleeding",3,NA,NA,NA
34301752,NCT02264678,95,Any other confirmed hematologic toxicity,>=4,NA,NA,NA
34301752,NCT02264678,95,Laboratory abnormalities,>=3,NA,FALSE,NA
34301752,NCT02264678,95,QTc prolongation (>500 ms),>=3,NA,NA,NA
34301752,NCT02264678,95,"Any other toxicity that was worse than that at baseline, was clinically significant and/or unacceptable, and did not respond to supportive care",NA,NA,NA,NA
34301752,NCT02264678,95,"Any event, including significant dose reductions or omissions, judged to be a DLT by the Safety Review Committee",NA,NA,NA,NA
16283312,NA,96,non-hematologic toxicities,3 or 4,NA,NA,NA
16283312,NA,96,thrombocytopenia,3 or 4,NA,NA,NA
16283312,NA,96,Neutropenia,3,NA,NA,NA
12506172,NA,97,neutropenia,4,NA,NA,NA
12506172,NA,97,thrombocytopenia,4,NA,NA,NA
12506172,NA,97,any nonhematologic toxic effect,3 or 4,NA,NA,NA
15218291,NA,98,neutropenia,4,>5 days,NA,NA
15218291,NA,98,thrombocytopenia,4,>5 days,NA,NA
15218291,NA,98,febrile neutropenia,3 or 4,NA,NA,NA
15218291,NA,98,nonhematologic toxicity,>=3,NA,FALSE,NA
15218291,NA,98,any treatment delay at day 8 of the first treatment cycle or at day1 of the second treatment cycle because of unresolved toxicity,NA,NA,NA,NA
11786589,NA,99,neutropenia,4,>3 days,NA,NA
11786589,NA,99,neutropenia associated with fever >= 38.1Â°C,3 or 4,NA,NA,NA
11786589,NA,99,thrombocytopenia,4,>3 days,NA,NA
11786589,NA,99,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11786589,NA,99,"nausea, vomiting, or mucositis not reduced to grade 1 with maximal supportive therapy",3 or 4,NA,NA,NA
11786589,NA,99,diarrhea or a second occurrence of grade 2 diarrhea,3 or 4,NA,NA,NA
11786589,NA,99,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,2,NA,NA,NA
11786589,NA,99,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,3,NA,NA,NA
11786589,NA,99,inability to administer two successive doses of gemcitabine within the first treatment cycle; or delay of  14 days in initiating the second cycle of therapy because of persistent toxicity of grade 2 or higher,NA,NA,NA,NA
16446337,NA,100,neutropenia,4,NA,NA,NA
16446337,NA,100,neutropenic fever/sepsis,NA,NA,NA,NA
16446337,NA,100,thrombocytopenia,>=3,NA,NA,NA
16446337,NA,100,nausea despite adequate supportive care,>=3,>=4 days,NA,NA
16446337,NA,100,vomiting despite adequate supportive care,>=3,>=4 days,NA,NA
16446337,NA,100,diarrhea despite adequate supportive care,>=3,>=4 days,NA,NA
16446337,NA,100,nonhematologic toxicity,>=3,NA,NA,NA
16446337,NA,100,asymptomatic lab abnormalities,4,NA,NA,NA
16446337,NA,100,any single interruption of radiation therapy >= 10 days or > 2 interruptions per radiation course,NA,NA,NA,NA
16446337,NA,100,delay of completion of radiation therapy > 14 days,NA,NA,NA,NA
16446337,NA,100,"inability to deliver > 85% of planned treatment, or any treatment-related hospitalization or death",NA,NA,NA,NA
12377646,NA,101,hematological toxicity,4,NA,NA,NA
12377646,NA,101,nonhematologic toxicity,>=3,NA,FALSE,NA
10561233,NA,102,ANC less than 500/ÂµL,NA,>5 days,NA,NA
10561233,NA,102,"ANC less than 1,000/ÂµL with fever",NA,NA,NA,NA
10561233,NA,102,"platelet count less than 25,000/ÂµL",NA,NA,NA,NA
10561233,NA,102,hemoglobin level less than 6.5 mg/dL,NA,NA,NA,NA
10561233,NA,102,"nonhematologic toxicity that did not improve to at least grade 1 within 2 days after the institution of appropriate therapy, or that led to the interruption of capecitabine treatment or delayed paclitaxel treatment for more than 2 weeks",>=3,NA,NA,NA
12393999,NA,103,neutropenia,4,>5 days,NA,NA
12393999,NA,103,thrombocytopenia,4,>5 days,NA,NA
12393999,NA,103,neutropenia associated with fever >= grade II,3 or 4,NA,NA,NA
12393999,NA,103,neutropenia on treatment day,>=3,NA,NA,NA
12393999,NA,103,handâ€“foot syndrome and not reduced to grade I before the scheduled nexttreatment course,>=2,NA,NA,NA
12393999,NA,103,diarrhea persisting after optimal antidiarrheal and/or antiemetic support,>=2,NA,NA,NA
12393999,NA,103,"nausea or vomiting persisting after optimal antidiarrheal and/or antiemetic support, respectively",>=3,NA,NA,NA
12393999,NA,103,"unable to complete more than 75% dose of either drug in course 1, that is, missing more than 14 doses of capecitabine and/or a dose delay of more than 7 days in course 2 of irinotecan because of toxicity",NA,NA,NA,NA
12393999,NA,103,"any nonhematologic toxicity, which is probably or definitely related to irinotecan or capecitabine",>=3,NA,FALSE,NA
15312392,NA,104,hematologic toxicity,3 or 4,>7 days,NA,NA
15312392,NA,104,mucositis,3 or 4,>3 weeks,NA,NA
15312392,NA,104,hand-foot syndrome,2,>3 weeks,NA,NA
15312392,NA,104,hand-foot syndrome,3,NA,NA,NA
15312392,NA,104,diarrhea,4,NA,NA,NA
15312392,NA,104,a delay in the administration of >7 days of radiotherapy due to toxicity,NA,NA,NA,NA
16062072,NA,105,hematologic toxicity,4,NA,NA,NA
16062072,NA,105,nonhematologic toxicity,3,NA,NA,NA
16062072,NA,105,peripheral neuropathy,2,NA,NA,NA
16504126,NA,106,neutropenia,4,>3 days,NA,NA
16504126,NA,106,neutropenia associated with fever â‰¥ 38.1Â°C,3 or 4,NA,NA,NA
16504126,NA,106,thrombocytopenia,4,>3 days,NA,NA
16504126,NA,106,anemia,4,NA,NA,NA
16504126,NA,106,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16504126,NA,106,"nausea, vomiting, or mucositis",3 or 4,NA,NA,NA
16504126,NA,106,diarrhea or a second occurrence of grade 2 diarrhea,3 or 4,NA,NA,NA
16504126,NA,106,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,2,NA,NA,NA
16504126,NA,106,hand-foot syndrome not reduced to grade 1 before the start of cycle 2,3,NA,NA,NA
16504126,NA,106,delay of â‰¥ 14 days in initiating the second or the third cycle of therapy because of persistent toxicity of grade 2 or higher,NA,NA,NA,NA
12351595,NA,107,any nonhematologic toxicity,3,NA,FALSE,NA
12351595,NA,107,vomiting,4,NA,NA,NA
12351595,NA,107,stomatitis,3,NA,NA,NA
12351595,NA,107,diarrhea that does not resolve to grade 0 to 2 within 2 days,NA,NA,NA,NA
12351595,NA,107,hand-foot syndrome that does not resolve to grade 0 to 2 within 1 week of starting symptomatic/prophylactic treatment,3,NA,NA,NA
12351595,NA,107,neutropenia,4,NA,NA,NA
12351595,NA,107,neutropenic fever,3 or 4,NA,NA,NA
12351595,NA,107,"thrombocytopenia, hemorrhage, or infection",4,NA,NA,NA
12351595,NA,107,hyperbilirubinemia,4,NA,NA,NA
12351595,NA,107,shift in liver transaminase concentrations,3,NA,NA,NA
15894361,NA,109,diarrhoea,3 or 4,NA,NA,NA
15894361,NA,109,mucositis,3 or 4,NA,NA,NA
15894361,NA,109,skin toxicity,3 or 4,NA,NA,NA
15894361,NA,109,bladder toxicity,3 or 4,NA,NA,NA
15894361,NA,109,neutropenia associated with fever,4,NA,NA,NA
15894361,NA,109,neutropenia,4,>7 days,NA,NA
15894361,NA,109,thrombocytopenia,3 or 4,NA,NA,NA
34562230,NCT02419495,111,any selinexor-related hematologic adverseevent,4,NA,NA,NA
34562230,NCT02419495,111,thrombocytopenia associated with clinically signifcant bleeding,>=3,NA,NA,NA
34562230,NCT02419495,111,febrile neutropenia,NA,NA,NA,NA
34562230,NCT02419495,111,non-hematologic adverse event despite optimal supportive medications,>=3,NA,FALSE,NA
34607210,NCT02944396,112,thrombocytopenia,4,NA,NA,NA
34607210,NCT02944396,112,neutropenia,4,NA,NA,NA
34607210,NCT02944396,112,febrile neutropenia,4,NA,NA,NA
34607210,NCT02944396,112,febrile neutropenia with fever,3,>7 days,NA,NA
34607210,NCT02944396,112,nonhematological toxicity representing â‰¥2 grade increase from baseline attributed to veliparib,>=3,NA,NA,NA
34607210,NCT02944396,112,nonhematologic or non-skin toxicity representing â‰¥2 grade increase from baseline attributed to veliparib or nivolumab,2,NA,NA,NA
34607210,NCT02944396,112,"any toxicity representing increase from baseline attributed to veliparib requiring dose modification or omission of carboplatin, paclitaxel, or pemetrexed at Cycle 2 or 3",>=2,NA,NA,NA
34607210,NCT02944396,112,any treatment related uveitis/eye pain that did not improve with topical therapy,2,NA,NA,NA
34607210,NCT02944396,112,any treatment related pneumonitis/interstitial lung disease that did not resolve with dose delay and systemic steroids,2,NA,NA,NA
34311345,NCT02412371,113,non-hematological toxicity,>=3,NA,NA,NA
34311345,NCT02412371,113,esophagitis,>=4,NA,NA,NA
34311345,NCT02412371,113,dysphagia,4,NA,NA,NA
34311345,NCT02412371,113,odynophagia requiring treatment interruption for >7 days,4,NA,NA,NA
34311345,NCT02412371,113,clinically severe radiation-related toxicity,NA,NA,NA,NA
34311345,NCT02412371,113,discontinuation of RT (<50 Gy),NA,NA,NA,NA
34311345,NCT02412371,113,neutropenia,>=4,7 days,NA,NA
34311345,NCT02412371,113,febrile neutropenia,NA,NA,NA,NA
34311345,NCT02412371,113,thrombocytopenia,>=4,NA,NA,NA
34311345,NCT02412371,113,seizure,>=2,NA,NA,NA
34311345,NCT02412371,113,nausea and vomiting despite antiemetic treatment,4,>48 h,NA,NA
16284056,NA,114,absolute neutrophil count (ANC)<500 mm3,NA,>=5 days,NA,NA
16284056,NA,114,neutropenic fever defined as ANC <500 mm3 with fever >38.5C (single evaluation) or temperature >38 C in two evaluations lasting 12 h each,NA,NA,NA,NA
16284056,NA,114,platelets <25 000/mm3,NA,>5 days,NA,NA
16284056,NA,114,platelets <25 000/mm3 with bleedingrequiring transfusions,NA,NA,NA,NA
16284056,NA,114,non-hematological toxicity,3 or 4,NA,FALSE,NA
31174889,NCT02092363,115,any possible treatment emergent,>=3,NA,FALSE,NA
31174889,NCT02092363,115,"any AE that results in the subject being discontinued from study that occurs any time from study days 0 to 28, unless the event could be clearly attributed to another cause.",NA,NA,NA,NA
31174889,NCT02092363,115,NA,4,NA,NA,NA
31190276,NCT00268905,116,toxicity which resolved to grade 2 or lower toxicity within 14 days,>=3,NA,FALSE,NA
31190276,NCT00268905,116,thrombocytopenia,4,NA,NA,NA
31190276,NCT00268905,116,thrombocytopenia with clinically signifcant bleeding,3,NA,NA,NA
31190276,NCT00268905,116,neutropenia not reversible to grade 3 or better inâ‰¤5 days without growth factor support,4,NA,NA,NA
31190276,NCT00268905,116,febrile neutropenia,NA,NA,FALSE,NA
31190276,NCT00268905,116,neutropenia associatedwith bacteremia or sepsis,NA,NA,NA,NA
29500276,NCT01696032,117,thrombocytopenia,4,>7 days,NA,NA
29500276,NCT01696032,117,neutropenia,4,>7 days,NA,NA
29500276,NCT01696032,117,febrile neutropenia,3 or 4,NA,NA,NA
29500276,NCT01696032,117,"nonhematologic toxicity, which could not be appropriately managed by supportive treatment",>=3,NA,NA,NA
29500276,NCT01696032,117,"any incidence of failure to recover absolute neutrophil count (ANC) to 1,000 cells/mm3 and/or platelets to >75,000 cells/mm3 by cycle 1, day 42",NA,NA,NA,NA
29500276,NCT01696032,117,any other clinically significant AE placing patients at undue safety risk or resulting in discontinuation of treatment,NA,NA,NA,NA
33539540,NCT02418624,118,toxicity that resulted in missing more than five doses of olaparib or that delayed the administration of carboplatin more than 7 days,>2,NA,NA,NA
33539540,NCT02418624,118,a dose delay of 7 days or more of the second cycle of olaparib-carboplatin,NA,NA,NA,NA
33539540,NCT02418624,118,anemia,4,NA,NA,NA
33539540,NCT02418624,118,neutropenia,4,>7 days,NA,NA
33539540,NCT02418624,118,febrile neutropenia,3 or 4,NA,NA,NA
33539540,NCT02418624,118,thrombocytopenia,4,NA,NA,NA
33539540,NCT02418624,118,thrombocytopenia with bleeding events,3,NA,NA,NA
33539540,NCT02418624,118,"diarrhea, vomiting and nausea despite adequate supportive treatment",>=3,NA,NA,NA
33539540,NCT02418624,118,increased liver biochemistry,>=3,>3 days,NA,NA
30327308,NCT02289690,119,thrombocytopenia,4,NA,NA,NA
30327308,NCT02289690,119,neutropenia,4,NA,NA,NA
30327308,NCT02289690,119,febrile neutropenia with fever,3,>7 days,NA,NA
30327308,NCT02289690,119,febrile neutropenia occurring during cycle 1 and associated with treatment delay of more than 14 days in initiating cycle 2 chemotherapy,4,NA,NA,NA
30327308,NCT02289690,119,nonhematologic toxicity that increased at least 2 grade levels from baseline,>=3,NA,TRUE,NA
30327308,NCT02289690,119,nonhematologic toxicity that increased at least 2 grade levels from baseline and required a treatment delay of more than 14 days in initiation of cycle 2,2,NA,NA,NA
30327308,NCT02289690,119,"any toxicity that increased at least 2 grade levels from baseline and required at least 1 of: dose modification within cycle 1 or omission of carboplatin, more than 1 daily etoposide dose, or >30% veliparib doses in cycle 1",NA,NA,NA,NA
31231786,NCT03201146,120,hematologic toxicity,4,NA,NA,NA
31231786,NCT03201146,120,other AEs,>=3,NA,FALSE,NA
31231786,NCT03201146,120,other AEs persisting more than two weeks afterappropriate treatment,NA,>2 weeks,NA,NA
30174176,NA,121,dose delay >3 weeks due to failure to recover counts,NA,NA,NA,NA
30174176,NA,121,febrile neutropenia,NA,NA,NA,NA
30174176,NA,121,neutropenia,4,>7 days,NA,NA
30174176,NA,121,thrombocytopenia,4,NA,NA,NA
30174176,NA,121,thrombocytopenia associated with clinically significant bleeding,3,NA,NA,NA
30174176,NA,121,non-hematologic toxicity,3 or 4,NA,FALSE,NA
33634324,NCT01304303,122,neutropenia,4,>7 days,NA,NA
33634324,NCT01304303,122,febrile neutropenia requiring parenteral antibiotic,4,NA,NA,NA
33634324,NCT01304303,122,thrombocytopenia,3,>7 days,NA,NA
33634324,NCT01304303,122,thrombocytopenia requiring platelet transfusion,3,NA,NA,NA
33634324,NCT01304303,122,hemorrhage,>=2,NA,NA,NA
33634324,NCT01304303,122,non-hematologic PICN-related toxicities,>=3,NA,FALSE,NA
33634324,NCT01304303,122,treatment delay for more than 7 days during the frst cycle (Cycle 1) of treatment with PICN monotherapy or its combination with carboplatin,NA,NA,FALSE,NA
31953695,NA,123,non-hematologic toxicity,3 or 4,NA,FALSE,NA
31953695,NA,123,electrolyte abnormalities that do not resolve within 72 h after appropriate electrolyte replacement therapy or are associated with EKG changes,3,NA,NA,NA
31953695,NA,123,thrombocytopenia,4,NA,NA,NA
31953695,NA,123,neutropenia complicated byfever,4,NA,NA,NA
31953695,NA,123,neutropenia without fever,4,>7 days,NA,NA
31388792,NCT00891072,124,nonhematological toxicity,>=3,NA,FALSE,NA
31388792,NCT00891072,124,"nausea, vomiting, or diarrhea uncontrolled bymaximal antiemetic/antidiarrheal therapy",3,NA,NA,NA
31388792,NCT00891072,124,neutropenia,4,>=7 days,NA,NA
31388792,NCT00891072,124,neutropenia with fever >38.5 Â°C,4,NA,NA,NA
31388792,NCT00891072,124,neutropenia with > grade 3 infection,3,NA,NA,NA
31388792,NCT00891072,124,elevated serum troponin,NA,NA,NA,NA
31388792,NCT00891072,124,carboplatin/paclitaxel infusionrelated events,4,NA,NA,NA
31388792,NCT00891072,124,thrombocytopenia of any grade if associatedwith clinically significant bleeding,NA,NA,NA,NA
31388792,NCT00891072,124,thrombocytopenia,NA,NA,NA,NA
34052705,NCT02185690,125,an inability to administer binimetinib on â‰¥75% of treatment days during cycle 1 due to an unresolved and related AE,NA,NA,NA,NA
34052705,NCT02185690,125,treatment delay of â‰¥14 days due to unresolved toxicity,NA,NA,NA,NA
34052705,NCT02185690,125,non-hematological toxicity,>=3,NA,NA,NA
34052705,NCT02185690,125,hematologic toxicity,>=4,NA,NA,NA
34052705,NCT02185690,125,febrile neutropenia,>=3,NA,NA,NA
34052705,NCT02185690,125,QTc prolongation â‰¥501ms,NA,NA,NA,NA
34052705,NCT02185690,125,ocular toxicity,NA,NA,NA,NA
34052705,NCT02185690,125,serum creatinine >2 times upper limit normal,NA,NA,NA,NA
34052705,NCT02185690,125,non-hematologic toxicity considered to be dose limiting at the discretion of the principal investigator,>=2,NA,NA,NA
31708167,NCT00989651,126,study related non-hematologic toxicity,3 or 4,NA,FALSE,NA
31708167,NCT00989651,126,any drug related death,NA,NA,NA,NA
31708167,NCT00989651,126,a dose delay >3 weeks due to failure to recover counts,NA,NA,NA,NA
31708167,NCT00989651,126,febrile neutropenia,NA,NA,NA,NA
31708167,NCT00989651,126,neutropenia,4,>=7 days,NA,NA
31708167,NCT00989651,126,thrombocytopenia,4,NA,NA,NA
31708167,NCT00989651,126,thrombocytopenia associated with bleeding,3,NA,NA,NA
30088048,NCT00809133,127,uncomplicated neutropenia,4,>7 days,NA,NA
30088048,NCT00809133,127,neutropenia associated withfever>38.5 Â°C,NA,NA,NA,NA
30088048,NCT00809133,127,platelets<25Ã—109/L,NA,NA,NA,NA
30088048,NCT00809133,127,thrombocytopenia associated with bleeding requiring transfusion,3,NA,NA,NA
30088048,NCT00809133,127,decrease in LVEF,>=2,NA,NA,NA
30088048,NCT00809133,127,uncontrolled hypertension despite multiple anti-hypertension therapies,NA,NA,NA,NA
30088048,NCT00809133,127,worsening of renal function,>=2,NA,NA,NA
30088048,NCT00809133,127,diarrhea despite anti-diarrheal treatment,>2,NA,NA,NA
30088048,NCT00809133,127,diarrhea despite supportive care,>=2,>=7 days,NA,NA
30088048,NCT00809133,127,nausea and/or vomiting despite antiemetic treatment,>2,NA,NA,NA
30088048,NCT00809133,127,vomiting despite supportive care,>=2,>=7 days,NA,NA
30088048,NCT00809133,127,all other non-hematologic toxicities,>=3,NA,FALSE,NA
33513474,NCT01711541,128,neutropenia,4,>14 days,NA,NA
33513474,NCT01711541,128,febrile neutropenia,NA,NA,NA,NA
33513474,NCT01711541,128,thrombocytopenia,4,NA,NA,NA
33513474,NCT01711541,128,a dose delay of greater than 3 weeks due to failed count recovery,NA,NA,NA,NA
33513474,NCT01711541,128,Non-hematologic toxicity,3 or 4,NA,FALSE,NA
33513474,NCT01711541,128,hypertension,3,NA,NA,NA
33513474,NCT01711541,128,Any non-hematologic toxicity leading to a dose delay ofgreater than 3 weeks or any drug-related death,NA,NA,NA,NA
31791552,NCT01663857,130,nonhematologic toxicity,3 or 4,NA,FALSE,NA
31791552,NCT01663857,130,nausea/vomiting or diarrhea despite the use of adequate or maximal medical intervention,3 or 4,>=2 days,NA,NA
31791552,NCT01663857,130,electrolyte disturbances despite maximal supportive treatment,3 or 4,>=5 days,NA,NA
31791552,NCT01663857,130,hematologic toxicity,4,>5 days,NA,NA
31791552,NCT01663857,130,thrombocytopenia with bleeding,3,NA,NA,NA
31791552,NCT01663857,130,thrombocytopenia,4,NA,NA,NA
31791552,NCT01663857,130,neutropenia with fever,3 or 4,NA,NA,NA
31446228,NCT01868022,131,clinically significant non-hematologic toxicity,3 or 4,NA,NA,NA
31446228,NCT01868022,131,neutropenia,4,>7 days,NA,NA
31446228,NCT01868022,131,febrile neutropenia,NA,NA,NA,NA
31446228,NCT01868022,131,thrombocytopenia,4,NA,NA,NA
31446228,NCT01868022,131,clinically significant laboratory abnormalities,4,>48 days,NA,NA
31446228,NCT01868022,131,treatment delay of at least 14 days due to unresolved drug-related toxicity,NA,NA,NA,NA
30596402,NCT01165112,132,"any nonhaematological adverse event that is possibly, probably or definitely related to the drug combination within 28 days of the last dose of the study drug",>=4,NA,NA,NA
30596402,NCT01165112,132,the patient did not complete one full cycle of therapy due totoxicity from the treatment,NA,NA,NA,NA
30596402,NCT01165112,132,"any serious AE that is possibly, probably or definitely related to the drug combination, but does not meet the criteria above for a DLT, could be considered a DLT at the discretion of the study team",NA,NA,NA,NA
32665311,NCT01934361,133,NA,NA,NA,NA,Not defined
30842183,NA,134,neutropenia,4,>=5 days,NA,NA
30842183,NA,134,febrile neutropenia,3 or 4,NA,NA,NA
30842183,NA,134,thrombocytopenia,4,NA,NA,NA
30842183,NA,134,nonhematological toxicity,3,>=5 days,NA,NA
28790114,NCT02358200,135,nonhematologic treatment-related adverse event,>=3,NA,NA,NA
28790114,NCT02358200,135,neutropenia,4,>7 days,NA,NA
28790114,NCT02358200,135,febrile neutropenia,NA,NA,NA,NA
28790114,NCT02358200,135,thrombocytopenia with bleeding,3,NA,NA,NA
28790114,NCT02358200,135,thrombocytopenia,4,NA,NA,NA
28790114,NCT02358200,135,ailure to receive at least 75% of doses in cycle 1 (first 21 days) due to toxicity,NA,NA,NA,NA
28356425,NCT01149083,136,nonhematologic toxicity not reversible to grade  2 within 96 hours,3,NA,NA,NA
28356425,NCT01149083,136,Patients unable to take 80% of the planned veliparib due to toxicity/tolerability,NA,NA,NA,NA
28356425,NCT01149083,136,toxicity,4,NA,FALSE,NA
32669375,NCT01590160,137,nonhematologic events,3 or 4,NA,TRUE,NA
32669375,NCT01590160,137,thrombocytopenia,4,>7 days,NA,NA
32669375,NCT01590160,137,neutropenia,4,>7 days,NA,NA
32669375,NCT01590160,137,febrile neutropenia,NA,NA,NA,NA
32669375,NCT01590160,137,any drug-related adverse event leading to an interruption of ganetespib for longer than 14 days,NA,NA,NA,NA
32669375,NCT01590160,137,any clinically significant toxicity leading to dose reduction for ganetespib,NA,NA,NA,NA
30383888,NCT01636622,138,hemolytic anemia,>=3,NA,NA,NA
30383888,NCT01636622,138,thrombocytopenia,4,NA,NA,NA
30383888,NCT01636622,138,febrile neutropenia,>=3,NA,NA,NA
30383888,NCT01636622,138,neutropenia,4,>7 days,NA,NA
30383888,NCT01636622,138,creatinine elevation,3,NA,NA,NA
30383888,NCT01636622,138,"elevation of bilirubin, alanine aminotransferase, or aspartate aminotransferase",3,NA,NA,NA
30383888,NCT01636622,138,nonhematologic toxicity leading to treatment interruption for longer than 7 consecutive days,3,NA,NA,NA
30383888,NCT01636622,138,nonhematologic toxicity,4,NA,NA,NA
30383888,NCT01636622,138,any intolerable nonhematologic toxicity requiring a dose reduction for the second cycle of treatment,2,NA,NA,NA
30383888,NCT01636622,138,any intolerable nonhematologic toxicity requiring a dose reduction for the second cycle of treatment,3,NA,NA,NA
30383888,NCT01636622,138,any treatment-related adverse events resulting in a treatment delay longer than 7 consecutive days during cycle 1,NA,NA,NA,NA
31549216,NCT00535119,1,nonhematologic toxicity (including nausea or vomiting that lasted longer than 48 h despite maximal medical therapy),>=3,NA,NA,NA
31549216,NCT00535119,1,absolute neutrophil count<1000,NA,>7 days,NA,NA
31549216,NCT00535119,1,thrombocytopenia,4,NA,NA,NA
31549216,NCT00535119,1,neutropenia associated with sepsis or fever>38 Â°C,3 or 4,NA,NA,NA
31549216,NCT00535119,1,delay in starting cycle 3 by more than 2 weeks due to toxicity,NA,NA,NA,NA
31549216,NCT00535119,1,abnormal non-hematological laboratory if clinically signifcant and drug related,>=3,NA,NA,NA
32534811,NA,2,neutropenia,>=4,>5 days,NA,NA
32534811,NA,2,neutropenia associated with fever,>=4,NA,NA,NA
32534811,NA,2,anemia or thrombocytopenia,>=4,NA,NA,NA
32534811,NA,2,thrombocytopenia complicated by clinically significant bleeding requiring medical intervention,3,NA,NA,NA
32534811,NA,2,non-hematologic toxicity not attributable to disease progression or other identifiable cause,>=3,NA,FALSE,NA
29352572,NCT01063816,3,cycle delay N1 week entering C3 due to veliparib-related toxicity,NA,NA,NA,NA
29352572,NCT01063816,3,neutropenia,4,NA,NA,NA
29352572,NCT01063816,3,thrombocytopenia,4,NA,NA,NA
29352572,NCT01063816,3,neutropenia with fever,3,NA,NA,NA
29352572,NCT01063816,3,Nonhematologic adverse events that were a 2-grade or higher increase from baseline,>=3,NA,FALSE,NA
32146550,NCT02312661,7,Absolute neutrophil count (ANC) < 0.5 x 109/L,NA,>=7 days,NA,NA
32146550,NCT02312661,7,"Febrile Neutropenia (ANC < 1.0 x 109/L, fever > 38.5 0C)",NA,NA,NA,NA
32146550,NCT02312661,7,Platelets < 25 x 109/L,NA,NA,NA,NA
32146550,NCT02312661,7,Bleeding felt to be due to thrombocytopenia,NA,NA,NA,NA
32146550,NCT02312661,7,Diarrhea despite optimal loperamide use persisting â‰¥ 2 weeks,>3,NA,NA,NA
32146550,NCT02312661,7,"Nausea / vomiting despite optimal use of anti-emetics, persisting â‰¥ 2 weeks or leading to > 7 missed doses of metformin.",>3,NA,NA,NA
32146550,NCT02312661,7,other effects thought to be treatment related,3 or 4,NA,NA,NA
32146550,NCT02312661,7,Missing >7 doses of metformin treatment for toxicity reasons,NA,NA,NA,NA
32146550,NCT02312661,7,Inability to administer next cycle of carboplatin/paclitaxel within 5 weeks after previous cycle,NA,NA,NA,NA
28413662,UMIN000007600,8,thrombocytopenia,4,NA,NA,NA
28413662,UMIN000007600,8,thrombocytopenia requiring transfusion,3,NA,NA,NA
28413662,UMIN000007600,8,neutropenia,4,>7 days,NA,NA
28413662,UMIN000007600,8,neutropenia with fever â‰¥38.5ËšC,3,NA,NA,NA
28413662,UMIN000007600,8,non-hematological toxicity,3 or 4,NA,FALSE,NA
28595616,NCT01256268,9,"non-hematologic toxicity (specifically, rash, mucositis, pneumonitis)",>=3,NA,FALSE,NA
28595616,NCT01256268,9,thrombocytopenia requiring platelet transfusion,>=3,NA,NA,NA
28595616,NCT01256268,9,thrombocytopenia,4,>7 days,NA,NA
28595616,NCT01256268,9,neutropenia,4,>7 days,NA,NA
28595616,NCT01256268,9,neutropenic fever requiring hospitalization,4,NA,NA,NA
28595616,NCT01256268,9,unresolved toxicity resulting in delay of retreatment >2 weeks,NA,NA,NA,NA
28595616,NCT01256268,9,non-surgical hemorrhages,3 or 4,NA,NA,NA
28595616,NCT01256268,9,failure of administration of ridaforolimus for 5 days or more (consecutive or nonconsecutive) due to any toxicity,NA,NA,NA,NA
33147935,NCT03212937,10,failure to resolve any non-hematologic toxicities,>=3,NA,NA,NA
33147935,NCT03212937,10,platelet count of less than 75x109/L or absolute neutrophil count of less than 1x109/L by day 29,NA,NA,NA,NA
33147935,NCT03212937,10,a platelet count of less than 25x109/L or an absolute neutrophil count of less than 0.5x109/L,NA,>14 days,NA,NA
33147935,NCT03212937,10,a platelet nadir of 10x109/L or less,NA,NA,NA,NA
33147935,NCT03212937,10,any toxicities,5,NA,NA,NA
32452601,NCT01251874,11,nonhematologic toxicity,>=3,NA,FALSE,NA
32452601,NCT01251874,11,reversible electrolyte abnormalities unable to be corrected within 24 hours,>=3,NA,NA,NA
32452601,NCT01251874,11,thrombocytopenia,4,NA,NA,NA
32452601,NCT01251874,11,febrile neutropenia,NA,NA,NA,NA
32452601,NCT01251874,11,neutropenia,4,>=7 days,NA,NA
32452601,NCT01251874,11,toxicity,5,NA,NA,NA
32568634,NCT02157792,12,toxicities,>=2,NA,NA,NA
33373402,NCT01644955,13,"toxicity that is possibly, probably, or definitely related to the study drug",3 or 4,NA,NA,NA
33373402,NCT01644955,13,"Non-hematologic toxicities such as rash, nausea, vomiting and hypertension despite maximal medical therapy 72 hours after maximal medical therapy is initiated",>=3,NA,NA,NA
31080557,NCT01445418,14,hematologic adverse events related to study medications,4,NA,NA,NA
31080557,NCT01445418,14,nonhematologic adverse events related to study medications,3 or 4,NA,FALSE,NA
31080557,NCT01445418,14,neutropenia,3,>=7 days,NA,NA
31080557,NCT01445418,14,neutropenia with fever,3,NA,NA,NA
31080557,NCT01445418,14,thrombocytopenia,3,>=7 days,NA,NA
31080557,NCT01445418,14,thrombocytopenia requiring transfusion,3,NA,NA,NA
32559454,UMIN000011216,15,neutropenia,4,>=4 days,NA,NA
32559454,UMIN000011216,15,thrombocytopenia,4,NA,NA,NA
32559454,UMIN000011216,15,non-hematological toxicity,3,NA,FALSE,NA
32559454,UMIN000011216,15,the inability to administer nab-PTX on both day 8 and 15 during the same course,NA,NA,NA,NA
32559454,UMIN000011216,15,a delayed start of the second course for more than two weeks,NA,NA,NA,NA
30563934,NCT01653912,16,nonhematologic toxicity,3 or 4,NA,FALSE,NA
30563934,NCT01653912,16,anemia,4,NA,NA,NA
30563934,NCT01653912,16,thrombocytopenia,4,NA,NA,NA
30563934,NCT01653912,16,neutropenia,4,>=5 days,NA,NA
30563934,NCT01653912,16,febrile neutropenia,NA,NA,NA,NA
30563934,NCT01653912,16,thrombocytopenia with bleeding,3,NA,NA,NA
30563934,NCT01653912,16,alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN) with bilirubin > 2 x ULN,NA,NA,NA,NA
30563934,NCT01653912,16,any toxicity that was unresolved after a treatment delay of >14 days,NA,NA,NA,NA
29781056,NCT01862328,17,hematologic toxicity,4,NA,FALSE,NA
29781056,NCT01862328,17,neutropenia with fever >38.5ÂºC,>=3,>=1 h,NA,NA
29781056,NCT01862328,17,non-hematologic toxicity,>=3,NA,FALSE,NA
29781056,NCT01862328,17,non-hematologic toxicity requiring pevonedistat dose reduction/discontinuation,>=2,NA,NA,NA
29781056,NCT01862328,17,a delay of >4 weeks starting cycle 2 due to a hematologic toxicity not related to tumor infiltration (bone marrow evaluation may be required),NA,NA,NA,NA
29781056,NCT01862328,17,delay of >2 weeks due to non-hematologic toxicity,NA,NA,NA,NA
29781056,NCT01862328,17,any adverse event during cycle 1 leading to dose modification in the next cycle,NA,NA,NA,NA
29781056,NCT01862328,17,any drug-related toxicity resulting in administration of only one dose of gemcitabine per cycle,NA,NA,NA,NA
30089585,NCT01573338,18,absolute neutrophil counts < 0.5 Ã— 109/L,NA,>=7 days,NA,NA
30089585,NCT01573338,18,febrile neutropenia with absolute neutrophil counts < 0.5 Ã— 109/L and fever â‰¥38.5 Â°C,NA,NA,NA,NA
30089585,NCT01573338,18,non-hematologic toxicity,>=3,NA,NA,NA
30089585,NCT01573338,18,vomiting event,4,>48h,NA,NA
30089585,NCT01573338,18,nausea or vomiting,3,>48h,NA,NA
28792260,NCT01169636,19,Nonhematologic toxicity,>=3,NA,FALSE,NA
28792260,NCT01169636,19,neutropenia,4,>14 days,NA,NA
28792260,NCT01169636,19,febrile neutropenia,4,NA,NA,NA
28792260,NCT01169636,19,thrombocytopenia (platelet count <25  109/L),4,>14 days,NA,NA
30552156,NCT01844947,20,neutropenia (absolute neutrophil count <0.5 Ã— 109 for â‰¥7 days or <0.1 Ã— 109 for â‰¥3 days),>=4,NA,NA,NA
30552156,NCT01844947,20,febrile neutropenia,>=3,NA,NA,NA
30552156,NCT01844947,20,platelet count <25 Ã— 109/L,NA,NA,NA,NA
30552156,NCT01844947,20,thrombocytopenia with bleeding or requiring platelet transfusion,NA,NA,NA,NA
30552156,NCT01844947,20,liver toxicity (alanine aminotransferase or aspartate aminotransferase),>=3,>7 days,NA,NA
30552156,NCT01844947,20,major organ toxicity,>=3,NA,NA,NA
26403509,NCT01287520,21,non-hematologic toxicity,>=3,NA,TRUE,NA
26403509,NCT01287520,21,hematologic toxicity,4,>5 days,NA,NA
26403509,NCT01287520,21,febrile neutropenia,NA,NA,NA,NA
26403509,NCT01287520,21,thrombocytopenia,4,NA,NA,NA
26403509,NCT01287520,21,thrombocytopenia plus bleeding,>=2,NA,NA,NA
26403509,NCT01287520,21,prolonged QTc interval,>=3,NA,NA,NA
26403509,NCT01287520,21,visual disturbance,NA,NA,NA,NA
22988282,NA,22,febrile neutropenia,3,NA,NA,NA
22988282,NA,22,neutropenia,4,NA,NA,NA
22988282,NA,22,thrombocytopenia,3 or 4,NA,NA,NA
22988282,NA,22,anaemia,3 or 4,NA,NA,NA
22988282,NA,22,nonhaematologic toxicities,3 or 4,NA,FALSE,NA
22988282,NA,22,toxicity,5,NA,NA,NA
27323902, NCT02418624,23,NA,NA,NA,NA,Not reported
26705063,NCT01732640,24,neutropenia associated with a fever > 38.5 Â°C,3 or 4,NA,NA,NA
26705063,NCT01732640,24,neutropenia,3 or 4,>5 days,NA,NA
26705063,NCT01732640,24,thrombocytopenia with bleeding,3,NA,NA,NA
26705063,NCT01732640,24,thrombocytopenia,4,NA,NA,NA
26705063,NCT01732640,24,non-hematologic toxicity,3 or 4,NA,FALSE,NA
23835505,NA,25,neutropenia,4,NA,NA,NA
23835505,NA,25,neutropenia with associated fever (>=38.5C),3,NA,NA,NA
23835505,NA,25,thrombocytopenia,4,NA,NA,NA
23835505,NA,25,nonhematologic toxicities,3 or 4,>7 days,NA,NA
23835505,NA,25,any treatment-related toxicity that caused a radiation treatment delay of more than 7 days or caused the radiation treatment to last for more than 8 weeks,NA,NA,NA,NA
23835505,NA,25,Any toxicity that held up the chemotherapy for 2 consecutive weeks,NA,NA,NA,NA
22644799,NCT01016769,26,dysphagia,3,NA,NA,NA
22644799,NCT01016769,26,lymphopenia,3 or 4,NA,NA,NA
22644799,NCT01016769,26,fatigue,3,NA,NA,NA
22644799,NCT01016769,26,nausea/vomiting,3,<=72 h,NA,NA
22644799,NCT01016769,26,thrombocytopenia,3,NA,NA,NA
22644799,NCT01016769,26,low hemoglobin,3,NA,NA,NA
27551000,NA,27,nonhematologic toxicity,4,NA,FALSE,NA
27551000,NA,27,nonhematologic toxicity that did not resolve â‰¤ grade 2 within 48 hours,3,NA,FALSE,NA
27551000,NA,27,"mucositis, diarrhea, nausea, or vomiting was considered dose limiting only if resolution to â‰¤ grade 2 (including use of supportive care) required â‰¥7 days",3,NA,NA,NA
27551000,NA,27,neurotoxicity or nephrotoxicity,3,NA,NA,NA
22943879,NA,29,dose delay > two weeks due to failure to recover counts,NA,NA,NA,NA
22943879,NA,29,febrile neutropenia,NA,NA,NA,NA
22943879,NA,29,neutropenia,4,>7 days,NA,NA
22943879,NA,29,thrombocytopenia,4,NA,NA,NA
22943879,NA,29,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
22943879,NA,29,study related non-hematological toxicity,3 or 4,NA,FALSE,NA
22943879,NA,29,Any drug-related death,NA,NA,NA,NA
22943879,NA,29,study treatmentrelated neuropathy,>=2,>2 weeks,NA,NA
23147218,NCT00735878,30,febrile neutropenia,NA,NA,NA,grade 4 neutropenia ( <500/ul) ) lasting more than 6 days or any episode of febrile neutropenia or neutropenia with documented infection or sepsis
23147218,NCT00735878,30,"thrombocytopenia (< 50,000/ ul) that occurred on the day of scheduled treatment",>=3,NA,NA,NA
23147218,NCT00735878,30,nonhematologic toxicity,>=3,NA,FALSE,NA
23147218,NCT00735878,30,inability to begin the next cycle of therapy within 2 weeks of its scheduled start due to delayed recovery,NA,NA,NA,NA
23147218,NCT00735878,30,Any nonreversible toxicity,>=2,NA,NA,NA
22837181,NCT00672295,31,"non-hematologic toxicity (specifically diarrhea, rash, nonmalignant pleural effusion, and ascites not attributable to malignancy)",>=3,NA,FALSE,NA
22837181,NCT00672295,31,thrombocytopenia,4,NA,NA,NA
22837181,NCT00672295,31,neutropenic fever,NA,NA,NA,NA
22837181,NCT00672295,31,neutropenia,NA,>7 days,NA,NA
22837181,NCT00672295,31,dose delay of greater than 2 weeks due to failure to recover counts to â‰¤ grade 1,NA,NA,NA,NA
22837181,NCT00672295,31,nonsurgical hemorrhage,3 or 4,NA,NA,NA
26616225,26616225,32,dose delay of >3 weeks due to failure to recover counts,NA,NA,NA,NA
26616225,26616225,32,febrile neutropenia,NA,NA,NA,NA
26616225,26616225,32,neutropenia,4,>7 days,NA,NA
26616225,26616225,32,thrombocytopenia,4,NA,NA,NA
26616225,26616225,32,hrombocytopenia with clinically significant bleeding,3,NA,NA,NA
26616225,26616225,32,adverse event,3 or 4,NA,FALSE,NA
26616225,26616225,32,any drug-related death.,NA,NA,NA,NA
26616225,26616225,32,ny dose delay for >3 weeksdue to toxicity,NA,NA,NA,NA
23468081,NCT00420186,34,febrile neutropenia,NA,NA,NA,NA
23468081,NCT00420186,34,neutropenia,4,>= 7 days,NA,NA
23468081,NCT00420186,34,anemia were managed with subsequent prophylactic growth factor support and transfusions,4,NA,NA,NA
23468081,NCT00420186,34,non-hematologic toxicity considered attributable to PC or BMS690514,3 or 4,NA,NA,NA
28028994,NA,35,"hypersensitivity, despite the premedication recommended by the NCI CTCAE V3.0",>=3,NA,NA,NA
28028994,NA,35,non-hematologic toxicity,3 or 4,NA,FALSE,NA
28028994,NA,35,neutropenia,4,>7 days,NA,NA
28028994,NA,35,"febrile neutropenia, despite granulocyte-colony stimulating factor (G-CSF) administration",NA,NA,NA,NA
28028994,NA,35,thrombocytopenia,4,>7 days,NA,NA
28028994,NA,35,thrombocytopenia with bleeding,3,NA,NA,NA
22610355,NA,36,neutropenia,4,>7 days,NA,NA
22610355,NA,36,neutropenic fever with greater than grade 3 neutropenia,NA,NA,NA,NA
22610355,NA,36,thrombocytopenia,4,NA,NA,NA
22610355,NA,36,non-hematological toxicities,>3,NA,FALSE,NA
22610355,NA,36,more than 8 days delay of administration of CPT-11 on day 8,NA,NA,NA,NA
23957889,NA,37,radiation pneumonitis,>=3,NA,NA,NA
23957889,NA,37,oesophagitis,>=3,NA,NA,NA
23957889,NA,37,other non-haematologic toxicities,>=3,NA,TRUE,NA
23957889,NA,37,febrile neutropenia,3,NA,NA,NA
23957889,NA,37,neutropenia,4,NA,NA,NA
23957889,NA,37,thrombocyotpenia,3 or 4,NA,NA,NA
23957889,NA,37,anaemia,3 or 4,NA,NA,NA
23957889,NA,37,adverse effects,5,NA,NA,NA
23907406,NCT00529022,38,"platelets less than 25,000/uL",NA,NA,NA,NA
23907406,NCT00529022,38,"bleeding associated with platelets less than 50,000/uL",NA,NA,NA,NA
23907406,NCT00529022,38,absolute neutrophil count less than 500/uL,NA,>7 days,NA,NA
23907406,NCT00529022,38,neutropenic fever,NA,NA,NA,NA
23907406,NCT00529022,38,more than 14 days of delay in initiation of subsequent treatment because of inadequate hematological parameters,NA,NA,NA,NA
23907406,NCT00529022,38,non-hematological toxicity,>=3,NA,FALSE,NA
22665539,NA,39,death related to toxicity,NA,NA,NA,NA
22665539,NA,39,more than a 2-week delay in completion of RT,NA,NA,NA,NA
22665539,NA,39,inability to start MC within 7 weeks of completing RT,NA,NA,NA,NA
22665539,NA,39,nonhematologic toxicity,4,NA,FALSE,NA
22665539,NA,39,nonhematologic toxicity,3,NA,FALSE,NA
22665539,NA,39,VCR-related toxicities,NA,NA,NA,NA
27421044,NA,40,nonhematologic event,3 or 4,NA,FALSE,NA
27421044,NA,40,febrile neutropenia,NA,NA,FALSE,defined as grade 3-4 neutropenia with fever â‰¥ 38.5Â°C and/or infection
27421044,NA,40,neutropenia,4,>=5 days,NA,NA
27421044,NA,40,thrombocytopenia,4,NA,NA,NA
27421044,NA,40,failure of ANC to recover to â‰¥ 1000/ÂµL,NA,NA,NA,NA
27421044,NA,40,"platelets to recover to â‰¥ 50,000/ÂµL within 14 days of therapy",NA,NA,NA,NA
27421044,NA,40,anemia,4,NA,NA,NA
27421044,NA,40,Any clinically significant abnormallaboratory value that results in dose delay of >14 days,NA,NA,NA,NA
25103371,NA,41,hematological toxicity as long they were not deemed to be related to cetuximab or carboplatin,>=3,NA,NA,NA
25103371,NA,41,nonhematological toxicities as long they were not deemed to be related to cetuximab or carboplatin,>=3,NA,NA,NA
25103371,NA,41,an inability to start cycle 2 of therapy within 2 weeks of the planned start date,NA,NA,NA,NA
25103371,NA,41,an inability to complete at least 21 days of everolimus during cycle 1 of therapy,1,NA,NA,NA
23860537, NCT00832819,42,thrombocytopenia requiring blood transfusion,3,NA,NA,NA
23860537, NCT00832819,42,thrombocytopenia,4,NA,NA,NA
23860537, NCT00832819,42,neutropenia,4,>7 days,NA,NA
23860537, NCT00832819,42,non-haematological toxicity,>=3,NA,TRUE,NA
24387695,NCT00848718,43,neutropenia,4,>7 days,NA,NA
24387695,NCT00848718,43,neutropenia with fever â‰¥38.5Â°C and/or infection requiring therapy,3 or 4,NA,NA,NA
24387695,NCT00848718,43,thrombocytopenia,4,NA,NA,NA
24387695,NCT00848718,43,any drug-related AE that led to dose modification of MK-2206 or erlotinib,NA,NA,NA,NA
24387695,NCT00848718,43,unresolved drug-related toxicity regardless of grade that resulted in a 3-week or longer delay of the start of cycle 2,NA,NA,NA,NA
24387695,NCT00848718,43,persistent increase in QTc interval (>60 ms from baseline and/or >500 ms),NA,NA,NA,NA
24387695,NCT00848718,43,clinically significant bradycardia,NA,NA,NA,NA
24387695,NCT00848718,43,nonhematologic toxicity,>=3,NA,TRUE,NA
24849582,NCT00881166,46,hematologic AE with increased duration expected from standard regimen alone,4,NA,NA,NA
24849582,NCT00881166,46,febrile neutropenia,NA,NA,NA,ANC <1.0 Ã— 109 and fever â‰¥38.5 Â°C of unknown origin without clinically or microbiologically documented infection
24849582,NCT00881166,46,thrombocytopenia accompanied by a â‰¥Grade 2 hemorrhage,>=3,NA,NA,NA
24849582,NCT00881166,46,left ventricular systolic dysfunction,>=3,NA,NA,NA
24849582,NCT00881166,46,non-hematologic AE,>=3,NA,FALSE,NA
23267154,UMIN 000005263,51,neutropenia,4,>4 days,NA,NA
23267154,UMIN 000005263,51,non-hematological toxicity,3,NA,NA,NA
23267154,UMIN 000005263,51,cessation of treatment for more than eight days from the scheduled date due to toxicities,NA,NA,NA,NA
24942022,NCT00101205,52,neutropenia,4,>7 days,NA,NA
24942022,NCT00101205,52,thrombocytopenia,4,>7 days,NA,NA
24942022,NCT00101205,52,any nonhematologic toxicity,>=3,NA,FALSE,NA
24942022,NCT00101205,52,Toxicity that prevented initiation of course 2 within 28 days after starting course 1,NA,NA,NA,NA
23609829,NA,54,non-hematological toxicity,>=3,NA,NA,NA
23609829,NA,54,nausea or vomiting uncontrolled by aggressive antiemetic support,>=3,NA,NA,NA
23609829,NA,54,granulocytopenia s despite the administration of granulocyte macrophage colony-stimulating factor (GMCSF) or granulocyte colony stimulating factor (G-CSF),4,>7 days,NA,NA
23609829,NA,54,granulocytopenia with fever (â‰¥38.5 Â°C),>=3,NA,NA,NA
23609829,NA,54,thrombocytopenia,4,NA,NA,NA
23609829,NA,54,inability to begin the next cycle of treatment within 2 weeks of scheduled dosing due to unresolved toxicity,NA,NA,NA,NA
28275119,NCT00756847,55,NA,NA,NA,NA,Not defined
26119093,NA,57,non-hematologic event,3 or 4,NA,FALSE,NA
26119093,NA,57,febrile neutropenia,NA,NA,NA,grades 3â€“4 neutropenia with fever â‰¥38.5 Â°C and/or infection
26119093,NA,57,neutropenia,4,>= 5 days,FALSE,NA
26119093,NA,57,thrombocytopenia,4,NA,NA,NA
26119093,NA,57,"failure of the absolute neutrophil count (ANC) to recover to â‰¥1000/ÂµL or platelets to recover to â‰¥50,000/ÂµL within 14 days of therapy",NA,NA,NA,NA
26119093,NA,57,anemia,4,NA,NA,NA
26119093,NA,57,any clinically significant abnormal laboratory value that resulted in dose delay of >14 days,NA,NA,NA,NA
26119093,NA,57,<75 % of vorinostat dosing taken by the patient during the first cycle due to any toxicity,NA,NA,NA,NA
27995307,"UMIN 000,020,359",59,non-hematological toxicities,>=3,NA,FALSE,NA
27995307,"UMIN 000,020,359",59,thrombocytopenia,4,NA,NA,NA
27995307,"UMIN 000,020,359",59,neutropenia,4,NA,NA,NA
27995307,"UMIN 000,020,359",59,neutropenia complicated by fever,3 or 4,NA,NA,NA
27995307,"UMIN 000,020,359",59,any unresolved toxicity requiring a delay in the administration of a subsequent course exceeding 14 days,NA,NA,NA,NA
27995307,"UMIN 000,020,359",59,any toxicity requiring a delay in the planning of radiotherapy within 60 days,NA,NA,NA,NA
23483678,NCT00607048,60,neutropenia,4,>7 days,NA,NA
23483678,NCT00607048,60,febrile neutropenia,3 or 4,NA,NA,NA
23483678,NCT00607048,60,"platelets â‰¤ 25,000/mm3",NA,NA,NA,NA
23483678,NCT00607048,60,non-hematologic adverse event despite optimal supportive care,>=3,NA,NA,NA
23483678,NCT00607048,60,cytokine release syndrome,>=3,NA,NA,NA
23483678,NCT00607048,60,failure to recover to â‰¤ grade 1 toxicity after delaying the initiation of the next cycle for a maximum of two weeks,NA,NA,NA,NA
23483678,NCT00607048,60,"inability to give CP-870,893 on either day 3 or 8 of cycle 1 due to absolute neutrophil counts < 1,000 mm3 or platelet counts < 80,000 mm3 or clinically meaningful nonhematologic toxicity â‰¥ grade 2",NA,NA,NA,NA
27016411,NA,61,neutropenia,4,>=7 days,NA,NA
27016411,NA,61,febrile neutropenia (> 38.5Â°C),NA,NA,NA,NA
27016411,NA,61,infection,3 or 4,NA,NA,NA
27016411,NA,61,thrombocytopenia,4,NA,NA,NA
27016411,NA,61,elevated serum creatinine,4,NA,NA,NA
27016411,NA,61,proteinuria,3,NA,NA,NA
27016411,NA,61,cardiac toxicity,3 or 4,NA,NA,NA
27016411,NA,61,neurological toxicity,3 or 4,NA,NA,NA
27016411,NA,61,liver toxicity,3 or 4,NA,NA,NA
27016411,NA,61,auditory toxicity,3 or 4,NA,NA,NA
27016411,NA,61,digestive toxicity,4,NA,NA,NA
27016411,NA,61,interruption of radiotherapy > 7 days or a delay between radiotherapy-brachytherapy > 15 days due to toxicity,NA,NA,NA,NA
27016411,NA,61,persistence of G3-4 hematological or renal toxicity > 21 days after the end of treatments,NA,NA,NA,NA
27016411,NA,61,less than two injections of Cidofovir during CRT,NA,NA,NA,NA
27016411,NA,61,a toxicity-related death,NA,NA,NA,NA
26072101,NA,64,nonhematologic toxicity,4,NA,NA,NA
26072101,NA,64,toxicity,5,NA,NA,NA
26395450,NA,65,neutropenia,4,>5 days,NA,NA
26395450,NA,65,febrile neutropenia,3 or 4,NA,NA,NA
26395450,NA,65,thrombocytopenia,4,NA,NA,NA
26395450,NA,65,non-hematalogic toxicities,>2,NA,FALSE,NA
27565810,JapicCTI-132162,66,non-hematologic toxicity,>=3,NA,FALSE,NA
27565810,JapicCTI-132162,66,neutropenia (<500/mm3) accompanied by fever,4,>5 days,NA,NA
27565810,JapicCTI-132162,66,neutropenia (<500/mm3) accompanied by fever of â‰¥38 Â°C,4,NA,NA,NA
27565810,JapicCTI-132162,66,thrombocytopenia (<2.5 Ã— 104/mm3),4,NA,NA,NA
27565810,JapicCTI-132162,66,reduction in the diffusing capacity of the lungs for carbon monoxide (DLCO),3,NA,NA,NA
27565810,JapicCTI-132162,66,interstitial lung disease not recovering to grade 1 or less within 7 days,>=2,NA,NA,NA
27565810,JapicCTI-132162,66,requiring cessation for a total of â‰¥14 days during the DLT evaluation period due to AEs for which a causative relationship with pictilisib could not be ruled out,NA,NA,NA,NA
27565810,JapicCTI-132162,67,non-hematologic toxicity,>=3,NA,FALSE,NA
27565810,JapicCTI-132162,67,neutropenia (<500/mm3) accompanied by fever,4,>=7 days,NA,NA
27565810,JapicCTI-132162,67,neutropenia (<500/mm3) accompanied by fever of â‰¥38 Â°C,4,NA,NA,NA
27565810,JapicCTI-132162,67,thrombocytopenia (<2.5 Ã— 104/mm3),4,NA,NA,NA
27565810,JapicCTI-132162,67,reduction in the DLCO,3,NA,NA,NA
27565810,JapicCTI-132162,67,interstitial lung disease not recovering to grade 1 or less within 7 days,>=2,NA,NA,NA
27565810,JapicCTI-132162,67,requiring cessation for a total of â‰¥7 days during the DLT evaluation period due to AEs for which a causative relationship with pictilisib + CP + BEV could not be ruled out,NA,NA,NA,NA
27565810,JapicCTI-132162,67,"cases where, due to AEs for which a causative relationship with pictilisib + CP + BEV could not be ruled out, treatment discontinuation prevented the initiation of cycle 2 within 6 weeks from day 1 in cycle 1",NA,NA,NA,NA
27246305,NCT02217956,68,NA,NA,NA,NA,DLT not defined
27663600,NCT01237067,69,nonhematologic adverse events,3 or 4,NA,FALSE,NA
27663600,NCT01237067,69,hematologic adverse events,3 or 4,NA,NA,NA
27663600,NCT01237067,69,thrombocytopenia,3,>=7 days,NA,NA
27663600,NCT01237067,69,thrombocytopenia  requiring transfusion,3,NA,NA,NA
27663600,NCT01237067,69,neutropenia,4,>=7 days,NA,NA
27663600,NCT01237067,69,neutropenia with fever,4,NA,NA,NA
23963796,NCT00528619,70,neutropenia with grade â‰¥3 infection,>=3,NA,NA,NA
23963796,NCT00528619,70,neutropenia,4,>=7 days,NA,NA
23963796,NCT00528619,70,neutropenia with fever >38.5 Â°C,4,>24h,NA,NA
23963796,NCT00528619,70,thrombocytopenia with bleeding,>=3,NA,NA,NA
23963796,NCT00528619,70,thrombocytopenia,4,>=7 days,NA,NA
23963796,NCT00528619,70,lymphopenia accompanied by an opportunistic infection,NA,NA,NA,NA
23963796,NCT00528619,70,Nonhematologic toxicities,3 or 4,>=7 days,NA,NA
23963796,NCT00528619,70,"Nausea, vomiting, and diarrhea despite maximal medical therapy",3 or 4,>=7 days,NA,NA
23963796,NCT00528619,70,drug-related toxicities that resulted in a delay in administering cycle 2,3 or 4,NA,NA,NA
22843927,NCT00930475,71,febrile neutropenia,NA,NA,NA,NA
22843927,NCT00930475,71,neutropenia,4,>7 days,NA,NA
22843927,NCT00930475,71,hematological toxicity,3,>7 days,NA,NA
22843927,NCT00930475,71,nonhematological toxicity,4,NA,NA,NA
22843927,NCT00930475,71,pneumonitis,2,NA,NA,NA
22843927,NCT00930475,71,toxicity that required a dose reduction of everolimus within the first cycle suspected as being drug-related,2,NA,NA,NA
26100175,NA,72,leukocyte count o1000/mm3,NA,NA,NA,NA
26100175,NA,72,neutropenia (neutrophil count <500/mm3),NA,>= 4 days,NA,NA
26100175,NA,72,"thrombocytopenia (platelet count o25,000/mm3)",NA,NA,NA,NA
26100175,NA,72,platelet transfusion,NA,NA,NA,NA
26100175,NA,72,non-hematological toxicity,>3,NA,FALSE,NA
21826439,NA,73,ANC <500/Î¼l,NA,>7 days,NA,NA
21826439,NA,73,"febrile neutropenia (ANC<1.0Ã—109/L, fever â‰¥38.5Â°C)",NA,NA,NA,NA
21826439,NA,73,thrombocytopenia,4,NA,NA,platelets <25.0Ã—109/L or a bleeding episode requiring platelet transfusion
21826439,NA,73,anemia,4,NA,NA,hemoglobin <6.5 g/dL
21826439,NA,73,non-hematologic toxicity,>=3,NA,TRUE,NA
21826439,NA,73,nausea and/or vomiting despite the use of maximal medical intervention and/or prophylaxis,>=3,NA,NA,NA
21826439,NA,73,treatment delay of more than 3 weeks due to prolonged recovery from a drug-related toxicity,4,NA,NA,NA
19088046,NA,74,absolute neutrophil count <500 cells/mm3,NA,>=5 days,NA,NA
19088046,NA,74,febrile neutropenia,3 or 4,NA,NA,NA
19088046,NA,74,"thrombocytopenia <25,000 cells/mm3",NA,NA,NA,NA
19088046,NA,74,a bleeding episode requiring platelet transfusion,NA,NA,NA,NA
19088046,NA,74,nausea and vomiting despite adequate treatment,3 or 4,NA,NA,NA
19088046,NA,74,any toxicity,3 or 4,NA,FALSE,NA
19088046,NA,74,prolonged recovery from a drug-related toxicity that delayed re-treatment at 3 wk,NA,NA,NA,NA
19088046,NA,74,and omission of day 8 treatment on schedule B due to hematologic toxicity,NA,NA,NA,NA
19889612,NA,75,gastrointestinal toxicity despite optimal supportive care/intervention,>=3,NA,NA,"nausea, vomiting, diarrhea,
abdominal pain"
19889612,NA,75,hypertension despite optimal supportive care/intervention,>=3,NA,NA,NA
19889612,NA,75,non-hematological toxicity,3 or 4,NA,FALSE,NA
19889612,NA,75,neutropenia,4,>7 days,NA,NA
19889612,NA,75,neutropenia associated with fever >38.3C,3 or 4,NA,NA,NA
19889612,NA,75,thrombocytopenia,4,NA,NA,NA
19889612,NA,75,thrombocytopenia associated with bleeding requiring transfusion,3,NA,NA,NA
19889612,NA,75,inability to resume BIBF 1120 dosing within 14 days of stopping due to treatment-related toxicity,NA,NA,NA,NA
19404211,NA,76,leukopenia,4,>=4 days,NA,NA
19404211,NA,76,neutropenia,4,>=4 days,NA,NA
19404211,NA,76,febrile neutropenia,3,NA,NA,NA
19404211,NA,76,"platelets <20,000/l",NA,NA,NA,NA
19404211,NA,76,nonhematological toxicity,>=3,NA,FALSE,NA
18618082,NA,77,any non-hematologic toxicity,>3,NA,FALSE,NA
18618082,NA,77,thrombocytopenia,4,NA,NA,NA
18618082,NA,77,thrombocytopenia requiring platelet transfusion to maintain the clinical safety of the patient,3,NA,NA,NA
18618082,NA,77,neutropenia,4,>5 days,NA,NA
18618082,NA,77,neutropenia complicated by fever,4,NA,NA,NA
18618082,NA,77,any treatment delay due to toxicity lasting more than 2 weeks,NA,NA,NA,NA
19520688,NA,78,thrombocytopenia,4,NA,NA,NA
19520688,NA,78,febrile neutropenia,3 or 4,NA,NA,NA
19520688,NA,78,non-hematological toxicity,3,NA,FALSE,NA
19520688,NA,78,omission of the treatment on day 8,NA,NA,NA,NA
18692224,NA,79,prolonged skin rash or diarrhea,3 or 4,>21 days,NA,NA
18692224,NA,79,non-hematologic/non-constitutional toxicity,3 or 4,NA,NA,NA
18692224,NA,79,febrile neutropenia,3 or 4,NA,NA,NA
18692224,NA,79,neutropenia,4,>7 days,NA,NA
18692224,NA,79,thrombocytopenia,4,>7 days,NA,NA
19479255,NA,80,Neutrophils <0.5 x 109/L,4,.5 days,NA,NA
19479255,NA,80,Platelets <10x109/L,4,NA,NA,NA
19479255,NA,80,Febrile neutropenia,NA,NA,NA,NA
19479255,NA,80,neutropenia with a single elevation of fever >= 38.5Â°C (rectal) or >=38.0Â°C,4,NA,NA,NA
19479255,NA,80,Non-hematological,3 or 4,NA,FALSE,NA
19843663,NA,81,"nonhematologic toxicity thought possibly, probably, or definitely related to sirolimus",>=3,NA,TRUE,NA
19843663,NA,81,Marrow aplasia (<10% cellularity with <10% blasts),NA,>=4 weeks,NA,NA
20588278,NA,82,an absolute neutrophil count <0.5 x 109 l-1,NA,>=7 days,NA,NA
20588278,NA,82,absolute neutrophil count <0.5  109 l-1 with sepsis,NA,NA,NA,NA
20588278,NA,82,platelet count <25 x 109 l-1,NA,NA,NA,NA
20588278,NA,82,any other drug-related non-haematological toxicity,3 or 4,NA,FALSE,NA
19297278,NA,85,hematologic toxicities,4,NA,NA,NA
19297278,NA,85,neutropenia with a fever of >38Â°C,3 or 4,NA,NA,NA
19297278,NA,85,non-hematological toxicities,3 or 4,NA,FALSE,NA
19297278,NA,85,any toxicities requiring more than 3-day omission of Ts-1 administration,NA,NA,NA,NA
19297278,NA,85,any unresolved toxicity requiring a delay exceeding 8 days in the administration of the second cycle,NA,NA,NA,NA
21277623,NA,4,a dose delay of >2 weeks due to failure to recover counts adequately due to hematologic toxicity,NA,NA,NA,NA
21277623,NA,4,study-treatment-related febrile neutropenia (fever â‰¥38.5 Â°C) whenthe absolute neutrophil count (ANC) is <1.0 Ã— 109/L,NA,NA,NA,NA
21277623,NA,4,neutropenia,4,>7 days,NA,NA
21277623,NA,4,thrombocytopenia,3 or 4,NA,NA,NA
21277623,NA,4,study-treatment-related toxicities,3 or 4,NA,NA,NA
21277623,NA,4,"fatigue, hypersensitivity reaction, nausea andvomiting",NA,NA,NA,NA
21277623,NA,4,any drug-related death,NA,NA,NA,NA
22155262,NA,5,a dose delay>2 weeks due to failure to recover counts,NA,NA,NA,NA
22155262,NA,5,febrile neutropenia,NA,NA,NA,NA
22155262,NA,5,neutropenia,4,>7 days,NA,NA
22155262,NA,5,thrombocytopenia,4,NA,NA,NA
22155262,NA,5,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
22155262,NA,5,non-hematological toxicity,3 or 4,NA,FALSE,NA
22155262,NA,5,any drugrelated death,NA,NA,NA,NA
22155262,NA,5,Treatment-related neuropathy,>=2,2 weeks,NA,NA
20580118,NCT00573690,6,non-hematological toxicities,>=3,NA,FALSE,NA
20580118,NCT00573690,6,anemia,4,NA,NA,NA
20580118,NCT00573690,6,thrombocytopenia,4,NA,NA,NA
20580118,NCT00573690,6,neutropenia,4,>7 days,NA,NA
20580118,NCT00573690,6,a >2 weeks delay in initiating cycle 2 due to toxicities,NA,NA,NA,NA
22345119,NA,8,gastrointestinal toxicity despite optimal supportive care/intervention,>3,NA,NA,NA
22345119,NA,8,hypertension despite optimal supportive care/intervention,>3,NA,NA,NA
22345119,NA,8,non-hematologic toxicity,>=3,NA,NA,NA
22345119,NA,8,neutropenia that was uncomplicated,4,>7 days,NA,NA
22345119,NA,8,neutropenia of any duration associated with fever,NA,NA,NA,NA
22345119,NA,8,platelet levels of < 25 000/Î¼l,NA,NA,NA,NA
22345119,NA,8,thrombocytopenia associated with bleeding requiring transfusion,3,NA,NA,NA
22345119,NA,8,the inability to resume BIBF 1120 dosing within 14 days of stopping due to treatment-related toxicity,NA,NA,NA,NA
22306126,NA,9,neutropenia,4,>7 days,NA,NA
22306126,NA,9,febrile neutropenia,3,NA,NA,NA
22306126,NA,9,thrombocytopenia,4,NA,NA,NA
22306126,NA,9,need for platelet transfusions,NA,NA,NA,NA
22306126,NA,9,non-hematologicaltoxicities,3,NA,NA,NA
22306126,NA,9,delayed administration of the subsequent course by more than 2 weeks,NA,NA,NA,NA
22306126,NA,9,delayed administration of gemcitabine on day 8 by more than one week,NA,NA,NA,NA
18506181,NA,10,neutropaenia,4,>7 days,NA,NA
18506181,NA,10,febrile neutropaenia,NA,NA,NA,absolute neutrophil count <1 x 109 l-1; temperature >= 38.5C
18506181,NA,10,thrombocytopaenia (<10 x 109 l-1) associated with bleeding or requiring platelet transfusion,4,NA,NA,NA
18506181,NA,10,diarrhoea despite loperamide treatment,2,>48 h,NA,NA
18506181,NA,10,any non-haematologic toxicity,>=3,NA,FALSE,NA
18506181,NA,10,"treatment delays exceeding 1 (erlotinib) or 2 weeks (chemotherapy), as a result of lack of recovery from grade 2 toxicity",NA,NA,NA,NA
20054549,NA,11,neutropenia,4,>=7 days,NA,NA
20054549,NA,11,febrile neutropenia,NA,NA,NA,NA
20054549,NA,11,thrombocytopenia,4,NA,NA,NA
20054549,NA,11,thrombocytopenia with any grade hemorrhage,>=3,NA,NA,NA
20054549,NA,11,non-hematologic toxicity,>=3,NA,TRUE,NA
20054549,NA,11,treatment delay of more than 1 week due to unresolved Grade 3 or 4 toxicity,NA,NA,NA,NA
19404408,NA,12,thrombocytopenia,3 or 4,NA,NA,NA
19404408,NA,12,neutropenia,4,NA,NA,NA
19404408,NA,12,nonhematologic toxicity,3 or 4,NA,NA,NA
19520687,NA,13,leukopenia,4,>=4 days,NA,NA
19520687,NA,13,neutropenia,4,>=7 days,NA,NA
19520687,NA,13,leukopenia or neutropenia with fever  (>= 38C),4,NA,NA,NA
19520687,NA,13,thrombocytopenia <= 25 000/mm3,NA,NA,NA,NA
19520687,NA,13,thrombocytopenia requiring platelet transfusion,NA,NA,NA,NA
19520687,NA,13,nonhematological toxicities,3 or 4,NA,FALSE,NA
19520687,NA,13,a delay for the following cycle within 2 weeks.,NA,NA,NA,NA
19800673,NA,14,non-hematologic toxicity,3 or 4,NA,FALSE,NA
19800673,NA,14,thrombocytopenia,4,NA,NA,NA
19800673,NA,14,febrile neutropenia,NA,NA,NA,NA
19800673,NA,14,neutropenia,4,>=7 days,NA,NA
19800673,NA,14,any cycle delay in Arm 3,NA,NA,NA,NA
19652058,NA,17,neutropenia,4,>7 daus,NA,NA
19652058,NA,17,febrile neutropenia,NA,NA,NA,NA
19652058,NA,17,thrombocytopenia,4,NA,NA,NA
19652058,NA,17,nonhematologic AEs,>=3,NA,NA,NA
19652058,NA,17,nausea/vomiting despite optimal medical intervention,>=3,NA,NA,NA
19652058,NA,17,neuropathy,2,>=2 weeks,NA,NA
19652058,NA,17,neuropathy,>=3,NA,NA,NA
19652058,NA,17,fatigue,4,NA,NA,NA
20049927,NA,19,"recovery of ANC >750/ml and platelets >75,000/ml after day 28 of the prior cycle",NA,NA,NA,NA
20049927,NA,19,non-hematologic toxicity,4,NA,FALSE,NA
20049927,NA,19,toxicity not reversed by day 28,3,NA,FALSE,NA
20049927,NA,19,cardiac toxicity even if it resolved by day28,3,NA,NA,NA
20049927,NA,19,stomatitis requiring intubation,NA,NA,NA,NA
20049927,NA,19,severe diarrhea resulting in inability to maintain albumin and or serum volume despite medical management,NA,NA,NA,NA
20049927,NA,19,decrease in glomerular filtration rate (GFR) <60 ml/min/1.73 m2 on day 28,NA,NA,NA,NA
20049927,NA,19,PBSC collection yield inadequate to support upcoming Induction II cycles,NA,NA,NA,NA
19090012,NA,20,neutropenia,4,>=7 days,NA,NA
19090012,NA,20,febrile neutropenia,4,NA,NA,NA
19090012,NA,20,thrombocytopenia,NA,>7 days,NA,NA
19090012,NA,20,thrombocytopenia requiring >2 platelet transfusions within a period of 7 consecutive days,NA,NA,NA,NA
19090012,NA,20,nausea and/or vomiting despite the use of adequate/maximal medical intervention and/or prophylaxis,>=3,NA,NA,NA
19090012,NA,20,diarrhea despite the use of adequate/maximal medical intervention and/or prophylaxis,>=3,NA,NA,NA
19090012,NA,20,nonhematologic toxicity,>=3,NA,TRUE,NA
19090012,NA,20,retreatment delay of >1 week between consecutive irinotecan doses within a cycle because ofdelayed recovery from a toxicity related to treatment with carboplatin and irinotecan,NA,NA,NA,NA
19090012,NA,20,retreatment delay of >2 weeks from the scheduled start date of a subsequent cycle because of delayed recovery from a toxicity related to treatment with carboplatin and irinotecan,NA,NA,NA,NA
20159815,NA,21,a dulanermin-related nonhematologic toxicity,>=3,NA,NA,NA
20159815,NA,21,neutropenia,>=4,>7 days,NA,NA
20159815,NA,21,neutropenia with fever higher than 38.5Â°C,3 or 4,NA,NA,NA
20159815,NA,21,thrombocytopenia where a relationship to dulanermin could not be ruled out,>=4,>7 days,NA,NA
20028752,NCT00094835,22,fatigue,3,>=7 days,NA,NA
20028752,NCT00094835,22,"nausea, diarrhea, and vomiting despite maximum supportive care",3 or 4,NA,NA,NA
20028752,NCT00094835,22,neutropenia with fever >38.5Â°C,3 or 4,NA,NA,NA
20028752,NCT00094835,22,"neutropenia (absolute neutrophil count, <0.5 Ã— 109/L)",4,>7 days,NA,NA
20028752,NCT00094835,22,"thrombocytopenia (platelet count, <25.0 Ã— 109/L)",4,NA,NA,NA
20028752,NCT00094835,22,anemia,4,NA,NA,NA
20028752,NCT00094835,22,hypertension,4,NA,NA,NA
20028752,NCT00094835,22,aspartate aminotransferase or alanine aminotransferase of >10 times the upper limit of normal,NA,NA,NA,NA
20028752,NCT00094835,22,rash/desquamation,4,NA,NA,NA
20028752,NCT00094835,22,any other treatment-related adverse event occurring during the first cycle,3 or 4,NA,NA,NA
20927639,NA,25,ANC <0.5Ã—109/l,NA,>=7 days,NA,NA
20927639,NA,25,ANC <0.5Ã—109/l with fever (â‰¥38.5Â°C),NA,NA,NA,NA
20927639,NA,25,platelets <25Ã—109/l,NA,NA,NA,NA
20927639,NA,25,any toxicity causing a delay of >14 days in the following cycle,NA,NA,NA,NA
20927639,NA,25,any other nonhematological toxicities,3 or 4,NA,FALSE,NA
21035955,NCT00721292,26,nonhematologic toxicity,>=3,NA,FALSE,NA
21035955,NCT00721292,26,hematologic toxicity,>=4,NA,NA,NA
21035955,NCT00721292,26,Prolongation of the QTc interval >= 550 ms or increased by >= 100 ms from baseline measurement,NA,NA,NA,NA
19531625,NA,27,neutropenia,4,>=7 days,NA,NA
19531625,NA,27,neutropenia associated with fever/infection,4,NA,NA,NA
19531625,NA,27,thrombocytopenia,4,NA,NA,NA
19531625,NA,27,thrombocytopenia requiring platelet transfusion,NA,NA,NA,NA
19531625,NA,27,mucositis,>=3,>=7 days,NA,NA
19531625,NA,27,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19390943,NA,28,leucopenia (<1000/Î¼l),NA,>4 days,NA,NA
19390943,NA,28,a day-8 vinorelbine delay of more than 1 week,NA,NA,NA,NA
19390943,NA,28,neutropenia with active infection or fever (>38Â°C),3 or 4,NA,NA,NA
19390943,NA,28,PLT count less than 20000/Î¼l,NA,NA,NA,NA
19390943,NA,28,nonhematological toxicities,3 or 4,NA,FALSE,NA
19390943,NA,28,a delay of second cycle within 2 weeks,NA,NA,NA,NA
19596976,NA,29,non-hematological toxicities,3 or 4,NA,FALSE,NA
19596976,NA,29,thrombocytopenia,>=3,NA,NA,NA
19596976,NA,29,anemia,4,NA,NA,NA
19596976,NA,29,absolute neutrophil count of <750 (ANC=750-999 was considered tolerable grade 4 neutropenia),NA,NA,NA,NA
21397973,NA,30,leucopenia,4,>=3 days,NA,NA
21397973,NA,30,febrile neutropenia,NA,NA,NA,NA
21397973,NA,30,discontinuation of weekly chemotherapy more than twice,NA,NA,NA,NA
21397973,NA,30,RTRT,NA,>=9 weeks,NA,NA
21397973,NA,30,non-hematologic toxicities,3 or 4,NA,FALSE,NA
18621626,NA,31,nonhematologic toxicity,>=3,NA,FALSE,NA
18621626,NA,31,platelet count < 50 Ã— 109/L,NA,3 days,NA,NA
18621626,NA,31,neutrophil count < 0.5 Ã— 109/L,NA,3 days,NA,NA
18166842,NA,32,thrombocytopenia,4,NA,NA,NA
18166842,NA,32,neutropenia,4,NA,NA,NA
18166842,NA,32,neutropenic fever,NA,NA,NA,NA
18166842,NA,32,need for platelet transfusion,NA,NA,NA,NA
18166842,NA,32,ongoing myelosuppression,>=2,NA,NA,NA
18166842,NA,32,esophagitis,4,NA,NA,NA
18166842,NA,32,vomiting or diarrhea despite maximal antiemetic or antidiarrheal support,4,NA,NA,NA
18166842,NA,32,nonhematologic toxicities,>=3,>7 days,FALSE,NA
18802151,NA,33,neutropenia,4,>7 days,NA,NA
18802151,NA,33,thrombocytopenia,4,>7 days,NA,NA
18802151,NA,33,documented infection during grade 4 neutropenia,NA,NA,NA,NA
18802151,NA,33,nonhematologic toxicity,>=3,NA,FALSE,NA
18802151,NA,33,peripheral neuropathy not resolved before initiation of the following cycle,2,NA,NA,NA
18802151,NA,33,lifethreatening toxicity,NA,NA,NA,NA
20623160,NA,34,neutropenia,4,>=5 days,NA,NA
20623160,NA,34,"neutropenia concomitant with fever (â‰¥ 38.5Â°C), sepsis or other severe infection",4,NA,NA,NA
20623160,NA,34,thrombocytopenia <25Ã—109/l,NA,NA,NA,NA
20623160,NA,34,nonhematological AE suspected to be related to study drug(s),3 or 4,NA,FALSE,NA
20623160,NA,34,any delays in the administration of a subsequent dose of plitidepsin and/or carboplatin exceeding 2 weeks due to adverse events (AEs) suspected to be related to study drug(s),1,NA,NA,NA
20647930,ACTRN12609000790246,35,nonhematological toxicity,>=3,NA,FALSE,NA
20647930,ACTRN12609000790246,35,hematological toxicity,4,>4 days,NA,NA
20647930,ACTRN12609000790246,35,diarrhea,>=2,NA,NA,NA
20647930,ACTRN12609000790246,35,neutropenia,>=3,NA,NA,NA
20647930,ACTRN12609000790246,35,a delay of the next scheduled treatment of greater than or equal to 14 days because of toxicity,NA,NA,NA,NA
20107803,NA,36,toxicities,3 or 4,NA,NA,NA
19096311,NA,37,acute nonhematologic toxicities,3 or 4,NA,NA,"acute nonhematologic toxicity is defined to be a toxicity occurring from day 1 of study entry to day 1 of adjuvant chemotherapy or within 90 days from the start of RT treatment, which ever occurs first"
19096311,NA,37,hematologic toxicities occurring during concurrent chemoradiation therapy,4,NA,FALSE,NA
19096311,NA,37,pneumonitis,3 or 4,NA,NA,NA
19096311,NA,37,delayed onset esophagitis occurring during the consolidation phase,3 or 4,NA,NA,NA
21140147,NA,39,neutropenia,4,>=7 days,NA,NA
21140147,NA,39,febrile neutropenia,NA,>24 h,NA,NA
21140147,NA,39,neutropenic infection,NA,NA,NA,NA
21140147,NA,39,thrombocytopenia with bleeding,>=3,NA,NA,NA
21140147,NA,39,thrombocytopenia,4,>=7 days,NA,NA
21140147,NA,39,lymphopenia accompanied by an infection,NA,NA,NA,NA
21140147,NA,39,non-hematologic toxicities,3 or 4,>=7 days,NA,NA
21140147,NA,39,"Persistent nausea, vomiting, or diarrhea (despite maximal medical therapy)",NA,NA,NA,NA
21447615,NA,40,non-hematological toxicity,3 or 4,NA,FALSE,NA
21447615,NA,40,thrombocytopenia,4,NA,NA,NA
21447615,NA,40,thrombocytopenic bleeding,4,NA,NA,NA
21447615,NA,40,uncomplicated neutropenia,4,>=7 days,NA,NA
21447615,NA,40,febrile neutropenia,NA,NA,NA,NA
21447615,NA,40,neutropenia with >= grade 3 infection,3 or 4,NA,NA,NA
21447615,NA,40,treatment delay >2 weeks due to any toxicity,NA,NA,NA,NA
21447615,NA,40,other toxic effects of concern to the NCIC-CTG,NA,NA,NA,NA
21447615,NA,40,missing or reducing two doses of temsirolimus,NA,NA,NA,NA
17278895,NA,43,leukopenia,3 or 4,NA,NA,NA
17278895,NA,43,thrombocytopenia,3 or 4,NA,NA,NA
17278895,NA,43,anemia,3 or 4,NA,NA,NA
17278895,NA,43,neutropenic feverwith grade 4 neutropenia,3 or 4,NA,NA,NA
17278895,NA,43,nephrotoxity,2,NA,NA,NA
17278895,NA,43,any other nonhematological toxicities,3,NA,FALSE,NA
17278895,NA,43,Omission of chemotherapy on day 8 or 15,NA,NA,NA,NA
16047343,NA,44,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16047343,NA,44,A leukocyte count < 1000/L,NA,NA,NA,NA
16047343,NA,44,neutrophil count < 500/L,NA,>3 days,NA,NA
16047343,NA,44,"a platelet count < 25,000/L",NA,NA,NA,NA
17409916,NA,45,nonhematological toxicities,>=3,NA,FALSE,NA
17409916,NA,45,"thrombocytopenia <20,000/mm3",NA,NA,NA,NA
17409916,NA,45,neutropenia,4,>=4 days,NA,NA
17409916,NA,45,febrile neutropenia,NA,NA,NA,NA
17197129,NA,46,"nausea, vomiting, diarrhea, or esophagitis",>=3,>=4 days,NA,NA
17197129,NA,46,neutropenia,4,NA,NA,NA
17197129,NA,46,thrombocytopenia,4,NA,NA,NA
17197129,NA,46,Febrile neutropenia,NA,NA,NA,T > 38.2Â°C and absolute neutrophil count < 500/mm3
17197129,NA,46,neutropenia,3,>=7 days,NA,NA
17197129,NA,46,thrombocytopenia,3,>=7 days,NA,NA
17197129,NA,46,other toxicity,>=3,NA,NA,NA
17197129,NA,46,Inability to deliver >= 75% of planned capecitabine dose,NA,NA,NA,NA
17197129,NA,46,Any treatment delay > 3 days,NA,NA,NA,NA
15737558,NA,47,absolute neutrophil count (ANC) < 0.5 x 109/l associated with grade 3 fever/infection,NA,NA,FALSE,NA
15737558,NA,47,platelets <20 x109/l requiring platelets transfusion,NA,NA,NA,NA
15737558,NA,47,thrombocytopenia,4,>5 days,NA,NA
15737558,NA,47,fatigue,3,NA,TRUE,NA
17881149,NA,48,"nausea, vomiting, diarrhea, or esophagitis",>=3,>=7 days,NA,NA
17881149,NA,48,neutropenia,4,>=7 days,NA,NA
17881149,NA,48,leukopenia,4,>=7 days,NA,NA
17881149,NA,48,Febrile neutropenia (T > 38.2C and absolute neutrophil count <500/ml),1,NA,NA,NA
17881149,NA,48,thrombocytopenia,>=3,>=7 days,NA,NA
17881149,NA,48,thrombocytopenia with clinical evidence of bleeding,>=3,NA,NA,NA
17881149,NA,48,other toxicity,>=3,NA,NA,NA
17881149,NA,48,Inability to deliver >= 75% of planned UFT/leucovorin dose,NA,NA,NA,NA
17881149,NA,48,Any treatment delay >7 days,NA,NA,NA,NA
16203659,NA,49,neutropenia,4,>=10 days,NA,NA
16203659,NA,49,"thrombocytopenia (platelet count less than 10,000/mm3)",4,NA,NA,NA
16203659,NA,49,nonhematologic toxicity,3 or 4,NA,NA,NA
16463061,NA,50,leukopenia,4,>=4 days,NA,NA
16463061,NA,50,neutropenia,4,>=4 days,NA,NA
16463061,NA,50,"thrombocytopenia (less than 25,000/ll)",4,NA,NA,NA
16463061,NA,50,nonhematologic toxicities,>=3,NA,TRUE,NA
17882655,NCT00117572,51,hematologic toxicity,4,>=7 days,NA,NA
17882655,NCT00117572,51,afebrile neutropenia,>=3,>=7 days,NA,NA
17882655,NCT00117572,51,thrombocytopenia,>=3,>=7 days,NA,NA
17882655,NCT00117572,51,neutropenia associated with fever,4,NA,NA,"oral temperature >38.5â—¦C, or 3 readings
of >38.0â—¦/24 hours"
17882655,NCT00117572,51,any nonhematologic toxicity,>=3,lasting until the next treatment cycle that is attributable to therapy,FALSE,NA
17882655,NCT00117572,51,mucositis or dermatitis,4,>7 days,NA,NA
17882655,NCT00117572,51,mucositis or dermatitis not resolved to <Grade 3 at the beginning of any CRT cycle,4,NA,NA,NA
16622691,NA,52,neutropenia,4,NA,NA,NA
16622691,NA,52,any episode of febrile neutropenia,>=3,NA,NA,NA
16622691,NA,52,thrombocytopenia,4,NA,NA,NA
16622691,NA,52,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16193241,NA,53,leukopenia,4,>5 days,NA,NA
16193241,NA,53,neutropenia,4,>5 days,NA,NA
16193241,NA,53,thrombocytopenia,4,NA,NA,NA
16193241,NA,53,febrile neutropenia,3 or 4,NA,NA,NA
16193241,NA,53,nonhematologic toxicity,3,NA,FALSE,NA
15246197,NA,54,thrombocytopenia,4,NA,NA,NA
15246197,NA,54,neutropenia,4,NA,NA,NA
15246197,NA,54,neutropenic fever,NA,NA,NA,NA
15246197,NA,54,need for platelet transfusion,NA,NA,NA,NA
15246197,NA,54,ongoing myelosuppression on anysubsequent chemotherapytreatment day,>=2,NA,NA,NA
15246197,NA,54,esophagitis,4,NA,NA,NA
15246197,NA,54,All other non-hematologic toxicities,>=3,NA,FALSE,NA
15246197,NA,54,ongoing non-hematologic toxicityon a subsequent treatment day,>=2,NA,NA,NA
15246197,NA,54,inability to administer chemotherapy due to prolonged toxicityrelated to therapy,NA,NA,NA,NA
17634546,NA,55,neutropenia with an absolute neutrophil count <500/uL,4,>5 days,NA,NA
17634546,NA,55,febrile neutropenia requiring i.v. antibiotics and hospitalization,NA,NA,NA,NA
17634546,NA,55,thrombocytopenia,NA,NA,NA,"platelet count <25,000/uL or need for platelet transfusion"
17634546,NA,55,any toxicity,>=3,NA,FALSE,NA
17634546,NA,55,a two-grade increase in serum creatinine,NA,NA,NA,NA
17634546,NA,55,Treatment delays of >2weeks for any reason,NA,NA,NA,NA
15690136,NA,56,NA,NA,NA,NA,DLT not defined
17523723,NA,57,absolute neutrophil count (ANC) <0.5 Ã— 109/L,NA,>7 days,NA,NA
17523723,NA,57,ANC <0.1 Ã— 109/L,NA,>3 days,NA,NA
17523723,NA,57,febrile neutropenia requiring antibiotics and hospitalisation,NA,NA,NA,NA
17523723,NA,57,thrombocytopenia requiring substitution,NA,NA,NA,NA
17523723,NA,57,non-haematological toxicity,>=3,NA,TRUE,NA
17523723,NA,57,lack of recovery of neutrophil count to a value of â‰¥1.5 Ã— 109/L and/or platelets to a count of 100 â‰¥109/L within 6 weeks after the start of treatment,NA,NA,NA,NA
15150564,NA,58,leukopenia,4,NA,NA,NA
15150564,NA,58,neutropenia,4,>4 days,NA,NA
15150564,NA,58,thrombocytopenia <20 000 ul-1,NA,NA,NA,NA
15150564,NA,58,febrile neutropenia,3,NA,NA,NA
15150564,NA,58,nonhaematologic toxicity,3,NA,FALSE,NA
15150564,NA,58,delay of administration of gemcitabine on day 8 over a week for toxicities,NA,NA,NA,NA
15007250,NA,59,ANC < 0.5 Ã— 109/l,NA,>5 days,NA,NA
15007250,NA,59,any episode of febrile neutropenia,NA,NA,NA,"e.g. fever â‰¥38.2Â°, CTC grade 4 granulocytopenia, requiring i.v. antibiotics and hospitalization"
15007250,NA,59,thrombocytopenia,4,NA,NA,NA
15007250,NA,59,non-hematological toxicity,>=3,NA,FALSE,NA
15007250,NA,59,no recovery of neutrophils (â‰¥1.5 Ã— 109/l) and/or platelets (â‰¥100 Ã— 109/l) at day 36,NA,NA,NA,NA
15007250,NA,59,persistence of non-hematological toxicity at day 36,>=2,NA,NA,NA
15054448,NA,60,nonhaematological toxicity,3 or 4,NA,NA,NA
17498782,NA,61,neutropenia,4,NA,NA,NA
17498782,NA,61,thrombocytopenia,4,NA,NA,NA
17498782,NA,61,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16959305,NA,62,neutropenic fever,NA,NA,NA,NA
16959305,NA,62,thrombocytopenia,4,NA,NA,NA
16959305,NA,62,a delay >14 days in starting a subsequent cycle based on the first cycle of chemotherapy,NA,NA,NA,NA
16959305,NA,62,missing >2 consecutive weekly paclitaxel treatments,NA,NA,NA,NA
16959305,NA,62,palmarâ€“plantar erythrodysesthesia (PPE),3 or 4,NA,NA,NA
16959305,NA,62,stomatitis,3 or 4,NA,NA,NA
16959305,NA,62,development of congestive heart failure,NA,NA,NA,NA
16959305,NA,62,a reduction in left ventricular ejection fraction (LVEF) below the institutional range,NA,NA,NA,NA
16282248,NA,63,Neutrophils (ANC) <= 0.5 x 109/l,NA,7 days,NA,NA
16282248,NA,63,Neutrophils (ANC) no increase to 1.5 x 109/l before the start of the next treatment cycle,NA,NA,NA,NA
16282248,NA,63,Platelets <= 25 x 109 or no increase to 100 x 109/l before the start of the next treatment cycle,NA,NA,NA,NA
16282248,NA,63,Febrile neutropenia/Infection,NA,NA,NA,ANC <= 0.5x109/l associated with fever and/or hospitalization and/or the need for intravenous antibiotics
16282248,NA,63,Hyperbilirubinemia ( Bilirubin >= 2xULN),4,NA,NA,NA
16282248,NA,63,"ALT, AST or alkaline phosphatase >= 5xULN",NA,NA,NA,NA
16282248,NA,63,Neuropathy Sensory,3 or 4,NA,NA,NA
16282248,NA,63,Neuropathy Motor,2,>5 weeks,NA,NA
16282248,NA,63,PPE,3 or 4,NA,NA,NA
16282248,NA,63,PPE,2,>5 weeks,NA,NA
16282248,NA,63,Other toxicity,3 or 4,NA,NA,NA
16115936,NA,64,NA,NA,NA,NA,not defined
15812395,NA,66,NA,1,NA,NA,not defined
17950919,NA,67,Any nonhematologic regimen-related toxicities,3,NA,NA,NA
17285317,NA,68,nonhematologic toxicity,>=3,NA,NA,NA
17285317,NA,68,anemia,4,NA,NA,NA
17285317,NA,68,thrombocytopenia,4,NA,NA,NA
17285317,NA,68,neutropenia,4,>= 7 days,NA,NA
17285317,NA,68,neutropenia associated with fever,4,NA,NA,NA
17285317,NA,68,A >2-week treatment delay of initiating the second cycle of chemotherapy,NA,NA,NA,NA
17285317,NA,68,myelosuppression that required omission of two of the three weekly treatments,NA,NA,NA,NA
17049403,NA,69,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17049403,NA,69,neutropenia,4,>3 days,NA,NA
17049403,NA,69,"failure to recover neutrophils â‰¥1500/l or platelets â‰¥100,000/l by day 28 from start of treatment",NA,NA,NA,NA
15589596,NA,70,hematologic adverse effect,3 or 4,NA,NA,NA
16421427,NA,71,nonhematologic toxicity,4,NA,FALSE,NA
16421427,NA,71,renal toxicity,3,"hemorrhagic cystitis, dysuria, urinary frequency/urgency, and urinary electrolyte wasting",NA,NA
16421427,NA,71,pancreatitis,3,NA,NA,NA
16421427,NA,71,CNS bleeding,3,NA,NA,NA
16421427,NA,71,cerebrovascular ischemia,3,NA,NA,NA
16421427,NA,71,seizures,3,NA,NA,NA
16421427,NA,71,aphasia,3,NA,NA,NA
16421427,NA,71,hemolysis,4,NA,NA,NA
16421427,NA,71,platelet transfusion refractoriness associated with life-threatening bleeding,4,NA,NA,NA
16421427,NA,71,hemorrhage,4,NA,NA,NA
16421427,NA,71,hemolysis associated with life-threatening anemia,4,NA,NA,NA
16421427,NA,71,failure to engraft,4,NA,NA,NA
16421427,NA,71,other life-threatening blood/bone marrow toxicity,4,NA,NA,NA
15249718,NA,72,neutropenia,4,>= 7 days,NA,NA
15249718,NA,72,thrombopenia,4,NA,NA,NA
15249718,NA,72,non-hematologic toxicity,>=3,NA,NA,NA
17921708,NA,73,nonhematologic toxicities,>=3,NA,FALSE,NA
17921708,NA,73,leukopenia,4,NA,NA,NA
17921708,NA,73,thrombocytopenia,4,NA,NA,NA
17921708,NA,73,anemia,4,NA,NA,NA
17921708,NA,73,neutropenic fever with grade 3/4 neutropenia,NA,NA,NA,NA
17921708,NA,73,treatment delay (4 cycles treatment duration > 8 weeks),NA,NA,NA,NA
17326096,NA,74,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17326096,NA,74,neutropenia,4,>=5 days,NA,NA
17326096,NA,74,"failure to recover neutrophils (>= 1.5 x 109/L) or platelets (>= 100,000 x 106/L) by Day 29",NA,NA,NA,NA
17326096,NA,74,thrombocytopenia,4,NA,NA,NA
17326096,NA,74,thrombocytopenia that required platelet transfusion,NA,NA,NA,NA
17326096,NA,74,Inability to deliver Day 8 chemotherapy on the first cycle,NA,NA,NA,NA
16377585,NA,75,nonhematologic toxicity,3 or 4,NA,NA,NA
16377585,NA,75,neurotoxicity,3,NA,NA,NA
16377585,NA,75,thrombocytopenia,3,NA,NA,NA
16377585,NA,75,febrile neutropenia,NA,NA,NA,NA
16377585,NA,75,neutropenia with a Grade 3 infection,4,NA,NA,NA
17917089,NA,77,any non-reversible toxicity,3 or 4,NA,FALSE,NA
17917089,NA,77,platelet count less than 25 x 109/l,NA,NA,NA,NA
17917089,NA,77,neutrophil count less than 0.5x109/l,NA,>7 days,NA,NA
17917089,NA,77,febrile neutropenia,4,NA,NA,NA
17917089,NA,77,platelet count less than 100 x 109/l or a neutrophil count less than 1.5x109/l leading to a greater than 2-week delay in chemotherapy,NA,NA,NA,NA
17917089,NA,77,toxicity,2,until day 1 of the second course,FALSE,NA
17103043,NA,79,neutropenia,4,NA,NA,NA
17103043,NA,79,febrile neutropenia,NA,NA,NA,NA
17103043,NA,79,thrombocytopenia,4,NA,NA,NA
17103043,NA,79,(fatal) toxicity related to treatment,5,NA,NA,NA
17103043,NA,79,any treatment related nonhematological toxicity,>=3,NA,FALSE,NA
17103043,NA,79,nausea and vomiting while receiving an optimal 5-day anti-emetic regimen for prophylaxis and management,>=3,NA,NA,NA
17103043,NA,79,diarrhea while receiving an optimal 5-day anti-diarrheal regimen,>=3,NA,NA,NA
17103043,NA,79,treatment delay for toxicity lasting greater than 2 weeks,NA,NA,NA,NA
17103043,NA,79,an inability to complete 14 days of lenalidomide therapy due to treatment related toxicity,NA,NA,NA,NA
15494716,NA,80,neutropenia,4,>7 days,NA,NA
15494716,NA,80,neutropenia complicated by fever or infection regardless of duration,4,NA,NA,NA
15494716,NA,80,thrombocytopenia <25 x 109 l-1,4,NA,NA,NA
15494716,NA,80,nonhaematological toxicities including diarrhoea,>=3,NA,FALSE,NA
15494716,NA,80,haemorrhage toxicities,2,NA,NA,NA
15494716,NA,80,neurological toxicities,2,NA,NA,NA
15494716,NA,80,failure to recover from any drug-related toxicity by day 22,NA,NA,NA,NA
16445611,NA,81,nonhematologic organ toxicity,3 or 4,NA,FALSE,NA
15856233,NA,82,a leukocyte count less than 1000/ul,NA,>3 days,NA,NA
15856233,NA,82,a neutrophil count less than 500/ul,NA,>3 days,NA,NA
15856233,NA,82,"a neutrophil count less than 500/ul with fever  and a platelet count less than25,000/ul",NA,NA,NA,NA
15856233,NA,82,nonhematological toxicity,>=3,NA,FALSE,NA
17922272,NA,83,neutropenia with a treatment delay of more than 1 week,>=3,NA,NA,NA
17922272,NA,83,thrombocytopenia with a treatment delay of more than 1 week,>=3,NA,NA,NA
17922272,NA,83,non-hematological toxicity,>=3,NA,FALSE,NA
12120886,NA,84,neutropenia,4,>3 days,NA,NA
12120886,NA,84,thrombocytopenia,4,NA,NA,NA
12120886,NA,84,neutropenic fever,NA,NA,NA,NA
12120886,NA,84,non-hematologic toxicity,3 or 4,NA,FALSE,NA
14612900,NA,85,haematological toxicity,3 or 4,NA,NA,NA
14612900,NA,85,nonhaematological toxicity,4,NA,NA,NA
14612900,NA,85,cardiac or pulmonary toxicity,2,NA,NA,NA
12201492,NA,86,non-hematologic toxicity,3 or 4,NA,FALSE,NA
12201492,NA,86,nausea and vomiting in patients who had received prophylaxis and treatment with an optimal antiemetic regimen,3 or 4,NA,NA,NA
12201492,NA,86,neutropenia,4,>=5 days,NA,NA
12201492,NA,86,neutropenia associated with fever or infection,4,NA,NA,NA
12201492,NA,86,thrombocytopenia,4,NA,NA,NA
12201492,NA,86,anemia,4,NA,NA,NA
12201492,NA,86,NA,4,NA,NA,NA
12404295,NA,87,failure to receive less than 80% of the intended chemotherapy doses,NA,NA,NA,NA
12404295,NA,87,nonhematologic toxicity,3 or 4,NA,NA,NA
11127946,NA,88,NA,NA,NA,NA,DLT not defined
14733637,NA,89,Hematologic toxicity,>=4,NA,NA,NA
14733637,NA,89,Nohematologic toxicity,>=3,NA,NA,NA
11733958,NA,90,an absolute neutrophil count less than 0.5 x 109/L,4,>3 days,NA,NA
11733958,NA,90,thrombocytopenia,4,NA,NA,NA
11733958,NA,90,nonhematological toxicity,3,NA,FALSE,NA
11733958,NA,90,any episode of febrile neutropenia,NA,NA,NA,NA
11768362,NA,91,febrile neutropenia,NA,NA,NA,"single oral temperature
>38.5â—¦C, or three elevations to 38â—¦C during a 24-h period associated with grade 4 neutropenia and antibiotic administration"
11768362,NA,91,neutropenia,4,>=7 days,NA,NA
11768362,NA,91,thrombocytopenia,4,NA,NA,NA
11768362,NA,91,non-hematological toxicity,>=3,NA,FALSE,NA
11506300,NA,92,Absolute neutrophil count (ANC) of <500/ul,NA,>3 days,NA,NA
11506300,NA,92,Absolute neutrophil count (ANC) of <500/ul associated with fever exceeding 38Â°C,NA,NA,NA,NA
11506300,NA,92,"platelet count of <25,000/ul",NA,NA,NA,NA
11506300,NA,92,nonhematologic toxicities,3,NA,FALSE,NA
14984965,NA,93,neutropenia <=0.5 x 109/l,NA,>=7 days,NA,NA
14984965,NA,93,neutropenia no recovery to 1.5 x 109/l,NA,NA,NA,NA
14984965,NA,93,platelet count <=25 x 109/l,NA,NA,NA,NA
14984965,NA,93,platelet count no recovery to 100 x 109/l before the start of the next treatment cycle,NA,NA,NA,NA
14984965,NA,93,neutropenic fever or infection,NA,NA,NA,"absolute neutrophil count <=0.5 x 109/l with fever and
hospitalization and/or the need for intravenous antibiotics"
14984965,NA,93,any clinically relevant non-hematological toxicity,3 or 4,NA,NA,NA
14984965,NA,93,"any clinically relevant non-hematological persisting toxicity that requires hospitalization, drug therapy or treatment withdrawal",NA,NA,NA,NA
11398884,NA,94,NA,NA,NA,NA,Not defined
11828945,NA,95,nonhematologic toxicities,>=3,NA,NA,NA
11828945,NA,95,"hematologic toxicity despite the use of G-CSF, or the presence of fever",3,>3 days,NA,NA
11142482,NA,96,neutropenia with neutrophil count <500/ul,4,>7 days,NA,NA
11142482,NA,96,neutrophil count < 100/ul,4,>3 days,NA,NA
11142482,NA,96,febrile neutropenia,NA,NA,NA,NA
11142482,NA,96,thrombocytopenia requiring platelet transfusion,4,NA,NA,NA
11142482,NA,96,Non-hematological toxicity,>=3,NA,FALSE,NA
11134194,NA,97,thrombocytopenia,3 or 4,.2 weeks,NA,NA
11134194,NA,97,neutropenia,3 or 4,.2 weeks,NA,NA
11134194,NA,97,gastrointestinal toxicity,3 or 4,NA,NA,NA
11134194,NA,97,neurologic toxicity,3 or 4,NA,NA,NA
14613998,NA,98,ANC >= 500 cells/mm3,NA,>=7 days,NA,NA
14613998,NA,98,febrile neutropenia,NA,NA,NA,NA
14613998,NA,98,"thrombocytopenia < 10,000 cells/mm3",NA,NA,NA,NA
14613998,NA,98,thrombocytopenia bleeding episode requiring platelet transfusion,NA,NA,NA,NA
14613998,NA,98,nonhematological toxicity,>=3,NA,TRUE,NA
14613998,NA,98,continuing toxicity that delayed retreatment for 21 days,NA,NA,NA,NA
14613998,NA,98,more than one dose omission within one treatment course of three weekly doses,NA,NA,NA,NA
12743738,NA,99,leukopenia despite G-CSF treatment,4,>=4 days,NA,NA
12743738,NA,99,neutropenia despite G-CSF treatment,4,>=4 days,NA,NA
12743738,NA,99,thrombocytopenia,4,NA,NA,NA
12743738,NA,99,nonhematological toxicities,>=3,NA,FALSE,NA
12743738,NA,99,the treatment had to be postponed for more than 8 days from the scheduled date for reasons such as leukopenia,NA,NA,NA,NA
12177114,NA,100,neutropenia,4,>=5 days,NA,absolute neutrophil count < 0.5 x 109/L
12177114,NA,100,febrile neutropenia,NA,NA,NA,NA
12177114,NA,100,thrombocytopenia,4,NA,NA,platelet count <= 25 x 109/L
12177114,NA,100,nonhematologic toxicity,>=3,NA,FALSE,NA
11398891,NA,101,absolute neutrophil count nadir <500/ul,NA,>5 days,NA,NA
11398891,NA,101,febrile neutropenia,NA,NA,NA,NA
11398891,NA,101,"platelet nadir < 25,000",NA,NA,NA,NA
11398891,NA,101,any other nonhematologic toxicity,3 or 4,NA,FALSE,NA
11925132,NA,103,failure to achieve hematologic recovery within 28 days,NA,NA,NA,NA
11925132,NA,103,ANC < 500 cells/mm3,NA,>5 days,NA,NA
11925132,NA,103,"platelet counts < 10,000/mm3",NA,NA,NA,NA
11925132,NA,103,"platelet counts or < 25,000/mm3 if accompanied by bleeding",NA,NA,NA,NA
11925132,NA,103,any nonhematologic toxicity,>=3,NA,NA,NA
11142689,NA,104,non-hematological toxicity,4,NA,NA,NA
11142689,NA,104,thrombocytopenia,4,NA,NA,NA
11142689,NA,104,neutropenia,4,>5 days,NA,NA
12649113,NA,105,neutropenia,4,>7 days,NA,NA
12649113,NA,105,thrombocytopenia,4,>7 days,NA,NA
12649113,NA,105,non-haematological toxicity,3 or 4,NA,FALSE,NA
12649113,NA,105,any toxic death,NA,NA,NA,NA
12045462,NA,106,neutropenia,4,>5 days,NA,NA
12045462,NA,106,febrile neutropenia,NA,NA,NA,fever > 38C with grade 4 neutropenia
12045462,NA,106,thrombocytopenia,4,NA,NA,NA
12045462,NA,106,non-hematological toxicity,4,NA,NA,NA
12045462,NA,106,cessation of chemotherapy on day 8 due to toxicity,NA,NA,NA,NA
11325490,NA,107,leukopenia,4,>=7 days,NA,NA
11325490,NA,107,thrombocytopenia,4,>=7 days,NA,NA
11325490,NA,107,hemorrhage,>=3,NA,NA,NA
11325490,NA,107,non-hematologic toxicity,>=3,NA,FALSE,NA
11325490,NA,107,inability to deliver 100% dose on time,NA,NA,NA,NA
11800024,NA,108,leukopenia,4,>= 4 days,NA,NA
11800024,NA,108,neutropenia,4,>= 4 days,NA,NA
11800024,NA,108,thrombocytopenia,4,NA,NA,NA
11800024,NA,108,nonhematological toxicity,>=3,NA,FALSE,NA
11914594,NA,109,neutropenia,4,>=5 days,NA,NA
11914594,NA,109,thrombocytopenia,4,>=5 days,NA,NA
11914594,NA,109,febrile neutropenia,NA,NA,NA,NA
11914594,NA,109,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11914594,NA,109,any treatment delay due to unresolved toxicity,NA,NA,NA,NA
11550166,NA,110,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11925132,NA,111,failure to achieve hematologic recovery within 28 days,NA,NA,NA,NA
11925132,NA,111,ANC > 500 cells/mm3,NA,>5 days,NA,NA
11925132,NA,111,"platelet counts<10,000/mm3",NA,NA,NA,NA
11925132,NA,111,"platelet counts<25,000/mm3 if accompanied by bleeding;",NA,NA,NA,NA
11925132,NA,111,any nonhematologic toxicity,>=3,NA,NA,NA
12750842,NA,112,neutropenia,4,>=7 days,NA,NA
12750842,NA,112,thrombocytopenia,4,NA,NA,NA
12750842,NA,112,neutropenia with fever,3,NA,NA,NA
12750842,NA,112,thrombocytopenia with active bleeding,3,NA,NA,NA
12750842,NA,112,failure to recover from toxicity to receive a second cycle of chemotherapy despite a delay of more than 1 week from the scheduled day,NA,NA,NA,NA
12750842,NA,112,non-hematologic toxicity,>=3,NA,FALSE,NA
11955654,NA,113,any non-reversible toxicity,3 or 4,NA,FALSE,NA
11955654,NA,113,a platelet count of less than 25Ã—109 per l,NA,NA,NA,NA
11955654,NA,113,a neutrophil count of less than 0.5Ã—109 per l,NA,>=7 days,NA,NA
11955654,NA,113,febrile neutropenia,4,NA,NA,NA
11955654,NA,113,a platelet count of less than 100Ã—109 per l or a neutrophil count of less than 1.5Ã—109 per l leading to more than a 2 weeks delay for chemotherapy,NA,NA,NA,NA
11955654,NA,113,toxicity lasting until day 1of the second course,2,NA,FALSE,NA
11710627,NA,114,toxicity,>=3,NA,FALSE,NA
11710627,NA,114,neutrophil count not returned to >= 1500/ul,NA,NA,NA,NA
11710627,NA,114,"platelet count not returned to >= 100,000/ul by 6 weeks posttherapy",NA,NA,NA,NA
11710627,NA,114,a drop in systolic blood pressure to < 60 mmHg or a drop in diastolic blood pressure to <25 mmHg lasting for >= 5 min,NA,NA,NA,NA
11710627,NA,114,"a >25% drop in blood pressure associated with syncope or an increase in the heart rate to >180 bpm for children <= 2 years of age, >160 bpm for children aged 3 to 12 years,a nd >140 bpm for children >12 years",NA,NA,NA,NA
11714542,NA,115,thrombocytopenia,>=3,NA,NA,NA
11714542,NA,115,anemia,>=3,NA,NA,NA
11714542,NA,115,neutropenia,4,NA,NA,NA
11714542,NA,115,febrile neutropenia requiring hospitalization,NA,NA,NA,NA
11714542,NA,115,gastrointestinal toxicity by RTOG acute toxicity criteria despite maximal medical intervention,>=3,NA,NA,NA
11714542,NA,115,temporary suspension of dosing with docetaxel due to gastrointestinal toxicity,NA,NA,NA,NA
11714542,NA,115,"non-hematologic toxicity including renal, hepatic, neurologic,cardiac, skin, and pulmonary toxicity",>=3,NA,FALSE,NA
11714542,NA,115,retreatment delay with docetaxel of>7 days total due to toxicity,NA,NA,NA,NA
11800029,NA,117,hematologic toxicity,4,NA,NA,NA
11800029,NA,117,non-hematologic toxicity,>=3,NA,FALSE,NA
12702526,NA,118,thrombocytopenia,4,>5 days,NA,NA
12702526,NA,118,neutropenia,4,>5 days,NA,NA
12702526,NA,118,neutropenic fever,NA,NA,NA,as defined by absolute neutrophil count (ANC) â‰¤500 cells/Âµl and fever of â‰¥38.2Â°C
12702526,NA,118,the need for platelet transfusion,NA,NA,NA,NA
12702526,NA,118,failure to achieve recovery to grade â‰¤1  hematological toxicity by day 21,NA,NA,NA,NA
12702526,NA,118,Any non-hematological toxicity,>=3,>7 days,NA,NA
12942108,NA,119,myelosuppression,4,>=4 days,NA,NA
12942108,NA,119,nonhaematologic toxicity,3 or 4,NA,FALSE,NA
11330952,NA,120,nonhematological toxicity,4,NA,NA,NA
11330952,NA,120,inability to receive a subsequent cycle of therapy because of haematological toxicity,NA,NA,NA,NA
11330952,NA,120,neurological toxicity,3,NA,NA,NA
11330952,NA,120,cardiac toxicity,3,NA,NA,NA
11330952,NA,120,renal toxicity,3,NA,NA,NA
11330952,NA,120,withdrawal from HDT because of combined or cumulative toxicity,3,NA,NA,NA
11583193,NA,121,ANC < 0.5 x 1O9/I,NA,>7 days,NA,NA
11583193,NA,121,febrile neutropenia,NA,NA,NA,NA
11583193,NA,121,thrombocytopenia,4,NA,NA,NA
11583193,NA,121,clinically relevant non hematological toxicity,>=3,NA,NA,NA
11583193,NA,121,treatment delays of more than 14 days due to myelosuppression,NA,NA,NA,NA
11325487,NA,122,any event,4,NA,NA,NA
11325487,NA,122,neurological or cardiac toxicity,3,NA,NA,NA
11325487,NA,122,complete AV-block,3,NA,NA,NA
11325487,NA,122,any other side effect causing treatment abortion or interruption,3,NA,FALSE,NA
12468349,NA,123,any hematological toxicity,>=3,NA,NA,NA
12468349,NA,123,peripheral sensory neuropathy,>=2,NA,NA,NA
12468349,NA,123,mucositis,4,NA,NA,NA
15341977,NA,125,toxicity,3 or 4,NA,NA,NA
11066051,NA,126,NA,NA,NA,NA,DLT not defined
9610696,NA,128,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9610696,NA,128,hematologic toxicity,3 or 4,NA,NA,NA
10654007,NA,129,myelosuppression,4,>=5 days,NA,NA
10654007,NA,129,non-hematologic toxicity,3 or 4,NA,FALSE,NA
11127945,NA,131,any toxicity,3 or 4,NA,NA,NA
9486605,NA,132,NA,NA,NA,NA,DLT not defined
9404925,NA,133,toxicity not resolved within 30 days,4,NA,NA,NA
10491535,NA,134,toxicity,3 or 4,NA,NA,NA
9000605,NA,135,toxicity,3 or 4,NA,NA,NA
8656258,NA,136,neutropenia with an ANC less than 500 cells/uL,4,>5 days,NA,NA
8656258,NA,136,febrile neutropenia;,NA,NA,NA,NA
8656258,NA,136,"thrombocytopenia with less than 25,000 platelets/uL",4,>5 days,NA,NA
8656258,NA,136,failure to recover counts resulting in a delay in subsequent therapy of more than 7 days,NA,NA,NA,NA
9001351,NA,138,hematologic toxicity,4,NA,NA,NA
9001351,NA,138,non-hematologic toxicity,>=3,NA,FALSE,NA
9514802,NA,139,hematological toxicity,4,NA,NA,"presence of less than 1000 WBC/ml or less than 500 granulocytes/ml and/or less than 25,000 platelets/ml"
9514802,NA,139,toxicity,4,NA,NA,NA
10762746,NA,140,neutropenia,4,>2 days,NA,NA
10762746,NA,140,thrombocytopenia,4,>2 days,NA,NA
10762746,NA,140,neutropenia and fever >38.2C,>=2,>2 days,NA,NA
10762746,NA,140,non-haematological toxicity,3 or 4,NA,FALSE,NA
11036956,NA,141,absolute neutrophil count <500/ml,NA,>7 days,NA,NA
11036956,NA,141,absence of recovery of neutrophils (i.e. absolute neutrophil count <= 1500/ml) or platelets (< 100 000/ml) at day 35,NA,NA,NA,NA
11036956,NA,141,any febrile neutropenia,NA,NA,NA,NA
11036956,NA,141,thrombocytopenia,4,NA,NA,NA
11036956,NA,141,mucositis,>=3,>7 days,NA,NA
11036956,NA,141,non-hematological toxicity,>=3,NA,NA,NA
11036956,NA,141,persitent non-hematological toxicity,>=2,NA,TRUE,NA
9508176,NA,142,nonhematologic toxicity,3 or 4,NA,NA,NA
8151314,NA,143,NA,NA,NA,NA,DLT not defined
8201386,NA,144,inability to receive a full dose of cycle 2 after 28 days,NA,NA,NA,NA
8201386,NA,144,ANC less than 500/uL,NA,NA,NA,NA
8201386,NA,144,"platelet count less than 25,000/uL",NA,NA,NA,NA
8201386,NA,144,any other nonmyelosuppressive toxicity,3 or 4,NA,FALSE,NA
7620926,NA,145,myelosuppresion,NA,NA,NA,DLT not defined in details
7844593,NA,146,toxicity,3 or 4,NA,NA,NA
9440750,NA,147,nonhematologic toxicity,3 or 4,NA,NA,NA
9440750,NA,147,absolute granulocyte count <=500/uL,NA,>7 days,NA,NA
9440750,NA,147,"platelet count <= 25,000/uL",NA,NA,NA,NA
9440750,NA,147,NA,4,NA,NA,NA
11095134,NA,148,neutropenia,4,NA,NA,NA
11095134,NA,148,leukopenia,3,NA,NA,NA
11095134,NA,148,thrombocytopenia,3,NA,NA,NA
11095134,NA,148,anemia,3,NA,NA,NA
11095134,NA,148,diarrhea,3,NA,NA,NA
11095134,NA,148,neurotoxicity,3,NA,NA,NA
11095134,NA,148,bilirubin elevation,3,NA,NA,NA
11095134,NA,148,other non-hematological toxicity,2,NA,FALSE,NA
11054441,NA,149,ANC < 500/uL,NA,>7 days,NA,NA
11054441,NA,149,ANC < 500/uL associated with fever,NA,NA,NA,NA
11054441,NA,149,"ANC < 1,500/uL",NA,>2 weeks beyond the scheduled start date of the second cycle,NA,NA
11054441,NA,149,"platelet count < 25,000/uL",NA,NA,NA,NA
11054441,NA,149,"platelet count < 100,000/uL",NA,>2 weeks beyond the scheduled start date of the second cycle,NA,NA
11054441,NA,149,nonhematologic toxicity,>=3,NA,FALSE,NA
11054441,NA,149,vomiting that could not be reduced to <= grade 1 within 2 days despite optimal use of antiemetic therapy,4,NA,NA,NA
7790322,NA,150,leukocyte,4,NA,NA,NA
7790322,NA,150,platelet nadir,4,NA,NA,NA
7790322,NA,150,non-hematoÂ­logical toxicity,3 or 4,NA,FALSE,NA
8931678,NA,151,NA,NA,NA,NA,DLT not defined
9220292,NA,152,an ANC < 500/uL,NA,.5 days,NA,NA
9220292,NA,152,"a platelet count < 25,000/uL",NA,NA,NA,NA
9220292,NA,152,nonhematologic toxicity,>=3,NA,NA,NA
9220292,NA,152,a delay in the subsequent course of therapy by greater than 7 days,NA,NA,NA,NA
10944128,NA,153,neutropenic fever,NA,NA,NA,NA
10944128,NA,153,thrombocytopenia,4,NA,NA,NA
10944128,NA,153,"absolute neutrophil count less than 1,000/uL",NA,NA,NA,NA
10944128,NA,153,"platelet count less than 50,000/uL during treatment with etoposide",NA,NA,NA,NA
10944128,NA,153,a delay in starting a subsequent course of more than 14 days based on the first cycle of chemotherapy,NA,NA,NA,NA
7666081,NA,154,NA,NA,NA,NA,DLT not defined
10785477,NA,155,"failure to achieve a neutrophil count >= 1500/uL or platelets >= 100,000/uL by Day 29",NA,NA,NA,NA
10785477,NA,155,"absolute neutrophil count >= 500/uL or platelets >= 20,000/uL despite dosereduction as described",NA,>7 days,NA,NA
10785477,NA,155,unexpected life-threatening toxicity of any kind,NA,NA,NA,NA
10785477,NA,155,irreversible nonhematologic toxicity,3 or 4,NA,NA,NA
9740546,NA,156,"hematologic toxicity (absolute granulocyte nadir < 500/Âµl or platelet nadir < 25,000/Âµl)",4,NA,NA,NA
9740546,NA,156,non-hematologic toxicity,3 or 4,NA,NA,NA
9020283,NA,157,leukopenia,4,>7 days,NA,NA
9020283,NA,157,thrombocytopenia,4,>7 days,NA,NA
9020283,NA,157,hemorrhage,>=3,NA,NA,NA
9020283,NA,157,nonhematologic toxicity,>=3,NA,FALSE,NA
9020283,NA,157,inability to receive 100% of cycle two drug on time,NA,NA,NA,NA
9143391,NA,158,"significant systemic symptoms of fever (one with hallucinations), chills, and hypotension",3 or 4,NA,NA,NA
10071285,NA,159,neutropenia,4,NA,NA,NA
10071285,NA,159,thrombocytopenia,4,NA,NA,NA
10071285,NA,159,nonhematologic toxicity,3 or 4,NA,FALSE,NA
10466861,NA,160,absolute neutrophil count <0.5Ã—109/l,NA,> 7 days,NA,NA
10466861,NA,160,absolute neutrophil count < 0.1Ã—109 /l,NA,>3 days,NA,NA
10466861,NA,160,thrombocytopenia requiring platelets transfusions,4,NA,NA,NA
10466861,NA,160,absence of neutrophil (>= 1.5Ã—109/l) and/or platelet (>= 100Ã—109/l) recovery at day 28,NA,NA,NA,NA
10466861,NA,160,mucositis,>=3,>7 days,NA,NA
10466861,NA,160,non-hematological toxicity,>=3,NA,FALSE,NA
8882989,NA,161,hematological toxicity,>=3,NA,NA,NA
9209665,NA,162,ANC < 0.5 x 109/l,NA,>7 days,NA,NA
9209665,NA,162,ANC <0.1 x 1O9/1,NA,>3 days,NA,NA
9209665,NA,162,febrile neutropenia,NA,NA,NA,NA
9209665,NA,162,thrombocytopenia,4,NA,NA,NA
9209665,NA,162,clinically relevant neurotoxicity,3,NA,NA,NA
9209665,NA,162,other toxicities,4,NA,NA,NA
10231137,NA,163,Ototoxicity,NA,NA,NA,NA
8398708,NA,164,NA,NA,NA,NA,DLT not defined
2651580,NA,165,NA,NA,NA,NA,Dose-limiting toxicity was determined to have occurred when two or more patients developed life-threatening or fatal toxicity.
32590047,NCT02442531,166,drug-related neutropenia,>3,>1 week,NA,NA
32590047,NCT02442531,166,febrile neutropenia,>=3,NA,NA,NA
32590047,NCT02442531,166,thrombocytopenia,4,NA,NA,NA
32590047,NCT02442531,166,thrombocytopenia with bleeding requiring platelet transfusion,3,NA,NA,NA
32590047,NCT02442531,166,anaemia,>=3,NA,NA,NA
32590047,NCT02442531,166,any drug-related toxicity,>=3,NA,FALSE,NA
32590047,NCT02442531,166,Delayed administration of the study drug for more than two weeks and any other toxicity which in the view of the investigator represented a clinically significant hazard to the patient - even outside the DLT window,NA,NA,NA,NA
25762000,NCT00566410,168,non-hematological toxicity,>=3,NA,NA,NA
25762000,NCT00566410,168,clinically significant non-hematological toxicity,2,NA,NA,NA
25762000,NCT00566410,168,"nausea, vomiting and/or diarrhea despite supportive care therapies",>=3,NA,NA,NA
25762000,NCT00566410,168,febrile neutropenia,NA,NA,NA,NA
25762000,NCT00566410,168,neutropenia without hematopoeitic growth factor support,4,>5 days,NA,NA
25762000,NCT00566410,168,thrombocytopenia,4,NA,NA,NA
25762000,NCT00566410,168,liver transaminitis,>=3,>5 days,NA,NA
25762000,NCT00566410,168,elevated alkaline phosphatase,>=3,>5 days,NA,NA
25762000,NCT00566410,168,neurological toxicity,>=2,NA,NA,NA
25762000,NCT00566410,168,absolute reduction of ejection fraction toâ‰¤45 % or a relative reduction of â‰¥20 % from baseline,NA,NA,NA,NA
1846407,NA,169,NA,NA,NA,NA,DLT not defined
23335436,CCI-06-00092,170,neutropenia,4,>7 days,NA,NA
23335436,CCI-06-00092,170,thrombocytopenia,4,>7 days,NA,NA
23335436,CCI-06-00092,170,myelosuppression which caused delay in chemotherapy for >14 days,NA,NA,NA,NA
23335436,CCI-06-00092,170,non hematological toxicity,3 or 4,NA,FALSE,NA
23335436,CCI-06-00092,170,cardiac shortening fraction <25%,NA,NA,NA,NA
23335436,CCI-06-00092,170,dysesthesia that persisted through the beginning of next course,2,NA,NA,NA
23335436,CCI-06-00092,170,pharyngolaryngeal dysesthesia that lasted more than 7 days,1,NA,NA,NA
1698110,NA,171,NA,NA,NA,NA,DLT not defined
2162912,NA,174,NA,NA,NA,NA,DLT not defined
2072142,NA,175,neutropenia,3 or 4,NA,NA,NA
2072142,NA,175,thrombocytopenia,3 or 4,NA,NA,NA
33144248,NA,178,radiation esophagitis,4,NA,NA,NA
33144248,NA,178,radiation esophagitis,3,>7 days,NA,NA
33144248,NA,178,neutropenia,4,NA,NA,NA
33144248,NA,178,febrile neutropenia,3,NA,NA,NA
33144248,NA,178,thrombocytopenia,4,NA,NA,NA
33144248,NA,178,thrombocytopenia with hemorrhage,3,NA,NA,NA
33144248,NA,178,other non-hematologic toxicities,3 or 4,NA,FALSE,NA
33144248,NA,178,"Nausea, vomiting and diarrhea under best supportive treatment",3 or 4,>7 days,NA,NA
33144248,NA,178,death of subject of any reason,NA,NA,NA,NA
33870151,NCT02223247,179,a treatment interruption >3 days (or inability to begin C2 for >3 days) due to any TVB-2640-related toxicity,NA,NA,NA,NA
33870151,NCT02223247,179,"hematologic toxicity that initially improved after dose interruption for 3 days, but recurred upon treatment resumption",>=3,NA,NA,NA
33870151,NCT02223247,179,hematologic toxicity with complications,>=3,NA,NA,NA
33870151,NCT02223247,179,febrile neutropenia,NA,NA,NA,NA
33870151,NCT02223247,179,non-hematologic toxicity,>=3,NA,FALSE,NA
33870151,NCT02223247,179,any vision-threatening adverse event (AE),NA,NA,NA,NA
8281628,NA,182,NA,NA,NA,NA,DLT not defined
1403054,NA,184,NA,NA,NA,NA,DLT not defined
8270975,NA,185,life-threatening nonhematopoietic toxicity,3 or 4,NA,NA,NA
8422699,NA,186,NA,NA,NA,NA,DLT not defined
21152384,NA,187,ANC < 0.5 x 109/L,NA,>=7 days,NA,NA
21152384,NA,187,febrile neutropenia,NA,NA,NA,NA
21152384,NA,187,platelets less than 25 x 109/L,NA,NA,NA,NA
21152384,NA,187,thrombocytopenia associated with bleeding,3,NA,NA,NA
21152384,NA,187,nonhematologic toxicity,>=3,NA,FALSE,NA
21152384,NA,187,any toxicity resulting in treatment delay of more than 2 weeks,NA,NA,NA,NA
34310349,NA,188,neutropenia,4,>7 days,NA,NA
34310349,NA,188,febrile neutropenia of any duration with temperature â‰¥ 38.5Â°C,NA,NA,NA,NA
34310349,NA,188,anemia or thrombocytopenia which required transfusion therapy on > 2 occasions in 7 days,4,NA,NA,NA
34310349,NA,188,nonhematologic toxicity,3 or 4,NA,FALSE,NA
34310349,NA,188,triglycerides only for patients who had grade 3 elevations despite appropriate lipid lowering drug therapy,3,NA,NA,NA
34310349,NA,188,delay in treatment for >14 days before beginning cycle 2,NA,NA,NA,NA
2258073,NA,189,leukocyte nadir <=1.0x109/liter,NA,NA,NA,NA
2258073,NA,189,platelet nadir <= 25x109/liter,NA,NA,NA,NA
2258073,NA,189,creatinine clearance <=30 ml/min,NA,NA,NA,NA
2258073,NA,189,intractable vomiting,NA,>48 hr,NA,NA
2258073,NA,189,other severe or life threatening toxicity,NA,NA,NA,NA
9427692,NA,190,adverse event,3 or 4,NA,NA,NA
34263358,NA,191,neutrophil depletion,>=4,>=8 days,NA,NA
34263358,NA,191,febrile neutropenia,NA,>= 4 days,NA,NA
34263358,NA,191,thrombocytopenia,4,NA,NA,NA
34263358,NA,191,non-hematological toxicity,>=3,NA,TRUE,NA
34263358,NA,191,"discontinuation of protocol treatment due to adverse events, even when thephysician determined that dose reduction was necessary to ensure patient safety",NA,NA,NA,NA
32600929,NCT00916123,192,hematological toxicity causing >3 weeks delay for scheduled cycle 4 or 5 of docetaxel,NA,NA,NA,NA
32600929,NCT00916123,192,need for >2 platelet transfusions,NA,NA,NA,NA
32600929,NCT00916123,192,febrile neutropenia,NA,NA,NA,NA
32600929,NCT00916123,192,nonhematological toxicity following 177Lu-J591,>=3,NA,NA,NA
32600929,NCT00916123,192,>2 dose reductions for cycle 4 or 5 of docetaxel,NA,NA,NA,NA
10071279,NA,193,febrile neutropenia,NA,NA,NA,NA
10071279,NA,193,thrombocytopenia,4,NA,NA,NA
10071279,NA,193,nonhematologic toxicity,>=3,NA,NA,NA
10071279,NA,193,neutrophil count of less than 500/ÂµL,NA,>3 days,NA,For patients who were treated without G-CSF
10071279,NA,194,febrile neutropenia,NA,NA,NA,NA
10071279,NA,194,thrombocytopenia,4,NA,NA,NA
10071279,NA,194,nonhematologic toxicity,>=3,NA,NA,NA
10071279,NA,194,neutrophil count of less than 500/ÂµL,NA,>3 days,NA,NA
17442993,NA,195,neutropenia,4,>7 days,NA,NA
17442993,NA,195,thrombocytopenia,4,>7 days,NA,NA
17442993,NA,195,Hematologic toxicity that caused a delay of  14 days beyond the planned interval between treatment courses,NA,NA,NA,NA
17442993,NA,195,hematologic toxicity attributable to G3139 before day 5 initiation of cytotoxic chemotherapy,>=3,NA,NA,NA
17442993,NA,195,nonhematologic toxicity attributable to G3139,3 or 4,NA,FALSE,NA
8383914,NA,196,toxicity,3 or 4,NA,NA,NA
29463550,NCT01546038,197,nonhematologic AEs,>=3,NA,FALSE,uncontrolled despite optimal medical management
29463550,NCT01546038,197,"prolonged myelosuppression (absolute neutrophil count < 500/mL, or platelet count < 10 x 109/L) in patients with a normal bone marrow (<5% blasts and no evidence of disease or dysplasia)",NA,>42 days,NA,NA
29463550,NCT01546038,197,inability to deliver at least 80% of the planned study doses for all agents in a combination due to nonhematologic AEs,NA,NA,NA,NA
29463550,NCT01546038,197,"a treatment delay >28 days due to persistent, nonhematologic AEs",NA,NA,NA,NA
15113758,NA,200,"renal dysfunction (hemodialysis, serum creatinine level > 3 x baseline/ULN)",NA,NA,NA,NA
15113758,NA,200,"hepatic dysfunction (ALT or AST > 5 x baseline/ULN, total bilirubin > 3 x baseline/ULN with no GVHD on liver biopsy)",NA,NA,NA,NA
15113758,NA,200,respiratory failure requiring mechanical ventilation,NA,NA,NA,NA
15113758,NA,200,hypotension requiring vasopressors for more than 24 hours,NA,NA,NA,NA
15113758,NA,200,cardiac arrhythmia requiring electrical intervention,NA,NA,NA,NA
15113758,NA,200,death from a cause other than GVHD or disease relapse,NA,NA,NA,NA
18719348,NA,201,neutropenia,4,>3 days,NA,NA
18719348,NA,201,leukopenia,4,>3 days,NA,NA
18719348,NA,201,neutropenia with fever (body temperature >= 38 Â° C) or infection,3,NA,NA,NA
18719348,NA,201,a platelet count <25 x 10 3/ul,NA,NA,NA,NA
18719348,NA,201,nonhematologic toxicity,>=3,NA,FALSE,NA
18719348,NA,201,postponement of the resumption of treatment by 8 or more days because of adverse events or other factors,NA,NA,NA,NA
18719348,NA,201,"treatment-related death, septic shock or serious adverse events such as grade 4 nonhematologic toxicity",NA,NA,NA,NA
17519066,NA,202,neutropenia,4,>7 days,NA,NA
17519066,NA,202,neutropenia associated with fever,NA,NA,NA,NA
17519066,NA,202,thrombocytopenia,3,>7 days,NA,NA
17519066,NA,202,thrombocytopenia,4,NA,NA,NA
17519066,NA,202,non-hematologic toxicity,>=3,NA,FALSE,NA
17519066,NA,202,"a required delay to the next treatment cycle of more than 2 weeks for any reason, as determined by a physician",NA,NA,NA,NA
19251309,NA,203,severe adverse event,>=3,NA,NA,NA
17909805,NA,204,neutropenia,4,>=7 days,NA,NA
17909805,NA,204,neutropenia with fever,3 or 4,NA,NA,NA
17909805,NA,204,thrombocytopenia,4,NA,NA,NA
17909805,NA,204,thrombocytopenia with active bleeding,3,NA,NA,NA
17909805,NA,204,failure to recover from toxicity despite a delay of more than 7 days from the next scheduled cycle,1,NA,NA,NA
17909805,NA,204,non-hematologic toxicity,>=3,NA,FALSE,NA
18405987,NA,205,leukopenia,4,>=3 days,NA,NA
18405987,NA,205,neutropenia,4,>=3 days,NA,NA
18405987,NA,205,a body temperature of at least 38 C or infection associated with grade 3 neutropenia,NA,NA,NA,NA
18405987,NA,205,thrombocytopenia,4,NA,NA,NA
18405987,NA,205,non-hematologic toxicity,>=3,NA,FALSE,NA
18405987,NA,205,the need to delay therapy for more than 7 days because of toxicity,NA,NA,NA,NA
18172649,NA,206,diarrhea despite appropriate intervention,>=3,NA,NA,NA
18172649,NA,206,neutropenia,4,>= 5 days,NA,NA
18172649,NA,206,febrile neutropenia,NA,NA,NA,NA
18172649,NA,206,hemoglobin,4,NA,NA,NA
18172649,NA,206,platelet count <25 x 109 l-1,NA,NA,NA,NA
18172649,NA,206,neuropathy,>=3,NA,NA,NA
18172649,NA,206,any other non-hematologic toxicity,>=3,NA,NA,NA
19499186,NA,207,nonhematologic toxicity unresponsive to symptomatic treatment,>=3,NA,NA,NA
19499186,NA,207,hematological toxicity (neutropenia or thrombocytopenia),4,NA,NA,NA
19499186,NA,207,neutropenia,3,>=7 days,NA,NA
19499186,NA,207,neutropenia with neutropenic fever,NA,NA,NA,NA
19499186,NA,207,neutropenia associated with hospitalization,NA,NA,NA,NA
19499186,NA,207,thrombocytopenia associated with bleeding or requiring platelet transfusion,3,NA,NA,NA
18319713,NA,208,clinically significant nonhaematological toxicity,>=3,NA,FALSE,NA
18319713,NA,208,nausea/vomiting/diarrhoea uncontrolled by aggressive therapy,>=3,NA,NA,NA
18319713,NA,208,neutropaenia,4,>=5 days,NA,NA
18319713,NA,208,neutropaenia with fever >= 38.5 C or infection,3 or 4,NA,NA,NA
18319713,NA,208,thrombocytopaenia,4,NA,NA,NA
18319713,NA,208,inability to commence next cycle of treatment within 2 weeks of scheduled dosing due to an unresolved toxicity such that the original eligibility criteria were no longer met,NA,NA,NA,NA
18319713,NA,208,"toxicity, which is considered a DLT by the investigator",2,NA,NA,NA
18319713,NA,208,non-haematological toxicity that persisted beyond cycle 1,>=2,NA,NA,NA
17896192,NA,209,neutropenia,4,>7 days,NA,NA
17896192,NA,209,neutropenic fever,NA,NA,NA,NA
17896192,NA,209,anemia,4,NA,NA,NA
17896192,NA,209,thrombocytopenia,3 or 4,NA,NA,NA
17896192,NA,209,nonhematologic toxicity,3 or 4,NA,TRUE,NA
17896192,NA,209,Any toxicity causing a total of 14 days delay,NA,NA,NA,NA
17940076,NA,210,leukopenia,4,>=5 days,NA,NA
17940076,NA,210,neutropenia,4,>=5 days,NA,NA
17940076,NA,210,neutropenia with fever (>38C) even with G-CSF rescue,4,NA,NA,NA
17940076,NA,210,platelet count less than 30 000/mm3,NA,NA,NA,NA
17940076,NA,210,non-hematological toxicity,3 or 4,NA,FALSE,NA
19704337,NA,211,neutropenia,4,>7 days,NA,NA
19704337,NA,211,febrile neutropenia,>=3,NA,NA,NA
19704337,NA,211,platelet count < 25 x 109/L,NA,NA,NA,NA
19704337,NA,211,thrombocytopenia resulting in grade >= 2 hemorrhage,NA,NA,NA,NA
19704337,NA,211,infection with neutropenia (<1.0 x 109/L),>=3,NA,NA,NA
19704337,NA,211,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19704337,NA,211,inability to administer cycle 2 day 1 of combination within 2 weeks of completing previous cycle,NA,NA,NA,NA
19066894,NA,212,hematologic toxicities,4,NA,NA,NA
19066894,NA,212,non-hematologic toxicities,>=3,NA,FALSE,NA
19066894,NA,212,thrombocytopenia with grade 2 hemorrhage,3,NA,NA,NA
18000498,NA,213,non-hematological toxicity,>=3,NA,FALSE,NA
18000498,NA,213,neutropaenia,4,7 days,NA,NA
18000498,NA,213,neutropaenia complicated by fever or infection,4,NA,NA,NA
18000498,NA,213,thrombocytopenia <25  x 109 l-1,NA,NA,NA,NA
18000498,NA,213,any thrombocytopenia requiring platelet transfusion,NA,NA,NA,NA
18000498,NA,213,any subjectively intolerable toxicity felt to be related to either one of the compounds,NA,NA,NA,NA
17826308,NA,214,leukopenia,4,>=2 days,NA,NA
17826308,NA,214,thrombocytopenia,3 or 4,NA,NA,NA
17826308,NA,214,neurological toxicities,3 or 4,NA,NA,NA
17826308,NA,214,non-hematological toxicities,3 or 4,NA,FALSE,NA
18493840,NA,215,neutropenia,4,NA,NA,NA
18493840,NA,215,thrombocytopenia,>=3,NA,NA,NA
18493840,NA,215,neutropenia with fever of 38C or more,3,NA,NA,NA
18493840,NA,215,non-hematological toxicity,3 or 4,NA,FALSE,NA
18493840,NA,215,a delay in treatment of 22 days as a result of drug-related toxicity,1,NA,NA,NA
17594929,NA,216,neutropenia,4,>7 days,NA,NA
17594929,NA,216,febrile neutropenia,>=3,NA,NA,NA
17594929,NA,216,thrombocytopenia,4,NA,NA,NA
17594929,NA,216,non-hematologic toxicity,3 or 4,NA,FALSE,NA
18758179,NA,217,absolute neutrophil count (ANC) < 0.5 x 10 9 /l,NA,>7 days,NA,NA
18758179,NA,217,FN (ANC < 0.5 x 10 9/l and body temperature >= 38 Â° C),NA,NA,NA,NA
18758179,NA,217,platelet counts < 2.5 x 10 9 /l,NA,NA,NA,NA
18758179,NA,217,hemoglobin levels,4,NA,NA,NA
18758179,NA,217,nonhematolological toxicity,>=3,NA,FALSE,NA
19190908,NA,218,neutropenia,4,>7 days,NA,NA
19190908,NA,218,thrombocytopenia,4,NA,NA,NA
19190908,NA,218,febrile neutropenia,NA,NA,NA,NA
19190908,NA,218,non-hematological toxicities,3 or 4,NA,NA,NA
18425392,NA,219,NA,NA,NA,NA,DLT not defined
19543076,NA,220,neutropenia,4,>3 days,NA,NA
19543076,NA,220,febrile neutropenia,3 or 4,NA,NA,NA
19543076,NA,220,thrombocytopenia,4,NA,NA,NA
19543076,NA,220,nonhaematological toxicity,3,NA,FALSE,NA
18477581,NA,221,neutropenia with a body temperature >38.5C,4,NA,NA,NA
18477581,NA,221,thrombocytopenia,4,NA,NA,NA
18477581,NA,221,non-hematologic toxicity,3 or 4,NA,FALSE,NA
19415031,NA,222,neutropenia,4,>3 days,NA,NA
19415031,NA,222,neutropenia with fever,4,NA,NA,NA
19415031,NA,222,thrombocytopenia,4,NA,NA,NA
19415031,NA,222,stomatitis,4,NA,NA,NA
19415031,NA,222,non-hematologic toxicity,3 or 4,NA,NA,NA
18824702,NA,223,nonhematologic toxicity,3 or 4,NA,NA,"including grade >= 3 nausea, vomiting, or diarrhea despite optimal prophylaxis"
18824702,NA,223,thrombocytopenia,4,NA,NA,NA
18824702,NA,223,neutropenia,4,>4 days,NA,NA
18824702,NA,223,neutropenia accompanied by fever,4,NA,NA,NA
18824702,NA,223,treatment delaysmore than 2 weeks owing to failure to meet re-treatment criteria,NA,NA,NA,NA
19074216,NA,224,"any hematological toxicity, causing >7 days delay of a subsequent cycle",NA,NA,NA,NA
19074216,NA,224,febrile neutropenia,NA,NA,NA,NA
19074216,NA,224,thrombopenia associated with hemorrhage,3 or 4,NA,NA,NA
19074216,NA,224,non-hematological toxicity,3 or 4,NA,FALSE,NA
18493761,NA,225,"febrile neutropenia (ANC < 1,000/ul with fever >= 38.5Â°C)",3,NA,NA,NA
18493761,NA,225,neutropenia,4,>=7 days,NA,NA
18493761,NA,225,thrombocytopenia,4,NA,NA,NA
18493761,NA,225,thrombocytopenic bleeding,4,NA,NA,NA
18493761,NA,225,nonhematological toxicities,3 or 4,NA,FALSE,NA
19636016,NA,226,toxicity leading to withdrawal of treatment,>=3,NA,NA,NA
19636016,NA,226,fever,3,NA,NA,NA
19636016,NA,226,edema,3,NA,NA,NA
19636016,NA,226,hypotension,3,NA,NA,NA
19636016,NA,226,hepatic andhematologic toxicities,3,NA,NA,NA
19636016,NA,226,cardiovascular,2,NA,NA,NA
19636016,NA,226,allergic reactions,2,NA,NA,NA
19636016,NA,227,toxicity occurring up to day 33 after treatment,>=3,NA,FALSE,NA
18343924,NA,228,neutropenia,4,NA,NA,NA
18343924,NA,228,thrombocytopenia,4,NA,NA,NA
18343924,NA,228,any episodes of febrile neutropenia,NA,NA,NA,NA
18343924,NA,228,non-hematologic toxicities,3 or 4,NA,FALSE,NA
18751437,NA,229,leukopenia,4,NA,NA,NA
18751437,NA,229,neutropenia,4,NA,NA,NA
18751437,NA,229,neutropenia with a fever (>38.0ËšC),3,NA,NA,NA
18751437,NA,229,thrombocytopenia,4,NA,NA,NA
18751437,NA,229,thrombocytopenia with a bleeding tendency,3,NA,NA,NA
18751437,NA,229,nonhaematological toxicity,3 or 4,NA,FALSE,NA
19704061,NA,230,non-hematological toxicity considered to be a direct result of therapy,3,NA,FALSE,NA
19704061,NA,230,febrile neutropenia,4,NA,NA,NA
19704061,NA,230,neutropenia,4,>7 days,NA,NA
19704061,NA,230,thrombocytopenia,4,NA,NA,NA
17695429,NA,231,neutropenia,4,>=5 days,NA,NA
17695429,NA,231,febrile neutropenia (grade 3 or 4 neutropenia with fever (â‰¥38.5 C)),NA,NA,NA,NA
17695429,NA,231,thrombocytopenia,4,NA,NA,NA
17695429,NA,231,non-hematological toxicity,3 or 4,NA,FALSE,NA
17695429,NA,231,failure to administer docetaxel on day 8,NA,NA,NA,NA
17695429,NA,231,"failure to administer docetaxel on day 15, even if postponed for one week",NA,NA,NA,NA
17695429,NA,231,failure to administer S-1 for 14 days continuously during treatment,NA,NA,NA,NA
19768460,NA,232,leukopenia/neutropenia,4,>4 days,NA,NA
19768460,NA,232,fever associated with grade 3 or 4 neutropenia or infection,1,NA,NA,NA
19768460,NA,232,thrombocytopenia,4,NA,NA,NA
19768460,NA,232,non-hematologic toxicity,3 or 4,NA,FALSE,NA
19768460,NA,232,any other event that could be classified as a DLT at the discretion of the data and safety monitoring committee,NA,NA,NA,NA
17695421,NA,233,neutropenia,4,NA,NA,NA
17695421,NA,233,thrombocytopenia,4,NA,NA,NA
17695421,NA,233,vasculitis,4,NA,NA,NA
17695421,NA,233,otitis of the external ear,4,NA,NA,NA
17695421,NA,233,fatigue,4,NA,NA,NA
17695421,NA,233,infection,4,NA,NA,NA
17695421,NA,233,nonmalignant ascites,4,NA,NA,NA
17695421,NA,233,constipation,4,NA,NA,NA
17695421,NA,233,central nervous system hemorrhage,4,NA,NA,NA
17695421,NA,233,hyponatremia,4,NA,NA,NA
17695421,NA,233,esophagitis,4,NA,NA,NA
17695421,NA,233,dysphagia,4,NA,NA,NA
17695421,NA,233,other nonhematological toxicity,3,NA,FALSE,NA
19437020,NA,234,neutropenia,4,>7 days,NA,NA
19437020,NA,234,platelets,4,NA,NA,NA
19437020,NA,234,"anorexia, despite prophylaxis and/or treatment with anti-emetics",4,NA,NA,NA
19437020,NA,234,"fatigue, despite prophylaxis and/or treatment with anti-emetics",4,NA,NA,NA
19437020,NA,234,"nausea or vomiting, despite prophylaxis and/or treatment with anti-emetics",4,NA,NA,NA
19437020,NA,234,any other toxicity(including febrile neutropenia and neutropenic infection),3 or 4,NA,FALSE,NA
17848958,NA,235,neutropenia,4,>3 days,NA,NA
17848958,NA,235,neutropenia with fever,3 or 4,NA,NA,NA
17848958,NA,235,thrombocytopenia,4,NA,NA,NA
17848958,NA,235,non-haematological toxicity,3,NA,NA,NA
17848958,NA,235,treatment delay of greater than 2 weeks as a result of toxicity,NA,NA,NA,NA
19002462,NA,236,neutropenia with infection or fever (temperature >= 38.3Â°C),4,NA,NA,NA
19002462,NA,236,neutropenia,4,>7 days,NA,NA
19002462,NA,236,"platelet counts <20,000/ul",NA,NA,NA,NA
19002462,NA,236,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19002462,NA,236,delay of chemotherapy for >7 days owing to toxicity,NA,NA,NA,NA
19002462,NA,236,administration of less than 75% of the planned dose of docetaxel owing to toxicity,1,NA,NA,NA
19237630,NA,237,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19237630,NA,237,thrombocytopenia,3 or 4,>=7 days,NA,NA
19237630,NA,237,thrombocytopenia associated with active bleeding or requiring platelet transfusion,3 or 4,NA,NA,NA
19237630,NA,237,anemia,3,NA,NA,NA
19237630,NA,237,neutropenia,4,NA,NA,NA
19237630,NA,237,drug-related death,NA,NA,NA,NA
19237630,NA,237,a treatment-related  two-fold increase in both Bb and C3a complement levels,NA,NA,NA,NA
18470481,NA,238,any drug-related non-hematologic toxicity,>=2,NA,FALSE,NA
18470481,NA,238,hematologic toxicity,>=3,NA,NA,NA
19011760,NA,239,the inability to deliver 14 days of lenalidomide due to toxicity,NA,NA,NA,NA
19011760,NA,239,non-hematological toxicity,>=3,NA,FALSE,NA
19011760,NA,239,neutropenia with fever,4,NA,NA,NA
19011760,NA,239,anemia or thrombocytopenia,4,NA,NA,NA
19011760,NA,239,inability to begin cycle 2 within 7 days of the planned start date due to toxicity,NA,NA,NA,NA
19011760,NA,239,NA,NA,NA,FALSE,NA
18626572,NA,240,an adverse event or a laboratory abnormality,>=3,NA,NA,NA
19434371,NA,241,"An inability to deliver 2 or more scheduled doses of intravenous chemotherapy during the initial 6 weeks of therapy because of an absolute neutrophil count (ANC) of <1000/Î¼L, platelet count of <75,000/Î¼L or non-hematologic toxicity of grade 2 or worse",NA,NA,NA,NA
19434371,NA,241,neutropenia,4,>7 days,NA,NA
19434371,NA,241,thrombocytopenia,4,NA,NA,NA
19434371,NA,241,neutropenia complicated by fever of >38.5Â°C or infection,4,NA,NA,NA
19434371,NA,241,Non-hematologic,>=3,NA,NA,NA
19740565,C000000281,242,non-hematological toxicities,3 or 4,NA,FALSE,NA
19740565,C000000281,242,febrile neutropenia,NA,NA,NA,NA
19740565,C000000281,242,neutropenia,4,>3 days,NA,NA
19740565,C000000281,242,thrombocytopenia,4,NA,NA,NA
19740565,C000000281,242,low compliance of S-1 of less than 10 days out of 14 days on day 21,NA,NA,NA,NA
19740565,C000000281,242,failure to start the second course at no later than day 29,NA,NA,NA,NA
18362939,NA,243,neutropenia,4,>7 days,NA,NA
18362939,NA,243,neutropenia associated with infection or fever (>= 38.3C as single temperature or >= 38.0C for 1 h),3 or 4,NA,NA,NA
18362939,NA,243,thrombocytopenia with grade 3/4 haemorrhage,3,NA,NA,NA
18362939,NA,243,thrombocytopenia,4,NA,NA,NA
18362939,NA,243,non-haematological toxicity,3 or 4,NA,FALSE,NA
18362939,NA,243,nausea/vomiting not reduced to grade <= 1 with aggressive antiemetic support,3 or 4,NA,NA,NA
18362939,NA,243,inability of the patient to take >=75% of the planned chemotherapy dose during the treatment period.,NA,NA,NA,NA
18481067,NA,244,neutropenia,4,>7 days,NA,NA
18481067,NA,244,throbocytopenia,4,>7 days,NA,NA
18481067,NA,244,febrile neutropenia,NA,NA,NA,NA
18481067,NA,244,nonhematological toxicities,3 or 4,NA,FALSE,NA
20043166,NA,245,non-hematologic toxicity,3 or 4,>=7 days,NA,NA
20043166,NA,245,neutropenia,4,>=7 days,NA,NA
20043166,NA,245,febrile neutropenia (fever > 38.5C),NA,>=24 h,NA,NA
20043166,NA,245,neutropenic infection,NA,NA,NA,NA
20043166,NA,245,thrombocytopenia with bleeding,>=3,NA,NA,NA
20043166,NA,245,thrombocytopenia,>=3,>=7 days,NA,NA
17569044,NA,246,neutropenia,4,>=7 days,NA,NA
17569044,NA,246,Febrile neutropenia,NA,NA,NA,"single elevation in oral temperature to 38.5Â°C or three elevations to >38Â°C during a
24-h period concomitant with grade 4 neutropenia"
17569044,NA,246,Neutropenic infection,NA,NA,NA,deWned as grade 3 or 4 infection concomitant with grade >= 3 neutropenia
17569044,NA,246,thrombocytopenia,3,NA,NA,NA
17569044,NA,246,non-haematological toxicity,>=3,NA,NA,"alopecia, asthenia, inadequately treated nausea,
vomiting or diarrhea"
17569044,NA,246,Cancellation of oral vinorelbine administration on day 15 of cycle 1 or delay of 1 week or more in the day 1 treatment of cycle 2 due to haematological reason,NA,NA,NA,NA
16683205,NA,247,neutropenia,4,>=5 days,NA,NA
16683205,NA,247,neutropenia associated with fever,4,NA,NA,NA
16683205,NA,247,thrombocytopenia or anemia,4,NA,NA,NA
16683205,NA,247,thrombocytopenia associatedwith grade â‰¥1 hemorrhage,3,NA,NA,NA
16683205,NA,247,"coagulation defect defined by grade 4 PT/aPTT elevation associated with either grade â‰¥2 thrombocytopenia, and/or grade â‰¥1 hemorrhage",4,NA,NA,NA
16683205,NA,247,nausea and/or vomiting on maximal antiemetic therapy,4,NA,NA,NA
16683205,NA,247,non-hematologic toxicity,>=3,NA,NA,NA
16619558,NA,248,leukopenia,4,NA,NA,NA
16619558,NA,248,neutropenia,4,NA,NA,NA
16619558,NA,248,thrombocytopenia,4,NA,NA,NA
16619558,NA,248,non-hematological toxicity,3,NA,FALSE,NA
16683073,NA,249,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16683073,NA,249,Nausea and vomiting despite optimal anti-emetic therapy,3 or 4,NA,NA,NA
16683073,NA,249,thrombocytopenia,4,NA,NA,NA
16683073,NA,249,neutropenia complicated by either fever or treatment delay of more than 1 week,4,NA,NA,NA
15277270,NA,250,toxicity,3,>=2 weeks,NA,NA
15277270,NA,250,non-hematologic toxicity,4,NA,NA,NA
15277270,NA,250,transaminase or alkaline phosphatase (ALP) elevation,3 or 4,NA,NA,NA
15277270,NA,250,abnormality of hepatic toxicity,2,>1 week,NA,NA
15277270,NA,250,neutropenia,3 or 4,NA,NA,NA
15277270,NA,250,thrombocytopenia,<3,>2 weeks,NA,NA
17009034,NA,251,hematological toxicity,4,>= 3 days,NA,NA
17009034,NA,251,hematological toxicity accompanied with fever (>38Â°C),3,NA,NA,NA
17009034,NA,251,non-hematological toxicity,3,NA,FALSE,NA
15494635,NA,252,any toxicity causing a more than a 2-week delay in the administration of the next treatment course,NA,NA,NA,NA
15494635,NA,252,hematological toxicity,4,NA,NA,NA
15494635,NA,252,non-hematological toxicity,3 or 4,NA,FALSE,NA
17357187,NA,253,neutropenia,4,>7 days,NA,NA
17357187,NA,253,any episode of febrile â‰¥ grade 3 neutropenia,NA,NA,NA,NA
17357187,NA,253,thrombocytopenia,4,NA,NA,NA
17357187,NA,253,any non-hematologic toxicity,3 or 4,NA,FALSE,NA
17180514,NA,254,neutropenia,4,>=3 days,NA,NA
17180514,NA,254,febrile neutropenia,3,NA,NA,NA
17180514,NA,254,thrombocytopenia or anemia,4,NA,NA,NA
17180514,NA,254,renal toxicity,2,NA,NA,NA
17180514,NA,254,non-hematologic toxicity,3 or 4,NA,FALSE,NA
17180514,NA,254,delay of more than 14 days in carrying out any treatment or in initiating the second cycle of therapy and discontinuation of this protocol treatment due to hematologic adverse effects,NA,NA,NA,NA
16162980,NA,255,febrile neutropenia,NA,NA,NA,grade 4 neutropenia with a body temperature > 38.5C
16162980,NA,255,thrombocytopenia,4,NA,NA,NA
16162980,NA,255,non-hematologic toxicity,3 or 4,NA,FALSE,NA
15519516,NA,256,febrile neutropenia,NA,NA,NA,NA
15519516,NA,256,thrombocytopenia,4,NA,NA,NA
15519516,NA,256,non-haematological toxicity,3 or 4,NA,FALSE,NA
15140550,NA,257,neutropenia,4,>5 days,NA,NA
15140550,NA,257,thrombocytopenia,4,>5 days,NA,NA
15140550,NA,257,any febrile (>38.5 â—¦C) neutropenia,NA,NA,NA,NA
15140550,NA,257,non-hematologic toxicity,3 or 4,NA,FALSE,NA
15140550,NA,257,any treatment delay on days 8 and/or 15 due to unresolved toxicity,NA,NA,NA,NA
15509491,NA,258,leucocytopenia,4,>=5 days,NA,NA
15509491,NA,258,neutropenia,4,>=5 days,NA,NA
15509491,NA,258,neutropenia with fever of 38 C or above,4,NA,NA,NA
15509491,NA,258,thrombocytopenia,4,NA,NA,NA
15509491,NA,258,non-hematologic toxicity,3 or 4,NA,FALSE,NA
15809878,NA,259,non-hematological toxicity,3 or 4,NA,FALSE,NA
15809878,NA,259,thrombocytopenia,4,NA,NA,NA
15809878,NA,259,neutropenia,4,>5 days,NA,NA
15809878,NA,259,neutropenia associated with fever,4,NA,NA,NA
16379039,NA,260,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16379039,NA,260,thrombocytopenia,4,NA,NA,NA
16379039,NA,260,neutropenia,4,>7 days,NA,NA
16379039,NA,260,neutropenia  associated with fever,4,NA,NA,NA
16042786,NA,261,febrile neutropenia,NA,NA,NA,NA
16042786,NA,261,toxicity of any other kind,3 or 4,NA,FALSE,NA
16969706,NA,262,hematologic toxicity,4,NA,NA,NA
16969706,NA,262,non-hematologic toxicity,3,NA,NA,NA
15274365,NA,264,neutropenia,4,NA,NA,NA
15274365,NA,264,thrombocytopenia,4,NA,NA,NA
15274365,NA,264,nonhematological toxicity,3,NA,FALSE,NA
16525670,NA,265,leukopenia despite the use of granulocyte-colony stimulating factor (G-CSF),4,>3 days,NA,NA
16525670,NA,265,neutropenia despite the use of granulocyte-colony stimulating factor (G-CSF),4,>3 days,NA,NA
16525670,NA,265,neutropenia with a fever of >38ËšC despite the use of G-CSF,3,>3 days,NA,NA
16525670,NA,265,thrombocytopenia,4,NA,NA,NA
16525670,NA,265,thrombocytopenia with bleeding tendency,3,NA,NA,NA
16525670,NA,265,non-hematological toxicity,3 or 4,NA,FALSE,NA
16127289,NA,267,neutropenia,4,>5 days,NA,NA
16127289,NA,267,thrombocytopenia,4,>5 days,NA,NA
16127289,NA,267,any febrile ( > 38.5 Â° C) neutropenia,NA,NA,NA,NA
16127289,NA,267,non-hematologic toxicity,3 or 4,NA,FALSE,NA
16127289,NA,267,any treatment delay on days 8 and/or 15 during the fi rst cycle due to unresolved tox icity,NA,NA,NA,NA
15221599,NA,268,thrombocytopenia,4,NA,NA,NA
15221599,NA,268,nephrotoxicity,2,NA,NA,NA
15221599,NA,268,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16809732,NA,269,plasma docetaxel values greater than 10 ng/mL,NA,NA,NA,NA
16809732,NA,269,systemic toxicity,>=2,NA,NA,NA
16809732,NA,269,hematuria,3 or 4,NA,NA,NA
16809732,NA,269,dysuria,3 or 4,NA,NA,NA
16809732,NA,269,urinary retention,3 or 4,NA,NA,NA
16809732,NA,269,urinary frequency/urgency,3 or 4,NA,NA,NA
16809732,NA,269,bladderspasm,3 or 4,NA,NA,NA
16809732,NA,269,missed more than one dose of docetaxel,NA,NA,NA,NA
15849219,NA,270,neutropenia,4,>7 days,NA,NA
15849219,NA,270,febrile neutropenia,NA,NA,NA,NA
15849219,NA,270,non-hematologic toxicity,4,NA,NA,NA
15849219,NA,270,mucositis or stomatitis,3,>3 days,NA,NA
15849219,NA,270,non-hematologic toxicity that did not revert to grade 1 or less within 35 days.,3,NA,NA,NA
15143084,NA,271,nonhematologic toxicity (including neurotoxicity),3 or 4,NA,NA,NA
15143084,NA,271,hematologic toxicity,4,>7 days,NA,NA
16773074,NA,272,neutropenia,4,>= 5 days,NA,NA
16773074,NA,272,neutropenia with fever (> 38.5C),4,NA,NA,NA
16773074,NA,272,thrombocytopenia,4,NA,NA,NA
16773074,NA,272,nonhaematological toxicities,3 or 4,NA,FALSE,NA
16773074,NA,272,haematological toxicity during S-1 administration,4,NA,NA,NA
16943532,NA,273,mucositis,3 or 4,6 weeks or more from the completion of therapy,NA,NA
16791410,NA,274,neutropenia,4,>7 days,NA,NA
16791410,NA,274,neutropenia complicated by fever â‰¥38.5â—¦C,4,NA,NA,NA
16791410,NA,274,neutropenia complicated by infection,4,NA,NA,NA
16791410,NA,274,thrombocytopenia,4,NA,NA,NA
16791410,NA,274,non-hematologic toxicity,3 or 4,NA,NA,NA
16416334,NA,275,leukopenia,4,>=3 days,NA,NA
16416334,NA,275,neutropenia,4,>=3 days,NA,NA
16416334,NA,275,"a platelet count of <= 20,000/mm3",NA,NA,NA,NA
16416334,NA,275,febrile neutropenia,NA,NA,NA,NA
16416334,NA,275,nonhematologic toxicities,3 or 4,NA,FALSE,NA
16416334,NA,275,Suspension of docetaxel and cisplatin two or more times,NA,NA,NA,NA
16565832,NA,276,anemia,>=3,NA,NA,NA
16565832,NA,276,thrombocytopenia,4,>=3 days,NA,NA
16565832,NA,276,neutropenia,4,>=3 days,NA,NA
16565832,NA,276,febrile neutropenia,4,>=3 days,NA,NA
16565832,NA,276,radiation esophagitis,>=3,NA,NA,NA
16565832,NA,276,"nonhematologic toxicity, including renal, hepatic, neurologic, cardiac, skin, and pulmonary toxicity",>=3,NA,FALSE,NA
15838660,NA,277,neutropenia requiring intravenous antibiotics,4,NA,NA,NA
15838660,NA,277,thrombocytopenia,4,NA,NA,NA
15838660,NA,277,bleeding episodes requiring platelet transfusion,NA,NA,NA,NA
15838660,NA,277,fatigue,3,NA,NA,NA
15838660,NA,277,hypotension,3,NA,NA,NA
15838660,NA,277,weight gain/peripheral edema,3,NA,NA,NA
15838660,NA,277,cardiac toxicity,3,NA,NA,NA
15838660,NA,277,pulmonary toxicity,3,NA,NA,NA
15838660,NA,277,kidney/bladder toxicity,3,NA,NA,NA
15838660,NA,277,neurocortical or neurocerebellar,2,NA,NA,NA
15838660,NA,277,urine protein >3 g dL-1 24 h,NA,NA,NA,NA
15838660,NA,277,serumalbumin <2.0 g dL-1,NA,NA,NA,NA
15310776,NA,278,any toxicity that resulted in a delay of 1 week or more in the administration of either docetaxel or imatinib during the combination module of the study,NA,NA,NA,NA
15310776,NA,278,any toxicity that resulted in a dosereduction during the combination module of the study,NA,NA,NA,NA
15567941,NA,279,neutropenia,4,>= 7 days,NA,NA
15567941,NA,279,febrile neutropenia,NA,NA,NA,defined as absolute neutrophil count (ANC) <1000/mm3 with fever T>=38.5 C
15567941,NA,279,thrombocytopenia,3 or 4,NA,NA,NA
15567941,NA,279,non-hematological toxicity,>=3,NA,FALSE,NA
15581049,NA,280,neutropenia,4,>7 days,NA,NA
15581049,NA,280,febrile neutropenia,NA,NA,NA,NA
15581049,NA,280,thrombocytopenia,4,NA,NA,NA
15581049,NA,280,"nausea and vomiting, despite maximal antiemetic treatment;",4,NA,NA,NA
15581049,NA,280,"diarrhea, despite intensive loperamide therapy",4,NA,NA,NA
15581049,NA,280,other nonhematologic toxicity,>=3,NA,NA,NA
15581049,NA,280,failure to recover to grade 1 or lower toxicity by day 43,NA,NA,NA,NA
17327701,NA,281,non-hematologic toxicity,3 or 4,NA,NA,NA
16020963,NA,282,neutropenia,4,NA,NA,NA
16020963,NA,282,complicated (fever lasting > 3 days) neutropenia,3 or 4,NA,NA,NA
16020963,NA,282,thrombocytopenia,4,NA,NA,NA
16020963,NA,282,neurotoxicity,>=2,NA,NA,NA
16020963,NA,282,fluid retention or fatigue,3,NA,NA,NA
16020963,NA,282,infection,3,NA,NA,NA
16020963,NA,282,mucositis,3,NA,NA,NA
16020963,NA,282,any other toxicity,3 or 4,NA,FALSE,NA
15111343,NA,283,hematological toxicity with fever,4,NA,NA,"single oral temperature >38.5Â°C, or three elevations to 38Â°C during a 24-h period"
15111343,NA,283,toxicity,3,NA,NA,NA
15075667,NA,284,febrile neutropenia,NA,NA,NA,NA
15075667,NA,284,thrombocytopenia,4,NA,NA,NA
15075667,NA,284,non-hematologic toxicity,3 or 4,NA,NA,NA
12702535,NA,285,platelets <25 Ã— 109/l,NA,NA,NA,NA
12702535,NA,285,"prolonged febrile neutropenia, despite intravenous antibiotics",NA,â‰¥3 days,NA,grade 4 neutropenia with fever â‰¥38.5Â°C on one occasion or 38Â°C on three occasions during a 24-h period
12702535,NA,285,infection,3 or 4,NA,NA,NA
12702535,NA,285,failure to recover neutrophils â‰¥1.5 Ã— 109/l or platelets â‰¥100 Ã— 109/l by day 28,NA,NA,NA,NA
12702535,NA,285,Neurosensory DLT,>=2,NA,NA,NA
12702535,NA,285,nausea or diarrhoea despite adequate prophylaxis,3,NA,NA,NA
12702535,NA,285,vomiting despite adequate prophylaxis,4,NA,NA,NA
12702535,NA,285,Other non-haematological toxicity,>=3,NA,FALSE,NA
12901280,NA,286,myelosuppression (fever and neutropenia),3 or 4,NA,NA,NA
12901280,NA,286,diarrhea,3 or 4,NA,NA,NA
12381903,NA,287,neutropenia,4,>=7 days,NA,NA
12381903,NA,287,thrombocytopenia,4,>=7 days,NA,NA
12381903,NA,287,febrile neutropenia,NA,>48 h,NA,NA
12381903,NA,287,any non-hematological toxicities,>=3,NA,FALSE,NA
12381903,NA,287,any treatment delay for more than 1 week due to unresolved toxicities,NA,NA,NA,NA
12138236,NA,288,neutropenia,4,>7 days,NA,NA
12138236,NA,288,neutropenic fever,NA,NA,NA,NA
12138236,NA,288,thrombocytopenia requiring platelet transfusion,4,NA,NA,NA
12138236,NA,288,nonhematologic toxicity causing a delay of greater than 2 weeks in initiating the next cycle,3 or 4,NA,NA,NA
12138236,NA,288,inability to deliver all planned doses,NA,NA,NA,NA
14725740,NA,289,thrombocytopenia,>=3,NA,NA,NA
14725740,NA,289,anemia,>=3,NA,NA,NA
14725740,NA,289,neutropenia,4,NA,NA,NA
14725740,NA,289,febrile neutropenia requiring hospitalization,NA,NA,NA,NA
14725740,NA,289,"gastrointestinal toxicity,  despite maximal medical intervention or temporary suspension of dosing with docetaxel",>=3,NA,NA,NA
14725740,NA,289,"nonhematologic toxicity, including renal, hepatic, neurologic, cardiac, skin, and pulmonary toxicity",>=3,NA,FALSE,NA
14725740,NA,289,retreatment delay with docetaxel of > 7 days total due to toxicity,NA,NA,NA,NA
11857398,NA,290,neutropenia,4,>7 days,NA,NA
11857398,NA,290,any episode of febrile >= grade 3 neutropenia,NA,NA,NA,NA
11857398,NA,290,thrombocytopenia requiring platelet transfusions,4,NA,NA,NA
11857398,NA,290,any nonhematologic toxicity,3 or 4,NA,FALSE,NA
11551421,NA,291,neutropenia,4,>=5 days,NA,NA
11551421,NA,291,fever (>38Â°C) with grade 4 neutropenia,NA,NA,NA,NA
11551421,NA,291,leukopenia,4,NA,NA,NA
11551421,NA,291,thrombocytopenia,4,NA,NA,NA
11551421,NA,291,renal or central nervous system (CNS) toxicity,>=2,NA,NA,NA
11551421,NA,291,other non-hematologic toxicity,>=3,NA,FALSE,NA
12237916,NA,292,"acute radiation toxicity, which was defined as a treatment break > 14 days",NA,NA,NA,NA
14520528,NA,293,neutropenia,4,>=3 days,NA,NA
14520528,NA,293,neutropenia associated with fever of 38.0Â°C or more,3 or 4,NA,NA,NA
14520528,NA,293,thrombocytopenia,4,NA,NA,NA
14520528,NA,293,renal dysfunction,>=2,NA,NA,NA
14520528,NA,293,liver dysfunction,3 or 4,NA,NA,NA
14520528,NA,293,nonhematologic toxicity,3 or 4,NA,FALSE,NA
14520528,NA,293,delay of more than 14 days in initiating the second cycle of therapy because of not fulfilling the same organ function criteria as those at the initiation of treatment or because of persistent toxicity of grade 2 or higher,NA,NA,FALSE,NA
12581570,NA,294,"uncontrollable non-hematologic toxicity (neuropathy, fluid retention, asthenia, esophagitis)",3,NA,NA,NA
12581570,NA,294,neutropenia,4,>1 weeks,NA,NA
12581570,NA,294,thrombocytopenia,4,>1 weeks,NA,NA
14584067,NA,295,neutropenia associated with fever > 38.0 Â°C,3 or 4,NA,NA,NA
14584067,NA,295,neutropenia,4,>7 days,NA,NA
14584067,NA,295,thrombocytopenia,4,>7 days,NA,NA
14584067,NA,295,"nonhematologic toxicity, including refractory nausea/emesis, fatigue/weakness, diarrhea not responsive to treatment, and neuropathy",3 or 4,NA,NA,NA
14584067,NA,295,any toxicity resulting in a treatment delay > 3 weeks,NA,NA,NA,NA
14508124,NA,296,nonhematologic toxicity,3 or 4,NA,NA,NA
14508124,NA,296,hematologic toxicity,4,NA,NA,NA
11583191,NA,297,ANC < 500/ul,NA,>7 days,NA,NA
11583191,NA,297,ANC < 100/ul,NA,>3 days,NA,NA
11583191,NA,297,febrile neutropenia (ANC < 500/ul and fever > 38.5 Â°C (single evaluation) or fever > 38 Â°C in two evaluations lasting 12 hours each),NA,NA,NA,NA
11583191,NA,297,"PLT <25,000/ul",NA,>7 days,NA,NA
11583191,NA,297,"PLT <25,000/ul with bleeding requiring PLT transfusion",NA,NA,NA,NA
11583191,NA,297,infection,>=3,NA,NA,NA
11583191,NA,297,Nonhematological toxicity,3 or 4,NA,FALSE,NA
11583191,NA,297,vomiting,4,NA,NA,NA
11583191,NA,297,neurologic toxicity,>=2,NA,NA,NA
11583191,NA,297,Any other loxicity persisting on day 28 that did not allow the administration of chemotherapy,NA,NA,NA,NA
11598413,NA,298,hematologic toxicity,4,>7 days,NA,NA
11598413,NA,298,neutropenic fever,NA,NA,NA,NA
11598413,NA,298,any nonhematologic toxicity,>=3,NA,NA,NA
12665678,NA,299,nonhematologic toxicity probably or definitely related to docetaxel,>=3,NA,FALSE,NA
12665678,NA,299,nausea or vomiting despite maximal antiemetics,>=3,NA,NA,NA
12665678,NA,299,neutropenia,4,>4 days,NA,NA
12665678,NA,299,neutropenia accompanied by a single elevation in oral temperature > 38.5Â°C or three elevations > 38Â°C during a 24-h period,4,NA,NA,NA
12665678,NA,299,neutropenia or thrombocytopenia on d 1 of the next cycle,>=2,NA,NA,NA
12665678,NA,299,thrombocytopenia,4,NA,NA,NA
12665678,NA,299,SGOT or SGPT toxicity on d 1 of the next cycle,>=2,NA,NA,NA
12665678,NA,299,"persistent WBC, granulocyte, or platelet toxicity despite a 1-wk delay of the next treatment cycle",>=2,NA,NA,NA
12419756,NA,300,febrile neutropenia (grade 4 neutropenia with fever >38.5Â°C or >38Â°C on three separate occasions in a 24 h period),NA,NA,NA,NA
12419756,NA,300,neutropenia,4,>=7 days,NA,NA
12419756,NA,300,thrombocytopenia,4,NA,NA,NA
12419756,NA,300,nausea/ vomiting,4,NA,NA,NA
12419756,NA,300,sensory or motor neuropathy,2,NA,NA,NA
12419756,NA,300,nonhematological toxicity,3 or 4,NA,FALSE,NA
11561784,NA,301,myelosuppression,4,>= 1 week of the first treatment cycle,NA,NA
11561784,NA,301,myelosuppression,3 or 4,during the first 7 days of the first treatment cycle,NA,NA
11561784,NA,301,nonhematologic toxicities,>=3,within the first treatment cycle,NA,NA
12879480,NA,302,neutropenia,4,>7 days,NA,NA
12879480,NA,302,any episode of febrile neutropenia,NA,NA,NA,NA
12879480,NA,302,anemia that required transfusion therapy on more than two occasions in 7 days,4,NA,NA,NA
12879480,NA,302,thrombocytopenia,3 or 4,NA,NA,NA
12879480,NA,302,any toxicity that caused a delay of 14 days or longer (consecutive or cumulative) in treatment during the first cycle,NA,NA,NA,NA
12879480,NA,302,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11521794,NA,303,non-hematologic toxicity,3 or 4,NA,NA,NA
11521794,NA,303,neutropenia,4,>7 days,NA,NA
11521794,NA,303,no recovery (ANC < 1.5 I09/l) at day 21,NA,NA,NA,NA
11521794,NA,303,neutropenia with fever >= 38.5Â°C,3 or 4,>3 days,NA,NA
11521794,NA,303,infection,3 or 4,NA,NA,NA
11521794,NA,303,thrombocytopenia,4,NA,NA,NA
11521794,NA,303,no recovery (platelets >= 100 x 109/l) at day 21,NA,NA,NA,NA
11521794,NA,303,bleeding,3 or 4,NA,NA,NA
15139070,NA,304,febrile neutropenia (fever of 38.5 Â°C with an absolute neutrophil count [ANC] <= 1000/L),NA,NA,NA,NA
15139070,NA,304,neutropenia (ANC <= 500/L),4,>7 days,NA,NA
15139070,NA,304,thrombocytopenia,4,NA,NA,NA
15139070,NA,304,nonhematologic toxicity,3 or 4,NA,FALSE,NA
12736567,NA,305,leukopenia,4,>=3 days,NA,NA
12736567,NA,305,neutropenia,4,>=3 days,NA,NA
12736567,NA,305,infectious febrile grade 4 leukopenia or neutropenia,NA,NA,NA,NA
12736567,NA,305,adverse events or toxicities,>=3,NA,FALSE,NA
12373597,NA,306,febrile neutropenia,NA,NA,NA,NA
12373597,NA,306,neutropenia,4,>5 days,NA,NA
12373597,NA,306,thrombocytopenia,4,NA,NA,NA
12373597,NA,306,potentially life threatening toxicity,3,NA,NA,NA
11852999,NA,307,nonhematologic toxicity,>=3,NA,NA,NA
11852999,NA,307,"a platelet count of less than 20,000/mm3",NA,NA,NA,NA
11852999,NA,307,any platelet count resulting in bleeding,NA,NA,NA,NA
11852999,NA,307,"granulocytopenia with documented infection, sepsis, fever occurring during neutropenia (,500/mm3) and documented or strongly suspected to be bacterial inorigin, or failure to recover to an AGC of at least 1,000/mm3 by day 29",NA,NA,NA,NA
12140145,NA,308,ANC < 0.5 x 109 cells/l,NA,>5 days,NA,NA
12140145,NA,308,leukocyte count > 1.0 x 109 cells/l,NA,>5 days,NA,NA
12140145,NA,308,febrile neutropenia (fever > /38 C with ANC < 0.5x109 cells/l),NA,NA,NA,NA
12140145,NA,308,platelet count < 25x 109 cells/l,NA,NA,NA,NA
12140145,NA,308,diarrhea,>=3,NA,NA,NA
12140145,NA,308,and other non-hematologic toxicity,>=3,NA,FALSE,NA
11777624,NA,309,nonhematologic toxicity,>=3,NA,FALSE,NA
11777624,NA,309,vomiting despite the use of antiemetics,4,NA,NA,NA
11777624,NA,309,neutropenia,4,>4 days,NA,NA
11777624,NA,309,neutropenic fever requiring hospitalization,NA,NA,NA,NA
11777624,NA,309,thrombocytopenia,4,>4 days,NA,NA
11777624,NA,309,thrombocytopenia with either a bleeding tendency or that needed transfusion of platelets,NA,NA,NA,NA
12913084,NA,310,leukocytopenia,4,NA,NA,NA
12913084,NA,310,neutropenia,4,NA,NA,NA
12913084,NA,310,platelets <20 000,NA,>3 days,NA,NA
12913084,NA,310,any non-hematologic toxicity,>=3,NA,FALSE,NA
12913084,NA,310,nausea,4,NA,NA,NA
12913084,NA,310,vomiting,4,NA,NA,NA
12913084,NA,310,fatigue,4,NA,NA,NA
12913084,NA,310,mucositis,4,NA,NA,NA
12913084,NA,310,dysphasia,4,NA,NA,NA
12913084,NA,310,dermatitis,4,NA,NA,NA
12913084,NA,310,radiationor chemotherapy-induced toxicities resulting in a delay of radiotherapy of >8 days,3 or 4,NA,NA,NA
12913084,NA,310,chemotherapy-induced toxicities requiring two skips of chemotherapy,NA,NA,NA,NA
14977829,NA,311,nonhematological toxicity,3,NA,NA,NA
14977829,NA,311,hematological toxicity,4,NA,NA,NA
14735175,NA,312,mucositis that interrupts treatment for over 2 weeks,4,NA,NA,NA
14735175,NA,312,thrombocytopenia,4,NA,NA,NA
14735175,NA,312,nephrotoxicity,2,NA,NA,NA
14735175,NA,312,nonhaematologic toxicity,3 or 4,NA,FALSE,NA
14676112,NA,313,nonhematological toxicity,3 or 4,NA,NA,with grade 3 mucositis being an inability to eat or drink
14676112,NA,313,thrombocytopenia,4,NA,NA,NA
14676112,NA,313,neutropenia,4,>5 days,NA,NA
14676112,NA,313,neutropenia associated with fever,4,NA,NA,NA
12491518,NA,314,nonhematologic toxicity,>=3,NA,NA,NA
12491518,NA,314,neutropenia,4,>=7 days,NA,NA
12491518,NA,314,neutropenia associated with fever or infection,4,NA,NA,NA
12491518,NA,314,thrombocytopenia,4,NA,NA,NA
12491518,NA,314,toxicity,5,NA,NA,NA
11557122,NA,315,febrile neutropenia (fever > 38Â°C with grades 3â€“4 neutropenia),NA,NA,NA,NA
11557122,NA,315,neutropenia,4,>4 days,NA,NA
11557122,NA,315,thrombocytopenia,4,>4 days,NA,NA
11557122,NA,315,"non-recovery of neutrophils to neutrophil counts > 2Ã—103/ul, or platelet counts > 100Ã—103/ul by 28th day",NA,NA,NA,NA
11557122,NA,315,nephrotoxity,2,NA,NA,NA
11557122,NA,315,any other non-hematological toxicities,3,NA,FALSE,NA
12602908,NA,316,non hematological toxicity,3 or 4,NA,FALSE,NA
12602908,NA,316,febrile leukopenia,3 or 4,NA,NA,NA
12602908,NA,316,absolute neutrophil count â‰¤500 cells/ml,NA,>5 days,NA,NA
12602908,NA,316,thrombocytopenia,3 or 4,NA,NA,NA
12602908,NA,316,any persistent side-effect that caused treatment delay of 1 week in two of three patients enroled at a single dose level,>=2,NA,NA,NA
12698179,NA,317,neutropenia,4,>7 days,NA,NA
12698179,NA,317,febrile neutropenia,>=3,NA,NA,NA
12698179,NA,317,thrombocytopenia,4,NA,NA,NA
12698179,NA,317,nonhaematologic toxicity,3 or 4,NA,FALSE,NA
12942107,NA,318,haematologic toxicity,>=3,>=3 days,NA,NA
12942107,NA,318,radiation oesophagitis,>=3,NA,NA,NA
12942107,NA,318,nonhaematologic toxicities,>=3,NA,FALSE,NA
15122076,NA,319,non-hematologic toxicity not reversible to grade II or less within 96 hours,3,NA,NA,NA
15122076,NA,319,toxicity,4,NA,NA,NA
11943893,NA,320,absolute neutrophil count less than 200 cell/mm3,NA,>5 days,NA,NA
11943893,NA,320,"thrombocytopenia less than 20,000 cells/mm3",NA,>7 days,NA,NA
11943893,NA,320,mucositis after 5-FU dose reduction,4,NA,NA,NA
11943893,NA,320,neurotoxicity,>=3,NA,NA,NA
11943893,NA,320,other toxicity,>=4,NA,NA,NA
15108042,NA,321,leukopenia,4,>5 days,NA,NA
15108042,NA,321,neutropenia,4,>5 days,NA,NA
15108042,NA,321,"neutropenia with fever (temperature >= 38Â°C), even with granulocyte-colony-stimulating factor (G-CSF) rescue",4,NA,NA,NA
15108042,NA,321,platelet count less than 30000/mm3,NA,NA,NA,NA
15108042,NA,321,nonhematological toxicity,3 or 4,NA,FALSE,NA
12172503,NA,322,febrile neutropenia,NA,NA,NA,NA
12172503,NA,322,neutropenia,4,>7 days,NA,NA
12172503,NA,322,thrombocytopenia,4,NA,NA,NA
12172503,NA,322,neurosensory toxicity,>=3,NA,NA,NA
12172503,NA,322,neuromotor toxicity,>=3,NA,NA,NA
12172503,NA,322,renal toxicity,>=3,NA,NA,NA
12172503,NA,322,hepatic toxicity,>=3,NA,NA,NA
11810041,NA,323,hematologic toxicity,>3,NA,NA,NA
11810041,NA,323,"stomatitis, asthenia, diarrhea or organ-specific toxicity",>2,NA,FALSE,NA
11810041,NA,323,delay of chemotherapy lasting 11 week due to grade 2 or 3 WHO hematological toxicity detected for more than two consecutive recycle evaluations,NA,NA,NA,NA
14663635,NA,324,leukopenia,3 or 4,>3 days,NA,NA
14663635,NA,324,neutropenia,3 or 4,>3 days,NA,NA
14663635,NA,324,neutropenia accompanied by a fever,3 or 4,NA,NA,NA
14663635,NA,324,nephropathy,>=2,NA,NA,NA
14663635,NA,324,hepatic dysfunction,>=3,NA,NA,NA
14663635,NA,324,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25947565,NCT01624441,325,NA,NA,NA,NA,DLT not defined
25312684, NCT01337505,326,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25312684, NCT01337505,326,"platelet count <25,000 cells/mL",NA,>7 days,NA,NA
25312684, NCT01337505,326,neutrophil count <500 cells/mL,NA,>7 days,NA,NA
25312684, NCT01337505,326,"platelet count <25,000 cells/mL associated with a fever>38.5C",NA,NA,NA,NA
25312684, NCT01337505,326,neutrophil count <500 cells/mL associated with a fever>38.5C,NA,NA,NA,NA
24807889,NA,1,hematologic toxicity,4,NA,NA,NA
24807889,NA,1,nonhematologic toxicity,3 or 4,NA,FALSE,NA
24807889,NA,1,"uveitis or ocular toxicities of any grade, or death",NA,NA,NA,NA
24585045,NA,2,leukopenia,4,>4 days,NA,NA
24585045,NA,2,neutropenia,4,>4 days,NA,NA
24585045,NA,2,leukopenia or neutropenia accompanied by pyrexia of â‰¥38 Â°C,>=3,NA,NA,NA
24585045,NA,2,thrombocytopenia,>=4,NA,NA,NA
24585045,NA,2,thrombocytopenia requiring platelet transfusion,NA,NA,NA,NA
24585045,NA,2,nonhematological toxicity,>=3,NA,FALSE,NA
25958319,NA,3,thrombocytopenia,4,NA,NA,NA
25958319,NA,3,thrombocytopenia and associated with clinically significant bleeding,3,NA,NA,NA
25958319,NA,3,neutropenia,4,>7 days,NA,NA
25958319,NA,3,treatment related febrile neutropenia,NA,NA,NA,NA
25958319,NA,3,related toxicity of any grade leading to a treatment delay > 2 weeks,NA,NA,NA,NA
25958319,NA,3,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25958319,NA,3,any drug related death,NA,NA,NA,NA
21625179,NA,4,nonhematologic toxicity,3 or 4,NA,NA,NA
21625179,NA,4,febrile neutropenia,NA,NA,NA,NA
21625179,NA,4,neutropenia,4,>5 days,NA,NA
21625179,NA,4,thrombocytopenia,4,NA,NA,NA
21625179,NA,4,any requirement for platelet transfusion,NA,NA,NA,NA
21625179,NA,4,anemia,4,NA,NA,NA
21625179,NA,4,nonhematologic toxicity that does not improve by the start of cycle 2,>=2,NA,NA,NA
21625179,NA,4,an inability to start cycle 2 of the treatment within 2 weeks of the scheduled dosing date due to unresolved toxicity,NA,NA,NA,NA
25189481,NCT01100944,5,neutropenia despite prophylactic or therapeutic use of granulocyte colony-stimulating factor (G-CSF),4,>7 days,NA,NA
25189481,NCT01100944,5,febrile neutropenia,NA,NA,NA,absolute neutrophil count (ANC) less than 1000/mm3 and temperature more than 38.5Â°C or 100.4Â°F or life threatening sepsis
25189481,NCT01100944,5,thrombocytopenia,4,NA,NA,NA
25189481,NCT01100944,5,thrombocytopenia associated with bleeding,3,NA,NA,NA
25189481,NCT01100944,5,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25858498,NCT00789633,6,any drug-related death,NA,NA,NA,NA
25858498,NCT00789633,6,treatment-related non-hematologic toxicity,3 or 4,NA,FALSE,NA
25858498,NCT00789633,6,cardiac LV dysfunction resulting in discontinuation in treatment,NA,NA,NA,NA
25858498,NCT00789633,6,neutropenia,4,>7 days,NA,NA
25858498,NCT00789633,6,febrile neutropenia,3,NA,NA,NA
25858498,NCT00789633,6,thrombocytopenia,4,NA,NA,NA
25858498,NCT00789633,6,hematologic toxicity,4,NA,NA,NA
25858498,NCT00789633,6,any toxicity leading to â‰¥1 dose interruption or requiring dose reduction,NA,NA,NA,NA
25615852,NA,7,neutropenia,4,.=7 days,NA,NA
25615852,NA,7,febrile neutropenia,NA,NA,NA,NA
25615852,NA,7,thrombocytopenia,4,NA,NA,NA
25615852,NA,7,thrombocytopenia requiring for a platelet transfusion,NA,NA,NA,NA
25615852,NA,7,nausea and/or emesis in spite of the use of optimal antiemetic therapy,>=3,NA,NA,NA
25615852,NA,7,non-hematologic toxicity,3 or 4,NA,NA,NA
25615852,NA,7,inability to administer all of the planned treatment during cycle 1,NA,NA,NA,NA
24141374,NA,8,PNN nadir <0.5 Ã— 109/L,NA,>7 days,NA,NA
24141374,NA,8,PNN nadir <0.1 Ã— 109/L,NA,>3 days,NA,NA
24141374,NA,8,thrombopenia <25 Ã— 109/L,NA,NA,NA,NA
24141374,NA,8,febrile neutropenia,NA,NA,NA,NA
24141374,NA,8,haemorrhage requiring platelet transfusion,NA,NA,NA,NA
24141374,NA,8,non-haematological toxicities,3 or 4,NA,FALSE,NA
24141374,NA,8,"cutaneous toxicity (palmarâ€“plantar erythrodysesthesia, PPE)",4,NA,NA,NA
24141374,NA,8,other toxicities leading to more than two chemotherapy dose reductions or toxic death.,NA,NA,NA,NA
25536954,NCT01027910,9,prolongation of the QTc interval,3 or 4,NA,NA,NA
25536954,NCT01027910,9,vomiting not controlled by maximal supportive care measures,3 or 4,NA,NA,NA
25536954,NCT01027910,9,thrombocytopenia,3 or 4,>7 days,NA,NA
25536954,NCT01027910,9,thrombocytopenia associated with bleeding,3 or 4,NA,NA,NA
25536954,NCT01027910,9,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25536954,NCT01027910,9,thrombocytopenia,4,NA,NA,NA
25536954,NCT01027910,9,neutropenia on growth factors,4,>5 days,NA,NA
25536954,NCT01027910,9,any other toxicities that caused failure to restart PCI-24781 administration within 2 weeks of the first missed dose,NA,NA,NA,NA
20629034,NA,10,toxicities,4,NA,NA,NA
20629034,NA,10,neutropenia,3,NA,NA,NA
20629034,NA,10,the occurrence of neutropenic sepsis,NA,NA,NA,NA
20629034,NA,10,thrombocytopenia,3,NA,NA,NA
20629034,NA,10,toxicities that did not return back to grade 1-2 within 3 weeks,3,NA,FALSE,NA
25698442,NCT00710125,11,neutropenia with fever,4,NA,NA,NA
25698442,NCT00710125,11,neutropenia,4,>= 5 days,NA,NA
25698442,NCT00710125,11,thrombocytopenia,4,NA,NA,NA
25698442,NCT00710125,11,inability to start the next cycle after a 2-week delay,NA,NA,NA,NA
25698442,NCT00710125,11,vomiting with maximum supportive care,3 or 4,NA,NA,NA
25698442,NCT00710125,11,neurotoxicity,>=2,NA,NA,NA
25698442,NCT00710125,11,decrease in cardiac ejection fraction,>=2,NA,NA,NA
25698442,NCT00710125,11,cardiac rhythm or conduction abnormalities,>=3,NA,NA,NA
25698442,NCT00710125,11,any other toxicity,>=3,NA,FALSE,NA
25058346,NA,12,NA,NA,NA,NA,DLT not defined
22752217,NA,13,neutropenia,4,>5 days,NA,NA
22752217,NA,13,neutropenia with fever,3 or 4,NA,NA,NA
22752217,NA,13,thrombocytopenia,4,NA,NA,NA
22752217,NA,13,non-hematological toxicity,3,NA,FALSE,NA
22752217,NA,13,"a delay of more than 2 weeks following the time of planned treatment, resulting from toxicities",NA,NA,NA,NA
22178041,NA,14,thrombocytopenia,4,NA,NA,NA
22178041,NA,14,febrile neutropenia,NA,NA,NA,NA
22178041,NA,14,neutropenia without growth factor support,4,> 5 days,NA,NA
22178041,NA,14,Nonhematologic toxicity,3,NA,FALSE,NA
22178041,NA,14,20% Reduction in left ventricular ejection fraction,NA,NA,NA,NA
22178041,NA,14,Events clearly unrelated to ThermoDox as assessed by the principal investigator were not considered DLTs,NA,NA,NA,NA
26115930,NA,15,persistence of neutropenia,4,NA,NA,NA
26115930,NA,15,thrombocytopenia,3 or 4,NA,NA,NA
26115930,NA,15,thrombocytopenia or requiring platelet transfusions,NA,>7 days,NA,NA
26115930,NA,15,neurotoxicity,3,NA,NA,NA
26115930,NA,15,non-haematological toxicity,3 or 4,NA,FALSE,NA
20352294,NA,16,thrombocytopenia,4,NA,NA,NA
20352294,NA,16,thrombocytopenia associated with grade 2 bleeding,3,NA,NA,NA
20352294,NA,16,neutropenia,4,>7 days,NA,NA
20352294,NA,16,febrile neutropenia,NA,NA,NA,NA
20352294,NA,16,toxicities that did not resolve to grade 1 within 2 weeks,3 or 4,NA,FALSE,NA
20352294,NA,16,nonhematologic toxicities,4,NA,FALSE,NA
20405155,NA,17,hematological toxicity,4,>72 h,FALSE,NA
20405155,NA,17,fever and neutropenia,NA,NA,NA,NA
20405155,NA,17,"nonhematological toxicity thought to be possibly, probably, or definitely related to study treatment",3 or 4,NA,NA,NA
25278449,NCT01240629,18,neutropenia,3 or 4,> 7 days,NA,NA
25278449,NCT01240629,18,thrombocytopenia,4,NA,NA,NA
25278449,NCT01240629,18,thrombocytopenia,3,>7 days,NA,NA
25278449,NCT01240629,18,thrombocytopenia with hemorrhage,3,NA,NA,NA
25278449,NCT01240629,18,development of clinical congestive heart failure or reduction in LVEF to <50%,NA,NA,NA,NA
25278449,NCT01240629,18,evidence of pituitary dysfunction based on scheduled thyroid function tests or cosyntropin stimulation tests,NA,NA,NA,NA
25278449,NCT01240629,18,delay in treatment beyond 21 days,NA,NA,NA,NA
25278449,NCT01240629,18,nonhematologic toxicity,>=3,NA,FALSE,NA
23763920,NCT00271063,19,drug-related nonhematologic toxicity,>=3,NA,NA,NA
20495918,NA,21,absolute neutrophil count (ANC) less than 500/mm3,NA,>5 days,NA,NA
20495918,NA,21,"ANC less than 1,000/mm3 with fever greater than 38.5Â°C",NA,NA,NA,NA
20495918,NA,21,"platelet count less than 25,000/mm3",NA,NA,NA,NA
20495918,NA,21,diarrhea despite maximal loperamide support,3,NA,NA,NA
20495918,NA,21,receipt of less than 75% of the planned dose of all three drugs in a cycle,NA,NA,NA,NA
20495918,NA,21,nonhematologic toxicity,>=3,NA,NA,NA
17551496,NA,23,neutropaenia,4,NA,NA,NA
17551496,NA,23,thrombocytopaenia,4,NA,NA,NA
17551496,NA,23,febrile neutropaenia,NA,NA,NA,NA
17551496,NA,23,non-haematological toxicity,>=3,NA,FALSE,NA
17551496,NA,23,any treatment delay > 2 days due to unresolved haematological or non-haematological toxicity,NA,NA,NA,NA
17960381,NA,24,hematologic toxicity,4,>3 days,NA,NA
17960381,NA,24,neutropenia with fever >38.2Â°C,3 or 4,NA,NA,NA
17960381,NA,24,non-hematologic toxicity,3 or 4,NA,FALSE,NA
17960381,NA,24,any treatment delay in the first 4 weeks of treatment due to unresolved toxicity grade > 1,1,NA,NA,NA
17641537,NA,25,neutropenia,4,NA,NA,NA
17641537,NA,25,thrombocytopenia,4,NA,NA,NA
17641537,NA,25,neutropenia with a single temperature > 38.3 Â° C or a sustained temperature > 38 Â° C for more than 1 h,3 or 4,NA,NA,NA
17641537,NA,25,nonhematological toxicity,3 or 4,NA,NA,NA
17641537,NA,25,any treatment delay because of toxicity,NA,NA,NA,NA
16880787,NA,26,neutropenia,4,>7 days,NA,NA
16880787,NA,26,thrombocytopenia,4,>7 days,NA,NA
16880787,NA,26,leucopenia,4,>7 days,NA,NA
16880787,NA,26,>20% fall in the ejection fraction at day 21 compared with initial values,NA,NA,NA,NA
16880787,NA,26,Clinically relevant nonhaematological,3 or 4,NA,NA,NA
18497430,NA,27,an absolute neutrophil count <= 500/ul,NA,>5 days,NA,NA
18497430,NA,27,an absolute neutrophil count <= 500/ul withfever or sepsis,NA,NA,NA,NA
18497430,NA,27,platelet count <25 000/ul,NA,NA,NA,NA
18497430,NA,27,non-hematologic toxicity,3 or 4,NA,FALSE,NA
18497430,NA,27,a delay of therapy for >3 weeks,NA,NA,NA,NA
19082825,NA,28,adverse event thought to be related to TriapineÂ® or doxorubicin,>=3,NA,FALSE,NA
16126736,NA,29,neutropenia,4,NA,NA,NA
16126736,NA,29,neutropenia with fever,3,NA,NA,NA
16126736,NA,29,thrombocytopenia,3,NA,NA,NA
16126736,NA,29,mucositis,3,NA,NA,NA
16126736,NA,29,other toxicity,3 or 4,NA,FALSE,NA
17609947,NA,31,neutropenia,4,>7 days,NA,NA
17609947,NA,31,febrile neutropenia,NA,NA,NA,fever >38Â°C with grade 3 or grade 4 neutropenia
17609947,NA,31,thrombocytopenia,4,NA,NA,NA
17609947,NA,31,thrombocytopenia associated with bleeding disorders,3,NA,NA,NA
17609947,NA,31,non-hematological toxicity,3 or 4,NA,FALSE,NA
15466828,NA,32,leukopenia (<1000/m3 ),4,NA,NA,NA
15466828,NA,32,neutropenia (<500/m3),4,>=4 days,NA,NA
15466828,NA,32,fever (>=38C) and/or bacteremia during grade 3 leukopenia (<2000/m3) or neutropenia (<1000/m3),2,3 days,NA,NA
15466828,NA,32,thrombocytopenia (<25 000/m3),4,NA,NA,NA
15466828,NA,32,non-hematological toxicities,3 or 4,NA,FALSE,NA
17852117,NA,33,neutropenia,4,>7 days,NA,NA
17852117,NA,33,febrile neutropenia,NA,NA,NA,NA
17852117,NA,33,thrombocytopenia,4,NA,NA,NA
17852117,NA,33,anemia,4,NA,NA,NA
17852117,NA,33,nausea and vomiting despite maximal anti-emetic treatment,4,NA,NA,NA
17852117,NA,33,diarrhea in spite of intensive loperamide therapy,4,NA,NA,NA
17852117,NA,33,other non-hematological toxicity,>=3,NA,NA,NA
17852117,NA,33,other non-hematological toxicity failure to recover to Grade 1 or lower toxicity by Day 43,NA,NA,NA,NA
16107496,NA,34,neutropenia,4,>=4 days,NA,NA
16107496,NA,34,febrile neutropenia,NA,NA,NA,defined as absolute neutrophil count Â£1000/mm3 with fever (temperature of >= 38C)
16107496,NA,34,thrombocytopenia,3 or 4,NA,NA,NA
16107496,NA,34,non-hematological toxicity,3,NA,FALSE,NA
17045160,NA,35,neutropenia,4,>1 week,NA,NA
17045160,NA,35,neutropenia associated with fever >= 38.5 C requiring >48 h of intravenous antibiotic treatment.,4,NA,NA,NA
17045160,NA,35,thrombocytopenia associated with hemorrhage,4,NA,NA,NA
17045160,NA,35,Persistence of a nonhematologic toxicity at scheduled retreatment.,>=2,NA,FALSE,NA
17045160,NA,35,"gastrointestinal distress (diarrhea or constipation) or flu-like symptoms (fever, myalgia/arthralgia, and fatigue)",3 or 4,NA,NA,NA
17045160,NA,35,Other toxicities,3 or 4,NA,FALSE,NA
16980599,NA,36,hematologic toxicity,4,NA,NA,NA
16980599,NA,36,non-hematologic toxicity,>=3,NA,NA,NA
19182205,NCT00306813,37,hematologic toxicity,4,NA,NA,NA
19182205,NCT00306813,37,febrile neutropenia,NA,NA,NA,NA
19182205,NCT00306813,37,toxicity in any other organ system,3,NA,FALSE,NA
19182205,NCT00306813,37,a treatment delay of 2 weeks or more,NA,NA,NA,NA
19182205,NCT00306813,37,the inability to administer the full scheduled dose of RAD in cycle 1 due to toxicity,NA,NA,NA,NA
15675483,NA,38,limb reaction,4,NA,NA,NA
17095524,NA,39,nonhematological toxicity,>=3,NA,FALSE,NA
17095524,NA,39,febrile neutropenia,>=3,NA,NA,NA
17095524,NA,39,hematological toxicity,4,NA,FALSE,NA
16891112,NA,40,absolute neutrophil count (ANC) <0.5 x 109,NA,>7 days,NA,NA
16891112,NA,40,absolute neutrophil count (ANC) <0.5 x 109 + fever (=38.5 C),NA,3 days,NA,NA
16891112,NA,40,thrombocytopenia,4,NA,NA,NA
16891112,NA,40,toxicity,3 or 4,NA,FALSE,NA
16891112,NA,40,any toxicity requiring a 2-week delay,NA,NA,NA,NA
15477860,NA,41,neutropenia,4,>5 days,NA,NA
15477860,NA,41,neutropenia associated neutropenic fever of more than 38.5C,4,NA,NA,NA
15477860,NA,41,a platelet count of less than 25 000 ul-1,NA,NA,NA,NA
15477860,NA,41,nonhaematological toxicity,>=3,NA,FALSE,NA
20204368,NA,42,adverse event,3 or 4,NA,FALSE,NA
20204368,NA,42,hematologic toxicity,4,>5 consecutive days,NA,NA
20204368,NA,42,hematologic toxicity requiring transfusion or growth factor support,4,NA,NA,NA
20204368,NA,42,nausea/vomiting,4,>5 days,NA,NA
20204368,NA,42,"any other non-hematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome, or any severe life-threatening complication",3,NA,NA,NA
16377584,NA,43,any nonhematologic toxicity (with Grade 3 mucositis being an inability to eat or drink),>=3,NA,NA,NA
16377584,NA,43,thrombocytopenia,4,NA,NA,NA
16377584,NA,43,neutropenia,4,>7 days,NA,NA
16377584,NA,43,neutropenia associated with a fever,4,NA,NA,NA
18927308,NA,44,neutropenia despite G-CSF,4,>=7 days,NA,NA
18927308,NA,44,neutropenia with fever >= 38.5C,4,NA,NA,NA
18927308,NA,44,neutropenia associated with sepsis or documented infection,NA,NA,NA,NA
18927308,NA,44,delay in therapy >3 weeks due to drug-related adverse events,NA,NA,NA,NA
18927308,NA,44,"toxicity that was severe, unexpected, and deemed related to the combination",3 or 4,NA,FALSE,NA
17317836,NA,46,any hematologic toxicity,4,NA,NA,NA
17317836,NA,46,neutropenic fever,NA,NA,NA,NA
17317836,NA,46,any nonhematologic toxicity,3,NA,NA,NA
17317836,NA,46,radiographic evidence of interstitial disease with symptoms,2,NA,NA,NA
17317836,NA,46,resting SaO2 of <88% before the next dose,NA,NA,NA,NA
17317836,NA,46,decrease from baseline in diffusing capacity for carbon monoxide,NA,NA,NA,NA
17317836,NA,46,forced expiratory volume in 1s,NA,NA,NA,NA
17317836,NA,46,forced vital capacity >20% before the next dose,NA,NA,NA,NA
19582371,NA,47,neutropenia,4,>7 days,NA,NA
19582371,NA,47,neutropenic fever,NA,NA,NA,"defined as body temperature
above 38Â°C and absolute neutrophils<500Ã—10 9/L"
19582371,NA,47,thrombocytopenia,4,NA,NA,NA
19582371,NA,47,non hematological toxicity,3 or 4,NA,FALSE,NA
19582371,NA,47,any toxicity requiring a 2-week delay in the chemotherapy administration,NA,NA,NA,NA
15942626,NA,48,neutropenia,4,>7 days,NA,NA
15942626,NA,48,thrombocytopenia,4,>7 days,NA,NA
15942626,NA,48,a failure to recover the absolute neutrophil count (ANC) to >= 1000 cells ul-1 or the platelet count to >=75 000 cells ul-1 by day 21,NA,NA,NA,NA
15942626,NA,48,Any nonhaematologic toxicity,3 or 4,NA,FALSE,NA
15942626,NA,48,"cerebellar dysfunction, despite a prior 25% dose reduction in valspodar",3 or 4,NA,NA,NA
16891870,NA,49,neutropenia,4,>7 days,NA,NA
16891870,NA,49,febrile neutropenia,NA,NA,NA,NA
16891870,NA,49,thrombocytopenia,4,NA,NA,NA
16891870,NA,49,thrombocytopenia requiring platelet transfusion,3,NA,NA,NA
16891870,NA,49,nonhematological toxicity,3 or 4,NA,FALSE,NA
15528980,NA,50,Absolute granulocyte count <0.5 Ã— 109/L,NA,>=7 days,NA,NA
15528980,NA,50,platelet count <50 Ã— 109/L,NA,NA,NA,NA
15528980,NA,50,febrile neutropenia,NA,NA,NA,NA
15528980,NA,50,infection with neutropenia,>=3,NA,NA,NA
15528980,NA,50,thrombocytopenic bleeding requiring transfusion,NA,NA,NA,NA
15528980,NA,50,Congestive heart failure,NA,NA,NA,NA
15528980,NA,50,a fall in LVEF â‰¥20% or absolute value of <40%,NA,NA,NA,NA
15528980,NA,50,mucositis,>=3,NA,NA,NA
15528980,NA,50,major organ toxicity,3 or 4,NA,FALSE,NA
19997959,NA,51,any hematologic toxicity,4,>= 7 days,NA,NA
19997959,NA,51,non-hematologic toxicity,>=3,NA,FALSE,NA
19997959,NA,51,nausea or vomiting unresponsive to antiemetic therapy,>=3,NA,NA,NA
16755180,NA,52,neutropenia,4,>7 days,NA,NA
16755180,NA,52,febrile neutropenia,NA,NA,NA,NA
16755180,NA,52,thrombocytopenia,4,NA,NA,NA
16755180,NA,52,thrombocytopenia requiring platelet transfusions,3,NA,NA,NA
16755180,NA,52,nonhematological toxicity,3 or 4,NA,FALSE,NA
16755180,NA,52,mucocutaneous toxicity not recovering by day 35,2,NA,NA,NA
16755180,NA,52,cardiac toxicity,2,NA,NA,NA
18502128,NA,53,febrile neutropenia (absolute neutrophil count less than 500 /uL with fever >= 38 C),NA,NA,NA,NA
18502128,NA,53,prolonged neutropenia,NA,NA,NA,absolute neutrophil count less than 500 /uL for more than 5 days
18502128,NA,53,thrombocytopenia,4,NA,NA,"platelet nadir less than 25,000/uL"
18502128,NA,53,non-haematologic toxicity,4,NA,FALSE,NA
18502128,NA,53,non-haematologic toxicity,3,>3 weeks,FALSE,NA
18502128,NA,53,any treatment delays lasting beyond 3 weeks,NA,NA,NA,NA
16520906,NA,54,"neutropenia (ANC < 1,000/Âµl) and/or thrombocytopenia (PLT < 90,000/Âµl)",3,NA,NA,NA
16520906,NA,54,"any nonhematologic toxicity, such as abdominal pain/diarrhea (proctitis), dysuria/frequency (cystitis) not resolving to grade 1â€“2 within 2 days",>=3,NA,NA,NA
16520906,NA,54,asthenia/fatigue,2 or 3,NA,NA,NA
16520906,NA,54,any adverse event necessitating the interruption of CCRT for 1 week,NA,NA,NA,NA
18525299,NA,55,thrombocytopenia,3 or 4,NA,NA,NA
18525299,NA,55,neutropenia,4,NA,NA,NA
18525299,NA,55,nonhematologic toxicity,3 or 4,NA,NA,NA
16503137,NA,56,non-haematologic toxicity,3 or 4,NA,NA,NA
16503137,NA,56,ANC <1.0 x 109/l,NA,>7 days,NA,NA
16503137,NA,56,an episode of fever >38.5 Celsius with neutropenia,3 or 4,NA,NA,NA
16503137,NA,56,anaemia,4,NA,NA,NA
16503137,NA,56,thrombocytopenia,4,NA,NA,NA
16503137,NA,56,an ANC of <1.5 x 109/l on day 8 or day 15 (only for dose level 1) of cycle 1 leading to a delay in administering gemcitabine dosing beyond day 15,NA,NA,NA,NA
16503137,NA,56,a platelet count of <50 x 109 on day 8 or day 15 of cycle 1 leading to a delay in chemotherapy,NA,NA,NA,NA
16503137,NA,57,non-haematologic toxicity,3 or 4,NA,NA,NA
16503137,NA,57,ANC <1.0 x 109/l,NA,>7 days,NA,NA
16503137,NA,57,an episode of fever >38.5 Celsius with neutropenia,3 or 4,NA,NA,NA
16503137,NA,57,anaemia,4,NA,NA,NA
16503137,NA,57,thrombocytopenia,4,NA,NA,NA
16503137,NA,57,an ANC of <1.5 x 109/l on day 1 of cycle 2 leading to a delay of planned doxorubicin dosing,NA,NA,NA,NA
16503137,NA,57,bilirubin toxicity on day 1 of cycle 2,NA,NA,NA,NA
16503137,NA,57,clinically apparent congestive cardiac failure or a reduction in LVEF below the institutional lower limit of normal (50%),NA,NA,NA,NA
16503137,NA,57,a fall in LVEF of >15% in a patient whose baseline LVEF was >65%,NA,NA,NA,NA
15367419,NA,59,febrile neutropenia (fever >388C with grade 3 or 4 neutropenia),NA,NA,NA,NA
15367419,NA,59,neutropenia resulting in a treatment delay of >2 weeks,>=2,NA,NA,NA
15367419,NA,59,thrombocytopenia,4,NA,NA,NA
15367419,NA,59,thrombocytopenia associated with bleeding disorders,3,NA,NA,NA
15367419,NA,59,a relative decline of the LVEF by >20%,NA,NA,NA,NA
15367419,NA,59,non-hematological toxicity,3 or 4,NA,FALSE,NA
10942057,NA,60,febrile neutropenia,NA,NA,NA,NA
10942057,NA,60,neutropenia (ANC < 500/mm3),NA,>5 days,NA,NA
10850343,NA,61,NA,NA,NA,NA,DLT not defined
10870069,NA,62,nonhematologic toxicity,4,NA,FALSE,NA
10870069,NA,62,"renal, cardiac, or neurologic toxicity",3,NA,NA,NA
10870069,NA,62,other toxicity that had not reverted within 28 days,NA,NA,NA,NA
10870069,NA,62,failure of the ANC to reach 1000/uL,NA,NA,NA,NA
10870069,NA,62,"the platelet count to reach 75,000/uL by Day 28",NA,NA,NA,NA
10389912,NA,63,nonhematological toxicity,3,NA,NA,NA
10389912,NA,63,hematological toxicity,4,NA,NA,NA
10389912,NA,63,Neutropenia associated with fever,4,NA,NA,NA
10907958,NA,64,thrombocytopenia,4,NA,NA,NA
10907958,NA,64,febrile neutropenia (fever >38Â°C with neutrophils <1000/mmc),NA,NA,NA,NA
10907958,NA,64,non-hematological toxicity,3 or 4,NA,FALSE,NA
10907958,NA,64,neutropenia or thrombocytopenia persisting at day 35,NA,NA,NA,NA
10343189,NA,65,neutropenia,4,NA,NA,only for levels without filgrastim
10343189,NA,65,thrombocytopenia,4,NA,NA,NA
10343189,NA,65,"febrile neutropenia (fever >38Â°C with neutrophils <1,000/mm3)",NA,NA,NA,NA
10343189,NA,65,nonhematological toxicity,3 or 4,NA,FALSE,NA
10343189,NA,65,neutropenia or thrombocytopenia persisting at day 35,NA,NA,NA,NA
9887248,NA,66,nonhematologic toxicity,>=3,NA,FALSE,NA
9887248,NA,66,"a platelet count of < 20,000",NA,>5 days,NA,NA
9887248,NA,66,an absolute granulocyte count < 500,NA,>5 days,NA,NA
9887248,NA,66,febrile neutropenia,NA,NA,NA,NA
9887248,NA,66,if the next course of chemotherapy was delayed by more than 7 days,NA,NA,NA,NA
9815746,NA,67,"lack of recovery of blood counts (granulocyte count, >=1,500/u.l; platelet count, >=90,000/ul) by day 21, which subsequently resulted in a delay of the next cycle,",NA,NA,NA,NA
9815746,NA,67,granulocyte nadir of <500 cells/ul,NA,>5 days,NA,NA
9815746,NA,67,"a single platelet count <20,000/ul",NA,NA,NA,NA
9815746,NA,67,Nonhematological toxicity,3 or 4,NA,FALSE,NA
8909321,NA,69,NA,NA,NA,NA,DLT not defined
8909321,NA,70,NA,NA,NA,NA,DLT not defined
8909321,NA,71,NA,NA,NA,NA,DLT not defined
8909321,NA,72,NA,NA,NA,NA,DLT not defined10321510||73|Nonhematologic toxicity|3 or 4|||
10321510,NA,73,an absolute neutrophil count (ANC) <500/ul,NA,>5 days,NA,NA
10321510,NA,73,platelet count <25 000/ul,NA,>5 days,NA,NA
10321510,NA,73,subsequent chemotherapy was delayed for more than 7 days due to unresolved toxicities,NA,NA,NA,NA
10573115,NA,74,neutropenia,4,>7 days,NA,NA
10573115,NA,74,ANC count < 100/mm3,NA,>3 days,NA,NA
10573115,NA,74,febrile neutropenia,NA,NA,NA,NA
10573115,NA,74,thrombocytopenia,4,>4 days,NA,NA
10573115,NA,74,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11106111,NA,75,neutropenia,4,>= 3 days,NA,NA
11106111,NA,75,neutropenia accompanied by fever (> 38 Â°C),4,3 days,NA,NA
11106111,NA,75,thrombocytopenia,4,NA,NA,NA
11106111,NA,75,non-hematological toxicity,>=3,NA,FALSE,NA
9215819,NA,77,ANC less than 500/uL,NA,>7 days,NA,NA
9215819,NA,77,ANC less than 300/uL,NA,>3 days,NA,NA
9215819,NA,77,febrile neutropenia (ANC < 500/uL and fever > 38 C),NA,NA,NA,NA
9215819,NA,77,thrombocytopenia,4,NA,NA,NA
9215819,NA,77,"failure to recover to neutrophils greater than 1,500/uL and/or platelets greater than 100,000/uL by day 28",NA,NA,NA,NA
9215819,NA,77,nonhematologic toxicity,3,NA,FALSE,NA
9848577,NA,78,thrombocytopenia,4,NA,NA,NA
9848577,NA,78,thrombocytopenia associated with bleeding,NA,NA,NA,NA
9848577,NA,78,non-hematological toxicity,3,NA,FALSE,NA
9848577,NA,78,lack of recovery of neutrophils to â‰¤ WHO grade 1 and/or platelets to WHO grade 0 at day 28,NA,NA,NA,NA
9848577,NA,78,persistent non-hematological toxicity at scheduled retreatment,>=2,NA,FALSE,NA
10949988,NA,79,ANC <0.5 x 109 /l,NA,>7 days,NA,despite the administration of GCSF support
10949988,NA,79,ANC <0.3 x 109 /l,NA,>3 days,NA,despite the administration of GCSF support
10949988,NA,79,febrile neutropenia (ANC <0.5 x 109/l and fever >38Â°C),NA,NA,NA,NA
10949988,NA,79,thrombocytopenia requiring platelet transfusion,4,NA,NA,NA
10949988,NA,79,non-hematological toxicity requiring a longer than 7-day delay,3,NA,FALSE,NA
9193334,NA,80,NA,NA,NA,NA,DLT not defined
9150898,NA,81,adverse event,3 or 4,NA,FALSE,NA
9150898,NA,81,"persistent neutropenia (< 2,000/ÂµL)",NA,>7 days beyond the planned starting date for cycle 2,NA,NA
9150898,NA,81,ANC < 500/ÂµL,NA,>5 days,NA,NA
9150898,NA,81,"thrombocytopenia defined as failure to reach a platelet count of 100,000/ÂµL by day 21 of cycle 1",NA,NA,NA,NA
9150898,NA,81,"a platelet count â‰¤ 20,000/ÂµL in cycle 1",NA,NA,NA,NA
9402167,NA,82,"thrombocytopenia requiring platelet transfusion,",4,NA,NA,NA
9402167,NA,82,ANC <= 0.5 x 1O9/1,NA,>7 days,NA,NA
9402167,NA,82,ANC <= 0.1 x 1O9/1,NA,>3 days,NA,NA
9402167,NA,82,"episodes of febrile neutropenia (temperature >=38.5Â°C and ANC <=0.5 x 1O9/1 requiring i.v. antibiotics),",NA,NA,NA,NA
9402167,NA,82,mucositis,>=3,>7 days,NA,NA
9402167,NA,82,non-haematological toxicity,>=3,NA,FALSE,NA
10370782,NA,83,granulocytopenia,NA,NA,NA,"defined as fever suspectedof bacterial or fungal origin; documented infection or sepsis with a granulocyte count of <500/ul; a granulocyte  count of 3= 1500/ul by day 22. A platelet count of < 20,000/ul at any count of < 250/ul for >= 5 days; or failure to recover to a granulocyte count of >= 1500/ul by day 22. A platelet count of < 20,000/ul at any
time was also considered dose-limiting hematologic toxicity."
10370782,NA,83,toxicity,>=3,NA,FALSE,NA
11244325,NA,84,an ANC less than 500/ul,NA,>5 days,NA,NA
11244325,NA,84,febrile neutropenia,NA,NA,NA,NA
11244325,NA,84,"a platelet count less than 25,000/ul",NA,NA,NA,NA
11244325,NA,84,nonhematologic toxicity,>=3,NA,NA,NA
10509151,NA,86,persistent neutropenia (failure to reach an ANC > 2 x 109/l) despite protracted filgrastim therapy by day 36 from the previous cycle,NA,NA,NA,NA
10509151,NA,86,persistent thrombocytopenia (failure to reach platelets > 100 x 1O9/1) by day 36 from the previous cycle,NA,NA,NA,NA
10509151,NA,86,adverse eve,4,NA,TRUE,NA
9488597,NA,88,hematologic toxicity,3 or 4,NA,NA,NA
9488597,NA,88,non-hematologic toxicity,>=2,NA,NA,NA
10501914,NA,89,neutropenia,4,>=5 days,NA,NA
10501914,NA,89,neutropenia associated with >= 3 infection,4,NA,NA,NA
10501914,NA,89,thrombocytopenia,>=3,NA,NA,NA
10501914,NA,89,nonhematologic toxicity,>=3,NA,NA,NA
10501914,NA,89,neurotoxicity,>=2,NA,NA,NA
10673526,NA,90,thrombocytopenia,4,NA,NA,NA
10673526,NA,90,neutropenia,4,NA,NA,NA
10673526,NA,90,nonhematologic toxicity that fulfilled the following two conditions: (1) the toxicity was dose-related and not idiosyncratic; and (2) the toxicity lasted 2 or more weeks preventing rapid (14 day) repetition of the AG regimen,3 or 4,NA,NA,NA
9789611,NA,91,neutrophil count <=0.1 x 109/l,NA,>4 days,NA,NA
9789611,NA,91,platelet count <=25 x 109/l,NA,>4 days,NA,NA
9789611,NA,91,nonhematological toxicity,3 or 4,NA,FALSE,NA
9443614,NA,92,nadir granulocytes <= 0.5 x 109/l,NA,NA,NA,NA
9443614,NA,92,nadir platelet count <= 25 x 109/l,NA,>=5 days,NA,NA
9443614,NA,92,the development of septicemia or febrile neutropenia,NA,NA,NA,NA
9443614,NA,92,stomatitis,>=3,NA,NA,NA
9443614,NA,92,diarrhea,>=3,NA,NA,NA
9443614,NA,92,neuromotor,>=2,NA,NA,NA
9443614,NA,92,neurosensory,>=3,NA,NA,NA
10811502,NA,94,neutropenia,4,NA,NA,NA
10811502,NA,94,thrombocytopenia,4,NA,NA,NA
10811502,NA,94,febrile neutropenia,3,NA,NA,NA
10811502,NA,94,thrombocytopenia with bleeding,3,NA,NA,NA
10811502,NA,94,non-hematologic toxicity,3,NA,FALSE,NA
10811502,NA,94,> 2 week delay in chemotherapy recycling,NA,NA,NA,NA
11187897,NA,95,NA,NA,NA,NA,DLT not defined
10037175,NA,96,nonhematological toxicity,3 or 4,NA,NA,DLt not defined
10394119,NA,97,hematologic toxicity,4,NA,NA,NA
10394119,NA,97,nonhematologic toxicity,3,NA,FALSE,NA
11127949,NA,98,NA,NA,NA,NA,DLT not defined
9164225,NA,99,any toxicity that prevented recycling of treatment on day 15,NA,NA,NA,NA
9037361,NA,100,febrile neutropenia,4,NA,NA,NA
9037361,NA,100,mucositis,3 or 4,NA,NA,NA
10445421,NA,101,nonhematologic toxicity,3 or 4,NA,NA,NA
10445421,NA,101,infection either documented or presumed if the patient had persistent fever in the setting of granulocytopenia,NA,NA,NA,NA
29719113,NCT02171260,102,nonhematologic toxicities attributable to eribulin,3 or 4,NA,TRUE,NA
29719113,NCT02171260,102,neutropenia on day 8,4,NA,NA,NA
29719113,NCT02171260,102,"platelets < 75,000/mm3 on day 8",NA,NA,NA,NA
29719113,NCT02171260,102,"the toxicity did not resolve to an ANC â‰¥ 750/mm3 and platelets â‰¥ 75,000/mm3 by day 11",NA,NA,NA,NA
29719113,NCT02171260,102,thrombocytopenia  requiring a platelet transfusion on two separate days,NA,NA,NA,NA
29719113,NCT02171260,102,thrombocytopenia on two separate days,NA,NA,NA,NA
29719113,NCT02171260,102,neutropenia,4,>7 days,NA,NA
29719113,NCT02171260,102,myelosuppression that caused a delay of >14 days between treatment cycles,NA,NA,NA,NA
29719113,NCT02171260,102,A nonhematologic toxicity that caused a delay of â‰¥14 days between treatment cycles,NA,NA,NA,NA
29719113,NCT02171260,102,nonhematologic toxicity attributable to the study drug,>=2,NA,NA,For patients <12 months of age
34773474,NCT02206763,103,neutropenia,4,NA,NA,NA
34773474,NCT02206763,103,thrombocytopenia,4,NA,NA,NA
34773474,NCT02206763,103,nonhematologic toxicities,3,NA,FALSE,NA
34773474,NCT02206763,103,Treatment delays ofâ‰¥28 days due to a treatment-emergent AEs (TEAEs),NA,NA,NA,NA
6957420,NA,104,NA,NA,NA,NA,DLT not defined
26554651,NCT00410553,105,non-haematologic toxicity,3 or 4,NA,FALSE,NA
26554651,NCT00410553,105,haematologic toxicity,4,>7 days,NA,NA
26554651,NCT00410553,105,febrile neutropenia,NA,NA,NA,NA
26554651,NCT00410553,105,inability to deliver days 8 and/or 15 in a 28-day cycle (during cycle 1) or day 8 in a 21-day cycle (during cycle 1),NA,NA,NA,NA
26554651,NCT00410553,105,the inability to initiate study drugs on day 1 of cycle 2 for more than 2 weeks from the scheduled date due to drug-related AEs,NA,NA,NA,NA
25654665,"UMIN-CTR, UMIN 000009716",106,non-haematological toxicity,3 or 4,NA,FALSE,NA
25654665,"UMIN-CTR, UMIN 000009716",106,platelet count <25 000 cells per ul,NA,NA,NA,NA
25654665,"UMIN-CTR, UMIN 000009716",106,platelet count <50 000 cells per ul accompanied by bleeding requiring blood transfusion,NA,NA,NA,NA
25654665,"UMIN-CTR, UMIN 000009716",106,neutropenia (absolute neutrophil count < 500 cells per ul for >7 days),NA,NA,NA,NA
25654665,"UMIN-CTR, UMIN 000009716",106,"febrile neutropenia (absolute neutrophil count <500 cells per ul accompanied by a fever >=38.5 C (single evaluation), a fever > 38 C for >12 h and unable to have S-1 for more than 6 days in the first cycle due to any toxicity)",4,NA,NA,NA
19509177,NA,107,a nonhematologic toxicity,3,NA,FALSE,NA
19509177,NA,107,thrombocytopenia,4,NA,NA,NA
19509177,NA,107,thrombocytopenia accompanied by clinically significant bleeding,3,NA,NA,NA
19509177,NA,107,neutropenia not reversible to at least grade 3 within 5 d without the use of growth factors,4,NA,NA,NA
19509177,NA,107,febrile neutropenia,NA,NA,NA,NA
19509177,NA,107,neutropenia associated with bacteremia or sepsis,NA,NA,NA,NA
19509177,NA,107,a treatment delay >14 d after which the patient had not recovered from study-related toxicities,NA,NA,NA,NA
34468905,NCT02942095,108,non-hematologic toxicity,3 or 4,NA,NA,NA
34468905,NCT02942095,108,"hematologic toxicity, despite supportive care",4,>= 2 weeks,NA,NA
34468905,NCT02942095,108,"nausea, vomiting or diarrhea  despite maximum anti-nausea regimens",4,> 5 days,NA,NA
12477447,NA,109,hematologic toxicities,3 or 4,NA,NA,NA
12477447,NA,109,nonhematologic toxicities,3 or 4,NA,NA,NA
30703739,UMIN00009498,110,Neutropenia,4,NA,NA,NA
30703739,UMIN00009498,110,Thrombocytopenia,4,NA,NA,NA
30703739,UMIN00009498,110,Febrile neutropenia,NA,NA,NA,NA
30703739,UMIN00009498,110,Non-hematotoxicity,3 or 4,NA,FALSE,NA
30703739,UMIN00009498,110,Administration of eribulin deferred on day 8 or 15,NA,NA,NA,NA
30703739,UMIN00009498,110,Onset of cycle 2 delayed for over 14 days 1) Cycle 2 cannot be started before day 36 if eribulin is administered on days 1 and 8 2) Cycle 2 cannot be started before day 43 if eribulin is administered on days 1 and 15,NA,NA,NA,NA
30703739,UMIN00009498,110,Other AEs determined by the principal investigator and coordinating investigator to constitute DLT (including trial-related deaths),NA,NA,NA,NA
26943987,EudraCT number: 2014-000135-17,111,NA,NA,NA,NA,Not defined
3367191,NA,113,NA,NA,NA,NA,Not defined
32943461,NCT02207504,114,neutropenia,4,>7 days,NA,NA
32943461,NCT02207504,114,neutropenic fever,3 or 4,NA,NA,NA
32943461,NCT02207504,114,thrombocytopenia,4,NA,NA,NA
32943461,NCT02207504,114,nonâ€hematologic toxicities despite optimal prophylaxis and/or treatment including toxicities which affect patient safety and require a dose reduction per protocol,>=3,NA,FALSE,NA
32943461,NCT02207504,114,Asymptomatic pancreatic enzyme elevations,3,>7 days,NA,NA
32943461,NCT02207504,114,Electrolyte or glucose alterations that cannot be corrected within 48 hours,NA,NA,NA,NA
32943461,NCT02207504,114,"fatigue, nausea, vomiting, or diarrhea despite optimal medical management",3,>48 hours,NA,NA
32943461,NCT02207504,114,hypertension (SBP â‰¥160 and/or DBP â‰¥100)) that is sustained at multiple visits despite at least one medication adjustment and confirmed at least 5 minutes apart on 3 occasions after patient has rested for 30 minutes.,3,NA,NA,NA
32943461,NCT02207504,114,Any seizure,NA,NA,NA,NA
32943461,NCT02207504,114,Any toxicity deemed by the investigators to represent a clinically significant hazard to the patient,NA,NA,NA,NA
32943461,NCT02207504,114,"toxicities related to study treatment, which result in dose holds >4 days and if the patient cannot tolerate a reâ€challenge at that dose level",2,NA,NA,NA
21887501,NCT00326950,115,neutropenia,4,>5 days,NA,NA
21887501,NCT00326950,115,neutropenia requiring i.v. antibiotic therapy,>=3,NA,NA,NA
21887501,NCT00326950,115,febrile neutropenia,NA,NA,NA,NA
21887501,NCT00326950,115,thrombocytopenia,4,NA,NA,NA
21887501,NCT00326950,115,non-hematologic toxicity,>=3,NA,FALSE,NA
21887501,NCT00326950,115,"omission of the Day 8 dose within a cycle due to the occurrence of â‰¥ grade 3 neutropenia defined as <1,000/mm3, â‰¥ grade 3 thrombocytopenia defined as <50,000/mm3, or investigator decision to skip the administration",NA,NA,TRUE,NA
33926914,NCT03386942,116,febrile neutropenia,NA,NA,NA,NA
33926914,NCT03386942,116,neutropenia,4,>7 days,NA,NA
33926914,NCT03386942,116,neutropenia requiring administration of hematopoieticstimulating agents,NA,NA,NA,NA
33926914,NCT03386942,116,thrombocytopenia,4,NA,NA,NA
33926914,NCT03386942,116,thrombocytopenia that requires platelet transfusion,NA,NA,NA,NA
33926914,NCT03386942,116,anemia,4,NA,NA,NA
33926914,NCT03386942,116,anemia requiring blood transfusion,NA,NA,NA,NA
33926914,NCT03386942,116,nonhematologic toxicities,3,NA,FALSE,NA
33926914,NCT03386942,116,nonhematologic toxicities,4,NA,NA,NA
33926914,NCT03386942,116,and adverse events in which the second treatment with MORAb-202 required postponement by more than 14 days from the scheduled day,NA,NA,NA,NA
26362045,NA,117,Non-hematologic toxicity,3 or 4,NA,FALSE,NA
26362045,NA,117,thrombocytopenia,4,NA,NA,NA
26362045,NA,117,neutropenia not reversible to â‰¤ grade 3 within 120 h,4,NA,NA,NA
26362045,NA,117,febrile neutropenia,NA,NA,NA,NA
26362045,NA,117,neutropenia associated with bacteremia or sepsis,NA,NA,TRUE,NA
9402745,NA,118,hematological toxicity,4,NA,NA,NA
9402745,NA,118,febrile neutropenia,NA,NA,NA,NA
9402745,NA,118,hematological toxicity,3,NA,NA,NA
25242374,NCT01432886,119,neutropenia,4,>7 days,NA,NA
25242374,NCT01432886,119,febrile neutropenia,>=3,NA,NA,NA
25242374,NCT01432886,119,thrombocytopenia,4,NA,NA,NA
25242374,NCT01432886,119,thrombocytopenia requiring blood transfusion,3,NA,NA,NA
25242374,NCT01432886,119,non-hematologic toxicity,>=3,NA,FALSE,NA
25242374,NCT01432886,119,The 2nd eribulin mesylate administration per cycle was delayed and the study treatment could not be resumed from day 22 of cycle 1,NA,NA,NA,NA
30679780,NA,120,neutropenia,4,>5 days,NA,NA
30679780,NA,120,"neutropenia complicated by fever and/or infection (absolute neutrophil count [ANC] < 1.0 Ã— 109/L, fever â‰¥ 38.5 Â°C)",3 or 4,NA,NA,NA
30679780,NA,120,thrombocytopenia,4,NA,NA,NA
30679780,NA,120,thrombocytopenia complicated by bleeding and/or requiring platelet or blood transfusion,3,NA,NA,NA
30679780,NA,120,hypersensitivity reactions,3 or 4,NA,NA,NA
30679780,NA,120,symptomatic bronchospasm requiring parenteral medication(s) with or without urticaria,3 or 4,NA,NA,NA
30679780,NA,120,allergy-related oedema/angioedema,3 or 4,NA,NA,NA
30679780,NA,120,"other clinically significant nonhematologic toxicities considered related to the study drug, including peripheral neuropathy",3 or 4,NA,FALSE,NA
29468456,NCT01585870,121,hematologic toxicity,>=3,NA,TRUE,NA
29468456,NCT01585870,121,nausea,4,NA,NA,NA
29468456,NCT01585870,121,diarrhea,4,NA,NA,NA
29468456,NCT01585870,121,hypophosphatemia,4,NA,NA,NA
29468456,NCT01585870,121,nausea,3,>3 days,NA,NA
29468456,NCT01585870,121,any other non-hematologic toxicity,>=3,NA,FALSE,NA
31703728,NCT02120469.,122,febrile neutropenia,3,NA,NA,NA
31703728,NCT02120469.,122,neutropenia,3,>7 days,NA,NA
31703728,NCT02120469.,122,neutropenia,4,NA,NA,NA
31703728,NCT02120469.,122,thrombocytopenia,4,NA,NA,NA
31703728,NCT02120469.,122,any non-hematological toxicity,>=3,NA,NA,NA
31703728,NCT02120469.,122,controllable nausea and vomiting,3,NA,NA,NA
31703728,NCT02120469.,122,fatigue,3,<5 days,NA,NA
31703728,NCT02120469.,122,triglycerides < 1500 mg/dL which recovers in 1 week,NA,NA,NA,NA
31703728,NCT02120469.,122,lab abnormalities that are correctable to grade 2 or less with 24 h,3,NA,NA,NA
31703728,NCT02120469.,122,hyperglycemia that is controlled to grade 2,3,NA,NA,NA
31703728,NCT02120469.,122,treatment delays > 2 weeks as a result of unresolved toxicity during the first cycle of therapy,NA,NA,NA,NA
31703728,NCT02120469.,122,failure to complete at least 75% of planned dose of either drugs during cycle 1 due to toxicity,NA,NA,NA,NA
6590530,NA,124,NA,NA,NA,NA,DLT not defined
19509146,NA,125,neutropenia not reversible to grade 3 or less within 5 d without the use of growth factors,4,NA,NA,NA
19509146,NA,125,febrile neutropenia,NA,NA,NA,NA
19509146,NA,125,neutropenia associated with bacteremia or sepsis,NA,NA,NA,NA
19509146,NA,125,thrombocytopenia,4,NA,NA,NA
19509146,NA,125,thrombocytopenia accompanied by clinically significant bleeding,3,NA,NA,NA
19509146,NA,125,nonhematologic toxicity,>=3,NA,FALSE,NA
25349975,NA,126,treatment-related non-haematologic toxicity,>=3,NA,FALSE,NA
25349975,NA,126,thrombocytopenia,>=4,NA,NA,NA
25349975,NA,126,febrile neutropenia requiring hospitalisation,>=4,NA,NA,NA
25349975,NA,126,treatment delay of > 2 weeks as a result of unresolved toxicity during the first cycle of therapy,NA,NA,NA,NA
1963273,NA,127,toxicity,3 or 4,NA,FALSE,NA
6511241,NA,128,NA,NA,NA,NA,DLT not defined
15886476,NA,129,s any toxicity causing a > 2 week delay in the administration of the next treatment cycle,NA,NA,NA,NA
15886476,NA,129,any episode of febrile neutropenia (fever > 38 Â° C with grade 3 or 4 neutropenia),NA,NA,NA,NA
15886476,NA,129,neutropenia,4,> 7 days,NA,NA
15886476,NA,129,thrombocytopenia,4,NA,NA,NA
15886476,NA,129,thrombocytopenia associated with bleeding disorders,3,NA,NA,NA
15886476,NA,129,non-hematological toxicity,3 or 4,NA,FALSE,NA
24132922,NA,130,anemia,4,NA,NA,NA
24132922,NA,130,neutropenia,4,>7 days,NA,NA
24132922,NA,130,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
24132922,NA,130,thrombocytopenia,4,>5 days,NA,NA
24132922,NA,130,nonhematologic toxicity,3 or 4,NA,FALSE,NA
34036220,NCT01911507,131,neutropenia,>=3,NA,NA,NA
34036220,NCT01911507,131,thrombocytopenia,>=3,NA,NA,NA
34036220,NCT01911507,131,febrile neutropenia,>=3,NA,NA,NA
34036220,NCT01911507,131,Serum creatinine,>=3,NA,NA,NA
34036220,NCT01911507,131,Bilirubin,>=3,NA,NA,NA
34036220,NCT01911507,131,AST or ALT,>=3,NA,NA,NA
34036220,NCT01911507,131,AST/ALT elevation > 3 X ULN and bilirubin > 2 X ULN,NA,NA,NA,NA
34036220,NCT01911507,131,"Symptomatic serum amylase or lipase elevation, medical intervention required",NA,NA,NA,NA
34036220,NCT01911507,131,Any neurological abnormality or toxicity,>=2,NA,NA,NA
34036220,NCT01911507,131,Cardiac toxicity,>=3,NA,NA,NA
34036220,NCT01911507,131,Non-laboratory toxicity,>=3,NA,NA,NA
33235994,NA,132,hematologic toxicity,4,NA,NA,NA
33235994,NA,132,thrombocytopenia,3,>=7 days,NA,NA
33235994,NA,132,nonhematologic toxicity,3 or 4,NA,NA,"electrolyte imbalances, diarrhea, nausea, and vomiting
are only considered DLTs if they remain Grade 3 or 4 despite maximal medical therapy"
33235994,NA,132,"any intolerable Grade 2 nonhematological, or Grade 3 hematological toxicity requiring dose reduction during the first treatment cycle (28 days)",NA,NA,NA,NA
33235994,NA,132,and any toxicity resulting in a treatment delay of more than 1 week during the first treatment cycle (28 days),NA,NA,NA,NA
32548867,NCT02642913,133,NA,NA,NA,NA,not report
31822498,NCT02457910,135,rash or photosensitivity despite skin toxicity treatment including oral steroids and antihistamines,3,>7 days,NA,NA
31822498,NCT02457910,135,photosensitivity,>=4,NA,NA,NA
31822498,NCT02457910,135,hyperglycemia confirmed with a repeat FPG within 24 hours for >7 consecutive days despite oral antidiabetic treatment,3,NA,NA,NA
31822498,NCT02457910,135,hyperglycemia,4,NA,NA,NA
31822498,NCT02457910,135,hyperglycemia leading to diabetic keto-acidosis and hospitalization for i.v. insulin infusion,NA,NA,NA,NA
31822498,NCT02457910,135,diarrhea despite the use of optimal antidiarrheal therapy,>=3,>= 48 hours,NA,NA
31822498,NCT02457910,135,nausea/vomiting,>=3,>= 48 hours,NA,NA
31822498,NCT02457910,135,febrile neutropenia,>=3,NA,NA,NA
31822498,NCT02457910,135,ANC,3,>7 consecutive days,NA,NA
31822498,NCT02457910,135,ANC,4,NA,NA,NA
31822498,NCT02457910,135,platelet count and/or with signs of excessive bleeding,3,>7 consecutive days,NA,NA
31822498,NCT02457910,135,platelet count,4,NA,NA,NA
31822498,NCT02457910,135,"total bilirubin, if less normal-grade 1 at baseline",2,>7 consecutive days,NA,NA
31822498,NCT02457910,135,total bilirubin if grade 2 at baseline,>=3,NA,NA,NA
31822498,NCT02457910,135,AST or ALT in conjunction with blood bilirubin grade 2,>=2,NA,NA,NA
31822498,NCT02457910,135,AST or ALT,3,>7 consecutive days,NA,NA
31822498,NCT02457910,135,AST or ALT,4,NA,NA,NA
31822498,NCT02457910,135,serum alkaline phosphatase,4,NA,NA,NA
31822498,NCT02457910,135,serum lipase and/or serum amylase (asymptomatic),3,>7 consecutive days,NA,NA
31822498,NCT02457910,135,serum lipase and/or serum amylase (asymptomatic),4,NA,NA,NA
31822498,NCT02457910,135,ALT/AST of 3 ULN and concomitant bilirubin of >2  ULN with no other explanation other than study drug,NA,NA,NA,NA
31822498,NCT02457910,135,serum creatinine,>=3,NA,NA,NA
31822498,NCT02457910,135,fatigue,3,>7 consecutive days,NA,NA
31822498,NCT02457910,135,persistent hypertension requiring more than one drug or more intensive therapy than previously,3,NA,NA,NA
31822498,NCT02457910,135,cardiac toxicity,>=3,NA,NA,NA
31822498,NCT02457910,135,cardiac toxicity requires medical intervention,NA,NA,NA,NA
31822498,NCT02457910,135,"clinical signs of cardiac disease, such as unstable angina or myocardial infarction",NA,NA,NA,NA
31822498,NCT02457910,135,cardiac event that is symptomatic,NA,NA,NA,NA
31822498,NCT02457910,135,troponin,3,NA,NA,NA
31822498,NCT02457910,135,ECG QTc interval prolonged,>=3,NA,NA,NA
18465342,NA,136,NA,NA,NA,NA,DLT not defined
25985977,NCT01642251,138,thrombocytopenia,4,NA,NA,NA
25985977,NCT01642251,138,anemia,4,NA,NA,NA
25985977,NCT01642251,138,neutropenia,4,NA,NA,NA
25985977,NCT01642251,138,neutropenia with persistent fever (febrile neutropenia),3,>7 days,NA,NA
25985977,NCT01642251,138,fever and neutropenia (febrile neutropenia),4,NA,NA,NA
25985977,NCT01642251,138,non-hematologic toxicity that is not an expected toxicity of CE regimen,>=3,NA,FALSE,NA
25985977,NCT01642251,138,All hematologic toxicities must have resulted in a delay of more than 14 days in initiating cycle 2,NA,NA,NA,NA
29980894,NCT00858377,139,febrile neutropenia,NA,NA,NA,NA
29980894,NCT00858377,139,neutropenic infection,NA,NA,NA,NA
29980894,NCT00858377,139,neutropenia,4,NA,NA,NA
29980894,NCT00858377,139,thrombocytopenia,>=3,>7 days,NA,NA
29980894,NCT00858377,139,thrombocytopenia,4,NA,NA,NA
29980894,NCT00858377,139,"nausea, vomiting, or diarrhea despite treatment",>=3,NA,NA,NA
29980894,NCT00858377,139,fatigue,3,>7 days,NA,NA
29980894,NCT00858377,139,fatigue,4,NA,NA,NA
29980894,NCT00858377,139,any other nonhematologic toxicity,>=3,NA,FALSE,NA
19956953,NA,140,toxicity,3 or 4,NA,FALSE,the occurrence of any CTC grade 3 or 4 toxicity had to also represent at least a 2-grade increase from baseline
19956953,NA,140,AST and/or ALT,3,>=7 days,NA,NA
19956953,NA,140,AST and/or ALT,4,NA,NA,NA
23860642,NA,141,neutropenia,4,>=7 days,NA,NA
23860642,NA,141,neutropenia and fever,4,NA,NA,NA
23860642,NA,141,neutropenia with >=grade 3 infection,>=3,NA,NA,NA
23860642,NA,141,thromobytopenia associated with clinically significant bleeding,NA,NA,NA,NA
23860642,NA,141,thromobytopenia,4,NA,NA,NA
23860642,NA,141,any non-hematologic toxicity,>=3,NA,FALSE,NA
23860642,NA,141,"nausea, vomiting, or diarrhea not controlled by medical therapy",3 or 4,NA,NA,NA
23860642,NA,141,ileus or small bowel obstruction,>=3,NA,NA,NA
26376115,NCT01279096,142,pancytopenia with hypocellular bone marrow (< 5% cellularity),4,>=6 weeks,NA,NA
26376115,NCT01279096,142,"nausea, vomiting or diarrhoea if persistent despite optimal antiemetic or anti-diarrhoeal treatment",>=3,NA,NA,NA
26376115,NCT01279096,142,any other drug-related gastrointestinal toxicity,>=3,NA,NA,NA
26376115,NCT01279096,142,elevation of transaminases,>=3,>7 days,NA,NA
26376115,NCT01279096,142,Other toxicity,>=3,NA,NA,NA
17878176,NA,143,thrombocytopenia,4,NA,NA,NA
17878176,NA,143,neutropenia,3,>=4 days,NA,NA
17878176,NA,143,neutropenic fever,NA,NA,NA,NA
17878176,NA,143,diarrhea,3 or 4,NA,NA,NA
17878176,NA,143,gastrointestinal bleeding,3 or 4,NA,NA,NA
17878176,NA,143,any other toxicity,3 or 4,NA,TRUE,NA
17878176,NA,143,fatigue,4,>7 days,NA,NA
17878176,NA,143,Any toxicity-related treatment interruptions that resulted in a 2 week or greater delay in completing chemoradiation,NA,NA,NA,NA
29119643,NCT01681537,144,rash,4,NA,NA,NA
29119643,NCT01681537,144,neuropathy,4,NA,NA,NA
29119643,NCT01681537,144,"delayed neutrophil (ANC <500/mL) or platelet (platelet count <20,000/mL) recovery beyond Day 45 after the start of protocol therapy and in the absence of persistent AML",NA,NA,NA,NA
12544260,NA,145,neutropenia,4,>5 days,NA,NA
12544260,NA,145,febrile neutropenia,4,NA,NA,NA
12544260,NA,145,non-hematologic toxicity occurring in the first two cyles of treatment,3 or 4,NA,FALSE,NA
23370364,NCT00537511,146,inability to deliver all 3 doses of cisplatin and etoposide due to toxicity,NA,NA,NA,NA
23370364,NCT00537511,146,"inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: â‰¥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count [ANC] <1,000/ÂµL and fever >101ÂºF, core temperature)",NA,NA,NA,NA
23370364,NCT00537511,146,neutropenia with onset on or before Day 14 of pomalidomide dosing,4,>7 days,NA,NA
23370364,NCT00537511,146,"platelet count <25,000/ÂµL occurring before Day 14 of pomalidomide dosing",NA,NA,NA,NA
26920889,NCT01411267,147,"failure to recover a peripheral ANC > 500/mL and nontransfusionâ€“dependent platelet count > 20,000/mL due to documented bone marrow aplasia/hypoplasia (as opposed to malignant infiltration or other cause) for greater than or equal to 56 days, which is approximately 2 SDs greater than the average duration of neutropenia in the aforementioned cytarabine/etoposide regimens",NA,NA,NA,NA
26920889,NCT01411267,147,nonhematologic toxicities,3 or 4,NA,FALSE,NA
31876107,NCT01331135,148,neutropenia,4,>7 days,NA,NA
31876107,NCT01331135,148,"platelet count < 20 000/ ÂµL on two separate days, requiring a platelet transfusion on two separate days within a seven-day period",NA,NA,NA,NA
31876107,NCT01331135,148,myelosuppression that caused a delay of â‰¥ 14 days between cycles,NA,NA,NA,NA
31876107,NCT01331135,148,Nonhematological toxicity,3 or 4,NA,FALSE,NA
20150371,NA,149,thrombocytopenia,4,NA,NA,NA
20150371,NA,149,anemia,4,NA,NA,NA
20150371,NA,149,neutropenia,4,NA,NA,NA
20150371,NA,149,nonhematologic toxicity,3 or 4,NA,NA,NA
20150371,NA,149,failure to recover from toxicities within 2 weeks of the last dose of erlotinib treatment,NA,NA,NA,NA
20965266,NA,150,nonhematologic toxicity,3 or 4,that did not resolve to grade 2 or less by day +30 after transplantation,FALSE,NA
20965266,NA,150,NA,NA,NA,FALSE,NA
27565909,NCT01579929,151,NA,NA,NA,NA,DLT not defined
11391583,NA,152,NA,NA,NA,NA,Not defined
24368401,NCT00466466,153,nonhematologic event despite appropriate prophylactic treatment,3,NA,FALSE,NA
24368401,NCT00466466,153,nonhematologic event despite appropriate prophylactic treatment,4,NA,NA,NA
24368401,NCT00466466,153,thrombocytopenia,3,>7 days,NA,NA
24368401,NCT00466466,153,neutropenia,3 or 4,>7 days,NA,NA
24368401,NCT00466466,153,thrombocytopenia,4,NA,NA,NA
24368401,NCT00466466,153,Febrile neutropenia (defined as ANC < 1 Ã— 109/L and fever  â‰¥38.5Â°C),NA,NA,NA,NA
24368401,NCT00466466,153,pneumonitis,3,NA,NA,NA
24368401,NCT00466466,153,Any intolerable grade 2 event requiring dose reduction of everolimus,NA,NA,FALSE,NA
24368401,NCT00466466,153,Any adverse event resulting in a longer than 2-week interruption of or delay in any study treatment,NA,NA,NA,NA
20922800,NCT00569114,154,neutropenia,4,>5 days,NA,NA
20922800,NCT00569114,154,febrile neutropenia,3,NA,NA,NA
20922800,NCT00569114,154,thrombocytopenia,4,NA,NA,NA
20922800,NCT00569114,154,"nonhematologic toxicities, including diarrhea, nausea, or vomiting despite adequate treatment.",3 or 4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,infection,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,febrile neutropenia,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,bleeding,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,vomiting,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,infusion reaction,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,liver toxicities,>=4,NA,NA,NA
33230647,"UMIN-CTR (ID, 000015373)",155,other nonhematological toxicities,>=3,NA,FALSE,NA
33230647,"UMIN-CTR (ID, 000015373)",155,Prolonged severe myelosuppression (peripheral neutrophil counts<0.5Ã—109/L and platelet counts<20Ã—109/L) that persisted until 42 days from the start of chemotherapy,NA,NA,NA,NA
17440682,NA,156,thrombocytopeni,4,NA,NA,NA
17440682,NA,156,"thrombocytopenia associated with bleeding, requirement for transfusion",3,NA,NA,NA
17440682,NA,156,thrombocytopenia,3,>=7 days,NA,NA
17440682,NA,156,febrile neutropenia,NA,NA,NA,NA
17440682,NA,156,neutropenia,4,>=7 days,NA,NA
17440682,NA,156,anemia,4,NA,NA,NA
17440682,NA,156,peripheral neuropathy that did not resolve to grade 0 or 1 after holding treatment for a maximum of 3 weeks,>=2,NA,NA,NA
17440682,NA,156,cutaneous toxicity necessitating holding erlotinib for greater than 2 weeks,>=3,NA,NA,NA
17440682,NA,156,diarrhea that did not resolve after holding the drug for 2 weeks or that reoccurred despite adequate treatment with anti-diarrheal agents,>=3,NA,NA,NA
17440682,NA,156,any other non-hematologic toxicity considered by the investigator to be related to study drug,>=3,NA,NA,NA
28531881,NCT02094560,157,nonhaematological AEs,>=3,NA,NA,NA
28531881,NCT02094560,157,neutropenia,4,>7 days,NA,NA
28531881,NCT02094560,157,neutropenia complicated by fever,4,NA,NA,NA
28531881,NCT02094560,157,thrombocytopenia,4,NA,NA,NA
28531881,NCT02094560,157,"thrombocytopenia complicated by bleeding, which were considered to be drug related and occurred during the first cycle",NA,NA,NA,NA
29427728,NCT02028949,158,"AE (for haemoglobin level, neutrophil and platelet count)",4,NA,FALSE,NA
29427728,NCT02028949,158,hepatobiliary disorders,3,NA,FALSE,NA
29427728,NCT02028949,158,investigations,3,NA,FALSE,NA
29427728,NCT02028949,158,renal disorders,3,NA,NA,NA
29427728,NCT02028949,158,urinary disorders,3,NA,NA,NA
19164205,NA,160,"erlotinib-related, nonhematologic toxicity",>=3,NA,FALSE,NA
18794549,NA,161,thrombocytopenia,3 or 4,NA,NA,NA
18794549,NA,161,neutropenia,4,NA,NA,NA
18794549,NA,161,nonhematologic toxicity considered sufficiently severe to warrant treatment interruption,2,>7 days,NA,NA
18794549,NA,161,nonhematologic toxicity attributable to erlotinib,3 or 4,NA,FALSE,NA
19117350,NA,162,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19117350,NA,162,neutropenia,4,>7 days,NA,NA
19117350,NA,162,thrombocytopenia,4,>7 days,NA,NA
19117350,NA,162,Any persistent toxicity attributable to the chemotherapy that prevented the initiation of the second course within 28 days after the start of the first course,NA,NA,NA,NA
34543383,NCT02306291,163,myelosuppression (failure of recovery to absolute neutrophil count [ANC] >= 0.5 x 109/L and platelet count of >= 25 x 109/L) beyond day 42 in the absence of persistent morphologic evidence of leukemia in the marrow,NA,NA,NA,NA
34543383,NCT02306291,163,nonhematologic toxicity attributable to uproleselan and not resolving to grade 2 by day 42,3,NA,NA,NA
17255274,NA,164,neutropenia,4,>5 days,NA,NA
17255274,NA,164,"thrombocytopenia  (<= 25,000/mm3 thrombocytes or bleeding episodes requiring platelet transfusions",NA,NA,NA,NA
17255274,NA,164,febrile neutropenia,NA,NA,NA,NA
17255274,NA,164,any nonhematologic toxicity,>=3,NA,FALSE,NA
19147777,NA,165,thrombocytopenia,3 or 4,NA,NA,NA
19147777,NA,165,neutropenia,4,NA,NA,NA
19147777,NA,165,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17634483,NA,166,an increase in AST or alkaline phosphatase >= 2.5 x baseline,NA,NA,NA,"For cohorts 1, 1a, and 2"
17634483,NA,166,an increase in bilirubin >= 1.5 x baseline,NA,NA,NA,"For cohorts 1, 1a, and 2"
17634483,NA,166,an increase in creatinine >= 2 x ULN,NA,NA,NA,"For cohorts 1, 1a, and 2"
17634483,NA,166,elevations in AST or alkaline phosphatase >= 5 x ULN,NA,NA,NA,For cohorts 3 and 3a
17634483,NA,166,bilirubin >= 2.5 x ULN,NA,NA,NA,For cohorts 3 and 3a
17634483,NA,166,an increase in creatinine >= 2.5 x baseline,NA,NA,NA,For cohorts 3 and 3a
17634483,NA,166,Other nonhematologic toxicity,>=3,NA,NA,NA
17634483,NA,166,"nausea, vomiting, diarrhea, and anorexia despite optimal supportive care",>=3,NA,NA,NA
17634483,NA,166,neutropenia,4,NA,NA,NA
17634483,NA,166,thrombocytopenia,4,NA,NA,NA
22156765,NA,167,NA,4,NA,NA,NA
22156765,NA,167,neutropenia,4,>7 days,NA,NA
22156765,NA,167,neutropenic fever of 38.5C,NA,>24h,NA,NA
22156765,NA,167,sepsis,NA,NA,NA,NA
22156765,NA,167,thrombocytopenia,4,NA,NA,NA
22156765,NA,167,thrombocytopenia with bleeding that required transfusion,NA,NA,NA,NA
22156765,NA,167,nonhematologic toxicity,3 or 4,NA,FALSE,NA
23666235,NA,168,neutropenia,4,>7 days,NA,NA
23666235,NA,168,anemia or thrombocytopenia requiring transfusion on two occasions in 7 days,4,NA,NA,NA
23666235,NA,168,anemia or thrombocytopenia as a delay of 14 days between treatment cycles,4,NA,NA,NA
23666235,NA,168,nonhematologic toxicity,3 or 4,NA,FALSE,NA
20538454,NA,169,neutropaenia,4,>7 d,NA,NA
20538454,NA,169,anaemia or thrombocytopaenia requiring transfusion on two occasions in 7 d,4,NA,NA,NA
20538454,NA,169,anaemia or thrombocytopaenia as a delay of 14 d between treatment cycles,4,NA,NA,NA
20538454,NA,169,non-haematologic toxicity,3 or 4,NA,FALSE,NA
22028494,NA,170,NA,NA,NA,NA,DLT not defined
20209646,NA,171,"Any nonhematologic toxicity that was possibly, probably, or definitely attributable to valspodar",>=3,NA,FALSE,NA
20209646,NA,171,cerebellar ataxia,3,NA,NA,NA
16626884,NA,172,radiation dermatitis,>=4,NA,NA,NA
16626884,NA,172,neutropenia,>=4,NA,NA,NA
16626884,NA,172,diarrhea,>=3,NA,NA,NA
16626884,NA,172,rash/desquamation,>=3,NA,NA,NA
16626884,NA,172,thrombocytopenia,>=3,NA,NA,NA
16626884,NA,172,nonhematologic toxicity,>=3,NA,NA,NA
16626884,NA,172,"severe acute central nervous system deterioration attributable to radiation or erlotinib, which cannot be controlled with corticosteroid administration",NA,NA,NA,NA
23445779,NA,173,All toxicities,3 or 4,NA,FALSE,NA
19495755,NA,174,"drugrelated non-hematologic toxicity such as nausea, vomiting, or diarrhea in the absence of optimal preventive and supportive measures",3 or 4,NA,NA,NA
19495755,NA,174,drug-related hematologic toxicity,4,NA,NA,NA
25316653,NCT00667615,175,NA,NA,NA,NA,Not reported
23403629,NCT00357305,176,drug-related nonhematologic toxicity,>=4,NA,NA,NA
23403629,NCT00357305,176,drug-related nonhematologic toxicity,3,>24 hours,FALSE,NA
23403629,NCT00357305,176,diarrhea or mucositis during vorinostat treatment,3,NA,NA,NA
23403629,NCT00357305,176,diarrhea or mucositis during or following cytarabine/etoposide treatment was considered DLT only if resolution to <= grade 2 required more than 2 days,3,NA,NA,NA
23403629,NCT00357305,176,neurologic toxicity,>=3,NA,NA,NA
23403629,NCT00357305,176,myelosuppression for 42 or more days following the start of cytarabine and etoposide with a bone marrow cellularity of 5% or less and no evidence of leukemia,4,NA,NA,NA
12506184,NA,177,nonhematologic toxicity,3,NA,FALSE,NA
12506184,NA,177,nonhematologic toxicity,4,NA,NA,NA
12506184,NA,177,"platelet count less than 25,000/uL",NA,NA,NA,NA
12506184,NA,177,neutropenia (ANC < 500/uL),4,>5 days,NA,NA
12506184,NA,177,neutropenia (ANC < 500/uL) associated with fever ( >= 38.5Â°C),4,NA,NA,NA
12506184,NA,177,unresolved toxicity delaying retreatment more than 2 weeks,NA,NA,NA,NA
15661261,NA,178,pancytopenia,4,>42 days,NA,NA
15661261,NA,178,non-hematologic toxicity,>=3,NA,NA,NA
10867130,NA,179,nonhematologic toxicities,>=4,NA,FALSE,NA
9493138,NA,180,neutrophil count >500/ul,NA,>7 days,NA,NA
9493138,NA,180,neutrophil count >100/ul,NA,>3 days,NA,NA
9493138,NA,180,"febrile neutropenia (temperature >=38.5Â°C and neutrophil count >500/ul, requiring i.v. antibiotics and hospitalization)",NA,NA,NA,NA
9493138,NA,180,thrombocytopenia,4,NA,NA,NA
9493138,NA,180,mucositis,>=3,>7 days,NA,NA
9493138,NA,180,neurotoxicity,>=3,NA,NA,NA
9493138,NA,180,absence of recovery of neutrophils (>=1500/ul) and/or platelets (>=100 000/ul) at day 28,4,NA,NA,NA
11822756,NA,182,hematological toxicity,4,>5 days,NA,NA
11822756,NA,182,neutropenic fever,NA,NA,NA,NA
11822756,NA,182,any other toxicity,>=3,NA,FALSE,NA
8882988,NA,184,NA,NA,NA,NA,DLT not defined
10561292,NA,186,febrile neutropenia,NA,NA,NA,NA
10561292,NA,186,thrombocytopenia,4,NA,NA,NA
10561292,NA,186,bleeding,NA,NA,NA,NA
10561292,NA,186,other nonhematologic toxicity,3 or 4,NA,NA,NA
9445186,NA,187,febrile neutropenia,NA,NA,NA,NA
9445186,NA,187,thrombocytopenia,4,NA,NA,NA
9445186,NA,187,bleeding,4,NA,NA,NA
9445186,NA,187,nonhematologic toxicity,3 or 4,NA,NA,NA
11233806,NA,188,neutrophil count below 500/mm3,NA,>7 days,NA,NA
11233806,NA,188,neutropenia with fever,NA,NA,NA,NA
11233806,NA,188,thrombocytopenia,4,NA,NA,NA
11233806,NA,188,mucositis,3 or 4,NA,NA,NA
11233806,NA,188,other toxicities,3 or 4,NA,FALSE,NA
8683232,NA,189,NA,NA,NA,NA,DLT not defined
9457817,NA,190,neutropenia,4,.5 days,NA,NA
9457817,NA,190,neutropenia associated with fever or infection,4,NA,NA,NA
9457817,NA,190,bleeding,NA,NA,NA,NA
9457817,NA,190,thrombocytopenia,3 or 4,NA,NA,NA
9457817,NA,190,nonhematologic toxicity,3 or 4,NA,NA,NA
10694563,NA,191,any nonhematologic toxicity,>=3,NA,NA,NA
10694563,NA,191,a nadir neutrophil count of fewer than 500/uL,NA,NA,NA,NA
10694563,NA,191,"platelet count of fewer than 25,000/uL",NA,NA,NA,NA
10694563,NA,191,a delay in initiation of the next course of treatment for more than 7 days,NA,NA,NA,NA
8652278,NA,192,NA,NA,NA,NA,DLT Not Defined
9053503,NA,193,mucositis,>=2,NA,NA,NA
9053503,NA,193,extraoral toxicity,>=3,NA,NA,NA
10378670,NA,194,organ toxicity noted in at least two out of six patients at agiven dose level,>=3,NA,NA,NA
10378670,NA,194,a granulocyte count less than 0.5 x 109/l with fever of 38.5C or above requiring i.v. antibiotics.,NA,NA,NA,NA
10378670,NA,194,nausea/vomiting if not improved to at least grade 1 by symptomatic treatment,3-Feb,NA,NA,NA
10378670,NA,194,constipation if not improved to at least grade 1 by symptomatic treatment,3-Feb,NA,NA,NA
10378670,NA,194,hypertriglyceridemia if not improved to at least grade 1 by symptomatic treatment,3-Feb,NA,NA,NA
9400949,NA,195,neutropenia,4,>7 days,NA,NA
9400949,NA,195,thrombocytopenia,4,>7 days,NA,NA
9400949,NA,195,"neutropenic fever requiring hospitalization and i.v. antibiotics,",4,NA,NA,NA
9400949,NA,195,the impossibility to re-treat a patient according to schedule,NA,NA,NA,NA
9400949,NA,195,other toxicities,3 or 4,NA,FALSE,NA
7799021,NA,196,NA,NA,NA,NA,DLT not defined
12448655,NA,197,neutropenia,4,>5 days,NA,NA
12448655,NA,197,febrile neutropenia,4,NA,NA,NA
12448655,NA,197,"platelet count <40,000/Âµl",NA,>5 days,NA,NA
12448655,NA,197,thrombocytopenia of any duration associated with bleeding,NA,NA,NA,NA
12448655,NA,197,delay in treatment for more than seven days due to toxicity,NA,NA,NA,NA
8083713,NA,198,NA,NA,NA,NA,DLT not defined
11155918,NA,199,non-hematological toxicity,>=3,NA,FALSE,NA
11155918,NA,199,platelet count of <50000/mm3,NA,NA,NA,NA
11155918,NA,199,persistence of WBC <1000/mm3 or absolute granulocyte count <500/mm3,NA,>=4 days,NA,NA
11155918,NA,199,WBC <1000/mm3 or absolute granulocyte count <500/mm3 with fever >=38C due to infection,NA,NA,NA,NA
8636778,NA,200,the occurrence of clinically unacceptable toxicity directly due to the PSC 833,NA,NA,NA,NA
15959778,NA,201,thrombocytopenia,4,NA,NA,NA
15959778,NA,201,neutropenia,4,>5 days,NA,NA
15959778,NA,201,febrile neutropenia,NA,NA,NA,NA
15959778,NA,201,the combination of grade 2 or higher diarrhea with grade 3 or higher neutropenia,NA,NA,NA,NA
15959778,NA,201,nonhematological toxicity,3,NA,FALSE,NA
8021737,NA,202,Any grade 4 toxicity that interrupted a 21-day course,NA,NA,NA,NA
8021737,NA,202,Any toxicity,4,>7 days,NA,NA
8021737,NA,202,ANC remained less than 0.5 X 109/L for longer than the planned 7-day rest period,NA,NA,FALSE,NA
8021737,NA,202,the platelet count less than 25 x 109/L for longer than the planned 7-day rest period,NA,NA,FALSE,NA
9537196,NA,203,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9537196,NA,203,neutropenia,3,>7 days,NA,NA
9537196,NA,203,thrombocytopenia,3,>7 days,NA,NA
9537196,NA,203,neutropenia,4,NA,NA,NA
9537196,NA,203,thrombocytopenia,4,NA,NA,NA
9537196,NA,203,delay in administration of a second cycle of chemotherapy for more than one week due to persistent toxicity,NA,NA,NA,NA
12673724,NA,204,neutropenia,4,>7 days,NA,NA
12673724,NA,204,anemia or thrombocytopenia that required transfusion on two occasions in 7 days,4,NA,NA,NA
12673724,NA,204,hematologic toxicity as a delay of 14 days between treatment cycles,NA,NA,NA,NA
12673724,NA,204,any chemotherapy-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
14596703,NA,205,neutropenia,4,>4 days,NA,NA
14596703,NA,205,neutropenic fever,4,NA,NA,NA
14596703,NA,205,thrombocytopenia,4,NA,NA,NA
14596703,NA,205,nonhematologic toxic effects,3 or 4,NA,FALSE,NA
10512128,NA,206,NA,NA,NA,NA,DLT not defined
7916039,NA,207,NA,NA,NA,NA,DLT not defined
10086724,NA,208,renal toxicity,>=3,NA,NA,NA
10086724,NA,208,hepatic toxicity,>=3,NA,NA,NA
10086724,NA,208,gastrointestinal toxicity,>=3,>= 3 days,NA,NA
10086724,NA,208,any sign of congestive heart failure or arrhythmia,NA,NA,NA,NA
10086724,NA,208,central nervous system toxicity or skin rash,>=3,NA,NA,NA
10086724,NA,208,pulmonary toxicity,2,NA,NA,NA
10086724,NA,208,pancytopenia with a hypocellular marrow (<= 5% cellular and no marrow blasts),NA,>= 6 weeks from the start of treatment,NA,NA
8270989,NA,209,NA,NA,NA,NA,DLT not defined
16649219,NA,210,neutropenia,4,>=3 days,NA,NA
16649219,NA,210,febrile neutropenia,4,NA,NA,NA
16649219,NA,210,thrombocytopenia,4,NA,NA,NA
16649219,NA,210,drug-induced pneumonitis,NA,NA,NA,NA
16649219,NA,210,nonhematologic toxicity,>=3,NA,FALSE,NA
15756278,NA,211,haematotoxicity,4,NA,NA,NA
15756278,NA,211,nonhaematological toxicity,3 or 4,NA,NA,NA
12609572,NA,212,ANC <= 0.5 x 109/l,NA,>7 days,NA,NA
12609572,NA,212,ANC <= 0.1 x 109/l,NA,>3 days,NA,NA
12609572,NA,212,platelet count <= 25 x 109/l or <= 50 x 109/l with bleeding,NA,NA,NA,NA
12609572,NA,212,neutropenic fever,NA,NA,NA,NA
12609572,NA,212,non-hematologic toxicity,4,NA,FALSE,NA
12394265,NA,213,NA,NA,NA,NA,DLT not defined
8194024,NA,214,NA,NA,NA,NA,DLT not defined
16412499,NA,215,neutropenic fever,NA,NA,NA,NA
16412499,NA,215,"thrombocytopenia (platelets <20,000/ul)",NA,NA,NA,NA
16412499,NA,215,absolute neutrophil count <1000/ul,NA,NA,NA,NA
16412499,NA,215,"platelets <50,000/ul",NA,NA,NA,NA
16412499,NA,215,a delay of >14 days in starting a subsequent course,NA,NA,NA,NA
16412499,NA,215,non-hematologic toxicity,>=3,NA,NA,NA
15719439,NA,216,neutropenia,4,>1 week,NA,NA
15719439,NA,216,neutropenic fever 38.5 Â°C .24 hours or sepsis,NA,NA,NA,NA
15719439,NA,216,thrombocytopenia,4,>1 week,NA,NA
15719439,NA,216,thrombocytopenia with bleeding that required transfusion,NA,NA,NA,NA
15719439,NA,216,nonhematologic toxicity,>=3,NA,FALSE,NA
16757061,NA,217,nonhematological toxicity,>=3,NA,FALSE,NA
16757061,NA,217,thrombocytopenia,3,NA,NA,NA
16757061,NA,217,"neutropenia leading to complications (temperature over 38.5 â—¦C, clinical signs of infection)",4,NA,NA,NA
16757061,NA,217,neutropenia,4,more than 7 days,NA,NA
9137533,NA,218,WBC <= 1.9 Ã— 106/mm3,NA,NA,NA,NA
9137533,NA,218,PLT <= 49 000/mm3,NA,NA,NA,NA
9137533,NA,218,Hb <= 8 mg/dl,NA,NA,NA,NA
9137533,NA,218,nonhematologic toxicity,3,NA,NA,NA
21387258,NA,219,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21387258,NA,219,Hypertension requiring admission to the hospital or intravenous medication for control,NA,NA,NA,NA
21387258,NA,219,thrombocytopenia,4,NA,NA,NA
21387258,NA,219,thrombocytopenia with bleeding,3,NA,NA,NA
21387258,NA,219,neutropenia,4,>7 days,NA,NA
21387258,NA,219,neutropenia associated with fever >38.5C,4,NA,FALSE,NA
24190702,NCT01136733,220,neutropenia,4,>7 days,NA,NA
24190702,NCT01136733,220,febrile neutropenia with neutrophils <1 Ã— 103 /Î¼L and a recorded temperature >38.5 Â°C,NA,NA,NA,NA
24190702,NCT01136733,220,thrombocytopenia with bleeding,>=3,NA,NA,NA
24190702,NCT01136733,220,thrombocytopenia,>=3,>7 days,NA,NA
24190702,NCT01136733,220,Nonhematologic toxicities,3,>7 days,FALSE,NA
24190702,NCT01136733,220,"nausea, vomiting, or diarrhea had to persist despite maximal medical therapy",3 or 4,NA,NA,NA
33547201,NCT03387020,221,thrombocytopenia,>=3,NA,NA,NA
33547201,NCT03387020,221,neutropenia,4,>7 days,NA,NA
33547201,NCT03387020,221,myelosuppression that causes a delay for >14 days between treatment cycles,NA,NA,NA,NA
33547201,NCT03387020,221,AST/ALT and/or bilirubin,>=3,NA,NA,NA
33547201,NCT03387020,221,QTc,>=2,NA,NA,NA
33547201,NCT03387020,221,mucositis,>=2,NA,NA,NA
33547201,NCT03387020,221,pneumonitis,>=2,NA,NA,NA
33547201,NCT03387020,221,nonhematologic toxicity persisting for â‰¥7 days and considered medically significant or sufficiently intolerable,2,NA,NA,NA
27206639,NCT01217177,222,neutrophils lower than 500/mm3,4,NA,NA,NA
27206639,NCT01217177,222,neutrophils lower than 1000/mm3 with fever,NA,NA,NA,NA
27206639,NCT01217177,222,platelets count lower than 25 Ã— 103/mL,4,NA,NA,NA
27206639,NCT01217177,222,thrombocytopenia,3,>2 weeks,NA,NA
27206639,NCT01217177,222,creatinine clearance remaining lower than 45 mL/min,NA,"two consecutive weeks, or for three non-consecutive weeks",NA,NA
27206639,NCT01217177,222,ototoxicity,3 or 4,NA,NA,NA
27206639,NCT01217177,222,neuropathy,3 or 4,NA,NA,NA
27206639,NCT01217177,222,diarrhea,4,NA,NA,NA
27206639,NCT01217177,222,diarrhea,3,"more than two consecutive weeks s, or for three non-consecutive weeks",NA,NA
27206639,NCT01217177,222,rash,4,NA,NA,NA
27206639,NCT01217177,222,rash,3,>1 week,NA,NA
27206639,NCT01217177,222,fatigue,4,NA,NA,NA
27206639,NCT01217177,222,pneumonitis,3 or 4,NA,NA,NA
27206639,NCT01217177,222,non-hematologic toxicity,3 or 4,NA,NA,NA
27206639,NCT01217177,222,lymphopenia associated with an opportunistic infection,4,NA,NA,NA
32005746,NCT01470209,223,hematologic toxicity,4,>7 days,FALSE,NA
32005746,NCT01470209,223,anemia,4,NA,NA,NA
32005746,NCT01470209,223,anemia,3,>7 days,NA,NA
32005746,NCT01470209,223,anemia requiring blood transfusion,3,NA,NA,NA
32005746,NCT01470209,223,febrile neutropenia,>=3,NA,NA,NA
32005746,NCT01470209,223,nausea and or vomiting in spite of standard supportive therapy,>=3,>72 h,NA,NA
32005746,NCT01470209,223,nonhematologic toxicity,>=3,NA,FALSE,NA
32005746,NCT01470209,223,electrolyte abnormality of significant clinical consequence and directly attributed to the receipt of the investigational agents and inability to re-treat patient within 14 days of scheduled treatment because of treatmentrelated toxicity,>=3,NA,NA,NA
24819684,NCT00610948,224,non-hematologic toxicity,3 or 4,NA,FALSE,NA
24819684,NCT00610948,224,ANC of less than 500 cells/mm3,NA,>7 days,NA,NA
24819684,NCT00610948,224,ANC of less than 500 cells/mm3 associated with fever or infection,NA,NA,NA,NA
24819684,NCT00610948,224,"a platelet count of less than 25,000/mm3 with major bleeding",NA,NA,NA,NA
25788492,NA,226,NA,NA,NA,NA,DLT not defined
34903452,NCT01149356,227,neutropenia,4,>5 days,NA,NA
34903452,NCT01149356,227,Febrile neutropenia (i.e.: CTCAE Grade 3 or 4 neutropenia (ANC <1.0 10 9/ L) associated with a fever 38.5C),NA,NA,NA,NA
34903452,NCT01149356,227,documented infection associated with Grade 3-4 neutropenia,NA,NA,NA,NA
34903452,NCT01149356,227,thrombocytopenia < 25 Ã— 10 9/ L,4,NA,NA,NA
34903452,NCT01149356,227,< 50-25 Ã— 10 9/L thrombocytopenia with bleeding,3,NA,NA,NA
34903452,NCT01149356,227,non-hematologic toxicity (including grade 3 diarrhea) despite symptomatic therapy where existing,3 or 4,NA,NA,NA
34903452,NCT01149356,227,Inability to initiate Cycle 2 within 2 weeks of scheduled treatment due to slow recovery from study drug-induced toxicities and failure to meet re-treatment criteria,NA,NA,NA,NA
34903452,NCT01149356,227,"hypophosphatemia, hypocalcemia, hypomagnesemia were considered a DLT on this if they had not resolved within in 72 hrs of appropriate therapy or were associated with new EKG findings",3,NA,NA,NA
24908540,NCT01714765,228,NA,NA,NA,NA,DLT not defined
24685058,NA,229,nonhematologic toxicity,>=3,NA,FALSE,NA
24685058,NA,229,neutropenia,3,>=7 days,NA,NA
24685058,NA,229,thrombocytopenia,3,>=7 days,NA,NA
24685058,NA,229,hematologic toxicity,4,NA,NA,NA
28616837,NA,230,neutropenia,4,>5 days,NA,NA
28616837,NA,230,febrile neutropenia,3,NA,NA,NA
28616837,NA,230,anemia,>=3,NA,NA,NA
28616837,NA,230,trombocytopenia,>=4,NA,NA,NA
28616837,NA,230,trombocytopenia with bleeding,3,NA,NA,NA
28616837,NA,230,vomiting,>=2,NA,NA,NA
28616837,NA,230,diarrhoea,>=2,NA,NA,NA
28616837,NA,230,any other toxicity despite optimal supportive care,>=3,NA,NA,NA
25335932,NCT01154335,231,neutropenia,4,>7 days,NA,NA
25335932,NCT01154335,231,thrombocytopenia,4,>7 days,NA,NA
25335932,NCT01154335,231,febrile neutropenia,NA,NA,NA,NA
25335932,NCT01154335,231,"nausea, vomiting, or diarrhea despite maximal medical management",>=3,>7 days,NA,NA
25335932,NCT01154335,231,mucositis,4,NA,NA,NA
25335932,NCT01154335,231,mucositis,3,>4 days,NA,NA
25335932,NCT01154335,231,hyperglycemia,3 or 4,NA,NA,NA
25335932,NCT01154335,231,non-hematologic toxicity despite optimal supportive care,>=3,NA,NA,NA
25335932,NCT01154335,231,"inability to receive 75 % of the required doses of both OSI-906 and everolimus, secondary to toxicity",NA,NA,NA,NA
33451345,NCT02123823,232,hyperglycaemia,3,>48 hours,NA,NA
33451345,NCT02123823,232,hyperglycaemia,4,NA,NA,NA
33451345,NCT02123823,232,stomatitis (oral mucositis) despite appropriate supportive care,>=3,NA,NA,NA
33451345,NCT02123823,232,thrombocytopenia,>=3,>=7 days,NA,NA
33451345,NCT02123823,232,thrombocytopenia associated with active bleeding or requiring platelet transfusion,NA,NA,NA,NA
33451345,NCT02123823,232,decreased platelet count,>=4,NA,NA,NA
33451345,NCT02123823,232,febrile neutropenia and/or documented infection with ANC <1.0x109/L,>=3,NA,NA,NA
33451345,NCT02123823,232,decreased neutrophil count,4,>=7 days,NA,NA
33451345,NCT02123823,232,AST or ALT >5x ULN (for baseline AST/ALT â‰¤ ULN) or > baseline value + 4x ULN (for baseline AST/ALT > ULN),NA,NA,NA,NA
33451345,NCT02123823,232,"diarrhoea, nausea, or vomiting despite adequate supportive care",>=3,NA,NA,NA
33451345,NCT02123823,232,skin rash despite adequate supportive care measures,>=3,NA,NA,NA
33451345,NCT02123823,232,fatigue/asthenia,>=3,>=7 days,NA,NA
33451345,NCT02123823,232,hyperlipidaemia (total cholesterol > 400 mg/dL or triglycerides > 500 mg/dL) not improving despite appropriate treatment for 4 weeks,3 or 4,NA,NA,NA
33451345,NCT02123823,232,Any AE necessitating a 2-week treatment interruption,NA,NA,NA,NA
33451345,NCT02123823,232,All other toxicities,>=3,NA,FALSE,NA
23963141,NCT01079481,233,non-haematological toxicity despite the fully preventive therapy,3 or 4,NA,NA,NA
23963141,NCT01079481,233,fever with grade 3 or 4 neutropenia,NA,NA,NA,NA
23963141,NCT01079481,233,neutropenia,4,>7 days,NA,NA
23963141,NCT01079481,233,thrombocytopenia,3 or 4,NA,NA,NA
23963141,NCT01079481,233,neutropenia or thrombocytopenia failing to revert to grade p1 within 3 weeks,NA,NA,NA,NA
33964572,NCT02077933,234,Febrile neutropenia,>=3,NA,NA,NA
33964572,NCT02077933,234,Cardiac toxicity,>=3,NA,NA,NA
33964572,NCT02077933,234,cardiac event that is symptomatic or requires medical intervention,NA,NA,NA,NA
33964572,NCT02077933,234,"Clinical signs of cardiac disease, such as unstable angina or myocardial infarction, or Troponin",3,NA,NA,NA
33964572,NCT02077933,234,ECG QTc interval prolonged,>=3,NA,NA,NA
33964572,NCT02077933,234,Persistent hypertension requiring more than one drug or more intensive therapy than previously administered,>=3,NA,NA,NA
33964572,NCT02077933,234,Fatigue,>=3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Rash or photosensitivity despite skin toxicity treatment,>=3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Rash or photosensitivity,4,NA,NA,NA
33964572,NCT02077933,234,Hyperglycemia that does not resolve to baseline status or to grade 1 or less (< 140 mg/dL; < 7.8 mmol/L) within 14 consecutive days (after initiation of oral anti-diabetic treatment,2,NA,NA,NA
33964572,NCT02077933,234,Hyperglycemia despite oral antidiabetic treatment,3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Hyperglycemia,4,NA,NA,NA
33964572,NCT02077933,234,"Hyperglycemia leading to diabetic keto-acidosis, hospitalization for IV insulin infusion, or non-ketotic coma",NA,NA,NA,NA
33964572,NCT02077933,234,peripheral sensory or motor neuropathy,>=3,NA,NA,NA
33964572,NCT02077933,234,"Diarrhea, despite the use of anti- diarrhea therapy",>=3,>=48 hours,NA,NA
33964572,NCT02077933,234,"Nausea/ vomiting, despite the use of anti-emetic therapy",>=3,>=48 hours,NA,NA
33964572,NCT02077933,234,Pancreatitis,>=3,NA,NA,NA
33964572,NCT02077933,234,Blood bilirubin,2,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Blood bilirubin,>=3,NA,NA,NA
33964572,NCT02077933,234,AST or ALT in conjunction with blood bilirubind CTCAE grade â‰¥ 2,>=3,NA,NA,NA
33964572,NCT02077933,234,AST or ALT,>=3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,AST or ALT,4,NA,NA,NA
33964572,NCT02077933,234,Serum alkaline phosphatase,4,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Serum lipase and/or serum amylase (asymptomatic),3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Serum lipase and/or serum amylase (asymptomatic),4,NA,NA,NA
33964572,NCT02077933,234,Serum creatinine,>=3,NA,NA,NA
33964572,NCT02077933,234,Neutrophil count,>=3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Platelet count and/or with signs of bleeding,3,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Platelet count,4,NA,NA,NA
33964572,NCT02077933,234,Hypomagnesaemia,3,>3 consecutive days,NA,NA
33964572,NCT02077933,234,Hypomagnesaemia,4,NA,NA,NA
33964572,NCT02077933,234,Stomatitis/mucositis,2,>=7 consecutive days,NA,NA
33964572,NCT02077933,234,Stomatitis/mucositis,>=3,NA,NA,NA
33964572,NCT02077933,234,"For subjects with baseline negative HBV-DNA and HbsAg AND positive HBs Ab (with no prior history of vaccination against HBV), OR positive HBc Ab, reactivation is defined as new appearance of measurable HBV-DNA",NA,NA,NA,NA
33964572,NCT02077933,234,"For subjects with baseline knowledge of past hepatitis C infection with no detectable HCV-RNA, reactivation is defined as new appearance of detectable HCV-RNA",NA,NA,NA,NA
33964572,NCT02077933,234,Other hematologic & non- hematologic toxicities,>=3,NA,FALSE,NA
30635337,NA,236,any nonhematologic adverse event that was at least possibly treatment-related,>=3,NA,TRUE,NA
30635337,NA,236,neutropenia,4,>7 days,NA,NA
30635337,NA,236,febrile neutropenia,NA,NA,NA,NA
30635337,NA,236,"platelet count less than 25,000/mm3",NA,NA,NA,NA
30635337,NA,236,toxicity considered at least possibly related to hydroxychloroquine,3 or 4,NA,NA,NA
21177764,NCT00927966,237,noninfectious pneumonitis,>=2,NA,NA,NA
21177764,NCT00927966,237,nonhematological toxicities,>=3,NA,FALSE,NA
21177764,NCT00927966,237,febrile neutropenia,3 or 4,NA,NA,NA
21177764,NCT00927966,237,neutropenia,4,NA,NA,NA
21177764,NCT00927966,237,thrombocytopenia,4,NA,NA,NA
21177764,NCT00927966,237,study drugrelated death,NA,NA,NA,NA
25029236,NCT00560963,238,treatmentrelated adverse events,>=3,NA,NA,NA
18332469,NA,239,hematologic toxicity,>=3,NA,NA,NA
18332469,NA,239,nonhematologic toxicity despite the use of adequate/maximal medical intervention and/or prophylaxis,>=3,NA,NA,NA
21984222,NA,240,neurotoxicity,>=1,NA,NA,NA
21984222,NA,240,renal or cardiac toxicities,>=2,NA,NA,NA
21984222,NA,240,hematologic or hepatic toxicity or nausea/vomiting despite antiemetic administration,>=3,NA,NA,NA
21984222,NA,240,toxicity resulting in a 7-day or greater delay in AEE788 or RAD001 administration,>=3,NA,NA,NA
32704173,NCT01218555,241,haematological toxicity,4,>7 days,NA,NA
32704173,NCT01218555,241,neutropenia of any duration in the presence of fever â‰¥38.5 Â°C,4,NA,NA,NA
32704173,NCT01218555,241,nausea and/or vomiting despite standard supportive therapy,>=3,NA,NA,NA
32704173,NCT01218555,241,non-haematologic toxicity,>=3,NA,FALSE,NA
32704173,NCT01218555,241,inability to re-treat within 2 weeks of a scheduled cycle due to treatment-related AE,NA,NA,NA,NA
32704173,NCT01218555,241,inability to deliver all planned doses of lenalidomide and or everolimus during the first cycle due to an unexpected drug-related toxicity,NA,NA,NA,NA
34819039,NCT02623751,242,neutrophil count decreased,4,>=1 week,NA,NA
34819039,NCT02623751,242,anemia requiring red blood cell transfusion,NA,NA,NA,NA
34819039,NCT02623751,242,platelet count decreased or platelet count decreased requiring platelet transfusion,4,NA,NA,NA
34819039,NCT02623751,242,neutrophil count < 500/Î¼L and fever â‰¥ 38.0 Â°C observed on the same day,NA,NA,NA,NA
34819039,NCT02623751,242,nonhematological toxicities,>=3,NA,FALSE,NA
34819039,NCT02623751,242,AEs resulting in â‰¥ 2 interruptions in one cycle or discontinuation of ENT in the next cycle,NA,NA,NA,NA
34819039,NCT02623751,242,increased hazards to patients that were considered serious,NA,NA,NA,NA
34819039,NCT02623751,242,ENT dose reduction that was required in the opinion of the investigator,NA,NA,NA,NA
21898375,NA,244,neutropenia,4,>7 days,NA,NA
21898375,NA,244,febrile neutropenia,NA,NA,NA,NA
21898375,NA,244,thrombocytopenia,>=3,>7 days,NA,NA
21898375,NA,244,thrombocytopenia complicated by bleeding,>=3,NA,NA,NA
21898375,NA,244,Nonhematologic  toxicity,3 or 4,>= 7 days,FALSE,NA
21898375,NA,244,"persistent nausea, vomiting, or diarrhea despite maximal medical care",3 or 4,NA,NA,NA
21898375,NA,244,clinical evidence of congestive heart failure,NA,NA,NA,NA
21898375,NA,244,hypertension,4,NA,NA,NA
21898375,NA,244,hypertension not controlled by medication,3,NA,NA,NA
21898375,NA,244,proteinuria,4,NA,NA,NA
21898375,NA,244,episodes of gastrointestinal perforation,NA,NA,NA,NA
21898375,NA,244,hemorrhage,4,NA,NA,NA
21898375,NA,244,wound dehiscence requiring intervention,NA,NA,NA,NA
21898375,NA,244,thromboembolic event,NA,NA,NA,NA
32335374,NCT02577458,245,treatment-related failure to administer 75% of the planned dosage of vorolanib/everolimus combination,NA,NA,NA,NA
32335374,NCT02577458,245,escalation of ALT/AST >= 5 x ULN or 2 x baseline value,NA,2 weeks,NA,NA
32335374,NCT02577458,245,elevated ALT/AST >= 3 x baseline value together with elevated bilirubin >= 2 x ULN or international normalized ratio (INR) >= 1.5,NA,NA,NA,NA
32335374,NCT02577458,245,uncontrolled hypertension by medication within 7 days,3,NA,NA,NA
32335374,NCT02577458,245,proteinuria,>=3,NA,NA,NA
32335374,NCT02577458,245,proteinuria,2,>7 days,NA,NA
32335374,NCT02577458,245,neutropenia with fever,3,NA,NA,NA
32335374,NCT02577458,245,neutropenia,4,NA,NA,NA
32335374,NCT02577458,245,thrombocytopenia,3,>7 days,NA,NA
32335374,NCT02577458,245,thrombocytopenia with bleeding,3,NA,NA,NA
32335374,NCT02577458,245,nausea or vomiting with symptomatic treatment,3,NA,NA,NA
32335374,NCT02577458,245,other hematologic AEs and grade 3 or higher,4,NA,NA,NA
32335374,NCT02577458,245,other non-hematologic toxicities,>=3,NA,NA,NA
8336196,NA,246,leukocyte or platelet nadir,3,NA,NA,NA
8336196,NA,246,nonhematologic toxicity,2,NA,FALSE,NA
25902899,NA,247,non-hematologic toxicity believed to be related to the study medications,3 or 4,NA,FALSE,NA
25902899,NA,247,hematologic toxicity,4,>=2 weeks,NA,NA
25902899,NA,247,hematologic toxicity associated with bleeding and/or sepsis,4,NA,NA,NA
25902899,NA,247,nausea or vomiting despite maximum anti-nausea regimens,4,>3 days,NA,NA
25902899,NA,247,any other non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome,3,NA,NA,NA
25902899,NA,247,any severe or life-threatening complication,NA,NA,NA,NA
25902899,NA,247,abnormality not defined in the NCI-CTCAE v4.0 that was attributable to the therapy,NA,NA,NA,NA
24057042,NCT00352443,248,non-hematologic toxicity,3,NA,NA,NA
24057042,NCT00352443,248,neutropenia,4,>7 days,NA,NA
24057042,NCT00352443,248,febrile neutropenia,3 or 4,NA,NA,NA
24057042,NCT00352443,248,thrombocytopenia,4,NA,NA,NA
24057042,NCT00352443,248,thrombocytopenia with hemorrhage,3,NA,NA,NA
24057042,NCT00352443,248,"missing everolimus or lapatinib for 7 days or more, due to drug-related toxicities during the first cycle",NA,NA,NA,NA
23928403,NCT00828594,249,any non-hematologic toxicity requiring P7 days to resolve to grade <=1 despite medical therapy,3 or 4,NA,FALSE,NA
23928403,NCT00828594,249,HBV reactivation or hepatitis C virus flare,NA,NA,NA,NA
23928403,NCT00828594,249,bilirubin increase >= 2 x upper limit of normal (ULN),NA,NA,NA,NA
23928403,NCT00828594,249,creatinine increase >= 2 x ULN,NA,NA,NA,NA
23928403,NCT00828594,249,any non-hematologic toxicity requiring P7 days of treatment interruption,NA,NA,NA,NA
23928403,NCT00828594,249,hematologic toxicity,4,NA,NA,NA
23928403,NCT00828594,249,thrombocytopenia with bleeding,3,NA,NA,NA
23928403,NCT00828594,249,anemia requiring transfusion,3,NA,NA,NA
23928403,NCT00828594,249,neutropenia with fever,3,NA,NA,NA
23928403,NCT00828594,249,any persistent hematologic toxicity requiring dose interruption for >7 days to resolve to grade <= 1,3,NA,NA,NA
7692002,NA,250,granulocytopenia,4,>4 days,NA,NA
7692002,NA,250,toxicity in a specific organ,3,NA,FALSE,NA
23930209,NCT01042782,251,hypersensitivity reaction,>=2,NA,NA,NA
23930209,NCT01042782,251,nonhematologic toxicity,>=3,NA,FALSE,NA
23930209,NCT01042782,251,thrombocytopenia,4,NA,NA,NA
23930209,NCT01042782,251,neutropenia,4,>5 days,NA,NA
23930209,NCT01042782,251,"Abnormal laboratory values were considered dose limiting when they, in addition, were considered as clinically significant",NA,NA,NA,NA
17947729,NA,252,neutropenia related to everolimus,4,NA,NA,NA
17947729,NA,252,thrombocytopenia related to everolimus,3 or 4,NA,NA,NA
17947729,NA,252,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17947729,NA,252,transaminase elevations that returned to baseline within 7 days of interrupting treatment,3,NA,NA,NA
17947729,NA,252,hyperlipidemia,3,NA,NA,NA
17947729,NA,252,fever or infection,3,NA,NA,NA
17947729,NA,252,electrolyte abnormalities that resolved to <= grade 2 within 7 days of interrupting treatment,3 or 4,NA,NA,NA
20975068,NA,253,Febrile neutropenia (defined as ANC < 1 Ã— 109/L and fever â‰¥ 38.5Â°C),NA,NA,NA,NA
20975068,NA,253,thrombocytopenia,4,NA,NA,NA
20975068,NA,253,pneumonitis,>=3,NA,NA,NA
20975068,NA,253,nonhematologic event despite appropriate prophylactic treatment,4,NA,NA,NA
20975068,NA,253,neutropenia,4,>7 days,NA,NA
20975068,NA,253,neutropenia recurring in the same cycle,4,NA,NA,NA
20975068,NA,253,thrombocytopenia,3,NA,NA,NA
20975068,NA,253,nonhematologic event despite appropriate prophylactic treatment,3,NA,NA,NA
20975068,NA,253,pneumonitis,2,NA,NA,NA
20975068,NA,253,Any intolerable event Requiring dose reduction of everolimus,2,NA,NA,NA
20975068,NA,253,"Any adverse event, Resulting in a more than 2-week interruption or delay of study treatment",NA,NA,NA,NA
33115815,NCT02152943,254,treatment related hematologic toxicity,4,NA,NA,NA
33115815,NCT02152943,254,treatment related nonhematologic toxicity,3 or 4,NA,NA,NA
33115815,NCT02152943,254,treatment delays due to adverse events that lasted more than 14 days during the first 21 days of therapy,NA,NA,NA,NA
23475104,NCT00942682,255,non-hematologic toxicity,>=3,NA,FALSE,NA
23475104,NCT00942682,255,hematologic toxicity,>=3,>=7 days,NA,NA
23475104,NCT00942682,255,Isolated laboratory abnormalities were to be deemed clinically significant by the treating investigator to be considered DLT,3,NA,NA,NA
25900182,NCT01204476,256,hematological toxicity,>=4,NA,NA,NA
25900182,NCT01204476,256,neutropenia,3,NA,NA,NA
25900182,NCT01204476,256,thrombocytopenia that did not resolve to either grades 0 or 1 following dose interruption for >7 days,NA,NA,NA,NA
25900182,NCT01204476,256,non-hematologic toxicity,>=3,NA,FALSE,NA
25900182,NCT01204476,256,"any toxicity that led to >14 days of treatment delay that occurred during the first cyclewithdefinite,possible, or probableattribution to cixutumumab and/or everolimus",NA,NA,NA,NA
31654285,NCT01582009,257,any toxicity,3 or 4,NA,NA,NA
1403040,NA,258,NA,NA,NA,NA,DLT not defined
25701455,NA,259,neutropenia,4,>= 5 days,NA,NA
25701455,NA,259,neutropenia associated with a temperature â‰¥38.5Â°C requiring an hospitalization,4,NA,NA,NA
25701455,NA,259,thrombocytopenia,4,NA,NA,NA
25701455,NA,259,thrombocytopenia,3,>4 days,NA,NA
25701455,NA,259,nausea and emesis despite optimal antiemetic treatment,>=4,NA,NA,NA
25701455,NA,259,persistent grade 3 (15 days) or 4 (8 days) skin toxicity within the radiotherapy field,NA,NA,NA,NA
25701455,NA,259,other toxicity requiring an interruption of everolimus and/or radiotherapy lasting more than 2 weeks,NA,NA,NA,NA
25701455,NA,259,"others persistent grade 3â€“4 toxic effects despite an adequate management lasting more than 15 and 8 days, respectively",NA,NA,NA,NA
22169794,NA,260,toxicity,3,NA,FALSE,NA
22169794,NA,260,hematologic toxicity,4,NA,NA,NA
22169794,NA,260,nonhematologic toxicity,4,NA,FALSE,NA
24740268,NA,261,ANC,4,>= 5 days,NA,NA
24740268,NA,261,febrile neutropenia,NA,NA,NA,NA
24740268,NA,261,platelets,>=3,NA,NA,NA
24740268,NA,261,"nausea, vomiting, or diarrhea despite supportive care",>=3,NA,NA,NA
24740268,NA,261,stomatitis deemed intolerable by the patient,2,NA,NA,NA
24740268,NA,261,nonhematologic toxicity,>=3,NA,NA,NA
21107682,NCT00426530,263,Febrile neutropenia,NA,NA,NA,NA
21107682,NCT00426530,263,thrombocytopenia,4,NA,NA,NA
21107682,NCT00426530,263,pneumonitis,>=3,NA,NA,NA
21107682,NCT00426530,263,nonhematologic event despite appropriate prophylactic treatment,4,NA,NA,NA
21107682,NCT00426530,263,neutropenia,>=3,more than 7 days or recurring in the same cycle,NA,NA
21107682,NCT00426530,263,thrombocytopenia,3,more than 7 days or recurring in the same cycle,NA,NA
21107682,NCT00426530,263,nonhematologic event despite appropriate  prophylactic treatment,3,more than 7 days or recurring in the same cycle,NA,NA
21107682,NCT00426530,263,pneumonitis,2,more than 7 days or recurring in the same cycle,NA,NA
21107682,NCT00426530,263,Any intolerable event despite prophylactic treatment,2,more than 7 days or recurring in the same cycle,NA,NA
34562750,NCT02432274,264,neutropenia,4,>=7 days,NA,NA
34562750,NCT02432274,264,thrombocytopenia with bleeding,>=3,NA,NA,NA
34562750,NCT02432274,264,thrombocytopenia,>=3,>7 days,NA,NA
34562750,NCT02432274,264,febrile neutropenia,>=3,NA,NA,NA
34562750,NCT02432274,264,nonhematological toxicity despite supportive care,>=3,>7 days,NA,NA
34562750,NCT02432274,264,"hypertension, confirmed systolic or diastolic blood pressure more than 25mm Hg above the 95th percentile for age or elevated diastolic blood pressure not controlled by a single antihypertensive medication within 14 days of use",4,NA,NA,NA
34562750,NCT02432274,264,proteinuria,3,NA,NA,NA
34562750,NCT02432274,264,any recurrent grade 2 nonhematological toxicity requiring â‰¥2 dose interruptions or reductions,NA,NA,NA,NA
34562750,NCT02432274,264,any dose reductions or interruptions due to toxicity that resulted in administration of <75% of planned dose for lenvatinib,NA,NA,NA,NA
34562750,NCT02432274,264,"any other toxicity assessed as related to lenvatinib treatment, and which in the opinion of the principal investigator and sponsor constitutes a DLT",>=3,NA,NA,NA
32998962,NCT01857193,265,treatment-related toxicity,NA,NA,NA,DLT not defined
27093189,NA,266,NA,NA,NA,NA,DLT not defined
29739790,NA,267,febrile neutropenia,NA,NA,NA,NA
29739790,NA,267,thrombocytopenia,4,NA,NA,NA
29739790,NA,267,neutropenia,3 or 4,>14 days,NA,NA
29739790,NA,267,nonhematologic event,3,>7 days,NA,NA
29739790,NA,267,nonhematologic event,4,NA,NA,NA
29739790,NA,267,any treatment delays or omissions of 14 days or longer,1,NA,NA,NA
23725999,NA,268,thrombocytopenia,3 or 4,NA,NA,NA
23725999,NA,268,anemia,4,NA,NA,NA
23725999,NA,268,neutropenia,4,>7 days,NA,NA
23725999,NA,268,febrile neutropenia,NA,NA,NA,NA
23725999,NA,268,any non-hematologic toxicity despite maximal medical therapy,>=3,NA,FALSE,NA
23725999,NA,268,radiation-induced skin changes,4,NA,NA,NA
23725999,NA,268,any episode of non-infectious pneumonitis,NA,NA,NA,NA
33721621,NCT01582191,269,hematologic toxicity expected and believed to be related to the study medications,3 or 4,NA,NA,NA
33721621,NCT01582191,269,hematologic toxicity,4,>=14 days,NA,NA
33721621,NCT01582191,269,hematologic toxicity associated with bleeding and/or sepsis,4,NA,NA,NA
33721621,NCT01582191,269,thrombocytopenia,3 or 4,7 days,NA,NA
33721621,NCT01582191,269,thrombocytopenia associated with active bleeding or requiring platelet transfusion,NA,NA,NA,NA
33721621,NCT01582191,269,nausea/vomiting,3,>48 h,NA,NA
33721621,NCT01582191,269,nausea/vomiting despite maximum anti-nausea regimens,4,NA,FALSE,NA
33721621,NCT01582191,269,"any other clinically significant non-hematologic toxicity, including symptoms or signs of vascular leak or cytokine release syndrome",3,NA,FALSE,NA
33721621,NCT01582191,269,any severe or life-threatening complications or abnormality not defined in the NCI-CTCAE that is attributable to the therapy,NA,NA,NA,NA
18039566,NA,270,any toxicity suspected to be related to study drug,3 or 4,NA,FALSE,NA
18039566,NA,270,any toxicity leading to treatment interruption of >2 weeksâ€™ duration,NA,NA,NA,NA
26699397,NCT00935792,271,Absolute neutrophil count (ANC) <= 0.3 x 109/L,NA,NA,NA,NA
26699397,NCT00935792,271,platelet count < 10 x 109/L,NA,NA,NA,NA
26699397,NCT00935792,271,Any other non-hematologic toxicity,>=3,NA,FALSE,NA
33738668,NCT01784861,272,neutropenia,4,>5 days,NA,NA
33738668,NCT01784861,272,febrile neutropenia,NA,NA,NA,NA
33738668,NCT01784861,272,thrombocytopenia,4,NA,NA,NA
33738668,NCT01784861,272,thrombocytopenia associated with bleeding,3,NA,NA,NA
33738668,NCT01784861,272,Non-hematologic toxicity,3 or 4,NA,FALSE,NA
33738668,NCT01784861,272,Treatment delays of >14 days due to unresolved toxicity,NA,NA,NA,NA
20953860,NA,273,hematologic toxicity,4,NA,NA,NA
20953860,NA,273,"non-hematologic toxicity including diarrhea despite antidiarrheal prophylaxis, nausea despite maximum anti-emetic therapy",3 or 4,NA,NA,NA
20953860,NA,273,any delay in treatment resulting in fewer than 3 treatments in the Wrst 6-week cycle,NA,NA,NA,NA
20461440,NA,274,hematologic toxicity,4,NA,NA,NA
20461440,NA,274,non-hematologic toxicity including diarrhea despite antidiarrheal prophylaxis,3 or 4,NA,NA,NA
20461440,NA,274,any delay in treatment resulting in fewer than 2 treatments in the first 3 weeks of a cycle,NA,NA,NA,NA
9790795,NA,275,granulocytopenia,4,> 3 days,NA,NA
9790795,NA,275,thrombocytopenia,4,NA,NA,NA
9790795,NA,275,neutropenic fever,NA,NA,NA,NA
9790795,NA,275,nonhematologic toxicity,>=3,NA,NA,NA
33423090,NCT00387504,277,thrombocytopenia,4,NA,NA,NA
33423090,NCT00387504,277,neutropenia,4,>7 days,NA,NA
33423090,NCT00387504,277,febrile neutropenia,NA,NA,NA,NA
33423090,NCT00387504,277,any toxicity related to study drug that resulted in treatment delays of >3 weeks (one cycle),NA,NA,NA,NA
33423090,NCT00387504,277,non-hematological toxicity related to study drug,3 or 4,NA,TRUE,NA
23515411,NA,278,nonhematologic toxicity,4,NA,FALSE,NA
23515411,NA,278,nonhematologic toxicity,3,>7 days,NA,NA
23515411,NA,278,absolute neutrophil count or platelet toxicity persisting longer than 6 weeks in the absence of leukemia,4,NA,NA,NA
9681085,NA,279,hematologic toxicity,4,>4 days,NA,NA
9681085,NA,279,neutropenic fever,NA,NA,NA,NA
9681085,NA,279,nonhematologic toxicity,3,>7 days,NA,NA
9681085,NA,279,the inability to receive therapy on cycle 2 due to ongoing grade II or greater toxicity,NA,NA,NA,NA
29392425,NCT01435343,280,neutropenia persisting > 42 days following the last dose of plerixafor and not attributable to persistent leukemia,4,NA,NA,NA
29392425,NCT01435343,280,adverse events (AEs) attributable to leukostasis or tumor lysis syndrome,>=4,NA,NA,NA
29392425,NCT01435343,280,non-hematologic toxicity related to plerixafor,>=3,NA,NA,NA
27655665,NCT01096992,281,non-hematologic toxicity,>=3,NA,NA,NA
27655665,NCT01096992,281,Hematologic toxicity,>=2,>42 days,NA,NA
9256828,NA,282,toxicity,4,NA,NA,NA
9256828,NA,282,toxicity not returning to Grade â‰¤ II before initiation of the next cycle of chemotherapy,3,NA,NA,NA
23228986,NCT00559624,283,"toxicity, which may be local to the injection site or systemic",3 or 4,NA,NA,NA
27862308,NA,284,non-haematological toxicity,3 or 4,NA,NA,NA
27862308,NA,284,haematological toxicity occurring during or within 4 wk after the end of alemtuzumab therapy,4,>14 days,FALSE,NA
25684345,NCT00462358,286,non-hematologic AE,3 or 4,NA,FALSE,NA
25684345,NCT00462358,286,neurotoxicity,>=2,NA,NA,NA
25684345,NCT00462358,286,granulocytopenia,4,>=7 days,NA,NA
25684345,NCT00462358,286,febrile neutropenia,NA,NA,NA,NA
25684345,NCT00462358,286,thrombocytopenia,4,NA,NA,NA
25684345,NCT00462358,286,thrombocytopenia with spontaneous bleeding,NA,NA,NA,NA
23959599,NA,287,nonhematologic toxicity that did not resolve or decrease to Grade 1â€“2 within 2 weeks,3 or 4,NA,NA,NA
23959599,NA,287,hematologic toxicity that caused more than a one week delay in treatment,4,NA,NA,NA
22402597,NA,288,NA,NA,NA,NA,DLT not defined
9923543,NA,289,granulocytopenia <500/mm3,NA,>7 days,NA,NA
9923543,NA,289,thrombocytopenia at any assessment,4,NA,NA,NA
9923543,NA,289,febrile neutropenia,NA,NA,NA,NA
9923543,NA,289,nonhematologic toxicity,>=3,NA,NA,NA
9923543,NA,289,toxicity,4,NA,NA,NA
9626219,NA,290,toxicities,3,NA,FALSE,NA
9626219,NA,290,toxicities,4,NA,FALSE,NA
16463060,NA,291,neutropenia with or without colony stimulating factor support,4,>7 days,NA,NA
16463060,NA,291,Febrile neutropenia,NA,NA,NA,NA
16463060,NA,291,thrombocytopenia,4,NA,NA,NA
16463060,NA,291,CNS neurotoxicity,>=2,NA,NA,NA
16463060,NA,291,non-hematologic toxicity,3 or 4,NA,FALSE,NA
8622024,NA,292,ANC less than 500/uL,NA,> 5 days,NA,NA
8622024,NA,292,"platelet count less than 25,000/uL",NA,> 5 days,NA,NA
8622024,NA,292,delay in the initiation of further therapy for more than 7 days due to unresolved hematologic toxicity,NA,NA,NA,NA
12073049,NA,293,"ANC lessthan 0.5x109/l with fever of at least 38.5 C (febrile neutropenia, FN)",NA,NA,NA,NA
12073049,NA,293,platelet count less than 25x109/l,NA,>5 days,NA,NA
12073049,NA,293,any non-hematologic toxicity,>=3,NA,FALSE,NA
12351605,NA,294,reversible nonhematologic toxicity,>=3,NA,FALSE,NA
12351605,NA,294,irreversible nonhematologic toxicity,>=2,NA,NA,NA
12351605,NA,294,hematologic toxicity,4,NA,NA,NA
12451473,NA,295,toxicity,>=3,NA,FALSE,NA
9164208,NA,296,nonhematologic toxicity,3 or 4,NA,NA,NA
11822765,NA,297,hematologic toxicity,4,>=5 days,NA,NA
11822765,NA,297,febrile neutropenia,NA,NA,NA,NA
11822765,NA,297,diarrhea or vomiting that occurred despite supportive measures,4,NA,NA,NA
11822765,NA,297,any other non-hematologic toxicity,>=3,NA,NA,NA
18766965,NA,299,neutropenia (absolute neutrophil count 5100 cells/mL) not recovering before day 28 with less than 5% blasts in the marrow,NA,NA,NA,NA
18766965,NA,299,non-hematologic toxicity,3,>=7 days,NA,NA
18766965,NA,299,toxicity,4,>=3 days,NA,NA
32998965,NCT03298984,302,nonhematologic toxicity,4,NA,NA,NA
32998965,NCT03298984,302,nonhematologic toxicity considered at least possibly drug related and that did not resolve to â‰¤Grade 2 within 48 hours,3,NA,FALSE,NA
32998965,NCT03298984,302,cytopenias in the absence of residual leukemia if subject received one cycle of induction,4,â‰¥50 days from the start of the cycle,NA,NA
32998965,NCT03298984,302,cytopenias in the absence of residual leukemia if subject received 2 cycles of induction,4,â‰¥60 days,NA,NA
32998965,NCT03298984,302,"tumor lysis syndrome or related electrolyte disturbances (e.g., hyperkalemia, hypophosphatemia, hyperuricemia) that did not resolve to â‰¤Grade 2 within 14 days",3 or 4,NA,NA,NA
32998965,NCT03298984,302,elevations in creatinine that did not resolve to â‰¤Grade 2 within 7 days,>=3,NA,NA,NA
32998965,NCT03298984,302,Any AST and ALT elevation â‰¥5 Ã—ULN accompanied by serum bilirubin levels >2 Ã—ULN,NA,NA,NA,NA
32998965,NCT03298984,302,toxicity that was not clearly and incontrovertibly related to the underlying disease or extraneous causes,5,NA,NA,NA
9250790,NA,303,nonhematologic toxicities,3,NA,FALSE,NA
9250790,NA,303,hematologic toxicity,4,NA,NA,NA
7545219,NA,304,"neutropenia (< 25,000/uL)",4,>7 days,NA,NA
7545219,NA,304,"thrombocytopenia (< 25,000/uL)",4,>7 days,NA,NA
7545219,NA,304,hemorrhage,3 or 4,NA,NA,NA
7545219,NA,304,nonhematologic toxicity,3 or 4,NA,FALSE,NA
7545219,NA,304,"failure to recover neutrophils (>= 1,500/uL) or platelets (>= 100,000/uL) by day 28 from a prior cycle of therapy",NA,NA,NA,NA
7545219,NA,304,febrile neutropenia,NA,NA,NA,defined as a single elevation in oral temperature >=38.5'C or three elevations >= 38 C during a 24-hour period in a patient with an ANC <= 500/uL
7527456,NA,305,nonhematologic toxicity,3 or 4,NA,FALSE,NA
7527456,NA,305,neutropenia,4,>7 days,NA,NA
7527456,NA,305,thrombocytopenia,4,>7 days,NA,NA
7527456,NA,305,"failure to recover a neutrophil count >= 1,500/uL or platelet count >= 100,000/uL by day 28 from a prior cycle of therapy",NA,NA,NA,NA
7527456,NA,305,A need for platelet transfusions for more than 7 days,NA,NA,NA,NA
7527456,NA,305,"inability to maintain a platelet count more than 100,000/uL by day 28 without transfusion",NA,NA,NA,NA
9508177,NA,307,any ANC less than 500/uL,NA,>7 days,NA,NA
9508177,NA,307,"platelet count less than 25,000/uL",NA,>7 days,NA,NA
9508177,NA,307,Any nonhematopoietic toxicity,>=3,NA,NA,NA
16186597,NA,308,toxicity,>=3,NA,FALSE,NA
16186597,NA,308,neutropenia associated with fever or infection in cycle 1 or cycle 2,4,>5 days,NA,NA
21745173,NA,309,NA,NA,NA,NA,DLT not defined
9773805,NA,310,non-hematologic toxicity,3 or 4,NA,FALSE,NA
9773805,NA,310,granulocytopenia,4,>7 days,NA,NA
9773805,NA,310,thrombocytopenia,4,>7 days,NA,NA
9773805,NA,310,failure to recover granulocytes >1500/ul or platelets >100000/ul by day 35 of the cycle,NA,NA,NA,NA
9738567,NA,311,reversible toxicity,3 or 4,NA,FALSE,NA
9738567,NA,311,irreversible toxicity,2,NA,FALSE,NA
9738567,NA,311,hematologic toxicity,4,NA,NA,NA
9738567,NA,311,hematologic toxicity,>=2,>5 days,NA,NA
9738567,NA,311,inrreversible CNS,2,NA,NA,NA
23813912,NCT00295919,312,"platelets < 10,000 on one occasion",NA,NA,NA,NA
23813912,NCT00295919,312,more than one platelet transfusion required per week,NA,NA,NA,NA
23813912,NCT00295919,312,ANC,4,>14 days,NA,NA
23813912,NCT00295919,312,nonhematologic toxicity possibly/probably-related to 4-HPR LXS oral powder,3 or 4,NA,FALSE,NA
8823338,NA,313,febrile neutropenia,NA,NA,NA,NA
8823338,NA,313,"severe thrombocytopenia (< 20,000/uL) that required platelet transfusions on at least two occasions",NA,NA,NA,NA
8823338,NA,313,nonhematologic toxicity,3 or 4,NA,NA,NA
8823338,NA,313,"failure of the platelet count to recover to 2 90,000/pL or ANC to recover to > 2,000/pL (despite adjunctive filgrastim) after up to a 10-day delay in the planned therapy",NA,NA,NA,NA
16849757,NA,314,toxicity,3 or 4,NA,FALSE,NA
12151959,NA,315,febrile neutropenia,NA,NA,NA,NA
12151959,NA,315,neutropenia,4,>5 days,NA,NA
12151959,NA,315,thrombocytopenia requiring platelet transfusions,NA,NA,NA,NA
12151959,NA,315,failure to recover blood counts in time for day 1 of the second cycle of therapy,NA,NA,NA,NA
12151959,NA,315,the failure to receive day 8 vinorelbine,NA,NA,NA,NA
12151959,NA,315,Nonhematologic toxicities,3 or 4,NA,NA,NA
18182662,NA,316,"nonhematologic, treatmentrelated toxicity Involving a major organ system (brain, heart, kidney, liver, or lung)",>=3,NA,NA,NA
32401633,NCT02642965,317,nonhematologic toxicity related to CPX-351,>=3,NA,FALSE,NA
32401633,NCT02642965,317,"failure to recover ANC > 500 /uL or platelet count >20,000/uL by day 50 of cycle 1, unless due to persistent marrow leukemia",4,NA,NA,NA
9256119,NA,318,nonhematologic toxicity that did not return to grade 2 before initiation of the next cycle of therapy,3,NA,NA,NA
9256119,NA,318,nonhematologic toxicity,4,NA,NA,NA
9256119,NA,318,Death on treatment attributable to therapy,NA,NA,NA,NA
9256119,NA,318,Dose-limiting bone marrow toxicity,NA,NA,NA,"defined as severe marrow
defined as severe marrow aplasia that lasted longer than 7 weeks"
16292542,NA,319,non-haematological,3 or 4,NA,NA,NA
16292542,NA,319,haematological toxicity,4,NA,NA,NA
20479064,NA,320,an AE despite medical therapy,>=3,NA,FALSE,NA
20479064,NA,320,"an AE that was potentially immune mediated and involved critical organs,",>=2,NA,NA,NA
23104721,NA,321,3 toxicities considered to be at least possibly related to TNFeradeâ„¢ Biologic,>=3,NA,FALSE,NA
25612635,NCT01227239,322,neutropenia,4,NA,NA,NA
25612635,NCT01227239,322,anemia,4,NA,NA,NA
25612635,NCT01227239,322,febrile neutropenia,>=3,NA,NA,NA
25612635,NCT01227239,322,thrombocytopenia,>=3,NA,NA,NA
25612635,NCT01227239,322,nonhematologic toxicity,>=3,NA,FALSE,NA
25612635,NCT01227239,322,a delay of more than 3 days in oxaliplatin administration,NA,NA,NA,NA
25612635,NCT01227239,322,withholding 13 or more of the 40 scheduled doses of S-1 because of toxicity,NA,NA,NA,NA
25612635,NCT01227239,322,the interruption of radiation for 1 week or longer because of toxicity,1,NA,NA,NA
21567184,NA,323,febrile neutropenia,>=3,NA,NA,NA
21567184,NA,323,neutropenia(without granulocyte-colony stimulating factor [G-CSF] treatment),4,>5 days,NA,NA
21567184,NA,323,thrombocytopenia,>=3,NA,NA,NA
21567184,NA,323,non-hematologic toxicity (including â‰¥Grade 3 nausea/vomiting uncontrolled by aggressive antiemetic support; â‰¥Grade 3 diarrhea despite anti-diarrhea treatment,>=3,NA,NA,NA
21567184,NA,323,drug related adverse events (DRAEs) that delay the initiation of the second cycle by >14 days,NA,NA,NA,NA
21290246,NA,324,ANC<0.5 9 109/L,NA,.5 days,NA,NA
21290246,NA,324,ANC<1.0 9 109/L with fever,NA,NA,NA,NA
21290246,NA,324,thrombocytopenia,4,NA,NA,NA
21290246,NA,324,"any other non-hematologic toxicity, including nausea, diarrhea, and vomiting",3 or 4,NA,FALSE,NA
21290246,NA,324,[2 weeksâ€™ treatment delay of S-1 and CPT-11,NA,NA,NA,NA
22993353,NA,325,febrile neutropenia,>=3,NA,NA,NA
22993353,NA,325,haematologic toxicity,>=4,NA,NA,NA
22993353,NA,325,non-haematologic toxicity,>=3,NA,FALSE,NA
22508373,UMIN000000883,326,nonhematologic toxicity,3 or 4,NA,FALSE,NA
22508373,UMIN000000883,326,neutropenia,4,>4 days,NA,NA
22508373,UMIN000000883,326,neutropenia associated with fever (>= 37.5 Â° C),4,NA,NA,NA
22508373,UMIN000000883,326,thrombocytopenia,4,NA,NA,NA
22508373,UMIN000000883,326,bleeding tendency in the first cycle of treatment,3,NA,NA,NA
22508373,UMIN000000883,326,toxicity precluding administration of the fourth cycle of treatment within 9 weeks from day 1 of cycle 1,NA,NA,NA,NA
22508373,UMIN000000883,326,toxicity precluding administration of the next cycle of treatment within 4 weeks from the completion of the previous cycle,NA,NA,NA,NA
21152917,NA,327,leukocytopenia,4,NA,NA,NA
21152917,NA,327,neutropenia,4,NA,NA,NA
21152917,NA,327,neutropenia with fever over 38C,>=3,NA,NA,NA
21152917,NA,327,thrombocytopenia,>=3,NA,NA,NA
21152917,NA,327,major nonhematological toxicities,>=3,NA,NA,NA
21152917,NA,327,delay CPT-11 on day 8 more than 7 days or delay of the second course more than 7 days due to adverse effect,NA,NA,NA,NA
22623210,NA,328,neutropenia,4,>=7 days,NA,NA
22623210,NA,328,thrombocytopenia,4,>=7 days,NA,NA
22623210,NA,328,febrile neutropenia,NA,NA,NA,NA
22623210,NA,328,neutropenic infection,NA,NA,NA,NA
22623210,NA,328,thrombocytopenia with bleeding,>=3,NA,NA,NA
22623210,NA,328,non-hematologic AEs,>=3,>=7 days,NA,NA
22623210,NA,328,nausea/vomiting or diarrhea if persistent despite maximal medical intervention,>=3,NA,NA,NA
21447616,NA,329,neutropenia,4,>=7 days,NA,NA
21447616,NA,329,thrombocytopenia,4,>=7 days,NA,NA
21447616,NA,329,febrile neutropenia,NA,NA,NA,NA
21447616,NA,329,neutropenic infection,NA,NA,NA,NA
21447616,NA,329,thrombocytopenia with bleeding,>=3,NA,NA,NA
21447616,NA,329,non-haematologic toxicity,3 or 4,>=7 days,FALSE,NA
21447616,NA,329,nausea/vomiting/diarrhoea persisting despite optimal medical therapy,3 or 4,NA,NA,NA
21968516,NA,330,hematological toxicities,4,NA,NA,NA
21968516,NA,330,nonhematological toxicities,>=3,NA,NA,NA
25427841,NCT01183494,331,neutropenia,4,>5 days,NA,NA
25427841,NCT01183494,331,febrile neutropenia,NA,NA,NA,NA
25427841,NCT01183494,331,thrombocytopenia,4,NA,NA,NA
25427841,NCT01183494,331,"nonhematologic toxicities, including nausea, vomiting, and diarrhea that did not improve to grade 1 within 2 days despite management therapies",>=3,NA,NA,NA
25143299,UMIN000007556,332,hematological toxicity,4,NA,NA,NA
25143299,UMIN000007556,332,non-hematologic toxicity,3 or 4,NA,NA,NA
25143299,UMIN000007556,332,delay of recovery from treatment-related toxicity for more than 2 weeks,NA,NA,NA,NA
25143299,UMIN000007556,332,dose intensity of S-1 and LV <50 % during the first two cycles due to treatment-related toxicity,NA,NA,NA,NA
23575907,NCT00557557,333,major organ toxicity related to the research intervention and irreversible within 48 h of the IHP,3 or 4,NA,FALSE,NA
23575907,NCT00557557,333,"If serum SGOT and SGPT did not decrease and were greater than 10 x the upper normal limit (i.e., >410 U/L for ALT and >340 U/L for AST) at 14 days after IHP",NA,NA,NA,NA
23575907,NCT00557557,333,hyperbilirubinemia in the first 6 weeks associated with clinical signs of veno-occlusive disease (VOD),NA,NA,NA,NA
23575907,NCT00557557,333,hyperbilirubinemia that did not resolve by 6 weeks after the IHP,3 or 4,NA,NA,NA
24839048,UMIN_CTR00002845,334,neutrophils,4,NA,NA,NA
24839048,UMIN_CTR00002845,334,platelets,4,NA,NA,NA
24839048,UMIN_CTR00002845,334,non-hematological toxicity,3 or 4,NA,FALSE,NA
24839048,UMIN_CTR00002845,334,The administration of less than two-thirds of the scheduled total S-1 or oxaliplatin dose and more than eight successive days of discontinuation of radiation due to adverse effects,NA,NA,NA,NA
22318782,NA,335,leukocytopenia,4,NA,NA,NA
22318782,NA,335,neutropenia,4,NA,NA,NA
22318782,NA,335,thrombocytopenia,3,NA,NA,NA
22318782,NA,335,non-hematological toxicity,3 or 4,NA,NA,NA
22318782,NA,335,the duration of S-1 administration during concurrent radiotherapy was under 3 weeks,NA,NA,NA,NA
22615059,NA,336,neutropenia,4,>=7 days,NA,NA
22615059,NA,336,febrile neutropenia,>=3,NA,NA,NA
22615059,NA,336,neutropenic infection,>=3,NA,NA,NA
22615059,NA,336,thrombocytopenia,4,NA,NA,NA
22615059,NA,336,thrombocytopenia,3,>=7 days,NA,NA
22615059,NA,336,Non-hematologic toxicities,3,>=7 days,TRUE,NA
22615059,NA,336,Non-hematologic toxicities,4,NA,NA,NA
22615059,NA,336,"nausea, vomiting or diarrhea despite optimal therapy",3 or 4,NA,NA,NA
22615059,NA,336,Sunitinib dose missed >3 consecutive days/cycle,NA,NA,NA,NA
22615059,NA,336,"Delay >2 weeks in administration of cycle 2, due to inadequate recovery from toxicity in cycle 1",NA,NA,NA,NA
20463088,NA,337,any nonhematologic toxicity,>=3,NA,FALSE,NA
20463088,NA,337,thrombocytopenia,4,NA,NA,NA
20463088,NA,337,thrombocytopenia,3,>6 days,NA,NA
20463088,NA,337,neutropenia,4,>6 days,NA,NA
20463088,NA,337,neutropenia associated with fever,4,NA,NA,NA
20463088,NA,337,any dose delay secondary to toxicity that lasted >1 week,NA,NA,NA,NA
24599799,NA,338,thrombocytopenia,4,NA,NA,NA
24599799,NA,338,neutropenia,4,>7 days,NA,NA
24599799,NA,338,febrile neutropenia,3 or 4,NA,NA,NA
24599799,NA,338,non-hematological toxicity,>=3,NA,NA,NA
24599799,NA,338,AST or ALT â‰¥20 times the ULN,NA,NA,NA,NA
20062993,NA,339,neutropenia,4,NA,NA,NA
20062993,NA,339,neutropenia with fever,3,NA,NA,NA
20062993,NA,339,thrombocytopenia,4,NA,NA,NA
20062993,NA,339,non-hematologic toxicity,4,NA,NA,NA
20062993,NA,339,non-hematologic toxicity,3,NA,FALSE,NA
20062993,NA,339,Any toxicity resulting in a delay of treatment lasting longer than 3 weeks,NA,NA,NA,NA
25591799,NCT00660153,340,nonhematologic toxicity,4,NA,NA,NA
25591799,NCT00660153,340,neutropenia  associated with fever or sepsis,>=3,NA,NA,NA
25591799,NCT00660153,340,neutropenia,4,>=5 days,NA,NA
25591799,NCT00660153,340,thrombocytopenia or bleeding requiring transfusion of platelets,4,NA,NA,NA
25591799,NCT00660153,340,toxicity of any grade resulting in inability to complete cycle 1 or resulting in interruption of treatment for > 2 weeks,NA,NA,NA,NA
25591799,NCT00660153,340,nonhematologic toxicity despite optimal supportive care,3,>3 days,TRUE,NA
20103995,NA,341,neutropenia,4,NA,NA,NA
20103995,NA,341,hrombocytopenia,4,NA,NA,NA
20103995,NA,341,neutropenia associated with fever â‰§38â„ƒ,3,NA,NA,NA
20103995,NA,341,non-hematological toxicity,>=3,NA,FALSE,NA
20103995,NA,341,treatment delay of >7 days before the second cycle of treatment,NA,NA,NA,NA
20103995,NA,341,Any skip in CPT-11 administration or more than 5 days suspension of S-1 administration with no relationship to the above DLTs,NA,NA,NA,NA
25572362,NCT01310478 ,342,NA,NA,NA,NA,DLT not defined
21344302,NA,343,"Any drug-related toxicity that required a >1-week delay in the start of the next cycle (i.e., >Day 35 from start of the previous cycle)",NA,NA,NA,NA
21344302,NA,343,absolute neutrophil count <0.5 x 109/L,NA,>=7 days,NA,NA
21344302,NA,343,neutropenic infection/febrile neutropenia,>=3,NA,NA,NA
21344302,NA,343,platelets <50 x 109/L,NA,NA,NA,NA
21344302,NA,343,thrombocytopenic bleeding,NA,NA,NA,NA
21344302,NA,343,neurotoxicity,>=2,NA,NA,NA
21344302,NA,343,other non-hematological toxicity,>=3,NA,NA,NA
21344302,NA,343,inability to receive 3 weekly doses of EU and 5-FU due to toxicity,NA,NA,NA,NA
21344302,NA,343,diarrhea that is uncontrolled despite; supportive care,>=3,NA,NA,NA
21372498,NA,344,nonhematologic adverse events,>=3,NA,NA,NA
21372498,NA,344,hematologic adverse events,>=3,NA,NA,NA
24097815,NA,345,treatment-related AE,4,NA,NA,NA
24097815,NA,345,"AE among the common side-effects of cisplatin (neuropathy, tinnitus, increased creatinine level)",3,NA,NA,NA
23674135,NA,346,neutrophil count < 0.5 x 109/L,NA,>5 days,NA,NA
23674135,NA,346,febrile neutropenia,NA,NA,NA,NA
23674135,NA,346,latelets< 25 x 109/L,NA,NA,NA,NA
23674135,NA,346,diarrhea  despite optimal loperamide use,>=3,>5 days,NA,NA
23674135,NA,346,other effects thought to be treatment-related,>3,NA,FALSE,NA
23674135,NA,346,"patients received dose intensity < 70% for each drug (cetuximab, 5-FU, and CP)",NA,NA,NA,NA
23982118,NA,347,neutropenia,4,>=7 days,NA,NA
23982118,NA,347,neutropenia with infection or fever (â‰¥38.3 Â°C as single temperature or â‰¥38.0 Â°C for 1 h),3 or 4,NA,NA,NA
23982118,NA,347,thrombocytopenia,4,NA,NA,NA
23982118,NA,347,non-hematological toxicity,3 or 4,NA,FALSE,NA
23982118,NA,347,inability of the patient to take â‰¥75 % of the planned chemotherapy dose during the treatment period,NA,NA,NA,NA
21611734,NA,348,toxicity considered to be related to cediranib,>=3,NA,NA,NA
21611734,NA,348,"a single increase from baseline in the QT interval corrected for heart rate (QTc) of 60 ms resulting in a QTc of at least 460 ms, or a QTc interval of >490 ms on two electrocardiograms taken at least 24 h apart",NA,NA,NA,NA
21611734,NA,348,hypertension necessitating treatment pause of cediranib as detailed in the cediranib hypertension management protocol,NA,NA,NA,NA
25074036,NCT01291615,349,leucopenia,4,NA,NA,NA
25074036,NCT01291615,349,neutropenia,4,NA,NA,NA
25074036,NCT01291615,349,thrombocytopenia,4,NA,NA,NA
25074036,NCT01291615,349,neutropenia complicated by fever,3 or 4,NA,NA,NA
25074036,NCT01291615,349,clinically significant non-hematologic toxicities,3 or 4,NA,NA,NA
25074036,NCT01291615,349,need to withhold gemcitabine on day 8 or 15 due to an adverse event,NA,NA,NA,NA
25074036,NCT01291615,349,delay of more than 14 days following an adverse event,NA,NA,NA,NA
25877225,UMIN000006123,351,neutropenia,4,>=5 days,NA,NA
25877225,UMIN000006123,351,febrile neutropenia,NA,NA,NA,NA
25877225,UMIN000006123,351,thrombocytopenia,4,NA,NA,NA
25877225,UMIN000006123,351,non-hematological toxicities,>=3,NA,NA,NA
25877225,UMIN000006123,351,A next cycle delay of >7 days due to any toxicity,NA,NA,NA,NA
21786211,NA,352,hematological toxicity,3 or 4,NA,NA,NA
21786211,NA,352,leukopenia,3 or 4,NA,NA,NA
21786211,NA,352,neutropenia accompanied with a fever >38.0C,3 or 4,NA,NA,NA
21786211,NA,352,nonhematological toxicity,3 or 4,NA,FALSE,NA
21786211,NA,352,an event such that the next infusion was not carried out within 22 days after the previous infusion,NA,NA,NA,NA
22763610,NA,353,NA,NA,NA,NA,Not provided
24480865,NA,354,leukopenia,4,NA,NA,NA
24480865,NA,354,neutropenia,4,NA,NA,NA
24480865,NA,354,febrile neutropenia,3,>4 days,NA,NA
24480865,NA,354,thrombocytopenia,4,NA,NA,NA
24480865,NA,354,thrombocytopenia with hemorrhage/bleeding,3,NA,NA,NA
24480865,NA,354,nonhematological toxicities,3,NA,FALSE,NA
24480865,NA,354,the need for a drugfree rest period of >21 days,NA,NA,NA,NA
23292146,NA,356,nonhematologic toxicity,3 or 4,NA,FALSE,NA
23292146,NA,356,hematologic toxicity occurring during treatment or within two weeks after completing treatment,4,NA,NA,NA
23292146,NA,356,requirement for suspension of either S-1 or radiation therapy for seven days or more,NA,NA,NA,NA
23208490,NCT00220649,357,neutropenia,4,>5 days,NA,NA
23208490,NCT00220649,357,neutropenic fever (â‰¥38.5 Â°C),NA,NA,NA,NA
23208490,NCT00220649,357,thrombocytopenia,4,NA,NA,NA
23208490,NCT00220649,357,non-hematological toxicity,3 or 4,NA,FALSE,NA
23208490,NCT00220649,357,inability to receive at least 75 % of the planned chemotherapy dose during the treatment period,NA,NA,NA,NA
20934959,NA,358,neutropenia,4,>=4 days,NA,NA
20934959,NA,358,neutropenia with infection or a fever of 38.0ÂºC or higher,>=3,NA,NA,NA
20934959,NA,358,thrombocytopenia,>=3,NA,NA,NA
20934959,NA,358,non-hematological toxicity,>=3,NA,FALSE,NA
20934959,NA,358,postponement of drug administration by two weeks or longer during the course due to adverse events,NA,NA,FALSE,NA
21868555,NA,359,leukopenia,4,NA,NA,NA
21868555,NA,359,neutropenia,4,NA,NA,NA
21868555,NA,359,neutropenia along with fever (febrile neutropenia),3 or 4,>=3 days,NA,NA
21868555,NA,359,thrombocytopenia,3 or 4,NA,NA,NA
21868555,NA,359,nonhematologic toxicity,>=3,NA,FALSE,NA
21868555,NA,359,a decrease in LVEF compared with baseline of â‰¥20%,NA,NA,NA,NA
21868555,NA,359,treatment period <14 days,NA,NA,NA,NA
21868555,NA,359,the second treatment cycle did not start within 4 weeks after treatment discontinuation,NA,NA,NA,NA
23665950,NCT00553696,360,neutropenia,4,>=7 days,NA,NA
23665950,NCT00553696,360,febrile neutropenia,>=3,NA,NA,NA
23665950,NCT00553696,360,neutropenic infection,>=3,NA,NA,NA
23665950,NCT00553696,360,thrombocytopenia,4,NA,NA,NA
23665950,NCT00553696,360,thrombocytopenia with bleeding,3,NA,NA,NA
23665950,NCT00553696,360,Non-hematologic toxicities,3,>=7 days,FALSE,NA
23665950,NCT00553696,360,non-hematologic toxicity,4,NA,NA,NA
23665950,NCT00553696,360,"nausea, vomiting or diarrhea persisting despite maximum supportive therapy",3 or 4,NA,NA,NA
23665950,NCT00553696,360,Break from sunitinib dose â‰¥6/28 days on the CDD schedule or â‰¥3/14 days on Schedule 2/2,NA,NA,NA,NA
23665950,NCT00553696,360,Break from S-1 dose â‰¥5/21 days per cycle,NA,NA,NA,NA
23665950,NCT00553696,360,Delay of >3 weeks in starting the second treatment cycle,NA,NA,NA,NA
24829073,NA,361,a hematological adverse drug reaction,4,NA,NA,NA
24829073,NA,361,febrile neutropenia,3,NA,NA,NA
24829073,NA,361,non-hematological adverse drug reaction,3,NA,FALSE,NA
24829073,NA,361,AST and ALT levels of 10 times higher than the upper limit of normal values,NA,NA,NA,NA
24829073,NA,361,an adverse drug reaction requiring discontinuation of TSU-68 treatment for 15 consecutive days during a cycle,NA,NA,NA,NA
24829073,NA,361,an adverse drug reaction requiring discontinuation of S-1 treatment for 8 consecutive days during a cycle,NA,NA,NA,NA
24829073,NA,361,an adverse drug reaction requiring discontinuation of TSU-68 plus S-1 treatment,NA,NA,NA,NA
21134076,NA,362,febrile neutropenia,NA,>4 days,NA,NA
21134076,NA,362,thrombocytopenia,4,NA,NA,NA
21134076,NA,362,non-hematological toxicities,3 or 4,NA,FALSE,NA
21134076,NA,362,cessation of treatment due to an adverse event,NA,NA,NA,NA
21134076,NA,362,treatment-related death,NA,NA,NA,NA
25217393,NA,363,neutropenia,3 or 4,NA,NA,NA
25217393,NA,363,thrombocytopenia,3 or 4,NA,NA,NA
25217393,NA,363,"febrile neutropenia, defined as grade 3 or 4 neutropenia plus fever >38.3 Â°C",NA,NA,NA,NA
25217393,NA,363,diarrhea despite the use of loperamide,3 or 4,NA,NA,NA
25217393,NA,363,AST/ALT elevation or total bilirubin â‰¥3.0 mg/dL not caused by disease progression,3 or 4,NA,NA,NA
25217393,NA,363,serum creatinine â‰¥1.8 mg/dL that did not recover to <1.5 mg/dL within 2 weeks,NA,NA,NA,NA
22237958,NCT01284413,364,neutropenia complicated by fever,3 or 4,NA,NA,NA
22237958,NCT01284413,364,leucopenia,4,NA,NA,NA
22237958,NCT01284413,364,neutropenia,4,NA,NA,NA
22237958,NCT01284413,364,thrombocytopenia,4,NA,NA,NA
22237958,NCT01284413,364,any other non-hematological toxicity,3 or 4,NA,TRUE,NA
25687990,NA,365,hematological toxicity,4,NA,NA,NA
25687990,NA,365,neutropenia complicated by fever,3 or 4,NA,NA,NA
25687990,NA,365,non-hematological toxicity,3 or 4,NA,FALSE,NA
25687990,NA,365,treatment delay of more than 3 weeks due to treatment-related toxicity,NA,NA,NA,NA
25422155,UMIN000008415,366,hematological toxicity,4,NA,NA,NA
25422155,UMIN000008415,366,non-hematological toxicity,>=3,NA,NA,NA
25422155,UMIN000008415,366,any delay more than 14 days in the completion of treatment between the first day of the first cycle and of the second cycle,NA,NA,NA,NA
21077997,NA,367,neutropenia,4,>4 days,NA,NA
21077997,NA,367,febrile neutropenia,3,NA,NA,NA
21077997,NA,367,thrombocytopenia,3,NA,NA,NA
21077997,NA,367,non-hematological toxicity,3 or 4,NA,TRUE,NA
21077997,NA,367,a skip of irinotecan on day 8,NA,NA,NA,NA
21077997,NA,367,an 8-day interruption of administration of S-1,NA,NA,NA,NA
21077997,NA,367,8 days delay of the initiation of the second cycle,NA,NA,NA,NA
21540865,NCT00705016,368,haematological toxicity,4,NA,NA,NA
21540865,NCT00705016,368,non-haematological toxicity,4,NA,TRUE,NA
21540865,NCT00705016,368,Any treatment-related death observed within the first 3 weeks of therapy,NA,NA,NA,NA
23397499,NA,369,treatment-related toxicity,3 or 4,NA,NA,NA
16203658,NA,370,neutropenia,4,NA,NA,NA
16203658,NA,370,thrombocytopenia,4,NA,NA,NA
16203658,NA,370,febrile neutropenia,NA,NA,NA,NA
16203658,NA,370,any other adverse event or laboratory abnormality,3 or 4,NA,NA,NA
16203658,NA,370,any hematologic or nonhematologic toxicity requiring treatment delay for more than 3 days,NA,NA,NA,NA
16203658,NA,370,any adverse event requiring the interruption of L-OHP administration,NA,NA,NA,NA
22510347,NA,372,neutropenic fever,NA,NA,NA,NA
22510347,NA,372,absolute neutrophil count <500,NA,.5 days,NA,NA
22510347,NA,372,"platelet count <20,000",NA,NA,NA,NA
22510347,NA,372,any vector-related nonhematologic toxicity,3,NA,NA,NA
16163539,NA,373,an absolute leukocyte count < 1.0 x 109/L,4,>=4 days,NA,NA
16163539,NA,373,a body temperature higher than 38C or the occurrence of an infection with an absolute granulocyte count < 0.5 x 109/L (grade 4),NA,NA,NA,NA
16163539,NA,373,a platelet count < 20.0 x 109/L,NA,NA,NA,NA
16163539,NA,373,non-hematological toxicity,>=3,NA,FALSE,NA
16163539,NA,373,a treatment delay of 1 week or more because of toxicity,NA,NA,NA,NA
16319514,NA,374,leucopenia,4,NA,NA,NA
16319514,NA,374,neutropenia,4,NA,NA,NA
16319514,NA,374,febrile neutropenia,NA,NA,NA,NA
16319514,NA,374,thrombocytopenia,4,NA,NA,NA
16319514,NA,374,thrombocytopenia requiring transfusion,3,NA,NA,NA
16319514,NA,374,non-hematological toxicity,>=3,NA,FALSE,NA
16319514,NA,374,any toxicity that necessitated a treatment delay of more than 3 weeks,NA,NA,NA,NA
16466986,NA,375,neutropenia,4,NA,NA,NA
16466986,NA,375,thrombocytopenia,>=3,NA,NA,NA
16466986,NA,375,neutropenic fever or sepsis,NA,NA,NA,NA
16466986,NA,375,nausea/vomiting or diarrhea,>=3,NA,NA,NA
16466986,NA,375,any single interruption of radiation therapy â‰¥10 days,NA,NA,NA,NA
16466986,NA,375,â‰¥2 interruptions of radiation per course,NA,NA,NA,NA
16466986,NA,375,a delay in completion of radiation therapy by â‰¥14 days,NA,NA,NA,NA
16466986,NA,375,any treatment related death or hospitalization,NA,NA,NA,NA
15473585,NA,376,gastrointestinal toxicity,3,NA,NA,NA
15473585,NA,376,toxicity of any kind necessitating a cumulative treatment break of more than 7 days,4,NA,NA,NA
26783290,NCT01344031,377,hematologic event,4,NA,NA,NA
26783290,NCT01344031,377,uncontrollable hyperglycemia,NA,NA,NA,NA
26783290,NCT01344031,377,nonhematologic toxicity,3 or 4,NA,NA,NA
26783290,NCT01344031,377,nausea,3 or 4,NA,NA,NA
26783290,NCT01344031,377,vomiting,3 or 4,NA,NA,NA
26783290,NCT01344031,377,diarrhea,3 or 4,NA,NA,NA
26783290,NCT01344031,377,any intolerable nonhematologic toxicity requiring a dose reduction,2,NA,NA,NA
26783290,NCT01344031,377,any intolerable grade 3 hematologic toxicity requiring a dose reduction,3,NA,NA,NA
26783290,NCT01344031,377,a delay of MK-2206 or anastrozole for >1 week during cycle 1 or >3 total weeks during the first 3 cycles of therapy in RPTD determination,NA,NA,NA,NA
14605864,NA,378,neutropenia,4,>5 days,NA,NA
14605864,NA,378,febrile neutropenia,NA,NA,NA,NA
14605864,NA,378,thrombocytopenia,4,NA,NA,NA
14605864,NA,378,nonhaematological toxicity including diarrhoea despite loperamide treatment,3,NA,FALSE,NA
14739662,NA,379,hematologic toxicity,4,NA,NA,NA
14739662,NA,379,nonhematologic toxicity,>=3,NA,FALSE,NA
15818508,NA,380,haematological toxicity,4,NA,NA,NA
15818508,NA,380,febrile neutropenia,NA,NA,NA,NA
15818508,NA,380,sepsis concomitatnt to grade 3/4 neutropenia,NA,NA,NA,NA
15818508,NA,380,symptomatic thrombocytopenia,NA,NA,NA,NA
15818508,NA,380,any nonhaematological toxicity,3 or 4,NA,FALSE,NA
15818508,NA,380,"early infusion termination before 14 days for any reason other than technical issues, only for the first step and first infusion",NA,NA,NA,NA
16199307,NA,381,hematologic effects,4,NA,NA,NA
16199307,NA,381,nonhematologic systemic effects,3 or 4,NA,NA,NA
16199307,NA,381,mucositis,4,NA,NA,NA
16199307,NA,381,"Prolonged mucositis, lasting longer than 6 weeks from completion ofchemoradiation",4,NA,NA,NA
16249791,NA,382,diarrhoea,3 or 4,NA,NA,NA
16249791,NA,382,nausea,3 or 4,NA,NA,NA
16249791,NA,382,vomiting,3 or 4,NA,NA,NA
16249791,NA,382,thrombocytopaenia,3 or 4,NA,NA,NA
16249791,NA,382,neutropaenia,3 or 4,NA,NA,NA
16249791,NA,382,acute sensorimotor neuropathy,3,NA,NA,NA
15729600,NA,383,non-hematological toxicities,3 or 4,NA,NA,NA
15729600,NA,383,platelet count,4,NA,NA,NA
15729600,NA,383,platelet count with bleeding tendency,3,NA,NA,NA
15729600,NA,383,leucopenia,4,NA,NA,NA
15729600,NA,383,neutropenia,4,>3 days,NA,NA
15729600,NA,383,febrile neutropenia,3 or 4,NA,NA,NA
15729600,NA,383,A delay of the second course by at least 14 days,NA,NA,NA,NA
30684019,NCT02109016,384,febrile neutropenia,3,NA,NA,NA
30684019,NCT02109016,384,neutropenia,4,>5 days,NA,NA
30684019,NCT02109016,384,thrombocytopenia,3,>5 days,NA,NA
30684019,NCT02109016,384,any other haematological toxicities,4,NA,NA,NA
30684019,NCT02109016,384,All non-haematologic toxicity (grade 3 increase in AST and ALT lasting for more than 7 days; hypertension with SBP â‰¥160 mmHg or DBP â‰¥100 mmHg if not controlled by antihypertensive therapy within 7 days; grade 3 nausea and vomiting if not controlled by antiemetic treatment),>=3,NA,NA,NA
30684019,NCT02109016,384,proteinuria,2,>7 days,NA,NA
30684019,NCT02109016,384,administration of less than 75% of planned doses of lucitanib due to treatment related toxicities,NA,NA,NA,NA
30543347,NCT01219699,385,prespecified AEs or laboratory abnormalities that may have been associated with study treatment and occurred fewer than 28 days following the first alpelisib dose (cycle 1),NA,NA,NA,NA
16297614,NA,386,leukopenia,4,NA,NA,NA
16297614,NA,386,neutropenia,4,NA,NA,NA
16297614,NA,386,thrombocytopenia,4,NA,NA,NA
16297614,NA,386,febrile neutropenia,NA,NA,NA,NA
16297614,NA,386,severe infection (requiring hospitalisation and antibiotic therapy),NA,NA,NA,NA
16297614,NA,386,anaemia,4,NA,NA,NA
16297614,NA,386,diarrhoea,3,>3 days,NA,NA
16297614,NA,386,diarrhoea,4,NA,NA,NA
16297614,NA,386,vomiting despite satisfactory prophylactic and curative treatmen,3 or 4,NA,NA,NA
16297614,NA,386,mucositis,3 or 4,NA,NA,NA
16297614,NA,386,sensory neuropathy,3,NA,NA,NA
16297614,NA,386,any life-threatening event and/or any event resulting in hospitalisation not scheduled in the context of treatment,NA,NA,NA,NA
15205598,NA,387,NA,NA,NA,NA,DLT not defined
28854070,NA,388,hematologic toxicity,>=4,NA,NA,NA
28854070,NA,388,nonhematologic toxicity,>=3,NA,NA,NA
28854070,NA,388,toxicity that resulted in < 14 days of treatment during the first treatment cycle,>=2,NA,NA,NA
15274409,NA,389,haematological toxicity,4,NA,NA,NA
15274409,NA,389,nausea and vomiting,4,NA,NA,NA
15274409,NA,389,any other non-haematological toxicity,3,NA,FALSE,NA
16596209,NA,390,non-hematological toxicity,3 or 4,NA,FALSE,NA
16596209,NA,390,neutropenia,4,NA,NA,NA
16596209,NA,390,febrile neutropenia,NA,NA,NA,NA
16596209,NA,390,other hematological toxicity,4,NA,NA,NA
16596209,NA,390,any toxicity determining a treatment delay longer than 2 weeks,NA,NA,NA,NA
15596912,NA,391,neutropenia in GCSF-supported patients,4,NA,NA,NA
15596912,NA,391,thrombocytopenia,4,NA,NA,NA
15596912,NA,391,neutropenic fever,NA,NA,NA,NA
15596912,NA,391,nonhematological toxicity,4,NA,FALSE,NA
15596912,NA,391,more than 2-week treatment delay,NA,NA,NA,NA
16319513,NA,392,leukopenia/neutropenia,4,NA,NA,NA
16319513,NA,392,febrile grade 3 neutropenia,NA,>4 days,NA,NA
16319513,NA,392,thrombocytopenia,3,NA,NA,NA
16319513,NA,392,non-hematological toxicity,>=3,NA,NA,NA
14581279,NA,393,neutropenia,4,>=5 days,NA,NA
14581279,NA,393,thrombocytopenia,4,>=5 days,NA,NA
14581279,NA,393,neutropenia associated with grade â‰¥2 fever,4,NA,NA,NA
14581279,NA,393,neuropathy that did not resolve prior to initiation of next cycle,>=3,NA,NA,NA
14581279,NA,393,non-hematological toxicity related to study drugs,>=3,NA,NA,NA
14581279,NA,393,"nausea, vomiting or diarrhea that occurred despite maximal supportive therapy",>=3,NA,NA,NA
14581279,NA,393,cycle 2 delay of >2 weeks due to toxicity,NA,NA,NA,NA
23260601,NA,394,nonhematologic toxicity that was at least possibly attributable to protocol therapy,>=3,NA,FALSE,NA
23260601,NA,394,hematologic toxicity,4,>3 weeks,NA,NA
23260601,NA,394,infections,4,NA,NA,NA
15613903,NA,395,ANC < 500/ml,NA,>5 days,NA,NA
15613903,NA,395,platelets < 50 000/ml,NA,>5 days,NA,NA
15613903,NA,395,ANC < 500/ml with fever requiring parenteral antibiotics,NA,NA,NA,NA
15613903,NA,395,non-hematologic toxicity,3,NA,FALSE,NA
15613903,NA,395,nausea and vomiting,3,NA,NA,NA
15014353,NA,396,non-hematologic toxicity (including nausea/vomiting despite aggressive antiemetic therapy),>=3,NA,NA,NA
15014353,NA,396,inability of the patient to take 75% or more of planned chemotherapy,NA,NA,NA,NA
15961435,NA,397,leukopenia,4,>4 days,NA,NA
15961435,NA,397,neutropenia,4,>4 days,NA,NA
15961435,NA,397,leukopenia accompanied by high fever (>38C),4,NA,NA,NA
15961435,NA,397,neutropenia accompanied by high fever (>38C),4,NA,NA,NA
15961435,NA,397,thrombocytopenia (<20 000/mm3),3,NA,NA,NA
15961435,NA,397,non-hematological toxicities,3 or 4,NA,FALSE,NA
16145066,NA,398,nonhematologic toxicity,>=3,NA,FALSE,NA
16145066,NA,398,hematologic toxicity,4,NA,NA,NA
16145066,NA,398,febrile neutropenia,NA,NA,NA,NA
15719490,NA,399,neutropenia,4,>5 days,NA,NA
15719490,NA,399,neutropenia complicated by fever >38.5 Â°C,3 or 4,NA,NA,NA
15719490,NA,399,thrombocytopenia,>=3,NA,NA,NA
15719490,NA,399,any non-haematological toxicity,>=3,NA,FALSE,NA
15297392,NA,400,neutropenia,4,>4 days on day 1 of next cycle,NA,NA
15297392,NA,400,a neutropenic fever despite therapy with G-CSF,NA,NA,NA,NA
15297392,NA,400,thrombocytopenia,4,>4 days on day 1 of next cycle,NA,NA
15297392,NA,400,mucositis and/or dermatitis,>=4,>7 days,NA,NA
15297392,NA,400,mucositis and/or dermatitis not resolving to grade 3 on day 1 of next cycle,>=4,NA,NA,NA
15297392,NA,400,any other toxicity resulting in a failure to receive the full dose of chemotherapy within 24 h of the scheduled time during the first three cycles,3,NA,FALSE,NA
15108040,NA,401,nonhematologic toxicity,>=3,NA,FALSE,NA
15108040,NA,401,neutropenia,4,>4 days,NA,NA
15108040,NA,401,neutropenic fever,3,NA,NA,NA
15108040,NA,401,thrombocytopenia,4,NA,NA,NA
16141295,NA,402,neutropenia,4,>3 days,NA,NA
16141295,NA,402,thrombocytopenia,4,NA,NA,NA
16141295,NA,402,any febrile grade 3 or 4 (severe) hematological toxicity,NA,NA,NA,NA
16141295,NA,402,non-hematological toxicity,3,NA,FALSE,NA
16141295,NA,402,More than 7 days of rest following S-1 and the discontinuation of the second administration of CPT-11 during the first course,NA,NA,NA,NA
15028404,NA,403,"nausea, vomiting or diarrhoea despite medical intervention",3 or 4,NA,NA,NA
15028404,NA,403,neutropenia,4,>=7 days,NA,NA
15028404,NA,403,eutropenic fever,NA,NA,NA,NA
15028404,NA,403,thrombocytopenia,4,NA,NA,NA
15028404,NA,403,fatigue,>=3,NA,NA,NA
15028404,NA,403,urinary bladder problems,>=3,NA,NA,NA
15028404,NA,403,other non-haematological toxicity,>=3,NA,NA,NA
15028404,NA,403,compliance below 75% of the planned chemoradiotherapy due to toxicity,NA,NA,NA,NA
15122078,NA,404,"nausea, vomiting, or diarrhea, uncontrolled by aggressive support",>=3,NA,NA,NA
15122078,NA,404,neutropenia,4,>3 days,NA,NA
15122078,NA,404,leukopenia,4,>3 days,NA,NA
15122078,NA,404,"febrile neutropenia, defined as a body temperature â‰¥38.5â—¦C and an ANC <1,000/ÂµL",NA,NA,NA,NA
15122078,NA,404,hematologic toxicity other than neutropenia or leukopenia,>=3,NA,NA,NA
15122078,NA,404,nonhematologic toxicity,>=3,NA,NA,NA
15942632,NA,405,neutropenia complicated by fever,3 or 4,NA,NA,NA
15942632,NA,405,neutropenia,4,>4 days,NA,NA
15942632,NA,405,thrombocytopenia,4,NA,NA,NA
15942632,NA,405,any other nonhaematologic toxicity,3 or 4,NA,FALSE,NA
15942632,NA,405,delay of recovery from treatment-related toxicity for more than 2 weeks,NA,NA,NA,NA
15014354,NA,406,neutropenia,4,>7 days,NA,NA
15014354,NA,406,thrombocytopenia,4,>7 days,NA,NA
15014354,NA,406,neutropenia with fever >= 38.3C,4,NA,NA,NA
15014354,NA,406,mucositis,4,NA,NA,NA
15014354,NA,406,dermatitis,4,NA,NA,NA
15014354,NA,406,diarrhea (despite anti-diarrheal prophylaxis),4,NA,NA,NA
15014354,NA,406,failure of thrombocytopenia to resolve within 21 days,NA,NA,NA,NA
15014354,NA,406,failure of neutropenia to resolve to grade 1 or less,NA,NA,NA,NA
15014354,NA,406,failure of non-hematologic toxicity to resolve within 21 days,NA,NA,NA,NA
16009951,NA,407,neutropenia,4,NA,NA,NA
16009951,NA,407,thrombocytopenia,4,NA,NA,NA
16009951,NA,407,"neutropenic fever, defined as grade 3 or 4 neutropenia plus fever greater than 38.3Â°C",NA,NA,NA,NA
16009951,NA,407,diarrhea despite aggressive use of loperamide,3 or 4,NA,NA,NA
16009951,NA,407,total bilirubin >= 3.0 mg/dL not caused by disease progression,NA,NA,FALSE,NA
16009951,NA,407,serum creatinine >= 1.8 mg/dL that does not recover to less than 1.5 mg/dL within 2 weeks,NA,NA,NA,NA
14962716,NA,409,absolute neutrophil count < 0.5x109 cells/l,NA,5 days,NA,NA
14962716,NA,409,latelet count < 25x109 cells/,NA,NA,NA,NA
14962716,NA,409,diarrhoea despite loperamide support,3,NA,NA,NA
14962716,NA,409,other non-haematological toxicity,>=3,NA,NA,NA
14962716,NA,409,receipt of < 75% of planned dose of both drugs in a cycle,NA,NA,NA,NA
29289986,NA,410,febrile neutropenia with grade â‰¥ 3 neutropenia,NA,NA,NA,NA
29289986,NA,410,anemia,>=4,NA,NA,NA
29289986,NA,410,neutropenia,3,>=5 days,NA,NA
29289986,NA,410,neutropenia,>=4,NA,NA,NA
29289986,NA,410,thrombocytopenia with grade â‰¥ 3 bleeding,3,NA,NA,NA
29289986,NA,410,thrombocytopenia,>=4,NA,NA,NA
29289986,NA,410,acute kidney injury,>=3,NA,NA,NA
29289986,NA,410,somnolence,>=3,NA,NA,NA
29289986,NA,410,oral mucositis,>=3,NA,NA,NA
29289986,NA,410,other non-hematologic toxicity,>=3,NA,NA,NA
29289986,NA,410,a delay in treatment of greater than 2 weeks due to toxicity,NA,NA,NA,NA
15549585,NA,411,nonhematologic toxicity,3,NA,FALSE,NA
15549585,NA,411,leukopenia,4,>5 days,NA,NA
15549585,NA,411,febrile neutropenia,3,NA,NA,NA
15549585,NA,411,thrombocytopenia,4,NA,NA,NA
15549585,NA,411,thrombocytopenia with hemorrhage,3,NA,NA,NA
15549585,NA,411,a WBC count of less than 3000/Âµl,NA,NA,NA,NA
15549585,NA,411,a platelet count of less than 100000/Âµl requiring treatment to be discontinued for at least 8 days,NA,NA,NA,NA
15549585,NA,411,non-hematologic toxicity on day 22 requiring treatment to be discontinued for at least 8 days,>=2,NA,NA,NA
14676796,NA,412,neutropenia,4,>3 days,NA,NA
14676796,NA,412,any febrile grade 3 or 4 (severe) haematological toxicity,NA,NA,NA,NA
14676796,NA,412,nonhaematological toxicity,3,NA,FALSE,NA
14676796,NA,412,when the second course treatment was not resumed within 18 days after the first course,NA,NA,NA,NA
16570038,NA,413,neutropenia,4,NA,NA,NA
16570038,NA,413,thrombocytopenia,4,NA,NA,NA
16570038,NA,413,febrile grade 3 or 4 haematological toxicity,NA,NA,NA,NA
16570038,NA,413,nonhaematological toxicity,3,NA,FALSE,NA
15033659,NA,414,hematological toxicity (granulocyte level <0.5 Ã— 109/l or platelets <25 Ã— 109/l,4,NA,NA,NA
15033659,NA,414,febrile neutropenia,3 or 4,NA,NA,NA
15033659,NA,414,sepsis concomitant with grade 3/4 neutropenia,NA,NA,NA,NA
15033659,NA,414,symptomatic thrombocytopenia (hemorrhage),NA,NA,NA,NA
15033659,NA,414,non-hematological toxicity in the first course,3 or 4,NA,FALSE,NA
16601426,NA,415,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16601426,NA,415,hematologic toxicity,4,>7 days,NA,NA
16601426,NA,415,"hematologic toxicity complicated by fever, infection, or hemorrhage",4,NA,NA,NA
16601426,NA,415,nausea,3,NA,NA,NA
16601426,NA,415,vomiting,4,NA,NA,NA
33641211,NA,416,nonhematologic toxicity that was considered related to ixazomib,>=3,NA,NA,NA
33641211,NA,416,hematologic toxicity that was considered related to ixazomib,>=4,NA,NA,NA
14647137,NA,417,"haematological toxicity (neutrophile granulocyte, thrombocytes)",4,NA,NA,NA
14647137,NA,417,diarrhoea,3,NA,NA,NA
14647137,NA,417,febrile neutropenia with any grade of diarrhoea or any organ toxicity grade III (nephrotoxicity grade II),3,NA,FALSE,NA
15947933,NA,418,any non-hematologic toxicity,>=3,NA,FALSE,NA
15947933,NA,418,neutropenia,4,>7 days,NA,NA
15947933,NA,418,thrombocytopenia,4,NA,NA,NA
15947933,NA,418,thrombocytopenic bleeding,NA,NA,NA,NA
15947933,NA,418,febrile neutropenia (temperature >38.5C),NA,NA,NA,NA
15947933,NA,418,anemia,4,NA,NA,NA
16549999,NA,419,nausea and or vomiting despite adequate antiemetic therapy (steroids plus 5-HT3 antagonists at investigator criteria),>=3,NA,NA,NA
16549999,NA,419,any non-hematological toxicity,>=3,NA,FALSE,NA
16549999,NA,419,any hematological toxicity,>=3,NA,FALSE,NA
16549999,NA,419,neutropenia,4,>5 days,NA,NA
16549999,NA,419,febrile neutropenia defined as temperature >= 38.51C and neutrophil cell count <= 1000/mm3,NA,NA,NA,NA
16549999,NA,419,inability of the patient to receive >= 75% planned UFT dose,NA,NA,NA,NA
34417914,NA,420,febrile neutropenia,NA,NA,NA,NA
34417914,NA,420,neutropenia,4,NA,NA,NA
34417914,NA,420,thrombocytopenia,4,NA,NA,NA
34417914,NA,420,fatigue,4,NA,NA,NA
34417914,NA,420,nausea and vomiting,3,NA,NA,NA
34417914,NA,420,treatment interruptions ofâ‰¥7 days,NA,NA,NA,NA
34417914,NA,420,non-hematological AEs,>=3,NA,NA,NA
30635165,NCT01908478,421,thrombocytopenia/anemia,>=4,NA,NA,NA
30635165,NCT01908478,421,thrombocytopenia with bleeding,3,NA,NA,NA
30635165,NCT01908478,421,febrile neutropenia,>=3,NA,NA,NA
30635165,NCT01908478,421,ANC < 100,NA,>=3 days,NA,NA
30635165,NCT01908478,421,ANC < 500,NA,>=5 days,NA,NA
30635165,NCT01908478,421,any non-hematologic,>=3,NA,FALSE,NA
30635165,NCT01908478,421,any other toxicity,4,NA,NA,NA
17119113,NA,422,Toxicity,3 or 4,NA,NA,NA
31338636,NA,423,neutropenia,>=4,>7 days,NA,NA
31338636,NA,423,thrombocytopenia,>=4,>7 days,NA,NA
31338636,NA,423,febrile neutropenia,>=3,NA,NA,NA
31338636,NA,423,increase in total bilirubin or transaminases (unless elevated at baseline),>=3,NA,NA,NA
31338636,NA,423,non-hematologic toxicity,>=3,NA,TRUE,NA
20708924,NA,424,thrombocytopenia,3 or 4,NA,NA,NA
20708924,NA,424,neutropenia,4,NA,NA,NA
20708924,NA,424,non-haematologic toxicity,3 or 4,NA,NA,NA
20708924,NA,424,non-haematologic toxicity considered suffiÂ­ciently significant or intolerable by patients to warrant treatÂ­ment interruption and/or dose reduction,2,>7 days,NA,NA
20708924,NA,424,any toxicity requiring interruption of radiation therapy for >5 consecutive days or 10 d total,NA,NA,NA,NA
30895346,NA,425,neutropenia,>=4,>7 days,NA,NA
30895346,NA,425,thrombocytopenia,>=4,>7 days,NA,NA
30895346,NA,425,febrile neutropenia where ANC<500 and temperature>101 Â°F,NA,NA,NA,NA
30895346,NA,425,nausea/vomiting or diarrhea despite adequate supportive measures,>=3,â‰¥4 days,NA,NA
30895346,NA,425,other non-hematologic toxicity,>=3,NA,FALSE,NA
30895346,NA,425,any treatment-related death or treatment-related hospitalization,NA,NA,FALSE,NA
30895346,NA,425,"inability to deliver>85% of scheduled gemcitabine, dasatinib, and cetuximab (in case of intra-cycle dose modifications) due to treatment-related toxicity, delay in recovery of toxicity that is considered treatment-related that results in 14 day delay in starting cycle 2",NA,NA,NA,NA
30895346,NA,425,other severe or otherwise intolerable toxicities considered by the study Principal Investigator (PI) to be dose-limiting,NA,NA,NA,NA
32772340,jRCTs 031180095,426,neutropenia,>=4,â‰¥5 days,NA,NA
32772340,jRCTs 031180095,426,febrile neutropenia,>=3,NA,NA,NA
32772340,jRCTs 031180095,426,thrombocytopenia,>=4,NA,NA,NA
32772340,jRCTs 031180095,426,thrombocytopenia with obvious bleeding,3,NA,NA,NA
32772340,jRCTs 031180095,426,nonhematological AEs despite supportive care,>=3,>5 days,NA,NA
32772340,jRCTs 031180095,426,any AEs which preclude to meet the criteria of cycle 2 initiation,NA,NA,NA,NA
15744591,NA,427,toxicity,>=3,NA,FALSE,NA
15744591,NA,427,significant cardiac conduction defects (P-R interval > 217 msec),NA,NA,NA,NA
15744591,NA,427,ocular or renal toxicity,>=2,NA,NA,NA
15744591,NA,427,any toxicity necessitating reduction or a dose hold of â‰¥7 days,NA,NA,NA,NA
34319586,NCT02227940,428,neutropenia,4,NA,NA,"lasting more than 7 days, not reversible toâ‰¤grade 3 within 7 dayswithout the use of growth factors)"
34319586,NCT02227940,428,febrile neutropenia,NA,NA,NA,NA
34319586,NCT02227940,428,neutrope-nia associated with bacteremia or sepsis,NA,NA,NA,NA
34319586,NCT02227940,428,eutropeniaassociated with fever or infection,>=3,NA,NA,NA
34319586,NCT02227940,428,thrombocytopenia,4,NA,NA,NA
34319586,NCT02227940,428,hrombocytopenia with clinically significant bleeding,3,NA,NA,NA
34319586,NCT02227940,428,nonhematologic toxicity,>=3,NA,FALSE,NA
23261229,NA,431,neutropenia,4,â‰¥5 days,NA,NA
23261229,NA,431,neutropenia with fever >38.5 â—¦C and/or infection,3 or 4,NA,NA,NA
23261229,NA,431,thrombocytopenia,4,NA,NA,NA
23261229,NA,431,infusion reaction,4,NA,NA,NA
23261229,NA,431,skin toxicity that requires treatment interruption for â‰¥2weeks,3,NA,NA,NA
23261229,NA,431,any other non-hematologic toxicity,3 or 4,NA,NA,NA
25784657,NCT00372515,432,any gefitinib related toxicity,>=3,NA,FALSE,NA
33523334,NCT02624492,433,any non-hematologic AEs,>=3,NA,FALSE,NA
33523334,NCT02624492,433,neutropenia despite growth factor support,4,> 7 days,NA,NA
33523334,NCT02624492,433,any febrile neutropenia that did not resolve within 48 h with appropriate treatment,NA,NA,NA,NA
33523334,NCT02624492,433,thrombocytopenia,4,> 7 days,NA,NA
33523334,NCT02624492,433,thrombocytopenia with clinically significant bleeding,3 or 4,NA,NA,NA
33523334,NCT02624492,433,failure to recover platelets â‰¥ 75 Ã— 109/L by 4 weeks after the start of the cycle,NA,NA,NA,NA
33523334,NCT02624492,433,failure to recover neutrophils â‰¥ 1.0 Ã— 109/L by 4 weeks after start of the cycle,NA,NA,NA,NA
34066784,NCT02109341,434,treatment-related toxicities,NA,NA,NA,NA
30068505,NCT01582776,436,neutropenia,>=3,>=7 days,NA,NA
30068505,NCT01582776,436,thrombocytopenia,>=3,>=7 days,NA,NA
30068505,NCT01582776,436,neutropenia,4,>3 days,NA,NA
30068505,NCT01582776,436,thrombocytopenia,4,>3 days,NA,NA
30068505,NCT01582776,436,no recovery of absolute neutrophil count >=1.5 x 109/L or platelet count >=100 x 109/L by 8 weeks after the start of the previous cycle,4,NA,NA,NA
30068505,NCT01582776,436,blistering rash,3,NA,NA,NA
30068505,NCT01582776,436,rash not resolving within 7 days after standard treatment,3,NA,NA,NA
30068505,NCT01582776,436,rash,4,NA,NA,NA
30068505,NCT01582776,436,venous thrombosis/embolism despite adequate prevention,3,NA,NA,NA
30068505,NCT01582776,436,infusion-related reaction (IRR) during or within 24 hours after start of the first obinutuzumab infusion,4,NA,NA,NA
30068505,NCT01582776,436,"IRR not resolving to grade 2 despite intervention (reduced infusion rate, temporary stop, supportive care, and/or corticosteroids)",3,NA,NA,NA
30068505,NCT01582776,436,tumor flare reaction (TFR),3,NA,NA,NA
30068505,NCT01582776,436,TFR not resolving within 5 days after standard medical treatment,3,NA,NA,NA
30068505,NCT01582776,436,any other nonhematologic toxicity,>=3,NA,NA,NA
32758434,NCT02417285 ,437,"adverse events unrelated to disease progression, a medical procedure, or intercurrent illness that occurred during cycle 1 (the dose-limiting toxicity evaluation period) and led to dose reduction",NA,NA,NA,NA
30563938,NCT01828034,438,Central serous retinopathy (CSR),2,>14 days,NA,NA
30563938,NCT01828034,438,Central serous retinopathy (CSR),>=3,NA,NA,NA
30563938,NCT01828034,438,Central serous retinopathy (CSR) recurrence with same severity following suspension of study therapy followed by resolution and resumption of therapy at the same or lower dose,>=2,NA,NA,NA
30563938,NCT01828034,438,non-CSR retinopathy,>=1,NA,NA,NA
30563938,NCT01828034,438,"visual disturbances (blurring, floaters, flashing lights) without retinal changes",>=3,NA,NA,NA
30563938,NCT01828034,438,uveitis,>=2,NA,NA,NA
30563938,NCT01828034,438,Any other eye disorders,>=3,NA,NA,NA
30563938,NCT01828034,438,cardiac dysfunction,>=2,NA,NA,NA
30563938,NCT01828034,438,relative decrease in ejection fraction >= 20% from baseline value,NA,NA,NA,NA
30563938,NCT01828034,438,Elevation of AST/ALT > 4 times baseline level,NA,NA,NA,NA
30563938,NCT01828034,438,Liver dysfunction,3,NA,NA,NA
30563938,NCT01828034,438,Rash/photosensitivity despite skin toxicity treatment,>3,> 48 hours,NA,NA
30563938,NCT01828034,438,Delay of more than 4 weeks in receiving binimetinib due to toxicity,NA,NA,NA,NA
30563938,NCT01828034,438,"non-hematologic toxicity, considered potentially irreversible or life threatening despite best supportive efforts",>=3,NA,NA,NA
30563938,NCT01828034,438,hematologic toxicity,>=4,NA,NA,NA
33387490,NCT03214250 ,439,"treatment-related adverse event (ie, related to at least one of the study drugs in the combination) that was not related to the natural progression of the tumour and occurred during the first 28-day dosing cycle",>=3,NA,NA,NA
18317068,NA,441,infusion reaction,4,NA,NA,NA
18317068,NA,441,skin toxicity requiring interruption of any agent,3,>=14 days,NA,NA
18317068,NA,441,nonhematologic toxicity,>=3,NA,NA,NA
18317068,NA,441,toxicity (other than skin toxicity) requiring removal from study or the withholding of retreatment for >=4 weeks,NA,NA,NA,NA
18317068,NA,441,neutropenia,4,>=5 days,NA,NA
18317068,NA,441,neutropenia with sepsis or a fever >=38.5Â°C (oral),3 or 4,NA,NA,NA
18317068,NA,441,"thrombocytopenia of <=25,000 platelets/mm3 (or bleeding requiring a platelet infusion)",NA,NA,NA,NA
17237473,NA,442,neutropenia,4,>7 days,NA,NA
17237473,NA,442,neutropenia associated with fever >38.5Â°C at any time,4,NA,NA,NA
17237473,NA,442,platelet count <25 x 109/l,NA,NA,NA,NA
17237473,NA,442,treatment-related hepatic or renal toxicity,2,reversible grade 3 liver transaminase elevation,NA,NA
17237473,NA,442,diarrhoea despite aggressive antidiarrhoeal therapy,>=3,NA,NA,NA
17237473,NA,442,other nonhaematological toxicity,>=3,NA,FALSE,NA
17237473,NA,442,reatment delay >2 weeks due to toxicity,1,NA,NA,NA
34953624,NCT02040064,443,confirmed ILD/pneumonitis,NA,NA,NA,NA
34953624,NCT02040064,443,"severe alteration in liver function tests (ALT/AST > 8x upper limit of normal [ULN], bilirubin > 5xULN)",NA,NA,NA,NA
34953624,NCT02040064,443,colitis,>=3,NA,NA,NA
34953624,NCT02040064,443,any immune-related adverse event (irAE) not down- grading despite maximal supportive care and systemic corticosteroids,3 or 4,NA,NA,NA
34953624,NCT02040064,443,haematological toxicity,>=4,> 4 days,NA,NA
34953624,NCT02040064,443,febrile neutropenia,NA,NA,NA,NA
34953624,NCT02040064,443,platelets < 50.000/L requiring platelet transfusion,NA,NA,NA,NA
34953624,NCT02040064,443,any other clinically significant and/or unacceptable toxicity resulting in a disruption of dosing schedule > 7 days or judged to be a DLT by the Safety Review Committee,1,NA,NA,NA
30488350,ACTRN12611000643976,444,non-hematological toxicity,>=3,NA,NA,NA
30488350,ACTRN12611000643976,444,thrombocytopenia (platelets <25.000/Î¼L),4,NA,NA,NA
30488350,ACTRN12611000643976,444,neutropenia,4,>5 days,NA,NA
30488350,ACTRN12611000643976,444,inability to receive next scheduled dose due to toxicity (delay >14 days),NA,NA,NA,NA
33181832,NCT02558816,445,hematological toxicity,4,>10 days,FALSE,NA
33181832,NCT02558816,445,nonhematological toxicity,>=3,>10 days,NA,NA
33181832,NCT02558816,445,nonhematological toxicity leading to a treatment delay of >2 weeks,NA,NA,NA,NA
33181832,NCT02558816,445,life-threatening events,4,NA,NA,NA
31740568,NCT01473940,446,neutropenia,4,>7 days,NA,NA
31740568,NCT01473940,446,febrile neutropenia with â‰¥ grade 3 neutropenia,NA,NA,NA,NA
31740568,NCT01473940,446,thrombocytopenia with â‰¥ grade 3 hemorrhage,3,NA,NA,NA
31740568,NCT01473940,446,nonhematologic toxicities,>=3,NA,FALSE,NA
19879702,NA,447,Toxicities,>=3,NA,FALSE,NA
32334034,NCT01554410,450,neutropenia,4,>7 days,NA,NA
32334034,NCT01554410,450,neutropenic fever,NA,NA,NA,NA
32334034,NCT01554410,450,thrombocytopenia,4,NA,NA,NA
32334034,NCT01554410,450,symptomatic thrombocytopenia,3,NA,NA,NA
32334034,NCT01554410,450,nonhematologic toxicity,3 or 4,NA,FALSE,NA
32334034,NCT01554410,450,any treatment-related morbidity causing a delay of therapy for >2 weeks,NA,NA,NA,NA
16467100,NA,451,thrombocytopenia,4,>4 days,NA,NA
16467100,NA,451,neutropenia,4,>4 days,NA,NA
16467100,NA,451,nonhematologic toxicities felt to be related to the study regimen,>=3,NA,FALSE,NA
16467100,NA,451,>14 day delay in treatment due to related toxicity,NA,NA,NA,NA
31297636,NCT02732938,453,neutropenia,4,>5 days,NA,NA
31297636,NCT02732938,453,febrile neutropenia,NA,NA,NA,NA
31297636,NCT02732938,453,neutropenic infection,>=3,NA,NA,NA
31297636,NCT02732938,453,thrombocytopenia with grade â‰¥ 2 bleeding,>=3,NA,NA,NA
31297636,NCT02732938,453,thrombocytopenia,4,NA,NA,NA
31297636,NCT02732938,453,nonhematologic events,3,NA,TRUE,NA
30862645,NCT01685892,454,neutropenia,4,NA,NA,NA
30862645,NCT01685892,454,febrile neutropenia,3 or 4,NA,NA,NA
30862645,NCT01685892,454,thrombocytopenia,4,NA,NA,NA
30862645,NCT01685892,454,clinical TLS,NA,NA,NA,NA
30862645,NCT01685892,454,infusion-related reactions,4,NA,NA,NA
30862645,NCT01685892,454,All other AEs,>=3,NA,FALSE,NA
32973176,NCT03307148,455,Febrile Neutropenia,NA,NA,NA,NA
32973176,NCT03307148,455,Neutropenia,4,>7 days,NA,NA
32973176,NCT03307148,455,anaemia related to chemotherapy which requires transfusion therapy,4,NA,NA,NA
32973176,NCT03307148,455,thrombocytopenia,4,>7 days,NA,NA
32973176,NCT03307148,455,thrombocytopenia associated with active bleeding,4,NA,NA,NA
32973176,NCT03307148,455,thrombocytopenia which requires transfusion therapy,4,NA,NA,NA
32973176,NCT03307148,455,electrolyte abnormalities,3,NA,NA,NA
32973176,NCT03307148,455,"anorexia, nausea, vomiting or diarrhoea despite optimal treatment with anti-emetics or anti-diarrheal medication",3 or 4,NA,NA,NA
32973176,NCT03307148,455,biochemical AEs,3,NA,NA,NA
12796031,NA,456,any drug-related adverse effect,3 or 4,NA,NA,NA
12796031,NA,456,significant corneal epithelial change or PR interval (measured by 12-lead ECG) prolongation attributed to gefitinib (as prolongation of the PR interval was noted in preclinical animal toxicity studies),NA,NA,NA,NA
28955007,NCT02151721,457,neutropenia,>=4,>=5 days,NA,NA
28955007,NCT02151721,457,febrile neutropenia,NA,NA,NA,NA
28955007,NCT02151721,457,thrombopenia requiring platelet transfusion,>=3,NA,NA,NA
28955007,NCT02151721,457,thrombopenia,>=4,NA,NA,NA
28955007,NCT02151721,457,any grade uncontrollable skin toxicity,NA,NA,NA,NA
28955007,NCT02151721,457,nonhematological toxicity,>=3,NA,NA,NA
31782583,NCT02151721,458,ntestinal lung disease,>=1,NA,NA,NA
31782583,NCT02151721,458,neutropenia,>=4,>=5 days,NA,NA
31782583,NCT02151721,458,febrile neutropenia,NA,NA,NA,NA
31782583,NCT02151721,458,thrombocytopenia requiring platelet transfusion,>=3,NA,NA,NA
31782583,NCT02151721,458,thrombocytopenia,>=4,NA,NA,NA
31782583,NCT02151721,458,any grade uncontrollable skin toxicity,NA,NA,NA,NA
31782583,NCT02151721,458,nonhe-matological toxicity,>=3,NA,NA,NA
31910346,NA,459,nonhematologic toxicity,3,NA,NA,NA
31910346,NA,459,toxicity hematologic or nonhematologic toxicity related to the study drug,4,NA,NA,NA
25552401,NCT01027676,462,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25552401,NCT01027676,462,hematologic toxicity,4,NA,NA,NA
20142724,NCT00113529,463,hematologic or nonhematologic adverse event meeting prespecified criteria and considered to be attributable to treatment,3 or 4,NA,NA,NA
17694310,NA,464,non-hematological toxicity.,3,NA,NA,NA
17694310,NA,464,hematological toxicity,4,NA,NA,NA
17694310,NA,464,"cardiac, pulmonary, renal, or CNS toxicities",2,>2 weeks,NA,NA
17694310,NA,464,Toxicity that resulted in therapy interruption for greater than 2 weeks,NA,NA,NA,NA
23182702,NA,465,nonhematologic toxicity,3 or 4,NA,FALSE,NA
34837745,NCT01964287,466,toxicity,>=4,NA,NA,NA
34837745,NCT01964287,466,symptomatic thrombopenia,>=3,NA,NA,NA
34837745,NCT01964287,466,febrile neutropenia,>=3,NA,NA,NA
34837745,NCT01964287,466,neutropenia with grade >=3 infection,>=3,NA,NA,NA
34837745,NCT01964287,466,peripheral sensory neuropathy,>=3,NA,NA,NA
19687340,NA,467,hematologic toxicity,4,>7 days,NA,NA
19687340,NA,467,thrombocytopenia requiring transfusion on more than 2 occasions within 7 days,4,NA,NA,NA
19687340,NA,467,any interruption of gefitinib treatment for toxicity,NA,NA,NA,NA
19687340,NA,467,nonhematologic toxicity,3 or 4,NA,FALSE,NA
33121235,NCT01671904,468,neutropenia (that was not present at screening) not responsive to G-CSF,4,>14 days,NA,NA
33121235,NCT01671904,468,febrile neutropenia with fever,3 or 4,>4 days,NA,NA
33121235,NCT01671904,468,thrombocytopenia (or reduction of >50% for those patients with thrombocytopenia at baseline) resulting in bleeding,4,NA,NA,NA
33121235,NCT01671904,468,"thrombocytopenia that does not improve to grade <=2 (or to >=80% of the baseline value, whichever is lower) within 3 weeks",4,NA,NA,NA
33121235,NCT01671904,468,Clinical TLS,NA,NA,NA,NA
33121235,NCT01671904,468,IRRs secondary to rituximab or obinutuzumab despite appropriate premedication and administration rate,4,NA,FALSE,defined as an infusion-related toxicity occurring during or within 24h after completing an infusion of rituximab or obinutuzumab
33121235,NCT01671904,468,All other AEs attributable to venetoclax with or without treatment,>=3,>2 weeks,FALSE,NA
26289594,NA,470,non-haematological adverse events including nausea and vomiting despitemaximal anti-emetic treatment,>=3,NA,FALSE,NA
26289594,NA,470,treatment delay >2 weeks,NA,NA,NA,NA
26289594,NA,470,neutropaenia,4,â‰¥5 days,NA,NA
26289594,NA,470,febrile neutropaenia [absolute neutrophil count (ANC) <0.5 Ã— 109/L with fever â‰¥38.5 Â°C],NA,NA,NA,NA
26289594,NA,470,thrombocytopaenia,4,NA,NA,NA
28832976,NA,471,neutropenia,4,>7 days,NA,NA
28832976,NA,471,febrile neutropenia,NA,NA,NA,NA
28832976,NA,471,ymptomatic anemiarequiring a transfusion,3 or 4,NA,NA,NA
28832976,NA,471,hrombocytopeniarequiring a transfusion,4,NA,NA,NA
28832976,NA,471,"nonhematologic toxicity that was possibly, probably, or definitely related tothe drug combination",3 or 4,NA,FALSE,NA
28832976,NA,471,rash that had received 2 weeksof supportive care treatment with no improvement if they were assessed by the investigator as being clinicallysignificant,3,NA,NA,NA
28832976,NA,471,fatigue if they were assessed by the investigator as being clinicallysignificant,3 or 4,NA,NA,NA
28832976,NA,471,aboratory evalua-tions that were asymptomatic if they were assessed by the investigator as being clinicallysignificant,3 or 4,NA,NA,NA
26912134,NCT01242605,472,AE or laboratory abnormality that was deemed clinically significant by the investigator,3 or 4,NA,NA,NA
26912134,NCT01242605,472,infusion-related reactions were considered a DLT based on the study teamâ€™s medical review of the event,NA,NA,NA,NA
26912134,NCT01242605,472,fatigue,3,>7 days,NA,NA
26912134,NCT01242605,472,fatigue,4,NA,NA,NA
26912134,NCT01242605,472,"nausea, diarrhoea, or vomiting despite maximum supportive care",3 or 4,NA,NA,NA
26912134,NCT01242605,472,magnesium <0.4 mmol/L,NA,NA,NA,NA
26912134,NCT01242605,472,rash/desquamation,3,> 7 days,NA,NA
26912134,NCT01242605,472,neutropenia with fever â‰¥ 38.5 Â°C,3 or 4,>=3 days,NA,NA
26912134,NCT01242605,472,neutropenia or thrombocytopenia,4,>7 days,NA,NA
26912134,NCT01242605,472,ALT or AST > 10 x ULN,NA,NA,NA,NA
26912134,NCT01242605,472,patient was unable to tolerate a total of at least one three week dosing course due to adverse event(s),NA,NA,NA,NA
26912134,NCT01242605,472,any AE resulting in a more than 14 day treatment delay for any agent,NA,NA,NA,NA
23583440,NA,473,neutropenia,4,>= 5 days,NA,NA
23583440,NA,473,febrile neutropenia,NA,NA,NA,NA
23583440,NA,473,thrombocytopenia,4,NA,NA,NA
23583440,NA,473,non-haematologic toxicity,3 or 4,NA,NA,NA
23583440,NA,473,"non-haematologic toxicity the judgment of the investigator, is dose limiting",>=2,NA,NA,NA
23583440,NA,473,rash requiring dose reduction despite supportive care,>=3,NA,NA,NA
23583440,NA,473,treatment delay of >=14 days owing to unresolved toxicity,4,NA,NA,NA
23583440,NA,473,calcium phosphorusproduct >558 mg2/dL2,NA,NA,NA,NA
23583440,NA,473,alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 x upper limit of normal,NA,NA,NA,NA
24916770,NCT00887757,474,thrombocytopenia,4,NA,NA,NA
24916770,NCT00887757,474,bleeding associated with thrombocytopenia,2,NA,NA,NA
24916770,NCT00887757,474,any other event,4,NA,FALSE,NA
24916770,NCT00887757,474,any other event,3,NA,FALSE,NA
24916770,NCT00887757,474,An unexpected grade 2 toxicity was considered a DLT if dosing was delayed >1 week,NA,NA,NA,NA
24916770,NCT00887757,474,"baseline elevations of ALT, AST, and/or ALP due to bone or liver metastasis, further increase to >10Ã—ULN",NA,NA,NA,NA
24737778,NCT00874042,475,nonhematologic treatment-related toxicity,>=3,NA,FALSE,NA
24737778,NCT00874042,475,neutropenia,4,>7 days,NA,NA
24737778,NCT00874042,475,anemia,4,>7 days,NA,NA
24737778,NCT00874042,475,thrombocytopenia,4,NA,NA,NA
24737778,NCT00874042,475,thrombocytopenia in the presence of bleeding,3,NA,NA,NA
27234064, EudraCT No. 2010-019214-25,476,any non-hematologic,>=3,NA,NA,NA
27234064, EudraCT No. 2010-019214-25,476,clinical chemistry abnormalities,4,NA,NA,NA
27234064, EudraCT No. 2010-019214-25,476,hematologic (e.g. febrile neutropenia: absolute neutrophil count [ANC] < 0.5 x 109/L with fever > 38.5 C,4,NA,NA,NA
27234064, EudraCT No. 2010-019214-25,476,thrombocytopenia (<25 x 109/L) with bleeding,NA,NA,NA,NA
27234064, EudraCT No. 2010-019214-25,476,any other severe reaction considered by the investigator to indicate that further dose escalation was inappropriate,NA,NA,NA,NA
29362902,NCT02207465,477,non-hematologic toxicities,>=3,NA,FALSE,NA
29362902,NCT02207465,477,thrombocytopenia,>=3,NA,NA,NA
29362902,NCT02207465,477,hematologic toxicity,>=4,NA,NA,NA
29362902,NCT02207465,477,any substantial deterioration of performance status (to ECOGâ‰¥3) as related to study intervention and in the absence of disease progression,NA,NA,NA,NA
24907635,NCT00556023,478,treatment-related toxicity,4,NA,FALSE,NA
24907635,NCT00556023,478,toxicities not recovering to grade 1 or baseline within 7 days of maximal management and/or after delaying the gemcitabine infusion by a maximum of 2 weeks,3 or 4,NA,FALSE,NA
24907635,NCT00556023,478,autoimmune toxicity of critical organs,4-Feb,NA,FALSE,NA
24907635,NCT00556023,478,failure to recover to grade 1 or baseline severity for drug-related toxicity after delaying the initiation of gemcitabine infusion by a maximum of 2 weeks,NA,NA,NA,NA
25837499,NCT01547260,479,"inability to deliver all scheduled doses during cycle 1 due to an unexpected drug-related toxicity (if gemcitabine-related toxicity was an expected toxicity, it was not considered a DLT)",NA,NA,NA,NA
25837499,NCT01547260,479,"inability to deliver the intended doses of lenalidomide in cycle 1 due to drug-related toxicity as outlined below: any grade 3 or 4 nonhematological toxicity lasting for >= 14 days, febrile neutropenia, any grade 4 neutropenia lasting for >= 7 days, grade 4 thrombocytopenia or grade 4 liver enzyme toxicity",4,NA,TRUE,NA
30022224,NCT00078962,480,neutropenia,4,>5 days,NA,NA
30022224,NCT00078962,480,febrile neutropenia (>101 Â°F),3 or 4,NA,NA,NA
30022224,NCT00078962,480,"platelet count<25,000 ÂµL",NA,NA,NA,NA
30022224,NCT00078962,480,"platelet count between 25,000 and 50,000 ÂµL with bleeding requiring platelet transfusion",NA,NA,NA,NA
30022224,NCT00078962,480,non-hematological toxicity,3 or 4,NA,FALSE,NA
30022224,NCT00078962,480,diarrhea after optimal antidiarrheal therapy,>=3,NA,NA,NA
30022224,NCT00078962,480,nausea or vomiting despite aggressive anti-emetic support,3 or 4,NA,NA,NA
30022224,NCT00078962,480,transaminitis or elevation of bilirubin or alkaline phosphatase,3 or 4,>7 days,NA,NA
30022224,NCT00078962,480,inability to deliver at least 7-day GTI-2040 and 30-week treatments of gemcitabine during a cycle due to drug-related toxicities,NA,NA,NA,NA
30022224,NCT00078962,480,inability to resume treatment by day 43 of a cycle due to drug-related toxicities,NA,NA,NA,NA
30022224,NCT00078962,480,acute respiratory distress syndrome or hemolytic uremic syndrome secondary to gemcitabine,NA,NA,NA,NA
30022224,NCT00078962,480,any other toxicity deemed by the investigator that requires dose reduction or discontinuation,2,NA,NA,NA
23539344,NA,481,neutropenia,4,>=7 days,NA,NA
23539344,NA,481,thrombocytopenia,4,NA,NA,NA
23539344,NA,481,thrombocytopenia with bleeding,3,NA,NA,NA
23539344,NA,481,febrile neutropenia,NA,NA,NA,NA
23539344,NA,481,any other non-hematologic toxicity,3 or 4,NA,FALSE,NA
23539344,NA,481,neurologic toxicity,>=2,NA,NA,NA
23983255,NA,482,nonhematologic adverse events despite optimal supportive care,3 or 4,NA,NA,NA
23983255,NA,482,neutropenia,3 or 4,NA,NA,NA
23983255,NA,482,febrile neutropenia,3,NA,NA,NA
23983255,NA,482,thrombocytopenia,4,NA,NA,NA
23983255,NA,482,thrombocytopenia associated with bleeding,3,NA,NA,NA
23983255,NA,482,lymphopenia if complicated by infection,4,NA,NA,NA
23983255,NA,482,any other hematologic adverse event,3,NA,NA,NA
22864469,NA,483,non-hematological toxicity,3 or 4,NA,FALSE,NA
22864469,NA,483,neutropenia,4,>7 days,NA,NA
22864469,NA,483,anemia or thrombocytopenia that required transfusion therapy on greater than 2 occasions in 7 days or a delay greater or equal to 14 days between treatment cycles,4,NA,NA,NA
22864469,NA,483,Any toxicity requiring an additional 2 weeks delay between cycles,NA,NA,NA,NA
22864469,NA,483,cumulative toxicities after the first cycle,4,NA,NA,NA
29748012,NA,484,non-hematologic AEs,>=3,NA,FALSE,NA
29748012,NA,484,gastrointestinal toxicity despite optimal supportive care/intervention,>=3,NA,FALSE,NA
29748012,NA,484,hypertension despite optimal supportive care/intervention,>=3,NA,NA,NA
29748012,NA,484,alanine aminotransferase and/or aspartate aminotransferase elevation,>=3,NA,NA,NA
29748012,NA,484,neutropenia that was uncomplicated (not associated with fever â‰¥38.5 Â°C),4,>7 days (except for Cycle 1 where this definition did not apply),NA,NA
29748012,NA,484,febrile neutropenia associated with fever â‰¥38.5 Â°C,NA,NA,NA,NA
29748012,NA,484,platelet decrease,4,NA,NA,NA
29748012,NA,484,platelet decrease associated with bleeding or requiring transfusion,3,NA,NA,NA
22847785,NA,485,non-hematologic adverse event,>=3,NA,FALSE,NA
22847785,NA,485,hematologic adverse event,>=4,NA,FALSE,NA
29438372,NCT01098344,486,neutropenia,4,>=5 days,NA,NA
29438372,NCT01098344,486,febrile neutropenia,NA,NA,NA,NA
29438372,NCT01098344,486,thrombocytopenia,4,>=5 days,NA,NA
29438372,NCT01098344,486,toxicity to organs,3 or 4,NA,FALSE,NA
29438372,NCT01098344,486,biochemical adverse events (AEs),3 or 4,NA,FALSE,NA
28748343,EudraCT 2009-016080-11,487,"any clinically relevant, and likely drug-related adverse event",>=3,NA,NA,NA
22543215,NA,488,gastrointestinal toxicity,>=3,NA,NA,NA
22543215,NA,488,neutropenic fever,NA,NA,NA,NA
22543215,NA,488,deterioration in performance status to >=3,NA,NA,NA,NA
30082474,NCT02079636,489,nausea despite intervention,3 or 4,>2 days,NA,NA
30082474,NCT02079636,489,vomiting despite intervention,3 or 4,>2 days,NA,NA
30082474,NCT02079636,489,diarrhea despite intervention,3 or 4,>2 days,NA,NA
30082474,NCT02079636,489,electrolyte disturbance despite intervention,3 or 4,>2 days,NA,NA
30082474,NCT02079636,489,any other nonhematologic toxicity,3 or 4,NA,NA,NA
30082474,NCT02079636,489,hematologic toxicity,4,>5 days,NA,NA
30082474,NCT02079636,489,thrombocytopenia with evidence of bleeding,3 or 4,NA,NA,NA
30082474,NCT02079636,489,febrile neutropenia,NA,NA,NA,NA
30206366,NCT01621854,492,toxicity,>=3,NA,FALSE,NA
30206366,NCT01621854,492,nausea/vomiting/diarrhoea that occurs despite standard medical treatment,>=3,NA,NA,NA
30206366,NCT01621854,492,neutropaenia,4,NA,NA,NA
30206366,NCT01621854,492,thrombocytopaenia,4,NA,NA,NA
30206366,NCT01621854,492,febrile neutropaenia,NA,NA,NA,NA
30206366,NCT01621854,492,inability to begin next dose of treatment within 14 days of scheduled dosing due to unresolved toxicity relating to NUC-1031,NA,NA,NA,NA
25591040,NCT01426633,493,neutropenia,4,>5 days,NA,NA
25591040,NCT01426633,493,febrile neutropenia,NA,NA,NA,NA
25591040,NCT01426633,493,platelets < 25 Ã— 109/L,NA,NA,NA,NA
25591040,NCT01426633,493,thrombocytopenia accompanied by bleeding,>=3,NA,NA,NA
25591040,NCT01426633,493,diarrhea despite optimal loperamide use,>=3,NA,NA,NA
25591040,NCT01426633,493,rash,>=3,NA,NA,NA
25591040,NCT01426633,493,transaminases (ALT/AST) increase,3,>7 days,NA,NA
25591040,NCT01426633,493,transaminases (ALT/AST) increase,4,NA,NA,NA
25591040,NCT01426633,493,other effects thought to be treatment related,>=3,NA,FALSE,NA
24368064,NCT00556621,494,pulmonary toxicity,>=2,NA,NA,NA
24368064,NCT00556621,494,all other non-hematologic adverse events,>=3,NA,FALSE,NA
24368064,NCT00556621,494,thrombocytopenia,4,NA,NA,NA
24368064,NCT00556621,494,thrombocytopenia,3,>7 days,NA,NA
24368064,NCT00556621,494,thrombocytopenia complicated by hemorrhage,3,NA,NA,NA
24368064,NCT00556621,494,neutropenia,4,>7 days,NA,NA
24368064,NCT00556621,494,febrile neutropenia or severe infection,NA,NA,NA,NA
24936582,NA,495,nonhematologic toxicity necessitating a discontinuation or interruption of radiation and/or gemcitabine for >1 week,>=3,NA,FALSE,NA
24936582,NA,495,hematologic toxicity necessitating a discontinuation or interruption of radiation and/or gemcitabine for >1 week,>=3,NA,NA,NA
28224231,NA,496,hematologic toxicity,4,NA,NA,NA
28224231,NA,496,thrombocytopenia with bleeding,3,NA,NA,NA
28224231,NA,496,neutropenia with fever over 38.5Â°C,>=3,NA,NA,NA
28224231,NA,496,neutropenia with grade 2 or greater diarrhea,>=3,NA,NA,NA
28224231,NA,496,neutropenia without fever,>=3,>=5 days,NA,NA
28224231,NA,496,non-hematologic toxicity,>=3,NA,FALSE,NA
28224231,NA,496,treatment delay of greater than two weeks before the start of the next treatment cycle (NC-6004 or gemcitabine) due to unresolved toxicity,NA,NA,NA,NA
28224231,NA,496,hypersensitivity reaction,>=3,NA,NA,NA
28224231,NA,496,an eGFR toxicity of 30â€“59 mL/min/1.73  m2 delaying dosing by more than 14 days,NA,NA,NA,NA
28224231,NA,496,"an eGFR <30 mL/min/1.73  m2, or apparent renal failure identified by another index",NA,NA,NA,NA
26177983,NCT02046304,497,NA,NA,NA,NA,DLT not defined
30105668,NCT02101021,498,neutropenia,4,> 5 days,NA,NA
30105668,NCT02101021,498,neutropenia with fever (temperature â‰¥ 100.5Âº F),>=3,NA,NA,NA
30105668,NCT02101021,498,thrombocytopenia,4,NA,NA,NA
30105668,NCT02101021,498,non-hematologic toxicity,>=3,NA,FALSE,NA
30105668,NCT02101021,498,A treatment-emergent adverse event (AE) that in the opinion of the investigator is of potential clinical significance such that further dose escalation would expose participants to unacceptable risk,NA,NA,NA,NA
30105668,NCT02101021,498,Any treatment delay > 4 weeks that is due to study treatment-related adverse effects,NA,NA,NA,NA
29338080,NCT01585805,499,thrombocytopenia,4,NA,NA,NA
29338080,NCT01585805,499,neutropenia,4,NA,NA,NA
29338080,NCT01585805,499,thrombocytopenia with bleeding,3,NA,NA,NA
29338080,NCT01585805,499,febrile neutropenia (fever>38.5 C and neutrophilcount/lL<0.5),NA,NA,NA,NA
29338080,NCT01585805,499,"diarrhea, nausea, and vomiting refractory to loperamideor anti-emetic therapy and unable to be corrected to grade1 or lower within 24 hours.",3,NA,NA,NA
29338080,NCT01585805,499,metabolic toxicities,4,NA,FALSE,NA
27873130,NCT01970553,500,neutropenia,4,>7 days,NA,NA
27873130,NCT01970553,500,febrile neutropenia,NA,NA,NA,NA
27873130,NCT01970553,500,neutropenic sepsis,NA,NA,NA,NA
27873130,NCT01970553,500,thrombocytopenia,4,NA,NA,NA
27873130,NCT01970553,500,thrombocytopenia with bleeding requiring a platelet transfusion,3,NA,NA,NA
27873130,NCT01970553,500,alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase,4,NA,NA,NA
27873130,NCT01970553,500,alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase,3,>14 days,NA,NA
27873130,NCT01970553,500,treatment-related ALT/AST increase concomitantly with â‰¥2 Ã— upper limit of normal (ULN) total bilirubin increase and normal alkaline phosphatase (ALP),>=2,NA,NA,NA
27873130,NCT01970553,500,creatine phosphokinase increase,>=3,NA,NA,NA
27873130,NCT01970553,500,any other non-hematological adverse event (AE) suspected to be related to study drugs,>=3,NA,NA,NA
27873130,NCT01970553,500,delay >15 days in the administration of Cycle 2 due to any AE related to study drugs,NA,NA,NA,NA
26056353,NCT01175733,501,febrile neutropenia,NA,NA,NA,NA
26056353,NCT01175733,501,neutropenic infection,NA,NA,NA,NA
26056353,NCT01175733,501,neutropenia,4,>7 days,NA,NA
26056353,NCT01175733,501,thrombocytopenia,>=3,>7 days,NA,NA
26056353,NCT01175733,501,thrombocytopenia,4,NA,NA,NA
26056353,NCT01175733,501,"nausea, vomiting, or diarrhea despite optimal medical support",>=3,NA,NA,NA
26056353,NCT01175733,501,fatigue,3,>7 days,NA,NA
26056353,NCT01175733,501,fatigue,4,NA,NA,NA
26056353,NCT01175733,501,Any other AE,>=3,NA,FALSE,NA
26056353,NCT01175733,501,failure to recover from related toxicities to grade 1 or baseline severity (or grade 2 at investigator and sponsor discretion) after delaying the next cycle up to 7 days,NA,NA,NA,NA
26056353,NCT01175733,501,"failure to complete the first 6 weeks of treatment (75% of planned dose of RT, gemcitabine, and panitumumab)",NA,NA,NA,NA
26377590,NA,502,Non-hematological toxicity,>=3,NA,FALSE,NA
26377590,NA,502,neutropenia with fever,3,NA,NA,NA
26377590,NA,502,neutropenia,4,NA,NA,NA
26377590,NA,502,thrombocytopenia associated with â‰¥ G2 bleeding,3,NA,NA,NA
26377590,NA,502,thrombocytopenia,4,NA,NA,NA
26377590,NA,502,>14 days needed to recover from toxicity after the last dose of Cycle 1,NA,NA,NA,NA
26377590,NA,502,any other significant drug-related toxicity considered to be dose-limiting by the investigator,NA,NA,NA,NA
29348486,NCT01460537,503,anaemia,4,NA,NA,NA
29348486,NCT01460537,503,neutropenia,4,>7 days,NA,NA
29348486,NCT01460537,503,neutropenia with fever,>=3,NA,NA,NA
29348486,NCT01460537,503,thrombocytopenia,4,NA,NA,NA
29348486,NCT01460537,503,"thrombocytopenia (platelet count >50,000/mm3) with serious bleeding",3,NA,NA,NA
29348486,NCT01460537,503,signs of serious bleeding and/or prothrombin timeâ€“international normalised ratio or partial thromboplastin time elevation of grade 3 (>2.5 Ã— upper limit of normal [ULN]),NA,NA,NA,NA
29348486,NCT01460537,503,non-haematological toxicity,>=3,NA,FALSE,NA
25003665,NCT01684449,504,absolute neutrophil count <0.5 x 109 l-1,NA,>=5 days,NA,NA
25003665,NCT01684449,504,absolute neutrophil count <0.5 x 109 l-1 associated with fever >=38.5C,NA,NA,NA,NA
25003665,NCT01684449,504,platelets <50 x 109 l-1,NA,NA,NA,NA
25003665,NCT01684449,504,nonhaematological toxicity,3 or 4,NA,FALSE,NA
25003665,NCT01684449,504,skin rash related to treatment and not controlled with support medication,2,NA,NA,NA
24614947,NCT01297998,505,leucopenia,4,NA,NA,NA
24614947,NCT01297998,505,neutropenia,4,NA,NA,NA
24614947,NCT01297998,505,thrombocytopenia,4,NA,NA,NA
24614947,NCT01297998,505,neutropenia complicated by fever,3 or 4,NA,NA,NA
24614947,NCT01297998,505,clinically significant non-hematological toxicities,3 or 4,NA,NA,NA
24614947,NCT01297998,505,need to withhold GC on day 8 consecutively in the first 6 weeks due to an adverse event,NA,NA,NA,NA
24614947,NCT01297998,505,delay in course of more than 14 days following an adverse event,NA,NA,NA,NA
29502139,UMIN000012254,506,leukopenia,4,>3 days,NA,NA
29502139,UMIN000012254,506,neutropenia,4,>3 days,NA,NA
29502139,UMIN000012254,506,neutropenia complicated by feverâ‰¥38 Â°C or infection,3,NA,NA,NA
29502139,UMIN000012254,506,thrombocytopenia,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,platelet transfusion,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,pneumonitis,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,nausea or vomiting,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,diarrhea,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,gastrointestinal bleeding,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,nonhematological toxicities,3 or 4,NA,NA,NA
29502139,UMIN000012254,506,more than 2 weeks of drug withdrawal due to adverse events,NA,NA,NA,NA
27815358,NCT01359696,507,thrombocytopenia,>=4,NA,NA,NA
27815358,NCT01359696,507,anemia,>=4,NA,NA,NA
27815358,NCT01359696,507,febrile neutropenia,>=4,NA,NA,NA
27815358,NCT01359696,507,neutropenia,>=4,> 7 days,NA,NA
27815358,NCT01359696,507,elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST),>=3,> 7 days,NA,NA
27815358,NCT01359696,507,total bilirubin,>=3,NA,NA,NA
27815358,NCT01359696,507,nonhematologic or nonhepatic major organ adverse event,>=3,NA,NA,NA
27815358,NCT01359696,507,left ventricular ejection fraction reduction or asymptomatic left ventricular ejection fraction (LVEF) reduction to <=40%,>=3,NA,NA,NA
27815358,NCT01359696,507,asymptomatic left ventricular ejection fraction (LVEF) reduction to <=40%,NA,NA,NA,NA
23616084,NA,508,febrile neutropenia,NA,NA,NA,NA
23616084,NA,508,neutropenia,4,>=5 days,NA,NA
23616084,NA,508,thrombocytopenia,4,NA,NA,NA
23616084,NA,508,non-hematological toxicities,>=3,NA,TRUE,NA
23616084,NA,508,"other toxicities potentially related to study drug that required omissions of study drug, if the patient received study drug on less than 12 days during Cycle 1",NA,NA,NA,NA
23616084,NA,508,toxicities that were otherwise deemed as DLTs by the investigator,NA,NA,NA,NA
29788155,NCT01564251,509,neutropenia,4,NA,NA,NA
29788155,NCT01564251,509,thrombocytopenia,4,NA,NA,NA
29788155,NCT01564251,509,neutropenia,>3,NA,NA,NA
29788155,NCT01564251,509,thrombocytopenia,>3,NA,NA,NA
29788155,NCT01564251,509,elevation of alanine aminotransferase (ALT) or aspartate transaminase (AST),>=3,NA,NA,NA
29788155,NCT01564251,510,thrombocytopenia associated with clinically significant bleeding,3,NA,NA,NA
29788155,NCT01564251,510,thrombocytopenia,>=4,NA,NA,NA
29788155,NCT01564251,510,neutropenia,>=4,NA,NA,NA
29788155,NCT01564251,510,elevation of ALT or AST,>=3,>7 days,NA,NA
29788155,NCT01564251,510,febrile neutropenia,>=3,NA,NA,NA
29788155,NCT01564251,510,Symptomatic hypotension,NA,NA,NA,NA
29788155,NCT01564251,510,decrease in left ventricular ejection fraction to <50%,NA,NA,NA,NA
28770300,NCT01154426,511,hematologic toxicity,>=4,NA,NA,NA
28770300,NCT01154426,511,febrile neutropenia,3,NA,NA,NA
28770300,NCT01154426,511,diarrhea only when refractory to supportive care,3,NA,NA,NA
28770300,NCT01154426,511,nausea and vomiting or rise in creatinine only if unable to correct to grade â‰¤ 1 within 24 h,3,NA,NA,NA
28770300,NCT01154426,511,metabolic toxicities only if unable to correct to grade â‰¤ 2 within 24 h,3,NA,NA,NA
28770300,NCT01154426,511,"A delay in starting cycle 2 by more than 2 weeks due to toxicity, regardless of attribution or grade",NA,NA,NA,NA
28770300,NCT01154426,511,Inability to deliver cycle 1 day 8 or 15 gemcitabine,NA,NA,NA,NA
27685612,UMIN000005787,512,febrile neutropenia,3,NA,NA,NA
27685612,UMIN000005787,512,neutropenia,4,NA,NA,NA
27685612,UMIN000005787,512,platelets<25 000/mm3,NA,NA,NA,NA
27685612,UMIN000005787,512,thrombocytopeniarequiring transfusion by investigatorâ€™s judgment,NA,NA,NA,NA
27685612,UMIN000005787,512,"serum AST/ALT/c-GTP/alkaline phosphataseâ‰¥10 times the upper limit ofnormal, serum creatinineâ‰¥2.0 mg/dL",NA,NA,NA,NA
27685612,UMIN000005787,512,non-hema-tological toxicities,3 or 4,NA,FALSE,NA
27685612,UMIN000005787,512,need for treatment interruption for longerthan 15 consecutive days,NA,NA,NA,NA
22515232,UMIN000002152,513,hematologic toxicity,4,NA,NA,NA
22515232,UMIN000002152,513,creatinine or potassium abnormality,4-Feb,NA,NA,NA
22515232,UMIN000002152,513,arrhythmia or hypotension,4-Feb,NA,NA,NA
22515232,UMIN000002152,513,any other non-hematologic toxicit,3 or 4,NA,NA,NA
22515232,UMIN000002152,513,delay of recovery from treat-ment-related toxicity for more than 4 weeks,NA,NA,NA,NA
23483298,NA,514,hematologic toxicity,4,NA,NA,NA
23483298,NA,514,thrombocytopenia with hemorrhage or requiring platelet transfusion,3,NA,NA,NA
23483298,NA,514,febrile neutropenia,3,NA,NA,NA
23483298,NA,514,non-hematologic toxicity,>=3,NA,FALSE,NA
29238851,NCT00372437,515,non-hematologic adverse events (AEs),>=3,NA,FALSE,NA
29238851,NCT00372437,515,absolute neutrophil count<0.5 Ã— 109/L despite gemcitabinedose reduction,NA,â‰¥5 days,NA,NA
29238851,NCT00372437,515,febrile neutropenia,NA,NA,NA,NA
29238851,NCT00372437,515,neutropenic infection despite gemcitabine dose reduction,>=3,NA,NA,NA
29238851,NCT00372437,515,platelets<25Ã—109/L despite gemcitabine dose reduction or interruption,NA,NA,NA,NA
29238851,NCT00372437,515,clinically significant thrombocytopenic bleeding,NA,NA,NA,NA
29238851,NCT00372437,515,Any AEs which resulted in missing>3 doses of mocetinostat per cycle or delayed a subsequent cycle by > 14 days,NA,NA,NA,NA
29756206,NCT01016483,516,non-haematological toxicity,>=3,NA,NA,NA
29756206,NCT01016483,516,neutropenia,4,>5 days,NA,NA
29756206,NCT01016483,516,febrile neutropenia,NA,NA,NA,NA
29756206,NCT01016483,516,thrombocytopenia with bleeding,3,NA,NA,NA
29756206,NCT01016483,516,thrombocytopenia,4,NA,NA,NA
29756206,NCT01016483,516,anaemi,4,NA,NA,NA
29756206,NCT01016483,516,any treatment inter-ruption>2 weeks,NA,NA,NA,NA
29030354,NCT02043288,517,nonhematologic toxicity,3 or 4,NA,FALSE,NA
29030354,NCT02043288,517,hematologic toxicity,4,NA,NA,NA
29030354,NCT02043288,517,decreased neutrophil counts (<500/mm3) unresponsive to growth factor support,4,>=7 days,NA,NA
29030354,NCT02043288,517,"decreased neutrophil counts (<1,000 to 500/mm3) with a fever of 38C or greater",3,NA,NA,NA
26468947,NA,518,"leukopenia (leukocytes <1.0 Ã— 10 9 /l for >7 days, or leukocytes <1.0 Ã— 10 9 /l and temperature >38.5 Â° C)",4,NA,NA,NA
26468947,NA,518,thrombocytopenia (thrombocytes <25 Ã— 10 9/l for >7 days or thrombocytes <10 Ã— 10 9 /l),4,NA,NA,NA
26468947,NA,518,Any nonhematologic toxicity,>=3,NA,FALSE,NA
29158367,NCT01621243,519,any AE judged by the investigator to be drug-related,>=3,NA,NA,NA
28750271,NCT02018874,520,hrombocytopenia with bleeding,>=3,NA,NA,NA
28750271,NCT02018874,520,haematologic toxicity,4,>5 d,FALSE,NA
28750271,NCT02018874,520,non-haematologic toxicities,>=3,NA,TRUE,NA
28750271,NCT02018874,520,skin rash that can be controlled with standard therapy,3,NA,NA,NA
28750271,NCT02018874,520,elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) without evidence of other hepatic injury in blood tests,3,<5 days,NA,NA
28750271,NCT02018874,520,"hyperglycemia, hypertriglyceridemia or hyperlipidaemia that can be controlled with standard therapy",3,NA,NA,NA
28750271,NCT02018874,520,asymptomatic amylase or lipase elevation,3 or 4,NA,NA,NA
28750271,NCT02018874,520,asymptomatic creatinine phosphokinase elevation,3,NA,NA,NA
28750271,NCT02018874,520,asymptomatic abnormal laboratory value considered non-clinically relevant by the principal investigator,3 or 4,NA,NA,NA
23511559,NCT00615446,521,neutropenia,4,>=7 days,NA,NA
23511559,NCT00615446,521,febrile neutropenia (fever >38.5 C for >= 24 h),NA,NA,NA,NA
23511559,NCT00615446,521,neutropenic infection (>= grade 3 neutropenia with grade >= 3 infection),NA,NA,NA,NA
23511559,NCT00615446,521,"thrombocytopenia, with bleeding",>=4,NA,NA,NA
23511559,NCT00615446,521,thrombocytopenia,>=4,>=7 days,NA,NA
23511559,NCT00615446,521,lymphopenia accompanied by related infection,NA,NA,NA,NA
23511559,NCT00615446,521,Non-haematological toxicities,3 or 4,>=7 days,TRUE,NA
23511559,NCT00615446,521,"nausea, vomiting, or diarrhoea persisting despite treatment",3 or 4,NA,NA,NA
19415279,NA,523,hematologic toxicity,4,NA,NA,NA
19415279,NA,523,febrile neutropenia,NA,NA,NA,NA
19415279,NA,523,any non-hematologic toxicity,3 or 4,NA,NA,NA
19415279,NA,523,any adverse event causing delay of treatment on days 15 and/or 28,NA,NA,NA,NA
17641541,NA,524,neutropenia,4,>2 days,NA,NA
17641541,NA,524,thrombocytopenia,4,>2 days,NA,NA
17641541,NA,524,febrile neutropenia,NA,NA,NA,NA
17641541,NA,524,nonhematological toxicity,3 or 4,NA,FALSE,NA
17641541,NA,524,any delay of treatment for more than 7 days due to unresolved hematological or nonhematological toxicity,NA,NA,NA,NA
16328413,NA,525,neutropenia (neutrophil count <0.5 x 109/l),4,>5 days,NA,NA
16328413,NA,525,febrile neutropenia (neutrophil count <1.0 x 109/l with fever >=38.5C),NA,NA,NA,NA
16328413,NA,525,platelet count <25 x 109/l,NA,NA,NA,NA
16328413,NA,525,neurosensory toxicity,3 or 4,NA,NA,NA
16328413,NA,525,non-hematological toxicity,3 or 4,NA,FALSE,NA
17932893,NA,526,an ANC<500/mm3,NA,>5 days,NA,NA
17932893,NA,526,an ANC<1000/mm3with a fever>38.58C,NA,NA,NA,NA
17932893,NA,526,"a plate-let count<25,000/mm3",NA,NA,NA,NA
17932893,NA,526,diarrhea despitemaximal loperamide support,3,NA,NA,NA
17932893,NA,526,nonhematologic toxicity,>=3,NA,NA,NA
19556122,NA,527,haematologic toxicity,4,NA,NA,NA
19556122,NA,527,non-haematologic toxicity,3 or 4,NA,FALSE,NA
22371451,NCT00678132,528,thrombocytopenia,4,NA,NA,NA
22371451,NCT00678132,528,neutropenia accompanied by fever,4,NA,NA,NA
22371451,NCT00678132,528,neutropenia not accompanied by fever,4,>=5 days,NA,NA
22371451,NCT00678132,528,diarrhea,4,NA,NA,NA
22371451,NCT00678132,528,metabolic toxicities that are symptomatic,4,NA,NA,NA
22371451,NCT00678132,528,non-hematological toxicity,>=3,NA,FALSE,NA
18058098,NA,529,any non-hematologic toxicity,>=3,NA,NA,NA
18058098,NA,529,nausea while on optimal anti-emetic therapy,3 or 4,NA,NA,NA
18058098,NA,529,diarrhea while receiving an optimal anti-diarrheal regimen,3,NA,NA,NA
18058098,NA,529,neutropenia,4,>5 days,NA,NA
18058098,NA,529,neutropenia associated with fever >38.3Â°C,4,NA,NA,NA
18058098,NA,529,thrombocytopenia,4,NA,NA,NA
18058098,NA,529,hemoglobin <=6.5 g/dL,NA,NA,NA,NA
18058098,NA,529,neuropathy,>=2,NA,NA,NA
18058098,NA,529,treatment delay >4 weeks due to drug-related toxicity,NA,NA,NA,NA
17345085,NA,530,neutropenia,4,>5 days,NA,NA
17345085,NA,530,neutropenia associated with fever >=38.5Â°C,3 or 4,NA,NA,NA
17345085,NA,530,thrombocytopenia,4,>5 days,NA,NA
17345085,NA,530,non-hematologic toxicity,3 or 4,NA,FALSE,NA
17345085,NA,530,the need for a treatment delay of more than 2 weeks to permit resolution of toxicity,NA,NA,NA,NA
17688925,NA,531,neutropenia,4,>7 days,NA,NA
17688925,NA,531,neutropenia with associated fever or sepsis,3 or 4,NA,NA,NA
17688925,NA,531,thrombocytopenia,4,NA,NA,NA
17688925,NA,531,symptomatic  thrombocytopenia,3 or 4,NA,NA,NA
17688925,NA,531,on-hematologic toxicity,3 or 4,NA,FALSE,NA
17688925,NA,531,delays of therapy of greater than 2 weeks for any reason,NA,NA,NA,NA
17688925,NA,531,toxicity occurring more than 30 days after radiation therapy completion,3 or 4,NA,NA,NA
18305938,NA,532,myelotoxicity,4,NA,NA,NA
18305938,NA,532,constitutional symptoms,3,NA,NA,NA
18305938,NA,532,esophagitis,4,NA,NA,NA
18305938,NA,532,pneumonitis,4,NA,NA,NA
19855966,NA,533,non-hematologic toxicity,>=3,NA,NA,NA
19855966,NA,533,thrombocytopenia,4,NA,NA,NA
19855966,NA,533,thrombocytopenia associated with bleeding or requiring transfusion,3,NA,NA,NA
19855966,NA,533,neutropenia,>=3,>7 days,NA,NA
19855966,NA,533,neutropenic fever,NA,NA,NA,NA
19855966,NA,533,hospitalization related to neutropenia,NA,NA,NA,NA
17051371,NA,534,any treatment-related non-hematologic toxicities,4,NA,NA,NA
17051371,NA,534,any treatment-related non-hematologic toxicities not reversible to grade 2 or less in 96 h,3,NA,FALSE,NA
17051371,NA,534,peripheral neuropathy persistent between cycles,3,NA,NA,NA
17051371,NA,534,nausea if IV hydration was required for more than 24 h despite optimal antiemetics,3,NA,NA,NA
17051371,NA,534,thrombocytopenia,4,NA,NA,NA
17051371,NA,534,neutropenia,4,>5 days,NA,NA
17051371,NA,534,neutropenia complicated by neutropenic fever,4,NA,NA,NA
17051371,NA,534,treatment delay of >=4 weeks due to toxicity,NA,NA,NA,NA
21106728,NA,535,neutropenia,4,>= 7 days,NA,NA
21106728,NA,535,neutropenia with sepsis,4,NA,NA,NA
21106728,NA,535,platelet count <0.25 x 109/L,NA,NA,NA,NA
21106728,NA,535,neurotoxicity or cardiotoxicity,2,NA,NA,NA
21106728,NA,535,inability to tolerate 1 cycle of treatment due to toxicity,NA,NA,NA,NA
21106728,NA,535,any other drug-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
18217204,NA,536,"toxicity possibly, probably or definitely related to CEP 701",>=3,NA,FALSE,NA
18829514,NA,537,neutropenia,4,>7 days,NA,NA
18829514,NA,537,febrile neutropenia,NA,NA,NA,NA
18829514,NA,537,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
18829514,NA,537,nonhematologic toxicity,>=3,NA,FALSE,NA
18829514,NA,537,elevated ALT or AST,3,NA,NA,NA
18829514,NA,537,treatment delay of >=1 week due to unresolved hematologic or nonhematologic toxicity,NA,NA,NA,NA
21051221,NCT00540579,538,inability to complete cycle 1 of therapy due to a drug-related toxicity,NA,NA,NA,NA
21051221,NCT00540579,538,non-haematologic toxicities despite optimal supportive care,3 or 4,NA,FALSE,NA
21051221,NCT00540579,538,febrile neutropaenia,NA,NA,NA,NA
21051221,NCT00540579,538,neutropaenia that occurred prior to day 21,4,NA,FALSE,NA
21051221,NCT00540579,538,thrombocytopenia,4,NA,NA,NA
21051221,NCT00540579,538,the inability to initiate cycle 2 within 7 d of scheduled start date,NA,NA,NA,NA
21170669,NCT00265876,539,creatinine,>=2,NA,NA,NA
21170669,NCT00265876,539,proteinuria or hematuria,>=3,NA,NA,NA
21170669,NCT00265876,539,Hypotension,>=3,NA,NA,NA
21170669,NCT00265876,539,other adverse events not clearly attributable to gemcitabine,3 or 4,NA,NA,NA
21170669,NCT00265876,539,other toxicities of concern to the investigator or NCIC CTG,NA,NA,NA,NA
21170669,NCT00265876,539,the inability to administer saracatinib for more than 14 days due to toxicity,NA,NA,NA,NA
20589760,NA,540,hematologic toxicity,>=4,NA,NA,NA
20589760,NA,540,non-hematologic toxicity,>=3,NA,NA,NA
18608594,NA,541,renal,3,NA,NA,NA
18608594,NA,541,neurotoxicity,3,NA,NA,NA
18608594,NA,541,ototoxicity,3,NA,NA,NA
17987263,NA,542,ANC <= 500/ul,NA,>=7 days,NA,NA
17987263,NA,542,platelet count <= 25.000/ul,NA,>=7 days,NA,NA
17987263,NA,542,ANC >= 100/ul,NA,>=3 days,NA,NA
17987263,NA,542,febrile neutropenia,NA,>=3 days,NA,NA
17987263,NA,542,non-hematopoietic toxicity,3 or 4,NA,FALSE,NA
16673059,NA,543,CTC toxicity,3 or 4,NA,FALSE,NA
16673059,NA,543,"late RTOG toxicity with respect to the lungs, heart, esophagus, and spinal cord",3 or 4,NA,NA,NA
21969517,NA,544,hematologic toxicity,4,NA,NA,NA
21969517,NA,544,thrombocytopenia with hemorrhage,1,NA,NA,NA
21969517,NA,544,"nausea, vomiting, or diarrhea despite prophylaxis",>=3,NA,NA,NA
21969517,NA,544,treatment-related nonhematologic toxicity,>=3,NA,FALSE,NA
19023677,NA,546,febrile neutropenia,4,NA,NA,NA
19023677,NA,546,neutropenia,4,â‰¥5 days,NA,NA
19023677,NA,546,thrombocytopenia,4,â‰¥5 days,NA,NA
19023677,NA,546,"serum creatinine â‰¥2 times baseline or upper limit of normal, whichever was less",NA,NA,NA,NA
19023677,NA,546,nausea and vomiting despite maximal antiemetic treatment,4,NA,NA,NA
19023677,NA,546,diarrhea in spite of intensive loperamide therapy,4,NA,NA,NA
19023677,NA,546,other nonhematological toxicity,>=3,NA,NA,NA
18823054,NA,547,nonhematologic  toxicity,3,NA,FALSE,NA
18823054,NA,547,neutropenia with a neu-trophil count of <=500 mm-3,NA,>7 days,NA,NA
18823054,NA,547,neutrophil count <=1000 mm-3with fever (temperature of >=38C),NA,>3 days,NA,NA
18823054,NA,547,"thrombocytopenia<=25,000mm-3",NA,NA,NA,NA
18823054,NA,547,nutropenia associatedwith  infection  that  required  hospitalization,3,NA,NA,NA
19117344,NA,548,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19117344,NA,548,febrile neutropenia,NA,NA,NA,NA
19117344,NA,548,neutropenia,4,>4 days,NA,NA
19117344,NA,548,thrombocytopenia,4,NA,NA,NA
19117344,NA,548,toxicity,>=2,>35 days,NA,NA
20044630,NA,549,thrombocytopenia,>=3,>4 days,NA,NA
20044630,NA,549,neutropenia,4,NA,NA,NA
20044630,NA,549,nausea/vomiting or diarrhea despite adequate supportive care,>=3,>4 days,NA,NA
20044630,NA,549,other nonhematological toxicity,>=3,NA,FALSE,NA
20044630,NA,549,any treatment-related death or hospitalization or toxicity resulting in delay of cycle 2 by >14 days,NA,NA,NA,NA
20978761,NA,550,neutropenia,4,>5 days,NA,NA
20978761,NA,550,"febrile neutropenia (ANC < 1,000/mm3 with fever >38.5Â°C)",NA,NA,NA,NA
20978761,NA,550,"thrombocytopenia (platelet count <25,000/mm3)",4,NA,NA,NA
20978761,NA,550,non-hematologic toxicity,>=3,NA,FALSE,NA
21921646,NA,551,neutropenia,>=3,>= 5 days,NA,NA
21921646,NA,551,neutropenia associated with fever,4,NA,NA,NA
21921646,NA,551,thrombocytopenia,4,NA,NA,NA
21921646,NA,551,symptomatic thrombocytopenia or bleeding,NA,NA,NA,NA
21921646,NA,551,non-hematological toxicity,>=3,NA,NA,NA
21921646,NA,551,diarrhea,>=2,NA,NA,NA
20082116,NA,552,neutropenia,4,NA,NA,NA
20082116,NA,552,thrombocytope,3,NA,NA,NA
20082116,NA,552,serum creatinine â‰¥2 times baseline or ULN,NA,NA,NA,NA
20082116,NA,552,nonhematologic toxicity,>=3,NA,NA,NA
20082116,NA,552,patients had grade 2 alkaline phosphatase at baseline then grade 4 alkaline phosphatase,NA,NA,NA,NA
20082116,NA,552,any omission of day 8 dose during the first cycle,NA,NA,NA,NA
20082116,NA,552,"nausea, vomiting or diarrhea if receiving maximal supportive treatment",3,NA,NA,NA
18236006,NA,555,neutropenia,4,>5 days,NA,NA
18236006,NA,555,febrile neutropenia,NA,NA,NA,NA
18236006,NA,555,thrombocytopenia,4,NA,NA,NA
18236006,NA,555,thrombocytopenia with bleeding,3,NA,NA,NA
18236006,NA,555,nonhematologic toxicity,>=3,NA,FALSE,NA
18236006,NA,555,treatment delay because of unresolved toxicity (hematologic or nonhematologic) â‰¥14 days,NA,NA,NA,NA
17925553,NA,556,thrombocytopenia,4,NA,NA,NA
17925553,NA,556,neutropenia,4,>7 days,NA,NA
17925553,NA,556,neutropenia complicated by fever or infection,3,NA,NA,NA
17925553,NA,556,toxicityin other organ systems,3,NA,FALSE,NA
17925553,NA,556,Hyperbilirubinemia or cholangitis secondary to biliary obstruction occurred in the setting of grade 3 neutropenia,NA,NA,NA,NA
19556811,NA,557,febrile neutropenia with a temperature > 38.1 Â° C and an absolute neutrophil count of < 0.500 x 10 9/l,NA,NA,NA,NA
19556811,NA,557,thrombocytopenia,4,NA,NA,NA
19556811,NA,557,neutropenia,4,>3 days,NA,NA
19556811,NA,557,nonhematologic toxic effect,3 or 4,NA,FALSE,NA
20332663,NA,558,neutropenia despite the administration of G-CSF,4,>4 days,NA,NA
20332663,NA,558,neutropenia complicated by fever or infection despite the administration of G-CSF,4,24 h,NA,NA
20332663,NA,558,thrombocytopenia,3,NA,NA,NA
20332663,NA,558,"requiring platelet transfusion,",3,NA,NA,NA
20332663,NA,558,nonhematologic toxicity,3,NA,FALSE,NA
20332663,NA,558,the scheduled administration of gemcitabine on day 8 could not be given for more than 3 weeks because of failure to meet the standards of CRT,NA,NA,NA,NA
18449006,NA,559,nonhematological toxicity,>=3,NA,NA,NA
18449006,NA,559,thrombocytopenia or anemia,4,NA,NA,NA
18449006,NA,559,neutropenia,4,>=7 days,NA,NA
18449006,NA,559,Dose delay of initiating the second cycle of >2 wk,NA,NA,NA,NA
18449006,NA,559,"Day 8 gemcitabine being held related to ANC <500 x 106/l or platelet count <50,000 x 106/L",NA,NA,NA,NA
20349264,NA,560,neutropenia with fever,4,NA,NA,NA
20349264,NA,560,neutropenia,4,>=7 days,NA,NA
20349264,NA,560,neutropenia,3,>=14 days,NA,NA
20349264,NA,560,neutropenia with fever,3,NA,NA,NA
20349264,NA,560,thrombocytopenia,3,>=7 days,NA,NA
20349264,NA,560,nonhematological toxicity,3 or 4,NA,FALSE,NA
20349264,NA,560,delay of >2 consecutive weeks of treatment due to persistent toxicity,NA,NA,NA,NA
19194117,NA,561,neutropenia,3 or 4,>=7 days,NA,NA
19194117,NA,561,neutropenia complicated by documented infections,NA,NA,NA,NA
19194117,NA,561,thrombocytopenia,4,>=7 days,NA,NA
18379785,NA,562,neutropenia,4,>5 days,NA,NA
18379785,NA,562,febrile neutropenia (ANC < 500/uL with fever [body temperature >= 38.5Â°C] or sepsis),NA,NA,NA,NA
18379785,NA,562,thrombocytopenia,1,NA,NA,NA
18379785,NA,562,nonhematologic toxicity,>=3,NA,FALSE,NA
18379785,NA,562,delay of continuation of therapy >3 weeks,NA,NA,NA,NA
16566993,NA,563,neutropenia (ANC <500/mm3),NA,>5 days,NA,NA
16566993,NA,563,Episode of fever and neutropenia,NA,NA,NA,NA
16566993,NA,563,thrombocytopenia,4,NA,NA,NA
16566993,NA,563,"ANC <1500/mm3, platelets <100,000/mm3 at day 35",NA,NA,NA,NA
16566993,NA,563,non-hematologic toxicity,3 or 4,NA,NA,NA
16566993,NA,563,renal dysfunction as measured by an elevation of the serum creatinine to >1.5 mg/dl immediately prior to any cycle of treatment,NA,NA,NA,NA
16566993,NA,563,Greater than 50% dose reduction for gemcitabine,NA,NA,NA,NA
20153912,NA,564,neutropenia,4,NA,NA,NA
20153912,NA,564,febrile neutropenia,3,NA,NA,NA
20153912,NA,564,thrombocytopenia,4,NA,NA,NA
20153912,NA,564,nonhematological adverse events,3,NA,FALSE,NA
20153912,NA,564,a delay of gemcitabine infusion on day 15 for more than 7 days,NA,NA,NA,NA
20153912,NA,564,a delay of administration of the next course for more than 2 weeks.,NA,NA,NA,NA
20197102,NA,565,NA,NA,NA,NA,DLT not defined
20188433,NA,566,neutropenia,4,â‰¥7 days,NA,NA
20188433,NA,566,"Febrile neutropenia, defined as concurrent grade 4 neutropenia and fever >38.5 â—¦ C lasting over 24 h",NA,NA,NA,NA
20188433,NA,566,thrombocytopenia with bleeding,>=3,NA,NA,NA
20188433,NA,566,thrombocytopenia,4,â‰¥7 days,NA,NA
20188433,NA,566,lymphopenia accompanied by an opportunistic infection,NA,NA,NA,NA
20188433,NA,566,Non-hematologic toxicities including fatigue,3 or 4,NA,FALSE,NA
20188433,NA,566,"Nausea, vomiting, or diarrhea despite maximal medical therapy",3 or 4,NA,NA,NA
16337995,NA,567,hematological toxicity,4,NA,FALSE,NA
16337995,NA,567,non-hematological toxicity,3 or 4,NA,FALSE,NA
16337995,NA,567,chemotherapy was held for toxicity for two consecutive weeks or total treatment time was greater than 77 days due to treatment-related toxicity,NA,NA,NA,NA
16337995,NA,567,Other toxicities could be considered a DLT at the discretion of the principal investigators,NA,NA,NA,NA
21570216,NA,568,leukopenia with granulocyte colony-stimulating factor,4,>5 days,NA,NA
21570216,NA,568,neutropenia with granulocyte colony-stimulating factor,4,>5 days,NA,NA
21570216,NA,568,neutropenia with fever (>38 C) even with granulocyte colony- stimulating factor rescue,4,NA,NA,NA
21570216,NA,568,"platelet count of less than 30,000/mm3",NA,NA,NA,NA
21570216,NA,568,nonhematologic toxicity for mucositis and dermatitis,3 or 4,NA,NA,NA
17439736,NA,569,hematological toxicity,4,NA,NA,NA
17439736,NA,569,neurological toxicity,2,NA,NA,NA
10690391,NA,570,hematological toxicity,4,NA,NA,NA
10690391,NA,570,nausea and vomiting despite 5-HT3-prophylaxy,4,NA,NA,NA
10690391,NA,570,any other toxicity,>=3,NA,FALSE,NA
25052698,NA,571,neutropenia,4,>7 days,NA,NA
25052698,NA,571,thrombocytopenia,4,NA,NA,NA
25052698,NA,571,nonhaematologic toxicity,3 or 4,NA,FALSE,NA
28869617,NCT00477815,572,non-hematologic toxicity,4,NA,FALSE,NA
28869617,NCT00477815,572,pulmonary toxicity,4,>14 days,NA,NA
28869617,NCT00477815,572,any non-hematologic toxicity not resolving in 96 h,3,NA,FALSE,NA
28869617,NCT00477815,572,"delayed engraftment, defined as an ANC not recovered to â©¾ 500/mm3 by day 21 post transplant and/or platelet transfusion dependency >35 days.",4,NA,NA,NA
22149206,NA,573,non-hematologic toxicity,3,>=14 days,FALSE,NA
22149206,NA,573,non-hematologic toxicity,4,NA,FALSE,NA
22149206,NA,573,hematologic toxicity lasting beyond day 42 in the absence of residual leukemia,3 or 4,NA,NA,NA
16847470,NA,574,neurological or urinary toxicities,>=2,NA,NA,NA
16847470,NA,574,cardiac toxicity,>=3,NA,NA,NA
16847470,NA,574,pulmonary and digestive toxicities,>=3,NA,NA,NA
16847470,NA,574,All other toxicities,>=3,NA,NA,NA
16847470,NA,574,myelosuppression defined by neutrophil <500 ul-1 and/or platelets <20 000 ul-1 associated with empty bone marrow,NA,>=40 days,NA,NA
8695365,NA,575,NA,NA,NA,NA,DLT not defined
10426665,NA,576,non-hematologic toxicity,3,NA,NA,NA
10426665,NA,576,ANC < 500/mm3,NA,NA,NA,NA
10426665,NA,576,"platelet count < 50,000/mm3",NA,NA,NA,NA
32777116,NCT01132586,577,Nonhematologic toxicities,4,NA,FALSE,NA
32777116,NCT01132586,577,failure to recover absolute neutrophil count (ANC <500/Î¼L) platelet count (<25 000/Î¼L) by day 42 in the absence of persistent disease,NA,NA,NA,NA
32777116,NCT01132586,577,infection-related complications were not considered DLT unless severity or duration was longer than expected with conventional treatment,NA,NA,NA,NA
10683085,NA,578,neutropenia,4,>5 days,NA,NA
10683085,NA,578,neutropenia complicated by fever,4,NA,NA,NA
10683085,NA,578,thrombocytopenia,4,NA,NA,NA
10683085,NA,578,nonhematologic toxicity,3,NA,FALSE,NA
33914097,NCT03661515,579,non-hematologic toxicity during the induction phase,4,NA,FALSE,NA
33914097,NCT03661515,579,"neutropenia, not attributable to persistent leukemia",4,> 56 days from the end of the FLAG-Ida regimen,NA,NA
9547676,NA,580,non-laboratory toxicity,>=3,NA,NA,NA
9547676,NA,580,leukopenia,4,NA,NA,NA
9547676,NA,580,thromcobytopenia,>=3,NA,NA,NA
9436939,NA,581,NA,NA,NA,NA,DLT not defined
27342239,NCT01040559,582,allergy/immunology,>=4,NA,NA,NA
27342239,NCT01040559,582,blood/bone marrow,>=4,NA,FALSE,NA
27342239,NCT01040559,582,cardiac arrhythmia,>=4,NA,NA,NA
27342239,NCT01040559,582,general cardiac,>=4,NA,NA,NA
27342239,NCT01040559,582,coagulation,>=4,NA,NA,NA
27342239,NCT01040559,582,constitutional symptoms,>=4,NA,NA,NA
27342239,NCT01040559,582,gastrointestinal,>=4,NA,NA,NA
27342239,NCT01040559,582,haemorrhage/bleeding,>=4,NA,NA,NA
27342239,NCT01040559,582,infection,>=4,NA,NA,NA
27342239,NCT01040559,582,metabolic/laboratory,>=4,NA,NA,NA
27342239,NCT01040559,582,total bilirubin >5 times the upper limit of normal,NA,5 consecutive days,NA,NA
27342239,NCT01040559,582,creatine,>=3,NA,NA,NA
27342239,NCT01040559,582,musculoskeletal/soft tissue,>=4,NA,NA,NA
27342239,NCT01040559,582,ocular/visual,>=4,NA,NA,NA
27342239,NCT01040559,582,pain,>=4,NA,NA,NA
17158228,NA,583,NA,NA,NA,NA,DLT not defined
10561293,NA,584,neutropenia,4,>7 days,NA,NA
10561293,NA,584,ANC count < 100,NA,>3 days,NA,NA
10561293,NA,584,febrile neutropenia (temperature > 38Â°C),NA,NA,NA,NA
10561293,NA,584,thrombocytopenia,4,>7 days,NA,NA
10561293,NA,584,nonhematologic toxicity,3 or 4,NA,FALSE,NA
10561293,NA,584,The omission of day-8 chemotherapy administration in the first treatment cycle and a more than 1-week delay in the administration of the second treatment cycle,NA,NA,NA,NA
9818075,NA,585,NA,NA,NA,NA,DLT not defined
18756533,NA,586,"drug-related, nonhematologic toxicities",>=3,NA,FALSE,NA
24682421,NCT00838240,588,Non-hematological toxicity occurring during 8 weeks after the start of the remission induction,3 or 4,NA,FALSE,NA
24682421,NCT00838240,588,bone marrow hypoplasia leading to neutrophil or platelet recovery (neutrophils >0.5Ã—109/L and platelets >50Ã—109/L) later than 8 weeks after start of last remission induction.,NA,>8 weeks after start of last remission induction,NA,NA
20485286,NA,589,neutropenia,4,>=7 days,NA,NA
20485286,NA,589,febrile neutropenia,NA,NA,NA,NA
20485286,NA,589,thrombocytopenia,4,NA,NA,NA
20485286,NA,589,serum creatinine >=2 x ULN,NA,NA,NA,NA
20485286,NA,589,any drug-related non-haematological toxicity,3 or 4,NA,FALSE,NA
20485286,NA,589,A dose delay or interruption for longer than 2 weeks,NA,NA,NA,NA
11013279,NA,590,nonhematologic toxicities,3 or 4,NA,FALSE,NA
11013279,NA,590,hematologic toxicity,4,NA,NA,NA
11094306,NA,591,non-haematological toxicity necessitating a dose reduction,3 or 4,NA,FALSE,NA
11094306,NA,591,any haematological toxicity necessitating a dose reduction,NA,NA,NA,NA
11094306,NA,591,any drug-related adverse event that resulted in the omission of a treatment or treatment delay or warranted removal of the patient from the study including any grade 3 hypersensitivity reaction,NA,NA,NA,NA
24738629,NCT01040559,592,allergy/immunolog,>=4,NA,NA,NA
24738629,NCT01040559,592,blood/bone marrow (for neutrophil andplatelet count),>=4,NA,FALSE,NA
24738629,NCT01040559,592,cardiac arrhythmia,>=4,NA,NA,NA
24738629,NCT01040559,592,general cardiac,>=4,NA,NA,NA
24738629,NCT01040559,592,coagulation,>=4,NA,NA,NA
24738629,NCT01040559,592,constitutional symptoms,>=4,NA,NA,NA
24738629,NCT01040559,592,gastrointestinal,>=4,NA,NA,NA
24738629,NCT01040559,592,haemorrhage/bleeding,>=4,NA,NA,NA
24738629,NCT01040559,592,infection,>=4,NA,NA,NA
24738629,NCT01040559,592,metabolic/laboratory,>=4,NA,NA,NA
24738629,NCT01040559,592,total bilirubin >5 xthe upper limit of normal (ULN),NA,five consecutive days,NA,NA
24738629,NCT01040559,592,creatinine,>=3,NA,NA,NA
24738629,NCT01040559,592,musculoskeletal/soft tissue,>=4,NA,NA,NA
24738629,NCT01040559,592,ocular/visual,>=4,NA,NA,NA
24738629,NCT01040559,592,pain,>=4,NA,NA,NA
24738629,NCT01040559,592,any other categories of AE,>=3,NA,NA,NA
10673977,NA,593,neutropenia,4,>7 days,NA,NA
10673977,NA,593,thrombocytopenia,4,NA,NA,NA
10673977,NA,593,non-haematological toxicity,4,NA,FALSE,NA
10673977,NA,593,A delay longer than 1 week in administering the second cycle of therapy,NA,NA,NA,NA
11099327,NA,594,ANC less than 500/uL,NA,>5 days,NA,NA
11099327,NA,594,ANC less than 500/uL associated with fever or infection requiring hospitalization for parenteral antibiotics,NA,NA,NA,NA
11099327,NA,594,"platelets less than 50,000/uL",NA,>5 days,NA,NA
11099327,NA,594,"platelets less than 25,000/uL",NA,NA,NA,NA
11099327,NA,594,any drug-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
11099327,NA,594,omission of two consecutive doses of gemcitabine because of inability to meet hematologic criteria for re-treatment,NA,NA,NA,NA
10997809,NA,595,ANC of <0.5 x 103/ul,NA,>=7 days,NA,NA
10997809,NA,595,febrile neutropenia (fever >= 38.5 Â°C with G4 neutropenia or febrile G3 neutropenia requiring i.v. antibiotics or hospitalization),NA,NA,NA,NA
10997809,NA,595,platelets <25 x 103/ul,NA,NA,NA,NA
10997809,NA,595,neurotoxicity,>2,NA,NA,NA
10997809,NA,595,mucositis,>2,NA,NA,NA
10997809,NA,595,treatment withheld because of toxicity on days 8 or 15 or a treatment delay of > 1 week on day 2,NA,NA,NA,NA
11032598,NA,596,NA,NA,NA,NA,DLT not defined
11005695,NA,597,neutropenia,4,NA,NA,NA
11005695,NA,597,thrombocytopenia,4,NA,NA,NA
11005695,NA,597,non-haematological toxicity,3 or 4,NA,FALSE,NA
8622085,NA,598,an absolute neutrophil count less than 0.5 x 109/L,NA,NA,NA,NA
8622085,NA,598,a platelet count less than 25 x 109/L,NA,NA,NA,NA
8622085,NA,598,nonhematologic toxicity,3,NA,NA,NA
21519855,NA,599,drug related toxicity,>=3,NA,FALSE,NA
21519855,NA,599,bone marrow hypoplasia with a bone marrow cellularity of <5% and no evidence of leukemia,NA,>42 days,NA,NA
9400947,NA,600,NA,NA,NA,NA,DLT not defined
26750985,NCT01518556,601,neutrophils [absolute neutrophil count (ANC) <= 500/mL] or platelets (platelet count <= 20 000/mL),NA,>42 days after the start of induction therapy,NA,NA
26750985,NCT01518556,601,Non-hematologic toxicities,>=4,NA,NA,NA
10955861,NA,602,granulocytopenia,4,>=7 days,NA,NA
10955861,NA,602,"thrombocytopenia, complicated grade III or IV granulocytopenia, and/or nonhematologic toxicity grades",4,NA,NA,NA
10955861,NA,602,neutropenia,4,NA,NA,NA
10955861,NA,602,thrombocytopenia,4,NA,NA,NA
10955861,NA,602,nonhematologic toxicity,>=3,NA,FALSE,NA
22404399,NA,603,absolute neutrophil count <500 x 109/l,NA,NA,NA,NA
22404399,NA,603,a platelet count < 25 x 109/l,NA,NA,NA,NA
22404399,NA,603,non-haematological toxicity,3,NA,NA,NA
21585619, UMIN000001141 and UMIN000001142,604,All drug-related nonhematological toxicities,>=3,NA,FALSE,NA
21585619, UMIN000001141 and UMIN000001142,604,bone marrow aplasia,>6 weeks,NA,NA,NA
9739439,NA,606,neutropenia,4,>=5 days,NA,NA
9739439,NA,606,thrombocytopenia,4,>=5 days,NA,NA
9739439,NA,606,febrile neutropenia (grade 2 or greater fever occurring in the setting of grade 4 neutropenia),NA,NA,NA,NA
9739439,NA,606,non-hematologic toxicity,3 or 4,NA,FALSE,NA
9739439,NA,606,inability to begin cycle 2 within two weeks of the scheduled start date due to drug-related toxicity and delayed normal tissue recovery,NA,NA,NA,NA
23801301,NA,607,absolute neutrophil count<0.5Ã—109/L,NA,â‰¥5 days,NA,NA
23801301,NA,607,absolute neutrophil count<0.5Ã—109/L associated with feverâ‰¥38.5 Â°C,NA,NA,NA,NA
23801301,NA,607,platelets <50Ã—109/L,NA,NA,NA,NA
23801301,NA,607,non hematological toxicity,3 or 4,NA,FALSE,NA
11869937,NA,608,NA,NA,NA,NA,DLT not defined
10080603,NA,609,neutropenia complicated by fever,4,NA,NA,NA
10080603,NA,609,neutropenia,4,>5 days,NA,NA
10080603,NA,609,thrombocytopenia,4,NA,NA,NA
10080603,NA,609,nonhematologic toxicity,3 or 4,NA,FALSE,NA
10080603,NA,609,delay of recovery from treatmentrelated toxicity for more than 2 weeks,NA,NA,NA,NA
11137206,NA,610,neutro or thrombocytopenia,4,NA,NA,NA
11137206,NA,610,non-hematologic toxicity,3 or 4,NA,FALSE,NA
17154172,NA,611,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17154172,NA,611,"nausea, vomiting, and diarrhea uncontrolled by adequatesymptomatic therapy",3 or 4,NA,NA,NA
30378121,EudraCT 2010-021719-18,612,haematological toxicity persisting after day 42,4 or 5,NA,FALSE,NA
30378121,EudraCT 2010-021719-18,612,"clofarabine-associated, non-haematological toxicities",5-Mar,NA,FALSE,NA
12942571,NA,613,NA,NA,NA,NA,DLT not defined
9220290,NA,614,any toxicity in at least one third of the patients,>=3,NA,FALSE,NA
10885899,NA,615,non-hematologic toxicity,3 or 4,NA,FALSE,NA
10885899,NA,615,neutropenia,4,NA,NA,NA
10885899,NA,615,thrombocytopenia,4,NA,NA,NA
10885899,NA,615,any toxicity persisted over day 28 of course 1,>=2,NA,FALSE,NA
12637470,NA,616,NA,NA,NA,NA,DLT not defined
11150903,NA,619,neutropenia,4,>5 days,NA,NA
11150903,NA,619,thrombocytopenia,4,>5 days,NA,NA
11150903,NA,619,neutropenia complicated by fever/infection,4,NA,NA,NA
11150903,NA,619,thrombocytopenia complicated by hemorrhagic symptoms,4,NA,NA,NA
11150903,NA,619,nonhematological toxicity,3,NA,FALSE,NA
7860227,NA,620,any toxicity in at least one third of the patients.,>=3,NA,FALSE,NA
27677906,NCT00392691,621,treatmentâ€related death,NA,NA,NA,NA
27677906,NCT00392691,621,irreversible nonhematologic toxicity,3 or 4,NA,FALSE,NA
27677906,NCT00392691,621,failure to reach Gâ€CSFâ€indepen-dent neutrophils >0.5 Ã— 109/L after 3 weeks post transplantation,NA,NA,NA,NA
27677906,NCT00392691,621,failure to reach transfusionâ€independent thrombocytes >20 Ã— 109/Lafter 8 weeks post transplantation,NA,NA,NA,NA
29610115,NCT02200848,622,Nonhematologic adverse events,3 or 4,NA,FALSE,NA
29610115,NCT02200848,622,Stevens-Johnson syndrome,3 or 4,NA,NA,NA
29610115,NCT02200848,622,toxic epidermal necrolysis,any grade,NA,NA,NA
29610115,NCT02200848,622,hematologic toxicity,4,NA,FALSE,NA
29610115,NCT02200848,622,thrombocytopenia complicated by hemorrhage,2 or 3,NA,NA,NA
29610115,NCT02200848,622,neutropenia complicated by fever >=38.5Â°C or infection,3 or 4,NA,NA,NA
33828254,NCT03332498,623,immune-related adverse events (irAEs),>=4,NA,NA,NA
33828254,NCT03332498,623,non-infectious pneumonitis,>=3,NA,NA,NA
33828254,NCT03332498,623,irAEs that did not downgrade to grade â‰¤2 within 3 days or grade â‰¤1 within 14 days,>=3,NA,NA,NA
33828254,NCT03332498,623,pneumonitis or interstitial lung disease that did not resolve to grade 1 within 3 days,>=2,NA,NA,NA
33828254,NCT03332498,623,non-hematologic toxicity that did not resolve within 4 days,>=3,NA,NA,NA
31230047,NCT02401048,624,nonhematologic adverse event possibly related to either ibrutinib and/or durvalumab,>=3,NA,NA,NA
31230047,NCT02401048,624,hematologic adverse event possibly related to either ibrutinib and/or durvalumab,4,NA,NA,NA
17505827,NA,625,hematologic toxicity associated with sunitinib,4,>=7 days,NA,NA
17505827,NA,625,"hematologic toxicity complicated by grade >= 2 fever, , grade 3 or documented infection, hemorrhage, or the need for blood product support",4,NA,NA,NA
17505827,NA,625,thrombocytopenia with grade 3 or 4 hemorrhage,3,NA,NA,NA
17505827,NA,625,nausea and vomiting refractory to anti-emetic therapy,3 or 4,NA,NA,NA
17505827,NA,625,clinical or radiographic evidence of left ventricular dysfunction,NA,NA,NA,NA
17505827,NA,625,decline from baseline in LVEF by >=20% and to less than the LLN,NA,NA,NA,NA
17505827,NA,625,a LVEF of >= 10% below the LLN,NA,NA,NA,NA
17505827,NA,625,cTnT and/or cTnI above the institutional ULN,NA,NA,NA,NA
17505827,NA,625,any other nonhematologic toxicity at any time,>=3,NA,FALSE,NA
21469980,NA,626,absolute neutrophil count nadir < 500/ÂµL,NA,â‰¥7 days,NA,NA
21469980,NA,626,febrile neutropenia,NA,NA,NA,NA
21469980,NA,626,"platelets < 50,000/ÂµL",NA,â‰¥7 days,NA,NA
21469980,NA,626,documented bleeding episode associated with thrombocytopenia,NA,NA,NA,NA
21469980,NA,626,transfusion requirement,NA,NA,NA,NA
21469980,NA,626,nonhematologic toxicity due to treatment,3 or 4,NA,FALSE,NA
21469980,NA,626,any dose reduction secondary to drugrelated toxicity during the first cycle of therapy,NA,NA,NA,NA
24093213,NA,627,neutropenia,4,>5 days,NA,NA
24093213,NA,627,neutropenia with fever (>38.4C),NA,NA,NA,NA
24093213,NA,627,thrombocytopenia,4,NA,NA,NA
24093213,NA,627,non-haematological toxicity,>=3,NA,FALSE,NA
24093213,NA,627,nausea and vomiting despite maximal supportive therapy,>=3,NA,NA,NA
24093213,NA,627,treatment delays of more than 2 weeks because of treatment related toxicity,NA,NA,NA,NA
30101387,NCT02257541,628,Any unexpected adverse event or abnormal laboratory value assessed as at least possibly related to the study medication,NA,NA,NA,NA
33683501,NA,629,any non-hematologic adverse event related to BI 836826 or ibrutinib,>=3,NA,FALSE,NA
33683501,NA,629,neutropenia with concomitant infection,4,NA,NA,NA
33683501,NA,629,febrile neutropenia,4,NA,NA,NA
33683501,NA,629,febrile neutropenia,3,>72 hrs,NA,NA
33683501,NA,629,thrombocytopenia with clinically significant bleeding,4,NA,NA,NA
33683501,NA,629,anemia,4,NA,NA,NA
33683501,NA,629,hematologic adverse event,5,NA,NA,NA
7540421,NA,630,NA,NA,NA,NA,DLT not defined
23045577,NCT00849654,631,nonhematologic adverse event,>=3,NA,NA,NA
23045577,NCT00849654,631,prolongation of the QTc interval,>=3,NA,NA,NA
23045577,NCT00849654,631,neutropenia,>=3,NA,NA,NA
23045577,NCT00849654,631,febrile neutropenia,NA,NA,NA,NA
23045577,NCT00849654,631,thrombocytopenia,4,NA,NA,NA
23045577,NCT00849654,631,dosing delay because of toxicity for more than 7 days,NA,NA,NA,NA
25336693,NCT00878423,632,neutropenia (neutrophil count <0.5 x 109/L),NA,>5 days,NA,NA
25336693,NCT00878423,632,neutropenia (neutrophil counts <1 x 109 /L) with fever,NA,NA,NA,NA
25336693,NCT00878423,632,thrombocytopenia (platelet count <25 x 109/L) accompanied by bleeding,NA,NA,NA,NA
25336693,NCT00878423,632,thrombocytopenia (platelet counts <10 x 109/L),NA,NA,NA,NA
25336693,NCT00878423,632,nonhematologic toxicity that was not a consequence of tumor progression,3 or 4,NA,FALSE,NA
25336693,NCT00878423,632,more than 1 individual dose omission during the first cycle of treatment due to the appearance of toxicity that was considered related to AT13387,NA,NA,NA,NA
23403628,NA,633,neutropenia,4,>= 7 days,NA,NA
23403628,NA,633,febrile neutropenia,>=3,NA,NA,NA
23403628,NA,633,thrombocytopenia,4,NA,NA,NA
23403628,NA,633,nonhematologic toxicity of any duration,>=3,NA,FALSE,NA
23403628,NA,633,"hypertension, nausea, vomiting, and diarrhea were only considered as DLTs if they occurred despite optimal medical management",3,NA,NA,NA
23403628,NA,633,Interruption of dosing for 5 continuous days within the first treatment period,NA,NA,NA,NA
23403628,NA,633,an inability to begin a second treatment period by day 36,NA,NA,NA,NA
31331917,NA,634,neutropenia,3,>7 days,NA,NA
31331917,NA,634,life-threatening neutropenia with fever at least 38.3Â°C,>=3,NA,NA,NA
31331917,NA,634,thrombocytopenia despite holding treatment,4,>7 days,NA,NA
31331917,NA,634,thrombocytopenia with grade 2 or higher bleeding or requiring red blood cell or platelet transfusion,3,NA,NA,NA
31331917,NA,634,any nonhematologic adverse event (AE),>=3,NA,FALSE,NA
31331917,NA,634,"only grade 4 neutropenia was considered a DLT, ratherthan grade 3 neutropenia lasting >7 days",NA,NA,NA,after protocol amendments
31331917,NA,634,rash was only considered a DLT if it did not resolve with a dose hold and concomitant corticosteroids and/or antihistamines within 10 days.,NA,NA,NA,after protocol amendments
7625371,NA,635,NA,1,NA,NA,DLT not defined
8740798,NA,636,neutropenia,4,>4 days,NA,NA
8740798,NA,636,thrombocytopenia,4,>4 days,NA,NA
8740798,NA,636,neutropenic fever,NA,NA,NA,NA
8740798,NA,636,the need for platelet transfusion,NA,NA,NA,NA
8740798,NA,636,other toxicity,>=3,>7 days,FALSE,NA
32147671,NCT01468688,637,NA,NA,NA,NA,DLT not defined
9635927,NA,638,neutropenia,4,>5 days,NA,NA
9635927,NA,638,febrile neutropenia,NA,NA,NA,NA
9635927,NA,638,anemia,>=3,NA,NA,NA
9635927,NA,638,thrombopenia,>=3,NA,NA,NA
9635927,NA,638,other organ toxicity,>=2,NA,FALSE,NA
21263099,NA,639,"adverse event that was possibly, probably, or definitely attributed to dasatinib",3 or 4,NA,FALSE,NA
21263099,NA,639,nonhematologic toxicities,2,>7 days,NA,NA
12228203,NA,640,nonhematologic adverse event,3 or 4,NA,FALSE,NA
12228203,NA,640,hematologic toxicity,4,NA,NA,NA
19541476,NA,641,AE,4,NA,NA,NA
19541476,NA,641,"non-haematological AE with emergent toxicity at least possibly related to the study treatment, in patients with normal values/status at baseline",3,NA,NA,NA
20310049,NA,642,NA,NA,NA,NA,DLT not defined
11535501,NA,643,2 of 6 patients experienced grade 3 toxicity,NA,NA,NA,NA
11355147,NA,644,hematologic toxicity,4,NA,NA,NA
11355147,NA,644,nonhematologic adverse event,3 or 4,NA,FALSE,NA
18235116,NA,645,any drug-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
18235116,NA,645,neutropenia,4,NA,NA,NA
18235116,NA,645,"occurrence of fever with absolute neutrophil count less than 1,500/uL",NA,NA,NA,NA
18235116,NA,645,thrombocytopenia,4,NA,NA,NA
18235116,NA,645,nausea and/or vomiting occurring despite antiemetic therapy and requiring hydration for more than 24 hours,>=3,NA,NA,NA
18235116,NA,645,diarrhea occurring despite loperamide therapy,>=3,NA,NA,NA
18235116,NA,645,treatment delay lasting more than 4 weeks,NA,NA,NA,NA
11355147,NA,646,NA,NA,NA,NA,DLT not defined
15150579,NA,647,neutropenia,4,>=7 days,NA,NA
15150579,NA,647,neutropenia associated with severe systemic infection requiring parental treatment,4,NA,NA,NA
15150579,NA,647,febrile neutropenia,NA,NA,NA,NA
15150579,NA,647,thrombocytopenia with or without haemorrhagic complications,3 or 4,NA,NA,NA
15150579,NA,647,nonhaematological toxicity,3 or 4,NA,FALSE,NA
28428884,NCT01738139,648,nonhematologic/laboratory toxicities,>=3,NA,NA,NA
28428884,NCT01738139,648,hematologic/laboratory toxicities that were at least possibly related to the combination of imatinib and ipilimumab,>=4,NA,NA,NA
28428884,NCT01738139,648,fatigue,3,>7 days,NA,NA
28428884,NCT01738139,648,hematologic adverse events,4,>5 days,NA,NA
28428884,NCT01738139,648,neutropenia,4,>7 days,NA,NA
28428884,NCT01738139,648,thrombocytopenia,4,>7 days,NA,NA
16144928,NA,649,nonhematologic toxicity,>=3,NA,FALSE,NA
16144928,NA,649,thrombocytopenia,>=3,NA,NA,NA
16144928,NA,649,neutropenia,4,NA,NA,NA
16144928,NA,649,according to the clinical judgment of the investigator in consultation with the sponsor (Hoffmann-La Roche),NA,NA,NA,NA
9457812,NA,651,NA,1,NA,NA,DLT not defined
19248046,NA,652,attributable non-hematologic toxicities,>=3,NA,FALSE,NA
19248046,NA,652,neutropenia,4,NA,NA,NA
19248046,NA,652,thrombocytopenia,3,NA,NA,NA
19248046,NA,652,Any toxicity resulting in a >14-day delay to re-treat,NA,NA,NA,NA
22805325,NCT 00424385,653,any drug-related toxicity,4,NA,NA,NA
22805325,NCT 00424385,653,recurring non-haematological toxicity,3,NA,NA,NA
22805325,NCT 00424385,653,Hand-foot syndrome (HFS),NA,NA,FALSE,NA
22805325,NCT 00424385,653,hypertension that persisted more than 21 days after holding S despite maximal medical management,3,NA,NA,NA
22805325,NCT 00424385,653,symptomatic hypertension that persisted more than 21 days after holding S despite maximal medicalmanagement,2,NA,NA,NA
10410530,NA,654,leukopenia or granulocytopenia,4,NA,NA,NA
10410530,NA,654,thrombocytopenia,3 or 4,NA,NA,NA
10410530,NA,654,"diarrhea despite the administration of loperamide,",2,>4 days,NA,NA
10410530,NA,654,diarrhea,3,NA,NA,NA
10410530,NA,654,toxicity in a specific organ,3 or 4,NA,NA,NA
10410530,NA,654,the infusion of CPT-11 was skipped two or more times during 5 scheduled times;,NA,NA,NA,NA
10410530,NA,654,"initiation of second cycle (day 29) was delayed more than 8 days for such the reasons as leukopenia (less than 3,000/uL) or grade 1 or severe diarrhea",NA,NA,NA,NA
10410530,NA,654,NA,NA,NA,FALSE,NA
18284451,NA,655,a more than 7-day delay in the planned radiation therapy and/or planned chemotherapy (prior to the completion of two cycles) due to toxicity,NA,NA,NA,NA
10343194,NA,656,leukopenia,4,NA,NA,NA
10343194,NA,656,thrombocytopenia,4,NA,NA,NA
10343194,NA,656,nonhematological toxicity,4,NA,FALSE,NA
18989889,NA,657,"renal, pulmonary, cardiovascular or CNS toxicity",3,NA,NA,NA
18989889,NA,657,non-hematopoeitic toxicity,4,NA,NA,NA
18989889,NA,657,neutropenia (ANC<500/ul) for those without marrow involvement and marrow aplasia >=4 weeks,4,>14 days,NA,NA
18989889,NA,657,neutropenia (ANC<500/ul) for those without marrow involvement,4,NA,NA,NA
18989889,NA,657,marrow aplasia for those with marrow involvement,NA,>=4 weeks,NA,NA
18989889,NA,657,"platelet count <25,000/ul",NA,>7 days,NA,NA
18989889,NA,657,clinically significant bleeding for those without marrowinvolvement,NA,NA,NA,NA
24434430,EudraCT number: 2009-011417-24,658,neutropenia,3,>7 days,NA,NA
24434430,EudraCT number: 2009-011417-24,658,thrombocytopenia,3,>7 days,NA,NA
24434430,EudraCT number: 2009-011417-24,658,thrombocytopenia,4,NA,NA,NA
24434430,EudraCT number: 2009-011417-24,658,"neutropenic fever (ANC (including bands) < 1.0 x 109 l-1 , fever >=38.5 C)",4,NA,NA,NA
24434430,EudraCT number: 2009-011417-24,658,Non-haematologic toxicity,3 or 4,NA,NA,NA
31471313,NCT02164240,659,non-hematologic adverse events (AE),3 or 4,NA,NA,NA
31471313,NCT02164240,659,febrile neutropenia,3 or 4,NA,NA,NA
31471313,NCT02164240,659,neutropenia,4,â‰¥ 7 days,NA,NA
31471313,NCT02164240,659,thrombocytopenia,4,NA,NA,NA
31471313,NCT02164240,659,thrombocytopenia complicated by hemorrhage,3,NA,NA,NA
31471313,NCT02164240,659,Treatment delay of > 1 week due to delayed recovery,NA,NA,NA,NA
9060524,NA,660,neutropenia,4,>4 days,NA,NA
9060524,NA,660,thrombocytopenia,4,>4 days,NA,NA
9060524,NA,660,"neutropenic fever (defined as temperature >= 38.3Â°C with an ANC < 1,000/uL)",NA,NA,NA,NA
9060524,NA,660,the need for a platelet transfusion,NA,NA,NA,NA
9060524,NA,660,nonhematologic toxicity,>=3,>7 days,FALSE,NA
9363862,NA,661,neutropenia,4,>5 days,NA,NA
9363862,NA,661,thrombocytopenia,4,>5 days,NA,NA
9363862,NA,661,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9363862,NA,661,have the drug withheld for I week of the cycle,NA,NA,NA,NA
11032596,NA,662,nonhematologic toxicity,>=3,NA,NA,NA
11032596,NA,662,hematologic toxicity,4,NA,NA,NA
24492162,NA,663,febrile neutropenia (fever > grade 2 with grade 4 neutropenia and requiring intravenous antibiotics),NA,NA,NA,NA
24492162,NA,663,neutropenia (absolute neutrophil count < 500/uL),4,>7 days,NA,NA
24492162,NA,663,thrombocytopenia,4,NA,NA,NA
24492162,NA,663,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17293590,NA,664,thrombocytopenia,3 or 4,NA,NA,NA
17293590,NA,664,neutropenia,4,NA,NA,NA
17293590,NA,664,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17293590,NA,664,"the detection of hemorrhage on the MRI scan obtained after course 2 of therapy, which was performed within one week of completing this course",NA,NA,NA,NA
17909807,NA,667,non-hematologic toxicity,>=3,NA,NA,NA
17909807,NA,667,neutropenia associated with fever or infection,4,>=7 days,NA,NA
17909807,NA,667,other hematologic toxicity,4,NA,NA,NA
21242495,NCT00253474,668,neutropenia,4,â‰¥7 days,NA,NA
21242495,NCT00253474,668,thrombocytopenia,4,â‰¥7 days,NA,NA
21242495,NCT00253474,668,nonhematologic toxicity (NHT) attributable to PI,3 or 4,NA,FALSE,NA
21242495,NCT00253474,668,"intolerable behavioral/mood changes, such as hyperactivity, aggression, irritability, or depression that required dose reduction or discontinuation, and persistent (i.e., not transiently related to the injection) grade 2 or higher intolerable constitutional symptoms.",NA,NA,NA,NA
10755315,NA,669,neutropenia,4,>5 days,NA,NA
10755315,NA,669,thrombocytopenia,4,NA,NA,NA
10755315,NA,669,nonhematological toxicity,4,NA,FALSE,NA
18359865,NA,670,Nonhematologic attributable events,>=3,NA,FALSE,NA
18359865,NA,670,"Nausea, vomiting, and diarrhea that were refractory to standard medical therapy",NA,NA,NA,NA
18359865,NA,670,neutropenia,4,>=5 days,NA,occurred after a TMZ dose reduction to 150 mg/m2 per day
18359865,NA,670,thrombocytopenia,4,>=5 days,NA,occurred after a TMZ dose reduction to 150 mg/m2 per day
18359865,NA,670,any toxicity resulting in a >14-day delay to re-treat,NA,NA,NA,NA
17322542,NA,672,neutropenia,4,>=7 days,NA,NA
17322542,NA,672,Febrile neutropenia or neutropenic infection,NA,NA,NA,NA
17322542,NA,672,Thrombocytopenia <25 x 109/l,NA,NA,NA,NA
17322542,NA,672,Thrombocytopenia <50 x 109/l with haemorrhage,4,NA,NA,NA
17322542,NA,672,non-haematological toxic effects attributable to the study drug,>=3,NA,FALSE,NA
17322542,NA,672,Inability to complete repeated infusions of diflomotecan during cycle 1 as a consequence of drug-related toxicity,NA,NA,NA,NA
18927314,NA,673,hematologic toxicity,4,NA,NA,NA
18927314,NA,673,"febrile neutropenia (absolute neutrophil count <1,000/mm3 and fever >=38.5C)",NA,NA,NA,NA
18927314,NA,673,nonhematologic toxicity,>=3,NA,NA,NA
18927314,NA,673,any delay in treatment for >7 d,NA,NA,NA,NA
16328416,NA,674,neutropenia,4,>=5 days,NA,NA
16328416,NA,674,neutropenic fever or infection,NA,NA,NA,NA
16328416,NA,674,thrombocytopenia,4,NA,NA,NA
16328416,NA,674,"diarrhea, nausea or vomiting despite maximal antidiarrheal or antiemetic support",>=3,NA,NA,NA
16328416,NA,674,nonhematologic toxicity attributed to irinotecan therapy,3,NA,NA,NA
16328416,NA,674,failure to complete the first 5 days of irinotecan therapy due to drug-related toxicities,NA,NA,NA,NA
16328416,NA,674,failure to recover from toxicities ( <= grade 1) to be eligible for retreatment with irinotecan within 36 days of the start of Cycle 1,NA,NA,NA,NA
16489079,NA,675,any nonhematologic toxicity,3 or 4,NA,FALSE,NA
16489079,NA,675,thrombocytopenia,4,NA,NA,NA
16489079,NA,675,thrombocytopenia,3,>6 days,NA,NA
16489079,NA,675,neutropenia,4,>6 days,NA,NA
16489079,NA,675,neutropenia associated with fever,4,NA,NA,NA
16489079,NA,675,any dose delay secondary to toxicity that lasts z2 weeks or results in giving less than three of the four scheduled weekly irinotecan treatments on the first cycle,NA,NA,NA,NA
15196737,NA,676,any non-hematologic toxicities,>=3,NA,FALSE,NA
15196737,NA,676,platelet count â‰¤ 2 Ã— 104/ul,NA,NA,NA,NA
15196737,NA,676,leukopenia,4,NA,NA,NA
15196737,NA,676,neutropenia,4,>5 days,NA,NA
15196737,NA,676,neutropenia with fever â‰¥38 â—¦C or with infection,>=3,NA,NA,NA
15196737,NA,676,the cancellation of irinotecan and paclitaxel on day 8,NA,NA,NA,NA
15196737,NA,676,failure to recover from toxicities enough to begin a next cycle of treatment by day 29,NA,NA,NA,NA
16449240,NA,677,nausea and vomiting uncontrolled by aggressive antiemetic support,>=3,NA,NA,NA
16449240,NA,677,diarrhea uncontrolled by aggressive antidiarrheal support,>=3,NA,NA,NA
16449240,NA,677,neutropenia or neutropenic fever,4,NA,NA,NA
16449240,NA,677,thrombocytopenia,4,NA,NA,NA
16449240,NA,677,any other non-hematological toxicity,>=3,NA,NA,NA
15768380,NA,678,any irinotecan induced toxicity that did not return to grade1 prior to the time that the next dose was due,3,NA,FALSE,NA
15768380,NA,678,thrombocytopenia,4,NA,NA,NA
15768380,NA,678,non-hematologic toxicity despite maximal antiemetic andantidiarrheal support,4,NA,NA,NA
15768380,NA,678,neutropenia,4,>7 days,NA,NA
15768380,NA,678,dose reduction or delay wasrequired during the first cycle of therapy as outlined below,NA,NA,NA,NA
14551303,NA,679,neutropenia,4,>7 days,NA,NA
14551303,NA,679,thrombocytopenia,4,>7 days,NA,NA
14551303,NA,679,delayed diarrhea (despite appropriate treatment for more than 48 hours or requiring hospitalization for rehydration),3 or 4,NA,NA,NA
14551303,NA,679,any nonhematologic and nondigestive toxicity,4,NA,FALSE,NA
14551303,NA,679,any nonhematologic toxicity,3,NA,TRUE,NA
14551303,NA,679,infection,4,NA,NA,NA
14551303,NA,679,any life-threatening or fatal toxicity,NA,NA,NA,NA
16821636,NA,680,neutropenia,4,>4 days,NA,NA
16821636,NA,680,febrile neutropenia,3,NA,NA,NA
16821636,NA,680,"thrombocytopenia <20,000 ulâ€“1",NA,NA,NA,NA
16821636,NA,680,non-hematological toxicity,3,NA,FALSE,NA
16821636,NA,680,pneumonitis,>2,NA,NA,NA
16821636,NA,680,"delay of administration of CPT-11 on day 8 over a week, or delay of subsequent courses over 2 weeks for toxicities",NA,NA,NA,NA
16821636,NA,680,inability to administer AMR for 3 consecutive days,NA,NA,NA,NA
17146732,NA,681,non-hematologic toxicity,>=3,NA,FALSE,NA
17146732,NA,681,hyperbilirubinemia,2,>7 days,NA,NA
17146732,NA,681,diarrhea requiring parenteral support,3,NA,NA,NA
17146732,NA,681,an absolute granulocyte count of < 0.5 Ã— 109/L,NA,>=5 days,NA,NA
17146732,NA,681,febrile neutropenia (defined as absolute neutrophil count of < 1.0 Ã— 109/L and fever â‰¥ 38.5â—¦C),NA,NA,NA,NA
17146732,NA,681,platelets < 25 Ã— 109/L,NA,NA,NA,NA
17146732,NA,681,bleeding felt to be due to thrombocytopenia,NA,NA,NA,NA
12377659,NA,682,vomiting or diarrhea despite maximal antiemetic and antidiarrheal therapy,4,NA,NA,NA
12377659,NA,682,other non-hematologic toxicity,3 or 4,NA,NA,NA
12377659,NA,682,febrile neutropenia,NA,NA,NA,NA
12377659,NA,682,absolute neutrophil count (ANC) <500/Î¼l,NA,>5 days,NA,NA
12377659,NA,682,platelet count <25 000/Î¼l,NA,>5 days,NA,NA
12377659,NA,682,a treatment delay exceeding 3 weeks,NA,NA,NA,NA
20039040,NA,683,haematological toxicity,4,>5 days,NA,NA
20039040,NA,683,febrile neutropaenia,3 or 4,NA,NA,NA
20039040,NA,683,"non-haematological toxicity including diarrhoea, nausea or vomiting despite adequate treatment",3 or 4,NA,NA,NA
12881390,NA,684,neutropenia complicated by fever >38Â°C,>=3,NA,NA,NA
12881390,NA,684,neutropenia,>=3,>7 days,NA,NA
12881390,NA,684,thrombocytopenia,4,NA,NA,NA
12881390,NA,684,"thrombocytopenia complicated by bleeding, requiring platelet transfusion",>=3,NA,NA,NA
12881390,NA,684,thrombocytopenia,>=3,>7 days,NA,NA
12881390,NA,684,non-haematological toxicity,>=3,NA,FALSE,NA
12881390,NA,684,"renal, hepatic, cardiac or pulmonary toxicity",>=2,NA,NA,NA
12881390,NA,684,treatment delay of >2 weeks before the start of the next cycle of treatment,NA,NA,NA,NA
12598357,NA,685,neutropenia (absolute neutrophil count <0.5 Ã— 109/l),4,â‰¥7 days,NA,NA
12598357,NA,685,febrile neutropenia,NA,NA,NA,NA
12598357,NA,685,neutropenia concomitant with infection,3 or 4,NA,NA,NA
12598357,NA,685,neutropenia concomitant with any grade 3/4 diarrhea,3 or 4,NA,NA,NA
12598357,NA,685,neutropenia concomitant with grade 4 neutropenia,>=2,NA,NA,NA
12598357,NA,685,symptomatic thrombocytopenia,NA,NA,NA,NA
12598357,NA,685,peripheral sensitive neuropathy,4,NA,NA,NA
12598357,NA,685,necessitating treatment reduction at the 60 mg/m2 dose level for oxaliplatin,3,NA,NA,NA
12598357,NA,685,toxicity related to study treatment,4,NA,FALSE,NA
12598357,NA,685,any toxicity which necessitated a cycle delay of >15 days,NA,NA,NA,NA
16446328,NA,686,hematologic toxicity in two patients of a cohort of three to six patients,4,>=7 days,NA,NA
16446328,NA,686,nonhematologic toxicity in two patients of a cohort of three to six patients,3 or 4,NA,NA,NA
11839656,NA,688,NA,NA,NA,NA,DLT not defined
15138360,NA,689,neutropenia,4,>=4 days,NA,NA
15138360,NA,689,neutropenia with a fever of 38Â°C or higher,4,NA,NA,NA
15138360,NA,689,thrombocytopenia,4,NA,NA,NA
15138360,NA,689,depression of PaO2,>=2,NA,NA,NA
15138360,NA,689,dyspnea,2,NA,NA,NA
15138360,NA,689,other nonhematologic toxicity,3 or 4,NA,FALSE,NA
15138360,NA,689,failure to complete the 4 courses within 9 weeks because of toxicity,NA,NA,NA,NA
15138360,NA,689,Patient refusal,NA,NA,NA,NA
18179842,RCTN75771514,690,non-haematological toxicity despite adequate medication,3 or 4,NA,FALSE,NA
18179842,RCTN75771514,690,neutropenia,4,>=5 days,NA,NA
18179842,RCTN75771514,690,neutropenia complicated by fever and/or platelets <25 Ã— 109 Lâˆ’1,4,NA,NA,NA
18179842,RCTN75771514,690,oesophagitis,4,NA,NA,NA
18179842,RCTN75771514,690,oesophagitis,3,>=2 weeks,NA,NA
12187070,NA,691,non-hematological toxicity,3 or 4,NA,FALSE,NA
12187070,NA,691,hematological toxicity or complicated grade 3 myelotoxicty (neutropenic fever or hemorrhage),4,NA,NA,NA
20176476,NA,692,NA,NA,NA,NA,DLT not defined
12453855,NA,693,ANC <500/Î¼l,NA,>=7 days,NA,NA
12453855,NA,693,ANC <100/Î¼l,NA,>=3 days,NA,NA
12453855,NA,693,ever >38 Â°C associated with neutropenia,NA,NA,NA,NA
12453855,NA,693,PLT count <25 000/Î¼l,NA,NA,NA,NA
12453855,NA,693,PLT count <50 000/Î¼l with bleeding,NA,NA,NA,NA
12453855,NA,693,non-haematological toxicity,>=3,NA,FALSE,NA
12453855,NA,693,a delay of more than 2 weeks in treatment recycling,NA,NA,NA,NA
19402172,NA,695,NA,1,NA,NA,DLT not defined
19770383,NA,696,febrile neutropenia,NA,NA,NA,NA
19770383,NA,696,neutropenia (absolute neutrophil count <= 500/uL),4,>=7 days,NA,NA
19770383,NA,696,"thrombocytopenia (<= 25,000/uL)",4,>=7 days,NA,NA
19770383,NA,696,"nausea, vomiting, or diarrhea despite use of adequate supportive care",3 or 4,NA,NA,NA
19770383,NA,696,any other nonhematologic toxicity,>=3,NA,FALSE,NA
19770383,NA,696,infusion reaction/hypersensitivity reaction,NA,NA,NA,NA
19770383,NA,696,more than five omitted irinotecan doses within a cycle secondary to toxicity,NA,NA,NA,NA
19770383,NA,696,more than 4-week delay in treatment because of toxicity and discontinuation of cetuximab secondary to dermatologic toxicity,NA,NA,NA,NA
15083177,NA,697,haematological toxicity and/orassociated with fever,4,>=7 days,NA,NA
15083177,NA,697,nonhaematological toxicity,3 or 4,NA,FALSE,NA
15083177,NA,697,an interruption of treatment for more than 3 weeks due to unresolved toxicity,NA,NA,NA,NA
12357298,NA,698,neutropenic fever,NA,NA,NA,NA
12357298,NA,698,nonhematologic toxicity,3 or 4,NA,FALSE,NA
12357298,NA,698,hematologic toxicity,4,NA,NA,NA
12204669,NA,699,neutropenia,4,>=5 days,NA,NA
12204669,NA,699,neutropenia with fever of > 38 C,4,NA,NA,NA
12204669,NA,699,thrombocytopenia,4,NA,NA,NA
12204669,NA,699,non-haematological toxicity,>=3,NA,FALSE,NA
12204669,NA,699,cancellation of CPT-11 on both days 8 and 15.,NA,NA,NA,NA
14760509,NA,700,non-hematologic toxicity,>=3,NA,FALSE,NA
14760509,NA,700,thrombocytopenia,3,>5 days,NA,NA
14760509,NA,700,granulocytopenia,4,>5 days,NA,NA
14760509,NA,700,thrombocytopenia,4,NA,NA,NA
14760509,NA,700,neutropenia associated with fever or infection,4,NA,NA,NA
14760509,NA,700,omission of two or more doses of irinotecan in a cycle due to toxicity,NA,NA,NA,NA
14760509,NA,700,interruption of R115777 dosing for more than seven consecutive days due to drug-related toxicity,NA,NA,NA,NA
12963697,NA,701,"absolute neutrophil count or platelet count less than 25,000/uL",4,NA,NA,NA
12963697,NA,701,serum creatinine >= two times baseline,NA,NA,NA,NA
12963697,NA,701,treatment delay more than 14 days,NA,NA,NA,NA
12963697,NA,701,nonhematologic toxicity,3 or 4,NA,FALSE,NA
12963697,NA,701,"nausea, vomiting, or diarrhea in patients who had received prophylaxis and treatment with an optimal antiemetic or antidiarrheal regimen",3 or 4,NA,NA,NA
17429623,NA,702,Non-hematologic toxicity,3,NA,FALSE,NA
17429623,NA,702,Non-hematologic toxicity,4,NA,NA,NA
17429623,NA,702,diarrheadespite antidiarrheals,3,>24 h,NA,NA
17429623,NA,702,nausea/vomiting despite optimal antiemetics,3,NA,NA,NA
17429623,NA,702,hematologic toxicity,4,NA,FALSE,NA
17429623,NA,702,neutropenia,4,>5 days,NA,NA
17429623,NA,702,neutropenia presenting with neutropenic fever,4,NA,NA,NA
17429623,NA,702,"thrombocytopenia <25,000/ul",NA,NA,NA,NA
16832665,NA,703,the absolute neutrophil count (ANC) < 500/ul,NA,>=4 days,NA,NA
16832665,NA,703,"leukocyte count < 1,000/ul",NA,>=4 days,NA,NA
16832665,NA,703,"febrile neutropenia (fever > 38.5Â°C with ANC < 1,000/ul)",NA,NA,NA,NA
16832665,NA,703,"platelet count < 10,000/ul",NA,NA,NA,NA
16832665,NA,703,nonhematologic toxicity,>=3,NA,FALSE,NA
16832665,NA,703,The toxicity forcing the delay in CPT-11 treatment on day 8 > 7 days,NA,NA,NA,NA
16832665,NA,703,the toxicity resulting in treatment delay > 14 days in the next cycle,NA,NA,NA,NA
12912940,NA,704,absolute neutrophil count <500/ul,NA,>=3 days,NA,NA
12912940,NA,704,febrile neutropenia,NA,NA,NA,NA
12912940,NA,704,"platelet count < 25,000/ul",NA,NA,NA,NA
12912940,NA,704,a delay in starting the next cycle of treatment by >7 days to allow complete recovery from toxicity,NA,NA,NA,NA
12912940,NA,704,Unresolved major nonhematological toxicity that delayed the subsequent course of chemotherapy by >7 days,NA,NA,NA,NA
12912940,NA,704,Nonhematological toxicities,3 or 4,NA,FALSE,NA
12912940,NA,704,"chronic renal, pulmonary, some neurological toxicities, such as alterations in mental status, and cardiac toxicities",2,NA,NA,NA
12576438,NA,706,nonhematologic toxicity,3 or 4,NA,FALSE,NA
12576438,NA,706,neutropenia,4,>7 days,NA,NA
12576438,NA,706,thrombocytopenia,4,NA,NA,NA
12576438,NA,706,thrombocytopenia requiring at least two transfusions in 7 days,4,NA,NA,NA
12576438,NA,706,thrombocytopenia delaying treatment >= 14 days,4,NA,NA,NA
12576438,NA,706,an inability to complete the first four treatment doses in 29 days,NA,NA,NA,NA
12576438,NA,706,the failure to recover from toxicity by day 43,NA,NA,NA,NA
15746053,NA,708,neutropenia,4,>=5 days,NA,NA
15746053,NA,708,neutropenic fever (defined as grade 4 neutropenia with fever .=38.5C),NA,NA,NA,NA
15746053,NA,708,neutropenic infection (defined as grades 3 to 4 neutropenia with >= grade 3 infection or documented infection),NA,NA,NA,NA
15746053,NA,708,thrombocytopenia <25 X 109 cells/L,NA,NA,NA,NA
15746053,NA,708,"diarrhea, despite maximal loperamide support",>=3,NA,NA,NA
15746053,NA,708,"nausea or vomiting, failing maximal oral antiemetic therapy",>=2,NA,NA,NA
15746053,NA,708,vomiting leading to discontinuation of the study drug intake >=3 days,NA,NA,NA,NA
15746053,NA,708,other nonhematologic toxicities,>=3,NA,FALSE,NA
15746053,NA,708,treatment delay due to toxicities attributed to the study drug for >2 weeks,NA,NA,NA,NA
15592838,NA,709,neutropenia,4,>=7 days or within the 14 days of treatment,NA,NA
15592838,NA,709,febrile neutropenia,NA,NA,NA,NA
15592838,NA,709,neutropenic infection (grade 4 neutropenia with grade 3/4 or documented infection),NA,NA,NA,NA
15592838,NA,709,thrombocytopenia,4,NA,NA,NA
15592838,NA,709,diarrhoea despite maximal intensive loperamide support,3 or 4,NA,NA,NA
15592838,NA,709,nausea despite maximal oral antiemetic therapy,3,NA,NA,NA
15592838,NA,709,vomiting despite maximal oral antiemetic therapy,3 or 4,NA,NA,NA
15592838,NA,709,failure to complete the 14 days of full-dose irinotecan therapy,NA,NA,NA,NA
15592838,NA,709,non-haematological toxicity,3 or 4,NA,FALSE,NA
20213078,NA,710,nonhematologic toxicity,4,NA,NA,NA
20213078,NA,710,diarrhea or stomatitis despite optimal supportive care,>=3,>=7 days,NA,NA
20213078,NA,710,neutropenia complicated by fever >=38Â°C,4,NA,NA,NA
20213078,NA,710,hemorrhage or thrombocytopenia,4,NA,NA,NA
20213078,NA,710,"failure to recover neutrophils (Â¸1,500/mm3) or platelets (Â¸100,000/mm3) by day 28",NA,NA,NA,NA
16080470,NA,711,any non-haematological toxicity,>=3,NA,FALSE,NA
16080470,NA,711,platelet count <2x104 /uL,NA,NA,NA,NA
16080470,NA,711,leukopenia,4,NA,NA,NA
16080470,NA,711,neutropenia,4,>=4 days,NA,NA
16080470,NA,711,cancellation of irinotecan and amrubicin administration on day 8,NA,NA,NA,NA
16080470,NA,711,inability to begin the next course of treatment by day 56 due to failure to recover from toxicity,NA,NA,NA,NA
12376204,NA,712,leucopenia,4,>=4 days,NA,NA
12376204,NA,712,neutropenia,4,>=4 days,NA,NA
12376204,NA,712,neutropenic fever,NA,NA,NA,NA
12376204,NA,712,thrombocytopenia,4,NA,NA,NA
12376204,NA,712,non-haematological toxicities,>=3,NA,FALSE,NA
12376204,NA,712,Omission of the CPT-11 dose on both days 8 and 15 in each chemotherapy cycle,NA,NA,NA,NA
20028383,NA,713,non-hematological toxicity,3 or 4,NA,FALSE,NA
20028383,NA,713,hematological toxicity,3 or 4,NA,NA,NA
20028383,NA,713,discontinuation of treatmentdue to treatment-related toxicity during six courses of treatment,NA,NA,NA,NA
16001174,NA,714,neutropenia in two of a cohort of three to six patients,4,>10 days from the completion of chemotherapy administration,NA,NA
16001174,NA,714,thrombocytopenia in two of a cohort of three to six patients,4,>10 days from the completion of chemotherapy administration,NA,NA
16001174,NA,714,Non-hematologic toxicity in two of a cohort of three to six patients,3 or 4,NA,FALSE,NA
17717667,NA,715,hematological toxicities,4,>=4 days,NA,NA
17717667,NA,715,febrile neutropenia,4,NA,NA,NA
17717667,NA,715,non-hematological toxicities,3 or 4,NA,FALSE,NA
17717667,NA,715,the need to withhold both vinorelbine/irinotecan on day 8 and irinotecan on day 15,NA,NA,NA,NA
17717667,NA,715,failure to start the second cycle until day 36,NA,NA,NA,NA
12885811,NA,716,the need for a delay of therapy greater than 2 weeks because of hematologic or nonhematologic toxicity,NA,NA,NA,NA
16088964,NA,717,non-hematopoietic toxicity,>=3,NA,FALSE,NA
16088964,NA,717,diarrhea or emesis despite maximalantidiarrheal or antiemetic therapy,4,NA,NA,NA
16088964,NA,717,hematopoietic toxicity,4,>=4 days,NA,NA
19171709,NA,718,neutropenia,4,>7 days,NA,NA
19171709,NA,718,"platelets less than 10,000/uL",NA,NA,NA,NA
19171709,NA,718,the need for more than one platelet transfusion per week,NA,NA,NA,NA
19171709,NA,718,Nonhematologic toxicity,3 or 4,NA,FALSE,NA
19171709,NA,718,Any toxicity not resolving to eligibility criteria within 35 days after the start of chemotherapy,3 or 4,NA,NA,NA
14871959,NA,719,neutropenia,4,>10 days,NA,NA
14871959,NA,719,thrombocytopenia,3 or 4,>35 days after the first dose of chemotherapy,NA,NA
14871959,NA,719,thrombocytopenia requiring two or more platelet transfusions at least 48 h apart given because of grade 4 thrombocytopenia or clinical bleeding,NA,NA,NA,NA
14871959,NA,719,Nonhematolgical toxicity,3 or 4,NA,FALSE,NA
20049936,NA,720,neutropenia,4,>7 days,NA,NA
20049936,NA,720,thrombocytopenia,4,>7 days,NA,NA
20049936,NA,720,thrombocytopenia requiring platelet transfusion ongreater than two occasions per course,3 or 4,NA,NA,NA
20049936,NA,720,failure to recover blood counts to eligibility criteria resulting in a delay of >=14 days between treatment courses,NA,NA,NA,NA
20049936,NA,720,neutropenia or thrombocytopenia occurring before completion of irinotecan (Day 12),4,NA,NA,For patients enrolled on Schedule A
20049936,NA,720,Non-hematologic toxicity,3 or 4,NA,FALSE,NA
18956138,NA,721,absolute neutrophil count [ANC] <500/Î¼L,4,>7 days,NA,NA
18956138,NA,721,"platelets <25,000/Î¼L",4,>7 days,NA,NA
18956138,NA,721,dose delay lasting greater than 2 weeks,NA,NA,NA,NA
18956138,NA,721,"neutropenic fever (â‰¥38.1Â°C with ANC <1,000/Î¼L)",NA,NA,NA,NA
18956138,NA,721,serum creatinine >1.8 mg/dl,NA,>2 weeks,NA,NA
18956138,NA,721,diarrhea (despite intensive loperamide therapy),3,>2 days,NA,NA
18956138,NA,721,diarrhea,4,NA,NA,NA
18956138,NA,721,stomatitis despite intensive viscous lidocaine therapy,3,>7 days,NA,NA
18956138,NA,721,stomatitis,4,NA,NA,NA
18956138,NA,721,peripheral neuropathy,3 or 4,>2 weeks,NA,NA
18956138,NA,721,fatigue,4,>1 week,NA,NA
18956138,NA,721,Other non-hematologic toxicities determined treatment related DLT by the principal investigator,3 or 4,NA,FALSE,NA
11843251,NA,722,non-hematologica! toxicity,>=3,NA,FALSE,NA
11843251,NA,722,neutropenia,4,>=4 days,NA,NA
11843251,NA,722,neutropenia association with fever,4,NA,NA,NA
11843251,NA,722,thombocytopenia,4,NA,NA,NA
11843251,NA,722,Delay of administration due to toxicity of more than eight days,NA,NA,NA,NA
12750839,NA,723,neutropenia,4,>=4 days,NA,NA
12750839,NA,723,neutropenia with fever of 38C or above,4,NA,NA,NA
12750839,NA,723,thrombocytopenia,4,NA,NA,NA
12750839,NA,723,depression of PaO2,>=2,NA,NA,NA
12750839,NA,723,dyspnea,>=2,NA,NA,NA
12750839,NA,723,non-hematologic toxicity,3 or 4,NA,FALSE,NA
12750839,NA,723,skipping day-8 chemotherapy because of toxicity,NA,NA,NA,NA
12750839,NA,723,Patient refusal,NA,NA,NA,NA
12947066,NA,724,neutropenia,4,NA,NA,NA
12947066,NA,724,thrombocytopenia,4,NA,NA,NA
12947066,NA,724,"neutropenic fever, defined as grade 3 or 4 neutropenia plus fever higher than 38.3Â°C",NA,NA,NA,NA
12947066,NA,724,diarrhea despite aggressive use of loperamide,3 or 4,NA,NA,NA
12947066,NA,724,"total bilirubin â‰¥ 3.0 mg/dL not caused by disease progression (ie, biliary obstruction as a result of tumor was ruled out)",NA,NA,NA,NA
20127092,NA,725,leukopenia,4,>=7 days,NA,NA
20127092,NA,725,thrombocytopenia,3 or 4,>=7 days,NA,NA
20127092,NA,725,diarrhea not responsive to maximal antidiarrheal medications,3 or 4,NA,NA,NA
20127092,NA,725,"febrile neutropenia (ANC <=1,000 and temperature >=38.5Â°C)",4,NA,NA,NA
20127092,NA,725,other nonhematologic toxicity thought to be related to the study drugs,3 or 4,NA,NA,NA
24252402,NCT00963547,726,neutropenia,4,>=5 days,NA,NA
24252402,NCT00963547,726,neutropenia with fever >38.5Â°C and/or infection requiring antibiotic or antifungal treatment,3 or 4,NA,NA,NA
24252402,NCT00963547,726,thrombocytopenia,4,NA,NA,NA
24252402,NCT00963547,726,Nonhematological toxicity,>=3,NA,FALSE,NA
24252402,NCT00963547,726,any drug-related AE leading to a dose modification of MK-2206 in the first cycle,NA,NA,NA,NA
24252402,NCT00963547,726,unresolved drug-related AEs requiring drug interruption for 8 days or more in the first cycle,>=2,NA,NA,NA
24252402,NCT00963547,726,unresolved drug-related AEs requiring drug interruption for a total of 15 days or more in the first cycle,NA,NA,NA,NA
25641763,NA,727,neutropenia,4,>5 days,NA,NA
25641763,NA,727,thrombocytopenia,4,>5 days,NA,NA
25641763,NA,727,neutropenic infection,NA,NA,NA,NA
25641763,NA,727,other hematologictoxicity,4,NA,NA,NA
25641763,NA,727,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25641763,NA,727,diarrhea persisted despite optimal supportive care,3 or 4,NA,NA,NA
26210681,NA,728,nonhematological toxicity,>=3,NA,FALSE,NA
26210681,NA,728,hypertension,4,NA,NA,NA
26210681,NA,728,inadequately controlled hypertension,3,NA,NA,NA
26210681,NA,728,proteinuria related to renal impairment,3,NA,NA,NA
26210681,NA,728,neutropenia/febrile neutropenia,4,NA,NA,NA
26210681,NA,728,neutropenia or thrombocytopenia,>=3,>7 days,NA,NA
26210681,NA,728,inability to begin subsequent treatment period within 28 days of scheduled dosing due to unresolved toxicity,NA,NA,NA,NA
26210681,NA,728,toxicity that occurred beyond 28 days,>=2,NA,NA,NA
11205914,NA,729,nonhematological toxicity,3 or 4,NA,FALSE,NA
11205914,NA,729,neutropenia,4,>7 days,NA,NA
11205914,NA,729,anemia,4,>7 days,NA,NA
11205914,NA,729,thrombocytopenia,4,>7 days,NA,NA
24197661,NA,730,non-hematologic toxicity,3 or 4,NA,FALSE,NA
23292205,ACTRN12611000418976,731,ANC <0.5 x 109/L,4,over seven consecutive days,NA,NA
23292205,ACTRN12611000418976,731,febrile neutropenia [ANC <1.0 x 109/L (grade 3) when accompanied by fever],NA,NA,NA,NA
23292205,ACTRN12611000418976,731,hemoglobin <6.5 g/dL,4,NA,NA,NA
23292205,ACTRN12611000418976,731,thrombocytopenia (platelet count <25 x 109/L),4,NA,NA,NA
23292205,ACTRN12611000418976,731,non-hematological toxicity,3 or 4,NA,FALSE,NA
12440223,NA,732,thrombocytopenia,2,NA,NA,NA
12440223,NA,732,thrombocytopenia,3,NA,NA,after amendment
29315394,NCT00912275,733,NA,NA,NA,NA,DLT not defined
31097774, NCT01434303,734,neutropenia,4,>7 days,NA,NA
31097774, NCT01434303,734,any febrile neutropenia,NA,NA,NA,NA
31097774, NCT01434303,734,thrombocytopenia,4,NA,NA,NA
31097774, NCT01434303,734,non-haematologic toxicity,>=3,NA,NA,NA
31097774, NCT01434303,734,>14 days of treatment delay due to any therapy-related toxicity of any grade,NA,NA,NA,NA
31097774, NCT01434303,734,"Nausea/vomiting, diarrhoea, and electrolyte imbalances despite adequate supportive care",NA,48h,NA,NA
28464908,NA,735,non-hematologic toxicity,>=3,NA,FALSE,NA
28464908,NA,735,neutropenia,4,>=7 days,NA,NA
28464908,NA,735,neutropenia with fever,3 or 4,NA,NA,NA
28464908,NA,735,thrombocytopenia,4,NA,NA,NA
28464908,NA,735,anemia,4,NA,NA,NA
28464908,NA,735,thrombocytopenia associated with bleeding,NA,NA,NA,NA
28464908,NA,735,the inability to administer cycle-2 treatment within 14 days of the planned dose (i.e. cycle-2 treatment delayed by more than 2 weeks) due to persisting grade-2 drug-related toxicity,NA,NA,NA,NA
23632474,NCT00445458,736,non-haematologic toxicity,3 or 4,NA,FALSE,NA
23632474,NCT00445458,736,neutropenia,4,>=7 days,NA,NA
23632474,NCT00445458,736,neutropenia associated with fever,4,NA,NA,NA
23632474,NCT00445458,736,infection in the context of grade 3/4 neutropenia,3 or 4,NA,NA,NA
23632474,NCT00445458,736,delayed recovery to grade 0/1 toxicity that requires treatment interruption of more than 3 weeks,1,NA,NA,NA
10509152,NA,737,neutropenia,4,NA,NA,NA
10509152,NA,737,thrombocytopenia,4,NA,NA,NA
10509152,NA,737,neutropenia with fever >=38Â°C,3,>24 h,NA,NA
10509152,NA,737,thrombocytopenia with bleeding,3,NA,NA,NA
10509152,NA,737,any extra-haematological toxicity,3 or 4,NA,FALSE,NA
10509152,NA,737,a delay > 2 weeks in recycling,NA,NA,NA,NA
10561220,NA,738,"hematologic toxicity, in two of a cohort of three to six patients",4,>=7 days,NA,NA
10561220,NA,738,"nonhematologic toxicity, in two of a cohort of three to six patients",3 or 4,NA,NA,NA
24097864,NA,739,NA,NA,NA,NA,DLT not defined
10963644,NA,740,nonhematologic toxicity,3,NA,FALSE,NA
10963644,NA,740,nonhematologic toxicity,4,NA,NA,NA
10963644,NA,740,thrombocytopenia,4,NA,NA,NA
10963644,NA,740,neutropenia,4,>=5 days,NA,NA
10963644,NA,740,neutropenia associated with fever (>= 38.5Â°C),4,NA,NA,NA
9619758,NA,741,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9619758,NA,741,hematologic toxicity,3 or 4,NA,NA,NA
11241238,NA,742,extrahematologic toxicity,3 or 4,NA,FALSE,NA
11241238,NA,742,neutropenia with fever >= 38 Â°C,3,NA,NA,NA
11241238,NA,742,thrombocytopenia with bleeding,3,NA,NA,NA
11241238,NA,742,neutropenia,4,NA,NA,NA
11241238,NA,742,thrombocytopenia,4,NA,NA,NA
11244327,NA,743,ANC <500/mm3,NA,>=7 days,NA,NA
11244327,NA,743,ANC <100/mm3,NA,>=3 days,NA,NA
11244327,NA,743,febrile neutropenia (i.e. ANC <500/mm3 with fever >38Â°C),NA,NA,NA,NA
11244327,NA,743,"Plt count <25,000/mm3",NA,NA,NA,NA
11244327,NA,743,"Plt count <50,000/mm3 with bleeding",NA,NA,NA,NA
11244327,NA,743,nonhematological toxicity,3 or 4,NA,FALSE,NA
11244327,NA,743,a delay of more than 2 weeks in treatment recycling,NA,NA,NA,NA
31471376,NCT01998035,744,any missed dose or toxicity at least possibly related to the study drug that occurred up to 7 days after completion of cycle 1 and resulted in a delay of initiation of cycle 2,NA,NA,NA,NA
31471376,NCT01998035,744,AE,5,NA,NA,NA
31471376,NCT01998035,744,neutropenia that did not resolve to grade 2 or lower within 7 days,4,NA,NA,NA
31471376,NCT01998035,744,thrombocytopenia,4,NA,NA,NA
31471376,NCT01998035,744,"febrile neutropenia (ie, absolute neutrophil count <1000 cells/uL with a single temperature of >=38.3Â°C or a sustained temperature of >38Â°C for >1 hour)",NA,NA,NA,NA
31471376,NCT01998035,744,nonhematologic toxicity,>=3,NA,FALSE,NA
31471376,NCT01998035,744,electrolyte abnormalities that responded to medical intervention,3,NA,NA,NA
31471376,NCT01998035,744,acidosis or alkalosis that returned to grade 2 or lower within 48 hours with medical intervention,3,NA,NA,NA
31471376,NCT01998035,744,"isolated asymptomatic ALT, AST, or amylase elevation",NA,<5 days,NA,NA
31471376,NCT01998035,744,"hypercholesterolemia, hypertriglyceridemia, constipation, or fatigue",3,NA,NA,NA
25434923,EudraCT Number: 2009-017817-3,745,non-haematological toxicity,3 or 4,NA,NA,NA
25434923,EudraCT Number: 2009-017817-3,745,"nausea, vomiting or diarrhoea despite supportive therapy",2,>=7 days,NA,NA
7786821,NA,746,NA,NA,NA,NA,DLT not defined
32816943,NCT01638533,747,nonhematologic toxicity,>=3,NA,FALSE,NA
32816943,NCT01638533,747,neutropenia,4,NA,NA,NA
32816943,NCT01638533,747,thrombocytopenia,4,NA,NA,NA
32816943,NCT01638533,747,febrile neutropenia,4,NA,NA,NA
32816943,NCT01638533,747,neurotoxicity,>=2,NA,NA,NA
32816943,NCT01638533,747,"Worsening liver function, as defined by a rise in serum bilirubin not related to tumor progression or stent occlusion if a patient in the mild cohort progressedinto the severe dysfunction range for one week, or if a patient in either the moderate or severe cohorts had a >1.5 times increase in bilirubin lasting 1 week",NA,NA,NA,NA
10080615,NA,748,nonhematologic toxicity,3 or 4,NA,FALSE,NA
10080615,NA,748,neutropenia not resolving within 5 days,4,NA,NA,NA
10080615,NA,748,febrile neutropenia,NA,NA,NA,NA
10080615,NA,748,anemia,4,NA,NA,NA
10080615,NA,748,thrombocytopenia,4,NA,NA,NA
8229134,NA,749,nonhematologic toxicity,>=3,NA,FALSE,NA
8229134,NA,749,vomiting despite therapy with serotonin antagonists,4,NA,NA,NA
8229134,NA,749,neutropenia,4,>=5 days,NA,NA
8229134,NA,749,neutropenia associated with fever,4,NA,NA,NA
8918493,NA,750,nonhematologic toxicity,>=3,NA,FALSE,NA
8918493,NA,750,hematologic toxicity,4,NA,NA,NA
8918493,NA,750,neutropenic fever,NA,NA,NA,NA
8918493,NA,750,inability to receive all planned chemotherapy,NA,NA,NA,NA
9850031,NA,751,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9850031,NA,751,diarrhea despite aggressive loperamide therapy,3 or 4,NA,NA,NA
9850031,NA,751,leukopenia,4,NA,NA,NA
9850031,NA,751,neutropenia,4,NA,NA,NA
9850031,NA,751,thrombocytopenia,4,NA,NA,NA
9850031,NA,751,neutropenic fever,4,NA,NA,NA
9850031,NA,751,"inability to complete the first treatment cycle, receiving all four planned doses, and having recovered from toxicity in time to begin the second cycle as scheduled (beginning of week 7)",NA,NA,NA,NA
9850031,NA,751,Patients who required more than I week of dose delay in their first treatment cycle,NA,NA,NA,NA
11474256,NA,752,NA,NA,NA,NA,DLT not defined
24711549,NCT00544804,753,toxicity,>=3,NA,NA,NA
24711549,NCT00544804,753,diarrhea and nausea and vomiting despite maximal use of supportive medications,>=3,3 consecutive days,NA,NA
24711549,NCT00544804,753,transaminitis with a  two-fold increase over baseline,>=3,NA,NA,In patients with liver metastases
24711549,NCT00544804,753,fatigue persisted at the start of cycle 2,3,NA,NA,NA
10873073,NA,754,hematological toxicity,4,>=5 days,NA,NA
10873073,NA,754,febrile neutropenia,NA,NA,NA,NA
10873073,NA,754,diarrhea or vomiting that occurred despite adequate supportive measures,4,NA,NA,NA
10873073,NA,754,any other nonhematological toxicity,>=3,NA,NA,NA
10873073,NA,754,patients who had treatment delayed for 2 weeks as a result of toxicity related to CPT-11,NA,NA,NA,NA
10071283,NA,755,nonhematologic toxicity,>=3,NA,FALSE,NA
10071283,NA,755,hematologic toxicity,4,NA,NA,NA
10071283,NA,755,"hematologic toxicity associated with complications (eg, neutropenic fever or bleeding)",>=3,NA,NA,NA
27026198,NA,756,neutropenia,>=3,NA,NA,NA
27026198,NA,756,thrombocytopenia,4,NA,NA,NA
27026198,NA,756,thrombocytopenia associated with a clinically significant or lifethreatening bleed,any grade,NA,NA,NA
27026198,NA,756,Nonhematologic toxicities,3 or 4,NA,FALSE,NA
27026198,NA,756,"any toxicity preventing delivery of > 75% of the protocol specified cycle 1 treatment or dose delay of > 14 days starting prior to cycle 2 day 1 when at least possibly related to study drugs, given the planned chronic, continuous, oral nature of study drug administration",NA,NA,NA,NA
11352961,NA,757,neutropenia,4,NA,NA,NA
11352961,NA,757,thrombocytopenia,4,NA,NA,NA
11352961,NA,757,neutropenia plus fever more than 38.3Â°C,3 or 4,NA,NA,NA
11352961,NA,757,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11352961,NA,757,diarrhea despite the aggressive use of loperamide,3 or 4,NA,NA,NA
11435065,NA,758,leucopenia,4,>=4 days,NA,NA
11435065,NA,758,neutropenia,4,>=4 days,NA,NA
11435065,NA,758,thrombocytopenia,4,NA,NA,NA
11435065,NA,758,non-haematological toxicities,>=3,NA,FALSE,NA
11435065,NA,758,Omission of CPT-11 dose on both days 8 and 15 of each chemotherapy cycle,NA,NA,NA,NA
10901362,NA,759,non-haematological toxicity,3 or 4,NA,FALSE,NA
10901362,NA,759,neutropenia,4,NA,NA,NA
10901362,NA,759,neutropenia associated with fever (> 38Â°C) or sepsis,3 or 4,NA,NA,NA
10901362,NA,759,thrombocytopenia,4,NA,NA,NA
10901362,NA,759,thrombocytopenia associated with haemorrhage,any grade,NA,NA,NA
27902470,NCT01931943,760,cardiac dysfunction (LVEF decrease),>=2,NA,NA,NA
27902470,NCT01931943,760,renal function abnormality (creatinine),>=2,NA,NA,NA
27902470,NCT01931943,760,other non-hematologic toxicity,>=3,NA,FALSE,NA
27902470,NCT01931943,760,neutropenia,4,NA,NA,NA
27902470,NCT01931943,760,febrile neutropenia,4,NA,NA,NA
27902470,NCT01931943,760,thrombocytopenia,4,NA,NA,NA
27902470,NCT01931943,760,thrombocytopenia with clinical significance,3,NA,NA,NA
27902470,NCT01931943,760,anemia,4,NA,NA,NA
8382970,NA,761,nonhematologic toxicity,>=3,NA,NA,NA
8382970,NA,761,persistent pancytopenia with less than 5% cellular bone marrow without evidence of residual leukemia,NA,lasting for 6 weeks or more from the start of the course,NA,NA
24013582,NCT00614978,762,ANC < 0.5x109/L,NA,>=7 days,NA,NA
24013582,NCT00614978,762,Febrile Neutropenia (ANC < 0.5x109/L AND fever > 38.50C,NA,NA,NA,NA
24013582,NCT00614978,762,Platelets < 10 x 109/L,NA,NA,NA,NA
24013582,NCT00614978,762,Bleeding due to Thrombocytopenia,NA,NA,NA,NA
24013582,NCT00614978,762,Diarrhea despite optimal management and loperamide use,>=3,NA,NA,NA
24013582,NCT00614978,762,Rash,>=3,NA,NA,NA
24013582,NCT00614978,762,Rash if medically concerning or unacceptable to the patient,2,NA,NA,NA
24013582,NCT00614978,762,Other non-hematological events thought to be treatment-related,3,NA,FALSE,NA
24013582,NCT00614978,762,Bilirubin and/or ALAT,>=3,NA,NA,NA
24013582,NCT00614978,762,Bilirubin and/or ALAT,2,NA,NA,NA
24013582,NCT00614978,762,"Bilirubin accompanied by signs or symptoms which, in the opinion of the Investigator, are caused by lapatinib-induced liver injury",2,NA,NA,NA
24013582,NCT00614978,762,"ALAT accompanied by signs or symptoms which, in the opinion of the Investigator, are caused by lapatinib-induced liver injury",2,NA,NA,NA
24013582,NCT00614978,762,missing > 7 days of treatment for toxicity reasons,NA,NA,NA,NA
11895901,NA,763,hematological toxicity,4,NA,NA,NA
11895901,NA,763,nonhematological toxicity,3 or 4,NA,FALSE,NA
11720832,NA,764,non-haematological toxicity,>=3,NA,FALSE,NA
11720832,NA,764,haematological toxicity,4,NA,NA,NA
11720832,NA,764,haematological toxicity associated to complications (neutropenic fever or bleeding),3,NA,NA,NA
9060529,NA,765,nonhematologic toxicity,3 or 4,NA,FALSE,NA
9060529,NA,765,hematologic toxicity,4,NA,FALSE,NA
9060529,NA,765,"postponement of the second dose of CPT-I11 beyond day 23 due to any toxicity that included a level of less than 3,000/uL for leukocyte count, less than 100,000/uL for platelet count, or more than grade 1 diarrhea (ECOG)",NA,NA,NA,NA
28950146,NCT01589861,766,NA,NA,NA,NA,DLT not defined
25082342,NCT00466895,767,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25082342,NCT00466895,767,uncontrolled or intolerable non-hematologic toxicities,2,NA,NA,NA
25082342,NCT00466895,767,thrombocytopenia,4,NA,NA,NA
25082342,NCT00466895,767,neutropenia,4,NA,NA,NA
25082342,NCT00466895,767,neutropenia with fever and or infection,>=3,NA,NA,NA
25082342,NCT00466895,767,any toxicity that inhibited the ability to initiate cycle 2 of therapy,NA,NA,NA,NA
22426640,NCT01092091,768,toxicities,4,NA,NA,NA
22426640,NCT01092091,768,neutropenia,3,NA,NA,NA
22426640,NCT01092091,768,the occurrence of neutropenic sepsis,NA,NA,NA,NA
22426640,NCT01092091,768,thrombocytopenia,3,NA,NA,NA
22426640,NCT01092091,768,toxicities that did not return to grade1/2 within 3 weeks,3,NA,FALSE,NA
34735674,NCT02089633,769,diarrhoea or any gastrointestinal toxicities,>=3,NA,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
34735674,NCT02089633,769,palmar-plantar erythrodysesthesia,3,NA,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
34735674,NCT02089633,769,sensory neuropathy,3,NA,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
34735674,NCT02089633,769,any clinically relevant toxicity,>=3,NA,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
34735674,NCT02089633,769,prolonged granulocytopenia,4,>=5 days,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
34735674,NCT02089633,769,granulocytopenia with complications (such as grade â‰¥ 3 fever or mucositis),NA,NA,NA,occurring during the first 21-day treatment cycle which were unable to resolve to grade 1 within two days of symptomatic treatment
28483761,NCT01749969,770,any adverse event,>=3,NA,FALSE,NA
28483761,NCT01749969,770,neutropenia,4,>=7 days,NA,NA
28483761,NCT01749969,770,neutropenia complicated by fever or infection,3 or 4,NA,NA,NA
28483761,NCT01749969,770,thrombocytopenia associated with bleeding requiring platelet transfusion,3 or 4,NA,NA,NA
28483761,NCT01749969,770,any treatment delay for .14 days due to hematological toxicity,NA,NA,NA,NA
28853315,NCT01368757,771,non-hematologic toxicity,3 or 4,NA,FALSE,NA
28853315,NCT01368757,771,Febrile neutropenia,NA,NA,NA,NA
28853315,NCT01368757,771,neutropenia,4,>=7 days,NA,NA
28853315,NCT01368757,771,thrombocyopenia,4,NA,NA,NA
33040274,NCT01222754,772,Non-hematologic toxicity,4,NA,NA,NA
33040274,NCT01222754,772,Non-hematologic toxicity,3,NA,FALSE,NA
33040274,NCT01222754,772,Non-hematologic toxicity  considered medically signifcant or intolerable that it required treatment interruption,2,>3 days,NA,NA
33040274,NCT01222754,772,any other drug-related adverse event that required treatment interruption for>3 days and recurred with re-challenge of the drug,NA,NA,NA,NA
33040274,NCT01222754,772,"platelet counts<50,000/Î¼l",>=2,NA,NA,NA
33040274,NCT01222754,772,â‰¥1 week delay in beginning Maintenance Phase due to low ANC or platelet count,NA,NA,NA,NA
33040274,NCT01222754,772,neutropenia,4,NA,NA,NA
24914044,NCT00975806,773,nonhematologic adverse event (AE),3 or 4,>=14 days,NA,NA
24914044,NCT00975806,773,febrile neutropenia,NA,NA,NA,NA
24914044,NCT00975806,773,neutropenia,4,â‰¥7 days,NA,NA
24914044,NCT00975806,773,thrombocytopenia,4,NA,NA,NA
24914044,NCT00975806,773,"Toxicities that did not meet the above criteria, but resulted in the inability to continue treatment at the same dose beyond cycle 2 were considered â€˜functional DLTsâ€™.",NA,NA,NA,NA
19499221,NA,774,absolute neutrophil count <0.5 x 109 L-1,NA,NA,NA,NA
19499221,NA,774,febrile neutropenia with absolute neutrophil count <1.0 x 109 L-1,NA,NA,NA,NA
19499221,NA,774,platelet count < x 109 L-1,NA,NA,NA,NA
19499221,NA,774,bleeding felt to be due to thrombocytopenia,NA,NA,NA,NA
19499221,NA,774,diarrhea despite anti-diarrheal agents,>=3,NA,NA,NA
19499221,NA,774,other effects felt to be related to treatment,3,NA,NA,NA
19499221,NA,774,missing 7 days of therapy due to toxicity,NA,NA,NA,NA
28622959,NCT01460940,775,neutropenia,4,NA,NA,NA
28622959,NCT01460940,775,thrombocytopenia,4,NA,NA,NA
28622959,NCT01460940,775,infection or febrile neutropenia,4,NA,NA,NA
28622959,NCT01460940,775,infection or febrile neutropenia,3,>7 days,NA,NA
28622959,NCT01460940,775,treatment delays > 14 days,NA,NA,NA,NA
28622959,NCT01460940,775,other nonhematologic toxicity,3 or 4,NA,NA,NA
27126994,NCT01791478,776,toxicities,>=3,NA,FALSE,NA
21556801,NA,777,"inability to deliver 14 doses of daily lenalidomide on days 1â€“14 in combination with topotecan due to toxicity (if doses were missed inadvertently, they could be given during the 7-day rest period)",NA,NA,NA,NA
21556801,NA,777,nonhematological toxicity,>=3,NA,FALSE,NA
21556801,NA,777,"nausea, vomiting, or diarrhea despite receiving optimal symptomatic treatment",>=3,NA,NA,NA
21556801,NA,777,"febrile neutropenia (absolute neutrophil count <1,000 cells/ mm3 and fever >38.3C)",NA,NA,NA,NA
21556801,NA,777,"platelet count <10,000 cells/mm3",NA,NA,NA,NA
21556801,NA,777,"inability to initiate cycle 2, day 1 of therapy due to toxicity",NA,NA,NA,NA
12569301,NA,778,non-hematological toxicity,3 or 4,NA,FALSE,NA
12569301,NA,778,vomiting,4,NA,NA,NA
12569301,NA,778,hematologic toxicity,4,NA,NA,NA
12569301,NA,778,hematological toxicity with complications (e.g. neutropenic fever or bleeding),3,NA,NA,NA
12569301,NA,778,a recycling delay of over 2 weeks during the first two cycles,NA,NA,NA,NA
26384354,NCT01464034,779,treatmentemergent neuropathy with pain,2,NA,NA,NA
26384354,NCT01464034,779,neuropathy,>=3,NA,NA,NA
26384354,NCT01464034,779,any nonhematologic toxicity,>=3,NA,FALSE,NA
26384354,NCT01464034,779,"nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy",>=3,NA,NA,NA
26384354,NCT01464034,779,any nonhematologic toxicity requiring a dose reduction or dose hold within cycle 1,NA,NA,NA,NA
26384354,NCT01464034,779,a delay in the ability to receive the day 1 dose of cycle 2 due to drugrelated toxicity that persisted from cycle 1 >14 days,NA,NA,NA,NA
26384354,NCT01464034,779,neutropenia,4,>=7 days,NA,NA
26384354,NCT01464034,779,febrile neutropenia,NA,NA,NA,NA
26384354,NCT01464034,779,thrombocytopenia despite dose delay,4,>=7 days,NA,NA
26384354,NCT01464034,779,thrombocytopenia associated with bleeding,3 or 4,NA,NA,NA
26384354,NCT01464034,779,any hematologic toxicity requiring a dose reduction or dose hold within cycle 1,NA,NA,NA,NA
26384354,NCT01464034,779,an inability to receive the day 1 dose of cycle 2 owing to drug-related toxicity that persisted from cycle .14 days from the end of cycle 1,NA,NA,NA,NA
22451423,NCT01042704,780,neutropenia,3,>=7 days,NA,NA
22451423,NCT01042704,780,neutropenia with fever (temperature >= 38.5Â°C),>=3,NA,NA,NA
22451423,NCT01042704,780,neutropenia,4,NA,NA,NA
22451423,NCT01042704,780,platelets less than 25 x 109/L,NA,NA,NA,NA
22451423,NCT01042704,780,"other toxicity, which, in the judgment of the treating physician, was possibly related to bendamustine, lenalidomide, or dexamethasone",3 or 4,NA,NA,NA
20956622,NA,781,Nonhematologic toxicities,3 or 4,NA,NA,NA
20956622,NA,781,uncontrolled or intolerable toxicities attributable to lenalidomide,2,NA,NA,NA
15060739,NA,782,nonhematologic toxicity,3 or 4,NA,NA,NA
15060739,NA,782,hematologic toxicity,4,NA,NA,NA
15060739,NA,782,unresolved toxicity warranting a 2-week treatment delay at a specific dose level,NA,NA,NA,NA
12384400,NA,783,cardiac arrhythmia,>=2,NA,NA,NA
12384400,NA,783,nonhematologic toxicity,>=3,NA,NA,NA
12384400,NA,783,hematologic toxicity,4,NA,NA,NA
25617965,NCT01093183,784,non-hematologic toxicity,3 or 4,NA,NA,NA
25617965,NCT01093183,784,neutropenia,4,>5 days,NA,NA
25617965,NCT01093183,784,febrile neutropenia,NA,NA,NA,NA
25617965,NCT01093183,784,thrombocytopenia,4,NA,NA,NA
25617965,NCT01093183,784,thrombocytopenia associated with bleeding,3,NA,NA,NA
20724537,NCT00621400,785,cardiac arrhythmia,>=2,NA,NA,NA
20724537,NCT00621400,785,nonhematologic toxicity,>=3,NA,NA,NA
20724537,NCT00621400,785,neutropenia,4,>7 days,NA,NA
20724537,NCT00621400,785,any other hematologic toxicity,4,NA,NA,NA
20724537,NCT00621400,785,treatment delay due to toxicity occurring during the first cycle,NA,NA,NA,NA
26284823,NCT02302469,786,NA,NA,NA,NA,DLT not defined
27354719,NCT00963534,787,nonhematologic adverse event (AE),>=3,NA,FALSE,NA
23692564,NA,788,non-haematological toxicity,3 or 4,NA,FALSE,NA
23692564,NA,788,neutropenic fever,NA,>3 days,NA,NA
23692564,NA,788,neutropenia,4,>7 days,NA,NA
23692564,NA,788,thrombocytopenia<25 x 109/1,NA,>e days,NA,NA
23692564,NA,788,inabilityto receive the full drug schedule and dose of RBP in the firstand/or second treatment cycle,NA,NA,NA,NA
23692564,NA,788,a treatment delay>1 weekafter the first cycle due to toxicity,NA,NA,NA,NA
31126332,NCT02619162,789,anemia,4,NA,NA,NA
31126332,NCT02619162,789,thrombocytopenia,4,NA,NA,NA
31126332,NCT02619162,789,neutropenia,4,>=5 days,NA,NA
31126332,NCT02619162,789,"nausea, diarrhea, or vomiting in spite of maximal supportive care and prophylaxis",3,NA,NA,NA
31126332,NCT02619162,789,clinically significant non-hematologic toxicity,>=3,NA,FALSE,NA
31126332,NCT02619162,789,a serum creatinine value â‰¥ 2-fold the baseline value or â‰¥ 2-fold the ULN if the baseline value was less than the ULN,NA,NA,NA,NA
22640031,NCT00415064,790,non-haematological toxicity,>=3,NA,NA,NA
22640031,NCT00415064,790,thrombocytopeniawith platelet count<25x109/l on more than one occasion despite transfusion support,4,NA,NA,NA
22640031,NCT00415064,790,neutropenia and/or resulting in neutropenic fever,4,>5 d,NA,NA
22640031,NCT00415064,790,an inabilityto receive the day 1 dose in cycle 2 due to toxicity,NA,NA,NA,NA
31074316,NCT01400685,791,non-hematologic toxicity,>=3,NA,FALSE,NA
31074316,NCT01400685,791,allergic reactions or infusion reactions due to either bendamustine or rituximab,>=4,NA,NA,NA
31074316,NCT01400685,791,infections,>=4,NA,NA,NA
31074316,NCT01400685,791,rash unresponsive to supportive care,>=3,NA,NA,NA
31074316,NCT01400685,791,nausea and/or vomiting,>=3,>=7 d,NA,NA
31074316,NCT01400685,791,inability to receive day 1 of cycle 2 or 3 after up to a 3-week treatment delay due to drug related toxicity,NA,NA,NA,NA
33674736,NCT01665183,792,neutropenia,4,>7 days,NA,NA
33674736,NCT01665183,792,febrile neutropenia of any duration with temperature â‰¥38.5 Â°C,NA,NA,NA,NA
33674736,NCT01665183,792,"anaemia, which requires transfusion",4,NA,NA,NA
33674736,NCT01665183,792,thrombocytopenia which requires transfusion,4,NA,NA,NA
33674736,NCT01665183,792,"nonhematologic toxicity that occur during the first cycle that are attributed as possibly, probably or definitely related to the study treatment",3 or 4,NA,NA,NA
27531679,NCT01615029,793,NA,NA,NA,NA,DLT not defined
12853359,NA,794,toxicity,3 or 4,NA,FALSE,NA
12853359,NA,794,inability to receive one of the first four doses on schedule,NA,NA,NA,NA
12796032,NA,795,non-hematological toxicity,3 or 4,NA,FALSE,NA
12796032,NA,795,thrombocytopenia,4,NA,NA,NA
12796032,NA,795,uncomplicated neutropenia,4,>=5 days,NA,NA
12796032,NA,795,febrile neutropenia,NA,NA,NA,NA
12796032,NA,795,treatment delay â‰¥2 weeks due to any toxicity,NA,NA,NA,NA
11948111,NA,796,coagulation abnormality associated with >=grade 2 hemorrhage,>=4,NA,NA,NA
11948111,NA,796,thrombocytopenia,4,NA,NA,NA
11948111,NA,796,thrombocytopenia with any clinical evidence for bleeding,>=3,NA,NA,NA
11948111,NA,796,neutropenia associated with fever,4,NA,NA,NA
11948111,NA,796,neutropenia,4,>5 days,NA,NA
11948111,NA,796,anemia,4,NA,NA,NA
11948111,NA,796,any prolonged drug-related toxicity requiring treatment to be interrupted for more than 2 weeks,NA,NA,NA,NA
11948111,NA,796,diarrhea or vomiting requiring dose reduction of 5-FU below 200 mg/m2,4,NA,NA,NA
11948111,NA,796,nonhematological toxicity,>=3,NA,FALSE,NA
29237802,NCT01750983,797,"nonhematologic toxicity, expected and believed to be related to the study medications",3 or 4,NA,FALSE,NA
29237802,NCT01750983,797,hematologic toxicity,4,>=3 weeks,NA,NA
29237802,NCT01750983,797,hematologic toxicity associated with bleeding and/or sepsis,4,NA,NA,NA
29237802,NCT01750983,797,nausea or vomiting despite maximum antinausea regimens,4,>=5 days,NA,NA
29237802,NCT01750983,797,any other nonhematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome,3,NA,NA,NA
29237802,NCT01750983,797,any severe life-threating complication or abnormality not defined in the NCI-CTCAE v4.0 that is attributable to the therapy,NA,NA,NA,NA
20859231,NA,798,hematologic toxicities,4,NA,NA,NA
20859231,NA,798,nonhematologic toxicities,3 or 4,NA,NA,NA
20859231,NA,798,elevated serum glutamic pyruvic and/or oxaloacetic transaminase (> 5.0â€“10 upper limit of normal),3,>=7 days,NA,NA
20859231,NA,798,neutropenia with fever requiring hospitalization for parenteral antibiotics,3,NA,NA,NA
11432626,NA,799,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11432626,NA,799,hematologic toxicity,4,NA,NA,NA
11432626,NA,799,"hematologic toxicity associated with complications (e.g., neutropenic fever or bleeding)",3,NA,NA,NA
11432626,NA,799,hematologic toxicity associated with a delay >2 weeks,3,NA,NA,NA
22240778,NA,800,neutropenia,4,>7 days,NA,NA
22240778,NA,800,febrile neutropenia (>38.5 C),3 or 4,NA,NA,NA
22240778,NA,800,thrombocytopenia,4,NA,NA,NA
22240778,NA,800,symptomatic thrombocytopenia,3,NA,NA,NA
22240778,NA,800,omission or delay of day 8 of VNR owing to haematological toxicity,NA,NA,NA,NA
22240778,NA,800,non-haematological toxicity,3 or 4,NA,FALSE,NA
22240778,NA,800,considered clinically significant and drug-related by the investigator,NA,NA,NA,NA
21307147,NA,801,toxicity clearly related to NGR-hTNF,3 or 4,NA,FALSE,NA
12439334,NA,802,vomiting and diarrhea requiring treatment interruption of at least 7 days,4,NA,NA,NA
12439334,NA,802,gastrointestinal toxicity requiring treatment interruption of at least 7 days,>=2,NA,NA,NA
12439334,NA,802,the inability of the patient to take more than 75% of the planned chemotherapy dose during treatment period,NA,NA,NA,NA
12439334,NA,802,hematologic toxicity,>=3,NA,NA,NA
12439334,NA,802,non-hematologic toxicity,>=3,NA,FALSE,NA
29427149,NA,803,neutropenia a any time during the first 21 days,4,NA,NA,NA
29427149,NA,803,thrombocytopenia a any time during the first 21 days,4,NA,NA,NA
29427149,NA,803,neutropenia,4,>7 days,NA,NA
29427149,NA,803,thrombocytopenia,4,>7 days,NA,NA
29427149,NA,803,thrombocytopenia requiring a platelet transfusion on more than 2 occasions during a cycle,>=3,NA,NA,NA
29427149,NA,803,myelosuppression causing a â‰¥7 days delay between treatment cycles,NA,NA,NA,NA
29427149,NA,803,non-hematologic toxicity,4,NA,NA,NA
29427149,NA,803,non-hematologic toxicity,3,NA,FALSE,NA
29427149,NA,803,non-hematologic toxicity considered intolerable by the patient,2,>7 days,NA,NA
20713864,NA,804,neutropenia related to lapatinib,4,NA,NA,NA
20713864,NA,804,thrombocytopenia related to lapatinib,3 or 4,NA,NA,NA
20713864,NA,804,nonhematologic toxicity,3 or 4,NA,FALSE,NA
20713864,NA,804,nonhematologic toxicity that persisted and was considered sufficiently medically significant or sufficiently intolerable by patients to warrant treatment interruption and/or dose reduction,2,>7 days,NA,NA
21825263,NA,805,hematologic toxicity (neutropenia or thrombocytopenia),4,>=1 week,NA,NA
21825263,NA,805,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21825263,NA,805,intolerable nonhematologic toxicities requiring dose reduction during the first 28 days of treatment,2,NA,NA,NA
21825263,NA,805,intolerable hematologic toxicities requiring dose reduction during the first 28 days of treatment,3,NA,NA,NA
21825263,NA,805,AEs resulting in treatment delay longer than 1 week during the first 28 days of treatment,NA,NA,NA,NA
21149652,NA,806,Nonhematologic toxicity,>=4,NA,NA,NA
21149652,NA,806,Nonhematologic toxicity,3,NA,FALSE,NA
21149652,NA,806,Nonhematologic toxicity required treatment interruption,2,>3 days,NA,NA
21149652,NA,806,any adverse event that required treatment interruption for more than 3 days and recurred on rechallenge,NA,NA,NA,NA
21149652,NA,806,neutropenia during the dosing period,4,NA,NA,NA
21149652,NA,806,thrombocytopenia during the dosing period,4,NA,NA,NA
21149652,NA,806,neutropenia occurring during the 7-day rest period,4,>=5 days,NA,NA
21149652,NA,806,"the requirement for two or more platelet transfusions for platelet countsless than 50,000/uL during the first course",NA,NA,NA,NA
21149652,NA,806,>= 1 week delayin starting subsequent cycles as a result of neutropenia or thrombocytopenia,NA,NA,NA,NA
25666183,NA,807,"platelet level less than 25,000/Î¼L",NA,NA,NA,NA
25666183,NA,807,"bleeding associated with a platelet level less than 50,000/Î¼L",NA,NA,NA,NA
25666183,NA,807,absolute neutrophil count less than 500/Î¼L,NA,>7 days,NA,NA
25666183,NA,807,neutropenic fever,NA,NA,NA,NA
25666183,NA,807,more than 14 days of delay in initiation of subsequent treatment because of inadequate hematological parameters,NA,NA,NA,NA
25666183,NA,807,nonhematological toxicity,>=3,NA,FALSE,NA
33075165,NCT02509039 ,808,a clinically rel-evant nonhematologic TEAE,>=3,NA,FALSE,NA
33075165,NCT02509039 ,808,a clinically relevant laboratory abnormality,>=3,NA,NA,NA
33075165,NCT02509039 ,808,any febrile neutropenia,NA,NA,NA,NA
33075165,NCT02509039 ,808,neutropenia,4,>  7  day,NA,NA
33075165,NCT02509039 ,808,thrombocytopenia requiring platelet transfusions,any grade,NA,NA,NA
33075165,NCT02509039 ,808,thrombocytopenia,4,>24 hrs,NA,NA
33075165,NCT02509039 ,808,thrombocytopenia with clinically significant bleeding,3 or 4,NA,NA,NA
33075165,NCT02509039 ,808,liver function tests,4,NA,NA,NA
33075165,NCT02509039 ,808,ALT with grade â‰¥  2 bilirubin,3,NA,NA,NA
33075165,NCT02509039 ,808,any TEAE necessitating a dose reduction,NA,NA,NA,NA
34955443,NCT01578954,809,non-hematologic toxicity during cycle 1,>=3,NA,NA,NA
34955443,NCT01578954,809,hematologic toxicity beyond day 35 of cycle 1,>=3,NA,NA,NA
23592273,NA,810,therapy-related death,NA,NA,NA,NA
23592273,NA,810,six or more missed doses of lenalidomide due to trial drug-related toxicity,NA,NA,NA,NA
23592273,NA,810,delay of >2 weeks of cycle 2 due to trial drugrelated toxicity,NA,NA,NA,NA
23592273,NA,810,non-hematological AE related to trial treatment,3 or 4,NA,NA,NA
23592273,NA,810,neutrophils â‰¤0.5Ã—109/L,NA,>=6 days,NA,NA
23592273,NA,810,platelets â‰¤20 or 21â€“50Ã—109/L with major bleedings,NA,NA,NA,NA
22967996,NCT00706030,811,non-hematologic toxicity,3 or 4,NA,FALSE,NA
22967996,NCT00706030,811,diarrhea during optimal medical therapy,3,>2 days,NA,NA
22967996,NCT00706030,811,diarrhea associated with fever or dehydration,3,NA,NA,NA
22967996,NCT00706030,811,neutropenia,4,>=7 days,NA,NA
22967996,NCT00706030,811,febrile neutropenia,4,NA,NA,NA
22967996,NCT00706030,811,thrombocytopenia,4,>=3 days,NA,NA
22967996,NCT00706030,811,thrombocytopenia complicated with bleeding,4,NA,NA,NA
22967996,NCT00706030,811,delayed recovery (to grade 1/0 or baseline) from one of the above drug-related toxic effects delaying the initiation of the next dose by more than 3 weeks,NA,NA,NA,NA
21149673,NA,812,nonhematologic toxicity,4,NA,NA,NA
21149673,NA,812,nonhematologic toxicity,3,NA,FALSE,NA
21149673,NA,812,nonhematologic toxicity that persisted and was considered sufficiently medically significant or intolerable by patients that it required treatment interruption,2,>7 days,NA,NA
21149673,NA,812,any other adverse event that required interruption of lenalidomide for longer than 7 days or that recurred on rechallenge with lenalidomide,NA,NA,NA,NA
21149673,NA,812,neutropenia or thrombocytopenia that occurred during drug administration,4,NA,NA,NA
21149673,NA,812,neutropenia or thrombocytopenia that occurred during drug administration,4,>7 days,NA,NA
21149673,NA,812,thrombocytopenia that required transfusion therapy on more than two occasions during a course,3,NA,NA,NA
21149673,NA,812,any myelosuppression causing a delay of  7 days between treatment courses,NA,NA,NA,NA
20553268,NA,813,haematological  toxicity,4,NA,NA,NA
20553268,NA,813,febrile neutropenia,NA,NA,NA,NA
20553268,NA,813,non-haematological toxicity,3 or 4,NA,NA,NA
20553268,NA,813,failure to startcycle 2 within 7 d of scheduled day due to treatment-related toxicity,1,NA,NA,NA
29938772,NCT01383928,814,neutropenia (absolute neutrophil count <500/mm3),4,>=7 days,NA,NA
29938772,NCT01383928,814,"neutropenia with fever and/or infection, where fever was defined as a temperature â‰¥38Â·5ÂºC",3,NA,NA,NA
29938772,NCT01383928,814,"thrombocytopenia (platelets <25,000/mm3)",4,>=7 days,NA,NA
29938772,NCT01383928,814,"thrombocytopenia with clinically significant bleeding, where clinically significant bleeding is defined as a blood loss of >100 cc or the requirement for a red blood cell transfusion",3,NA,NA,NA
29938772,NCT01383928,814,"A platelet count <10,000/mm3",NA,NA,NA,NA
29938772,NCT01383928,814,peripheral neuropathy with pain,2,NA,NA,NA
29938772,NCT01383928,814,peripheral neuropathy,>=3,NA,NA,NA
29938772,NCT01383928,814,nausea and/or emesis despite the use of optimal anti-emetic prophylaxis,>=3,NA,NA,NA
29938772,NCT01383928,814,diarrhoea that occurred despite maximal supportive therapy,>=3,NA,NA,NA
29938772,NCT01383928,814,any other nonhaematological toxicity,>=3,NA,FALSE,NA
29938772,NCT01383928,814,A delay of more than 2 weeks in the subsequent cycle of treatment because of a lack of adequate recovery of combination study drug-related haematological or nonhaematological toxicities,NA,NA,NA,NA
29938772,NCT01383928,814,Inability to receive at least 80% of the planned lenalidomide doses due to drug-related adverse events,NA,NA,NA,NA
29938772,NCT01383928,814,"Other combination study drug-related nonhaematological toxicities that, in the opinion of the investigator, require discontinuation of therapy with combination study drugs",>=2,NA,NA,NA
9932161,NA,815,hematologic side effects,>=3,NA,NA,NA
9932161,NA,815,nonhematologic side effects,>=2,NA,NA,NA
10656432,NA,816,irreversible nonhematological toxicity,2,NA,NA,NA
10656432,NA,816,reversible nonhematological toxicity,3,NA,NA,NA
10656432,NA,816,hematological toxicity,4,NA,NA,NA
14970856,NA,817,any toxicity,>=2,NA,NA,NA
22892551,NCT00482846,818,Oral Mucositis,4,NA,FALSE,NA
22892551,NCT00482846,818,diarrhea,4,NA,NA,NA
22892551,NCT00482846,818,cardiac toxicity,>=3,NA,NA,NA
22892551,NCT00482846,818,skin rash,>=3,NA,NA,NA
22892551,NCT00482846,818,symptomatic elevations in amylase and lipase,4,NA,NA,NA
22549288,NA,819,absolute granulocyte count <0.5 x 109/L,NA,>=7 days,NA,NA
22549288,NA,819,neutropenic infection,>=3,NA,NA,NA
22549288,NA,819,febrile neutropenia,>=3,NA,NA,NA
22549288,NA,819,platelets <50 x 109/L,NA,>=7 days,NA,NA
22549288,NA,819,symptomatic bleeding sufficient to require therapeutic intervention,NA,NA,NA,NA
22549288,NA,819,nonhematological toxicity,>=3,NA,NA,NA
22549288,NA,819,drug-related regional toxicities as defined by specified areas pertinent to limb toxicity,>=4,NA,NA,NA
22549288,NA,819,inability to take two planned doses of sorafenib during the 14-day regimen,NA,NA,NA,NA
10863063,NA,820,"nausea, vomiting, or diarrhea despite medical intervention",>=3,NA,NA,NA
10863063,NA,820,neutropenia/thrombocytopnia,>=3,NA,NA,NA
10863063,NA,820,hepatic toxicity,>=3,NA,NA,NA
10863063,NA,820,inability of the patient to take 75% or more of the planned UFT/leucovorin,4,NA,NA,NA
10863063,NA,820,radiotherapy interruption of greater than 1 week,NA,NA,NA,NA
19034580,NA,821,serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST)[10-fold the upper limit of normal at 2 weeks after IHP,NA,NA,NA,NA
19034580,NA,821,hyperbilirubinemia that did not resolve by 6 weeks after IHP,3 or 4,NA,NA,NA
19034580,NA,821,any hyperbilirubinemia in the first 6 weeks associated with clinical signs of veno-occlusive disease (VOD),NA,NA,NA,NA
19034580,NA,821,major organ toxicity that was not reversible within 48 h,3 or 4,NA,NA,NA
9389936,NA,822,an absolute granulocyte count < 0.5 x 109/L,NA,>=7 days,NA,NA
9389936,NA,822,the development of infection or fever requiring parenteral antibiotics,NA,NA,NA,NA
9389936,NA,822,"a platelet count < 50 x 109/L, the requirement of two or more platelet transfusions within one cycle, or grade 2 or greater haemorrhage,",3,>=7 days,NA,NA
9389936,NA,822,non-haematological toxicity,>=3,NA,FALSE,NA
9389936,NA,822,dose reductions and/or treatment delays for longer than 1 week for reasons of toxicity.,NA,NA,NA,NA
9389916,NA,823,NA,NA,NA,NA,DLT not defined
10590370,NA,825,nonhematologic toxicity,3 or 4,NA,NA,NA
10590370,NA,825,nonhematologic toxicity that failed to reverse by Day 29,2,NA,NA,NA
10590370,NA,825,neutropenia,3 or 4,>=7 days,NA,NA
10590370,NA,825,neutropenic fever,NA,NA,NA,NA
10590370,NA,825,thrombocytopenia,4,NA,NA,NA
18497327,NA,826,neutropenia,4,>=7 days,NA,NA
18497327,NA,826,thrombocytopenia,4,>=7 days,NA,NA
18497327,NA,826,"failure of counts to recover to ANC >1,000/ul and platelet count >100,000/ul by day 42",NA,NA,NA,NA
18497327,NA,826,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17146474,NA,827,NA,NA,NA,NA,DLT not defined
15256243,NA,828,NA,NA,NA,NA,DLT not defined
10907951,NA,829,neutropenia,4,NA,NA,NA
10907951,NA,829,thrombocytopenia,4,NA,NA,NA
10907951,NA,829,febrile neutropenia,3,NA,NA,NA
10907951,NA,829,thrombocytopenia with bleeding,3,NA,NA,NA
10907951,NA,829,non-hematologic toxicity,3,NA,FALSE,NA
10907951,NA,829,> 2 week delay in chemotherapy recycling,NA,NA,NA,NA
9554592,NA,830,"leukopenia (WBC <2000/mm3) in >30% of patients, or the presence of other intolerable toxicity",NA,NA,NA,NA
8418223,NA,831,NA,NA,NA,NA,DLT not defined
23090987,NCT00948389,832,absolute neutrophil counts <0.5 Ã— 109/L,NA,7 consecutive days,NA,NA
23090987,NCT00948389,832,febrile neutropenia,NA,NA,NA,NA
23090987,NCT00948389,832,thrombocytopenia,4,NA,NA,NA
23090987,NCT00948389,832,nonhematological toxicity,3 or 4,NA,FALSE,NA
23090987,NCT00948389,832,any toxicity that prevented administration of at least 70% of the intended dose of either agent,NA,NA,NA,NA
26553306,NA,833,"nausea, vomiting, diarrhea, thrombocytopenia, or other medically relevant event",>=3,NA,FALSE,NA
26553306,NA,833,neutropenia or leucopenia,4,NA,NA,NA
8622018,NA,834,NA,1,NA,NA,DLT not defined
25125340,NA,835,thrombopenia,4,>7 days,NA,NA
25125340,NA,835,neutropenia,4,>7 days,NA,NA
25125340,NA,835,febrile neutropenia,NA,NA,NA,NA
25125340,NA,835,irreversible liver toxicity,3 or 4,NA,NA,NA
25125340,NA,835,other non-haematological toxicity,3 or 4,NA,FALSE,NA
9816300,NA,836,NA,NA,NA,NA,DLT not defined
20478715,NA,837,NA,NA,NA,NA,DLT not defined
22453252,NCT00482846,838,oral mucositis,4,NA,NA,NA
22453252,NCT00482846,838,diarrhea,4,NA,NA,NA
22453252,NCT00482846,838,skin rash,>=3,NA,NA,NA
22453252,NCT00482846,838,elevations of amylase and lipase (symptomatic),4,NA,NA,NA
22453252,NCT00482846,838,cardiac toxicity,>=3,NA,NA,NA
22453252,NCT00482846,838,Any other toxicity that is determined by the principal investigator to be probably or definitely related to study drugs will be considered as a DLT,3,NA,NA,NA
10442367,NA,839,ANC < 0.5 Ã— 109/L,NA,> 7 days,NA,NA
10442367,NA,839,ANC < 0.1 Ã— 109/L,NA,> 3 days,NA,NA
10442367,NA,839,any episode of febrile neutropenia,NA,NA,NA,NA
10442367,NA,839,platelets < 25 Ã— 109/L,NA,NA,NA,NA
10442367,NA,839,bleeding,NA,NA,NA,NA
10442367,NA,839,absence of recovery of absolute neutrophil count and/or platelets by day 35,NA,NA,NA,NA
10442367,NA,839,nonhematologic toxicity,>=3,NA,FALSE,NA
10442367,NA,839,persistence of nonhematologic toxicity of common toxicity at day 35,>=2,NA,FALSE,NA
10442367,NA,839,inability to take >= 75% of planned UFT dose,NA,NA,NA,NA
25784682,NCT01279694,840,hematologic toxicity,4,NA,NA,NA
25784682,NCT01279694,840,hematologic toxicity preventing the administration of >=2 of the 8 carfilzomib doses of the first treatment cycle,NA,NA,FALSE,NA
25784682,NCT01279694,840,febrile neutropenia,>=3,NA,NA,NA
25784682,NCT01279694,840,gastrointestinal toxicities,>=3,NA,FALSE,NA
25784682,NCT01279694,840,any other nonhematologic toxicity considered related to carfilzomib,>=3,NA,NA,NA
25784682,NCT01279694,840,PN persisting for >3 weeks after discontinuation of study drugs,>=3,NA,NA,NA
8004761,NA,841,NA,NA,NA,NA,DLT not defined
11432616,NA,842,toxicity,3 or 4,NA,NA,NA
12203099,NA,843,NA,NA,NA,NA,DLT not defined
10999043,NA,844,NA,NA,NA,NA,DLT not defined
9552052,NA,845,"renal, cardiovascular, pulmonary, or CNS toxicity",>=3,NA,NA,NA
9552052,NA,845,nonmyelotoxicity,4,NA,NA,NA
9552052,NA,845,myelotoxicity that lasted more than 1 week or resulted in sepsis,4,NA,NA,NA
9552051,NA,846,NA,NA,NA,NA,DLT not defined
8269603,NA,848,oral mucositis,>=2,NA,NA,NA
8269603,NA,848,diarrhea,>=2,NA,NA,NA
8269603,NA,848,hand/foot syndrome,>=2,NA,NA,NA
8558227,NA,849,"a lack of recovery of blood cell counts (granulocyte count >= 1,500/uL or platelet count >= 90,000/uL) by day 21 that subsequently resulted in a delay of the next cycle",NA,NA,NA,NA
8558227,NA,849,granulocyte nadir of less than 500 cells/uL,NA,>=5 days,NA,NA
8558227,NA,849,"a single platelet count less than 20,000/uL.",NA,NA,NA,NA
8558227,NA,849,Nonhematologic toxicity,>=3,NA,FALSE,NA
11032595,NA,850,"renal, hepatic, cardiac, or pulmonary toxicity",>=2,NA,NA,NA
11032595,NA,850,neurologic toxicity,>=3,NA,NA,NA
11032595,NA,850,"nausea, vomiting, or diarrhea requiring parenteral support",NA,NA,NA,NA
11032595,NA,850,other gastrointestinal toxicity,>=3,NA,NA,NA
11032595,NA,850,hematologic toxicity,>=3,NA,NA,NA
11032595,NA,850,inability of the patient to take >= 75% of the planned chemotherapy,NA,NA,NA,NA
16146748,NA,851,NA,NA,NA,NA,DLT not defined
9661893,NA,852,NA,NA,NA,NA,DLT not defined
9626215,NA,854,severe inflammatory polyarthritis,NA,NA,NA,NA
9193347,NA,855,NA,NA,NA,NA,DLT not defined
15084615,NA,856,neutropenia,4,>=7 days,NA,NA
15084615,NA,856,thrombocytopenia,4,>=7 days,NA,NA
15084615,NA,856,nonhematologic toxicity,3 or 4,NA,FALSE,NA
15084615,NA,856,any toxicity requiring a 2-week or longer additional delay before drug readministration ( 5 weeks from day 1),NA,NA,NA,NA
9720737,NA,857,unresolved non-hematologic toxicities in cycle 1,4,NA,NA,NA
9720737,NA,857,inability to administer the second cycle of HDM within 90 days from cycle 1,NA,NA,NA,NA
9720737,NA,857,non-hematologic toxicities in cycle 2 that were not resolved in 90 days or death from RRT,4,NA,NA,NA
9358936,NA,858,granulocytopenia associated with grade >=2 infection,3,NA,FALSE,NA
9358936,NA,858,"constipation, mucositis, stomatitis or diarrhea",>2,NA,NA,NA
9713314,NA,859,neutropenia,4,NA,NA,NA
9713314,NA,859,thrombocytopenia,4,NA,NA,NA
9713314,NA,859,febrile neutropenia,NA,NA,NA,NA
9713314,NA,859,non-haematological toxicity,>=3,NA,NA,NA
32400117,CTRI/2018/01/011542,860,life-threatening adverse events related to the combination of the investigational drug and other chemotherapeutic agent(s) and/or radiation which occurred during the assigned period of the protocol,3 or 4,NA,NA,NA
32400117,CTRI/2018/01/011542,860,neutropenia,>=4,NA,NA,NA
32400117,CTRI/2018/01/011542,860,thrombocytopenia,>=4,NA,NA,NA
32400117,CTRI/2018/01/011542,860,rise in SGPT or SGOT,3,1 week,NA,NA
32400117,CTRI/2018/01/011542,860,rise in SGPT or  SGOT,>=4,NA,NA,NA
7977165,NA,863,NA,NA,NA,NA,DLT not defined
12381899,NA,864,neutropenia,4,>=5 days,NA,NA
12381899,NA,864,thrombocytopenia,4,>=5 days,NA,NA
12381899,NA,864,febrile neutropenia,3 or 4,NA,NA,NA
12381899,NA,864,nonhematologic toxicity,>=3,NA,FALSE,NA
12381899,NA,864,any treatment delay at day 8 of the first treatment cycle or at day 1 of the second treatment cycle because of unresolved toxicity,NA,NA,NA,NA
33021083,NA,865,nonhematologic toxicity,3 or 4,NA,FALSE,NA
33021083,NA,865,"nausea, vomiting, and diarrhea despite maximum support",3 or 4,NA,NA,NA
33021083,NA,865,thrombocytopenia,4,>7 consecutive days,NA,NA
33021083,NA,865,neutropenia,4,>7 consecutive days,NA,NA
33021083,NA,865,febrile neutropenia,3 or 4,NA,NA,NA
33021083,NA,865,any other toxicity leading to the inability to begin thenext course within 3 weeks of scheduled dosing,NA,NA,NA,NA
30077789,NA,866,nonhematologic toxicity,>=3,NA,FALSE,NA
30077789,NA,866,vomiting not controlled by maximal supportive care with antiemetic therapy,>=3,NA,NA,NA
30077789,NA,866,prolongation of the corrected QT interval,>=3,NA,NA,NA
30077789,NA,866,failure to restart nilotinib administration within 2 weeks of the first missed dose when drug is withheld for clinically significant grade >=2 adverse events,NA,NA,NA,NA
30077789,NA,866,>1 week break in radiation because of radiation toxicity,NA,NA,NA,NA
30077789,NA,866,neutropenia (absolute neutrophil count [ANC] <500/uL),4,>5 days,NA,NA
30077789,NA,866,"thrombocytopenia (platelet count <50,000/uL)",3,>7 days,NA,NA
30077789,NA,866,"thrombocytopenia (platelet count <50,000/uL) associated with bleeding",3,NA,NA,NA
30077789,NA,866,"thrombocytopenia (platelet count <25,000/uL)",4,NA,NA,NA
15539916,NA,867,"platelets <25,000/mm3",NA,NA,NA,NA
15539916,NA,867,ANC <500/mm3,NA,>5 days,NA,NA
15539916,NA,867,ANC <500/mm3 associated with fever requiring antibiotics,NA,NA,NA,NA
15539916,NA,867,anemia,4,NA,NA,NA
15539916,NA,867,any nonhematologic toxicity,>=3,NA,FALSE,NA
33039812,NCT03294252,868,toxicity or unexpected post-operative complication,3 or 4,NA,NA,NA
34518310,NCT02366949,869,hematologic toxicity,4,>7 days,NA,NA
34518310,NCT02366949,869,febrile neutropenia,>3,>7 days,NA,NA
34518310,NCT02366949,869,nonhematologic toxicity,>=3,NA,NA,NA
29437791,NA,870,"any clinically relevant, nonhematologic, noninfectious toxicity attributed as probable or definitely related to CPI-613",>=3,NA,FALSE,NA
20445979,NA,871,non-hematologic toxicity,>=3,NA,FALSE,NA
20445979,NA,871,neutropenia,4,>=7 days,NA,NA
20445979,NA,871,febrile neutropenia (grade 3 neutropenia associated with fever >=38.5C),4,NA,NA,NA
20445979,NA,871,thrombocytopenia,4,NA,NA,NA
20445979,NA,871,bleeding requiring a platelet transfusion,NA,NA,NA,NA
20445979,NA,871,treatment delay of 14 days or greater because of treatment-related toxicity,NA,NA,NA,NA
19774342,NA,872,nonhematologic toxicity,3,NA,NA,NA
19774342,NA,872,hematologic toxicity,4,NA,NA,NA
9849448,NA,873,toxicity,>=3,NA,FALSE,NA
18493824,NA,874,toxicity that was attributable to the intraperitoneal administration of oxaliplatin,3,>=5 days,NA,NA
32816079,NA,875,any treatmentrelated hepatic toxicity,3 or 4,NA,NA,NA
32816079,NA,875,hematologic toxicity,>=4,NA,NA,NA
33602685,NCT2379247,876,NA,NA,NA,NA,DLT not defined
18394816,NA,877,systemic toxicities developed in 3 of 6 patients,3 or 4,NA,NA,NA
32037195,NCT01952249,878,NA,NA,NA,NA,DLT not defined
11281378,NA,879,ANC below 0.5 x 109/l,NA,>7 days,NA,NA
11281378,NA,879,platelets below 20 x 109/l requiring more than one platelet transfusion,NA,NA,NA,NA
11281378,NA,879,non-hematological toxicity,3 or 4,NA,FALSE,NA
16619562,NA,880,"any toxicity, with a neutrophil count <500 ml associated with fever persisting longer than 72 h in 50% of the patients",3 or 4,NA,NA,NA
16619562,NA,880,"Other toxicities, in particular neurotoxicity in at least 50% of the patients",3-Feb,NA,NA,NA
7544169,NA,881,major organ toxicity,>2,NA,NA,NA
7544169,NA,881,"nadir to < 500 neutrophils and < 25,000 platelets",NA,NA,NA,NA
7544169,NA,881,"failure of hematologic recovery (WBC >= 3,000, platelets >= 100,000) by day of CT administration",NA,NA,NA,NA
11283925,NCT01810718,882,hematologic toxicity,4,NA,NA,NA
11283925,NCT01810718,882,nonhematologic toxicity,>=3,NA,FALSE,NA
17681103,NA,883,neutropenia,4,>5 days,NA,NA
17681103,NA,883,neutropenia associated with fever/infection,4,NA,NA,NA
17681103,NA,883,thrombocytopenia associated with bleeding,3 or 4,NA,NA,NA
17681103,NA,883,nonhematologic toxicity,>=3,NA,FALSE,NA
17681103,NA,883,aspartate aminotransferase that returned to grade 2 or pretreatment values within 3 weeks.,3,NA,NA,NA
32520407,NCT00916630,884,any toxicity,4,NA,FALSE,NA
32520407,NCT00916630,884,"nonhematologic, non-neurologic toxicity",3,NA,FALSE,NA
34256279,NCT01677559,885,neutropenia,4,> 7 days,NA,NA
34256279,NCT01677559,885,Febrile neutropenia of any duration with temperature â‰¥ 38.5 Â°C,NA,NA,NA,NA
34256279,NCT01677559,885,thrombocytopenia,4,> 7 days,NA,NA
34256279,NCT01677559,885,fatigue,3,NA,NA,NA
34256279,NCT01677559,885,"nausea, vomiting, or anorexia that returns to Grade 1 prior to the start of Cycle 2",3 or 4,NA,NA,NA
34256279,NCT01677559,885,non-hematological laboratory abnormalities that resolve to grade 1 or baseline prior to the start of Cycle 2,3,NA,NA,NA
34256279,NCT01677559,885,"Any delay in treatment >14 days that is possibly, probably, or definitely related to study treatment",NA,NA,NA,NA
29720734,NCT02044796,886,non-hematologic toxicity,3,NA,FALSE,NA
29720734,NCT02044796,886,non-hematologic toxicity,>=4,NA,FALSE,NA
15205208,NA,887,neutropenia,4,>7 days,NA,NA
15205208,NA,887,febrile neutropenia (defined as grade 4 neutropenia with fever >38.58C and/or concomitant systemic infection),NA,NA,NA,NA
15205208,NA,887,thrombocytopenia,4,NA,NA,NA
15205208,NA,887,thrombocytopenia with bleeding requiring platelet transfusions,3,NA,NA,NA
15205208,NA,887,non-hematologic toxicity,>=3,NA,FALSE,NA
15205208,NA,887,elevated aspartate aminotransferase and alanine amino-transferase levels three or more times the baseline value,4,NA,NA,NA
15205208,NA,887,persistence of non-hematologic toxicity,>2,NA,FALSE,NA
17308894,NA,888,neurotoxicity,>=2,>2 weeks,NA,NA
17308894,NA,888,neurotoxicity of any type,3,NA,NA,NA
17308894,NA,888,other non-hematologic toxicity,>=3,NA,NA,NA
17308894,NA,888,neutropenia,4,>5 days,NA,NA
17308894,NA,888,neutropenia complicated by fever or infection,4,NA,NA,NA
17308894,NA,888,thrombocytopenia,4,NA,NA,NA
17308894,NA,888,inability to receive a second course of therapy within 2 weeks of day 29 for reasons of persistent toxicity,NA,NA,NA,NA
17308894,NA,888,inability to receive three weekly consecutive doses of the drug for toxicity reasons which were not dose-limiting,NA,NA,NA,NA
17538173,NA,889,neutropenia,4,>7 days,NA,NA
17538173,NA,889,thrombocytopenia,4,>7 days,NA,NA
17538173,NA,889,thrombocytopenia requiring platelet transfusion,NA,>7 days,NA,NA
17538173,NA,889,nonhematologic toxicity,3 or 4,NA,FALSE,NA
17538173,NA,889,"neuropathy that did not resolve before the next cycle of therapy, as was a delay in treatment  4 weeks",2,NA,NA,NA
30889492,NCT02848443,890,neutropenia,4,>7 days,NA,NA
30889492,NCT02848443,890,febrile neutropenia,>=3,NA,NA,NA
30889492,NCT02848443,890,thrombocytopenia if associated with bleeding,3,NA,NA,NA
30889492,NCT02848443,890,thrombocytopenia,4,NA,NA,NA
30889492,NCT02848443,890,"nausea, vomiting or diarrhoea  uncontrolled by optimal anti-emetic/anti-diarrhoeal support",>=3,lasting >48 h,NA,NA
30889492,NCT02848443,890,peripheral sensory neuropathy,>=3,NA,NA,NA
30889492,NCT02848443,890,Any other Non-haematological toxicity,>=3,NA,FALSE,NA
30889492,NCT02848443,890,Any drug-related toxicity leading to a >2-week delay in starting cycle 3 or preventing administration of >=80% of the planned cumulative dose of the combination during cycles 1 and 2,NA,NA,NA,NA
34272090,NCT02788708,891,study drug-related adverse events,NA,NA,NA,NA
15908652,NA,892,NA,NA,NA,NA,DLT not defined
33975862,NCT02630199,893,neutropenia (ANC <500 cells/mm3),4,>= 4 days,NA,NA
33975862,NCT02630199,893,febrile neutropenia,NA,NA,NA,NA
33975862,NCT02630199,893,neutropenia with documented infection,3,NA,NA,NA
33975862,NCT02630199,893,thrombocytopenia with bleeding requiring medical intervention,3,NA,NA,NA
33975862,NCT02630199,893,other hematologic toxicities,>=4,NA,NA,NA
33975862,NCT02630199,893,any non-hematologic toxicity,>=3,NA,NA,NA
33975862,NCT02630199,893,QTc prolongation of >500 ms,NA,NA,NA,NA
33975862,NCT02630199,893,"any other toxicity that was worse than at baseline, and was clinically significant and/or unacceptable, and did not respond to supportive care",NA,NA,NA,NA
31810960,UMIN 000010945,894,"neutropenia (neutrophils, <500/mm3)",4,NA,NA,NA
31810960,UMIN 000010945,894,febrile neutropenia,3 or 4,NA,NA,NA
31810960,UMIN 000010945,894,thrombocytopenia,4,NA,NA,NA
31810960,UMIN 000010945,894,thrombocytopenia requiring blood transfusion,3,NA,NA,NA
31810960,UMIN 000010945,894,non-hematological toxicity,3 or 4,NA,NA,NA
31810960,UMIN 000010945,894,other adverse events that led to discontinuation for at least 2 consecutive weeks,1,NA,NA,NA
16142489,NA,895,"local toxicity (mucositis, dysphagia, skin reaction, hoarseness, and xerostomia)",3,NA,NA,NA
16142489,NA,895,haematotoxicity,4,NA,NA,NA
33585999,NCT02041429,896,delay in ability to administer paclitaxel for more than 2 weeks due to toxicity,NA,NA,NA,NA
33585999,NCT02041429,896,"non-hematologic, non-hepatic organ toxicity not attributed to disease progression or another clearly identifed cause",>=3,NA,FALSE,NA
33585999,NCT02041429,896,thrombocytopenia,>=4,>24 h,NA,NA
33585999,NCT02041429,896,thrombocytopenia associated with clinically signifcant bleeding,>=4,NA,NA,NA
33585999,NCT02041429,896,neutropenia,>=4,>4 days,NA,NA
33585999,NCT02041429,896,neutropenia accompanied by fever (oral or tympanic temperature>100.4 Â°F or 38.0 Â°C),>=4,NA,NA,NA
33585999,NCT02041429,896,anemia,>=4,NA,NA,NA
33585999,NCT02041429,896,"total bilirubin, hepatic transaminase (ALT or AST), or alkaline phosphatase (ALP)",>=3,>72 h,NA,NA
33585999,NCT02041429,896,"patients with grade 2 hepatic transaminase at baseline as a result of liver metastases, only hepatic transaminase â‰¥ 10.0 X the upper limit of normal (ULN) lasting > 72 h",NA,NA,NA,NA
33585999,NCT02041429,896,"patients with grade 2 ALP at baseline as a result of bone or liver metastasis, only ALP â‰¥ 10 X ULN lasting > 72 h",NA,NA,NA,NA
31273010,NCT02316171,897,non-hematological toxicity judged to be clinically significant,>=3,>3 days,FALSE,NA
31273010,NCT02316171,897,"febrile neutropenia not related to underlying disease (defined as Grade 4 neutropenia with fever greater than 38.5C, both of which are sustained over a 24-hour period)",NA,NA,NA,NA
31273010,NCT02316171,897,"prolonged neutropenia (lasting 7 days or more, or with sepsis)",4,NA,FALSE,NA
31273010,NCT02316171,897,neutropenic infection (Grade 3 or greater neutropenia with Grade 3 or greater infection),NA,NA,NA,NA
31273010,NCT02316171,897,thrombocytopenia with bleeding,>=3,NA,NA,NA
31273010,NCT02316171,897,thrombocytopenia,4,>=7 days,NA,NA
10213209,NA,899,"hepatic function, metabolic disorders, vascular diseases, loss of appetite, and alopecia",4,NA,NA,NA
10213209,NA,899,hematological parameters,3,NA,NA,NA
10213209,NA,899,"coagulation parameters; stomatitis; diarrhea; gastritis; gastrointestinal tract ulcers; mucositis; diseases of the lung, kidneys, urinary tract, skin, eyes, and ears; and neurological or autoimmune disorders",3,NA,NA,NA
8157471,NA,900,nadir ANC < 500 mm 3,NA,>=5 days,NA,occurring in three or more of five patients
8157471,NA,900,nadir platelet count of < 25000 mm 3,NA,>=5 days,NA,NA
8157471,NA,900,nonhematologic toxicity,3,NA,NA,NA
8157471,NA,900,evidence of cardiac toxicity documented by a drop in LVEF > 15% from baseline or development of any clinically significant cardiac abnormality,NA,NA,NA,NA
8157471,NA,900,delay of therapy >= 7 days due to toxicity,NA,NA,NA,NA
18463792,NA,901,absolute granulocyte count <0.5Ã—109 per liter,4,>7 days,NA,NA
18463792,NA,901,absolute granulocyte count <0.5Ã—109 per liter associated with fever or infection,4,NA,NA,NA
18463792,NA,901,thrombocytopenia,4,NA,NA,NA
18463792,NA,901,thrombocytopenia with bleeding,3,NA,NA,NA
18463792,NA,901,nonhematologic toxicity that represented at least a twograde increase over the baseline,>=3,NA,FALSE,NA
18463792,NA,901,an inability to receive the second dose of treatment within 2 weeks of schedule due to drug-related toxicity,NA,NA,NA,NA
10829050,NA,902,"diarrhea, mucositis, or thrombocytopenia",3,NA,NA,NA
10829050,NA,902,leukoneutropenia,4,NA,NA,NA
10829050,NA,902,any other toxicity,>=2,NA,FALSE,NA
32918791,UMIN000012531,903,pneumonitis,3 or 4,NA,NA,NA
32918791,UMIN000012531,903,febrile neutropenia,3 or 4,NA,NA,NA
32918791,UMIN000012531,903,other nonhematologic toxicities,3 or 4,NA,NA,NA
32918791,UMIN000012531,903,thrombocytopenia,4,NA,NA,NA
32918791,UMIN000012531,903,any unresolved toxicity requiring a second consecutive skip in the administration of weekly nab-PTX or a delay of >2 weeks in the second cisplatin administration,NA,NA,NA,NA
32918791,UMIN000012531,903,any toxicity necessitating a delay of >2 weeks in the completion of radiotherapy,NA,NA,NA,NA
11208839,NA,904,neutropenia,4,>7 days,NA,NA
11208839,NA,904,neutropenia with fever,3 or 4,>3 days,NA,NA
11208839,NA,904,thrombocytopenia,3,NA,NA,NA
11208839,NA,904,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11208839,NA,904,"failure to recover neutrophil or PLT counts to >= 1.5 x 109/L and 100 x 109/L, respectively, on day 28 of treatment",NA,NA,NA,NA
8656247,NA,905,NA,NA,NA,NA,DLT not defined
10506618,NA,906,"a WBC count less than 1,000/ÂµL",NA,>4 days,NA,NA
10506618,NA,906,"a PLT count of less than 25,000/ÂµL",NA,NA,NA,NA
10506618,NA,906,febrile neutropenia,4,>3 days,NA,NA
10506618,NA,906,nonhematologic toxicities that met World Health Organization (WHO) criteria,3,NA,FALSE,NA
32803633,NCT01973309,907,"nonhematologic, non-hepatic AEs",>=3,NA,FALSE,NA
32803633,NCT01973309,907,thrombocytopenia,>=4,â‰¥7 days,NA,NA
32803633,NCT01973309,907,neutropenia,>=4,â‰¥7 days,NA,NA
32803633,NCT01973309,907,total bilirubin or hepatic transaminases,>=3,NA,NA,NA
32803633,NCT01973309,907,new fragility fracture during the bone safety window,NA,NA,NA,NA
34781168,NCT01980277,908,an AE or laboratory abnormality that is considered to be related or possibly related to the LY2780301 or paclitaxel treatment,NA,NA,NA,NA
34781168,NCT01980277,908,"an AE or laboratory abnormality that is unrelated to disease, disease progression, inter-current illness, or concomitant medications",NA,NA,NA,NA
34781168,NCT01980277,908,an AE or laboratory abnormality that occurs < 28 days following the first dose of LY2780301 or paclitaxel,NA,NA,NA,NA
34781168,NCT01980277,908,fatigue,3 or 4,>7 days,NA,NA
34781168,NCT01980277,908,diarrhea despite maximum supportive care,3 or 4,NA,NA,NA
34781168,NCT01980277,908,nausea or vomiting despite maximum supportive care,3 or 4,NA,NA,NA
34781168,NCT01980277,908,neutropenia with fever > 38.5Â°C,4,NA,NA,NA
34781168,NCT01980277,908,neutropenia (ANC < 0.5 x 109/L),4,>7 days,NA,NA
34781168,NCT01980277,908,thrombocytopenia (platelet count < 25.0 x 109/L),4,NA,NA,NA
34781168,NCT01980277,908,anemia,4,NA,NA,NA
34781168,NCT01980277,908,AST or ALT >10 x ULN per institutional laboratory ranges,NA,NA,NA,NA
34781168,NCT01980277,908,arthralgia or myalgia despite optimal supportive care,3 or 4,NA,NA,NA
34781168,NCT01980277,908,extrahematologic toxicity,>=3,NA,FALSE,NA
22781384,NCCCTS-09-387,909,nonhematologic toxicity,>=3,NA,NA,NA
25504632,NCT00866528,910,toxicity occurring after cycle 1 that was considered dose limiting by the investigator,>=2,NA,NA,NA
25504632,NCT00866528,910,febrile neutropenia,NA,NA,NA,NA
25504632,NCT00866528,910,granulocytopenia,4,>5 days,NA,NA
25504632,NCT00866528,910,thrombocytopenia,4,NA,NA,NA
25504632,NCT00866528,910,clinically significant non-hematologic toxicity,3 or 4,NA,FALSE,NA
25504632,NCT00866528,910,the inability to begin the next course of treatment within 2 weeks of scheduled dosing due to toxicity,NA,NA,NA,NA
20091169,NA,911,thrombocytopenia,4,NA,NA,NA
20091169,NA,911,neutropenia,4,>7 days,NA,NA
20091169,NA,911,febrile neutropenia,3 or 4,NA,NA,NA
20091169,NA,911,nonhematologic toxicity related to the combination therapy,3 or 4,NA,FALSE,NA
20091169,NA,911,toxicity resulting in inability to give day 8 of paclitaxel in cycle 2 or missing >7 days of PTK/ZK in cycles 1 or 2,NA,NA,NA,NA
22832803,NA,912,non-hematologic toxicities,>2,NA,FALSE,NA
22832803,NA,912,"nausea, vomiting, or skin reactions",4,NA,NA,NA
22832803,NA,912,neutropenia,4,NA,NA,NA
22832803,NA,912,neutropenia associated with complications (e.g. neutropenic fever),3,NA,NA,NA
22832803,NA,912,thrombocytopenia,4,NA,NA,NA
22832803,NA,912,toxicity-related discontinuation of treatment for more than 1 week,NA,NA,NA,NA
26433959,ChiECRCT2014025,913,neukopenia,>=3,NA,NA,NA
26433959,ChiECRCT2014025,913,febrile neutropenia (>=38.5 C over more than 24 h associated with a neutrophil count x 0.5 x 109/l),4,NA,NA,NA
26433959,ChiECRCT2014025,913,anemia,>=3,NA,NA,NA
26433959,ChiECRCT2014025,913,thrombocytopenia,>=3,NA,NA,NA
26433959,ChiECRCT2014025,913,nonhematological event,>=3,>=7 days,NA,NA
26433959,ChiECRCT2014025,913,any treatment-related event that caused a radiotherapy delay of more than 7 days,NA,NA,NA,NA
26433959,ChiECRCT2014025,913,Any toxicity that caused a chemotherapy delay of more than two consecutive weeks,NA,NA,NA,NA
28477227,NA,914,anemia,4,NA,NA,NA
28477227,NA,914,febrile neutropenia,NA,NA,NA,NA
28477227,NA,914,neutrophil count decreased,>=3,â‰¥7 days,NA,NA
28477227,NA,914,neutrophil count decreased,4,NA,NA,NA
28477227,NA,914,platelet count decreased,4,NA,NA,NA
28477227,NA,914,platelet count decreased with bleeding,3,NA,NA,NA
28477227,NA,914,treatment delay of >2 weeks for any drugrelated adverse event,NA,NA,NA,NA
28477227,NA,914,any other non-hematologic toxicities,3,NA,FALSE,NA
25073954,UMIN000009046,915,"thrombocytopenia, which required platelet transfusion",3 or 4,NA,NA,NA
25073954,UMIN000009046,915,neutropenia,4,>=4 days,NA,NA
25073954,UMIN000009046,915,febrile neutropenia,>=3,NA,NA,NA
25073954,UMIN000009046,915,non-hematologic toxicity,>=3,NA,FALSE,NA
25073954,UMIN000009046,915,other adverse events that led to at least a 21-day delay in the start of Cycle 2,NA,NA,NA,NA
21406471,NA,916,hematologic toxicity,3 or 4,>2 weeks,NA,NA
21406471,NA,916,non-hematologic toxicity,3 or 4,NA,NA,NA
21406471,NA,916,"non-hematologic toxicity that persists despite adequate medical management, requiring withholding dasatinib for >4 days in cycle 1",2,NA,NA,NA
22695940,NA,917,neutropenia,4,>=7 days,NA,NA
22695940,NA,917,febrile neutropenia,>=3,NA,NA,NA
22695940,NA,917,thrombocytopenia,>=3,NA,NA,NA
22695940,NA,917,"non-hematologic toxicity, including nausea, vomiting, and diarrhea, that did not improve within 2 days after the start of appropriate management",>=3,NA,NA,NA
22695940,NA,917,a treatment interruption lasting more than 2 weeks,NA,NA,NA,NA
19738417,NA,918,"nonhematological toxicity and/or hematological toxicity consisting of prolonged neutropenia while receiving filgrastim (>7 d with ANC <500/mm3 or platelet count â‰¤25,000/mm3 for >7 d, or development of transfusion-dependent anemia)",3,NA,NA,NA
30623229,NCT00825201,919,neutropenia,4,>=7 days,NA,NA
30623229,NCT00825201,919,neutropenia associated with fever or infection,4,NA,NA,NA
30623229,NCT00825201,919,thrombocytopenia,4,NA,NA,NA
30623229,NCT00825201,919,non hematological toxicity,3 or 4,NA,FALSE,NA
30623229,NCT00825201,919,Failure to complete at least 66% of planned dose during cycle 1 due to toxicity and any AE that resulted in a delay of treatment for >15 days,NA,NA,NA,NA
27998970,NCT01281852,920,dose delay >2 weeks due to failure to recover counts,NA,NA,NA,NA
27998970,NCT01281852,920,febrile neutropenia,NA,NA,NA,NA
27998970,NCT01281852,920,neutropenia,4,>7 days,NA,NA
27998970,NCT01281852,920,thrombocytopenia,3 or 4,NA,NA,NA
27998970,NCT01281852,920,study related non-hematological toxicity,3 or 4,NA,FALSE,NA
27998970,NCT01281852,920,any drug-related death,NA,NA,NA,NA
30876442, NCT02429622,921,"hematological toxicities (including anemia, neutropenia and thrombocytopenia)",>=4,NA,NA,NA
30876442, NCT02429622,921,"grade 3 or higher nonhematological toxicities (including radiation-induced esophagitis, pneumonitis, gastrointestinal reaction, dermatitis, weight loss, hepatic and renal dysfunction, etc.)",>=3,NA,NA,NA
19010522,NA,922,toxicity within 30 days of treatment,4,NA,NA,NA
19010522,NA,922,a toxicity that caused a dose delay/modification/reduction in any of the six planned cycles,NA,NA,NA,NA
30945121,NA,923,non-hematologic toxicities,>=3,NA,FALSE,NA
30945121,NA,923,"diarrhea, nausea and vomiting, despite maximal dosage of anti-diarrhea and/or anti-emetic medication (as applicable)",>=3,NA,NA,NA
30945121,NA,923,neutropenia,4,>=7 days,NA,NA
30945121,NA,923,neutropenia with fever or infection,3 or 4,NA,NA,NA
30945121,NA,923,thrombocytopenia,4,NA,NA,NA
30945121,NA,923,thrombocytopenia,3,>=7 days,NA,NA
30945121,NA,923,"thrombocytopenia with accompanying bleeding, or requiring transfusion",3,NA,NA,NA
28196905, NCT02890511,924,NA,NA,NA,NA,Not defined
20877350,NA,925,neutropenia,4,>=7 days,NA,NA
20877350,NA,925,neutropenic fever/sepsis,4,NA,NA,NA
20877350,NA,925,thrombocytopenia,4,NA,NA,NA
20877350,NA,925,"any drug-related, nonhaematological toxicity",3 or 4,NA,FALSE,NA
20877350,NA,925,a delay in retreatment with paclitaxel of >7 days,NA,NA,NA,NA
30635336,NCT01320592,926,neutropenia,4,>= 7 days,FALSE,NA
30635336,NCT01320592,926,neutropenia with fever >38.5C and/or infection requiring antibiotic or antifungal treatment,4,NA,NA,NA
30635336,NCT01320592,926,thrombocytopenia,4,NA,NA,NA
30635336,NCT01320592,926,"nonhematologic toxicity (note exceptions below), including treatment delay of greater than 7 days or (v) missing >1 of the 4 weekly doses of paclitaxel or palbociclib in the first cycle due to toxicity",>=3,NA,FALSE,NA
20530446,NA,927,NA,NA,NA,NA,DLT not defined
20530446,NA,928,NA,NA,NA,NA,DLT not defined
19386478,NA,929,neutropenia,3 or 4,>1 week,NA,"If two or more cases of SAEs were observed in a given cohort, dose escalation was stopped. This was designated as the dose-limiting toxicity."
19386478,NA,929,thrombocytopenia,3 or 4,>1 week,NA,"If two or more cases of SAEs were observed in a given cohort, dose escalation was stopped. This was designated as the dose-limiting toxicity."
19386478,NA,929,non-haematological toxicity,3 or 4,>1 week,FALSE,"If two or more cases of SAEs were observed in a given cohort, dose escalation was stopped. This was designated as the dose-limiting toxicity."
18956139,NA,930,AGC <0.5Ã—109/L,4,>5 days,NA,NA
18956139,NA,930,febrile neutropenia (fever â‰¥38.5Â°C and neutropenia <1.0Ã—109/L),NA,NA,NA,NA
18956139,NA,930,thrombocytopenia,4,NA,NA,NA
18956139,NA,930,nonhematological toxicity,>=3,NA,FALSE,NA
18794097,NA,931,neutropenia,4,>=3 days,NA,NA
18794097,NA,931,neutropenia of any duration with infection or fever >=38.5 C,>=3,NA,NA,NA
18794097,NA,931,thrombocytopenia,3,NA,NA,NA
18794097,NA,931,neurosensory or neuromotor toxicity,>=2,NA,NA,NA
18794097,NA,931,all other nonhematologic toxicity,>=3,NA,NA,NA
18794097,NA,931,all other hematologic toxicity,>=4,NA,NA,NA
21853310,NA,932,thrombocytopenia,4,NA,NA,NA
21853310,NA,932,thrombocytopenia with required platelet transfusion,3,NA,NA,NA
21853310,NA,932,neutropenia,4,>=4 days,NA,NA
21853310,NA,932,febrile neutropenia,3 or 4,NA,NA,NA
21853310,NA,932,non-hematologic toxicity,3 or 4,NA,FALSE,NA
21853310,NA,932,skipping of the second or third weekly administration,NA,NA,NA,NA
24658629,NA,933,non-hematologic toxicity,3 or 4,NA,FALSE,NA
24658629,NA,933,febrile neutropenia,NA,NA,NA,NA
24658629,NA,933,neutropenia,4,at least two consequent days,NA,NA
24658629,NA,933,thrombocytopenia,4,NA,NA,NA
24658629,NA,933,anemia,4,NA,NA,NA
20406837,NA,934,ANC of <0.5 Ã— 109/L,NA,.5 days,NA,NA
20406837,NA,934,ANC of <1.0 Ã— 109/L with fever (â‰¥38.5Â°C),NA,NA,NA,NA
20406837,NA,934,platelets of <25 Ã— 109/L,NA,NA,NA,NA
20406837,NA,934,transaminitis for >7 days resulting in cycle delay,3,NA,NA,NA
20406837,NA,934,transaminitis,4,NA,NA,NA
20406837,NA,934,any other nonhematologic toxicity,3 or 4,NA,FALSE,NA
20406837,NA,934,treatment delay exceeding 1 week due to treatment-induced toxicity,NA,NA,NA,NA
20941597,NA,935,hematologic toxicity,4,> 5 consecutive days,NA,NA
20941597,NA,935,hematologic toxicity requiring transfusion or growth factor support,4,NA,NA,NA
20941597,NA,935,nausea/vomiting,4,> 5 days,NA,NA
20941597,NA,935,"any other nonhematologic toxicity, including symptoms/signs of vascular leakage or cytokine release syndrome",3,NA,NA,NA
20941597,NA,935,any severe life-threatening complication,NA,NA,NA,NA
28868573,NCT02667743,936,febrile neutropenia,3,NA,NA,NA
28868573,NCT02667743,936,neutropenia,4,NA,NA,NA
28868573,NCT02667743,936,thrombocytopenia,4,NA,NA,NA
28868573,NCT02667743,936,nonhematological toxicities,>=3,NA,FALSE,NA
26266640,NA,937,neutropenia,4,>4 days,NA,NA
26266640,NA,937,thrombocytopenia,4,NA,NA,NA
26266640,NA,937,febrile neutropenia,3,NA,NA,NA
26266640,NA,937,nonhematologic toxicities,>=3,NA,FALSE,NA
26266640,NA,937,any unresolved toxicity requiring a delay in the administration of a subsequent cycle >14 days,NA,NA,NA,NA
26266640,NA,937,"any toxicity which, in the judgement of the investigator, required dose reduction or discontinuation of therapy",2,NA,NA,NA
21820161,NA,938,febrile neutropenia of unknown origin without clinically or microbiologically documented infection when ANC is <1000/Î¼L,NA,NA,NA,NA
21820161,NA,938,"thrombocytopenia with platelet nadir of <25,000/Î¼L",4,NA,NA,NA
21820161,NA,938,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
21820161,NA,938,any treatment-related death,NA,NA,NA,NA
21820161,NA,938,any non-hematologic adverse event,3 or 4,NA,FALSE,NA
21820161,NA,938,delay in therapy for more than 2 weeks during the first four cycles of treatment,NA,NA,NA,NA
19633055,NA,939,neutropenia,4,>=4 days,NA,NA
19633055,NA,939,neutropenia associated with fever,4,NA,NA,NA
19633055,NA,939,anemia,3,NA,NA,NA
19633055,NA,939,thrombocytopenia,4,NA,NA,NA
19633055,NA,939,elevation of total bilirubin,4,NA,NA,NA
19633055,NA,939,any other non-hematologic toxicity,3,NA,NA,NA
29936064,NCT01962103,940,a treatment-related AE that led to treatment discontinuatio,NA,NA,NA,NA
29936064,NCT01962103,940,non-haematologic AE,3 or 4,NA,FALSE,NA
29936064,NCT01962103,940,nausea or vomiting despite antiemetic treatment,3 or 4,>5 days,NA,NA
29936064,NCT01962103,940,thrombocytopenia or anaemia,4,>7 days,NA,NA
29936064,NCT01962103,940,thrombocytopenia or anaemia requires transfusion >7 days,4,NA,NA,NA
29936064,NCT01962103,940,thrombocytopenia with bleeding,3,NA,NA,NA
29936064,NCT01962103,940,uncomplicated neutropenia,4,>7 days,NA,NA
29936064,NCT01962103,940,febrile neutropenia with confirmed bacterial infection,NA,NA,NA,NA
29936064,NCT01962103,940,haematologic toxicity delaying treatment >21 days,3,NA,NA,NA
21372602,NA,941,leukopenia,4,NA,NA,NA
21372602,NA,941,febrile neutropenia,3,NA,NA,NA
21372602,NA,941,thrombocytopenia,3,NA,NA,NA
21372602,NA,941,nonhematological toxicity,3,NA,NA,NA
19509578,NA,942,neutropenia,4,>3 days,NA,NA
19509578,NA,942,neutropenia experiencing greater than 38.5-C temperature despite administration of granulocyte colony-stimulating factor,4,NA,NA,NA
19509578,NA,942,thrombocytopenia,4,NA,NA,NA
19509578,NA,942,hepatic toxicity,>=3,NA,NA,NA
19509578,NA,942,nonhematologic toxicities,>=3,NA,FALSE,NA
23349317,NA,943,nonhematologic toxicity,3 or 4,NA,NA,NA
23349317,NA,943,febrile neutropenia,NA,NA,NA,NA
23349317,NA,943,neutropenia,4,>=7 days,NA,NA
23349317,NA,943,thrombocytopenia,4,NA,NA,NA
23349317,NA,943,peripheral neuropathy,2,>7 days,NA,NA
23349317,NA,943,peripheral neuropathy,>=3,NA,NA,NA
23053259,NA,944,any non-hematological toxicity,3 or 4,NA,FALSE,NA
23053259,NA,944,an absolute neutrophil count (ANC)<0.5 x 109/L,NA,>7 days,NA,NA
23053259,NA,944,febrile neutropenia defined as ANC <1.0 x 109/L and fever at least 38.5 C,NA,NA,NA,NA
23053259,NA,944,thrombocytopenia,4,NA,NA,NA
23053259,NA,944,treatment delay for toxicity lasting more than 4 weeks,NA,NA,NA,NA
27595901,"JapicCTI-101,233",945,neutropenia,4,>=5 days,NA,NA
27595901,"JapicCTI-101,233",945,thrombocytopenia,4,NA,NA,NA
27595901,"JapicCTI-101,233",945,non-hematologic toxicities,>=3,NA,NA,NA
19034451,NA,946,neutropenia on retreatment day,3,NA,NA,NA
19034451,NA,946,febrile neutropenia,4,NA,NA,NA
19034451,NA,946,a drug-related non-hematologic toxicity,3 or 4,NA,FALSE,NA
19034451,NA,946,motor or sensory neuropathy,>=2,NA,NA,NA
19034451,NA,946,Treatment delay longer than 2 weeks due to drug-related toxicity and death,NA,NA,NA,NA
24496920,NCT00736619,947,neutropenia (absolute neutrophil count [ANC] < 500/mm3),4,>7 days,NA,NA
24496920,NCT00736619,947,neutropenia accompanied by fever,4,NA,NA,NA
24496920,NCT00736619,947,thrombocytopenia,4,NA,NA,NA
24496920,NCT00736619,947,any other toxicity requiring radiotherapy treatment delay of â‰¥7 calendar days,3,NA,FALSE,NA
24496920,NCT00736619,947,toxicity,3,NA,FALSE,NA
22421191,NA,948,febrile neutropenia,3 or 4,NA,NA,NA
22421191,NA,948,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
22421191,NA,948,neurologic toxicity,3 or 4,NA,NA,NA
22421191,NA,948,nonhematologic toxicities,3 or 4,NA,FALSE,NA
22421191,NA,948,neutropenia,4,>7 days,NA,NA
22421191,NA,948,thrombocytopenia,4,NA,NA,NA
22421191,NA,948,increased liver transaminases,4,NA,NA,NA
28317088,NCT01954355,949,absolute neutrophil count <0.5 Ã— 109/L,NA,â‰¥7 Â± 1 days,NA,NA
28317088,NCT01954355,949,febrile neutropenia,NA,NA,NA,NA
28317088,NCT01954355,949,platelets <25 Ã— 109/L or <50 Ã— 109/L requiring transfusion,NA,NA,NA,NA
28317088,NCT01954355,949,event that persisted despite adequate medical intervention,>=3,NA,NA,NA
28317088,NCT01954355,949,"treatment-related toxicities that resulted in failure to receive â‰¥75% of the planned doses of sonidegib in the first cycle (i.e. â‰¥21 of 28 doses of sonidegib in one 28-day cycle), despite maximal (as judged by the investigator) supportive care measures",NA,NA,NA,NA
28317088,NCT01954355,949,"any adverse event at least possibly related to trial treatment that, regardless of grade, resulted in dose modification of sonidegib",NA,NA,NA,NA
28317088,NCT01954355,949,inability to resume dosing for the subsequent cycle at the current dose level within 14 days due to treatment-related toxicity,NA,NA,NA,NA
18962846,NA,950,neutropenia,4,>7 days,NA,acute dose-limiting toxicity (ADLT)
18962846,NA,950,neutropenia (ANC < 1000/mm3) of any duration associated with fever and requiring antibiotics,3 or 4,NA,NA,acute dose-limiting toxicity (ADLT)
18962846,NA,950,thrombocytopenia,4,NA,NA,acute dose-limiting toxicity (ADLT)
18962846,NA,950,"thrombocytopenia (PLT < 50,000/mm3) in setting of bleeding which required platelet transfusion",3 or 4,NA,NA,acute dose-limiting toxicity (ADLT)
18962846,NA,950,non-hematologic adverse events,3 or 4,NA,FALSE,acute dose-limiting toxicity (ADLT)
18962846,NA,950,gastrointestinal toxicity of any other category,3 or 4,NA,NA,acute dose-limiting toxicity (ADLT)
18962846,NA,950,adverse event with onset greater than 30 days following completion of radiation therapy,3 or 4,NA,NA,Chronic dose-limiting toxicity (CDLT)
27411683,NCT01735409,951,neutropenia,4,> 7 days,NA,NA
27411683,NCT01735409,951,neutropenia with fever (defined as an absolute neutrophil count [ANC] < 1 Ã— 109/L with a body temperature of â‰¥ 38.3 Â°C),NA,NA,NA,NA
27411683,NCT01735409,951,thrombocytopenia,4,NA,NA,NA
27411683,NCT01735409,951,thrombocytopenia with hemorrhage,3,NA,NA,NA
27411683,NCT01735409,951,neuropathy,>=3,NA,NA,NA
27411683,NCT01735409,951,any other non-hematologic toxicity that did not resolve following symptomatic treatment,>=3,NA,NA,NA
25537644,NCT01042925,952,an adverse event (AE) that in the opinion of the investigator warranted a dose reduction or that in the opinion of the Cohort Review Committee (CRC) was of potential clinical significance such that further dose escalation would expose patients to unacceptable risk,NA,NA,NA,NA
25537644,NCT01042925,952,non-hematologic toxicity despite optimal prophylaxis or not easily managed using medical intervention,3 or 4,NA,NA,NA
25537644,NCT01042925,952,neutropenia,4,>=7 days,NA,NA
25537644,NCT01042925,952,febrile neutropenia,3,>=24 h,NA,NA
25537644,NCT01042925,952,febrile neutropenia,4,NA,NA,NA
25537644,NCT01042925,952,thrombocytopenia of any duration,4,NA,NA,NA
25537644,NCT01042925,952,"recurrent hyperglycemia despite oral hypoglycemic treatment (e.g., metformin) at standard doses",3-Feb,NA,NA,NA
25537644,NCT01042925,952,patient unable to take >=75 % of planned pilaralisib doses in Cycle 1 because of an AE related to pilaralisib,NA,NA,NA,NA
25537644,NCT01042925,952,patient unable to receive two out of three paclitaxel infusions in Cycle 1 because of an AE related to paclitaxel,NA,NA,NA,NA
31792036,NCT02810418,954,nonhematologic toxicity,>=3,NA,FALSE,NA
31792036,NCT02810418,954,specified severe hematologic toxicities,>=3,NA,NA,NA
26112004,NCT01491217,955,NA,NA,NA,NA,DLT not defined
24013936,NA,956,"thrombocytopenia (platelet count<25,000/mm3)",4,NA,NA,NA
24013936,NA,956,"thrombocytopenia (platelet count 25,000 - 49,999/mm3) associated with bleeding, requirement for transfusion",3,NA,NA,NA
24013936,NA,956,febrile neutropenia,3,NA,NA,NA
24013936,NA,956,neutropenia (ANC <1.0 x 109) with documented infection,3,NA,NA,NA
24013936,NA,956,nonhematologic toxicity that was clinically significant and considered by the investigator to be related to study drug,>=3,NA,FALSE,NA
29844129,NCT01649336,957,the inability to administer at least 75% of planned binimetinib doses and all three doses of paclitaxel in cycle 1 due to related adverse events (AE),NA,NA,NA,NA
29844129,NCT01649336,957,a decrease in left ventricular ejection fraction (LVEF) of >10% from baseline and below the institution's lower limit of normal,NA,NA,NA,NA
29844129,NCT01649336,957,alkaline phosphatase elevation,4,NA,NA,NA
29844129,NCT01649336,957,persistent hypertension despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,fatigue (if >=grade 2 increase from baseline) despite conservative management,NA,NA,NA,NA
29844129,NCT01649336,957,rash despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,diarrhea despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,nausea/vomiting despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,pancreatitis despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,aspartate transaminase/alanine transaminase (AST/ALT) or bilirubin elevation despite conservative management,>=3,NA,NA,NA
29844129,NCT01649336,957,thrombocytopenia with signs of bleeding,>=3,NA,NA,NA
29844129,NCT01649336,957,thrombocytopenia,4,NA,NA,NA
29844129,NCT01649336,957,creatinine elevation,>=3,NA,NA,NA
29844129,NCT01649336,957,electrocardiogram QTc prolongation,>=3,NA,NA,NA
29844129,NCT01649336,957,"eye disorders, creatine kinase (CK) elevation with an associated >=grade 2 increase in creatinine",>=3,NA,NA,NA
29844129,NCT01649336,957,any other clinically significant AE,>=3,NA,FALSE,NA
22203732,NA,958,nonhematologic toxicity,3 or 4,NA,NA,NA
22203732,NA,958,febrile neutropenia,NA,NA,NA,NA
22203732,NA,958,neutropenia,4,>=7 days,NA,NA
22203732,NA,958,thrombocytopenia,4,NA,NA,NA
22203732,NA,958,peripheral neuropathy,2,>=7 days,NA,NA
22203732,NA,958,peripheral neuropathy,3,NA,NA,NA
25103625,NA,959,febrile neutropenia,>=3,NA,NA,NA
25103625,NA,959,neutropenia,>=4,>7 days,NA,NA
25103625,NA,959,thrombocytopenia,>=4,NA,NA,NA
25103625,NA,959,anemia,>=4,NA,NA,NA
25103625,NA,959,any non-hematologic event that requiredreduction or delay beyond 1 week,>=2,NA,NA,NA
25688104,NCT01263145,960,nonhematologic toxicity,3 or 4,NA,NA,NA
25688104,NCT01263145,960,rash or hyperglycemia,3 or 4,>72 h,NA,NA
25688104,NCT01263145,960,febrile neutropenia that required hospitalization,4,NA,NA,NA
25688104,NCT01263145,960,hematologic toxicity that required treatment delay beyond two weeks,3,NA,NA,NA
30016392,NCT02193633,961,NA,NA,NA,NA,DLT not defined
15865080,NA,962,leukopenia (neutropenia),4,>4 days,NA,NA
15865080,NA,962,thrombocytopenia,4,NA,NA,NA
15865080,NA,962,leukopenia with fever >38 C,>=3,NA,NA,NA
15865080,NA,962,schedule delay of longer than 14 days,NA,NA,NA,NA
15865080,NA,962,non-hematological toxicity,>=3,NA,FALSE,NA
11474274,NA,963,any delay of paclitaxel administration because of unresolved hematologic or nonhematologic toxicity;,NA,NA,NA,NA
11474274,NA,963,neutropenia,4,NA,NA,NA
11474274,NA,963,thrombocytopenia,4,NA,NA,NA
11474274,NA,963,febrile neutropenia (.38.2Â°C for more than 3 days),NA,NA,NA,NA
11474274,NA,963,nonhematologic toxicity,>=3,NA,FALSE,NA
17668866,NA,964,"non-hematologic, non-resolving paclitaxel-related adverse event",3,NA,NA,NA
17668866,NA,964,non-hematologic paclitaxel-related adverse event,4,NA,NA,NA
11345652,NA,965,granulocytopenia,4,>5 days,NA,NA
11345652,NA,965,thrombocytopenia,4,NA,NA,NA
11345652,NA,965,non-hematological toxicity,3 or 4,NA,FALSE,NA
18682950,NA,966,hematologic toxicity,4,>7 days,NA,NA
18682950,NA,966,febrile neutropenia,4,NA,NA,NA
18682950,NA,966,drug-related nonhematologic toxicity,3 or 4,NA,NA,NA
15297186,NA,967,any toxicity attributed to Adp53,4,NA,NA,NA
16533873,NA,968,non-hematologic toxicities,>=2,NA,FALSE,NA
16533873,NA,968,"nausea, vomiting, or skin reactions",4,NA,NA,NA
16533873,NA,968,neutropenia,4,NA,NA,NA
16533873,NA,968,neutropenia associated with complications (e.g. neutropenic fever),3,NA,NA,NA
16533873,NA,968,thrombocytopenia,4,NA,NA,NA
16533873,NA,968,toxicity-related discontinuation of treatment for more than 1 week during the first two treatment cycles,NA,NA,NA,NA
12827291,NA,969,ANC <0.5 x 109/l associated with fever or infection of grade 2 or more,NA,NA,NA,NA
12827291,NA,969,ANC <0.5 x 109/l,NA,>7 days,NA,NA
12827291,NA,969,platelet count <25 x 109/l,NA,NA,NA,NA
12827291,NA,969,treatment-related non-haematological toxicity,3 or 4,NA,FALSE,NA
12827291,NA,969,treatment delay of more than 3 weeks due to unresolved toxicity,NA,NA,NA,NA
16626792,NA,970,neuropathy,>=2,NA,NA,NA
16626792,NA,970,abdominal pain,>=2,NA,NA,NA
16626792,NA,970,hematologic toxicity,>=3,NA,NA,NA
16626792,NA,970,non-hematologic toxicity,>=3,NA,NA,NA
12401907,NA,971,absolute neutrophil count (ANC) nadir <500/Âµl,NA,>5 days,NA,NA
12401907,NA,971,absolute neutrophil count (ANC) nadir <500/Âµl resulting in hospitalization for treatment of neutropenia and fever,NA,NA,NA,NA
12401907,NA,971,"platelet nadir <50,000/Âµl",NA,>4 days,NA,NA
12401907,NA,971,documented bleeding episode associated with thrombocytopenia or requirement for platelet transfusion,NA,NA,NA,NA
12401907,NA,971,nonhematologic toxicity due to treatment,3 or 4,NA,FALSE,NA
12768320,NA,972,non-hematologic toxicities,3 or 4,NA,FALSE,NA
12768320,NA,972,"hematologic toxicity occurring during treatment, or within 1 week of treatment completion",4,>7 days,NA,NA
12768320,NA,972,omission or delay for toxicity of two or more doses in a cycle because of toxicity,NA,NA,NA,NA
12768320,NA,972,delay in a cycleâ€™s initiation beyond the mandated 2 weeks because of toxicity,NA,NA,NA,NA
14566475,NA,973,toxicity,4,NA,NA,NA
14566475,NA,973,toxicity requiring treatment interruption or unplanned hospitalization,3,NA,NA,NA
14566475,NA,973,neurologic toxicity,3,NA,NA,NA
12140142,NA,974,esophagitis/acute pulmonary toxicity,>=3,NA,NA,NA
12140142,NA,974,any other non-hematologic toxicity,>=3,NA,FALSE,NA
12140142,NA,974,neutropenia,4,>5 day,NA,NA
12140142,NA,974,neutropenic fever (absolute neutrophil count <1000 per ul and fever of >=38.5 8C),NA,NA,NA,NA
12140142,NA,974,thrombocytopenia,4,NA,NA,NA
11710824,NA,975,neutropenia,4,>=5 days,NA,NA
11710824,NA,975,neutropenia complicated with fever requiring hospitalisation,4,NA,NA,NA
11710824,NA,975,thrombocytopenia,4,NA,NA,NA
11710824,NA,975,non-haematological toxicity,>=3,NA,FALSE,NA
11710824,NA,975,Treatment delay of more than 2 weeks due to toxicity,NA,NA,NA,NA
15216957,NA,976,toxicity,4,NA,NA,NA
15216957,NA,976,radiation  mucositisand/or dermatitis  requiring  a  radiation  treatmentbreak  longer  than  2  weeks.,3,NA,NA,NA
11603001,NA,977,NA,NA,NA,NA,DLT not defined
17021821,NA,978,neutropenia,4,>=7 days,NA,NA
17021821,NA,978,"Febrile neutropenia (single elevation in oral temperature to 38.5Â°C or three elevations to >38Â°C during a 24 h period concomitant with grade 4 neutropenia, according to Pizzoâ€™s deWnition)",NA,NA,NA,NA
17021821,NA,978,Neutropenic infection defined as grade 3 or 4 infection concomitant with grade >=3 neutropenia,NA,NA,NA,NA
17021821,NA,978,thrombocytopenia,3,NA,NA,NA
17021821,NA,978,non-haematological toxicity,>=3,NA,FALSE,NA
17021821,NA,978,Delays in oral VRL administration beyond day 15 of cycle 1 or delay of 1 week or more in the day 1 administration of cycle 2,NA,NA,NA,NA
16891865,NA,979,esophagitis,3,NA,NA,NA
16891865,NA,979,enteritis,3,NA,NA,NA
16891865,NA,979,gastritis,3,NA,NA,NA
16891865,NA,979,nausea (despite maximal antinausea treatment),3,NA,NA,NA
16891865,NA,979,dehydration,3,NA,NA,NA
16891865,NA,979,any other nonhematologic toxicity,3 or 4,NA,NA,NA
16891865,NA,979,neutropenia,4,>=1 week,NA,NA
16891865,NA,979,thrombocytopenia,4,>=1 week,NA,NA
18414864,NA,980,neutropenia,4,>=5 days,NA,NA
18414864,NA,980,neutropenia complicated by fever (>38.5Â°C) or infection,NA,NA,NA,NA
18414864,NA,980,thrombocytopenia,4,NA,NA,NA
18414864,NA,980,thrombocytopenia,3,>=5 days,NA,NA
18414864,NA,980,thrombocytopenia associated with bleeding,3,NA,NA,NA
18414864,NA,980,hemorrhage,2,NA,NA,NA
18414864,NA,980,non-hematological toxicity,>=3,NA,FALSE,NA
18414864,NA,980,hemorrhage or neurologic toxicities,2,NA,NA,NA
18414864,NA,980,any toxicity causing a delay of >14 days in cycle 1.,NA,NA,NA,NA
12006516,NA,981,toxic effect,3 or 4,NA,NA,NA
12231518,NA,982,neutropenia,4,>=5 consecutive days,NA,NA
12231518,NA,982,neutropenia associated with fever 38Â°C,4,NA,NA,NA
12231518,NA,982,thrombocytopenia,4,NA,NA,NA
12231518,NA,982,a bleeding episode requiring platelet transfusion,NA,NA,NA,NA
12231518,NA,982,nausea and/or emesis despite use of maximal antiemetics,>=3,NA,NA,NA
12231518,NA,982,neurosensory toxicity,>=3,NA,NA,NA
12231518,NA,982,"cardiac, pulmonary, or other neurotoxicity",>=2,NA,NA,NA
12231518,NA,982,nonhematological toxicity,>=3,NA,FALSE,NA
12231518,NA,982,Failure to recover from treatment-related toxicities to baseline or grade 1 by day 42,NA,NA,NA,NA
12231518,NA,982,severe hypersensitivity reactions despite adequate premedication was deemed to impact on the safe administration of the drug,NA,NA,NA,NA
16258082,NA,983,nonhematologic toxicity,3 or 4,NA,NA,NA
16258082,NA,983,hematologic toxicity,4,NA,NA,NA
12460783,NA,984,neutropenia,4,>=5 days,NA,NA
12460783,NA,984,febrile neutropenia,NA,NA,NA,NA
12460783,NA,984,thrombocytopenia,4,NA,NA,NA
12460783,NA,984,non-haematological toxicity,>=3,NA,FALSE,NA
12176795,NA,985,neutropenia,4,>7 days,NA,NA
12176795,NA,985,thrombocytopenia,4,NA,NA,NA
12176795,NA,985,febrile neutropenia defined as grade 2 fever with grade 4 neutropenia,NA,NA,NA,NA
12176795,NA,985,non-hematological toxicity,3 or 4,NA,FALSE,NA
16248762,NA,986,reversible neutropenia,4,NA,NA,NA
16248762,NA,986,reversible thrombocytopenia,4,NA,NA,NA
16248762,NA,986,irreversible neutropenia or thrombocytopenia,>=3,NA,NA,NA
16248762,NA,986,nonhematologic  toxicity,>=2,NA,FALSE,NA
12110496,NA,989,leucocytopenia with infection or fever requiring parenteral antibiotics,3 or 4,NA,NA,NA
12110496,NA,989,thrombocytopenia requiring 2 or more platelet transfusions,3 or 4,NA,NA,NA
12110496,NA,989,thrombocytopenia resulting in >= grade 2 haemorrhage,3 or 4,NA,NA,NA
12110496,NA,989,non-haematological toxicity,>=3,NA,FALSE,NA
17452427,NA,990,leukopenia,4,NA,NA,NA
17452427,NA,990,neutropenia,4,>=7 days,NA,NA
17452427,NA,990,febrile neutropenia,NA,NA,NA,NA
17452427,NA,990,platelet count <20 x 109/L,NA,NA,NA,NA
17452427,NA,990,non-hematological toxicity,>=3,NA,FALSE,NA
17452427,NA,990,treatment termination before two cycles of chemotherapy and thoracic radiotherapy were completed,NA,NA,NA,NA
17589845,NA,991,leukopenia,4,>=3 days,NA,NA
17589845,NA,991,neutropenia,4,>=3 days,NA,NA
17589845,NA,991,"a platelet count less than 20,000 ul-1",NA,NA,NA,NA
17589845,NA,991,febrile neutropenia,3,NA,NA,NA
17589845,NA,991,nonhematologic toxicity,3,NA,FALSE,NA
17589845,NA,991,a serum creatinine level greater than 2.0 mg dl-1,NA,NA,NA,NA
17589845,NA,991,the next chemotherapy administration being withheld for more than 2 weeks,NA,NA,NA,NA
15711828,NA,992,neutropenia,4,>7 days,NA,NA
15711828,NA,992,febrile neutropenia defined as fever (temperature >=38.6C) of unknown origin while the absolute neutrophil count (ANC) was <1000 mm-3,NA,NA,NA,NA
15711828,NA,992,"platelet count <25,000 mm-3",NA,NA,NA,NA
15711828,NA,992,any nonhematologic toxicity related to study treatment,>=3,NA,FALSE,NA
15711828,NA,992,any drug-related death,NA,NA,NA,NA
17519083,NA,993,non-haematological toxicities,3,NA,FALSE,NA
17519083,NA,993,haematological toxicities,3,NA,FALSE,NA
14701767,NA,994,a toxicity-related treatment break greater than 2 weeks,NA,NA,FALSE,NA
16537186,NA,995,neutropenic  feverrequiring hospitalization and intravenous antibiotics,NA,NA,NA,NA
16537186,NA,995,thrombocytopenia requiring transfusion,4,NA,NA,NA
16537186,NA,995,mucositis requiring total parenteral nutrition or hospitalization,4,NA,NA,NA
16537186,NA,995,side effects requiring a delay in resumption of chemoradiation by more than one week,NA,NA,NA,NA
17091249,NA,996,"non-hematologic toxicity, despite the subjects having received optimal medical therapy",3 or 4,NA,FALSE,NA
17091249,NA,996,Febrile neutropenia,NA,NA,NA,"defined as a fever of unknown origin or microbiologically documented infection and
having an absolute neutrophil count of <1,000 cells/mm3, and an oral or tympanic temperature of at least 38.5C"
17091249,NA,996,thrombocytopenia,4,NA,NA,NA
17091249,NA,996,hematologic toxicity,4,>5 days,NA,NA
17091249,NA,996,hemorrhage,>=2,NA,NA,NA
17091249,NA,996,neurotoxicity,>=2,>= five consecutive days,NA,NA
17091249,NA,996,neurosensory toxicity,>=3,NA,NA,NA
17510207,NA,997,neutropenia,4,>5 days,NA,NA
17510207,NA,997,febrile neutropenia,NA,NA,NA,NA
17510207,NA,997,"platelet count <25,000 cells/mm3 or platelet count <50,000 cells/mm3 associated with bleeding that required platelet transfusion",NA,NA,NA,NA
17510207,NA,997,peripheral neuropathy,>=2,NA,NA,NA
17510207,NA,997,nonhematologic toxicity,>=3,NA,FALSE,NA
17510207,NA,997,toxicity-induced treatment delays of more than 1 week,NA,NA,NA,NA
17510207,NA,997,QTc prolongations to >500 msec during the 24-h period postdosing,NA,NA,NA,NA
17510207,NA,997,any clinically significant arrhythmia occurring during the 24-h period postdosing,NA,NA,NA,NA
16551860,NA,998,neutropenia,4,>=5 consecutive days,NA,NA
16551860,NA,998,febrile neutropenia,NA,NA,NA,NA
16551860,NA,998,thrombocytopenia,4,NA,NA,NA
16551860,NA,998,thrombocytopenia with a bleeding episode requiring platelet transfusion,3,NA,NA,NA
16551860,NA,998,nonhematologic toxicity,>=3,NA,FALSE,NA
16551860,NA,998,retreatment delay of >1 week due to drug-related toxicity,NA,NA,NA,NA
16551860,NA,998,QTc interval >500 ms,NA,NA,NA,NA
16551860,NA,998,any clinically significant arrhythmia within 24 hours following drug administration,4,NA,NA,NA
16551860,NA,998,dose reduction or omission due to any drug-related toxicity before completion of the first cycle,NA,NA,NA,NA
15026799,NA,203,febrile neutropenia (fever >=381C with >=grade 3 neutropenia),NA,NA,NA,NA
15026799,NA,203,neutropenia despite receiving rhG-CSF,4,>=4 days,NA,NA
15026799,NA,203,thrombocytopenia,4,NA,NA,NA
15026799,NA,203,any other nonhaematologic toxicity,3 or 4,NA,FALSE,NA
15026799,NA,203,"failure to recover from toxicities sufficiently to begin a second course of treatment by day 43, and omission of chemotherapy on day 8 and/or 15 because of toxities",NA,NA,NA,NA
18235124,NA,204,treatment-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
18235124,NA,204,treatment-related hematologic toxicity,4,NA,NA,NA
18235124,NA,204,treatment-related hematologic toxicity requiring treatment delay of more than 2 weeks,3,NA,NA,NA
15596915,NA,205,absolute neutrophile count (ANC) less than 0.5 x 109/L,NA,>7 days,NA,NA
15596915,NA,205,absolute neutrophile count (ANC) less than 0.1 x 109/L,NA,>3 days,NA,NA
15596915,NA,205,"febrile neutropenia (eg, a temperature of at least 38.5Â°C and a count of ANC less than 0.5 x 109/L requiring intravenous antibiotics",NA,NA,NA,NA
15596915,NA,205,thrombocytopenia requiring platelet transfusion,4,NA,NA,NA
15596915,NA,205,mucositis,4,>7 days,NA,NA
15596915,NA,205,mucositis,3,>3 weeks,NA,NA
15596915,NA,205,dermatitis,4,NA,NA,NA
15596915,NA,205,dermatitis,3,>3 weeks,NA,NA
15596915,NA,205,nonhematologic toxicity,>3,NA,FALSE,NA
15596915,NA,205,radiation-induced toxicity resulting in delay of radiation therapy for more than 7 days,NA,NA,NA,NA
16889823,NA,206,toxicity within 30 days of treatment,4,NA,NA,NA
16889823,NA,206,the occurrence of a toxicity that caused a dose delay/modification/reduction in any of the six planned cycles,NA,NA,NA,NA
15010068,NA,207,neutropenia,4,>7 days,NA,NA
15010068,NA,207,haematological toxicity,4,NA,FALSE,NA
15010068,NA,207,febrile neutropenia,NA,NA,NA,NA
15010068,NA,207,non-haematological toxicities,>=3,NA,NA,NA
15010068,NA,207,severe hypersensitivity reaction suggestive of an anaphylactic reaction,NA,NA,NA,NA
15010068,NA,207,receiving less than 70% of the intended cumulative dose of LEP,NA,NA,NA,NA
33928486,NCT02613221,208,non-haematological toxicities,>=3,NA,FALSE,NA
33928486,NCT02613221,208,neutrophil count decreased,4,>7 days,NA,NA
33928486,NCT02613221,208,febrile neutropenia,>=3,NA,NA,NA
33928486,NCT02613221,208,thrombocytopenia,4,NA,NA,NA
33928486,NCT02613221,208,unresolved toxicities leading to a>2-week delay until the next cycle,NA,NA,NA,NA
15127231,NA,209,hematologic toxicity,4,NA,NA,NA
15127231,NA,209,nonhematologic toxicity,3 or 4,>3 days,FALSE,NA
15613553,NA,210,non-hematological toxicity,3 or 4,NA,FALSE,NA
15613553,NA,210,neutropenia,4,NA,NA,NA
15613553,NA,210,thrombocytopenia,3 or 4,NA,NA,NA
15613553,NA,210,esophagitis or pneumonitis,3 or 4,NA,NA,NA
31164456,NCT02352571,211,neutropenia,4,>=7 days,NA,NA
31164456,NCT02352571,211,neutropenia with fever or infection,3,NA,NA,NA
31164456,NCT02352571,211,thrombocytopenia,4,NA,NA,NA
31164456,NCT02352571,211,thrombocytopenia,3,>=7 days,NA,NA
31164456,NCT02352571,211,thrombocytopenia with bleeding or requiring platelet transfusion,3,NA,NA,NA
31164456,NCT02352571,211,nausea/vomiting or diarrhea despite optimal use of antiemetics or antidiarrheal drugs,3 or 4,NA,NA,NA
31164456,NCT02352571,211,skin rash despite optimal use of skin care,3 or 4,NA,NA,NA
31164456,NCT02352571,211,other nonhematological toxicity,3 or 4,NA,FALSE,NA
31164456,NCT02352571,211,delay of >2 weeks in next cycle administration because of inadequate recovery from toxicity,NA,NA,NA,NA
23054206,NCT00692159,212,nonhematologic adverse event,3,NA,NA,NA
23054206,NCT00692159,212,anemia,3,NA,NA,NA
23054206,NCT00692159,212,thrombocytopenia,4,NA,NA,NA
23054206,NCT00692159,212,febrile neutropenia,4,NA,NA,NA
23054206,NCT00692159,212,neutropenia,4,>=5 days,NA,NA
26386124,ACTRN12609000294257,213,"treatment-related non-haematologic adverse event, despite optimal supportive care",3 or 4,NA,NA,NA
26386124,ACTRN12609000294257,213,haematologic adverse events that did not recover to grade 1 or baseline,3,NA,NA,NA
26386124,ACTRN12609000294257,213,lymphopenia if complicated by infection,4,NA,NA,NA
26386124,ACTRN12609000294257,213,other haematologic adverse event,4,NA,NA,NA
26386124,ACTRN12609000294257,213,CRS/acute infusion reaction,>=3,NA,NA,NA
21989766,NCT00528619,214,neutropenia with infection,3,NA,NA,NA
21989766,NCT00528619,214,neutropenia,4,>=7 days,NA,NA
21989766,NCT00528619,214,febrile neutropenia,4,>24 h,NA,NA
21989766,NCT00528619,214,thrombocytopenia,4,>=7 days,NA,NA
21989766,NCT00528619,214,thrombocytopenia with bleeding,>=3,NA,NA,NA
21989766,NCT00528619,214,any non-hematologic toxicity,3 or 4,>=7 days,NA,NA
21989766,NCT00528619,214,any non-hematologic toxicity resulted in a delay in administration of cycle 2 as scheduled,3 or 4,NA,NA,NA
10501910,NA,215,NA,NA,NA,NA,DLT not defined
22658814,NA,216,nonhematologic toxicity,3 or 4,NA,FALSE,NA
22658814,NA,216,drug-related neutropenia,4,>=7 days,NA,NA
22658814,NA,216,drug-related neutropenia complicated by infection,4,NA,NA,NA
22658814,NA,216,drug-related neutropenia complicated by infection,4,>=7 days,NA,NA
22658814,NA,216,thrombocytopenia,4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,hematological toxicity,3 or 4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,febrile neutropenia,3 or 4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,esophagitis,3 or 4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,pneumonitis,3 or 4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,"persistent elevation of creatinine bilirubin and transaminase resulting in preventing treatment, or dosing delay because of toxicity (radiation therapy was delayed by a week or more; the following chemotherapy was delayed by 2 weeks or more, while consolidation therapy was delayed by 4 weeks or more after radiotherapy completion)",3 or 4,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,late bronchopulmonary,>=3,NA,NA,NA
27717315,ChiCTR-OPN-16008316,217,late esophageal toxicities,>=3,NA,NA,NA
17145830,NA,218,neutropenia,4,>=5 days,NA,NA
17145830,NA,218,febrile neutropenia,NA,NA,NA,NA
17145830,NA,218,thrombocytopenia,4,NA,NA,NA
17145830,NA,218,thrombocytopenia with bleeding requiring platelet transfusion,3,NA,NA,NA
17145830,NA,218,nonhematologic toxicity,>=3,NA,FALSE,NA
16940981,NA,219,nonhematologic toxicity,3 or 4,NA,FALSE,NA
16940981,NA,219,febrile neutropenia (<1000 mm-3 with >=38.0C),3 or 4,>=4 days,NA,NA
16940981,NA,219,leucopenia,4,>=4 days,NA,NA
16940981,NA,219,neutropenia,4,NA,NA,NA
16940981,NA,219,thrombocytopenia,4,NA,NA,NA
16940981,NA,219,thrombocytopenia (>=20 000 mm-3) requiring platelet transfusion,NA,NA,NA,NA
16940981,NA,219,A failure to start the second cycle by day 42 owing to toxicity,NA,NA,NA,NA
20091088,NA,220,AST/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic pyruvic transaminase (SGPT) of any duration,4,NA,NA,NA
20091088,NA,220,all other clinically significant non-hematologic AEs,3 or 4,NA,NA,NA
34724131,NCT04012619,221,hematological toxicity,>=4,NA,NA,NA
34724131,NCT04012619,221,non-hematological toxicity,>=3,NA,NA,NA
34724131,NCT04012619,221,liver and kidney function injury,>=2,NA,NA,NA
30382439,NA,222,absolute neutrophil count,4,>5 days,NA,NA
30382439,NA,222,thrombocytopenia,4,NA,NA,NA
30382439,NA,222,nonhematologic toxicity,>=3,NA,NA,NA
30382439,NA,222,"nausea, vomiting, or diarrhea in spite of maximal supportive treatment(s)",3,NA,NA,NA
30382439,NA,222,Any toxicity causing dose delays of greater than 2 weeks of the intended next dose,NA,NA,NA,NA
25920360,NCT01985295,223,skin toxicity during and/or after preopRT until day of surgery,>=3,NA,NA,DLT-I
25920360,NCT01985295,223,unexpectedly  neutrope-nia (ANC <0.5 x10 9/L),NA,>7 dyas,NA,DLT-I
25920360,NCT01985295,223,"neutropenic fever ANC  <1.0 x 10 9/L,  fever >=38.5 Â°C)",NA,NA,NA,DLT-I
25920360,NCT01985295,223,"a secondary operation under general or regional anesthesia for wound repair (debridement,  operative drainage, and secondary wound closure including rotationplasty, free flaps, or skingrafts)",NA,NA,NA,DLT-II
25920360,NCT01985295,223,"wound management without secondary operation, including invasive procedures without anesthesia (mainly seroma aspiration),  readmission for wound  care like intravenous antibiotics, or persistent deep packing for 120 days or longer",NA,NA,NA,DLT-II
31186313,NCT01438554,224,NA,NA,NA,NA,DLT not defined
15923057,NA,225,AGC <0.5 Ã— 109/L,4,>5 days,NA,NA
15923057,NA,225,febrile neutropenia,NA,NA,NA,NA
15923057,NA,225,thrombocytopenia,4,NA,NA,NA
15923057,NA,225,non-hematologic toxicity,>=3,NA,FALSE,NA
31506897,NCT01591421,226,"the second patient with persistent grade 2 rash despite optimal treatment, leading to an interruption in therapy for >14 days",NA,NA,NA,NA
31506897,NCT01591421,226,rash,>=3,NA,NA,NA
31506897,NCT01591421,226,the second patient with grade 3 mood alteration (or grade 2 interrupting therapy >2 weeks),NA,NA,NA,NA
31506897,NCT01591421,226,the second patient with > grade 3 hyperglycemia,NA,NA,NA,NA
31506897,NCT01591421,226,the second patient with other grade 3 or worse nonhematologic toxicity,NA,NA,FALSE,NA
31506897,NCT01591421,226,unexpected drug related toxicity,3 or 4,NA,NA,NA
31506897,NCT01591421,226,the inability to administer 75% of the planned dose of BKM120 due to BKM120 related toxicity,NA,NA,NA,NA
31506897,NCT01591421,226,the inability to administer cycle 2 treatment within 14 days of the planned dose (i.e. cycle 2 treatment delayed by more than 2 weeks) due to persisting > grade 2 drug related toxicity or discontinuation due to grade 4 drug related toxicity,NA,NA,NA,NA
31065954,NCT01868022,227,neutropenia,4,>7 days,NA,NA
31065954,NCT01868022,227,febrile neutropenia,4,NA,NA,NA
31065954,NCT01868022,227,thrombocytopenia,4,NA,NA,NA
31065954,NCT01868022,227,clinically significant laboratory abnormalities,4,>48 h,NA,NA
31065954,NCT01868022,227,clinically significant non-hematologic toxicity,>=3,NA,FALSE,NA
31065954,NCT01868022,227,toxicity occurring within or beyond the 21-day period which in the judgment of the investigator and GSK medical monitor is considered a DLT,2,NA,NA,NA
31065954,NCT01868022,227,Treatment delay of â‰¥ 14 days due to unresolved study drug-related toxicity,NA,NA,NA,NA
34740922,NCT02535325,228,NA,NA,NA,NA,DLT not defined
33933896,NCT02964689,229,Absolute decrease of LVEF > 10% compared to baseline and the LVEF is below the institutionâ€™s LLN,NA,NA,NA,NA
33933896,NCT02964689,229,Left ventricular systolic dysfunction,>=3,NA,NA,NA
33933896,NCT02964689,229,Cardiac disorders,>=3,NA,NA,NA
33933896,NCT02964689,229,Hypertension,3,> 14 consecutive days,NA,NA
33933896,NCT02964689,229,Hypertension,4,NA,NA,NA
33933896,NCT02964689,229,Fatigue,3,> 14 consecutive days,NA,NA
33933896,NCT02964689,229,Rash acneiform/Rash maculo-papular or Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome) or Photosensitivity for > 14 consecutive days despite maximal skin toxicity treatment (as per local practice),3,NA,NA,NA
33933896,NCT02964689,229,Rash acneiform or Photosensitivity,4,NA,NA,NA
33933896,NCT02964689,229,Diarrhea despite optimal use of antidiarrheal therapy (and is considered related to binimetinib),3,>=5 days,NA,NA
33933896,NCT02964689,229,Diarrhea,4,NA,NA,NA
33933896,NCT02964689,229,Nausea or Vomiting that does not improve to at least G1 within 1 week despite optimal use of antiemetic therapy (and is considered related to binimetinib),3,NA,NA,NA
33933896,NCT02964689,229,Nausea or Vomiting,4,NA,NA,NA
33933896,NCT02964689,229,Blood bilirubin increased,>=3,NA,NA,NA
33933896,NCT02964689,229,AST or ALT in conjunction with  â‰¥ G2 Blood bilirubin increased of any duration,>=3,NA,NA,NA
33933896,NCT02964689,229,AST or ALT,3,> 7 consecutive days,NA,NA
33933896,NCT02964689,229,AST or ALT,4,NA,NA,NA
33933896,NCT02964689,229,Creatinine increased,>=3,NA,NA,NA
33933896,NCT02964689,229,CPK increase associated with an increase in creatinine â‰¥ 1.5x the patientâ€™s baseline creatinine,>=3,NA,NA,NA
33933896,NCT02964689,229,Neutrophil count decreased,4,> 7 consecutive days,NA,NA
33933896,NCT02964689,229,Platelet count decreased with signs of clinically significant bleeding,3,NA,NA,NA
33933896,NCT02964689,229,Platelet count decreased,4,NA,NA,NA
33933896,NCT02964689,229,"Electrocardiogram QT corrected interval prolonged, on at least two separate ECGs",>=3,NA,NA,NA
33933896,NCT02964689,229,"Retinopathy or Retinal detachment, confirmed by ophthalmic examination",>=3,NA,NA,NA
33933896,NCT02964689,229,"Retinal vascular disorder including retinal vein occlusion (RVO), confirmed by ophthalmic examination",NA,NA,NA,NA
33933896,NCT02964689,229,Blurred vision or Flashing lights or Floaters (i.e. visual disturbances without ocular/retinal changes),>=3,NA,NA,NA
33933896,NCT02964689,229,other eye disorders,>=3,> 21 consecutive days,NA,NA
33933896,NCT02964689,229,other eye disorders confirmed by ophthalmic examination,4,NA,NA,NA
33933896,NCT02964689,229,Other hematologic and non-hematologic toxicities,>=3,NA,FALSE,NA
33933896,NCT02964689,229,Any cumulative (> 3 weeks) AE that is considered dose-limiting in the opinion of the treating investigator and after careful consideration with involved parties,>=2,NA,NA,NA
10506594,NA,230,neutropenia,4,>5 days,NA,NA
10506594,NA,230,febrile neutropenia,NA,NA,NA,NA
10506594,NA,230,thrombocytopenia,4,NA,NA,NA
10506594,NA,230,nonhematologic toxicity,>=3,NA,FALSE,NA
34180036,NCT01468922,231,non-hematologic toxicity,>=3,NA,FALSE,NA
34180036,NCT01468922,231,neutropenia,4,â‰¥3 days,FALSE,NA
34180036,NCT01468922,231,febrile neutropenia,NA,NA,NA,NA
34180036,NCT01468922,231,thrombocytopenia,4,NA,NA,NA
34180036,NCT01468922,231,QTc prolongation to â‰¥ 500 ms on at least two separate EKGs,NA,NA,NA,NA
34180036,NCT01468922,231,a â‰¥ 2-week delay in starting the next cycle due to toxicity,NA,NA,NA,NA
34180036,NCT01468922,231,"a signifcant elevation in liver test, defned as AST or ALT >8Ã— ULN or AST or ALT >3Ã—ULN with concurrent bilirubin elevation >2Ã—ULN",NA,NA,NA,NA
34180036,NCT01468922,231,bleeding in any site,>=3,NA,NA,NA
34180036,NCT01468922,231,pulmonary hemorrhage,>=2,NA,NA,NA
34180036,NCT01468922,231,"venous thrombosis, pulmonary embolism, or any grade of arterial thrombosis",4,NA,NA,NA
29081023,Eudract no. 2014â€“002415-41,232,neutropenia (absolute neutrophil count <0.5 Ã— 109 for â‰¥7 days or <0.1 Ã— 109 for â‰¥3 days),>=4,NA,NA,NA
29081023,Eudract no. 2014â€“002415-41,232,febrile neutropenia,>=3,NA,NA,(absolute neutrophil count <1.0 Ã— 109 and temperature â‰¥ 38.5 Â°C)
29081023,Eudract no. 2014â€“002415-41,232,platelet count <25 Ã— 109/L,NA,NA,NA,NA
29081023,Eudract no. 2014â€“002415-41,232,thrombocytopenia with bleeding or requiring platelet transfusion,NA,NA,NA,NA
29081023,Eudract no. 2014â€“002415-41,232,liver toxicity (ALAT/ASAT),>=3,>7 days,NA,NA
29081023,Eudract no. 2014â€“002415-41,232,side effects despite prophylactic medication and/or after adequate medical treatment had been instituted,3,>14 days,NA,NA
33203645,NCT01960023,233,diarrhea on optimal medical therapy,3,>=2 days,NA,NA
33203645,NCT01960023,233,diarrhea of any duration or of any grade associated with fever or dehydration,4,NA,NA,NA
33203645,NCT01960023,233,neutropenia associated with fever,3 or 4,NA,NA,NA
33203645,NCT01960023,233,neutropenia,4,>=7 days,NA,NA
33203645,NCT01960023,233,thrombocytopenia,4,NA,NA,NA
33203645,NCT01960023,233,nonhematologic toxicity,3 or 4,NA,NA,NA
33203645,NCT01960023,233,Toxicity-related delay of â‰¥2 weeks,NA,NA,NA,NA
28528917,NCT01238770,234,nonhematological toxicity,3 or 4,NA,FALSE,NA
28528917,NCT01238770,234,Hypertension resulted in a dose reduction or a treatment interruption for more than two weeks,NA,NA,NA,NA
28528917,NCT01238770,234,elevated liver enzymes resulted in a dose reduction or a treatment interruption for more than two weeks,NA,NA,NA,NA
28528917,NCT01238770,234,thrombocytopenia,4,NA,NA,NA
28528917,NCT01238770,234,thrombocytopenia associated with bleeding,3 or 4,NA,NA,NA
28528917,NCT01238770,234,neutropenia,4,>4 days,NA,NA
28528917,NCT01238770,234,febrile neutropenia defined as ANC < 1000/Î¼l concurrent with fever,NA,NA,NA,NA
28528917,NCT01238770,234,any toxicity requiring dose interruption for N 14 days,NA,NA,NA,NA
20096951,NA,235,neutropenia,4,>5 days,NA,NA
20096951,NA,235,ANC < 0.5 Ã— 109/L on two occasions 7 days apart,NA,NA,NA,NA
20096951,NA,235,Febrile neutropenia,NA,NA,NA,NA
20096951,NA,235,thrombocytopenia,4,NA,NA,NA
20096951,NA,235,thrombocytopenia with bleeding,3,NA,NA,NA
20096951,NA,235,pulmonary or esophageal toxicity that prohibits 5 or more consecutive days of radiation treatment,3,NA,NA,NA
20096951,NA,235,pulmonary or esophageal toxicity,4,NA,NA,NA
20096951,NA,235,Any other non-hematologic toxicity that prohibits 5 or more consecutive days of radiation treatment,3,NA,NA,NA
20096951,NA,235,non-hematologic toxicity,4,NA,FALSE,NA
20096951,NA,235,Death due to toxicity,NA,NA,NA,NA
20096951,NA,235,myelosuppression prohibiting retreatment on day 22,4-Feb,NA,NA,NA
19701110,NA,236,"any toxicity that required dose modifications or delays based on >= grade 3 toxicities including hematologic toxicity, mu- cositis, diarrhea, and rash",NA,NA,NA,NA
24989332,NCT01445392,237,nonhematologic AEs that were suspected of a causal relation to SS1P,>=3,NA,NA,NA
24989332,NCT01445392,237,vascular leak syndrome (VLS) (defined as a requirement for flu-ids>20 mL/kg per hour for at least 30 minutes to treathypotension,3,NA,NA,NA
24989332,NCT01445392,237,hypotension in temporal association with VLS,3,NA,NA,NA
24989332,NCT01445392,237,VLS resulting in symptomatic pulmonaryedema requiring supplemental oxygen or a decrease>10% in oxygen saturation,NA,NA,NA,NA
24989332,NCT01445392,237,hematologic AEs,>=4,>5 days,FALSE,NA
24989332,NCT01445392,237,allergic reactions of bronchospasm or urticaria,2,NA,NA,NA
24989332,NCT01445392,237,any allergic reaction in the presence of premedication,>=3,NA,NA,NA
26291057,NCT00732420,238,clinically significant non-haematological toxicity,3 or 4,NA,FALSE,NA
26291057,NCT00732420,238,neutropenia with fever or infection,4,NA,NA,NA
26291057,NCT00732420,238,neutropenia,4,>=5 days,NA,NA
26291057,NCT00732420,238,neutropenia requiring delay in the next cycle,>=3,NA,NA,NA
26291057,NCT00732420,238,thrombocytopenia,4,NA,NA,NA
26291057,NCT00732420,238,inadequately controlled hypertension in spite of maximal two antihypertensive drugs,3,NA,NA,NA
26291057,NCT00732420,238,proteinuria during uncontrolled hypertension and/or renal impairment or lack of improvement to grade <=2 upon interruption of pazopanib,3,NA,NA,NA
26291057,NCT00732420,238,proteinuria,4,NA,NA,NA
26291057,NCT00732420,238,delay of next cycle of <=2 weeks due to unresolved toxicity,NA,NA,NA,NA
26291057,NCT00732420,238,nonhaematological toxicity beyond cycle 1,2,NA,NA,NA
26291057,NCT00732420,238,any toxicity,<=2,NA,NA,NA
30496584,NA,239,non-hematological toxicities,3,NA,FALSE,NA
30496584,NA,239,neutropenia complicated by fever,3 or 4,NA,NA,NA
30496584,NA,239,thrombocytopenia,4,NA,NA,NA
30496584,NA,239,neutropenia,4,NA,NA,NA
30496584,NA,239,any unresolved toxicity requiring a delay in the administration of a subsequent course exceeding 14 days,NA,NA,NA,NA
30496584,NA,239,any toxicity requiring a delay in the planning of radiotherapy within 60 days,NA,NA,NA,NA
21831954,NCT00370513,240,clinically significant nonhematologic toxicity,3 or 4,NA,FALSE,NA
21831954,NCT00370513,240,liver toxicity for which clinical and radiologic criteria supported either progressive disease or viral reactivation as the cause of increased hepatic dysfunction,NA,NA,NA,NA
21831954,NCT00370513,240,"nausea, vomiting, or diarrhea for which adequate supportive therapy was not instituted",3,NA,NA,NA
21831954,NCT00370513,240,hypertension that was adequately controlled by antihypertensive medication(s),3,NA,NA,NA
21831954,NCT00370513,240,proteinuria without associated hypertension and/or renal impairment that improved to grade 2 or lower upon interruption of pazopanib,3,NA,NA,NA
21831954,NCT00370513,240,neutropenia,3,>=7 days,NA,NA
21831954,NCT00370513,240,neutropenia with the occurrence of neutropenic fever,3,NA,NA,NA
21831954,NCT00370513,240,neutropenia,4,NA,NA,NA
21831954,NCT00370513,240,thrombocytopenia,3 or 4,NA,NA,NA
21831954,NCT00370513,240,an increase in the Child-Pugh score by 2 or more in association with liver toxicity considered to be related to pazopanib,NA,NA,NA,NA
21831954,NCT00370513,240,inability to begin the next treatment period within 21 days of scheduled dosing because of unresolved toxicity,NA,NA,NA,NA
21831954,NCT00370513,240,inability to receive more than 75% of the scheduled doses in a 21-day treatment period because of toxicity,NA,NA,NA,NA
21831954,NCT00370513,240,toxicity that was judged by the investigator and the study physician to be a DLT,>=2,persisting > 21 days,NA,NA
21831954,NCT00370513,240,"toxicity (eg, renal, neurological, or cardiovascular) that was judged by the investigator and the study physician to be a DLT",2,NA,NA,NA
20460487,NA,241,nonhematologic toxicity,>=3,NA,FALSE,NA
20460487,NA,241,drug-related gastrointestinal toxicity or hypertension despite optimal supportive care/intervention,3,NA,NA,NA
20460487,NA,241,drug-related uncomplicated neutropenia (not associated with fever),4,7 days,NA,NA
20460487,NA,241,neutropenia of any duration associated with fever,NA,NA,NA,NA
20460487,NA,241,"platelet levels of <25,000/Î¼L",NA,NA,NA,NA
20460487,NA,241,thrombocytopaenia associated with bleeding that required transfusion,3,NA,NA,NA
20460487,NA,241,the inability to resume BIBF 1120 dosing within 14 days of stopping due to treatment-related toxicity,NA,NA,NA,NA
23857966,NCT00929903,242,neutropenia,4,NA,NA,NA
23857966,NCT00929903,242,thrombocytopenia,4,NA,NA,NA
23857966,NCT00929903,242,myelosuppression causing treatment delay of more than 14 days,NA,NA,NA,NA
23857966,NCT00929903,242,Nonhematologic toxicity,4,NA,NA,NA
23857966,NCT00929903,242,Nonhematologic toxicity,3,NA,FALSE,NA
23857966,NCT00929903,242,arterial thrombosis,2,NA,NA,NA
23857966,NCT00929903,242,ALT in the presence of grade 2 hyperbilirubinemia (with > 35% direct),2,NA,NA,NA
23857966,NCT00929903,242,"hypertension, confirmed systolic or diastolic BP more than 25 mmHg above the 95th percentile for age,8 or an elevated BP not controlled by antihypertensive medication within 14 days, according to a previously described algorithm",4,NA,NA,NA
26810581,NA,243,neutropenia,4,NA,NA,NA
26810581,NA,243,thrombocytopenia,4,NA,NA,NA
26810581,NA,243,Febrile neutropenia was defined as an absolute neutrophil count (ANC) of <1000 with fever of>101 F,NA,NA,NA,NA
26810581,NA,243,nonhematological toxicity,>=3,NA,FALSE,NA
26810581,NA,243,esophagitis and dehydration,3,NA,NA,NA
21353323,NA,244,neutropenia,4,>7 days,NA,NA
21353323,NA,244,thrombocytopenia,4,NA,NA,NA
21353323,NA,244,thrombocytopenia with bleeding,3,NA,NA,NA
21353323,NA,244,"hematological toxicity preventing treatment on day 28 of the first cycle (one week after the end of the first cycle), or on day 36 of cycles 2 or 3 (two weeks after cycles 2 or 3)",NA,NA,NA,NA
21353323,NA,244,non-hematological toxicity (including febrile neutropenia),3,>5 days,NA,NA
21353323,NA,244,non-hematological toxicity,4,NA,FALSE,NA
21353323,NA,244,esophageal or lung toxicity,3 or 4,NA,NA,NA
21353323,NA,244,"dysphagia/esophagitis, thrombocytopenia, febrile neutropenia and dermatitis that resulted in a more than 1 week (5 scheduled daily treatments) interruption of radiotherapy, or a more than 2 weeks delay in the administration of chemotherapy, or a more than 5 weeks delay in the first cycle of consolidation chemotherapy after completing chemoradiation therapy",3,NA,NA,NA
21353323,NA,244,"neutropenia that resulted in a more than 1 week (5 scheduled daily treatments) interruption of radiotherapy, or a more than 2 weeks delay in the administration of chemotherapy, or a more than 5 weeks delay in the first cycle of consolidation chemotherapy after completing chemoradiation therapy",3 or 4,NA,NA,NA
21353323,NA,244,"fatigue/malaise that resulted in a more than 1 week (5 scheduled daily treatments) interruption of radiotherapy, or a more than 2 weeks delay in the administration of chemotherapy, or a more than 5 weeks delay in the first cycle of consolidation chemotherapy after completing chemoradiation therapy",NA,NA,NA,NA
21353323,NA,244,toxicity likely related to concurrent therapy regardless of the impact on the administration of treatment,3 or 4,NA,FALSE,NA
21073623,NA,245,Neutropenia,>=3,NA,NA,NA
21073623,NA,245,Febrile neutropenia (>38Â°C and absolute neutrophil count <500 mL),NA,NA,NA,NA
21073623,NA,245,Thrombocytopenia,>=4,NA,NA,NA
21073623,NA,245,Non-hematological,>=3,NA,NA,NA
21073623,NA,245,Any treatment delay >7 days,NA,NA,NA,NA
26560486,NCT00979576,246,non-hematologic AEs,>=3,NA,NA,NA
26560486,NCT00979576,246,hematologic AEs,4,NA,NA,NA
26560486,NCT00979576,246,"neutropenia  associated with an absolute neutrophil count of <1.0 Ã— 109/L, and fever of â‰¥38.5 Â°C",>=3,NA,NA,NA
26560486,NCT00979576,246,thrombocytopenia associated with bleeding of grade â‰¥2,>=3,NA,NA,NA
26560486,NCT00979576,246,"Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevation of three times the upper limit of normal (ULN) or greater, along with bilirubin elevation of two times the ULN or greater",NA,NA,NA,NA
26560486,NCT00979576,246,the inability to resume nintedanib plus pemetrexed within 14 days of stopping due to drug-related toxicity,NA,NA,NA,NA
26560486,NCT00979576,246,"if non-compliance was judged to be caused by drug-related AEs, the decision as to whether the AEs were treated as DLTs was made after discussion between theinvestigator and the sponsor",NA,NA,NA,NA
23653147,NA,247,a required dose reduction before 17 doses (80%) of pazopanib were administered in the first cycle of treatment,NA,NA,NA,NA
23653147,NA,247,delays in next treatment cycle by 2 weeks due to treatment-related toxicity,NA,NA,NA,NA
23653147,NA,247,neutropenia,4,NA,NA,NA
23653147,NA,247,occurrence of neutropenic fever with ANC <1.5 x 109/L,NA,NA,NA,NA
23653147,NA,247,thrombocytopenia,4,NA,NA,NA
23653147,NA,247,nausea and vomiting if it occurred despite maximal antiemetic therapy and if hydration was required for >24 hours,3,NA,NA,NA
23653147,NA,247,diarrhea despite patient compliance with antidiarrheal therapy,3,NA,NA,NA
23653147,NA,247,bleeding/hemorrhage,3,NA,NA,NA
23653147,NA,247,hypertension,4,NA,NA,NA
23653147,NA,247,proteinuria,4,NA,NA,NA
23653147,NA,247,all other nonhematologic toxicities (if an increase in grade above baseline),4,NA,FALSE,NA
23653147,NA,247,"For group B, an increase of total bilirubin to the level defined for the group D",NA,>1 week,NA,NA
23653147,NA,247,"For patients in group C, a 1.5-fold increase from baseline total bilirubin to level defined for group D",NA,>1 week,NA,NA
23653147,NA,247,"For patients in group D, a 1.5-fold increase from baseline without recovery to <1.2  baseline",NA,>2 week,NA,NA
28238078,NCT01485042,248,neutropenia,4,NA,NA,NA
28238078,NCT01485042,248,thrombocytopenia,4,NA,NA,NA
28238078,NCT01485042,248,anemia,4,NA,NA,NA
28238078,NCT01485042,248,neutropenia,>=3,>7 days,NA,NA
28238078,NCT01485042,248,thrombocytopenia,>=3,>7 days,NA,NA
28238078,NCT01485042,248,thrombocytopenia associated with bleeding,3,NA,NA,NA
28238078,NCT01485042,248,neutropenic fever,NA,NA,NA,NA
28238078,NCT01485042,248,"nausea, vomiting or diarrhea despite adequate supportive measures",>=3,â‰¥4 days,NA,NA
28238078,NCT01485042,248,ALT or AST elevation,>=3,>7 days,NA,NA
28238078,NCT01485042,248,other non-hematologic toxicity,>=3,NA,FALSE,NA
28238078,NCT01485042,248,"Anorexia, fatigue and hypertension",4,NA,NA,NA
28238078,NCT01485042,248,"Anorexia, fatigue and hypertension considered unmanageable",NA,NA,NA,NA
28771961,NA,249,leukopenia,4,â‰¥4 days,NA,NA
28771961,NA,249,neutropenia,4,â‰¥4 days,NA,NA
28771961,NA,249,febrile  neutropenia,NA,NA,NA,NA
28771961,NA,249,thrombocytopenia,4,NA,NA,NA
28771961,NA,249,non-hematological toxicities,3 or 4,NA,FALSE,NA
28771961,NA,249,"esophagitis lasting two weeks after the last day ofRT, and not commencing the second round of pemetrexeduntil day 35",3,NA,NA,NA
27213589,NA,250,"any toxicity that was determined to be possibly, probably, or definitely related to study treatment",3 or 4,NA,FALSE,NA
23698253,NCT01072890,251,nonhematologic toxicity,3 or 4,NA,FALSE,NA
23698253,NCT01072890,251,thrombocytopenia,>=4,NA,NA,NA
23698253,NCT01072890,251,febrile neutropenia requiring hospitalization,>=4,NA,NA,NA
23698253,NCT01072890,251,treatment delay of more than 2 weeks as a result of unresolved toxicity during the first cycle of therapy,NA,NA,NA,NA
17442992,NA,252,toxicity attributable to pemetrexed,3 or 4,NA,FALSE,NA
17442992,NA,252,"hepatic aminotransferase (AST/ALT) elevation, which returned to  grade 1 before the next treatment course",3,NA,NA,NA
17442992,NA,252,fever or infection,3,NA,NA,NA
17442992,NA,252,neutropenia,4,>7 days,NA,NA
17442992,NA,252,thrombocytopenia requiring transfusion therapy on more than two occasions in 7 days,4,NA,NA,NA
17442992,NA,252,Thrombocytopenia or neutropenia resulting in treatment delays of more than 14 days,NA,NA,NA,NA
19830387,NA,253,toxicity,3 or 4,NA,FALSE,NA
19830387,NA,253,constipation,3 or 4,â‰¥7 days,NA,NA
19830387,NA,253,rash unresponsive to supportive care,3,NA,NA,NA
19830387,NA,253,fatigue,4,NA,NA,NA
19830387,NA,253,ANC <0.5Ã—109 cells/L,NA,>5 days,NA,NA
19830387,NA,253,ANC <0.5Ã—109 cells/L associated with fever or infection,NA,NA,NA,NA
19830387,NA,253,platelet count <25Ã—109 cells/L of any duration or <50Ã—109 cells/L with major bleeding,NA,NA,NA,NA
23179337,NCT00619424,254,hypertension,4,NA,NA,NA
23179337,NCT00619424,254,hypertension not controlled by antihypertensive medications,3,NA,NA,NA
23179337,NCT00619424,254,proteinuria,4,NA,NA,NA
23179337,NCT00619424,254,proteinuria without improvement to lower than Grade 2 upon interruption of pazopanib,3,NA,NA,NA
23179337,NCT00619424,254,neutropenia,4,>=7 days,NA,NA
23179337,NCT00619424,254,febrile neutropenia defined as concurrent Grade 4 neutropenia and fever above 38.5Â°C lasting more than 24 h,NA,NA,NA,NA
23179337,NCT00619424,254,thrombocytopenia,4,NA,NA,NA
23179337,NCT00619424,254,any unresolved toxicity that delayed the initiation of the next treatment cycle more than 14 days,NA,NA,NA,NA
23179337,NCT00619424,254,toxicity that occurred before the end of the second treatment cycle and was thought by the investigators to be dose-limiting,>=2,NA,NA,NA
24919569,NCT00788957,255,therapy-related adverse event (AE) or laboratory abnormality that was deemed clinically significant by the investigator,3 or 4,NA,FALSE,NA
24919569,NCT00788957,255,fatigue,3,>7 days,NA,NA
24919569,NCT00788957,255,fatigue,4,NA,NA,NA
24919569,NCT00788957,255,"nausea, diarrhea, or vomiting despite maximum supportive care",3 or 4,NA,NA,NA
24919569,NCT00788957,255,hypomagnesemia despite IV maximal magnesium replacement,4,NA,NA,NA
24919569,NCT00788957,255,rash/desquamation,4,NA,NA,NA
24919569,NCT00788957,255,neutropenia with persistent fever 38.5C,3 or 4,NA,NA,NA
24919569,NCT00788957,255,neutropenia or thrombocytopenia,4,>7 days,NA,NA
24919569,NCT00788957,255,elevated ALT or AST > 10 upper limit of normal,NA,NA,NA,NA
23108697,NCT00528619,256,neutropenia with grade >=3 infection,>=3,NA,NA,NA
23108697,NCT00528619,256,neutropenia,4,>=7 days,NA,NA
23108697,NCT00528619,256,neutropenia with fever >38.5 C,4,>24 h,NA,NA
23108697,NCT00528619,256,thrombocytopenia with bleeding,>=3,NA,NA,NA
23108697,NCT00528619,256,thrombocytopenia,4,>=7 days,NA,NA
23108697,NCT00528619,256,non-hematologic toxicity,3 or 4,>=7 days,NA,NA
23108697,NCT00528619,256,non-hematologic toxicity resulting in any delays in administration of the next planned cycle starting within the first 22 days of therapy,3 or 4,NA,NA,NA
33715996,NCT01642017,257,geriatric criterion: decrease in ADL of 2 points or more,NA,NA,NA,NA
33715996,NCT01642017,257,neutropenia,4,>5 days,NA,NA
33715996,NCT01642017,257,febrile neutropenia,NA,>1 days,NA,NA
33715996,NCT01642017,257,thrombocytopenia,4,NA,NA,NA
33715996,NCT01642017,257,thrombocytopenia with bleeding,3,NA,NA,NA
33715996,NCT01642017,257,hypertension,4,NA,NA,NA
33715996,NCT01642017,257,treatment delayed (two weeks) for side-effects,NA,NA,NA,NA
33715996,NCT01642017,257,hypophosphatemia,4,NA,NA,NA
33715996,NCT01642017,257,lipase (>2N),3,NA,NA,NA
33715996,NCT01642017,257,non-hematologic side effects,>=3,NA,FALSE,NA
30958892,NCT01973868,258,bsolute neutrophil count <500/mm3,NA,>7 days,NA,NA
30958892,NCT01973868,258,febrile neutropenia,4,NA,NA,NA
30958892,NCT01973868,258,"platelet count <25,000/mm3",NA,NA,NA,NA
30958892,NCT01973868,258,hemorrhage associated with thrombocytopenia ofgrade â‰¥3,3,NA,NA,NA
30958892,NCT01973868,258,nonhematologic toxicity,3 or 4,NA,FALSE,NA
29438091,NCT00338494,259,neutropenia,4,NA,NA,NA
29438091,NCT00338494,259,febrile neutropenia,3,>7 days,NA,NA
29438091,NCT00338494,259,thrombocytopenia,4,NA,NA,NA
29438091,NCT00338494,259,"nonhematologic toxicity and/or grade 3 or 4 nausea, vomiting, or diarrhea in patients who received optimal treatment with antiemetics and antidiarrheals",3 or 4,NA,NA,NA
29438091,NCT00338494,259,"elevations in alanine, aspartate transaminase, or bilirubin",4,NA,NA,NA
29438091,NCT00338494,259,"treatment delay >2 weeks because of unresolved toxicity in patients who experienced at least grade 3 thrombocytopenia, grade 4 neutropenia, or any grade 3 nonhematologic toxicity",NA,NA,NA,NA
22893631,NCT00347971,260,rIL-21-related toxicity,>=3,NA,FALSE,NA
22893631,NCT00347971,260,nonhematologic lab abnormalities,4,NA,NA,NA
22893631,NCT00347971,260,"anemia, neutropenia, or thrombocytopenia",4,NA,FALSE,NA
22893631,NCT00347971,260,"anemia, neutropenia, or thrombocytopenia",3,>=7 days,NA,NA
22893631,NCT00347971,260,laboratory abnormality resulting in withholding 2 doses,3,NA,NA,NA
22893631,NCT00347971,260,Lymphopenia associated with grade 3 clinical AEs,NA,NA,NA,NA
11332149,NA,261,thrombocytopenia,3,NA,NA,NA
11332149,NA,261,leuco/neutropenia,>=4,NA,NA,NA
11332149,NA,261,non-haematological toxicity,3 or 4,NA,FALSE,NA
19894051,NA,262,non-hematologic toxicities,3 or 4,NA,FALSE,NA
19894051,NA,262,granulocytopenia,4,NA,NA,NA
19894051,NA,262,thrombocytopenia,4,NA,NA,NA
19894051,NA,262,hyperglycemia,3,>4 days,NA,NA
19894051,NA,262,hyperglycemia,4,>1 days,NA,NA
19894051,NA,262,metabolic acidosis with pH <7.25 (with grade 3 or 4 hyperglycemia),NA,>1 days,NA,NA
28735378,NCT01610570,263,neutropenia,4,NA,NA,NA
28735378,NCT01610570,263,"thrombocytopenia (<25,000/ÂµL) refractory to platelet transfusion",4,NA,NA,NA
28735378,NCT01610570,263,bleeding not promptly (within 6  h of appropriate intervention) corrected with blood product support,2,NA,NA,NA
28735378,NCT01610570,263,mithramycin-related non-hematologic toxicity,>=3,NA,FALSE,NA
28735378,NCT01610570,263,NA,4,NA,NA,NA
23799873,NCT01653067,264,toxicity that are potentially related to the trial treatment,5,NA,NA,NA
23799873,NCT01653067,264,any hematological toxicity not recovering to at least NCI CTCAE grade II after 28 days after start of the last STORM-cycle,NA,NA,FALSE,NA
23799873,NCT01653067,264,any non-hematological toxicity not recovering to grade II within 14 days after initial occurrence and potentially related to the trial treatment,3 or 4,NA,NA,NA
31420468,NCT02649686,265,diarrhea/colitis,>=3,NA,NA,NA
31420468,NCT02649686,265,pneumonitis,>=3,NA,NA,NA
31420468,NCT02649686,265,liver transaminase elevation >8 Ã— upper limit of normal (ULN),NA,NA,NA,NA
31420468,NCT02649686,265,total bilirubin >5 Ã— ULN,NA,NA,NA,NA
31420468,NCT02649686,265,other toxicity that did not resolve to grade 1 within 3 days with intensive management,3,NA,FALSE,NA
31420468,NCT02649686,265,immune-related adverse event,4,NA,NA,NA
31420468,NCT02649686,265,toxicity requiring infliximab,NA,NA,NA,NA
28402581,NCT01369849,266,Aspartate aminotransferase increased (AST/SGOT) and/or Alanine aminotransferase increased (ALT/ SGPT),4,NA,NA,NA
28402581,NCT01369849,266,Aspartate aminotransferase increased (AST/SGOT) and/or Alanine aminotransferase increased (ALT/ SGPT),3,â‰¥7 consecutive days,NA,NA
28402581,NCT01369849,266,Persistent neutropenia with ANC â‰¤0.5 X 109/L at Day 35 of Cycle 1  AND ANC does not recover to â‰¥1 X 109/L after delay of therapy for more than 7 days (by Day 42),NA,NA,NA,NA
28402581,NCT01369849,266,"hypokalemia, hyponatremia, hypophosphatemia or hypomagnesemia if uncontrolled with several days of electrolyte supplementation",3 or 4,NA,NA,NA
28402581,NCT01369849,266,"nausea, vomiting, or diarrhea despite maximal supportive treatment(s)",3,NA,NA,NA
28402581,NCT01369849,266,Mucositis despite maximal supportive treatment(s),3,NA,NA,NA
28402581,NCT01369849,266,"Mucositis despite maximal supportive treatment(s) that are considered to be due to treatment (definitely, probably, or possibly related)",NA,NA,NA,NA
28402581,NCT01369849,266,"Rash acneiform, rash maculo-papular, Stevens Johnson syndrome",>=3,NA,NA,NA
28402581,NCT01369849,266,Electrocardiogram QTc interval prolonged,4,NA,NA,NA
28402581,NCT01369849,266,Other non-hematologic Toxicity,>=3,NA,FALSE,NA
28402581,NCT01369849,266,hyperglycemic events If glucose levels do no return to Grade 2 or lower within one week of appropriate therapy,3,NA,NA,NA
21425150,NCT00156013,267,neutropenia that lasted until 24 hours before the beginning of the next cycledespite the use of growth factor support,4,NA,NA,NA
21425150,NCT00156013,267,febrile neutropenia that lasted until 24 hours before the beginning of the next cycledespite the use of growth factor support,3,NA,NA,NA
21425150,NCT00156013,267,drug-related thrombocytopenia that did not resolve before thenext cycle begins,4,NA,NA,NA
21425150,NCT00156013,267,"drug-related nonhematologic toxicity and/or grade 3 or 4 nausea, vomiting, or diarrheain patients who received optimal treatment with antiemet-ics and antidiarrheals if they did not resolve to grade 1 orless within 24 hours of starting the subsequent cycle",4,NA,NA,NA
21425150,NCT00156013,267,"drug-related elevations in liver function tests (ala-nine and aspartate aminotransferase levels, bilirubin, andalkaline phosphatase",4,NA,NA,NA
32144134,NCT01307267,268,neutropenia,4,NA,NA,NA
32144134,NCT01307267,268,febrile neutropenia,NA,NA,NA,NA
32144134,NCT01307267,268,neutropenic infection,NA,NA,NA,NA
32144134,NCT01307267,268,thrombocytopenia with associated bleeding,>=3,NA,NA,NA
32144134,NCT01307267,268,thrombocytopenia,4,NA,NA,NA
32144134,NCT01307267,268,anemia,4,NA,NA,NA
32144134,NCT01307267,268,hemolysis,>=3,NA,NA,NA
32144134,NCT01307267,268,"nonhematologic toxicities, if they were attributable to combination treatment with utomilumab and rituximab and not to disease progression, and occurred within the first two treatment cycles (up to 28 days following the second treatment dose)",>=3,NA,FALSE,NA
11508814,NA,269,toxicity,3 or 4,NA,FALSE,NA
7595747,NA,270,NA,NA,NA,NA,DLT not defined
23568716,NA,271,neutropenia,4,>7 days,NA,NA
23568716,NA,271,neutropenia with fever,4,NA,NA,NA
23568716,NA,271,thrombocytopenia,4,NA,NA,NA
23568716,NA,271,non-hematologic toxicity that was possibly related to study treatment,>=3,NA,FALSE,NA
23568716,NA,271,rash/desquamation despite aggressive skin toxicity management,4,NA,NA,NA
23568716,NA,271,diarrhea requiring hospitalization or lasting more than 24 h despite aggressive anti-diarrheal therapy,3,NA,NA,NA
23568716,NA,271,diarrhea despite aggressive anti-diarrheal therapy,4,NA,NA,NA
23568716,NA,271,vomiting despite optimal anti-emetic therapy,4,NA,NA,NA
23568716,NA,271,"left ventricular dysfunction (i.e., symptomatic congestive heart failure)",>=3,NA,NA,NA
23568716,NA,271,Toxicity-related treatment delays lasting more than 3 weeks,NA,NA,NA,NA
23568716,NA,271,requirement of more than two dose reductions of cetuximab due to treatment-related toxicity,NA,NA,NA,NA
34157616,NCT02085148,272,NA,NA,NA,NA,DLT not defined
32697348,NCT00943943,273,nonhematological toxicity at least possibly related to the combination of agents in study,>=3,NA,FALSE,NA
32697348,NCT00943943,273,prolonged myelosuppression in the absence of active leukemia,4,lasting â‰¥8 weeks,NA,NA
30262659,NCT01722305,274,thrombocytopenia,4,NA,NA,NA
30262659,NCT01722305,274,thrombocytopenia with active bleeding,3,NA,NA,NA
30262659,NCT01722305,274,febrile neutropenia,NA,>=7 days,NA,NA
30262659,NCT01722305,274,hematological toxicities,4,NA,NA,NA
30262659,NCT01722305,274,"nonhematologic toxicity including diarrhea, nausea, and vomiting that did not respond to supportive therapy",3 or 4,NA,NA,NA
33025730,NCT03257631,275,non-hematological toxicity,4,NA,NA,NA
33025730,NCT03257631,275,any adverse event attributed to the study agent that required treatment interruption for>3 days during the first 21-day treatment period,>=2,NA,NA,NA
33025730,NCT03257631,275,greater than 7 days delay in starting the sub-sequent course due to a non-hematological toxicity that does not meet requirements to start next course,NA,NA,NA,NA
33025730,NCT03257631,275,skin rash,3,NA,NA,NA
33025730,NCT03257631,275,any other nonhematologic toxicity,3,NA,FALSE,NA
33025730,NCT03257631,275,neutropenia that occurred during the 21-day dosing period,4,NA,NA,NA
33025730,NCT03257631,275,neutropenia of â‰¥5 days duration that occurred during the rest period,4,>=5 days,NA,NA
33025730,NCT03257631,275,thrombocytopenia that occurred during the 21-day dosing period,3 or 4,NA,NA,NA
33025730,NCT03257631,275,thrombocytopenia with clinically significant bleeding a tany time during DLT phase,3 or 4,NA,NA,NA
33025730,NCT03257631,275,anemia,4,NA,NA,NA
33025730,NCT03257631,275,any grade o ffebrile neutropenia,NA,NA,NA,NA
33025730,NCT03257631,275,greater than 7-day delay in starting the subsequent course due to neutropenia or thrombocytopenia that did not meet starting requirements,NA,NA,NA,NA
34581757,NCT03255096,276,neutropenia,4,>=5 days,NA,NA
34581757,NCT03255096,276,neutropenia with fever and/or infection,3 or 4,NA,NA,NA
34581757,NCT03255096,276,thrombocytopenia,4,NA,NA,NA
34581757,NCT03255096,276,thrombocytopenia with bleeding,3,NA,NA,NA
34581757,NCT03255096,276,anemia,4,NA,NA,NA
34581757,NCT03255096,276,nonhematologic toxicity,3 or 4,NA,FALSE,NA
34581757,NCT03255096,276,skin ulceration or other skin and SC tissue disorders related to the SC injection of RO,3 or 4,NA,NA,NA
34581757,NCT03255096,276,a dosing delay .14 days caused by treatment-emergent AEs or related severe laboratory abnormalities,NA,NA,NA,NA
19261664,NA,278,hematological toxicities,4,NA,NA,NA
19261664,NA,278,non-hematological toxicities,3 or 4,NA,FALSE,NA
19261664,NA,278,AST/ALT elevations >150 IU/l,NA,NA,NA,NA
19261664,NA,278,serum creatinine elevation >2.0 mg/dl,NA,NA,NA,NA
11955653,NA,279,diarrhea,>=3,NA,NA,NA
11955653,NA,279,mucositis,>=3,NA,NA,NA
11955653,NA,279,thrombocytopenia,>=3,NA,NA,NA
11955653,NA,279,leucopenia and neutropenia,4,NA,NA,NA
11955653,NA,279,other toxicity,>=2,NA,FALSE,NA
11955653,NA,279,creatinine clearance < 65 ml/min,NA,NA,NA,NA
22753910,NCT00539682,280,nonhematologic toxicity,3 or 4,NA,FALSE,NA
22753910,NCT00539682,280,neutropenia,4,>7 days,NA,NA
22753910,NCT00539682,280,thrombocytopenia,4,>7 days,NA,NA
22753910,NCT00539682,280,re-treatment delay of more than 2 weeks because of delayed recovery from toxicity related to SAR3419,NA,NA,FALSE,NA
22921184,NA,281,febrile neutropenia,NA,NA,NA,NA
22921184,NA,281,neutropenia,4,>4 days,NA,NA
22921184,NA,281,thrombocytopenia,3 or 4,NA,NA,NA
22921184,NA,281,non-haematologic toxicitie,3 or 4,NA,NA,NA
22921184,NA,281,neuropathy,>1,NA,NA,NA
15249589,NA,282,nonhematologic toxicity,3 or 4,NA,NA,NA
15249589,NA,282,hematologic toxicity,4,NA,NA,NA
27154915,NCT01055496,283,febrile neutropenia,NA,NA,NA,NA
27154915,NCT01055496,283,neutropenia,4,â‰¥7 days,NA,NA
27154915,NCT01055496,283,thrombocytopenia,4,â‰¥7 days,NA,NA
27154915,NCT01055496,283,thrombocytopenia with bleeding requiring a platelet transfusion,3 or 4,NA,NA,NA
27154915,NCT01055496,283,non-hematologic toxicity,3 or 4,â‰¥7 days,FALSE,NA
27154915,NCT01055496,283,corrected QT interval prolongation,>=3,NA,NA,NA
27154915,NCT01055496,283,alanine aminotransferase or aspartate aminotransferase elevation,4,NA,NA,NA
27154915,NCT01055496,283,hyperbilirubinemia,>=2,>7 days,NA,NA
27154915,NCT01055496,283,treatment with granulocyte-colony stimulating factor during Cycle 1,NA,NA,NA,NA
27154915,NCT01055496,283,drug-related toxicity causing dose delay of >7 days,NA,NA,NA,NA
27601593,NCT01209130,284,nonhematologic toxicity,>=3,NA,FALSE,NA
27601593,NCT01209130,284,febrile neutropenia,NA,NA,NA,NA
27601593,NCT01209130,284,neutropenia without recovery by at least one grade/week in the absence of growth factor support (growth factor support was permitted beyond the first cycle),>=3,NA,NA,NA
27601593,NCT01209130,284,"thrombocytopenia without recovery by at least one grade/week in the absence of bleeding, associated with bleeding, or requirement for platelet transfusion",>=3,NA,NA,NA
33451977,NCT02663518,286,thrombocytopenia,4,NA,NA,NA
33451977,NCT02663518,286,thrombocytopenia with bleeding,3,NA,FALSE,NA
33451977,NCT02663518,286,thrombocytopenia with requiring platelet transfusion,3,NA,NA,NA
33451977,NCT02663518,286,anemia unexplained by disease,4,NA,NA,NA
33451977,NCT02663518,286,neutropenia,4,>5 days,NA,NA
33451977,NCT02663518,286,febrile neutropenia (ANC < 1.0 x 109/L with fever >38.5C),NA,NA,NA,NA
33451977,NCT02663518,286,nonhematologic toxicity,>=3,NA,FALSE,NA
33451977,NCT02663518,286,hemorrhage,3 or 4,NA,NA,NA
33451977,NCT02663518,286,cytokine release syndrome,3 or 4,NA,NA,NA
30082475,NCT01397825,287,neutropenia  (ANC <500 cells/mm3),4,>7 days,NA,NA
30082475,NCT01397825,287,neutropenia with fever (oral temperature >=38.5C),4,NA,NA,NA
30082475,NCT01397825,287,"thrombocytopenia (platelets <25,000 cells/mm3)",4,>7 days,NA,NA
30082475,NCT01397825,287,"platelet count <10,000 cells/mm3",NA,NA,NA,NA
30082475,NCT01397825,287,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
30082475,NCT01397825,287,any other nonhematologic toxicity,>=3,NA,FALSE,NA
30082475,NCT01397825,287,delay in initiation of the subsequent cycle of therapy >14 days due to treatment-related toxicity,NA,NA,NA,NA
22875080,NA,289,nonhematological toxicity that occurs during cycle 1 and that does not resolve to Bgrade 1 by day 35,>=3,NA,NA,NA
22875080,NA,289,"nausea, vomiting, or diarrhea despite of optimal symptomatic treatment",>=3,NA,NA,NA
22875080,NA,289,transaminitis,4,NA,NA,NA
22875080,NA,289,transaminitis,3,>=7 days,NA,NA
22875080,NA,289,febrile neutropenia,3,NA,NA,NA
22875080,NA,289,"neutropenia, without a fever, if the neutropenia did not improve to Bgrade 1 by day 35 of cycle one",4,NA,NA,NA
22875080,NA,289,"Platelet count <=25,000/mm3 not improve to >=75,000/mm3 by day 35 of cycle one",NA,NA,FALSE,NA
25057177, NCT00787969,290,absolute neutrophil count (ANC) (<500/mm3),4,>5 days,NA,NA
25057177, NCT00787969,290,ANC with fever >100.5 F or active infection,4,NA,NA,NA
25057177, NCT00787969,290,platelets <25 000/mm3,NA,NA,NA,NA
25057177, NCT00787969,290,infection,4,NA,NA,NA
25057177, NCT00787969,290,nonhematologic toxicity at least possibly related to therapy,>=3,NA,FALSE,NA
11432631,NA,291,"nadir granulocyte or platelet count below 500/ul or 25,000/ul, respectively",NA,>=5 days,NA,NA
11432631,NA,291,a creatinine elevation of more than 2 times the baseline,NA,NA,NA,NA
11432631,NA,291,"Severe or life-threatening respiratory, cardiac, CNS, GI and dermatologic toxicities",3 or 4,NA,FALSE,NA
11432631,NA,291,nausea and vomiting in patients who had received an optimal antiemetic regimen,4,NA,NA,NA
8622063,NA,292,NA,NA,NA,NA,DLT not defined
27293194,NCT01410513,293,neutropenia,4,>7 d,NA,NA
27293194,NCT01410513,293,febrile neutropenia defined as an ANC<1 x 109/l with a single temperature>38.3Â°C or a sustained temperatureâ‰¥38Â°C formore than 1 h,NA,NA,NA,NA
27293194,NCT01410513,293,thrombocytopenia,4,>7d,NA,NA
27293194,NCT01410513,293,thrombocytopenia associated with grade >3 haemorrhage,4,NA,NA,NA
27293194,NCT01410513,293,non-haematolo-gical toxicity,>=3,NA,FALSE,NA
27293194,NCT01410513,293,"nausea, vomiting or diarrhoea occurring despiteoptimal prophylaxis and/or treatment",>=3,> 2 d,NA,NA
27293194,NCT01410513,293,diarrhoea,4,NA,NA,NA
27293194,NCT01410513,293,rash failing to recover to grade â‰¤1 toxicity by day 28 in patients receiving voxtalisib in combination with bendamustin,3,NA,NA,NA
27293194,NCT01410513,293,any toxicity resulting in a treatment delay >2 weeks and any other clinically significant AE that pre-cluded further dose escalation because of unacceptable riskto the patient,NA,NA,NA,NA
19652067,NA,295,nonhematologic toxicity,3 or 4,NA,FALSE,NA
19652067,NA,295,"nausea, vomiting, or diarrhea that persists beyond 10 days of dosing uncontrolled by aggressive treatments",NA,NA,NA,NA
19652067,NA,295,febrile neutropenia that preempts administration of the next dose,3,NA,NA,NA
19652067,NA,295,neutropenia that preempts administration of the next dose,4,NA,NA,NA
27381904,NCT01570387,296,thrombocytopenia,4,>=7 days,NA,NA
27381904,NCT01570387,296,neutropenia,4,>=7 days,NA,NA
27381904,NCT01570387,296,thrombocytopenia with significant bleeding,3,NA,NA,NA
27381904,NCT01570387,296,febrile neutropenia with infection,3,NA,NA,NA
27381904,NCT01570387,296,nonhematologic toxicity,>=3,NA,NA,NA
11597383,NA,298,acute toxicity,3 or 4,NA,NA,NA
23572496,NA,299,NA,NA,NA,NA,DLT not defined
11038040,NA,300,significant and symptomatic moist skin desquamation at day 21,NA,NA,NA,for radiotherapy
11038040,NA,300,diarrhoea with abdominal pain,2,NA,NA,for radiotherapy
11038040,NA,300,"investigator concern at day 21 that general toxicity, if continued, would necessitate incompletion of radiotherapy treatment",NA,NA,NA,for radiotherapy
11038040,NA,300,other pelvic toxicities considered by the investigator to indicate that the therapies were associated with unacceptable clinical side effect,NA,NA,NA,for radiotherapy
11038040,NA,300,neutropenia,3 or 4,NA,NA,for raltitrexed
11038040,NA,300,thrombocytopenia,3 or 4,NA,NA,for raltitrexed
11038040,NA,300,non-haematological toxicity,3 or 4,NA,NA,for raltitrexed
10645208,NA,301,neutropenic fever with a neutrophil count of < 500/mm3 plus fever > 38.3C,NA,NA,NA,Raltitrexed/bolus 5-FU study
10645208,NA,301,haematological toxicities of neutropenia or thrombocytopenia,4,> 7 days,NA,Raltitrexed/bolus 5-FU study
10645208,NA,301,non-haematological toxicities of mucositis or diarrhoea that develop despite antidiarrhoeal prophylaxi,4,NA,NA,Raltitrexed/bolus 5-FU study
10645208,NA,301,"failure of thrombocytopenia, neutropenia or any of the non-haematological toxicities to recover within 21 days after causing a dose delay",NA,NA,NA,Raltitrexed/bolus 5-FU study
10645208,NA,301,diarrhoea,3 or 4,NA,NA,Raltitrexed/infusional 5-FU study
10645208,NA,301,granulocytopenia,4,NA,NA,Raltitrexed/infusional 5-FU study
10645208,NA,301,granulocytopenia with complication,3,NA,NA,Raltitrexed/infusional 5-FU study
10645208,NA,301,mucositis,3 or 4,NA,NA,Raltitrexed/infusional 5-FU study
10645208,NA,301,thrombocytopenia,3 or 4,NA,NA,Raltitrexed/infusional 5-FU study
10645208,NA,301,other toxicity,>=2,NA,FALSE,Raltitrexed/infusional 5-FU study
32343640,NCT03406871,302,neutropenia,4,>= 7 days,NA,NA
32343640,NCT03406871,302,thrombocytopenia,4,NA,NA,NA
32343640,NCT03406871,302,thrombocytopenia  requiring transfusions,3,NA,NA,NA
32343640,NCT03406871,302,febrile neutropenia,>=3,NA,NA,NA
32343640,NCT03406871,302,uncontrollable nonhematologic toxicity despite maximal supportive care,>=3,NA,NA,NA
32343640,NCT03406871,302,toxicities that required discontinuation of the nivolumab or that resulted in administration of < 70% of the planned regorafenib dose,NA,NA,NA,NA
23295790,NCT00299494,303,febrile neutropenia,NA,NA,NA,NA
23295790,NCT00299494,303,neutropenia,4,â‰¥ 7 days,NA,NA
23295790,NCT00299494,303,thrombocytopenia,4,â‰¥ 3 days,NA,NA
23295790,NCT00299494,303,thrombocytopenia associated with hemorrhage requiring platelet transfusion,3,NA,NA,NA
23295790,NCT00299494,303,nonhematologic toxicity,3 or 4,NA,NA,NA
23295790,NCT00299494,303,delayed recovery (grade 1 or baseline) from a drug-related toxicity that prevented initiation of the next cycle by more than 14 days,NA,NA,FALSE,NA
28314788,NCT01326702,304,non-hematologic toxicity,>=3,NA,FALSE,NA
28314788,NCT01326702,304,"nausea, vomiting, and/or diarrhea despite use of adequate/maximal intervention",>=3,NA,NA,NA
28314788,NCT01326702,304,neutropenia,>=4,>=5 days,NA,NA
28314788,NCT01326702,304,neutropenia associated with fever,>=4,NA,NA,NA
28314788,NCT01326702,304,thrombocytopenia,>=4,>=5 days,NA,NA
28314788,NCT01326702,304,thrombocytopenia associated with bleeding episodes requiring transfusions,>=4,NA,NA,NA
28314788,NCT01326702,304,anemia with clinical indication for transfusion,3,NA,NA,NA
28314788,NCT01326702,304,anemia,4,NA,NA,NA
12451472,NA,305,neutropenia,4,>7 days,NA,NA
12451472,NA,305,febrile neutropenia,3 or 4,NA,NA,NA
12451472,NA,305,thrombocytopenia,4,NA,NA,NA
12451472,NA,305,vomiting,4,NA,NA,NA
12451472,NA,305,other nonhematological toxicity,3 or 4,NA,FALSE,NA
32052473,NCT01471210 (CA186-011) & NCT01775631 (CA186-017),306,NA,NA,NA,NA,DLT not defined
30060083,NCT01594229,308,adverse event (AE),5-Mar,NA,FALSE,NA
29563636,NCT01004003,309,nintedanib-related thrombocytopenia,4,NA,NA,NA
29563636,NCT01004003,309,nintedanib-related neutropenia,4,>=8 days,NA,NA
29563636,NCT01004003,309,nintedanib-related febrile neutropenia,NA,NA,NA,NA
29563636,NCT01004003,309,nintedanib-related non-hematologic toxicity,3 or 4,NA,FALSE,NA
29563636,NCT01004003,309,nintedanib-related liver toxicity,NA,NA,FALSE,NA
29563636,NCT01004003,309,AST/ALT/ALP was elevation >5Ã—ULN and for total bilirubin was elevation >3Ã—ULN,NA,NA,NA,For patients with normal liver enzymes at baseline
29563636,NCT01004003,309,AST/ALT/ALP was elevation >(baseline value + 4Ã—ULN) and for total bilirubin was elevation >3Ã—ULN,NA,NA,NA,For patients with elevated liver enzymes at baseline
25976292,NA,310,non-hematological toxicity attributable to ruxolitinib,3 or 4,NA,FALSE,NA
25976292,NA,310,non-hematological toxicity hat was consideredmedically significant or sufficiently intolerable by patients andrequired treatment interruption,2,>=7 days,NA,NA
25976292,NA,310,neutropenia,4,>14 dats,NA,for patients with STs
25976292,NA,310,thrombocytopenia,4,>14 dats,NA,for patients with STs
25976292,NA,310,"failure to recover an ANC>500/mm3 and platelets>20,000/mm3 by 42 days after first treatment day that wasnot due to malignant infiltration",NA,NA,NA,for patients with leukemia or MPNs
25248753,NA,311,neutropenia,4,â‰¥7 days,NA,NA
25248753,NA,311,neutropenia with fever,3 or 4,NA,NA,NA
25248753,NA,311,thrombocytopenia,4,â‰¥7 days,NA,NA
25248753,NA,311,diarrhea requiring hospitalization or lasting â‰¥24 h despite optimal anti-diarrheal therapy,3,NA,NA,NA
25248753,NA,311,diarrhea despite optimal anti-diarrheal therapy,4,NA,NA,NA
25248753,NA,311,serum transaminases (AST/ALT) for patients with grade 0â€“1 at baseline or â‰¥7Ã—ULN serum transaminases (AST/ALT) for patients with grade 2 at baseline,3,NA,NA,NA
25248753,NA,311,non-hematologic toxicity,>=3,NA,FALSE,NA
25248753,NA,311,the amylase or lipase elevations were symptomatic or when the nausea and vomiting despite optimal anti-emetic therapy,3 or 4,NA,NA,NA
21045832,NA,312,non-haematological toxicity,3 or 4,NA,FALSE,NA
21045832,NA,312,neutropenia,4,>=7 days,NA,NA
21045832,NA,312,febrile neutropenia defined as absolute neutrophil count <=1.0 x 109 l-1 and fever >=38.5C,NA,NA,NA,NA
21045832,NA,312,thrombocytopenia,4,NA,NA,NA
21045832,NA,312,uncontrolled hypertension,4,NA,NA,NA
22415798,NA,313,"non-hematological toxicity including nausea, vomiting and diarrhea in spite of adequate supportive care",>=3,NA,NA,NA
22415798,NA,313,hematologic toxicity,4,NA,NA,NA
22415798,NA,313,an unplanned interruption of dosing with either drug for more than 14 days before the start of the second cycle,NA,NA,NA,NA
25371323,NA,314,febrile neutropenia,NA,NA,NA,NA
25371323,NA,314,neutropenia,4,>7 days,NA,NA
25371323,NA,314,thrombocytopenia <25Ã—109/L,NA,NA,NA,NA
25371323,NA,314,thrombocytopenia in the presence of bleeding,3,NA,NA,NA
25371323,NA,314,nonhematological toxicity,3,NA,FALSE,NA
25371323,NA,314,skin toxicity (including hand-foot syndrome) despite optimal medical management,3 or 4,â‰¥2 weeks,NA,NA
26644411,NCT00785226,315,neutropenia,4,>7 days,NA,NA
26644411,NCT00785226,315,febrile neutropenia,3 or 4,NA,NA,NA
26644411,NCT00785226,315,thrombocytopenia,4,NA,NA,NA
26644411,NCT00785226,315,laboratory or non-hematologic toxicity,>=3,NA,NA,NA
26644411,NCT00785226,315,lipase and/or amylase elevation,>=3,NA,NA,NA
26644411,NCT00785226,315,skin toxicity (not hand-foot skin reaction),>=3,NA,NA,NA
26644411,NCT00785226,315,anemia,4,NA,NA,NA
26644411,NCT00785226,315,pulmonary hemorrhage/bleeding within 2 weeks of initial dose,>=2,NA,NA,NA
26644411,NCT00785226,315,diarrhea (if persists with anti-diarrheal medication),>=3,NA,NA,NA
26644411,NCT00785226,315,international normalized ratio or partial thromboplastin time with associated bleeding,>=3,NA,NA,NA
26644411,NCT00785226,315,hemorrhage/bleeding,>=3,NA,NA,NA
26644411,NCT00785226,315,missing 7 or more consecutive refametinib daily doses because of drug-related toxicity,NA,NA,NA,NA
22962440,NA,316,neutropenia,4,NA,NA,NA
22962440,NA,316,thrombocytopenia,4,NA,NA,NA
22962440,NA,316,any sorafenib-related nonhematologic toxicity,4,NA,NA,NA
22962440,NA,316,any sorafenib-related nonhematologic toxicity,3,NA,FALSE,NA
22962440,NA,316,toxicities intolerable,2,>=7 days,NA,NA
22962440,NA,316,"hypertension (a confirmed diastolic blood pressure >25 mm Hg above the ULN, or an elevated diastolic blood pressure not controlled by anti-hypertensive medication within 14 days)",4,NA,NA,NA
28488066,NCT01276210,317,neurologic toxicities which were attributable to the combination of sorafenib and SRS,>=3,NA,NA,NA
28488066,NCT01276210,317,NA,NA,NA,FALSE,NA
29520435,NCT01008566,318,as any treatment related non-hematologic toxicity,3 or 4,NA,FALSE,NA
29520435,NCT01008566,318,thrombocytopenia,4,NA,NA,NA
29520435,NCT01008566,318,neutropenia,4,NA,NA,NA
34109515,NCT01724606  ,319,non-hematologic toxicity,>=3,NA,FALSE,NA
34109515,NCT01724606  ,319,"nausea, vomiting, or dehydration",3,NA,FALSE,NA
34109515,NCT01724606  ,319,diarrhea not responsive to supportive care measures within 72 h,3,NA,NA,NA
34109515,NCT01724606  ,319,hand-foot skin reaction,>=3,NA,NA,NA
34109515,NCT01724606  ,319,symptomatic/persistent drug-related hypertension,>=2,NA,NA,NA
34109515,NCT01724606  ,319,lipase elevation only in the presence of clinical signs or symptoms of pancreatitis,3,NA,NA,NA
34109515,NCT01724606  ,319,lipase elevation with or without signs or symptoms of pancreatitis,4,NA,NA,NA
34109515,NCT01724606  ,319,"serum bilirubin, hepatic transaminases except for patients with liver or bone metastases with asymptomatic hepatic transaminase elevations related to the disease under the study â‰¥ 10 times upper limit of normal were considered as DLT",>=3,>2 weeks,NA,NA
34109515,NCT01724606  ,319,neutropenia,>=4,â‰¥4 days,NA,NA
34109515,NCT01724606  ,319,neutropenia with fever,>=4,NA,NA,NA
34109515,NCT01724606  ,319,"thrombocytopenia <10,000",>=4,one day,NA,NA
34109515,NCT01724606  ,319,thrombocytopenia,>=4,â‰¥7 days,NA,NA
34109515,NCT01724606  ,319,"thrombocytopenia <50,000 associated with bleeding",NA,NA,NA,NA
34109515,NCT01724606  ,319,anemia,4,NA,NA,NA
34109515,NCT01724606  ,319,Any unresolved drugrelated toxicity requiring drug interruption for>14 days,NA,NA,NA,NA
23061485,NA,320,absolute  granulocytes  < 0.5 x 1 0 9 /L,NA,>42 days,NA,NA
23061485,NA,320,febrile neutropenia,>=4,NA,NA,NA
23061485,NA,320,"infection with >= grade 3 neutropenia,",>=4,NA,NA,NA
23061485,NA,320,"thrombocytopenic bleeding,",>=3,NA,NA,NA
23061485,NA,320,any non-hematologic toxicity,>=3,NA,FALSE,NA
23061485,NA,320,decrease in calculated creatinine clearance to <40 mL/min,NA,NA,NA,NA
23061485,NA,320,inability to complete >= 8 days of cytarabine or  >= 22  days of sorafenib due to toxicity.,NA,NA,NA,NA
25818407,NCT00783653,321,haematological toxicity,4,longer than 35 d from start of chemotherapy,FALSE,NA
25818407,NCT00783653,321,hypertension,4,NA,NA,NA
25818407,NCT00783653,321,pancreatitis,2,NA,NA,NA
25818407,NCT00783653,321,non-haematological toxicities,>=3,NA,FALSE,NA
27681866,NCT01029418,322,afebrile neutropenia,4,>5 days,NA,NA
27681866,NCT01029418,322,neutropenia with fever,4,NA,NA,NA
27681866,NCT01029418,322,thrombocytopenia,4,NA,NA,NA
27681866,NCT01029418,322,inability to resume dosing within 14 days of drug interruption,NA,NA,NA,NA
27681866,NCT01029418,322,non-haematological toxicities,3,>7 days,NA,NA
30352941,NCT02024087,323,NA,NA,NA,NA,DLT not defined
20109071,NA,324,NA,NA,NA,NA,DLT not defined
26714427,NA,325,"thrombocytopenia  (platelet  count  <25,000/Î¼L) that was attributable to sorafenib or topotecan",4,>7  days,NA,NA
26714427,NA,325,neutropenia  (<500/Î¼L) that was attributable to sorafenib or topotecan,4,>7  days,NA,NA
26714427,NA,325,non-hematological toxicity,4,NA,NA,NA
26714427,NA,325,nonhematological toxicity,3,NA,FALSE,NA
26714427,NA,325,any adverse event considered intolerable by the patient/family and requiring treatment interruption >14 days,NA,NA,NA,NA
26714427,NA,325,any adverse event requiring interruption of study drug for >7 days and that recurred upon drug reintroduction,NA,NA,NA,NA
26714427,NA,325,hypertension,4,NA,NA,NA
26867886,NA,326,radiation-induced liver toxicity,>=4,NA,NA,NA
26867886,NA,326,iver enzymes >15 x ULN,NA,NA,NA,NA
26867886,NA,326,biliary,3 or 4,NA,NA,NA
26867886,NA,326,esophagus,NA,NA,NA,NA
26867886,NA,326,stomach,NA,NA,NA,NA
26867886,NA,326,small bowel,NA,NA,NA,NA
26867886,NA,326,large bowel toxicity (in the radiation field),NA,NA,NA,NA
26867886,NA,326,thrombocytopenia,4,NA,NA,NA
26867886,NA,326,thrombocytopenia with bleeding within 3 months,>=3,NA,NA,NA
26867886,NA,326,"toxicities within 4 weeks of SBRT, deemed likely related to radiation treatment",>=3,NA,NA,NA
26867886,NA,326,toxicities arising within the irradiated tissues 3 months or longer after the completion of SBRT were reviewed and could be designated as DLT at the discretion of the principal investigator,>=3,NA,NA,NA
25294187,NA,327,absolute neutrophil count (ANC),4,NA,NA,NA
25294187,NA,327,thrombocytopenia in the presence of bleeding,3,NA,NA,NA
25294187,NA,327,nonhematological toxicity,>=3,NA,FALSE,NA
25294187,NA,327,nausea/vomiting or diarrhea despite optimal medical management and reversible laboratory abnormalities with no clinical sequelae and/or no clinical significance in the opinion of an Investigator,3 or 4,NA,NA,NA
25294187,NA,327,any other toxicity that in the view of the Principal Investigator represented a clinically significant hazard to the patient,NA,NA,NA,NA
29313954,NCT00329719,328,hematologic toxicity,4,NA,NA,NA
29313954,NCT00329719,328,nonhematologic toxicity in the face ofmaximal supportive measure,3 or 4,NA,NA,NA
29313954,NCT00329719,328,intolerable nonhematological toxicity requiring a dose reduction during the first 28 days of treatment,2,NA,NA,NA
29313954,NCT00329719,328,intolerable hematological toxicity requiring a dose reduction during the first 28 days of treatment,3,NA,NA,NA
29313954,NCT00329719,328,any toxicity resulting in a treatment delay of >1 week during the first 28 days of treatment,NA,NA,NA,NA
33824476,NCT02115373,329,neutropenia,4,>7 days,NA,NA
33824476,NCT02115373,329,febrile neutropenia,>=3,>1 days,NA,NA
33824476,NCT02115373,329,thrombocytopenia,4,NA,NA,NA
33824476,NCT02115373,329,thrombocytopenia with non-traumatic bleeding,3,NA,NA,NA
33824476,NCT02115373,329,nausea/vomiting and/or diarrhoea despite optimal treatment,>=3,>3 days,NA,NA
33824476,NCT02115373,329,non-haematological adverse event,>=3,NA,FALSE,NA
33824476,NCT02115373,329,liver adverse event requiring a recovery period of more than 7 days to the baseline or to grade 1 (or less; this criterion was not limited to liver function tests),>=3,NA,NA,NA
33824476,NCT02115373,329,"lipase and/or amylase elevation with confirmation of pancreatitis, either based on clinical or radiological signs",>=3,NA,FALSE,NA
28465443,NCT01306058,330,treatment-related non-hematological toxicities,3,NA,NA,NA
28465443,NCT01306058,330,Drug-related  hematological toxicities,4,NA,NA,NA
28465443,NCT01306058,330,electrolyte toxicities to be corrected to Grade 1 or less within 24 hours,3,NA,NA,NA
28465443,NCT01306058,330,proteinuria >3.5g/24 hour,NA,NA,NA,NA
28465443,NCT01306058,330,toxicity requiring a dose reduction or a delay in treatment for >7 days,NA,NA,NA,NA
28465443,NCT01306058,330,Other toxicity related to TRC105,>=3,NA,NA,NA
28668472,NA,331,acute toxicities attributable to RT,>=3,NA,FALSE,NA
33649501,NCT01128998,332,un-manageable non-hematological toxicity,3 or 4,NA,FALSE,NA
33649501,NCT01128998,332,hematological toxicity,4,>7 days,NA,NA
33649501,NCT01128998,332,"hematological toxicity associated with complications (e.g., febrile neutropenia or bleeding)",3 or 4,NA,NA,NA
33649501,NCT01128998,332,prolonged (>21 days) delay of study drug administration at C3D1 due to persistent drug-related adverse events afer previous cycle of treatment,NA,NA,NA,NA
29898591,NCT01942083,333,Clinically significant non-hematological toxicities,>=3,NA,TRUE,NA
29898591,NCT01942083,333,"Nausea, vomiting, and diarrhea, uncontrollable by supportive therapy",>=3,NA,NA,NA
29898591,NCT01942083,333,Febrile neutropenia,NA,NA,NA,NA
29898591,NCT01942083,333,"neutropenia, even after receiving hematopoietic growth factor treatment",4,>=5 days,NA,NA
29898591,NCT01942083,333,thrombocytopenia,4,NA,NA,NA
29898591,NCT01942083,333,thrombocytopenia with bleeding,3,NA,NA,NA
29898591,NCT01942083,333,Any toxicity that was at least possibly drug-related requiring the delay of study treatment longer than 8 days,NA,NA,NA,NA
33785364,NCT02046291,334,NA,NA,NA,NA,DLT not defined
15870716,NA,335,nonhaematological toxicity,>=3,NA,FALSE,NA
15870716,NA,335,neutropenia,4,>=4 days,NA,NA
15870716,NA,335,thrombocytopenia,>=3,NA,NA,NA
15073100,NA,336,hematological or febrile events,4,NA,NA,NA
15073100,NA,336,other adverse events,3 or 4,NA,NA,NA
27103123,NA,337,non-hematologic toxicity,3 or 4,NA,FALSE,NA
27103123,NA,337,non-hematologic toxicities which caused more than 30 % of the doses of both drugs to be held,2,NA,NA,NA
27103123,NA,337,decrease in ventricular function,>=2,NA,NA,NA
27103123,NA,337,neutropenia,4,>3 days,NA,NA
27103123,NA,337,neutropenia associated with fever,4,NA,NA,NA
27103123,NA,337,"Platelet count <25,000/Î¼l",NA,NA,NA,NA
27103123,NA,337,Any treatment-related toxicity that persists without sufficient recovery to permit the start of a new cycle within 4 weeks of the planned date,NA,NA,NA,NA
28988377,NA,338,hematologic toxicity,4,NA,NA,NA
28988377,NA,338,thrombocytopenia,3,>7 days,NA,NA
28988377,NA,338,non-hematologic toxicity,3 or 4,NA,FALSE,NA
28988377,NA,338,any intolerable non-hematological toxicity requiring a dose reduction during the first 28 days of treatment,2,NA,NA,NA
28988377,NA,338,hematological toxicity requiring a dose reduction during the first 28 days of treatment,3,NA,NA,NA
28988377,NA,338,any toxicity resulting in a treatment delay of >1 week during the first 28 days of treatment,NA,NA,NA,NA
31305287,NCT01075113,339,"nausea, vomiting, or diarrhea responsive to medical management",3,NA,FALSE,NA
31305287,NCT01075113,339,fatigue responsive to medical management,3,NA,NA,NA
31305287,NCT01075113,339,hypertension,3,NA,NA,NA
31305287,NCT01075113,339,clinically insignificant laboratory abnormalities,3,NA,NA,NA
31305287,NCT01075113,339,palmar-plantar erythrodysesthesia,3,NA,NA,NA
24786603,NCT00884416,340,thrombocytopenia,4,NA,NA,NA
24786603,NCT00884416,340,neutropenia,4,>7 days,NA,NA
24786603,NCT00884416,340,febrile neutropenia,3 or 4,NA,NA,NA
24786603,NCT00884416,340,nonhaematologic toxicities,3 or 4,NA,FALSE,NA
25711511,NCT01656265,341,neutropenia,4,>7 days,NA,NA
25711511,NCT01656265,341,thrombocytopenia,4,>5 days,NA,NA
25711511,NCT01656265,341,any thrombocytopenia requiring platelet transfusion,NA,NA,NA,NA
25711511,NCT01656265,341,febrile neutropenia,NA,>2 days,NA,NA
25711511,NCT01656265,341,anemia,4,NA,NA,NA
25711511,NCT01656265,341,non-hematologic  toxicity,>=3,NA,FALSE,NA
25711511,NCT01656265,341,any drug-related AE requiring interruption of tivantinib at theassigned dose a total ofâ‰¥15 times,NA,NA,NA,NA
25711511,NCT01656265,341,any drug-related AEconsidered DLT by the investigator,1,NA,NA,NA
16006586,NA,342,hematological toxicity,>=3,NA,NA,NA
16006586,NA,342,non-hematological toxicity,>=3,NA,NA,NA
16006586,NA,342,clinically significant hematological or non-hematological toxicity considered by the primary investigator to warrant withholding the study medication and to be at least possibly related to study drug,1,NA,NA,NA
22961690,NA,343,femoralgrowth plate volume expansion on MRI greater than 2 times frombaseline,NA,NA,NA,NA
22961690,NA,343,Patients with a >6% bone mineral density (BMD) decrease on lumbar spinedual-energy X-ray absorptionmetry (DEXA) scan relative frombaseline and a BMD Z score of<2.5,NA,NA,NA,NA
22961690,NA,343,any toxicity,>=3,NA,FALSE,NA
22961690,NA,343,Persistent (>=7 days) toxicities if they are intolerable with standard supportive measures,2,NA,NA,NA
25239228,NCT01398501,344,drug-related AE that did not resolve to grade or less in 14 days or recurs after resuming sorafenib,NA,NA,FALSE,NA
25239228,NCT01398501,344,neutropenia,4,NA,NA,NA
25239228,NCT01398501,344,thrombocytopenia,4,NA,NA,NA
24554062,NCT00805727,345,anemia,4,NA,NA,NA
24554062,NCT00805727,345,neutropenia,4,>7 days,NA,NA
24554062,NCT00805727,345,thrombocytopenia with clinically significant bleeding,3 or 4,NA,NA,NA
24554062,NCT00805727,345,thrombocytopenia,4,>5 days,NA,NA
24554062,NCT00805727,345,non-hematologic toxicity,3 or 4,NA,TRUE,NA
28202227,NCT00892424,346,classic or non-classic radiation induced liver disease (RILD),>=3,NA,NA,NA
28202227,NCT00892424,346,treatment-related toxicity,>=4,NA,NA,NA
21246251,NA,348,non-hematological toxicity,>=3,NA,FALSE,NA
21246251,NA,348,absolute neutrophil count decrease,4,â‰¥7 days,NA,NA
21246251,NA,348,absolute neutrophil count decrease with fever exceeding 38.5Â°Celsius,4,NA,NA,NA
21954442,NA,349,absolute neutrophil count â‰¤500/uL,NA,NA,NA,NA
21954442,NA,349,platelet count â‰¤25 000/uL,NA,NA,NA,NA
21954442,NA,349,febrile neutropenia,NA,NA,NA,NA
21954442,NA,349,any nonhematological toxicities,>3,NA,NA,NA
21954442,NA,349,treatment delay .14 days because of treatment-related toxicity,NA,NA,NA,NA
30478190, NCT01296581,350,NA,NA,NA,NA,DLT not defined
23099651,NA,351,hematologic toxicity,4,NA,NA,NA
23099651,NA,351,thrombocytopenia,4,>7 days,NA,NA
23099651,NA,351,nonhematologic toxicity,>=3,NA,FALSE,NA
23099651,NA,351,any intolerable grade 2 nonhematological or grade â‰¥3 hematological toxicity requiring dose reduction during the first 28 days of treatment,NA,NA,NA,NA
23099651,NA,351,any toxicity resulting in treatment delay greater than 1 week during the first 28 days of treatment,NA,NA,NA,NA
27992451, NCT00764972,352,"Febrile neutropenia, defined as a temperature >=38.5 C in the presence of ANC <1.0 X 109/L",NA,NA,NA,NA
27992451, NCT00764972,352,neutropenia,4,>5 days,NA,NA
27992451, NCT00764972,352,thrombocytopenia or anemia,4,NA,NA,NA
27992451, NCT00764972,352,thrombocytopenia,3,>5 days,NA,NA
27992451, NCT00764972,352,AST-ALT increase,3,>5 days,NA,NA
27992451, NCT00764972,352,rash,3,>24 h from supension of sorafenib and adequate treatment with loperamide or diphenoxylate/atropine,NA,NA
27992451, NCT00764972,352,other non-hematological toxicity,>=3,NA,FALSE,NA
27992451, NCT00764972,352,"impossibility to start the second cycle of therapy within 14 days from the planned day, as a consequence of toxicity",4,NA,NA,NA
33646489,NA,353,toxicity attributed to study treatment,5,NA,NA,NA
33646489,NA,353,neutropenia,4,>7 days,NA,NA
33646489,NA,353,Febrile neutropenia,NA,NA,NA,NA
33646489,NA,353,thrombocytopenia,4,NA,NA,NA
33646489,NA,353,ischemia cerobrovascular,NA,NA,NA,NA
33646489,NA,353,stroke,NA,NA,NA,NA
33646489,NA,353,transient ischemic attack,NA,NA,NA,NA
33646489,NA,353,non-hematological AEs,>=3,>=14 days,NA,NA
33646489,NA,353,Other non-hematologic laboratory criteria,>3,>=14 days,NA,NA
33646489,NA,353,elevated lipase only qualifies as DLT if it is in the presence of clinical pancreatits,>3,>=14 days,NA,NA
21594722,NA,354,thrombocytopenia (platelets <25 K/mm3),4,NA,NA,NA
21594722,NA,354,"hematologic toxicity (ANC <= 0.5 K/mm3, leukocytes <1 K/mm3, hemoglobin <6.5 g/dL)",4,>=5 days,FALSE,NA
21594722,NA,354,non-hematologic toxicity despite appropriate supportive care,>=3,NA,NA,NA
21594722,NA,354,neutropenic fever,NA,NA,NA,NA
21594722,NA,354,neurotoxicity,>=2,>=1 week,NA,NA
21594722,NA,354,Any toxicity that had not resolved within 4 weeks of the end of cycle 1 (except grade 2 alopecia) was reviewed by the safety committee for consideration of DLT,>=2,NA,NA,NA
33972742,NCT01988493,355,neutropenia,4,>7 days,NA,NA
33972742,NCT01988493,355,febrile neutropenia,>=3,>1 day,NA,NA
33972742,NCT01988493,355,thrombocytopenia,4,NA,NA,NA
33972742,NCT01988493,355,thrombocytopenia with non-traumatic bleeding,3,NA,NA,NA
33972742,NCT01988493,355,nausea/vomiting and/or diarrhea despite optimal treatment,>=3,NA,NA,NA
33972742,NCT01988493,355,non-hematologic event,>=3,NA,FALSE,NA
33972742,NCT01988493,355,liver AE requiring a recovery period of more than 7 days to the baseline or to grade 1 (or less; this criterion was not limited to liver function tests),>=3,NA,NA,NA
11304768,NA,356,NA,NA,NA,NA,DLT not defined
32634234,NCT01787552,357,"an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria",NA,NA,NA,NA
16061863,NA,358,hematologic toxicity,>=4,>5 days,NA,NA
16061863,NA,358,nonhematologic toxicity,>=3,NA,NA,NA
23519998,NA,359,hematologic toxicity,4,NA,FALSE,NA
23519998,NA,359,thrombocytopenia,3,â‰¥7 days,NA,NA
23519998,NA,359,"clinically-relevant, non-hematologic toxicity despite optimal supportive care.",>=3,NA,FALSE,NA
23519998,NA,359,Toxicity from chronic liver disease required increase â‰¥2 grades from baseline,NA,NA,NA,NA
23519998,NA,359,any treatment-related toxicity requiring dose reduction or delay >8 days within cycle 1,NA,NA,NA,NA
25145500,NA,360,"all limb-related, systemicrelated, nonhematologic drugâ€“ or procedure-related adverse events that occurred up to15 days after ILI",>=3,NA,NA,NA
23554030,NCT01076530,361,neutropenia,4,>7 days,NA,NA
23554030,NCT01076530,361,"platelet count <20,000/ml on 2 separate days or requiring a platelet transfusion on 2 separate days (within a 7-day period)",NA,NA,NA,NA
23554030,NCT01076530,361,myelosuppression that causes a delay of >14 days between treatment cycles,NA,NA,NA,NA
23554030,NCT01076530,361,any nonhematological toxicity that precludes administration of at least 80% of the planned dose intensity of VOR or TEM during a given cycle,NA,NA,NA,NA
23554030,NCT01076530,361,non-hematologicaltoxicity that causes a delay of >=14 days between treatment cycles,NA,NA,NA,NA
23554030,NCT01076530,361,non-hematological toxicity attributable to VORor TEM,3 or 4,NA,FALSE,NA
28295182,NCT01403415,362,"aboratory abnormalities included electrolyteabnormalities, elevated hepatic function tests and hypofib-rinogenaemia",3 or 4,NA,FALSE,NA
28295182,NCT01403415,362,Any tox-icity resulting in temsirolimus dose omission,NA,NA,FALSE,NA
28295182,NCT01403415,362,bone marrow aplasia at â‰¥day 42 not attribu-table to leukaemia progression,NA,NA,NA,NA
26235333,NA,363,toxicity,5,NA,NA,NA
26235333,NA,363,neurotoxicity,3,NA,NA,NA
26235333,NA,363,neutropenia,4,>=7 days,NA,NA
26235333,NA,363,thrombocytopenia,4,>=7 days,NA,NA
26235333,NA,363,thrombocytopenia with bleeding,3,NA,NA,NA
26235333,NA,363,elevation of transaminases,3,>=7 days,NA,NA
26235333,NA,363,cardiotoxicity,2,NA,NA,NA
26235333,NA,363,any other non-hematologictoxicity,3,NA,FALSE,NA
25467181,NA,365,neutropenia,4,">7 days or before drug administration on days 8, 15, or 21",NA,NA
25467181,NA,365,"platelet count <20,000/mm3 on 2 separate days or requiring platelet transfusions on 2 separate days within a 7-day period",NA,NA,NA,NA
25467181,NA,365,myelosuppression that caused a delay of >=14 days between treatment cycles,NA,NA,NA,NA
25467181,NA,365,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25467181,NA,365,nonhematologic toxicity that caused a delay of >=14 days between treatment cycles,NA,NA,NA,NA
24194293,NA,366,non-hematologic toxicity,>=3,NA,NA,NA
24194293,NA,366,hematologic toxicity,>=4,NA,NA,NA
24194293,NA,366,Any radiation treatment delay longer than 2 weeks due to NFV,NA,NA,NA,NA
28004284,NA,367,"nausea, vomiting, diarrhea, stomatitis, hyperlipidemia or rash uncontrolled despite maximal medical management",>=3,NA,NA,NA
28004284,NA,367,any other non-hematologic toxicity,>=3,NA,FALSE,NA
28004284,NA,367,inability to deliver more than 75% of the protocol specified cycle 1 treatment due to an at least probably treatment-related toxicity,NA,NA,NA,NA
28004284,NA,367,dose delay of more than 7 days starting prior to day 1 of cycle 2 if the delay is due to an at least probably treatment-related toxicity,NA,NA,NA,NA
28004284,NA,367,neutropenia,>=3,>7 days,NA,NA
28004284,NA,367,neutropenia or neutropenic fever,4,NA,NA,NA
28004284,NA,367,thrombocytopenia,>3,>7 days,NA,NA
28004284,NA,367,thrombocytopenia associated with a clinically significant or lifethreatening bleed,>3,NA,NA,NA
28004284,NA,367,thrombocytopenia,4,NA,NA,NA
11302252,NA,368,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11302252,NA,368,nausea and vomiting,4,NA,NA,NA
11302252,NA,368,"thrombocytopenia (<25,000/liter)",4,5 days,NA,NA
11302252,NA,368,neutropenia (<500/liter),4,7 days,NA,NA
11302252,NA,368,neutropenia with fever requiring hospital admission,4,NA,NA,NA
26686201,NA,369,non-hematologic toxicity,4,NA,NA,NA
26686201,NA,369,non-hematologic toxicity which did not resolve to G1 within 48 h,3,NA,NA,NA
26686201,NA,369,toxicities that resulted in failure to receive â‰¥75 % of the pre-planned doses of trebananib and/or temsirolimus,NA,NA,NA,NA
26686201,NA,369,neutropenia <0.5 Ã— 109/L,NA,â‰¥7 days,NA,NA
26686201,NA,369,neutropenic fever,NA,NA,NA,NA
26686201,NA,369,thrombocytopenia <25 Ã— 109/L or thrombocytopenic bleeding,NA,NA,NA,NA
16134182,NA,370,ANC nadir <500/uL,NA,>4 days,NA,NA
16134182,NA,370,resulting in hospitalization for thetreatment  of  febrile  neutropenia,NA,NA,NA,NA
16134182,NA,370,"platelet  nadir <50,000/uL",NA,>4 days,NA,NA
16134182,NA,370,a documented bleeding episode associated with thrombocytopenia or a requirement for a platelet transfusion,NA,NA,NA,NA
16134182,NA,370,treatment-related nonhematologic toxicity,3 or 4,NA,FALSE,NA
21735117,NA,371,non-hematologic toxicity,>=3,NA,NA,NA
21735117,NA,371,hematologic toxicity,4,NA,NA,NA
21735117,NA,371,"failure to recover from any toxicity to Bgrade 1 within 2 weeks of the end of the cycle (i.e., 6 weeks from day 1 of temozolomide administration)",NA,NA,NA,NA
21735117,NA,371,Any toxicity resulting in a >14-day delay to re-treat,NA,NA,NA,NA
23605083,NA,372,hematologic toxicity,4,NA,NA,NA
23605083,NA,372,hyperglycemia that could not be controlled with diabetic mediation,NA,NA,NA,NA
23605083,NA,372,nonhematologic toxicity,>=3,NA,FALSE,NA
23605083,NA,372,dose reduction or treatment delay of greater than 1 week during first treatment cycle,NA,NA,NA,NA
20934264,NA,373,hematologic toxicity,4,NA,NA,NA
20934264,NA,373,any nonhematologic toxicity,3,NA,NA,NA
20934264,NA,373,radiation-induced skin changes,4,NA,NA,NA
20934264,NA,373,failure to recover from toxicities within 3 weeks from the last dose of study drug,NA,NA,NA,NA
20934264,NA,373,holding radiation therapy for more than 2 weeks because of toxicity,NA,NA,NA,NA
24908656,NA,375,neutropenia,4,>7 days,NA,NA
24908656,NA,375,thrombocytopenia on 2 separate days,4,within a 7-day period,NA,NA
24908656,NA,375,thrombocytopenia on 2 separate days requiring a transfusion on 2 separate days,4,within a 7-day period,NA,NA
24908656,NA,375,a delay of .14 days in starting the next course,NA,NA,NA,NA
24908656,NA,375,nonhematologic toxicity,3 or 4,NA,FALSE,NA
24908656,NA,375,nonhematologic toxicity,2,>14 days,NA,NA
23860641,NCT 01198184,377,neutropenia complicated by fever â‰¥38.5 Â°C,3 or 4,NA,NA,NA
23860641,NCT 01198184,377,neutropenia,4,>=7 days,NA,NA
23860641,NCT 01198184,377,thrombocytopenia complicated by hemorrhage,3,NA,NA,NA
23860641,NCT 01198184,377,thrombocytopenia,4,NA,NA,NA
23860641,NCT 01198184,377,non-hematologic toxicity,>=3,NA,FALSE,NA
23860641,NCT 01198184,377,"electrolyte abnormality including hypophosphatemia, hypocalcemia, or hypomagnesemia that did not resolve within 72 h with appropriate therapy or if it was associated with new ECG changes",>=3,NA,NA,NA
23860641,NCT 01198184,377,treatment-related toxicities that resulted in failure to receive at least 75 % of the planned doses of RO4929097 and of temsirolimus despite maximal supportive care measures,NA,NA,NA,NA
23860641,NCT 01198184,377,inability to resume dosing for cycle 2 at the current dose level within 14 days due to treatment-related toxicity,NA,NA,NA,NA
15014015,NA,378,nonhematological toxicity,>=3,NA,FALSE,NA
15014015,NA,378,transaminitis,3,>2 weeks,NA,NA
15014015,NA,378,ANC <500/ul,NA,>5 days,NA,NA
15014015,NA,378,ANC <500/ul associated with fever,NA,NA,NA,NA
15014015,NA,378,hemoglobin <6.5 g/dl,NA,NA,NA,NA
15014015,NA,378,"platelet count <25,000/ul",NA,NA,NA,NA
20156802,NA,379,thrombocytopenia,>=3,NA,NA,NA
20156802,NA,379,anemia or neutropenia,4,NA,NA,NA
20156802,NA,379,nonhematologic toxicity,>=3,NA,NA,NA
20156802,NA,379,radiation-induced skin changes,4,NA,NA,NA
24880570,NA,380,nonhematologic toxicity,>=3,NA,FALSE,NA
24880570,NA,380,neutropenia,4,>7 days,NA,NA
24880570,NA,380,neutropenia with fever of 38.5 Â°C (101.3 Â°F) or higher,3,NA,NA,NA
24880570,NA,380,thrombocytopenia,4,NA,NA,NA
24880570,NA,380,thrombocytopenia with clinically significant bleeding,3,NA,NA,NA
24880570,NA,380,QTc interval >500 ms or QTc variation from baseline >60 ms on â‰¥2 electrocardiograms (ECGs) performed at the same visit,NA,NA,NA,NA
24880570,NA,380,persistence of nonhematologic toxicity at the initiation of cycles 2 or 3,>=2,NA,NA,NA
24880570,NA,380,any prolonged myelotoxicity that delays initiation of cycle 3 by more than 1 week,>=2,NA,NA,NA
23633392,NA,381,thrombocytopenia,4,NA,NA,NA
23633392,NA,381,anemia and/or neutropenia,4,NA,NA,NA
23633392,NA,381,any nonhematologic toxicity including grade 3 vomiting or diarrheauncontrolled by supportive therapy,3,NA,FALSE,NA
25832688,NA,382,neurological adverse events considered to be related to the RT-TMZ-MGd combination treatment,>=4,NA,NA,NA
26503473,NCT00121680,383,any hematologic toxicity,>=3,NA,NA,NA
26503473,NCT00121680,383,any nonhematologic toxicity,>=3,NA,FALSE,NA
26503473,NCT00121680,383,any failure to administer â‰¥ 75% of the study drugs during cycle 1 due to treatment-related toxicities,NA,NA,NA,NA
10561328,NA,384,ANC less than 500/ÂµL,NA,>5 days,NA,NA
10561328,NA,384,ANC less than 500/ÂµL associated with fever requiring hospitalization for parenteral antibiotics,NA,NA,NA,NA
10561328,NA,384,hemoglobin less than 6.5 mg/dL,NA,NA,NA,NA
10561328,NA,384,"platelets less than 25,000/ÂµL",NA,NA,NA,NA
10561328,NA,384,serum creatinine elevation greater than twice the upper limit of normal,NA,NA,NA,NA
10561328,NA,384,nonhematologic toxicity,3 or 4,NA,FALSE,NA
32293798,NCT01051557,385,hrombocytopenia,3,NA,NA,NA
32293798,NCT01051557,385,anemia or neutropenia,4,NA,NA,NA
32293798,NCT01051557,385,nacceptable non-hematologic toxicity resulting in a treatment delay of >7 days despite maximal medical treatment,2,NA,NA,NA
32293798,NCT01051557,385,nonhematologic toxicity,3 or 4,NA,FALSE,NA
32293798,NCT01051557,385,failure to recover from toxicities to be eligible for retreat-ment within 14 days of last dose,NA,NA,NA,NA
25374407,NA,386,non-hematological toxicity considered to be a direct result of therapy,3 or 4,NA,FALSE,NA
25374407,NA,386,neutropenia,4,>7 days,NA,NA
25374407,NA,386,thrombocytopenia,4,>7 days,NA,NA
10576660,NA,387,neutropenia (absolute neutrophil count of < 0.5 Ã— 109 lâ€“1),4,NA,NA,NA
10576660,NA,387,anaemia (haemoglobin of < 6.5 g dlâ€“1),4,NA,NA,NA
10576660,NA,387,thrombocytopenia (platelet count of <50 Ã— 109 lâ€“1),3,NA,NA,NA
10576660,NA,387,serum creatinine of > 2.0 mg dlâ€“1,NA,NA,NA,NA
10576660,NA,387,another adverse event,3 or 4,NA,FALSE,NA
26285766,NA,388,non-hematological toxicities,3 or 4,NA,FALSE,NA
26285766,NA,388,ANC <=500/mm3,NA,NA,NA,NA
26285766,NA,388,"Platelets <=25,000/mm3",NA,NA,NA,NA
26285766,NA,388,WBC <1000/mm3,NA,NA,NA,NA
26285766,NA,388,Any drug-associated toxicity that prevented administration of >=80 % of the planned TMZ and iniparib doses for the first cycle,NA,NA,NA,NA
24323026,NCT00838539,389,"nausea, vomiting, hyperglycemia, hypophosphatemia, hypertriglyceridemia, and hypercholesterolemia despite of receiving optimal medical therapy",3 or 4,NA,NA,NA
24323026,NCT00838539,389,diarrhea on optimal therapy,3 or 4,>2 days,NA,NA
24323026,NCT00838539,389,neutropenia,4,>3 days,NA,NA
24323026,NCT00838539,389,neutropenia with sepsis/fever,3 or 4,NA,NA,NA
24323026,NCT00838539,389,thrombocytopenia,4,NA,NA,NA
24323026,NCT00838539,389,bleeding requiring platelet transfusion,NA,NA,NA,NA
16234526,NA,390,Nonhematologic toxicity,>=3,NA,FALSE,NA
16234526,NA,390,failure to recover to grade <= 1 toxicity level by day 42 of a treatment cycle,NA,NA,NA,NA
16234526,NA,390,neutropenia,4,>= 5 days,NA,NA
16234526,NA,390,"a platelet count less than 10,000/uL on two separate days of a treatment cycle",NA,NA,NA,NA
16234526,NA,390,"failure to recover to an absolute neutrophil count (ANC) of 1,500/uL and platelet count of 100,000/uL by day 42 of a treatment cycle",4,NA,NA,NA
16234526,NA,390,the requirement for more than two platelet transfusions in a treatment cycle,NA,NA,NA,"For brain tumor patients transfused for platelet counts less than 50,000/uL"
20511167,NA,391,"treatment-related, nonhematologic toxicity that did not resolve to grade â‰¤ 2 within 24 hours (with protocol-defined exceptions)",3,NA,NA,NA
20511167,NA,391,nonhematologic toxicity,4,NA,NA,NA
20511167,NA,391,bone marrow hypoplasia â‰¥ 42 days with cellularity â‰¤ 5% and no evidence of leukemia,NA,NA,NA,NA
9738573,NA,392,nonhematologic toxicity,4,NA,NA,NA
9738573,NA,392,hematologic toxicity,4,NA,NA,NA
9738573,NA,392,nonhematologic toxicity that did not resolve within 7 days,3,NA,NA,NA
9744506,NA,393,neutropenia that did not resolve within 7 days,4,NA,NA,NA
9744506,NA,393,anaemia that did not resolve within 7 days,4,NA,NA,NA
9744506,NA,393,thrombocytopenia that did not resolve within 7 days,3,NA,NA,NA
9744506,NA,393,thrombocytopenia,4,NA,NA,NA
9744506,NA,393,other toxicity,3 or 4,NA,FALSE,NA
28618305,NA,394,"non-hematological toxicity, not resolved to a grade â‰¤ 2, 14 days after drug interruption and appropriate supportive care",3,NA,FALSE,NA
28618305,NA,394,non-hematological toxicity occurring despite appropriate supportive care,4,NA,NA,NA
28618305,NA,394,"neutropenia, lymphocytopenia or thrombocytopenia",4,>=7 days,NA,NA
28618305,NA,394,"Any toxicity leading to a treatment interruption for more than 14 days, or the omission of two of the four planned injections",NA,NA,NA,NA
28618305,NA,394,Any toxicity leading to a delay of the second cycle for more than 14 days,NA,NA,NA,NA
21881915,NA,395,Nonhematologic toxicity,>=3,NA,NA,NA
21881915,NA,395,neutropenia,4,NA,NA,NA
21881915,NA,395,anemia,4,NA,NA,NA
21881915,NA,395,"platelets <25,000",NA,NA,NA,NA
21881915,NA,395,serum creatinine â‰¥2 times baseline,NA,NA,NA,NA
21881915,NA,395,Any persistent or intolerable toxicity leading to dose delay or dose reduction,NA,NA,NA,NA
30393943,NA,396,hrombocytopenia,4,>=7 days,NA,NA
30393943,NA,396,hrombocytopenia requiring â‰¥2 transfusions within 7 days,4,NA,NA,NA
30393943,NA,396,febrile neutropenia or infection with grade 4 neutropenia,NA,NA,NA,NA
30393943,NA,396,neutropenia,4,>=7 days,NA,NA
30393943,NA,396,hematologic toxicity requiring treatment hold that did not recover within two weeks.,NA,NA,NA,NA
30393943,NA,396,any nonhematologic toxicity,>=3,NA,FALSE,NA
30393943,NA,396,oral mucositis,3,>5 days,NA,NA
30393943,NA,396,the inability to administer one or both drugs on at least four of six weeks in cycle 1 due to nonhematologic toxicity,NA,NA,NA,NA
22923449,NCT00268385,397,thrombocytopenia,3 or 4,NA,NA,NA
22923449,NCT00268385,397,anemia,4,NA,NA,NA
22923449,NCT00268385,397,neutropenia,4,NA,NA,NA
22923449,NCT00268385,397,any nonhematologic toxicity,>=3,NA,FALSE,NA
22923449,NCT00268385,397,"nausea, vomiting, or diarrhea not be controlled by medical therapy",3 or 4,NA,NA,NA
21750201,NA,398,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21750201,NA,398,thrombocytopenia,3 or 4,>7 days,NA,NA
21750201,NA,398,thrombocytopenia associated with active bleeding or requiring platelet transfusion,NA,NA,NA,NA
21750201,NA,398,anemia,3,NA,NA,NA
21750201,NA,398,neutropenia,4,NA,NA,NA
21750201,NA,398,drug related death,NA,NA,NA,NA
24991839,NA,399,any treatment-related adverse event that occurred during the first 6 wk of this study that was at least possibly related to the study drugs,>=3,NA,NA,NA
24991839,NA,399,Nausea and vomiting in the setting of multimodal antiemetic prophylaxis,>=3,NA,NA,NA
24991839,NA,399,neutropenia,4,>7 days,NA,NA
24991839,NA,399,febrile  neutropenia,NA,NA,NA,NA
24991839,NA,399,"platelet  count  <  10,000/mm3",NA,NA,NA,NA
28194539,NCT01378377,400,nonhematologic toxicity,>=3,NA,NA,NA
28194539,NCT01378377,400,neutropenia,4,> 5 days,NA,NA
28194539,NCT01378377,400,febrile neutropenia,NA,> 1 day,NA,NA
28194539,NCT01378377,400,thrombocytopenia with bleeding,3,NA,NA,NA
28194539,NCT01378377,400,thrombocytopenia,4,NA,NA,NA
28194539,NCT01378377,400,any treatment interruption of > 2 weeks that was due to adverse events (AEs) not related to the underlying disease or concomitant medication,NA,NA,NA,NA
28194539,NCT01378377,400,any severe or life-threatening condition not defined by NCI-CTCAE that was attributable to study treatment,NA,NA,NA,NA
18006772,NA,401,neutropenia,4,>7 days,NA,NA
18006772,NA,401,anemia,4,NA,NA,NA
18006772,NA,401,thrombocytopenia,4,NA,NA,NA
18006772,NA,401,need of >= 2 platelet transfusions within 7 days,NA,NA,NA,NA
18006772,NA,401,delay of >=14 days of planned interval between courses because of hematologic toxicity,NA,NA,NA,NA
18006772,NA,401,nonhematologic toxicity,3 or 4,NA,FALSE,NA
18006772,NA,401,failure to recover from any non-DLT to <= grade 1 within 6 weeks from temozolomide administration,NA,NA,NA,NA
19289491,NA,402,neutropenia,4,>4 days,NA,NA
19289491,NA,402,"febrile neutropenia (absolute neutrophil count <1 x 109/L, fever .>38.5Â°C)",>3,NA,NA,NA
19289491,NA,402,thrombocytopenia,>4,NA,NA,NA
19289491,NA,402,nonhematologic toxicity that is related to study drug,>3,NA,FALSE,NA
19289491,NA,402,"Any adverse event causing .14 days of interruption to therapy (ie, a delay beyond day 42)",NA,NA,NA,NA
16192602,NA,403,nonhematopoietic toxicity,>=3,NA,NA,NA
16192602,NA,403,hematologic toxicity,4,NA,NA,NA
20821342,NA,404,neutropenia,4,NA,NA,NA
20821342,NA,404,thrombocytopenia,>=3,NA,NA,NA
20821342,NA,404,treatment delay >7 days due to hematologic toxicity,NA,NA,NA,NA
20821342,NA,404,serum creatinine >=2.0 x upper limit of normal,NA,NA,NA,NA
20821342,NA,404,hypertension or hematuria,>=2,NA,NA,NA
20821342,NA,404,clinically significant adverse events attributed to vatalanib,>=3,NA,NA,NA
25962426,NCT00321594,405,hematological toxicity,4,NA,NA,NA
25962426,NCT00321594,405,non-hematological toxicity,>=3,NA,FALSE,NA
25962426,NCT00321594,405,"nausea, vomiting, or diarrhoea that did not respond to therapy",3,NA,NA,NA
25962426,NCT00321594,405,treatment delay > 2 weeks,NA,NA,NA,NA
23726267,NA,406,nonhematologic toxicity despite optimal supportive care,3,>3 days,FALSE,NA
23726267,NA,406,nonhematologic toxicity,4,NA,NA,NA
23726267,NA,406,Neutropenia  associated with fever (oral temperature >39ÂºC) and requiring antibiotic therapy,3 or 4,NA,NA,NA
23726267,NA,406,Neutropenia,4,>5 days,NA,NA
23726267,NA,406,thrombocytopenia,4,NA,NA,NA
23726267,NA,406,Toxicity of any grade that results in interruption of treatment for >2 weeks,NA,NA,NA,NA
16899365,NA,407,"renal, cardiovascular, pulmonary or CNS toxicities",>=3,NA,NA,NA
16899365,NA,407,non-myelotoxicity,4,NA,NA,NA
16899365,NA,407,myelotoxicity,4,>=1 week,NA,NA
16899365,NA,407,severe infection,NA,NA,NA,NA
16614943,NA,408,hematologic toxicity that could be directly attributed to protocol therapy,4,NA,NA,NA
16614943,NA,408,non-hematologic toxicity that could be directly attributed to protocol therapy,3 or 4,NA,NA,NA
11606103,NA,409,nadir hematologic values for absolute neutrophil count and platelet counts,3 or 4,NA,NA,NA
11606103,NA,409,nonhematologic toxicity,>=3,NA,NA,NA
21063221,NA,410,toxicity  that occurred within 30 days of taking study drug or while on protocol therapy,5,NA,NA,NA
21063221,NA,410,toxicity,4,NA,FALSE,NA
21063221,NA,410,central nervous system/peripheral nervous system (CNS/PNS) toxicity,3,NA,NA,NA
21063221,NA,410,toxicity that was considered medically significant or intolerable by patients so that it required treatment interruption longer than 7 days,2,>7 days,NA,NA
11742479,NA,411,haematologic toxicity,4,NA,NA,NA
11742479,NA,411,non-haematologic toxicity,3,NA,NA,NA
29138343,NCT01012817,412,anemia or thrombocytopenia,4,NA,NA,NA
29138343,NCT01012817,412,neutropenia,4,>=5 days,NA,NA
29138343,NCT01012817,412,"nausea, diarrhea, or vomiting in spite of maximal supportive care and prophylaxis",3,NA,NA,NA
29138343,NCT01012817,412,clinically significant nonhematologic toxicity,>=3,NA,FALSE,NA
29138343,NCT01012817,412,serum creatinine >= 2 times baseline or >= 2 times ULN if baseline is less than the ULN,NA,NA,NA,NA
11721172,NA,413,neutropenia,4,>5 days,NA,NA
11721172,NA,413,thrombocytopenia,4,>5 days,NA,NA
11721172,NA,413,febrile neutropenia,NA,NA,NA,NA
11721172,NA,413,non-hematologic toxicity,>=3,NA,FALSE,NA
11721172,NA,413,any treatment delay on day 15 because of unresolved toxicity,NA,NA,NA,NA
23604531,NA,414,neutropenia,4,NA,NA,NA
23604531,NA,414,thrombocytopenia,4,NA,NA,NA
23604531,NA,414,"neutropenia with fever >38.3 C, or a sustained temperature >38 C for more than 1 h",3 or 4,NA,NA,NA
23604531,NA,414,non-hematologic toxicity,3 or 4,NA,NA,NA
23604531,NA,414,any treatment delay within the first cycle because of toxicity,NA,NA,NA,NA
23604531,NA,414,delay of the second cycle for more than 7 days,NA,NA,NA,NA
23604531,NA,414,Inability to deliver the day 8 or day 15 dose of the first cycle,NA,NA,NA,NA
16208519,NA,415,any non-hematological toxicities,>=3,NA,FALSE,NA
16208519,NA,415,neutropenia,4,>=4 days,NA,NA
16208519,NA,415,leukopenia,4,>=4 days,NA,NA
16208519,NA,415,platelet count <=1â€“104/ul,NA,NA,NA,NA
22198338,NA,416,neutropenia (ANC < 500/mcL),4,>7 days,NA,NA
22198338,NA,416,neutropenia (ANC < 1000/mcL) of any duration associated with fever (â‰¥38.5 Â°C) requiring antibiotics,3 or 4,NA,NA,NA
22198338,NA,416,"thrombocytopenia (platelets â‰¤20,000/mcL",4,NA,NA,NA
22198338,NA,416,"thrombocytopenia (platelets â‰¤50,000/mcL) associated with bleeding requiring platelet transfusion",3 or 4,NA,NA,NA
22198338,NA,416,non-hematological toxicity,>=3,NA,FALSE,NA
22198338,NA,416,any treatment-related toxicity causing a delay in radiation more than 1 week or causing the radiation treatment to extend more than 8 weeks,NA,NA,NA,NA
20165849,NA,417,treatment-related thrombocytopenia,>=3,>=14 days,NA,NA
20165849,NA,417,neutropenia despite treatment with pegfilgrastim,NA,>=7 days,NA,NA
20165849,NA,417,neutropenia with fever (>=38.5Â°C) or clinically documented infection,>=3,NA,NA,NA
20165849,NA,417,neurotoxicity,>=3,NA,NA,NA
20165849,NA,417,persistent neurotoxicity not resolving to grade 1 by the next cycle,2,NA,NA,NA
20165849,NA,417,treatment related non-hematologic toxicity considered by the investigator to be related or possibly related to the study drug,>=3,NA,NA,NA
12626128,NA,418,absolute neutrophil count <=500/mm3,NA,>=7days,NA,NA
12626128,NA,418,"platelets <=50,000/mm3",NA,>=7days,NA,NA
12626128,NA,418,platelet transfusions,NA,>7 days,NA,NA
12626128,NA,418,fever and neutropenia (absolute neutrophil count) <=500/mm3,NA,>=7 days,NA,NA
12626128,NA,418,nonhematologic toxicity,>=3,NA,FALSE,NA
15013589,NA,419,non-hematologic toxicity,>=3,NA,FALSE,NA
15013589,NA,419,hematologic toxicity,4,NA,NA,NA
15013589,NA,419,inability to complete the planned Topotecan and radiation therapy in an 8-week period for any toxicity-related reason,NA,NA,NA,NA
11104627,NA,420,neutropenia with fever/infection or requiring hospitalization,4,>5 days,NA,NA
11104627,NA,420,thrombocytopenia,4,NA,NA,NA
11104627,NA,420,any othe nonhematologic toxicity,3 or 4,NA,NA,NA
19885837,NA,421,any nonhematologic toxicity,>=3,NA,FALSE,NA
19885837,NA,421,neutropenia (absolute neutrophil count<300/uL) in the absence of persistent or progressivedisease,NA,>35 days,NA,NA
19885837,NA,421,"thrombocytopenia (platelets<30,000/uL) in the absence of persistent or progressivedisease",NA,>35 days,NA,NA
18752593,NA,422,non-haematological toxicity,>=3,NA,FALSE,NA
18752593,NA,422,thrombocytopenia,4,NA,NA,NA
18752593,NA,422,leucopenia (<1 x 109/l for more than 7 d or < 0.5 x 109/l for more than 3 d),4,NA,NA,NA
18752593,NA,422,febrile neutropenia,NA,NA,NA,NA
9849451,NA,423,haematological toxicity,4,NA,NA,NA
9849451,NA,423,non-haematological toxicity,>=3,NA,NA,NA
9607572,NA,424,hematological toxicities,4,NA,NA,NA
9607572,NA,424,nonhematological toxicities,>=3,NA,NA,NA
25677219,NCT00483860,425,non-haematological toxicity,3 or 4,NA,FALSE,NA
25677219,NCT00483860,425,neutropenia associated with fever or infection,4,NA,NA,NA
25677219,NCT00483860,425,neutropenia,4,â‰¥7 days,NA,NA
25677219,NCT00483860,425,dose delay due to grade â‰¥3 neutropenia,NA,NA,NA,NA
25677219,NCT00483860,425,thrombocytopenia,4,NA,NA,NA
25677219,NCT00483860,425,dose delay of >28 days or dose reduction of >75%,NA,NA,NA,NA
25677219,NCT00483860,425,toxicity,>=2,>28 days,NA,NA
25677219,NCT00483860,425,selected toxicity (if agreed to by the sponsor and investigator),>=2,NA,NA,NA
27793021,NCT01670175,426,neutropenia with fever,4,NA,NA,NA
27793021,NCT01670175,426,neutropenia,4,> 7 days,NA,NA
27793021,NCT01670175,426,platelet transfusion for a platelet count < 10 x 109/L or for clinical bleeding on 2 separate days within a 7 day period,NA,NA,NA,NA
27793021,NCT01670175,426,myelosuppression that delayed start of subsequent cycle by > 14 days,NA,NA,NA,NA
27793021,NCT01670175,426,nonhematological toxicity,3 or 4,NA,FALSE,NA
7949242,NA,427,NA,NA,NA,NA,DLT not defined
16520988,NA,428,somnolence,>=2,NA,NA,NA
16520988,NA,428,"peripheral neuropathy, erythema multiforme, Stevensâ€“Johnson syndrome and/or other allergic skin eruption that was unresponsive to antihistamine (Â±local corticosteroid) therapy",>=2,NA,NA,NA
16520988,NA,428,other unmanageable non-hematological toxicity,>=3,NA,NA,NA
16520988,NA,428,hematological toxicity and/or neutropenic fever,>=3,>7 days,NA,NA
16520988,NA,428,"repetitive, unexpected infection",>=2,NA,NA,NA
11099328,NA,429,thrombocytopenia,4,NA,NA,NA
11099328,NA,429,neutropenia,4,>5 days,NA,NA
11099328,NA,429,febrile neutropenia,NA,NA,NA,NA
11099328,NA,429,nonhematologic toxicity,>=3,NA,FALSE,NA
11099328,NA,429,vomiting despite maximal antiemetic supportive care,4,NA,NA,NA
11099328,NA,429,serious adverse event that would require intensive care,>=3,NA,NA,NA
8637048,NA,430,absolute neutrophil count (ANC) less than 500/uL or platelet count less than 50000/uL,NA,>5 days,NA,NA
8637048,NA,430,ANC less than 500/uL with fever requiring parenteral antibiotics,NA,NA,NA,NA
8637048,NA,430,nonhematologic toxicity,>=3,NA,NA,NA
9779705,NA,431,neutropenia,4,>7 days,NA,NA
9779705,NA,431,thrombocytopenia,4,>7 days,NA,NA
9779705,NA,431,hemorrhage or nonhematologic toxicity,3 or 4,NA,FALSE,NA
9779705,NA,431,"failure to recover neutrophils (>= 1,500/uL) or platelets (>=100,000/uL) by day 35 from a prior cycle of therapy",NA,NA,NA,NA
9779705,NA,431,"febrile neutropenia, defined as a single elevation in oral temperature > 38.50C or three elevations > 38 C during a 24-hour period in a patient with an ANC less than 500/uL",NA,NA,NA,NA
9779705,NA,431,thrombocytopenia during the topotecan infusion (within the first 14 days of the treatment cycle),3,NA,NA,NA
8648378,NA,432,ANC less than 500/uL,NA,>5 days,NA,NA
8648378,NA,432,"platelet count less than 25,000/uL",NA,NA,NA,NA
8648378,NA,432,nonhematologic toxicity,>=3,NA,NA,NA
8648378,NA,432,more than 7-day delay in the count initiation of the subsequent course due to unresolved toxicity,NA,NA,NA,NA
9060549,NA,433,hematologic toxicity,4,NA,NA,NA
9060549,NA,433,nonhematologic toxicity,>=3,NA,NA,NA
7738619,NA,434,NA,NA,NA,NA,DLT not defined
10071262,NA,435,neutropenia with fever or infection or requiring hospitalization for administration of intravenous antibiotics,4,>5 days,NA,NA
10071262,NA,435,thrombocytopenia,4,NA,NA,NA
10071262,NA,435,clinically significant renal or neuromuscular toxicity,NA,NA,NA,NA
10071262,NA,435,any other nonhematologic toxicity,3 or 4,NA,FALSE,NA
20630830,NA,436,an absolute neutrophil count (ANC) < 500/Î¼L,NA,â‰¥ 3 days,NA,NA
20630830,NA,436,leukocyte count < 1000/Î¼L,NA,â‰¥ 3 days,NA,NA
20630830,NA,436,febrile neutropenia (fever > 38.5Â°C with ANC < 1000/Î¼L),NA,NA,NA,NA
20630830,NA,436,"platelet count < 20,000/Î¼L",NA,NA,NA,NA
20630830,NA,436,nonhematologic toxicity,3,NA,FALSE,NA
7602366,NA,437,NA,NA,NA,NA,DLT not defined
12506183,NA,438,toxicity,>=3,NA,NA,NA
18096059,NCT00287963,439,non-hematologic toxicity,3 or 4,NA,TRUE,NA
18096059,NCT00287963,439,neutropenia,4,NA,NA,NA
18096059,NCT00287963,439,thrombocytopenia,4,NA,NA,NA
18096059,NCT00287963,439,"inability to deliver any chemotherapy on day 8 of cycle 1 because of ANC < 1000/ul or platelet count < 50,000/ul",NA,NA,NA,NA
18096059,NCT00287963,439,"inability to begin the second cycle of chemotherapy by day 35 because of persisting hematologic or non-hematologic toxicity of â‰¥ grade 2 and possibly, probably, or clearly due to therapy.",NA,NA,NA,NA
12109520,NA,440,NA,NA,NA,NA,DLT not defined
16501591,NA,441,life-threatening infection,4,NA,NA,NA
16501591,NA,441,exfoliating dermatitis,4,NA,NA,NA
16501591,NA,441,diarrhoea,4,NA,NA,NA
16501591,NA,441,"renal, cardiac, neurological, pulmonary toxicities",4,NA,NA,NA
16501591,NA,441,increase in serum bilirubin level to three times normal,NA,NA,NA,NA
16501591,NA,441,increase in transaminases to 20 times normal,NA,NA,NA,NA
16501591,NA,441,absence of haematological recovery at 6 weeks (PMN <1 x 109/l or platelets <50 x 109/l),NA,NA,NA,NA
16501591,NA,441,therapy-related death,NA,NA,NA,NA
14752800,NA,442,non-hematological toxicity,3 or 4,NA,NA,NA
14752800,NA,442,an ANC of <500/mm3,4,>=5 days,NA,NA
14752800,NA,442,an ANC of <500/mm3 associated with fever,4,NA,NA,NA
14752800,NA,442,"platelet count of <20,000/mm3",NA,NA,NA,NA
14752800,NA,442,any unresolved toxicity resulting in a treatmentdelay of greater than 2 weeks,NA,NA,NA,NA
14519630,NA,443,Nonhematological toxicity,>=3,NA,FALSE,NA
21795476,NCT00553189,444,nonhematologic toxicity,>=3,NA,FALSE,NA
21795476,NCT00553189,444,thrombocytopenia,4,NA,FALSE,NA
21795476,NCT00553189,444,neutropenia,4,>=5 days,NA,NA
21690471,NA,445,thrombocytopenia,4,>7 days,NA,NA
21690471,NA,445,neutropenia,4,>7 days,NA,NA
21690471,NA,445,nonhematologic toxicities,3 or 4,NA,FALSE,NA
21690471,NA,445,Delayin treatment for more than 2 weeks because of an unresolved temsirolimusrelated toxicity,NA,NA,NA,NA
11925142,NA,446,NA,NA,NA,NA,DLT not defined
18202794,NA,447,leucopenia and/or thrombocytopenia,3 or 4,NA,NA,NA
18202794,NA,447,"any non-hematological toxicity, such as vomiting, nausea, fever/infection, cutaneous erythema, diarrhea, confusion, not resolving to grade 1-2 within 2 days",>=3,NA,NA,NA
18202794,NA,447,asthenia in at least 50% of patients found in the 3 dose groups,3 or 4,NA,NA,NA
18202794,NA,447,any adverse event confirmed to interrupt CCRT for >1 week in 50% of the patients treated in each of the 3 dose level groups,NA,NA,NA,NA
8888741,NA,448,nonhematopoietic toxicity,3 or 4,NA,NA,NA
8888741,NA,448,neutropenia (abÂ­ solute neutrophil count <500/ml),4,>7 days,NA,NA
8888741,NA,448,"thrombocytopenia (platelet count <25,000/ml)",4,>7 days,NA,NA
11990712,NA,450,NA,NA,NA,NA,DLT not defined
8120553,NA,451,NA,NA,NA,NA,DLT not defined
16683075,NA,452,side effects,>=3,NA,FALSE,NA
16284058,NA,453,non-hematologic toxicity,3 or 4,NA,NA,NA
16284058,NA,453,hematologic toxicity,4,>7 days,NA,NA
17848737,NA,454,NA,NA,NA,NA,DLT not defined
28283779,NA,455,NA,NA,NA,NA,DLT not defined
25683772,NCT01057225,456,neutropenia,4,>7 days,NA,NA
25683772,NCT01057225,456,febrile neutropenia,NA,NA,NA,NA
25683772,NCT01057225,456,thrombocytopenia associated with bleeding,3 or 4,NA,NA,NA
25683772,NCT01057225,456,thrombocytopenia,4,>=7 days,NA,NA
25683772,NCT01057225,456,neuropathy with pain,>=2,NA,NA,NA
25683772,NCT01057225,456,"nausea, vomiting or diarrhoea uncontrolled by antiemetic/antidiarrheal therapy",>=3,NA,NA,NA
25683772,NCT01057225,456,fatigue,4,>7 days,NA,NA
25683772,NCT01057225,456,any other nonhaematological toxicity,>=3,NA,NA,NA
25683772,NCT01057225,456,Any toxicity that resulted in a dose delay of >21 d of the intended next dose,NA,NA,NA,NA
11896112,NA,457,NA,NA,NA,NA,DLT not defined
21590367,NCT00516438,458,thrombocytopenia,4,NA,NA,NA
21590367,NCT00516438,458,neutropenia,4,>5 days,NA,NA
21590367,NCT00516438,458,febrile neutropenia (ANC <1.0Ã—109/L with feverâ‰¥38.5Â°C),NA,NA,NA,NA
21590367,NCT00516438,458,treatment delay of >2 weeks,NA,NA,NA,NA
21590367,NCT00516438,458,nausea and/or vomiting despite maximal anti-emetic therapy,>3,NA,NA,NA
21590367,NCT00516438,458,any other non-hematological toxicity,3 or 4,NA,FALSE,NA
8955652,NA,459,ANC less than 500/uL,NA,>5 days,NA,NA
8955652,NA,459,"platelet count less than 25,000/uL",NA,NA,NA,NA
8955652,NA,459,nonhematologic toxicity,>=3,NA,NA,NA
8955652,NA,459,delay more than 7 days in the initiation of the subsequent course due to unresolved toxicity,NA,NA,NA,NA
29051322,NA,460,"AE that was possibly, probably or definitely related to PX-866 or the combination of PX-866 and vemurafenib",>=3,NA,FALSE,NA
29051322,NA,460,Any patient who required a greater than 2-week delay in the start of cycle 2 due to unresolved toxicity related to PX-866 or the combination of PX-866 and vemurafenib,NA,NA,NA,NA
15701855,NA,461,nonhematologic toxicity attributable to the investigational drug,3 or 4,NA,FALSE,NA
15701855,NA,461,neutropenia which required transfusion therapy more than twice in 7 days or which caused a delay of more than 14 days beyond the planned interval between treatment courses,4,>7 days,NA,NA
15701855,NA,461,thrombocytopenia which required transfusion therapy more than twice in 7 days or which caused a delay of more than 14 days beyond the planned interval between treatment courses,4,>7 days,NA,NA
20809205,NA,462,neutropenia,4,NA,NA,NA
20809205,NA,462,thrombocytopenia,4,NA,NA,NA
20809205,NA,462,a bleeding episode requiring platelet transfusion,NA,NA,NA,NA
20809205,NA,462,nausea and/or emesis despite use of maximal antiemetics,3,NA,NA,NA
20809205,NA,462,neurosensory toxicity,3,NA,NA,NA
20809205,NA,462,"cardiac, pulmonary, or other neurotoxicity",2,NA,NA,NA
20809205,NA,462,any non-hematological toxicity,>=3,NA,FALSE,NA
20809205,NA,462,failure to recover from treatment-related toxicities to baseline or grade 1 by day 42,NA,NA,NA,NA
1330081,NA,463,NA,NA,NA,NA,DLT not defined
17409986,NA,464,any toxicity that was related to ZD6474 treatment,>=3,NA,NA,NA
17409986,NA,464,diarrhea daily,2,>7 days,NA,NA
17409986,NA,464,diarrhea despite maximum antidiarrheal support,3,NA,NA,NA
17409986,NA,464,"skin toxicity that affected the patientâ€™s subjective well-being and required cessation of treatment, despite supportive care",>=2,>7 days,NA,NA
17409986,NA,464,"QT or corrected QT (QTc) prolongation >=490 msec, or a rise of >=60 msec from baseline QT or QTc to >=460 msec",NA,NA,NA,NA
22781552,NA,465,"neutropenia, anemia, or thrombocytopenia with adequate management",4,>7 days,NA,NA
22781552,NA,465,"nausea, diarrhea, or vomiting that did not respond to maximal supportive care",>=3,NA,NA,NA
22781552,NA,465,nonhematologic toxicity,>=3,NA,FALSE,NA
22781552,NA,465,treatment delay of >3 weeks because of prolonged recovery from a drug-related toxicity,NA,NA,NA,NA
22781552,NA,465,clinically significant change in cardiac function (sinus tachycardia >140 bpm; new occurrence atrial dysrhythmia; any ventricular dysrhythmia; QTcF >500 msec or an absolute increase of 60 msec; LVEF <40%; cardiac troponin >UNL),NA,NA,NA,NA
33947692,NCT02167854,466,an adverse event or abnormal laboratory value assessed to be at least possibly related to the study medication,NA,NA,NA,NA
23429330,NCT01220284,467,"â‰¥ 3/5 S or â‰¥ 1/3 V doses missed (at DL I and in the second cycle) or 2/4 V doses missed (at DL II, III, and IV)",NA,NA,NA,NA
23429330,NCT01220284,467,> 2 weeks delay at the start of second cycle,NA,NA,NA,NA
23429330,NCT01220284,467,neutropenia,>=4,> 5 days,NA,NA
23429330,NCT01220284,467,neutropenia with fever and/or infection,3,NA,NA,NA
23429330,NCT01220284,467,thrombocytopenia,4,NA,NA,NA
23429330,NCT01220284,467,thrombocytopenia with signs of bleeding,3,NA,NA,NA
23429330,NCT01220284,467,persisting neuropathy,2,NA,NA,NA
23429330,NCT01220284,467,renal/ gastrointestinal/other non-hematological toxicity,>=3,NA,NA,NA
22847981,NA,468,ANC<500 mcL-1 on two or more consecutive measurements performed at least 72 hours apart,4,NA,NA,NA
22847981,NA,468,"a platelet count <25,000 mcL-1 on two separate days of a treatment cycle",4,NA,NA,NA
22847981,NA,468,thrombocytopenia,4,NA,NA,NA
22847981,NA,468,"failure to recover neutrophilcount to 1,000 mcL-1 or platelets to 75,000 mcL-1 by day 28of a treatment cycle",NA,NA,NA,NA
22847981,NA,468,serum AST or ALT >10 x ULN,NA,>7 days,NA,NA
22847981,NA,468,serum AST or ALT>10 x ULN and failure to recover to grade <=1 by day 28 of the treatment cycle,NA,NA,NA,NA
22847981,NA,468,Other non-hematological toxicity,>=3,NA,FALSE,NA
28623430,NCT00258349,469,thrombocytopenia,3 or 4,>7 days,NA,NA
28623430,NCT00258349,469,neutropenia,3 or 4,>7 days,NA,NA
28623430,NCT00258349,469,febrile neutropenia,3 or 4,NA,NA,NA
28623430,NCT00258349,469,anemia,4,NA,NA,NA
28623430,NCT00258349,469,anorexia,4,NA,NA,NA
28623430,NCT00258349,469,diarrhea and/or vomiting not responding to maximal therapy or prophylaxis,4,NA,NA,NA
28623430,NCT00258349,469,diarrhea and/or vomiting despite maximum treatment,3,>24 h,NA,NA
28623430,NCT00258349,469,any symptoms requiring sustained IV fluid replacement or hospitalization for IV fluid replacement,NA,NA,NA,NA
28623430,NCT00258349,469,fatigue,3 or 4,NA,NA,NA
28623430,NCT00258349,469,"fatigue, asthenia or malaise leading to a decrease in ECOG performance status to 3 or 4 (or 2 if the baseline performance status was 0)",NA,NA,NA,NA
23099652,NCT 00272350,470,hematologic toxicity,4,NA,NA,NA
23099652,NCT 00272350,470,any nonhematologic toxicity,>=3,NA,FALSE,NA
27450049,NCT01248858,471,hematologic toxicities,4,NA,NA,NA
27450049,NCT01248858,471,febrile neutropenia,4,NA,NA,NA
27450049,NCT01248858,471,non-hematologic toxicities,3,NA,FALSE,NA
27450049,NCT01248858,471,rash that did not improve to grade â‰¤ 2 within 7 days despite optimal supportive treatment(s) or required a dose reduction upon restarting therapy,3,NA,NA,NA
27450049,NCT01248858,471,ALT >3Ã— upper limit of normal (ULN) with concurrent bilirubin >2Ã— ULN,NA,NA,NA,NA
27450049,NCT01248858,471,absolute decrease of ejection fraction to less than lower limit of normal and >10 % decrease from baseline confirmed within 7 days,NA,NA,NA,NA
27450049,NCT01248858,471,inability to receive â‰¥75 % of scheduled doses due to toxicity,NA,NA,NA,NA
27450049,NCT01248858,471,toxicity that occurred beyond 28 days at the judgment of the investigator and medical monitor,>=2,NA,NA,NA
25500057,NCT01155453,472,"an adverse event (AE) or abnormal laboratory value assessed as at least possibly related to study medication, which also met the prespecified DLT criteria",NA,NA,NA,NA
30992546,NCT01938443,473,non-haematologic toxicity not controlled by routine supportive measures,>=3,NA,NA,NA
30992546,NCT01938443,473,neutropenia,4,>5 days,NA,NA
30992546,NCT01938443,473,febrile neutropenia,NA,NA,NA,NA
30992546,NCT01938443,473,thrombocytopenia,4,NA,NA,NA
30992546,NCT01938443,473,alanine aminotransferase >3x upper limit of normal (ULN) with bilirubin >2x ULN,NA,NA,NA,NA
30992546,NCT01938443,473,any toxicity that resulted in missing â‰¥14 consecutive or non-consecutive days of scheduled dosing during the initial 28-day period,NA,NA,NA,NA
30992546,NCT01938443,473,"toxicity that, in the investigatorâ€™s judgement, would be dose limiting",2,NA,NA,NA
29350463,NCT01519323,474,neutropenia (absolute neutrophil count <500/mm3),4,NA,NA,NA
29350463,NCT01519323,474,thrombocytopenia requiring transfusion on more than two occasions in 7 days,4,NA,NA,NA
29350463,NCT01519323,474,febrile neutropenia,>=3,NA,NA,NA
29350463,NCT01519323,474,hemorrhage,>=3,NA,NA,NA
29350463,NCT01519323,474,nausea or vomiting that resolved to grade â‰¤1 within 7 days of appropriate medical management,3,NA,NA,NA
29350463,NCT01519323,474,diarrhea that resolved to grade â‰¤1 within 7 days of appropriate medical management,3,NA,NA,NA
29350463,NCT01519323,474,rash that resolved to grade â‰¤2 within 7 days of appropriate medical management,3,NA,NA,NA
29350463,NCT01519323,474,photosensitivity that resolved to grade â‰¤2 within 7 days of appropriate medical management,3,NA,NA,NA
29350463,NCT01519323,474,infection or fever,3,NA,NA,NA
29350463,NCT01519323,474,electrolyte abnormalities responsive to oral supplementation,3,NA,NA,NA
29350463,NCT01519323,474,"elevations in hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), alkaline phosphatase, or bilirubin that returned to â‰¤2.5 Ã— upper limit of normal (ULN) for age, or that returned to â‰¤1.5 Ã— ULN for age (for bilirubin) within 7 days of stopping the drug with no concurrent elevation of both transaminases and bilirubin",3,NA,NA,NA
29350463,NCT01519323,474,"for patients with liver metastasis, hepatic transaminases (ALT or AST) must have returned to <5 Ã— ULN within 7 days of stopping the drug and must not occur concurrently with grade 3 elevations of bilirubin, development of cutaneous squamous cell carcinoma that was subsequently resected/treated, or grade 3 arthralgia/myalgia that resolved to grade â‰¤2 within 7 days with appropriate medical management",NA,NA,NA,NA
15905307,NA,475,"diarrhea daily, despite maximum antidiarrheal support",2,>7 days,NA,NA
15905307,NA,475,"diarrhea, despite maximum antidiarrheal support",3,>24 h,NA,NA
15905307,NA,475,"skin toxicity affecting the patientâ€™s subjective well being and requiring cessation of treatment, despite maximum supportive care",4,>7 days,NA,NA
15905307,NA,475,any toxicity that was not clearly related to disease progression,>=3,NA,NA,NA
11984084,NA,476,"rise in AST, ALT, bilirubin or AP, which have not recovered to grade 0 by day 21 and still present at day 28",3 or 4,NA,NA,NA
11984084,NA,476,neutropenia,4,>5 days,NA,NA
11984084,NA,476,neutropenia complicated febrile neutropenia,4,NA,NA,NA
11984084,NA,476,any toxicity,>=3,NA,FALSE,NA
18048823,NA,477,neutropenia,4,>=7 days,NA,NA
18048823,NA,477,"febrile neutropenia (ANC < 1.0 x 109/L, fever >= 38.5Â°C)",NA,NA,NA,NA
18048823,NA,477,thrombocytopenia,4,>=7 days,NA,NA
18048823,NA,477,bleeding episode requiring platelet transfusion,NA,NA,NA,NA
18048823,NA,477,anemia,4,>=7 days,NA,NA
18048823,NA,477,nonhematologic toxicity,>=3,NA,FALSE,NA
18048823,NA,477,nausea and/or vomiting despite the use of maximal medical intervention and/or prophylaxis,>=3,NA,NA,NA
18048823,NA,477,treatment delay of more than 2 weeks because of prolonged recovery from a drug-related toxicity,NA,NA,NA,NA
17325895,NA,478,an ANC < 500 cells/mm3,NA,>17 days,NA,NA
17325895,NA,478,an ANC < 750 cells/mm3,NA,>24 days,NA,NA
17325895,NA,478,platelet count < 25 000 cells/mm3,NA,>17 days,NA,NA
17325895,NA,478,platelet count < 50 000 cells/mm3,NA,>24 days,NA,NA
28119295,NCT01148849,479,any margetuximab-related adverse event (AE),>=3,NA,FALSE,NA
28119295,NCT01148849,479,AEs of clinical significance (per investigator discretion),2,NA,NA,NA
28119295,NCT01148849,479,AEs delayed dosing for >1 week,NA,NA,NA,NA
24954229,NA,480,neutropenia,4,>=7 days,NA,NA
24954229,NA,480,febrile neutropenia,NA,NA,NA,according to Pizzoâ€™s definition (a single elevation in oral temperature above 38.5C or 3 elevations above 38 C during a 24-hour period concomitant with a grade 4 neutropenia)
24954229,NA,480,neutropenic infection,4,NA,NA,defined as a grade 3 or 4 infection concomitant with grade >= 3 neutropenia
24954229,NA,480,symptomatic  thrombocytopenia,3,NA,NA,NA
24954229,NA,480,thrombocytopenia,4,NA,NA,NA
24954229,NA,480,nonhematologic toxicities due to treatment,>=3,NA,FALSE,NA
8439950,NA,482,nonhematological toxicity,3 or 4,NA,NA,NA
8439950,NA,482,hematological toxicity,4,NA,NA,NA
29882016,NCT00620594,483,NA,NA,NA,NA,DLT not defined
30087028,NCT02258607,485,neutropenia,4,NA,NA,NA
30087028,NCT02258607,485,thrombocytopenia,4,NA,NA,NA
30087028,NCT02258607,485,neutropenia with fever,>=3,NA,NA,NA
30087028,NCT02258607,485,thrombocytopenia with bleeding,>=3,NA,NA,NA
30087028,NCT02258607,485,nonhematologic toxicity,>=3,NA,NA,NA
31253596,NCT02016729,486,"treatment-related nonhematologic adverse event, where a relationship to AMG 232 cannot be ruled out",3 or 4,NA,FALSE,NA
31253596,NCT02016729,486,"nausea, vomiting, or diarrhea",>=3,> 48 hours after management,NA,NA
31253596,NCT02016729,486,fatigue,3,>7 days,NA,NA
31253596,NCT02016729,486,any treatmentrelated AEs not returning to grade <=1 or baseline severity after a treatment delay up to 7 days,4,NA,NA,NA
31253596,NCT02016729,486,pancytopenia in the presence of hypocellular bone marrow,NA,>42 days,NA,NA
27129177,NCT01271920,488,NA,NA,NA,NA,DLT not defined
11234874,NA,489,neutropenia,4,>=5 days,NA,NA
11234874,NA,489,thrombocytopenia,4,NA,NA,NA
11234874,NA,489,any drugrelated nonhematological toxicity,>=3,NA,FALSE,NA
11230466,NA,490,any toxicity,>=3,NA,FALSE,NA
11230466,NA,490,transaminitis,3 or 4,NA,NA,NA
11230466,NA,490,"bilirubin levels, AP levels, or both that did not recover to grade 0 by day 21 and that were still present at day 28",NA,NA,NA,NA
11230466,NA,490,neutropenia,4,>=5 days,NA,NA
11230466,NA,490,"febrile neutropenia (neutrophils < 0.5 x 109/L, with a temperature >= 38.5Â°C within a 24-hour period, with or without a causal organism)",NA,NA,NA,NA
22996801,NA,491,neutrophils<0.5Ã—109/L,NA,>=7 days,NA,NA
22996801,NA,491,neutrophils<0.5Ã—109/L,NA,â‰¥3 days,NA,NA
22996801,NA,491,platelets<25Ã—109/L,NA,NA,NA,NA
22996801,NA,491,thrombocytopenia with bleeding or requiring platelet transfusion,NA,NA,NA,NA
22996801,NA,491,febrile neutropenia (fever of unknown origin without clinically or micro-biologically documented infection; absolute granulocyte count<1.0Ã—109/L and feverâ‰¥38.5 Â°C),NA,NA,NA,NA
22996801,NA,491,major organ toxicity,3 or 4,NA,FALSE,NA
22996801,NA,491,"increase in bilirubin by>25 % or transaminases by>50 % and/or GGT by>25 %, as compared to baseline values if abnormal values at baseline",NA,NA,NA,NA
22996801,NA,491,withdrawal of any patient after the first cycle due to delayed recovery from toxicity,NA,NA,NA,NA
21660618,NA,492,neutropenia,4,>5 days,NA,NA
21660618,NA,492,febrile neutropenia (body temperature >38.58C),NA,NA,NA,NA
21660618,NA,492,thrombocytopenia,4,NA,NA,NA
21660618,NA,492,other non-hematological toxicity,>3,NA,NA,NA
21660618,NA,492,aspartate aminotransferase (AST)/alanine aminotransferase (ALT) not recovered to baseline 21 days after the last trabectedin infusion,NA,NA,NA,NA
21660618,NA,492,"if baseline bilirubin <=1.5 x ULN, grade 3 hyperbilirubinemia or grade 2 hyperbilirubinemia not recovered to baseline",NA,NA,NA,NA
21660618,NA,492,"if baseline bilirubin >1.5 x ULN, bilirubin increase >50% over baseline value, regardless of recovery, or bilirubin increase <=50% over baseline value, not recovered to baseline",NA,NA,NA,NA
21660618,NA,492,"if AP baseline value within normal range, AP increase >ULN, and if AP baseline value was >ULN, AP increase >2 x baseline value",NA,NA,NA,NA
19417019,NA,493,absolute neutrophil count <0.5 Ã— 109/L,NA,> 5 d,NA,NA
19417019,NA,493,absolute neutrophil count <0.5 Ã— 109/L with fever (â‰¥38Â°C); platelets < 25 Ã— 109/L,NA,NA,NA,NA
19417019,NA,493,any other nonhematologic toxicity,3 or 4,NA,FALSE,NA
19417019,NA,493,transaminase elevations,3 or 4,> 28 d,NA,NA
19417019,NA,493,"inability to receive at least two scheduled treatments during a single course due to drug-related toxicity, and delay of 2 consecutive wk due to persistent toxicity",NA,NA,NA,NA
12932661,NA,494,neutropenia complicated or associated with fever,4,>5 days,NA,NA
12932661,NA,494,"elevation of transaminases, bilirubin or alkaline phosphatase, which had not returned to baseline at day 28",3 or 4,NA,NA,NA
12932661,NA,494,Other toxicity,>=3,NA,FALSE,NA
19419856,NA,495,febrile neutropaenia,NA,NA,NA,NA
19419856,NA,495,neutropaenia,4,>5 d,NA,NA
19419856,NA,495,thrombocytopaenia,3,NA,NA,NA
19419856,NA,495,lack of recovery from haematological toxicity by day 35,NA,NA,NA,NA
19419856,NA,495,"increase of AP, ASAT, ALAT and bilirubi",NA,NA,NA,NA
19419856,NA,495,non-haematological toxicity,>=3,NA,NA,NA
19419856,NA,495,"failure to deliver treatment on day 8 due to grade 2 haematological toxicity, or grade > 1 liver toxicity",NA,NA,NA,NA
23299791,NA,496,ANC <0.5 x 109 l-1,NA,>=7 days,NA,NA
23299791,NA,496,platelet count <25 x 109 l-1,NA,NA,NA,NA
23299791,NA,496,platelet count <50 x 109 l-1 with bleeding,NA,NA,NA,NA
23299791,NA,496,febrile neutropenia,>=3,NA,NA,NA
23299791,NA,496,neutropenia with concomitant grade >=3 infection,>=3,NA,NA,NA
23299791,NA,496,"gastrointestinal toxicity included nausea, vomiting or diarrhoea if persistent despite optimal antiemetic or anti-diarrhoeal treatment",>=3,NA,NA,NA
23299791,NA,496,intestinal ileus,>=3,NA,NA,NA
23299791,NA,496,any other drug-related toxicity,>=3,NA,NA,NA
23299791,NA,496,any drug-related adverse event during cycle 1 that resulted in dosing omission for 14 (non-consecutive) days or a delay >=1 week (>=3 weeks of rest period) in the administration of cycle 2,NA,NA,NA,NA
22382883,NA,497,nadir neutrophils <0.5 x 109/L,NA,>=7 days,NA,NA
22382883,NA,497,neutropenia concomitant with fever >= 38.5C or grade >=3 infection,4,NA,NA,NA
22382883,NA,497,platelet count <25 x 109/L or <50 9 109/L with bleeding,4,NA,NA,NA
22382883,NA,497,"nausea, vomiting or diarrhea if persistent despite optimal antiemetic or anti-diarrheal treatment",>=3,NA,NA,NA
22382883,NA,497,intestinal ileus,3,NA,NA,NA
22382883,NA,497,any other drug-related toxicity,>=3,NA,NA,NA
22382883,NA,497,any drug-related adverse event that results in 50% dosing omission during cycle 1 or a delay C2 weeks in the administration of cycle 2,NA,NA,NA,NA
29635147,NCT01373710 ,498,toxicity attributable to IT trastuzumab persisting despite appropriate symptomatic treatment and requiring a postponement of IT trastuzumab treatment for more than 2 weeks,3 or 4,NA,NA,NA
29635147,NCT01373710 ,498,generalised seizure despite prophylactic antiepileptic treatment,NA,NA,NA,NA
29635147,NCT01373710 ,498,meningeal syndrome persisting for at least 3 days,3 or 4,NA,NA,NA
29635147,NCT01373710 ,498,headache,4,NA,NA,NA
25417902,NCT01476137,499,non-hematologic toxicity,3 or 4,NA,FALSE,NA
25417902,NCT01476137,499,neutropenia,4,â‰¥5 days,NA,NA
25417902,NCT01476137,499,febrile neutropenia,NA,NA,NA,NA
25417902,NCT01476137,499,thrombocytopenia with bleeding,3,NA,NA,NA
25417902,NCT01476137,499,thrombocytopenia,4,NA,NA,NA
25417902,NCT01476137,499,anemia,4,NA,NA,NA
25417902,NCT01476137,499,treatment delay of >14 days due to unresolved toxicity,NA,NA,NA,NA
25417902,NCT01476137,499,alanine aminotransferase (ALT) >3 Ã— upper limit of normal (ULN) with bilirubin >2 times ULN,NA,NA,NA,NA
25417902,NCT01476137,499,ejection fraction < lower limit of normal (LLN) with an absolute decrease of >10 % from baseline with confirming assessment within 7 days,NA,NA,NA,NA
20921456,NA,500,neutropenia,4,NA,NA,NA
20921456,NA,500,thrombocytopenia,3 or 4,NA,NA,NA
20921456,NA,500,nonhematologic toxicity,3 or 4,NA,FALSE,NA
20921456,NA,500,QTc interval prolongation associated with ventricular tachycardia or torsade de pointes,1,NA,NA,NA
20921456,NA,500,QTc interval prolongation associated with rhythm abnormalities in a 24-hour Holter monitor test,1 and 2,NA,NA,NA
20921456,NA,500,nonhematologic toxicity causing significant clinical repercussion,2,>7 days,NA,NA
25352401,NCT00450138,501,nonhematologic toxicity despite optimal symptomatic care,>=3,NA,NA,NA
25352401,NCT00450138,501,hematologic toxicity,4,NA,FALSE,NA
25352401,NCT00450138,501,thrombocytopenia associated with bleeding (not applicable to patients on therapeutic anticoagulation),3,NA,NA,NA
25352401,NCT00450138,501,"QTc prolongation (a single measurement >=550 ms or an increase of >=100 ms frobaseline; 2 consecutive measurements >=500 ms but <550ms; or an increase  of >=60  ms,  but <100 ms, from base-line to >=480 ms using Bazettâ€™s correction factor)",NA,NA,NA,NA
25352401,NCT00450138,501,dysphagia,4,NA,NA,during RT treatment
25352401,NCT00450138,501,mucositis/stomatitis,4,NA,NA,during RT treatment
25352401,NCT00450138,501,skin toxicity,4,NA,NA,during RT treatment
25352401,NCT00450138,501,xerostomia,4,NA,NA,during RT treatment
25352401,NCT00450138,501,hypogeusia,4,NA,NA,during RT treatment
25352401,NCT00450138,501,any delay in RT >5 days because of toxicity,NA,NA,NA,NA
26801247,NCT0110429,503,neutropenia (ANC < 0.5 x 109/L),4,> 5 days,NA,NA
26801247,NCT0110429,503,ANC < 0.1 x 109/L,NA,> 3 days,NA,NA
26801247,NCT0110429,503,neutropenia with fever,3,NA,NA,NA
26801247,NCT0110429,503,thrombocytopenia,4,NA,NA,NA
26801247,NCT0110429,503,non-hematologic toxicity that represented at least a 2 grade increase from baseline,>=3,NA,FALSE,NA
26801247,NCT0110429,503,a delay of more than 2 weeks in starting the next cycle due to toxicity,NA,NA,NA,NA
21373895,NA,504,neutrophil nadir <500/uL attributed to therapy,NA,NA,NA,NA
21373895,NA,504,"platelet nadir <50,000/uL attributed to therapy",NA,NA,NA,NA
21373895,NA,504,non-hematologic toxicity attributed to therapy,3 or 4,NA,NA,NA
21373895,NA,504,"neutropenia associated with grade 2 fever (i.e., febrile neutropenia)",NA,NA,NA,NA
23536435,NA,505,neutropenia,4,NA,NA,NA
23536435,NA,505,thrombocytopenia,3 or 4,NA,NA,NA
23536435,NA,505,nonhematologic toxicity,3 or 4,NA,FALSE,NA
23536435,NA,505,QTc interval prolongation associated with ventricular tachycardia or torsade de pointes,2,NA,NA,NA
23536435,NA,505,QTc interval prolongation associated with rhythm abnormalities in a 24-hour Holter,1 and 2,NA,NA,NA
23536435,NA,505,nonhematologic toxicity causing significant clinical repercussion,2,>7 days,NA,NA
33947696,NCT02202200,506,neutropenia,4,>5 days,NA,NA
33947696,NCT02202200,506,febrile neutropenia,1,>1 day,NA,NA
33947696,NCT02202200,506,thrombocytopenia,4,>1 day,NA,NA
33947696,NCT02202200,506,thrombocytopenia with bleeding,3,NA,NA,NA
33947696,NCT02202200,506,any non-hematological toxicity,3 or 4,NA,FALSE,NA
33947696,NCT02202200,506,toxicity,>=3,>2 weeks,NA,NA
33947696,NCT02202200,506,any treatment delay > 2 weeks due to drug-related adverse effects,NA,NA,NA,NA
24470511,NA,507,neutropenia,>=3,>7 consecutive days,NA,NA
24470511,NA,507,thrombocytopenia,3,>7 consecutive days,NA,NA
24470511,NA,507,thrombocytopenia,4,NA,NA,NA
24470511,NA,507,"Febrile neutropenia (ANC <1.0 x 109/l, fever â‰¥38.5Â°C)",NA,NA,NA,NA
24470511,NA,507,Serum creatinine â‰¥2.0 x ULN to â‰¤3.0 x ULN,1,>7 consecutive days,NA,NA
24470511,NA,507,serum creatinine,>=3,NA,NA,NA
24470511,NA,507,Total bilirubin â‰¥2.0 x ULN to â‰¤3.0 x ULN,NA,>7 consecutive days,NA,NA
24470511,NA,507,total bilirubin,>=3,NA,NA,NA
24470511,NA,507,AST or ALT,3,>7 consecutive days,NA,NA
24470511,NA,507,AST or ALT,4,NA,NA,NA
24470511,NA,507,"hyperglycemia (confirmed with a repeat FPG within 24 hours and that does not resolve to normal within 14 consecutive days after initiation of glibenclaminde, glimepiride, or metformin)",2,NA,NA,NA
24470511,NA,507,hyperglycemia (confirmed with a repeat FPG within 24 hours),>=3,NA,NA,NA
24470511,NA,507,asymptomatic amylase and/or lipase that does not reverse to â‰¤CTCAE G2,3,for >7 consecutive days,NA,NA
24470511,NA,507,asymptomatic amylase and/or lipase,4,NA,NA,NA
24470511,NA,507,Pancreatitis,>=2,NA,NA,NA
24470511,NA,507,Cardiac toxicity,>=3,NA,NA,NA
24470511,NA,507,cardiac event that is symptomatic or requires medical intervention,NA,NA,NA,NA
24470511,NA,507,"Clinical signs of cardiac disease, such as unstable angina, myocardial infarction, or troponin",>=3,NA,NA,NA
24470511,NA,507,Neurotoxicity (other than mood alterations),>=1,NA,NA,NA
24470511,NA,507,"mood alteration that does not resolve to â‰¤G1 within 14 days despite medical treatment (for anxiety, only if worsened from baseline)",2,NA,NA,NA
24470511,NA,507,mood alteration,>=3,NA,NA,NA
24470511,NA,507,photosensitivity,>=2,NA,NA,NA
24470511,NA,507,rash despite skin toxicity treatment,3,for >7 consecutive days,NA,NA
24470511,NA,507,rash,4,NA,NA,NA
24470511,NA,507,other adverse events,>=3,NA,FALSE,NA
24470511,NA,507,vomiting despite the use of standard antiemetics,>=3,NA,NA,NA
24470511,NA,507,nausea despite the use of standard antiemetics,3,NA,NA,NA
24470511,NA,507,diarrhea despite the use of optimal antidiarrheals,>=3,NA,NA,NA
24470511,NA,507,fatigue (asthenia),3,>7 consecutive days,NA,NA
24470511,NA,507,fatigue (asthenia),4,NA,NA,NA
22082325,NA,508,drug related nonhematologic toxicity,3 or 4,NA,FALSE,NA
22082325,NA,508,drug related hematologic toxicity,4,NA,FALSE,NA
22082325,NA,508,failure of the ANC (Absolute Neutrophil Count) to recover to 1.0 x109/L or platelets to recover to 100 x109/L within 7 days of the end of a cycle of therapy,NA,NA,NA,NA
22082325,NA,508,any delay in vinorelbine administration lasting more than one week,NA,NA,NA,NA
25503302,NCT00821080,509,thrombocytopenia,3 or 4,>1 week,NA,NA
25503302,NCT00821080,509,neutropenia,3 or 4,>1 week,NA,NA
25503302,NCT00821080,509,non-hematologic toxicities felt to be related to the study medications,3 or 4,>1 week,FALSE,NA
25503302,NCT00821080,509,"nausea, emesis, or diarrhea that is not controllable with medications",3 or 4,>1 week,NA,NA
25503302,NCT00821080,509,single QTc value of >=550 ms or a sustained increase of >=100 ms from baseline,NA,NA,NA,NA
25503302,NCT00821080,509,Subsequent episodes of DVT or PE,NA,NA,NA,NA
19184020,NA,510,neutropenia considered to be possibly related to vandetanib,4,> 5 days,NA,NA
19184020,NA,510,thrombocytopenia considered to be possibly related to vandetanib,4,> 5 days,NA,NA
19184020,NA,510,"febrile neutropenia (temperature >38.5Â°C on at least two occasions in 24 h, in association with grade 3 or 4 neutropenia)",NA,NA,NA,NA
19184020,NA,510,any other non-manageable drug-related non-haematological toxicity considered to be possibly treatment-related,3 or 4,NA,NA,NA
19184020,NA,510,"QTc prolongation (a single QTc measurement Â¸550 ms; two consecutive QTc measurements Â¸500 but <550 ms; an increase of >=100 ms from baseline; or an increase of >=60 ms, but <100 ms from baseline QTc to a QTc value >=460 ms)",NA,NA,NA,NA
30569244,NCT01810016,511,febrile neutropenia with or without infection,3 or 4,NA,NA,NA
30569244,NCT01810016,511,neutropenia,4,>7 days,NA,NA
30569244,NCT01810016,511,thrombocytopenia,4,NA,NA,NA
30569244,NCT01810016,511,hematologic toxicity,5,NA,NA,NA
30569244,NCT01810016,511,nonhematologic toxicity attributed to chemotherapy and/or vorinostat,3 or 4,NA,FALSE,NA
30569244,NCT01810016,511,Nausea and vomiting not controlled with adequate antiemetic therapy,3 or 4,NA,NA,NA
30569244,NCT01810016,511,any toxicity occurring in cycle 1 that resulted in a dose reduction in vorinostat,NA,NA,NA,NA
30569244,NCT01810016,511,five or more doses missed,NA,NA,NA,NA
30569244,NCT01810016,511,mucositis will not be considered dose limiting unless it fails to resolve to grade 2 with 10 day or less treatment break,NA,NA,NA,NA
30569244,NCT01810016,511,diarrhea persists after the initiation of antidiarrheal therapy,3,NA,NA,NA
30569244,NCT01810016,511,electrolyte abnormality not correctable by replacement,3 or 4,NA,NA,NA
11745237,NA,512,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11745237,NA,512,fever with neutropenia,NA,NA,NA,NA
11745237,NA,512,an absolute neutrophil count < 500,NA,> 4 days,NA,NA
10811501,NA,513,an ANC less than 500/ul and/or associated with fever that required hospitalization ofr parenteral antibiotic therapy,NA,>=5 days,NA,NA
10811501,NA,513,"a platelet count less than 25,000/ul",NA,NA,NA,NA
10811501,NA,513,non-hematologic toxicity (including nausea or vomiting despite antiemetics),>=3,NA,NA,NA
10811501,NA,513,any unresolved toxicity that resulted in treatment delays of at least two weeks,NA,NA,NA,NA
8194022,NA,514,diarrhea (four or more loose stools per day),>=2,NA,NA,. Dose-limiting toxicity for floxuridine
8194022,NA,514,stomatitis,>=2,NA,NA,. Dose-limiting toxicity for floxuridine
8194022,NA,514,"neurologic toxicity, including sensory or motor neuropathy and constipation",2,NA,NA,Dose-limiting toxicities for vinblastine
8194022,NA,514,thrombocytopenia,2,NA,NA,Dose-limiting toxicities for vinblastine
8194022,NA,514,neutropenia,3,NA,NA,Dose-limiting toxicities for vinblastine
8194022,NA,514,fatigue,2,NA,NA,Dose-limiting toxicities for vinblastine
23639470,JapicCTI-101264,515,thrombocytopenia,4,NA,NA,NA
23639470,JapicCTI-101264,515,neutropenia,4,>=4 days,NA,NA
23639470,JapicCTI-101264,515,non-haematological toxic effects,>=3,NA,FALSE,NA
23639470,JapicCTI-101264,515,events that required suspension of treatment for at least 7 day,NA,NA,NA,NA
9157072,NA,516,NA,NA,NA,NA,DLT not defined
29221762,NCT01118676,517,nonhematologic toxicity,4,NA,NA,NA
29221762,NCT01118676,517,neutropenia,4,5 days,NA,NA
29221762,NCT01118676,517,thrombocytopenia that required a transfusion,4,NA,NA,NA
29221762,NCT01118676,517,anemia,3 or 4,NA,NA,NA
29221762,NCT01118676,517,nonfebrile pneumonitis,NA,NA,NA,NA
29221762,NCT01118676,517,tracheobronchial fistula,NA,NA,NA,NA
29221762,NCT01118676,517,treatment interruption caused by toxicity that lasted > 2 weeks,NA,NA,NA,NA
29221762,NCT01118676,517,treatment-related death during the period of combined chemoradiotherapy and cilengitide,NA,NA,NA,NA
29221762,NCT01118676,517,reduced dose of chemotherapy (to < 75% of the planned dose),NA,NA,NA,NA
34301808,NCT03013491,518,pneumonitis,2,NA,NA,NA
34301808,NCT03013491,518,ocular toxicity necessitating discontinuation of pacmilimab,NA,NA,NA,NA
34301808,NCT03013491,518,treatment-related AEs,>=3,NA,FALSE,NA
32819972,NCT01557114,519,"vomiting, diarrhea or gastrointestinal bleeding",4,NA,NA,NA
32819972,NCT01557114,519,non-hematologic toxicity,3 or 4,NA,FALSE,NA
32819972,NCT01557114,519,radiation dermatitis,3 or 4,NA,FALSE,NA
31778074,NCT00585195,520,neutropenia,4,>7 days,NA,NA
31778074,NCT00585195,520,"Febrile neutropenia, defined here as grade 4 neutropenia with fever >38.5Â°C, both sustained over a 24-hour period",NA,NA,NA,NA
31778074,NCT00585195,520,Neutropenic infection,NA,NA,NA,NA
31778074,NCT00585195,520,thrombocytopenia with bleeding,>=3,NA,NA,NA
31778074,NCT00585195,520,thrombocytopenia,4,â‰¥7 days,NA,NA
31778074,NCT00585195,520,Lymphopenia was not considered a DLT unless accompanied by infection,NA,NA,NA,NA
31778074,NCT00585195,520,Non-hematologic toxicities,3 or 4,NA,FALSE,NA
31778074,NCT00585195,520,"Nausea, vomiting or diarrhea despite maximal medical therapy",3 or 4,NA,NA,NA
29563138,NCT01625234,521,neutropenia,4,>5 days,NA,NA
29563138,NCT01625234,521,febrile neutropenia,NA,NA,NA,NA
29563138,NCT01625234,521,thrombocytopenia,4,NA,NA,NA
29563138,NCT01625234,521,thrombocytopenia with bleeding,3,NA,NA,NA
29563138,NCT01625234,521,nonhematologic toxicity,>=3,NA,FALSE,NA
29563138,NCT01625234,521,a treatment delay of >=14 days due to unresolved toxicity,NA,NA,NA,NA
22234637,NA,522,neutropenia,4,>=5 days,NA,NA
22234637,NA,522,neutropenia with fever,>=3,NA,NA,NA
22234637,NA,522,thrombocytopenia requiring platelet transfusions,3,NA,NA,NA
22234637,NA,522,thrombocytopenia,4,NA,NA,NA
22234637,NA,522,non-hematological toxicities,>=3,NA,NA,NA
22234637,NA,522,AST/ALT elevation of over 300 IU/L,NA,NA,NA,NA
28032129,NCT00939770,523,crizotinib-related thrombocytopenia,4,NA,NA,NA
28032129,NCT00939770,523,crizotinib-related neutropenia,4,NA,NA,NA
28032129,NCT00939770,523,"non-haematological toxic eff ect possibly, probably, or definitely attributable to crizotinib",3 or 4,NA,FALSE,NA
26966027,NCT01284192,524,neutropenia,4,â‰¥7 days,NA,NA
26966027,NCT01284192,524,febrile neutropenia,NA,NA,NA,NA
26966027,NCT01284192,524,thrombocytopenia,3,NA,NA,NA
26966027,NCT01284192,524,non-hematologic toxicity,3,NA,FALSE,NA
26966027,NCT01284192,524,any study drug-related toxicity resulting in treatment delay >2 weeks or discontinuation of treatment at the assigned dose level,NA,NA,NA,NA
14597873,NA,525,ANC < 500/ul,NA,NA,NA,NA
14597873,NA,525,platelet count < 25 000/ul or bleeding,NA,NA,NA,NA
14597873,NA,525,non-hematological toxicity,>=3,NA,NA,NA
14597873,NA,525,persistence of ANC < 1500/ul or platelet count < 100 000/ul until day 22,NA,NA,NA,NA
14597873,NA,525,persistence of each toxicity until day 22 of the first cycle,>=2,NA,FALSE,NA
31898184,NA,526,thrombocytopenia,3 or 4,NA,NA,NA
31898184,NA,526,neutropenia,3 or 4,NA,NA,NA
31898184,NA,526,nonhematological toxicities related to study drug,>=3,NA,NA,NA
31898184,NA,526,nonhematological toxicity that has caused a dosing delay of â‰¥3 weeks,NA,NA,NA,NA
33148673,NCT02737475,527,NA,NA,NA,NA,DLT not defined
20606092,NA,530,neutropenia,4,NA,NA,children with leukemia were not considered evaluable for hematologic toxicity
20606092,NA,530,thrombocytopenia,4,NA,NA,children with leukemia were not considered evaluable for hematologic toxicity
20606092,NA,530,nonhematologicatoxicity,3 or 4,NA,FALSE,NA
20606092,NA,530,nonhematologic toxicity considered sufficiently medically significant or sufficiently intolerable by patients that it required treatment interruption,2,>=7 days,NA,NA
20606092,NA,530,allergic reactions that necessitated discontinuation of study drug,2,NA,NA,NA
20606092,NA,530,any adverse event requiring interruption of study drug for longer than 7 days or which recurred on drug rechallenge,NA,NA,NA,NA
22080430,NA,532,hematologic toxicity,4,>7 days,NA,NA
22080430,NA,532,a clinically significant non-hematologic toxicity,>3,NA,FALSE,NA
22080430,NA,532,any treatment delay >14 days secondary to recovery from drug related adverse events,NA,NA,NA,NA
19708032,NA,533,NA,NA,NA,NA,DLT not defined
31617432,NCT01567709,534,non-hematologic toxicity,>=3,NA,FALSE,NA
31617432,NCT01567709,534,neutropenia despite the use of growth factors,4,>7 days,NA,NA
31617432,NCT01567709,534,thrombocytopenia,4,NA,NA,NA
31617432,NCT01567709,534,thrombocytopenia associated with bleeding and/or requiring transfusion,3,>7 days,NA,NA
31617432,NCT01567709,534,toxicity withinthe first cycle that prevents administration of >=80% ofthe total planned dose,NA,NA,NA,NA
31617432,NCT01567709,534,any delay in therapy of greater than 14 days,NA,NA,NA,NA
17962510,NA,535,pancytopenia with no more than 5% bone marrow cellularity and no evidence of leukemia,NA,>= 42 days,NA,NA
17962510,NA,535,"nausea, vomiting, or diarrhea despite maximum supportive care",>=3,NA,NA,NA
17962510,NA,535,other nonhematologic toxicity related to the study drug,>=3,NA,NA,NA
29512900,NA,536,eutropenia,4,NA,NA,NA
29512900,NA,536,trombocytopenia,3 or 4,NA,NA,NA
29512900,NA,536,nonhematologic toxicity,3 or 4,NA,FALSE,NA
29512900,NA,536,nonhematologic toxicity and causing significant clinical repercussion,2,>7 days,NA,NA
14676117,NA,537,nonhematological toxicity,3,NA,NA,NA
14676117,NA,537,hematological toxicity,4,NA,NA,NA
22506596,NCT00771472,538,neutropenia,4,>5 days,NA,NA
22506596,NCT00771472,538,thrombocytopenia,4,NA,NA,NA
22506596,NCT00771472,538,other hematological toxicity (including a decrease in hemoglobin),4,NA,NA,NA
22506596,NCT00771472,538,neutropenia with afever of 38.5Â°C or higher or with an infection requiring antibiotic orantifungal treatment,3 or 4,NA,NA,NA
22506596,NCT00771472,538,non-hematological AE) during the first cycle of therapy,3 or 4,NA,FALSE,NA
11843245,NA,539,haematotoxicity,4,NA,NA,NA
11843245,NA,539,non haematological toxicity,>=3,NA,NA,NA
27589687,NCT01087554,540,non-hematologic toxic effects,3 or 4,NA,FALSE,NA
27589687,NCT01087554,540,hematologic toxic effects,4,>7 days,NA,NA
27589687,NCT01087554,540,hematologic toxic effects accompanied by fever (for neutropenia) or bleeding (for thrombocytopenia),4,NA,NA,NA
10080616,NA,541,nonhematologic toxicity,>=2,NA,NA,NA
11165410,NA,542,absolute neutrophil count less than 500/ul,NA,>7 days,NA,NA
11165410,NA,542,any febrile neutropenia (i.e. body temperature >= 38.5Â°C and neutrophil count <500/ul),NA,NA,NA,NA
11165410,NA,542,"absence of neutrophil recovery (i.e. absolute neutrophil count less than or equal to 1500/ul) and/or platelets (<=100 000/ul) on day 35,",NA,NA,NA,NA
11165410,NA,542,thrombocytopenia,4,NA,NA,NA
11165410,NA,542,neurotoxicity,>=3,NA,NA,NA
11165410,NA,542,non-haematological toxicity,>=3,NA,FALSE,NA
11165410,NA,542,Persistent non-haematological toxicity,>=2,NA,NA,NA
29047029,NCT01744652,543,non-hematologic toxicity,3 or 4,NA,NA,NA
29047029,NCT01744652,543,neutropenia,4,>=1 week,NA,NA
29047029,NCT01744652,543,thrombocytopenia,4,>=1 week,NA,NA
26091915,NCT01169532,544,Any drug-related toxicity,4,NA,FALSE,NA
11241232,NA,545,NA,NA,NA,NA,DLT not defined
9626216,NA,547,neutropenia,4,>14 days,NA,NA
9626216,NA,547,thrombocytopenia,4,>14 days,NA,NA
9626216,NA,547,neutropenic fever,NA,NA,NA,NA
9626216,NA,547,the need for a platelet transfusion,NA,NA,NA,NA
9626216,NA,547,Nonhematologic toxicity,>=3,>7 days,FALSE,NA
25695691,NCT01019850,548,ANC < 500/mm3 28 days after PBSC infusion,NA,NA,NA,NA
25695691,NCT01019850,548,"platelets < 20,000/mm3 56 days after PBSC infusion",NA,NA,NA,NA
25695691,NCT01019850,548,need for a second PBSC infusion before count recovery,NA,NA,NA,NA
25695691,NCT01019850,548,hemolysis,4,NA,NA,NA
25695691,NCT01019850,548,lifethreatening anemia,NA,NA,NA,NA
25695691,NCT01019850,548,refractoriness to platelet transfusions with life-threatening bleeding,NA,NA,NA,NA
25695691,NCT01019850,548,thrombocytopenia on days 1 to 7 or on days 8 to 14 with platelet transfusion refractoriness,4,NA,NA,NA
25695691,NCT01019850,548,neutropenia on days 1 to 7 or on days 8 to 14 with serious bacterial or fungal infection,4,NA,NA,NA
25695691,NCT01019850,548,Nonhematologic toxicity,>=3,NA,FALSE,NA
29603591,NA,549,"Non-hematologic toxicity possibly, probably or definitely attributable to the investigational combination",4,NA,FALSE,NA
29603591,NA,549,"thrombocytopenia (platelet count <25,000/mm3)",4,NA,NA,NA
29603591,NA,549,neutropenia (absolute neutrophil count <500/mm3) resulting in delays of greater than 7 days in protocol directed therapy,NA,NA,NA,NA
29603591,NA,549,thrombocytopenia requiring one or more platelet transfusions,4,NA,NA,NA
29603591,NA,549,any adverse event requiring omission of three or more doses of vorinostat.,NA,NA,NA,NA
18297527,NCT00109109,550,"nausea, vomiting, or diarrhea despite maximum supportive care",3 or 4,NA,NA,NA
18297527,NCT00109109,550,other non-hematologictoxicity,3 or 4,NA,NA,NA
18297527,NCT00109109,550,neutropenia despite the use of G-CSF,4,.5 days,NA,NA
18297527,NCT00109109,550,thrombocytopenia,4,NA,NA,NA
18297527,NCT00109109,550,neutropenic fever,NA,NA,NA,NA
18297527,NCT00109109,550,treatment delay due to toxicity lasting longer than 2 week,NA,NA,NA,NA
7747714,NA,551,hematologic toxicity,4,NA,NA,NA
7747714,NA,551,nonhematologic toxicity,3,NA,FALSE,NA
31409616,NCT02638090,552,immune-related adverse event (irAE),>=4,NA,NA,NA
31409616,NCT02638090,552,irAE,3,NA,TRUE,NA
31409616,NCT02638090,552,pneumonitis that did not resolve to <= grade 1 within 3 days of the initiation of maximal supportive care,2,NA,NA,NA
31409616,NCT02638090,552,colitis or noninfectious pneumonitisâ€”irrespective of duration,>=3,NA,NA,NA
31409616,NCT02638090,552,liver transaminase elevation > 8 x upper limit of normal,NA,NA,NA,NA
31409616,NCT02638090,552,total bilirubin > 5 x upper limit of normal,NA,NA,NA,NA
31409616,NCT02638090,552,other irAEs that did not downgrade to  grade 1 or baseline within 14 days,3,NA,NA,NA
31409616,NCT02638090,552,non-irAE,>=3,NA,FALSE,NA
31823832,NCT01422499,553,"any toxicity judged by the investigator as definitely, probably or possibly related to the study drug",3 or 4,NA,NA,NA
7931480,NA,554,NA,NA,NA,NA,DLT not defined
34347089,NCT01189266,555,any vorinostat-related toxicity that necessitated interruption of radiation for 5 consecutive days or 10 cumulative days,NA,NA,NA,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,nonhematologic toxicity,4,NA,NA,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,non-hematologic toxicity,3,NA,FALSE,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,non-hematologic toxicity considered sufficiently medically significant or intolerable by patients requiring treatment interruption,2,â‰¥ 7  days,NA,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,thrombocytopenia,3,NA,NA,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,neutropenia,4,NA,NA,During concurrent radiation therapy and vorinostat
34347089,NCT01189266,555,nonhematologic toxicity,4,NA,NA,During maintenance vorinostat
34347089,NCT01189266,555,non-hematologic toxicity,3,NA,FALSE,During maintenance vorinostat
34347089,NCT01189266,555,non-hematologic toxicity considered sufficiently medically significant or intolerable by patients requiring treatment interruption,2,â‰¥ 7  days,NA,During maintenance vorinostat
34347089,NCT01189266,555,thrombocytopenia,3,NA,NA,During maintenance vorinostat
34347089,NCT01189266,555,neutropenia,4,NA,NA,During maintenance vorinostat
34347089,NCT01189266,555,"any delay of >14 days in starting the subsequent cycle of vorinostat due to ANC < 1,000/ÂµL and/or platelet < 100,000/ÂµL",NA,NA,NA,During maintenance vorinostat
19817748,NCT00127140,556,neutropenia,4,>=5 days,NA,NA
19817748,NCT00127140,556,infection with Grade 3 or 4 neutropenia,>=3,NA,NA,NA
19817748,NCT00127140,556,thrombocytopenia requiring blood transfusion,>=3,NA,NA,NA
19817748,NCT00127140,556,thrombocytopenia or anemia,4,NA,NA,NA
19817748,NCT00127140,556,non-hematologic toxicities,>=3,NA,FALSE,NA
19817748,NCT00127140,556,"anorexia, nauseaâ„vomiting, and fatigue refractory to treatment",>=3,NA,NA,NA
34896762,NCT02521051,557,adverse events (AEs) occurring within the first cycle of treatment (21 days) attributed to the study drugs,NA,NA,NA,NA
32181989,NA,558,NA,NA,NA,NA,DLT not defined
10963843,NA,559,neutropenia,4,NA,NA,NA
10963843,NA,559,febrile neutropenia (neutrophil count less than 1000/mm3 and fever >38.5Â°C),NA,NA,NA,NA
10963843,NA,559,thrombocytopenia,4,NA,NA,NA
10963843,NA,559,symptomatic thrombocytopenia,3,NA,NA,NA
10963843,NA,559,esophagitis,4,NA,NA,NA
10963843,NA,559,peripheral neurotoxicity,>=2,NA,NA,NA
10963843,NA,559,any organ toxicity,>=2,NA,FALSE,NA
10963843,NA,559,treatment interruption longer than 2 weeks,NA,NA,NA,NA
26891067,NCT01222780,560,Nonhematologic toxicity related to VSLI,>=3,NA,FALSE,NA
26891067,NCT01222780,560,Hematologic toxicity,4,>5 days,FALSE,NA
26891067,NCT01222780,560,Hematologic toxicity,4,NA,NA,NA
26891067,NCT01222780,560,transfusion support was required for hematologic toxicity,4,NA,NA,NA
26891067,NCT01222780,560,"the failure to recover a neutrophil count to >=1,000/Î¼l or a baseline plateletcount by day 35 of the treatment cycle",4,NA,NA,NA
28816142,NCT00946673,561,nonhematologic adverse event (AE),>=3,NA,FALSE,NA
28816142,NCT00946673,561,ausea and/or vomiting despite optimal medical management,>=3,>=48 hours,NA,NA
28816142,NCT00946673,561,neutropenia,4,>=7 days,NA,NA
28816142,NCT00946673,561,febrile neutropenia with/without infection,>=3,NA,NA,NA
28816142,NCT00946673,561,thrombocytopenia,4,NA,NA,NA
28816142,NCT00946673,561,hematologic toxicity,5,NA,NA,NA
15736475,NA,562,neutropenia,4,>5 days,NA,NA
15736475,NA,562,thrombocytopenia,4,>5 days,NA,NA
15736475,NA,562,any febrile (>38.5C) neutropenia,NA,NA,NA,NA
15736475,NA,562,non-hematological toxicity,3 or 4,NA,FALSE,NA
15736475,NA,562,"and any treatment delay on day 15 due to unresolved toxicity (granulocytes < 1500/uL, platelets < 100,000/uL or nonhematological toxicity > grade 2)",NA,NA,NA,NA
20564083,NA,563,NA,NA,NA,NA,DLT not defined
23320927,NCT00132522,564,adverse drug reaction,3 or 4,NA,NA,NA
31506385,NCT01677741,565,hematologic AE,4,NA,NA,NA
31506385,NCT01677741,565,nonhematologic AE,3 or 4,NA,NA,NA
31506385,NCT01677741,565,treatment delay >7 days due to an unresolved AE,NA,NA,NA,NA
31506385,NCT01677741,565,"left ventricular ejection fraction less than the lower limit of normal, with an absolute decrease of >10% from baseline",NA,NA,NA,NA
31506385,NCT01677741,565,an AE requiring a dose reduction,NA,NA,NA,NA
22918078,NA,566,treatment-related adverse events (AEs),>=3,NA,FALSE,NA
22307137,NCT00810966,568,nonhematologic toxicity,>=3,NA,FALSE,NA
22307137,NCT00810966,568,neutropenia,4,NA,FALSE,NA
22307137,NCT00810966,568,thrombocytopenia,4,NA,NA,NA
22307137,NCT00810966,568,a 2-week or more delay in starting the next cycle due to toxicity,NA,NA,NA,NA
25728527,NCT01240538,569,"non-hematological toxicity possibly, probably, or definitely attributable to protocol therapy",3 or 4,NA,FALSE,NA
25728527,NCT01240538,569,non-hematologic toxicities that resulted in a delay of therapy for morethan 14 days,NA,NA,NA,NA
25728527,NCT01240538,569,allergic reactions that necessitated discontinuation of the study drug,NA,NA,NA,NA
25728527,NCT01240538,569,a decreased left ventricula rejection fraction of greater than 10% from baseline,NA,NA,NA,NA
25728527,NCT01240538,569,heart failure,2,NA,NA,NA
25728527,NCT01240538,569,neutropenia,4,NA,NA,NA
25728527,NCT01240538,569,febrile neutropenia,NA,>7 days,NA,NA
25728527,NCT01240538,569,"a platelet count less than 25,000/mm3 on 2 separate days within a 7 day period",NA,NA,NA,NA
25728527,NCT01240538,569,myelosuppression resulting in more than a 14 day delay between cycles,NA,NA,NA,NA
8751547,NA,571,"an absolute granulocyte count <500/cm3 and/or platelet count <20,000/cm3 for greater than 5 days that prohibits administration of the next cycle or delays it more than 1 week",NA,NA,NA,NA
8751547,NA,571,inability to give 100% of all three drugs for the subsequent cycle (for cycles 1â€“6),NA,NA,NA,NA
8751547,NA,571,significant reversible nonhematologic toxicity,>3,NA,NA,NA
8751547,NA,571,irreversible nonhematologic toxicity,>=2,NA,NA,NA
24991840,NCT00486603).,572,"any non-hematological toxicities possibly, probably, or definitely HCQ-related",3 or 4,NA,FALSE,NA
24991840,NCT00486603).,572,Known or reasonably suspected TMZ hematological toxicities were not considered dose-limiting unless the toxicity was felt to be significantly exacerbated by HCQ,NA,NA,NA,NA
24991840,NCT00486603).,572,"Any adverse effect (AE) attributed to HCQ (nausea, vomiting, diarrhea, rash, and visual field deficit) resulted in the dose being held until the AE had resolved to â‰¤ grade 1 or baseline",>=3,NA,NA,NA
11049969,NA,573,NA,NA,NA,NA,DLT not defined
25139740,NCT00741377,574,"an adverseevent (AE) or abnormal laboratory value assessed as unre-lated to disease progression, intercurrent illness, or concomitant medications",NA,NA,NA,NA
32998961,NCT03303339,575,Non-hematological AEs without decreasing in severity despite standard of care,3,> 7 days,NA,NA
32998961,NCT03303339,575,symptomatic non-hematological AEs,4,NA,NA,NA
32998961,NCT03303339,575,"Persistent pancytopenia resistant to current standard of care that continued for â‰¥42 days, not related to leukemic infiltration or considered related to study therapy",NA,NA,NA,NA
7607931,NA,577,NA,NA,NA,NA,DLT not defined
24682421,NCT 00838240,578,Non-hematological toxicity,3 or 4,NA,FALSE,NA
24682421,NCT 00838240,578,Hematological toxicity defined as bone marrow hypoplasia leading to neutrophil or platelet recovery (neutrophils >0.5Ã—109/L and platelets >50Ã—109/L) later than 8 weeks after start of last remission induction,NA,NA,NA,NA
23867058,NA,579,non-hematologic toxicity,3 or 4,NA,FALSE,NA
23867058,NA,579,hematologic toxicity that did not resolve to 20% of baseline by day 35 of therapy (unless disease-related),3 or 4,NA,NA,NA
23867058,NA,579,infection or febrile neutropenia,3,NA,NA,NA
9213323,NA,580,NA,NA,NA,NA,DLT not defined
24958809,NCT00880321,581,hematologic toxicity,4,NA,NA,NA
24958809,NCT00880321,581,non-hematologic toxicity,3 or 4,NA,NA,NA
24958809,NCT00880321,581,"nausea, vomiting, and diarrhea uncontrolled with standard supportive measures",3,NA,NA,NA
24958809,NCT00880321,581,Treatment delay of > 14 consecutive days due to unresolved toxicity,NA,NA,NA,NA
24958809,NCT00880321,581,"non-hematologic toxicity that, in the judgment of the investigator and GSK Medical Monitor",>=2,NA,NA,NA
24958809,NCT00880321,581,"Troponin level greater than the upper limit of normal (ULN) and > 10% coefficient of variance (CV) level with other clinical signs, symptoms, laboratory results, or tests consistent with cardiac toxicity",NA,NA,FALSE,NA
24958809,NCT00880321,581,Troponin value > ULN and > 10% CV level and increased by > 50% from baseline,NA,>3 days,NA,NA
24958809,NCT00880321,581,"Ejection fraction less than the lower limit of normal (LLN), with a relative decrease of > 20% from baseline and a confirming assessment within 7 days",NA,NA,NA,NA
24958809,NCT00880321,581,"Significant alteration in cardiac valve morphology from baseline, including any new grade 2 or higher valvular heart disease",NA,NA,NA,NA
31811016,NCT01677741,582,NA,NA,NA,NA,DLT not defined
31796520,NCT02383212,583,uveitis,>=2,NA,NA,NA
31796520,NCT02383212,583,neutropenia,4,>7 days,NA,NA
31796520,NCT02383212,583,thrombocytopenia,4,NA,NA,NA
31796520,NCT02383212,583,thrombocytopenia with bleeding,3,NA,NA,NA
31796520,NCT02383212,583,febrile neutropenia,>=3,NA,NA,NA
31796520,NCT02383212,583,neutropenia with documented infection,>=3,NA,NA,NA
31796520,NCT02383212,583,nonhematologic toxicity,>=3,NA,FALSE,NA
32741971,NCT02597036,587,nonhematological toxicity despite maximal medical management,>=3,NA,NA,NA
32741971,NCT02597036,587,haematological toxicity,4,>5 days,NA,NA
32741971,NCT02597036,587,febrile neutropenia,NA,NA,NA,NA
32741971,NCT02597036,587,thrombocytopenia,4,NA,NA,NA
32741971,NCT02597036,587,thrombocytopenia complicated with â‰¥ grade 2 bleeding,3,NA,NA,NA
32741971,NCT02597036,587,newly developed oedema characterised by a body weight increase of >10% as compared to the start of therapy,NA,NA,NA,NA
32741971,NCT02597036,587,"any toxicity deemed significant by investigator), possibly related to LY3127804 and occurring during the DLT period in parts A, B and C",NA,NA,NA,NA
8622060,NA,589,NA,NA,NA,NA,DLT not defined
21811257,NA,590,NA,NA,NA,NA,DLT not defined
27649551,NCT02239900,591,nonhematologic/laboratory toxicity,>=3,NA,NA,NA
27649551,NCT02239900,591,hematologic/laboratory toxicity related to the combination of ipilimumab and radiation,>=4,NA,NA,NA
26847165,NCT02340936,592,non-haematological toxicity,3 or 4,NA,FALSE,NA
26847165,NCT02340936,592,febrile neutropenia,NA,>=7 days,NA,NA
26847165,NCT02340936,592,delayed recovery (to NCI â‰¤ grade 1 or baseline) from a toxicity that delayed the secondcycle by >2 weeks,NA,NA,NA,NA
26847165,NCT02340936,592,"any related adverse event that did not meet the above criteria for a DLT, could be con-sidered DLT at the monitoring committeeâ€™s discretion",NA,NA,NA,NA
34428285,NCT02343536,593,neutropenia with fever,4,NA,NA,NA
34428285,NCT02343536,593,thrombocytopenia with significant bleeding,>=3,NA,NA,NA
34428285,NCT02343536,593,any other nonhematologic toxicity not related to the underlying disease,>=3,NA,NA,NA
34428285,NCT02343536,593,vomiting or diarrhea despite supportive care,>=2,>=48 h,NA,NA
34428285,NCT02343536,593,cumulative toxicity-related delays of R-CHOP for .21 days over 6 cycles,NA,NA,NA,NA
34428285,NCT02343536,593,a delay of >7 days in the start of R-CHOP in cycle 2,NA,NA,NA,NA
34428285,NCT02343536,593,if patients were ineligible to receive CC-486 within 48 hours of day 8 in >2 out of 5 cycles based on dose modification criteria,NA,NA,NA,NA
11840607,NA,594,non-hematologic toxicity,3 or 4,NA,FALSE,NA
11840607,NA,594,leukopenia,4,NA,NA,NA
11840607,NA,594,neutropenia,4,NA,NA,NA
11840607,NA,594,thrombocytopenia,4,NA,NA,NA
11840607,NA,594,neutropenic fever,4,NA,NA,NA
11840607,NA,594,the patient was unable to complete the first treatment cycle and having recovered from toxicity in time to begin the second cycle as scheduled (beginning week 4),NA,NA,NA,NA
30655615,NA,595,Actual neutrophil count (ANC) <0.5 x 109/L without fever,NA,>5 days,NA,NA
30655615,NA,595,ANC >0.5 x 109/L but less than 1.5 x 109/L with fever >=38.5 C and neutropenic sepsis,NA,NA,NA,NA
30655615,NA,595,Platelets <25 x 109/L,NA,NA,NA,NA
30655615,NA,595,non-hematological AEs,3 or 4,NA,FALSE,NA
30655615,NA,595,Any AEs not otherwise described that results in treatment delay of >21 consecutive days,NA,NA,NA,NA
30655615,NA,595,"AEs considered, in the opinion of the investigator, to be dose-limiting",3 or 4,NA,NA,NA
30655615,NA,595,Requirement for repeated blood transfusions within the first two cycles,NA,NA,NA,NA
33811482,NCT01246986,596,nonhematological toxicity,>=3,NA,FALSE,NA
33811482,NCT01246986,596,hematological toxicity,>=4,>5 days,NA,NA
33811482,NCT01246986,596,febrile neutropenia,NA,NA,NA,NA
33811482,NCT01246986,596,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
24440659,NA,597,drug-related nonhematologic toxicity,>=3,NA,NA,NA
21159616,NA,598,nonhematologic toxicity,>=3,NA,FALSE,NA
21159616,NA,598,nausea or vomiting uncontrolled by aggressive antiemetic support,>=3,NA,NA,NA
21159616,NA,598,neutropenia,4,>5 days,NA,NA
21159616,NA,598,any febrile (38.5 C or 101 F) grade 3 or 4 neutropenia,NA,NA,NA,NA
21159616,NA,598,thrombocytopenia,4,NA,NA,NA
21159616,NA,598,neurologic toxicity without resolution within 72 hours,>=2,NA,NA,NA
21159616,NA,598,NA,4,NA,NA,NA
34433633,NCT00562640,599,NA,NA,NA,NA,DLT not defined
22887831,NCT00293410,600,NA,NA,NA,NA,DLT not defined
20048182,NA,601,neutropenia,4,>7 days,NA,NA
20048182,NA,601,febrile neutropenia,>=3,NA,NA,NA
20048182,NA,601,thrombocytopenia,>=3,NA,NA,NA
20048182,NA,601,anemia,>=3,NA,NA,NA
20048182,NA,601,nonhematologic toxicity considered drug related by the investigator,>=3,NA,NA,NA
33046516,NCT02789345,602,nonhematologic toxicity,>=3,NA,FALSE,NA
33046516,NCT02789345,602,hematologic toxicities,4,>=7 days,NA,NA
33046516,NCT02789345,602,thrombocytopenia if associated with bleeding,3 or 4,NA,NA,NA
33046516,NCT02789345,602,febrile neutropenia,NA,NA,NA,NA
33046516,NCT02789345,602,toxicity (death) if considered related to study treatment,5,NA,NA,NA
12114412,NA,603,any toxicity,4,NA,FALSE,NA
12114412,NA,603,neutropenia,4,>4 weeks,NA,NA
12114412,NA,603,thrombocytopenia,4,>4 weeks,NA,NA
12114412,NA,603,any toxicity,3,NA,FALSE,NA
12114412,NA,603,transaminase toxicity,3,>7 days,NA,NA
12114412,NA,603,hyperbilirubinemia >5 x upper limit of normal,NA,>7 days,NA,NA
25307519,NCT01048892,605,neutropenia,4,>7 days,NA,NA
25307519,NCT01048892,605,"a platelet count<25,000/m3 on two separate days or requiring a platelet transfusion on two separate days, within a 7 day period",NA,NA,NA,NA
25307519,NCT01048892,605,non-hematologic toxicity attributable to NTX-010,3 or 4,NA,FALSE,NA
28439108,NCT00450814,607,adverse events (AE) attributed to therapy,>=3,NA,FALSE,NA
28439108,NCT00450814,607,Neutropenia,3,>7 days,NA,NA
28439108,NCT00450814,607,Neutropenia,4,NA,NA,NA
28439108,NCT00450814,607,Thrombocytopenia,4,>7 days,NA,NA
28439108,NCT00450814,607,Symptomatic measles infection,NA,>= t days,NA,NA
28439108,NCT00450814,607,10-fold increase in the measles N-gene RNA copy number (copies per microgram RNA) between sequential samples at least 3 days apart after day +15,NA,NA,NA,NA
11869937,NA,609,NA,NA,NA,NA,RRT (regimen-related toxicity) instead of DLT
10865980,NA,610,neutropenia,4,>7 days,NA,NA
10865980,NA,610,thrombocytopenia,4,NA,NA,NA
10865980,NA,610,a neutropenic fever,NA,NA,NA,NA
10865980,NA,610,nonhematological toxicity,2,NA,FALSE,NA
10865980,NA,610,"Toxicity-related treatment delays longer than 2 weeks, such as after prolonged cytopenia",NA,NA,NA,NA
10865980,NA,610,nausea/vomiting or diarrhea if observed despite curative treatment,2,NA,NA,NA
31895753,NA,611,any unexpected serious adverse event (SAE) and adverse event deemed related to the investigational treatment combination.,NA,NA,NA,NA
23954889,NCT01166113,612,neutropenia,4,>3 days,NA,NA
23954889,NCT01166113,612,other hematologic toxicity,4,NA,NA,NA
23954889,NCT01166113,612,nonhematologic toxicity,>=3,NA,NA,NA
23954889,NCT01166113,612,febrile neutropenia,NA,NA,NA,NA
23954889,NCT01166113,612,infection requiring antibiotics,NA,NA,NA,NA
33229456,NCT02791334,613,NA,NA,NA,NA,DLT not defined
28879519,NCT01582997,617,hematologic toxicity,4,NA,NA,NA
28879519,NCT01582997,617,"non-hematologic toxicity and rash, nausea, vomiting, and diarrhea, only if controlled with supportive therapy",3 or 4,NA,NA,NA
28879519,NCT01582997,617,rash that required dose reduction despite supportive care,>=3,NA,NA,NA
28879519,NCT01582997,617,non-hematologic toxicity that was considered dose limiting in the judgment of the investigator,>=2,NA,NA,NA
28879519,NCT01582997,617,treatment delay of greater than 14 consecutive days due to unresolved toxicity,NA,NA,NA,NA
28879519,NCT01582997,617,any new valvular heart disease,>=2,NA,NA,NA
28879519,NCT01582997,617,patients with significant alteration in cardiac valve morphology from baseline,NA,NA,NA,NA
27166393,NCT00566618,618,nonhematologic toxicity,4,NA,NA,NA
27166393,NCT00566618,618,neutropenia,4,>7 days,NA,NA
27166393,NCT00566618,618,febrile neutropenia,NA,NA,NA,NA
27166393,NCT00566618,618,nonhematological toxicity despite adequate supportive care,3,>72 hours,NA,NA
27166393,NCT00566618,618,"neutropenia (ANC < 1.5 x 109/L), or thrombocytopenia (PLT < 75 x 109/L) which failed to revert to grade 1 by the time of the scheduled start of cycle 2",>=2,NA,NA,NA
27166393,NCT00566618,618,50% decrease in calculated creatinine clearance,NA,NA,NA,NA
27166393,NCT00566618,618,a diagnosis of osteonecrosis of the jaw,NA,NA,NA,NA
16675578,NA,619,absolute neutrophil count,4,>7 days,NA,NA
16675578,NA,619,platelet count,4,NA,NA,NA
16675578,NA,619,absolute neutrophil count with fever,>=3,NA,NA,NA
16675578,NA,619,any other toxicity that represents a two-grade increase from baseline,>=3,NA,FALSE,NA
16675578,NA,619,neurotoxicity,>=2,persisting through the entire cycle (day 21),FALSE,NA
16675578,NA,619,"toxicity that represents at least a two-grade increase from baseline, which required a delay of more than 1 additional week of recovery before starting the next cycle of study drug administration",4,NA,NA,NA
26924128,NCT01365559,620,neutropenia,4,â‰¥7 days,NA,NA
26924128,NCT01365559,620,febrile neutropenia,NA,NA,NA,NA
26924128,NCT01365559,620,thrombocytopenia or anemia,4,â‰¥7 days,NA,NA
26924128,NCT01365559,620,thrombocytopenia with bleeding or requiring transfusion,>=3,NA,NA,NA
26924128,NCT01365559,620,nonhematologic toxicity,>=3,NA,FALSE,NA
26924128,NCT01365559,620,"nausea, vomiting, diarrhea, or constipation was only considered a DLT if it occurred despite optimal supportive care",3,NA,NA,NA
24916771,NA,621,"non-hematologic events considered possibly, probably, or definitely related to the combination study drug treatment",>=3,NA,FALSE,NA
24916771,NA,621,>2 week delay in the start of cycle 2 as result of PX866-related toxicity,NA,NA,NA,NA
24916771,NA,621,neutropenia with fever,3 or 4,NA,NA,NA
24916771,NA,621,"platelets<25,000/Î¼L",NA,NA,NA,NA
24916771,NA,621,absolute neutrophil count <500/Î¼L,NA,>7 d,NA,NA
24916771,NA,621,transaminitis,3,>7 d,NA,NA
24916771,NA,621,transaminitis,4,NA,NA,NA
24916771,NA,621,increase in serum glucose despite optimal therapy,3,NA,NA,NA
33713742,NCT01674842,622,neutropenia complicated by fever >38.5 ÌŠC or documented infection,3 or 4,NA,NA,NA
33713742,NCT01674842,622,neutropenia,4,>7 days,NA,NA
33713742,NCT01674842,622,thrombocytopenia,4,NA,NA,NA
33713742,NCT01674842,622,thrombocytopenia complicated by hemorrhag,3,NA,NA,NA
33713742,NCT01674842,622,skin toxicity,4,NA,NA,NA
33713742,NCT01674842,622,skin toxicity that did not regress to grade 2 within 2 weeks after completion of RT,3,NA,NA,NA
33713742,NCT01674842,622,any toxicity requiring a break in RT exceeding 2 days,NA,NA,NA,NA
33713742,NCT01674842,622,any toxicity requiring a reduction in RT dose,NA,NA,NA,NA
33713742,NCT01674842,622,any delay in chemotherapy greater than 2 weeks,NA,NA,NA,NA
33713742,NCT01674842,622,nonhematologic toxicity related to cisplatin,>=3,NA,FALSE,NA
33135391,NCT02429466,623,any  drug-related  non-hemato-logic toxicity,3 or 4,NA,FALSE,NA
33135391,NCT02429466,623,thrombocytopenia,4,NA,NA,NA
33135391,NCT02429466,623,thrombocytopenia with significant hemorrhage,3,NA,NA,NA
33135391,NCT02429466,623,febrile  neutropenia,NA,NA,NA,NA
33577866,NA,624,neutropenia,4,>=7 days,NA,NA
33577866,NA,624,thrombocytopenia,4,NA,NA,NA
33577866,NA,624,mucositis,4,NA,NA,NA
33577866,NA,624,dermatitis,4,NA,NA,NA
33577866,NA,624,thrombocytopenia (with major bleeding),3,NA,NA,NA
33577866,NA,624,nausea and vomiting despite maximal supportive intervention,>=3,persisting for >72 h,NA,NA
33577866,NA,624,febrile neutropenia,NA,NA,NA,NA
33577866,NA,624,toxicity resulting in treatment discontinuation (for >2 weeks),NA,NA,NA,NA
33577866,NA,624,dose delays/omissions greater than expected from usual chemoradiation,NA,NA,NA,NA
33577866,NA,624,any other significant toxicity in excess of what was expected from chemoradiation,NA,NA,NA,NA
19169687,NA,626,skin toxicity events,4,NA,NA,NA
19169687,NA,626,three incidences of skin toxicity events,3,NA,NA,NA
19169687,NA,626,the omission of three consecutive infusions due to grade 3 skin toxicity,NA,NA,NA,NA
19169687,NA,626,adverse drug reactions,>=3,NA,FALSE,NA
19169687,NA,626,"the development of acute pulmonary disease, interstitial pneumonia and other pulmonary symptoms",NA,NA,FALSE,NA
22761464,NCT00150462,627,"nausea, vomiting, or diarrhea not controlled by anti-emetic/antidiarrheal therapy",>=3,NA,NA,NA
22761464,NCT00150462,627,neuropathy with pain,>2,NA,NA,NA
22761464,NCT00150462,627,neutropenia (ANC <0.5 x 109/L) without growth factor support,4,>14 days,NA,NA
22761464,NCT00150462,627,Febrile neutropenia (ANC <1.0 x 109/L with fever 38.3C),NA,NA,NA,NA
22761464,NCT00150462,627,thrombocytopenia (<25.0 x 109/L),4,>7 days,NA,NA
22761464,NCT00150462,627,thrombocytopenia (<25.0 x 109/L) associated with bleeding,4,NA,NA,NA
22761464,NCT00150462,627,Other nonhematologic toxicity,>=3,NA,NA,NA
17465237,NA,628,febrile neutropenia,NA,NA,NA,NA
17465237,NA,628,neutropenia,4,>7 days,NA,NA
17465237,NA,628,thrombocytopenia,4,NA,NA,NA
17465237,NA,628,other toxicity despite adequate prophylaxis,3 or 4,NA,FALSE,NA
22960004,NA,638,neutropenia,4,>7 days,NA,NA
22960004,NA,638,febrile neutropenia requiring antibiotics,3 or 4,NA,NA,NA
22960004,NA,638,thrombocytopenia,4,NA,NA,NA
22960004,NA,638,thrombocytopenia with bleeding requiring platelet transfusion,3 or 4,NA,NA,NA
22960004,NA,638,a delay of more than one week for toxicity,NA,NA,NA,NA
22960004,NA,638,a delay due to toxicity causing RT to be extended >8 weeks,4,NA,NA,NA
22960004,NA,638,treatment-related death,NA,NA,NA,NA
22960004,NA,638,non-hematologic toxicity,3 or 4,NA,TRUE,NA
28363909,NCT01719380,640,Febrile neutropenia (absolute neutrophil count <1.0 x 109 /L with fever â‰¥38.5Â°C),4,NA,FALSE,NA
28363909,NCT01719380,640,absolute neutrophil count,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,absolute neutrophil count,4,NA,NA,NA
28363909,NCT01719380,640,platelet count for >7 consecutive days and/or with signs of bleeding,3,NA,NA,NA
28363909,NCT01719380,640,platelet count,4,NA,NA,NA
28363909,NCT01719380,640,rash/photosensitivity/hand-foot skin reaction (HFSR) despite skin toxicity treatment,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,rash/photosensitivity/hand-foot skin reaction (HFSR),4,NA,NA,NA
28363909,NCT01719380,640,hyperglycemia that does not resolve to grade 0 within 14 consecutive days (after initiation of oral antidiabetic treatment),2,NA,NA,NA
28363909,NCT01719380,640,hyperglycemia despite oral antidiabetic treatment,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,"hyperglycemia or hyperglycemia that leads to diabetic ketoacidosis, hospitalization for IV insulin infusion, or non-ketotic coma",4,NA,NA,NA
28363909,NCT01719380,640,Hyperglycemia occurring during corticosteroids administration was only considered a DLT if not resolved within 2 days after the end of corticosteroid treatment,NA,NA,NA,NA
28363909,NCT01719380,640,vomiting or nausea or diarrhea lasting more than 48 h despite optimal therapy,>=3,NA,NA,NA
28363909,NCT01719380,640,pancreatitis,>=3,NA,NA,NA
28363909,NCT01719380,640,serum creatinine,>=3,NA,NA,NA
28363909,NCT01719380,640,blood bilirubin,>=3,NA,NA,NA
28363909,NCT01719380,640,AST or ALT â‰¥3 x ULN in conjunction with blood bilirubin â‰¥2 x ULN of any duration,NA,NA,NA,NA
28363909,NCT01719380,640,AST or ALT,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,AST or ALT,4,NA,NA,NA
28363909,NCT01719380,640,serum alkaline phosphatase,4,>7 consecutive days,NA,NA
28363909,NCT01719380,640,lipase and/or serum amylase,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,lipase and/or serum amylase,4,NA,NA,NA
28363909,NCT01719380,640,persistent hypertension requiring more than one drug or more intensive therapy than previously,>=3,NA,NA,NA
28363909,NCT01719380,640,Cardiac disorders,>=3,NA,NA,NA
28363909,NCT01719380,640,TLS (life-threatening),>=4,NA,NA,NA
28363909,NCT01719380,640,fatigue,3,>7 consecutive days,NA,NA
28363909,NCT01719380,640,edema,>=3,>14 consecutive days,NA,NA
28363909,NCT01719380,640,retinopathy/uveitis,3,>21 days,NA,NA
28363909,NCT01719380,640,retinopathy/uveitis confirmed by ophthalmologic examination,4,NA,NA,NA
28363909,NCT01719380,640,retinal vein occlusion,NA,NA,NA,NA
28363909,NCT01719380,640,Any other eye disorders,3,NA,NA,NA
28363909,NCT01719380,640,Any other eye disorders,4,>14 days,NA,NA
28363909,NCT01719380,640,Any other AE,>=3,NA,FALSE,NA
31486207,NCT01816984,642,any nonhematologic toxicity,>=3,NA,NA,NA
31486207,NCT01816984,642,thrombocytopenia,>=4,NA,NA,NA
31486207,NCT01816984,642,neutropenia,>=4,NA,NA,NA
31486207,NCT01816984,642,anemia,>=4,NA,NA,NA
31486207,NCT01816984,642,any toxicity that was deemed tobe intolerable,>=2,NA,NA,NA
31486207,NCT01816984,642,any neuropsychiatric symptoms,>=3,NA,NA,NA
33741296,NCT03502681,643,NA,NA,NA,NA,DLT not defined
31486872,NA,644,non-hematological toxicities,3 or 4,NA,NA,NA
31486872,NA,644,thrombocytopenia,4,NA,NA,NA
31486872,NA,644,neutropenia,4,>4 days,NA,NA
31486872,NA,644,leukopenia,4,>4 days,NA,NA
31486872,NA,644,febrile neutropenia,NA,NA,NA,NA
31486872,NA,644,the second cycle not starting by day 35,NA,NA,NA,NA
20148348,NA,645,thrombocytopenia,4,NA,NA,NA
20148348,NA,645,thrombocytopenia associated with bleeding or requirement for transfusion or febrile neutropenia,3,NA,NA,NA
20148348,NA,645,cutaneous toxicity,4,NA,NA,NA
20148348,NA,645,cutaneous toxicity necessitating holding cetuximab for greater than 4 weeks,3,NA,NA,NA
20148348,NA,645,diarrhea,4,NA,NA,NA
20148348,NA,645,diarrhea that did not resolve after holding the drug for 2 weeks or that recurred despite adequate treatment with anti-diarrheal agents,3,NA,NA,NA
20148348,NA,645,any other non-hematologic toxicity considered by the investigator to be related to study drug,>=3,NA,FALSE,NA
30084837,NA,646,toxicity attributable to olaparib,>=3,NA,FALSE,NA
17203757,NA,647,NA,NA,NA,NA,DLT not defined
29567334,UMIN000010369,648,myelosuppression,4,>3 days,NA,NA
29567334,UMIN000010369,648,renal dysfunction,3 or 4,NA,NA,NA
29567334,UMIN000010369,648,vomiting,4,NA,NA,NA
34040175,NCT02157792,649,Neutropenia,4,>7 days,NA,NA
34040175,NCT02157792,649,Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection).,NA,NA,NA,NA
34040175,NCT02157792,649,Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (absolute neutrophil count <1.0 Ã— 109/L).,NA,NA,NA,NA
34040175,NCT02157792,649,Thrombocytopenia associated with clinically significant bleeding; requiring platelet transfusion,3,NA,NA,NA
34040175,NCT02157792,649,Thrombocytopenia,4,NA,NA,NA
34040175,NCT02157792,649,toxicity to organs other than the bone marrow,3 or 4,NA,FALSE,NA
34040175,NCT02157792,649,A concurrent elevation of ALT >3 Ã— the ULN and total bilirubin >2 Ã— ULN in a patient in whom there was no evidence of biliary obstruction or other causes that could reasonably explain the concurrent elevation,NA,NA,NA,NA
34040175,NCT02157792,649,Death due to drug-related complications.,NA,NA,NA,NA
34040175,NCT02157792,649,"Cardiac: QTc prolongation (any QTc interval â‰¥500 msec or any change in QTc interval â‰¥60 msec from baseline) on ECG, unless related to an electrolyte abnormality and prolongation resolved with correction of electrolyte abnormality",NA,NA,NA,NA
34040175,NCT02157792,649,"ventricular arrhythmia (second or third degree AV block), severe sustained/symptomatic sinus bradycardia less than 45 beats per minute (bpm) or sinus tachycardia >120 bpm not due to other causes (e.g., fever), persistent supraventricular arrhythmia (e.g., uncontrolled/new atrial fibrillation, flutter, atrioventricular nodal tachycardia, etc.) lasting more than 24 hours, ventricular tachycardia defined as >9 beats in a row or any length of torsades de pointes (polymorphic ventricular tachycardia with long QTc), or unexplained recurrent syncope",>=2,NA,NA,NA
34040175,NCT02157792,649,Symptoms suggestive of congestive heart failure with confirmed EF <40% (by 2D-echocardiogram or Multiple Gated Acquisition [MUGA] scan) or a relative decrease >20% from historical assessment of EF performed within 12 months,NA,NA,NA,NA
34040175,NCT02157792,649,Any drug-related toxicity that caused interruption of treatment for >2 weeks (14 successive days).,NA,NA,FALSE,NA
34668982,NA,651,the occurrence of any toxicity,3 or 4,NA,NA,NA
12460785,NA,652,granulocytopenia,4,>5 days,NA,NA
12460785,NA,652,granulocytopenia associated with infection of severity grade >=3,4,NA,NA,NA
12460785,NA,652,febrile neutropenia,NA,NA,NA,NA
12460785,NA,652,platelets >=25.0 and < 50.0x109/l,NA,>=5 days,NA,NA
12460785,NA,652,platelets < 25.0x109/l,NA,NA,NA,NA
12460785,NA,652,haemoglobin < 4 mmol/l,NA,NA,NA,NA
12460785,NA,652,Non-haematological toxicity,>=3,NA,FALSE,NA
12460785,NA,652,neurotoxicity and bilirubin,2,NA,NA,NA
12460785,NA,652,"the occurrence of congestive heart failure or a decline in LVEF of either >=20% if the drop is within normal limits, or >=10% if the value attained is below the lower limit of normal",NA,NA,NA,NA
33262140,NCT01562210,654,Radiation pneumonitis,>=3,NA,NA,NA
33262140,NCT01562210,654,Any other nonâ€hematological toxicity,>=3,NA,FALSE,NA
33262140,NCT01562210,654,"radiation esophagitis/dysphagia, radiation dermatitis, fatigue, nausea and vomiting, weight loss, anorexia and dehydration in the presence of maximal support/treatment.",>=4,NA,NA,NA
33262140,NCT01562210,654,radiation dermatitis present â‰¥ 9 weeks after end of treatment,3,NA,NA,NA
33262140,NCT01562210,654,cardiac or neurological toxicity,2,NA,NA,NA
33262140,NCT01562210,654,"radiation pneumonitis, brachial plexopathy, esophageal stenosis, esophageal ulcer, esophageal necrosis, esophageal hemorrhage",>=3,NA,NA,NA
33262140,NCT01562210,654,"myelitis, esophageal perforation, esophageal fistula",>=2,NA,NA,NA
33262140,NCT01562210,654,Neutropenia,4,> 6 days,NA,NA
33262140,NCT01562210,654,Neutropenic fever,>=3,NA,NA,NA
33262140,NCT01562210,654,Thrombocytopenia in the presence of bleeding,3,NA,NA,NA
33262140,NCT01562210,654,Thrombocytopenia,>=4,NA,NA,NA
33262140,NCT01562210,654,Anemia in the presence of blood transfusion dependency as judged by the PI,3,NA,NA,NA
33262140,NCT01562210,654,Anemia,>=4,NA,NA,NA
33262140,NCT01562210,654,Any radiotherapy discontinuation,NA,NA,NA,NA
33262140,NCT01562210,654,Cisplatin cumulative discontinuation for > 20% of the total prescribed dose,NA,NA,NA,NA
33262140,NCT01562210,654,Olaparib total discontinuation for >20% of the total prescribed dose,NA,NA,NA,NA
33262140,NCT01562210,654,"Any other toxicity, which in the judgment of the Investigator is viewed as DLT",NA,NA,NA,NA
33262140,NCT01562210,654,"Blood transfusion dependency as judged by the PI, unless the patient has progressive disease",NA,NA,NA,NA
33262140,NCT01562210,654,Development of MDS/AML,NA,NA,NA,NA
19789325,NA,656,neutropenia,4,â‰¥5 consecutive days,NA,NA
19789325,NA,656,"febrile neutropenia (defined as absolute neutrophil count <1,000/mm3 with temperature â‰¥38.5Â°C)",NA,NA,NA,NA
19789325,NA,656,"thrombocytopenia (â‰¤25,000 cells/mm3 or bleeding requiring platelet transfusion)",NA,NA,NA,NA
19789325,NA,656,QTc interval of â‰¥500 ms,NA,NA,NA,NA
19789325,NA,656,"nausea, vomiting, or diarrhea despite maximal prophylaxis and intervention",3 or 4,NA,NA,NA
19789325,NA,656,any other nonhematologic event,>=3,NA,FALSE,NA
19789325,NA,656,drug-related toxicity that delayed scheduled retreatment for >14 d,NA,NA,NA,NA
19789325,NA,656,any grade of toxicity requiring dose reduction or discontinuation of study drug within the DLT assessment period,4,NA,NA,NA
33607477,NCT01946867,657,adverse event (AE) which was related to NBTXR3 and/or RT,>=3,NA,FALSE,NA
33607477,NCT01946867,657,"Any other toxicity that the investigator or the sponsor medical expert deemed to be dose limiting, regardless of the grade, was considered a DLT.",NA,NA,NA,NA
8402670,NA,658,granulocyte nadir <=0.5 x 109/liter,NA,NA,NA,NA
8402670,NA,658,platelet count <50 x 109/liter,NA,NA,NA,NA
8402670,NA,658,other toxicity,3 or 4,NA,NA,NA
8402670,NA,658,a decrease in left ventricular ejection fraction >=10% from baseline.,NA,NA,NA,NA
25225420,NCT00531284,659,nonhematologic toxicity,>=3,NA,NA,NA
25225420,NCT00531284,659,neuropathy with pain,>=2,NA,NA,NA
25225420,NCT00531284,659,neutropenia,4,>7 days,NA,NA
25225420,NCT00531284,659,febrile neutropenia,NA,NA,NA,NA
25225420,NCT00531284,659,thrombocytopenia despite withholding carfilzomib,4,>7 days,NA,NA
25225420,NCT00531284,659,thrombocytopenia with bleeding,>=3,NA,NA,NA
21781226,NCT00339144,660,neutropenia,4,>= five consecu-tive days,NA,NA
21781226,NCT00339144,660,febrile neutropenia,NA,NA,NA,NA
21781226,NCT00339144,660,thrombocytopenia,4,NA,NA,NA
21781226,NCT00339144,660,bleeding requiring platelet transfusion,NA,NA,NA,NA
21781226,NCT00339144,660,"nausea,vomiting or diarrhea despite adequate prophylaxis and therapy",3 or 4,NA,NA,NA
21781226,NCT00339144,660,other non-hematological toxicitie,>=3,NA,FALSE,NA
21781226,NCT00339144,660,adverse events (AE) that caused interruption of administrationfor more than 14 days or dose reduction of two levels or more,NA,NA,NA,NA
32464516,NCT02537223,661,febrile neutropenia,NA,NA,NA,NA
32464516,NCT02537223,661,neutropenia,4,> 7 days,NA,NA
32464516,NCT02537223,661,"RT-related mucosal, oropharyngeal or skin adverse events (AEs)",4,NA,NA,NA
32464516,NCT02537223,661,dermatitis or mucositis lasting > 8 weeks after RT completion,3,NA,NA,NA
32464516,NCT02537223,661,non-hematological AE despite optimal treatment,>=3,NA,FALSE,NA
32464516,NCT02537223,661,hyperglycemia despite treatment,2,> 14 days,NA,NA
32464516,NCT02537223,661,hyperglycemia despite treatment,3,> 7 days,NA,NA
32464516,NCT02537223,661,"an AE leading to inability to deliver â‰¥2 doses of cisplatin (cumulative dose â‰¥175 mg/m2), â‰¥75% of alpelisib, or â‰¥95% of RT on time",NA,NA,NA,NA
34322775,NCT02822482,662,hyperglycemia despite curative optimal glucose lowering therapy,>3,NA,NA,NA
34322775,NCT02822482,662,ALT/AST elevation,>=3,NA,NA,NA
34322775,NCT02822482,662,ANC<0.5 Ã— 109/L,NA,>7 days,NA,NA
34322775,NCT02822482,662,bleeding felt to be due to thrombocytopenia,NA,NA,NA,NA
34322775,NCT02822482,662,febrile neutropenia (both ANC<1.0Ã— 109/L and fever>38.5 Â°C),NA,NA,NA,NA
34322775,NCT02822482,662,platelets<25Ã— 109/L,NA,NA,NA,NA
34322775,NCT02822482,662,diarrhea,>=3,NA,NA,NA
34322775,NCT02822482,662,rash,>=4,NA,NA,NA
34322775,NCT02822482,662,hypertension despite optimal treatment,>=3,NA,NA,NA
34322775,NCT02822482,662,any clinically signifcant AE related to copanlisib and/or cetuximab,>=3,NA,NA,NA
27289242,NA,663,febrile neutropenia,NA,NA,NA,NA
27289242,NA,663,neutropenia,4,>7 days,NA,NA
27289242,NA,663,thrombocytopenia,4,NA,NA,NA
27289242,NA,663,thrombocytopenia with bleeding,>=3,NA,NA,NA
27289242,NA,663,"radiation-related mucosal, oropharyngeal or skin toxicity",4,NA,NA,NA
27289242,NA,663,dermatitis or mucositis >8 weeks in duration from completion of radiotherapy,3,>8 weeks,NA,NA
27289242,NA,663,intolerable non-hematological toxicity despite optimal treatment,2 or 3,NA,NA,NA
27289242,NA,663,"The inability to deliver either 2 doses of concurrent cisplatin (with total dose â‰¥175 mg/m2), â‰¥75 % of dacomitinib doses, or â‰¥95 % of planned radiotherapy doses on time",NA,NA,NA,NA
32994295,NCT02022098,664,neutropenia without fever >38.5Â°C,4,â‰¥7 days,NA,NA
32994295,NCT02022098,664,neutropenia with concomitant fever >38.5Â°C,3 or 4,NA,NA,NA
32994295,NCT02022098,664,infection,>=3,NA,NA,NA
32994295,NCT02022098,664,Thrombocytopenia <25000/Î¼L,NA,â‰¥5 days,NA,NA
32994295,NCT02022098,664,"Thrombocytopenia <50000/Î¼L, if bleeding or requiring platelets transfusion",NA,NA,NA,NA
32994295,NCT02022098,664,non-haematological toxicity,>=3,NA,FALSE,NA
32994295,NCT02022098,664,skin or mucosal reactions,4,NA,NA,NA
32994295,NCT02022098,664,decrease in LVEF,>=3,NA,NA,NA
32994295,NCT02022098,664,ototoxicity,>=2,NA,NA,NA
32994295,NCT02022098,664,worsening of renal function,>=2,NA,NA,NA
32994295,NCT02022098,664,Cisplatin or Debio 1143 treatment delay >2 weeks for related AE,NA,NA,NA,NA
32994295,NCT02022098,664,Any other life-threatening toxicity,NA,NA,NA,NA
33472913,ISRCTN 16332228,665,>14-day delay in cycle 2 due to treatment-induced toxicity,NA,NA,NA,NA
33472913,ISRCTN 16332228,665,neutropenia,4,â‰¥7 days,NA,NA
33472913,ISRCTN 16332228,665,neutropenia and temperature â‰¥38.5C,3 or 4,NA,NA,NA
33472913,ISRCTN 16332228,665,neutropenia and bacteriologically proven sepsis,3 or 4,NA,NA,NA
33472913,ISRCTN 16332228,665,thrombocytopenia,4,â‰¥7 days,NA,NA
33472913,ISRCTN 16332228,665,thrombocytopenia and nontraumatic bleeding,3,NA,NA,NA
33472913,ISRCTN 16332228,665,other clinically significant events,>=3,NA,FALSE,NA
28679776,NCT01584284,666,toxicity,>=4,NA,NA,NA
28679776,NCT01584284,666,mucositis or skin reaction in the radiation field persisting,>=3,>6 weeks after completion of therapy,NA,NA
21765046,NA,667,QTc prolongation as evidenced by a QTc interval of >=500 ms,NA,NA,NA,NA
21765046,NA,667,ventricular arrhythmia (second- or third-degree atrio-ventricular block),>=2,NA,NA,NA
21765046,NA,667,severe sinus bradycardia <45 or tachycardia >120 not due to other causes (e.g. fever),NA,NA,NA,NA
21765046,NA,667,persistent supraventricular arrhythmia,NA,>24 h,NA,NA
21765046,NA,667,ventricular tachycardia,NA,NA,NA,NA
21765046,NA,667,any length of torsades de pointes,NA,NA,NA,NA
21765046,NA,667,unexplained recurrent syncope,NA,NA,NA,NA
21765046,NA,667,any grade toxicity which required the removal of an individual patient from further treatment.,NA,NA,NA,NA
27810904,NCT01836029,668,hematologic toxicity,4,NA,NA,NA
27810904,NCT01836029,668,nonhematologic toxicity,>=3,NA,FALSE,NA
27810904,NCT01836029,668,"diarrhea, nausea, or vomiting despite adequate antiemetics/diarrhea medications",>=3,NA,NA,NA
27810904,NCT01836029,668,any treatment delay due to toxicity that lasted more than 21 days since the last dose of cetuximab or motolimod,NA,NA,NA,NA
27810904,NCT01836029,668,uveitis,NA,NA,NA,NA
27810904,NCT01836029,668,death,NA,NA,NA,NA
15865068,NA,669,granulocytes â‰¤500/mm3,NA,>7 days,NA,NA
15865068,NA,669,granulocytes â‰¤100/mm3,NA,>3 days,NA,NA
15865068,NA,669,"granulocytes <1,000/mm3 at retreatment day",NA,NA,NA,NA
15865068,NA,669,febrile neutropenia (fever with granulocytes â‰¤500/mm3),NA,NA,NA,NA
15865068,NA,669,"thrombocytopenia (platelets â‰¤25,000/mm3)",4,NA,NA,NA
15865068,NA,669,"non-hematological toxicity, in particular grade 3 mucositis â‰¥5 days",3,NA,FALSE,NA
16683074,NA,671,neutropenia,4,â‰¥7 days,NA,NA
16683074,NA,671,neutropenia complicated by fever or infection,3 or 4,NA,NA,NA
16683074,NA,671,thrombocytopenia,4,NA,NA,NA
16683074,NA,671,thrombocytopenia with bleeding,3,NA,NA,NA
16683074,NA,671,treatment-related nonhematological toxicity,3 or 4,NA,NA,NA
16683074,NA,671,treatment-related dosing omission or delay greater than 1 week within the first four dosings,NA,NA,NA,NA
17947485,NA,672,neutropenia (absolute neutrophil count <500/mm3),4,7 days,NA,NA
17947485,NA,672,neutropenia with fever (<=38.5C) or sepsis,4,NA,NA,NA
17947485,NA,672,"thrombocytopenia (platelet <10,000/mm3)",4,NA,NA,NA
17947485,NA,672,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21285987,NA,673,neutropenia associated with fever (>=38.5C) or diarrhoea >= grade 2,4,NA,NA,NA
21285987,NA,673,neutropenia without fever,4,>=5 days,NA,NA
21285987,NA,673,thrombocytopenia,4,>=5 days,NA,NA
21285987,NA,673,non-haematological toxicity,>=3,NA,FALSE,NA
21285987,NA,673,treatment delay >2 weeks before start of next cycle of treatment because of unresolved toxicity,NA,NA,NA,NA
21257722,NA,674,hematologic toxicity,4,NA,NA,NA
21257722,NA,674,nonhematologic toxicity attributable to the study drug in combination with cisplatin,3 or 4,NA,NA,NA
21257722,NA,674,any delay in treatment of more than 1 week,NA,NA,NA,NA
16884375,NA,675,A reduction in calculated creatinine clearance to less than 60 mL/min,NA,NA,NA,NA
16884375,NA,675,neutropenia,4,NA,NA,NA
16884375,NA,675,thrombocytopenia,4,NA,NA,NA
16884375,NA,675,"complicated hematologic toxicity (neutropenia with fever, thrombocytopenia with bleeding requiring platelet transfusion)",3,NA,NA,NA
16884375,NA,675,nonhematologic toxicity,3 or 4,NA,FALSE,NA
25573383,NA,676,nonhematologic toxicity that is considered a direct result of CUDC-101 therapy,3,NA,FALSE,NA
25573383,NA,676,dermatitis resulting in radiation break of >4 days,4,NA,NA,NA
25573383,NA,676,mucositis/esophagitis resulting in a radiation break of >4 days,4,NA,NA,NA
25573383,NA,676,neutropenia,4,>7 days,NA,NA
25573383,NA,676,thrombocytopenia,4,NA,NA,NA
25573383,NA,676,thrombocytopenia with bleeding,3,NA,NA,NA
10589753,NA,677,NA,NA,NA,NA,DLT not defined
16619579,NA,678,neutropenia,3,>5 days,NA,NA
16619579,NA,678,hematological toxicity,4,NA,NA,NA
16619579,NA,678,non-hematological toxicity,3,NA,NA,NA
16619579,NA,678,treatment delay of greater than 2 weeks as a result of toxicity,NA,NA,NA,NA
12796372,NA,679,febrile neutropenia,NA,NA,NA,NA
12796372,NA,679,neutropenia,4,>7 days,NA,NA
12796372,NA,679,thrombocytopenia,4,NA,NA,NA
12796372,NA,679,nonhematological toxicity,>=3,NA,NA,NA
21176985,NA,680,asymptomatic haematologic toxicity,4,NA,NA,NA
21176985,NA,680,neutropenia with fever,3,NA,NA,NA
21176985,NA,680,thrombopenia with haemorrhagic signs,3,NA,NA,NA
21176985,NA,680,epithelitis or mucositis,4,NA,NA,NA
21176985,NA,680,elevated creatinine level,>=2,NA,NA,NA
21176985,NA,680,diarrhoea,3 or 4,NA,NA,NA
21176985,NA,680,non-haematological toxicity,3 or 4,NA,FALSE,NA
9740093,NA,681,neutropenia,4,NA,NA,NA
9740093,NA,681,anemia,4,NA,NA,NA
9740093,NA,681,thrombocytopenia,4,NA,NA,NA
9740093,NA,681,nonhematologic toxicity,3 or 4,NA,FALSE,NA
11020576,NA,683,Absolute count of <0.5 x 109,NA,>=7 days,NA,NA
11020576,NA,683,Granulocyte count with infection/fever requiring parenteral antibiotics,NA,NA,NA,NA
11020576,NA,683,"Platelet count <50,000 x 109",NA,>=7 days,NA,NA
11020576,NA,683,requiring 2 or more platelet transfusions for Grade 3 hemorrhage,NA,NA,NA,NA
11020576,NA,683,Any nonhematological toxicity causing refusal to have treatment due to toxicity,NA,NA,NA,NA
11020576,NA,683,diarrhea,>=3,NA,NA,NA
11020576,NA,683,ototoxicity,>=3,NA,NA,NA
11020576,NA,683,muscular cramps,>=3,NA,NA,NA
11020576,NA,683,fatigue,>=3,NA,NA,NA
11020576,NA,683,"RT morbidity: bladder, rectal or skin",>=3,NA,NA,NA
11020576,NA,683,Interruptions >= 7 days due to RT morbidity,NA,NA,NA,NA
27110950,UMIN000005585,684,non-hematologic toxicity,3,NA,FALSE,NA
27110950,UMIN000005585,684,toxicity,4,NA,FALSE,NA
20801016,NA,685,neutropaenia,4,NA,NA,NA
20801016,NA,685,thrombocytopaenia,4,NA,NA,NA
20801016,NA,685,thrombocytopaenia complicated with bleeding,3,NA,NA,NA
20801016,NA,685,persistent neurotoxicity,2,NA,NA,NA
20801016,NA,685,persistent serum creatinine >=2 x upper limit of normal (ULN),NA,NA,NA,NA
20801016,NA,685,drug-related non-haematological toxicity,3 or 4,NA,NA,NA
20801016,NA,685,a delay in re-treatment with LiPlaCis of more than 2 weeks,NA,NA,NA,NA
20855460,NA,686,treatment-related adverse event,>=3,NA,NA,NA
16937305,NA,687,"Leukocyte count >1500/mm3, <12 000/mm3",NA,NA,NA,For radiation therapy
16937305,NA,687,Granulocyte count >1000/mm3,NA,NA,NA,For radiation therapy
16937305,NA,687,"Leukocyte count >1000/mm3, >12 000/mm3",NA,NA,NA,For chemotherapy
16937305,NA,687,Granulocyte count >500/mm3,NA,NA,NA,For chemotherapy
16937305,NA,687,Hemoglobin level >=8.0 g/dl,NA,NA,NA,NA
16937305,NA,687,Platelet count >=50 000/mm3,NA,NA,NA,NA
16937305,NA,687,"GOT, GPT <=2.5 Ã— normal limit",NA,NA,NA,NA
16937305,NA,687,Serum creatinine <=1.5 Ã— normal limit,NA,NA,NA,NA
16937305,NA,687,Creatinine clearance >50 ml/min,NA,NA,NA,NA
16937305,NA,687,Fever <38.0Â°C,NA,NA,NA,NA
16937305,NA,687,Performance status  <=ECOG 2,NA,NA,NA,NA
16937305,NA,687,Diarrhea,<=1,NA,NA,NA
16937305,NA,687,Non-hematologic toxicity,<=2,NA,FALSE,NA
10427950,NA,688,any toxicity precluding treatment continuation as originally scheduled,3,NA,NA,NA
16754599,NA,689,NA,NA,NA,NA,DLT not defined
16596187,NA,690,NA,NA,NA,NA,DLT not defined
18600301,NA,692,reversible hematological toxicity,3 or 4,>7 days,NA,NA
18600301,NA,692,a reversible non-hematologic toxicity,>=3,NA,NA,NA
18600301,NA,692,neurotoxicity,2,NA,NA,NA
28466360,UMIN000015595,693,"hematologic toxicity (neutropenia, leukocytopenia, anemia, thrombocytopenia)",4,NA,NA,NA
28466360,UMIN000015595,693,uncontrollable nonhematologic toxicity despite maximal supportive care,>=3,NA,NA,NA
28466360,UMIN000015595,693,toxicity that reduced adherence to SSZ treatment to less than 70 % of the planned dose,NA,NA,NA,NA
28466360,UMIN000015595,693,toxicity that resulted in interruption of SSZ administration for a consecutive period of 14 days or longer,NA,NA,NA,NA
20606530,NA,694,neutropenia,4,NA,NA,NA
20606530,NA,694,thrombocytopenia,4,NA,NA,NA
20606530,NA,694,thrombocytopenia with bleeding,3,NA,NA,NA
20606530,NA,694,febrile neutropenia,NA,NA,NA,NA
20606530,NA,694,diarrhea,4,NA,NA,NA
20606530,NA,694,diarrhea despite treatment with loperamide,3,>48 h,NA,NA
20606530,NA,694,other radiation-associated toxicity,3 or 4,NA,NA,NA
20606530,NA,694,nonhematological toxicity outside the radiation field,3 or 4,NA,FALSE,NA
20606530,NA,694,interruption of radiotherapy for more than 3 days due to treatment toxicity,NA,NA,NA,NA
20606530,NA,694,inability to complete radiation within 8 weeks,NA,NA,NA,NA
20606530,NA,694,chemotherapy omitted during weeks 1 to 5 because of toxicity,NA,NA,NA,NA
20480279,NA,696,neutropenia,4,>7 days,NA,NA
20480279,NA,696,febrile neutropenia,NA,NA,NA,NA
20480279,NA,696,thrombocytopenia,4,>7 days,NA,NA
20480279,NA,696,thrombocytopenia associated with bleeding,3,NA,NA,NA
20480279,NA,696,nausea or vomiting despite maximal antiemetic therapy,>=3,NA,NA,NA
20480279,NA,696,extrahematologic toxicity,3 or 4,NA,NA,NA
20480279,NA,696,ineligibility for re-treatment after a 2-week delay,NA,NA,NA,NA
26414837,NA,697,febrile neutropenia,3 or 4,NA,NA,NA
26414837,NA,697,neutropenia,4,>5 days,NA,NA
26414837,NA,697,leukopenia,4,>5 days,NA,NA
26414837,NA,697,nonhematologic toxicity,3 or 4,NA,FALSE,NA
21220472,NA,698,neutropenia,4,>=7 days,NA,NA
21220472,NA,698,neutropenia with fever and/or infection,3 or 4,NA,NA,NA
21220472,NA,698,thrombocytopenia,4,NA,NA,NA
21220472,NA,698,thrombocytopenia with bleeding,3,NA,NA,NA
21220472,NA,698,treatmentâ€“related nonhematological toxicity,3 or 4,NA,FALSE,NA
21220472,NA,698,dosing delay greater than 2 weeks following treatment-related adverse events or laboratory abnormalities,NA,NA,NA,NA
21220472,NA,699,neutropenia,4,>=5 days,NA,NA
21220472,NA,699,neutropenia with fever and/or infection,3 or 4,NA,NA,NA
21220472,NA,699,thrombocytopenia,4,NA,NA,NA
21220472,NA,699,thrombocytopenia with bleeding,3,NA,NA,NA
21220472,NA,699,treatmentâ€“related nonhematological toxicity,3 or 4,NA,FALSE,NA
21220472,NA,699,dosing delay greater than 2 weeks following treatment-related adverse events or laboratory abnormalities,NA,NA,NA,NA
16418184,NA,700,leukopenia,4,>=4 days,NA,NA
16418184,NA,700,neutropenia,4,>=4 days,NA,NA
16418184,NA,700,an ANC of <1000/ul associated with fever (>=38.5C),NA,NA,NA,NA
16418184,NA,700,a platelet count of <=20 000/ul,NA,NA,NA,NA
16418184,NA,700,non-hematological toxicity,>=3,NA,FALSE,NA
12695856,NA,701,NA,NA,NA,NA,DLT not defined
26891913,NA,702,neutropenia,>=3,NA,NA,NA
26891913,NA,702,febrile neutropenia >38Â°C and absolute neutrophil count <500 per ul,NA,NA,NA,NA
26891913,NA,702,thrombocytopenia,4,NA,NA,NA
26891913,NA,702,"non-haematologic toxicities, including nausea, vomiting, dermatitis, diarrhoeaand oesophagitis, which did not improve within 2 days after appropriate management was commenced",>=3,NA,NA,NA
26891913,NA,702,treatment interruption lasting more than 1 week,NA,NA,NA,NA
15589600,NA,703,neutropenia,3 or 4,NA,NA,NA
15589600,NA,703,thrombocytopenia,3 or 4,NA,NA,NA
15589600,NA,703,nonhematologic toxicity,3 or 4,NA,FALSE,NA
22994941,UMIN-CTR 000003541,704,nonhaematological toxicity,>=3,NA,NA,NA
22994941,UMIN-CTR 000003541,704,haematological toxicity,>=4,NA,NA,NA
21868563,NA,705,neutropenia,4,NA,NA,NA
21868563,NA,705,leukocytopenia,4,NA,NA,NA
21868563,NA,705,thrombocytopenia,4,NA,NA,NA
21868563,NA,705,febrile neutropenia,>=3,NA,NA,NA
21868563,NA,705,non-hematological toxicity,>=3,NA,FALSE,NA
21868563,NA,705,delay of more than 10 days for initiation of the second course of chemotherapy,NA,NA,NA,NA
21868563,NA,705,delay of more than 10 days for the day 8 and day 15 infusions of CDDP,NA,NA,NA,NA
21868563,NA,705,failure to complete radiation within 45 days or surgery not performed within 42 days after completion of the second cycle of chemotherapy,NA,NA,NA,NA
19443394,NA,706,nonhematological toxicity,>=3,NA,FALSE,NA
19443394,NA,706,neutropenia,4,>4 days,NA,NA
19443394,NA,706,neutropenic fever,3,NA,NA,NA
19443394,NA,706,thrombocytopenia,4,NA,NA,NA
16077976,NA,707,leukopenia,4,>=4 days,NA,NA
16077976,NA,707,neutropenia,4,>=4 days,NA,NA
16077976,NA,707,febrile grade 3 or 4 leukopenia,NA,NA,NA,NA
16077976,NA,707,febrile neutropenia,NA,NA,NA,NA
16077976,NA,707,platelet count <20000/u.l,NA,NA,NA,NA
16077976,NA,707,non-hematological toxicity,3 or 4,NA,FALSE,NA
16077976,NA,707,delay of second course for 2 weeks or more and failure to complete the 2 courses within 8 weeks because of toxicity,NA,NA,NA,NA
10847466,NA,708,NA,NA,NA,NA,DLT not defined
16575008,NA,709,renal toxicity,3,NA,NA,NA
16575008,NA,709,any toxicity not definitely related to the surgery,4,NA,NA,NA
27878356,NCT00024323,710,all severe or life-threatening toxicities,NA,NA,NA,NA
27878356,NCT00024323,710,non-hematologic toxicities,3,>24 h,NA,NA
27878356,NCT00024323,710,non-hematologic toxicities,4,NA,NA,NA
27878356,NCT00024323,710,persistent toxicities,2,>1 week,NA,NA
27878356,NCT00024323,710,neurotoxicity,2,NA,NA,NA
27878356,NCT00024323,710,tinnitus,2,NA,NA,NA
27878356,NCT00024323,710,loss of hearing,2,NA,NA,NA
27878356,NCT00024323,710,persistent toxicities requiring delay of scheduled treatment by more than two weeks,NA,NA,NA,NA
15653702,NA,711,leukopenia,4,>=4 days,NA,NA
15653702,NA,711,neutropenia,4,>=4 days,NA,NA
15653702,NA,711,febrile neutropenia,3,NA,NA,NA
15653702,NA,711,platelets <20 000/mm3,NA,NA,NA,NA
15653702,NA,711,non-hematological toxicity,>=3,NA,FALSE,NA
22922041,NA,712,leukopenia,4,NA,NA,NA
22922041,NA,712,neutropenia,4,NA,NA,NA
22922041,NA,712,thrombocytopenia,4,NA,NA,NA
22922041,NA,712,increase of AST or ALT levels,4,7 days,NA,NA
22922041,NA,712,hyperbilirubinemia exceeding 5.0 mg/dL or remaining greater than 3.0 mg/dL,NA,2 weeks,NA,NA
22922041,NA,712,"liver abscess, cholangitis, or cholecystitis requiring interventional radiologic, endoscopic, or surgical procedures",NA,NA,NA,NA
22922041,NA,712,nonhematologic toxicities,>=3,NA,FALSE,NA
10561301,NA,713,systemic toxicities in two of six patients,3 or 4,NA,NA,NA
10561301,NA,713,mucositis lasting longer than 6 weeks after completion of all therapies,4,NA,NA,NA
19723113,NA,714,neutropenia,>=3,>4 days,NA,NA
19723113,NA,714,thrombocytopenia,>=3,>4 days,NA,NA
19723113,NA,714,neutropenia accompanied by fever â‰¥38.5â—¦C,>=3,NA,NA,NA
19723113,NA,714,thrombocytopenia accompanied by hemorrhage or transfusion,>=3,NA,NA,NA
19723113,NA,714,nonhematological toxicity,>=3,NA,FALSE,NA
23692812,NCT00359359,715,neutropenia,4,>5 days,NA,NA
23692812,NCT00359359,715,febrile neutropenia,NA,NA,NA,NA
23692812,NCT00359359,715,thrombocytopenia,4,NA,NA,NA
23692812,NCT00359359,715,non-haematological toxicity,3 or 4,NA,FALSE,NA
23692812,NCT00359359,715,nausea/vomiting despite the use of standard antiemetics,3 or 4,NA,NA,NA
23692812,NCT00359359,715,any study drug-related toxicity which leads to a treatment delay of >2 weeks,>=2,NA,NA,NA
11821794,NA,716,toxicities and/or frequent and serious surgical complications related to intraperitoneal cisplatin,3,NA,NA,NA
27503200,NCT01139970,717,drug-related non-hematologic toxicity,4,NA,FALSE,NA
27503200,NCT01139970,717,"drug-related non-hematologic toxicity excluding infection, not resolving to â‰¤ grade 2 within 48 hours",3,NA,FALSE,NA
27503200,NCT01139970,717,neurotoxicity or nephrotoxicity,3,NA,NA,NA
27503200,NCT01139970,717,myelosuppression (ANC < 0.5 x 109/L and platelets < 20 x 109/L) with BM cellularity <5% more than 58 days from the start of therapy without residual leukemia,NA,NA,NA,NA
9041168,NA,718,NA,NA,NA,NA,DLT not defined
27716819,NCT01488344,719,every severe adverse reaction with possible or definite relationship to nintedanib,4,NA,TRUE,NA
27716819,NCT01488344,719,"therapy-related cytopenias as signs of an intended anti-leukemic activity and cytopenia-associatedcomplications (neutropenic fever, neutropenic infections, and thrombocytopenic bleedings) occurring in an unexpected high frequency, as judged by the DMC",NA,NA,NA,NA
7911736,NA,720,nonhematologic toxicity,3 or 4,NA,NA,NA
7911736,NA,720,neurotoxicity,2,NA,NA,NA
7911736,NA,720,hematologic toxicity,4,NA,NA,NA
21174612,NA,721,an  adverse event related to treatment with combined rIL-21  and  sunitinib,>=3,NA,FALSE,NA
31707687,NCT02619864,722,diarrhea or rash requiring dose hold â‰¥5 days or dose reduction,2,NA,NA,NA
31707687,NCT02619864,722,organ toxicity including QTc prolongation (>500 msec),>=3,NA,NA,NA
31707687,NCT02619864,722,myelosuppression,4,>=4 days,NA,NA
31707687,NCT02619864,722,febrile neutropenia,NA,NA,NA,NA
31707687,NCT02619864,722,thrombocytopenic bleeding,3,NA,NA,NA
31707687,NCT02619864,722,any toxicity,4,NA,NA,NA
31707687,NCT02619864,722,other toxicities of concern including toxicities requiring â‰¥14 days hold,NA,NA,NA,NA
26966095,NCT01907165,723,neutropenia,4,>21 days,NA,NA
26966095,NCT01907165,723,thrombocytopenia,4,>28 days,NA,NA
26966095,NCT01907165,723,nonhematological toxicities,>=3,NA,FALSE,NA
21909644,NA,725,non-haematological toxicity,>=3,NA,FALSE,NA
21909644,NA,725,neutropenia,4,NA,NA,NA
21909644,NA,725,febrile neutropenia,NA,NA,NA,NA
21909644,NA,725,"thrombocytopenia, treatment delay on day 8 by >2 days due to treatment-related toxicity",4,NA,NA,NA
21909644,NA,725,treatment delay >2 weeks of cycle 2 due to treatment-related toxicity,4,NA,NA,NA
30518523,ISRCTN (ISRCTN98335443) and ACTRN (ACTRN12615000702516),726,a venetoclax-related toxicity,>=3,NA,FALSE,NA
30518523,ISRCTN (ISRCTN98335443) and ACTRN (ACTRN12615000702516),726,clinical or laboratory tumor lysis syndrome (TLS),1,NA,NA,NA
34787778,NCT00977431,727,"neutropenia (absolute neutrophil count, including bands, < 500/mmÂ³)",4,> 7 days,NA,NA
34787778,NCT00977431,727,neutropenia of any duration associated with fever >38.3Â°C,3 or 4,NA,NA,NA
34787778,NCT00977431,727,"thrombocytopenia (platelet count < 50,000â€“25,000/mmÂ³)",3,NA,NA,NA
34787778,NCT00977431,727,All other hematologic toxicities  leading to an interruption of afatinib treatment (regimen U) or treatment with afatinib and TMZ (regimen M) for > 14 days,>=3,NA,NA,NA
34787778,NCT00977431,727,nausea or vomiting despite appropriate use of standard anti-emetics,>=3,â‰¥ 3 days,NA,NA
34787778,NCT00977431,727,diarrhea despite appropriate use of standard anti-diarrheal therapy,>=3,â‰¥ 3 days,NA,NA
34787778,NCT00977431,727,rash despite standard medical management,>=3,>7 days,NA,NA
34787778,NCT00977431,727,cardiac left ventricular function,>=2,NA,NA,NA
34787778,NCT00977431,727,"renal function as measured by serum creatinine, newly developed proteinuria, or newly developed decrease in glomerular filtration rate",>=2,NA,NA,NA
34787778,NCT00977431,727,All other non-hematologic toxicities,>=3,NA,NA,NA
32866424,NCT02378532,729,an absolute neutro-phil count â‰¤ 500/Î¼L,NA,7 days,NA,NA
32866424,NCT02378532,729,febrile neutropenia (neutrophil count less than 500 cells per microliter and fever of â‰¥ 38.5Â°C),NA,NA,NA,NA
32866424,NCT02378532,729,"thrombocytopenia (< 25 x 109/L), and/or requir-ing platelet transfusion or bleeding requiring medical intervention",4,NA,NA,NA
32866424,NCT02378532,729,non-hematological toxicity,>=3,NA,FALSE,NA
32866424,NCT02378532,729,interruption of radio-therapy or TMZ due to toxicity during concurrent chemo- radiation or delay of adjuvant cycles of TMZ,NA,NA,NA,NA
32866424,NCT02378532,729,Toxicity was considered a DLT if it was at least possibly related to CQ,NA,NA,NA,NA
14551141,NA,730,NA,NA,NA,NA,DLT not defined
11920222,NA,731,neutropenia (absolute neutrophil count [ANC] <0.5x109 cells/l or thrombocytopenia (<50x109 platelets/l) in the absence of AML,NA,>8 weeks after the start of treatment cycle 1,NA,NA
11920222,NA,731,death during or after treatment in cycle 1 without recovery of blood cell counts (ANC >=0.5x109 cells/l and platelets >=50x109 /l) or hypoplasia without evidence of persistent AML,NA,NA,NA,NA
11920222,NA,731,nonhematologic toxicity,3 or 4,NA,FALSE,NA
28039367,NCT01800695,732,neutropenia or anemia,4,>7 days,NA,NA
28039367,NCT01800695,732,febrile neutropenia,3 or 4,NA,NA,NA
28039367,NCT01800695,732,thrombocytopenia,3 or 4,>7 days,NA,NA
28039367,NCT01800695,732,nonhematologic adverse events,3 or 4,NA,FALSE,NA
28039367,NCT01800695,732,>14 days delay of treatment due to the failure to recover from attributable toxicity,NA,NA,NA,NA
29374809,NCT01907165,733,neutropenia,4,>21 days,NA,NA
29374809,NCT01907165,733,thrombocytopenia,4,>28 days,NA,NA
29374809,NCT01907165,733,nonhematological toxicities,>=3,NA,FALSE,NA
21282541,NA,734,"cytopenia (absolute neutrophil count < 500/uL), and/or platelet count < 10,000/uL",4,> 56 days,NA,NA
21282541,NA,734,platelet transfusion dependency in the absence of leukemia,NA,NA,NA,NA
21282541,NA,734,Nonhematologic AE due to study drug,>=3,NA,FALSE,NA
18607882,NA,735,any non-haematological AE,>=3,NA,FALSE,NA
18607882,NA,735,neutropenia,4,>=7 days,NA,NA
18607882,NA,735,febrile neutropenia definedas an absolute neutrophil count <500/uL lasting for >=3 days and fever at least 38.58C for 24 hr,NA,NA,NA,NA
18607882,NA,735,thrombocytopenia,4,NA,NA,NA
32347934,NCT01390571,736,NA,NA,NA,NA,DLT not defined
20922784,NA,737,nonhematologic treatment-related toxicity,4,NA,NA,NA
20922784,NA,737,adverse event (AE) despite medical therapy,>=3,NA,FALSE,NA
20922784,NA,737,AE that was potentiallyimmune mediated and involved critical organs,>=3,NA,NA,NA
20922784,NA,737,decrease in neutrophils,4,>=7 days,NA,NA
20922784,NA,737,febrile neutropenia sustained over a 24-hour period,NA,NA,NA,NA
20922784,NA,737,neutropenic infection,NA,NA,NA,NA
20922784,NA,737,decrease in platelets,4,>=7 days,NA,NA
20922784,NA,737,the inability to receive at least 75% of theplanned doses of sunitinib because of treatment-related toxicity,NA,NA,NA,NA
30359477,NCT01430351,738,"thrombocytopenia,",3,NA,NA,NA
30359477,NCT01430351,738,anemia,4,NA,NA,NA
30359477,NCT01430351,738,neutropenia,4,NA,FALSE,NA
30359477,NCT01430351,738,nonhematologic  toxic  effect  lasting  for  â‰¥14  days  that  did  not  resolve/regress  to  grade  1  or  less  within  14  days  of  onset  after  optimal  supportive  measures,>=3,NA,FALSE,NA
30359477,NCT01430351,738,"any  intolerable  grade  2  toxic  effect,  such  as  fatigue  or  nausea  (optimal  medical therapy must have failed for the event to be con-sidered a DLT)",NA,NA,NA,NA
19536893,NA,745,any toxicity,>=4,NA,NA,NA
19536893,NA,745,unexpected toxicity,3,NA,FALSE,NA
31724813,NCT02116777,746,Nonhematologic toxicity attributable to protocol therapy,>=3,NA,TRUE,NA
31724813,NCT02116777,746,neutropenia,4,> 7 days,NA,NA
31724813,NCT02116777,746,a platelet count < 20000/mm3 on two separate days or requiring a platelet transfusion on two separate days within a seven-day period,NA,NA,NA,NA
31724813,NCT02116777,746,Any AE resulting in a delay of > 14 days between cycles,NA,NA,NA,NA
21690570,NA,747,neutropenia,4,NA,NA,NA
21690570,NA,747,thrombocytopenia,4,NA,NA,NA
21690570,NA,747,nonhematologic toxicity,4,NA,NA,NA
21690570,NA,747,cardiac systolic dysfunction,2,NA,NA,NA
21690570,NA,747,"blood pressure more than 25 mmHg above the 95th percentile for age, height, and gender",NA,NA,NA,NA
21690570,NA,747,nonhematologic toxicity for 7 or more days that required drug interruption,2,>=7 days,NA,NA
21690570,NA,747,any nonhematologic toxicity that required drug interruption for more than 7 days,NA,NA,NA,NA
21690570,NA,747,any nonhematologic toxicity,3,NA,TRUE,NA
19933907,NA,748,nonhematologic toxicity despite maximum supportive care,3 or 4,NA,NA,NA
19933907,NA,748,"prolonged pancytopenia in the presence of a hypocellular bone marrow (ie, cellularity 5% or fewer without evidence of leukemia)",3 or 4,> 42 days from the start of therapy,NA,NA
12637486,NA,749,NA,NA,NA,NA,DLT not defined
21353747,NA,750,neutropenia,4,>7 days,NA,NA
21353747,NA,750,anemia,4,>7 days,NA,NA
21353747,NA,750,thrombocytopenia,3,>7 days,NA,NA
21353747,NA,750,thrombocytopenia,4,NA,NA,NA
21353747,NA,750,other toxicity,3 or 4,NA,TRUE,NA
11352969,NA,751,any toxicity,3 or 4,NA,FALSE,NA
31636097,NCT02403310,752,"neutropenia and/or thrombocytopenia due to bone marrow hypoplasia, without residual leukemic burden, that did not recover to grade <= 2 by day 56",3 or 4,NA,NA,NA
31636097,NCT02403310,752,drug-related nonhematologic toxicity,3 or 4,NA,TRUE,NA
23763917, NCT00926731,753,clinically significant adverse event (AE) or laboratory abnormality considered to be related to barasertib,NA,NA,NA,NA
23763917, NCT00926731,753,nonhematological (including biochemical) toxicity despite adequate supportive care,>=3,NA,NA,NA
23763917, NCT00926731,753,severe bone marrow suppression,NA,>= 56 days,NA,NA
24415560,NCT00727766,754,neutropenia,4,â‰¥ 14 days,NA,NA
24415560,NCT00727766,754,neutropenia with infection,3 or 4,NA,NA,NA
24415560,NCT00727766,754,thrombocytopenia,4,â‰¥ 7 days,NA,NA
24415560,NCT00727766,754,thrombocytopenia with bleeding,3 or 4,NA,NA,NA
24415560,NCT00727766,754,non-hematologic event,3 or 4,NA,FALSE,NA
25465491,NA,756,a therapy-related toxic effect,NA,NA,NA,NA
25465491,NA,756,nonhematologic toxic effect,>=3,NA,NA,NA
25465491,NA,756,thrombocytopenia,4,NA,NA,NA
25465491,NA,756,thrombocytopenia with bleeding,3,NA,NA,NA
25465491,NA,756,neutropenia,4,> 7 days,NA,NA
25465491,NA,756,neutropenic fever > 38.5C,4,NA,NA,NA
25465491,NA,756,removal of patient from therapy because of toxicity attributable to treatment,NA,NA,NA,NA
25465491,NA,756,delay of treatment for > 2 weeks because of toxicity,NA,NA,NA,NA
29016887,NCT00731731,757,thrombocytopenia,3 or 4,NA,NA,NA
29016887,NCT00731731,757,anemia,4,NA,NA,NA
29016887,NCT00731731,757,neutropenia,4,>7 days,NA,NA
29016887,NCT00731731,757,radiation-induced skin changes,4,NA,NA,NA
29016887,NCT00731731,757,any nonhematologic adverse event,>=3,NA,FALSE,NA
29077941,NCT01800695,758,anemia or neutropenia,4,>7 days,NA,NA
29077941,NCT01800695,758,febrile neutropenia,>=3,NA,NA,NA
29077941,NCT01800695,758,thrombocytopenia,>=3,>7 days,NA,NA
29077941,NCT01800695,758,nonhematologic AEs,>=3,NA,FALSE,NA
29077941,NCT01800695,758,>14 days dose delays due to attributable toxicity,NA,NA,NA,NA
20858843,NA,760,nonhematologic toxicity,4,NA,NA,NA
20858843,NA,760,abnormalities of liver function or serum creatinine,3,NA,NA,NA
20858843,NA,760,"leukopenia in patients with baseline leukocyte counts of >1,000/Î¼L",4,â‰¥35 days,NA,NA
28371832,NCT01480050,761,NA,NA,NA,NA,DLT not defined
30589027,NCT01465347,762,nonhematologic toxicity caused by radiotherapy,>=3,NA,FALSE,NA
16924496,NA,2,leukopenia,4,lasting for 4 days or more,NA,NA
16924496,NA,2,neutropenia,4,lasting for 4 days or more,NA,NA
16924496,NA,2,leukopenia ,3,NA,NA,NA
16924496,NA,2,neutropenia ,3,NA,NA,NA
16924496,NA,2,thrombocytopenia,NA,NA,NA,NA
16924496,NA,2,non-hematological toxicity,4-Mar,NA,FALSE,NA
20041339,NA,3,nonhematologic toxicity,>=3,NA,NA,NA
20041339,NA,3,neutropenia or thrombocytopenia,4,NA,NA,NA
20041339,NA,4,nonhematologic toxicity,>=3,NA,NA,NA
20041339,NA,4,neutropenia or thrombocytopenia,4,NA,NA,NA
20041339,NA,5,nonhematologic toxicity,>=3,NA,NA,NA
20041339,NA,5,neutropenia or thrombocytopenia,4,NA,NA,NA
20041339,NA,6,nonhematologic toxicity,>=3,NA,NA,NA
20041339,NA,6,neutropenia or thrombocytopenia,4,NA,NA,NA
20041339,NA,3,hepatic toxicity,4-Mar,lasting >7 days,NA,NA
20041339,NA,4,NA,NA,NA,NA,NA
20041339,NA,5,NA,NA,NA,NA,NA
20041339,NA,6,NA,NA,NA,NA,NA
19103671,NA,7,non- hematologic toxicity,4,NA,NA,NA
19103671,NA,7,thrombocytopenia or febrile neutropenia,4,persisting for >= 4 days,NA,NA
19103671,NA,7,NA,4,NA,NA,NA
19103671,NA,7,NA,NA,NA,NA,NA
19103671,NA,7,NA,NA,NA,NA,NA
19103671,NA,7,NA,4,NA,NA,NA
17533388,NA,8,leucocytopenia and/or neutropenia,3,a fever >= 38 lasting 3 days or more,NA,NA
17533388,NA,8,leucocytopenia and/or neutropenia,3,NA,NA,NA
17533388,NA,8,leucocytopenia and/or neutropenia,4,lasting 3 days or more,NA,NA
17533388,NA,8,leucocytopenia and/ or neutropenia,4,NA,NA,NA
17533388,NA,8,thrombocytopenia,3,NA,NA,NA
17533388,NA,8,nonhaematological toxicities,4-Mar,NA,FALSE,NA
17262086,NA,9,"diarrhoea, mucositis",4-Mar,NA,NA,NA
17262086,NA,9,thrombocytopaenia,4-Mar,NA,NA,NA
17262086,NA,9,neutropaenia,4,NA,NA,NA
17053988,NA,10,neutropenia,4,> 5 days,NA,NA
17053988,NA,10,thrombocytopenia ,4,NA,NA,NA
17053988,NA,10,thrombocytopenia,3,NA,NA,NA
17053988,NA,10,febrile neutropenia,NA,NA,NA,NA
17053988,NA,10,non-haematologic toxicity,4-Mar,NA,NA,NA
17053988,NA,10,NA,4,NA,NA,NA
17053988,NA,10,NA,4,NA,NA,NA
17053988,NA,10,oesophagitis,4,NA,NA,NA
17218488,NA,11, neutropenia,4,lasting >= 5 days,NA,NA
17218488,NA,11, thrombocytopenia,4,>= 5 days,NA,NA
17218488,NA,11,non-hematologic,4-Mar,NA,FALSE,NA
17218488,NA,11,proteinuria,>2,NA,NA,NA
17218488,NA,11, hematuria,>=2,NA,NA,NA
17218488,NA,11,NA,NA,NA,NA,NA
17976948,NA,12,haematological toxicity,4,NA,NA,NA
17976948,NA,12,esophagitis,4,NA,NA,NA
17976948,NA,12,vomiting,4,NA,NA,NA
17976948,NA,12,non-haematological,4-Mar,NA,NA,NA
17976948,NA,12,NA,4,NA,NA,NA
17976948,NA,12,adverse event,4-Mar,NA,NA,NA
18682717,NA,13,NA,NA,NA,NA,NA
19940007,NA,14,haematological,4-Mar,NA,FALSE,NA
19940007,NA,14,non-haematological toxicity,4-Mar,NA,FALSE,NA
19940007,NA,14,NA,NA,NA,NA,NA
20038727,NA,15,hematologic,4,NA,NA,NA
20038727,NA,15,nonhematologic,3 or 4,NA,NA,NA
17377918,NA,16,hypersensitivity reaction,>=2,NA,NA,NA
17377918,NA,16,nonhematologic toxicity,>=3,NA,FALSE,NA
17377918,NA,16,thrombocytopenia,4,NA,NA,NA
17377918,NA,16,neutropenia,4,persisted >5 days without the administration of hematopoietic growth factors.,NA,NA
18395356,NA,17,"any serious, acute, life-threatening adverse effects (e.g., angioedema not requiring intubation but intravenous hydrocortisone treatment, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias requiring blood transfusion or convulsions that did not result in hospitalization).",NA,NA,NA,NA
18797462,NA,18,adverse event (AE),>=3,NA,NA,NA
19002384,NA,19,neutropenia,4,NA,NA,NA
19002384,NA,19,hrombocytopenia,4,asting more than 5 days,NA,NA
19002384,NA,19,febrile neutropenia,NA,NA,NA,NA
19002384,NA,19,non-haematological toxicity,4-Mar,NA,NA,NA
19002384,NA,19,QTc prolongation,4,NA,NA,NA
16786333,NA,20,nonhematologic toxicity,>=3,NA,FALSE,NA
16786333,NA,20,nausea/vomiting,>=3,NA,NA,NA
16786333,NA,20,diarrhea,>=3,NA,NA,NA
16786333,NA,20,neutropenia,4,lasting more than 3 days,NA,NA
16786333,NA,20,thrombocytopenia,4,NA,NA,NA
16786333,NA,20,thrombocytopenia,3,NA,NA,NA
16786333,NA,20,febrile neutropenia,NA,NA,NA,NA
16786333,NA,20,a patientâ€™s inability to take more than 75% of the planned chemotherapy dose during the treatment cycle or toxicity which required more than a 14-day delay of a therapeutic cycle.,NA,NA,NA,NA
19194126,NA,21,leukopenia,4,NA,NA,NA
19194126,NA,21,neutropenia,4,prolonged for 4 days,NA,NA
19194126,NA,21,thrombocytopenia,3,NA,NA,NA
19194126,NA,21,nonhematological toxicity,3,NA,FALSE,NA
19194126,NA,21,treatment delay of 8 days because of toxicity,NA,NA,NA,NA
19299904,NA,22,leukopenia,4,NA,NA,NA
19299904,NA,22,febrile neutropenia,3,NA,NA,NA
19299904,NA,22,thrombocytopenia,3,NA,NA,NA
19299904,NA,22,nonhematological toxicity,3,NA,NA,NA
16704539,NA,23,neutropenia,4,exceeding 4 daysâ€™ duration,NA,NA
16704539,NA,23,febrile neutropenia,NA,NA,NA,NA
16704539,NA,23,platelet count <25 000/Î¼L,NA,NA,NA,NA
16704539,NA,23,failure to recover neutrophils â‰¥1500/Î¼L,NA,NA,NA,NA
16704539,NA,23,platelets â‰¥100 000/Î¼L by the end of the third week after the first or second dose of treatment,NA,NA,NA,NA
16704539,NA,23,nonhematological toxicity,>=3,NA,FALSE,NA
19225923,NA,24,leukocytes less than 1000/mm3,4,NA,NA,NA
19225923,NA,24,neutropenia less than 500/mm3 lasting 4 days,4,NA,NA,NA
19225923,NA,24,febrile neutropenia less than 1000/ mm3,4,NA,NA,NA
19225923,NA,24,thrombocytopenia less than 25 000/mm3,4,NA,NA,NA
19225923,NA,24,major nonhematological toxicity,>=3,NA,NA,NA
19225923,NA,24,causing a patient to omit CPT-11 twice or necessitating more than 7 days of rest from S-1 due to adverse effects,4,NA,NA,NA
18929446,NA,25,nonhematologic toxicities,>=3,NA,FALSE,NA
18929446,NA,25,thrombocytopenia,4,NA,NA,NA
18929446,NA,25,neutropenia,4,NA,NA,NA
18929446,NA,25,neutropenia complicated by fever,3 or 4,NA,NA,NA
18929446,NA,25,any unresolved toxicity requiring a delay in the administration of a subsequent course exceeding 10 days,NA,NA,NA,NA
18929446,NA,25,toxicity,2,NA,NA,NA
18004083,NA,26,neutropenia,4,more than 5 consecutive days,NA,NA
18004083,NA,26,febrile neutropenia,NA,NA,NA,NA
18004083,NA,26,thrombocytopenia,4,NA,NA,NA
18004083,NA,26,thrombocytopenia,3,NA,NA,NA
18004083,NA,26,nausea,>=3,NA,NA,NA
18004083,NA,26,vomiting despite the use of adequate medical intervention and/or prophylaxis,NA,NA,NA,NA
18004083,NA,26,nonhematological toxicity,>=3,NA,FALSE,NA
18004083,NA,26,failure to readminister treatment within 14 days of the previous study drug administration due to delayed recovery to ^grade 1 or baseline from a specific treatment-related toxicity,NA,NA,NA,NA
16821599,NA,27,hematological toxicities,4,NA,NA,NA
16821599,NA,27,febrile neutropenia,3,NA,NA,NA
16821599,NA,27,non-hematological toxicities,3,NA,FALSE,NA
16821599,NA,27,serum creatinine,2,NA,NA,NA
18323870,NA,29,febrile neutropenia,3,NA,NA,NA
18323870,NA,29,neutropenia,4,NA,NA,NA
18323870,NA,29,thrombocytopenia,4-Mar,NA,NA,NA
18323870,NA,29,anemia,4-Mar,NA,NA,NA
18323870,NA,29,nonhematologic toxicity,4-Mar,NA,FALSE,NA
27628195,NA,30,neutropenia,4,â‰¥7 days,NA,NA
27628195,NA,30,febrile neutropenia,4-Mar,NA,NA,NA
27628195,NA,30,thrombocytopenia,4,NA,NA,NA
27628195,NA,30,thrombocytopenia,3,NA,NA,NA
27628195,NA,30,non-hematological toxicity,4-Mar,NA,FALSE,NA
27628195,NA,30,ausea or vomiting,3 or 4,NA,NA,NA
17855009,NA,31,hematologic toxicity,4,NA,NA,NA
17855009,NA,31,neutropenia,3,NA,NA,NA
17855009,NA,31,thrombocytopenia,>=3,NA,NA,NA
17855009,NA,31,nonhematologic toxicity,>=3,NA,NA,NA
17855009,NA,31,"Dose-limiting toxicity was considered to have occurred if S-1 was given on less than two thirds of the days specified in the protocol (13 days or less), if irinotecan was not given on Days 8, 22, and 29, or if radiotherapy was stopped for 1 week or more.",NA,NA,NA,NA
18510175,NA,32,nonhematological toxicities,>=3,NA,FALSE,NA
18510175,NA,32,thrombocytopenia,4,NA,NA,NA
18510175,NA,32,neutropenia,4,lasting longer than 4 days,NA,NA
18510175,NA,32,neutropenia,3 or 4,NA,NA,NA
18510175,NA,32,any unresolved toxicity requiring a delay in the administration of a subsequent course exceeding 8 days,NA,NA,NA,NA
18510175,NA,32,toxicity,2,NA,NA,NA
27317556,NA,33,hematologic toxicity,4,NA,NA,NA
27317556,NA,33,neutropenia,3,NA,NA,NA
27317556,NA,33,thrombocytopenia,>=3,NA,NA,NA
27317556,NA,33,nonhematologic toxicity,>=3,NA,FALSE,NA
27317556,NA,33,the dose of S-1 was decreased or S-1 was given for 13 days or less because of adverse events,NA,NA,NA,NA
27317556,NA,33,"treatment with irinotecan was skipped on days 8, 22, and 29 or the dose of irinotecan was reduced because of adverse events",NA,NA,NA,NA
27317556,NA,33,chemotherapy scheduled for day 22 had to be postponed for 1 week or longer because of adverse events,NA,NA,NA,NA
27317556,NA,33,radiotherapy had to be discontinued for 1 week or longer because of adverse events,NA,NA,NA,NA
18841161,NA,34,thrombocytopenia,4,NA,NA,NA
18841161,NA,34,neutropenia,4,NA,NA,NA
18841161,NA,34,leucopoenia,4,NA,NA,NA
18841161,NA,34,a neutropenia leading to >7 days of interruption of radiotherapy,NA,NA,NA,NA
18841161,NA,34,"any grade 3 â€“ 4 non-haematological toxicity attributed to concomitant chemoradiotherapy (except oesophagitis, dysphagia, nausea and vomiting)",NA,NA,NA,NA
16638094,NA,35,neutropenia,4,NA,NA,NA
16638094,NA,35,thrombocytopenia,4,NA,NA,NA
16638094,NA,35,prolonged (>7 days) grade 3 or febrile neutropenia,NA,NA,NA,NA
16638094,NA,35,prolonged (>7 days) grade 3 thrombocytopenia or thrombocytopenia associated with bleeding,NA,NA,NA,NA
16638094,NA,35,non-hematological toxicity,>=3,NA,FALSE,NA
16638094,NA,35,delayed recovery from treatment-related toxicity for more than 2 weeks,NA,NA,NA,NA
31765987,NA,36,nonhaematological toxicity,4-Mar,NA,FALSE,NA
31765987,NA,36,neutropenia,3,NA,NA,NA
31765987,NA,36,neutropenia,4,lasting for >= 4 days,NA,NA
31765987,NA,36,thrombocytopenia,3,NA,NA,NA
31765987,NA,36,thrombocytopenia,4,NA,NA,NA
31765987,NA,36,failure to next cycle within 28 days.,NA,NA,NA,NA
19551382,NA,37,ANC <500 per uL for  >= 5 days,NA,NA,NA,NA
19551382,NA,37,febrile neutropenia,NA,NA,NA,NA
19551382,NA,37,thrombocytopenia,4,NA,NA,NA
19551382,NA,37,nonhematological toxicities,4-Mar,NA,FALSE,NA
19551382,NA,37,toxicity-related discontinuation of S-1 treatment for more than eight doses,NA,NA,NA,NA
19551382,NA,37,any toxicities that delayed S-1 and oxaliplatin treatment for more than 2 weeks,NA,NA,NA,NA
17579864,NA,38,ANC <500/uL for  >= 5day,NA,NA,NA,NA
17579864,NA,38,febrile neutropenia,4,NA,NA,NA
17579864,NA,38,thrombocytopenia,4,NA,NA,NA
17579864,NA,38,non-hematological,4-Mar,NA,FALSE,NA
17579864,NA,38,delay of treatment for more than 2 weeks,NA,NA,NA,NA
29971467,NCT02102022,39,neutropenia,4,> 7 days duration,NA,NA
29971467,NCT02102022,39,febrile neutropenia,4,NA,NA,NA
29971467,NCT02102022,39,anemia,4-Mar,NA,NA,NA
29971467,NCT02102022,39,thrombocytopenia,4,NA,NA,NA
29971467,NCT02102022,39,nonhematologic toxicity,4-Mar,NA,NA,NA
18176087,NA,40,leukopenia,4-Mar,NA,NA,NA
18176087,NA,40,neutropenia,4-Mar,NA,NA,NA
18176087,NA,40,thrombocytopenia,4-Mar,NA,NA,NA
18176087,NA,40,non-hematological toxicity,4-Mar,NA,FALSE,NA
18176087,NA,40,if the treatment course could not be finished within 6 weeks,NA,NA,NA,NA
18176087,NA,40,drug treatment was discontinued because toxicities lasted 2 consecutive weeks.,NA,NA,NA,NA
17720738,NA,41,leucopenia,4,NA,NA,NA
17720738,NA,41,neutropenia,4,NA,NA,NA
17720738,NA,41,thrombocytopenia,4,NA,NA,NA
17720738,NA,41,non-hematological toxicity,4-Mar,NA,FALSE,NA
17720738,NA,41,any non-hematological toxicity that resulted in skipping of the administration of CPT-11 on day 15 of the first course despite postponing treatment for up to 1 week,NA,NA,NA,NA
17720738,NA,41,"reduced the administration period of UFT-E (28 days) to ,14 days in the first course",NA,NA,NA,NA
17720738,NA,41,delayed administration of CPT-11 on day 1 of the second course,NA,NA,NA,NA
28293715,UMIN000016630,42,neutropenia,4-Mar,NA,NA,NA
28293715,UMIN000016630,42,leucopenia,4,NA,NA,NA
28293715,UMIN000016630,42,neutropenia,4,NA,NA,NA
28293715,UMIN000016630,42,anemia,4-Mar,NA,NA,NA
28293715,UMIN000016630,42,thrombocytopenia,4-Mar,NA,NA,NA
28293715,UMIN000016630,42,nonhematological toxicities,4-Mar,NA,NA,NA
28293715,UMIN000016630,42,more than 2Â weeks of drug withdrawal during the first cycle,NA,NA,NA,NA
16684860,NA,43,a neutrophil count of <500/ml,NA,NA,NA,NA
16684860,NA,43,febrile neutropenia,3,NA,NA,NA
16684860,NA,43,a platelet count of <50 000/ml,NA,NA,NA,NA
16684860,NA,43,non-hematologic toxicity,4-Mar,NA,FALSE,NA
16684860,NA,43,a longer than 1 week delay in treatment as a result of drug-related toxicity in the dose-escalation portion of the protocol,NA,NA,NA,NA
16636336,NA,44,neutropenia,4,NA,NA,NA
16636336,NA,44,thrombocytopenia,3,NA,NA,NA
16636336,NA,44,any nonhematologic toxicity,>=3,NA,NA,NA
16636336,NA,44,any neuropathy,>3,NA,NA,NA
16636336,NA,44,neuropathy that was not resolved by the time the next cycle of therapy was to be administered,NA,NA,NA,NA
17133268,NA,45,leucopenia,4,NA,NA,NA
17133268,NA,45,neutropenia,4,NA,NA,NA
17133268,NA,45,febrile neutropenia,3,lasting for more than 4 days,NA,NA
17133268,NA,45,thrombocytopenia,3,NA,NA,NA
17133268,NA,45,non-haematological toxicity,>=3,NA,FALSE,NA
19934112,NA,46,leukocytopenia,4,NA,NA,NA
19934112,NA,46,thrombocytopenia,4,NA,NA,NA
19934112,NA,46,neutropenia,4,lasting for 4 days,NA,NA
19934112,NA,46,leukocytopenia,3,NA,NA,NA
19934112,NA,46,neutropenia,3,NA,NA,NA
19934112,NA,46,non-hematologic toxicity,3,NA,NA,NA
19934112,NA,46,the second course of treatment was not resumed within 21 days after the first course.,NA,NA,NA,NA
18379784,NA,47,hematological toxicity,4,NA,NA,NA
18379784,NA,47,nonhematological toxicity,>=3,NA,NA,NA
18379784,NA,47,treatment discontinuation due to adverse reactions during the Wrst course of treatment.,NA,NA,NA,NA
18379784,NA,47,leukopenia,4,NA,NA,NA
18379784,NA,47,neutropenia,4,NA,NA,NA
18379784,NA,47,neutropenia,3,NA,NA,NA
17437021,NA,48,leukocytopaenia,3,NA,NA,NA
17437021,NA,48,neutropaenia,3,NA,NA,NA
17437021,NA,48,haematologic toxicities,4,NA,NA,NA
17437021,NA,48,nonhaematologic toxicity,4-Mar,NA,FALSE,NA
17437021,NA,48,nausea/vomiting,4-Mar,NA,NA,NA
17437021,NA,48,delay of recovery from treatment-related toxicity for more than 2 weeks,NA,NA,NA,NA
20694727,NA,49,neutropenia,4,NA,NA,NA
20694727,NA,49,febrile neutropenia,4,NA,NA,NA
20694727,NA,49,thrombocytopenia,4-Mar,NA,NA,NA
20694727,NA,49,non-hematologic toxicity,4-Mar,NA,FALSE,NA
20694727,NA,49,diarrhea,3,lasting more than 24 h despite optimal supportive medications,NA,NA
20694727,NA,49,vomiting,4,NA,NA,NA
20694727,NA,49,and any toxicity causing a delay of [14 days,NA,NA,NA,NA
28233053,NA,50,thrombocytopenia,>=3,persisting >5Â days,NA,NA
28233053,NA,50,neutropenia,4,persisting >5Â days,NA,NA
28233053,NA,50,anemia,4,NA,NA,NA
28233053,NA,50,toxicity,>=3,NA,FALSE,NA
28233053,NA,50,Failure to recover from toxicities to be eligible for re-treatment with nal-IRI within 35 days of the first dose of nal-IRI,NA,NA,NA,NA
28233053,NA,51,thrombocytopenia,>=3,persisting >5Â days,NA,NA
28233053,NA,51,neutropenia,4,persisting >5Â days,NA,NA
28233053,NA,51,anemia,4,NA,NA,NA
28233053,NA,51,toxicity,>=3,NA,FALSE,NA
28233053,NA,51,Failure to recover from toxicities to be eligible for re-treatment with nal-IRI within 35 days of the first dose of nal-IRI,NA,NA,NA,NA
27061418,NA,52,hematologic toxicity,4,NA,FALSE,NA
27061418,NA,52,febrile neutropenia,4-Mar,NA,NA,NA
27061418,NA,52,thrombocytopenia,4,NA,NA,NA
27061418,NA,52,non-hematologic toxicities,>=3,NA,FALSE,NA
27061418,NA,52,nausea or vomiting,3,NA,FALSE,NA
27061418,NA,52,prolonged QTc >500 ms,3,NA,NA,NA
27061418,NA,52,any toxicity resulting in a treatment delay beyond 1 week.,NA,NA,NA,NA
8217238,NA,54,toxicity,4-Mar,NA,NA,NA
8217238,NA,54,"anorexia, mucositis, diarrhoea, and fatigue",3,NA,NA,NA
7882458,NA,55,toxicity,4-Mar,NA,NA,NA
30838483,"UMIN-CTR, ID: 000015764",56,febrile neutropenia with a body temperature of â‰¥38.5 Â°C,NA,NA,NA,NA
30838483,"UMIN-CTR, ID: 000015764",56,thrombocytopenia or platelet transfusion,4,NA,NA,NA
30838483,"UMIN-CTR, ID: 000015764",56,nonhematologic toxicity,4-Mar,NA,FALSE,NA
30838483,"UMIN-CTR, ID: 000015764",56,any treatment-related death or septic shock,NA,NA,NA,NA
30838483,"UMIN-CTR, ID: 000015764",56,toxicity requiring the second cycle to be delayed by more than 8 days,NA,NA,NA,NA
25860347,NCT01136031,57,geutropenia,4,NA,NA,NA
25860347,NCT01136031,57,thrombocytopenia,4-Mar,NA,NA,NA
25860347,NCT01136031,57,nonthrombocytopenia toxicity,4-Mar,NA,FALSE,NA
33611805,NA,58,neutropenia,4,NA,NA,NA
33611805,NA,58,thrombocytopenia,4,NA,NA,NA
33611805,NA,58,nonhematological adverse effects,4-Mar,NA,FALSE,NA
33611805,NA,58,delay in starting the next treatment cycle within 7 days or treatment discontinuation due to adverse events,NA,NA,NA,NA
33611805,NA,58,treatment-related death,NA,NA,NA,NA
8426214,NA,60,toxicity,3,NA,NA,NA
8426214,NA,60,failed to have recovery of hematologic parameters to less than grade 2 by day 29.,NA,NA,NA,NA
21424369,NA,61,surgical and hematological complications,4,NA,NA,NA
21509928,NCT00143533,62,nonhematologic toxicity,4-Mar,NA,FALSE,NA
21509928,NCT00143533,62,neutropenia,4,NA,NA,NA
21509928,NCT00143533,62,thrombocytopenia for >7 days.,NA,NA,NA,NA
24958824,NA,63,neutropenia,4,lasting >= 4 days,NA,NA
24958824,NA,63,neutropenia,>=3,NA,NA,NA
24958824,NA,63,febrile neutropenia,>=3,NA,NA,NA
24958824,NA,63,anemia or thrombocytopenia,4,NA,NA,NA
24958824,NA,63,diarrhea,>=3,NA,NA,NA
24958824,NA,63,nonhematologic toxicity,>=3,NA,NA,NA
24958824,NA,63,nausea or nausea/vomiting,4,NA,NA,NA
24958824,NA,64,neutropenia,4,lasting >= 4 days,NA,NA
24958824,NA,64,neutropenia,>=3,NA,NA,NA
24958824,NA,64,febrile neutropenia,>=3,NA,NA,NA
24958824,NA,64,anemia or thrombocytopenia,4,NA,NA,NA
24958824,NA,64,diarrhea,>=3,NA,NA,NA
24958824,NA,64,nonhematologic toxicity,>=3,NA,NA,NA
24958824,NA,64,nausea or nausea/vomiting,4,NA,NA,NA
24958824,NA,65,neutropenia,4,lasting >= 4 days,NA,NA
24958824,NA,65,neutropenia,>=3,NA,NA,NA
24958824,NA,65,febrile neutropenia,>=3,NA,NA,NA
24958824,NA,65,anemia or thrombocytopenia,4,NA,NA,NA
24958824,NA,65,diarrhea,>=3,NA,NA,NA
24958824,NA,65,nonhematologic toxicity,>=3,NA,NA,NA
24958824,NA,65,nausea or nausea/vomiting,4,NA,NA,NA
7917927,NA,66,NA,NA,NA,NA,NA
20405511,NA,67,neutropenia,4,NA,NA,NA
20405511,NA,67,hrombocytopenia,4,NA,NA,NA
20405511,NA,67,"required transfusion for a platelet count of <20,000/ mm3 on >2 occasions in 7 days",NA,NA,NA,NA
20405511,NA,67,caused a delay of >14 days beyond the planned interval between courses.,NA,NA,NA,NA
20405511,NA,67,toxicity,4-Mar,NA,FALSE,NA
20405511,NA,67,NA,4,NA,NA,NA
33289920,NCT02044120,68,any drug-related death,4,NA,NA,NA
33289920,NCT02044120,68,any grade 3 or 4 treatment-related nonhematologic toxicity,NA,NA,FALSE,NA
33289920,NCT02044120,68,neutropenia,4,>7 days,NA,NA
33289920,NCT02044120,68,febrile neutropenia,4-Mar,NA,NA,NA
33289920,NCT02044120,68,thrombocytopenia,4,NA,NA,NA
33289920,NCT02044120,68,any adverse event leading to a dose interruption for >7 days,4,NA,NA,NA
33289920,NCT02044120,69,any drug-related death,4,NA,NA,NA
33289920,NCT02044120,69,any grade 3 or 4 treatment-related nonhematologic toxicity,NA,NA,FALSE,NA
33289920,NCT02044120,69,neutropenia,4,>7 days,NA,NA
33289920,NCT02044120,69,febrile neutropenia,4-Mar,NA,NA,NA
33289920,NCT02044120,69,thrombocytopenia,4,NA,NA,NA
33289920,NCT02044120,69,any adverse event leading to a dose interruption for >7 days,4,NA,NA,NA
22674635,NCT00520637,70,febrile neutropenia,NA,NA,NA,NA
22674635,NCT00520637,70,neutropenia,4,lasting >= 5 days,NA,NA
22674635,NCT00520637,70,thrombocytopenia,4,NA,NA,NA
22674635,NCT00520637,70,nonhematologic toxicity,4-Mar,NA,FALSE,NA
30406838,NA,71,neutropenia or thrombocytopenia,4,NA,NA,NA
30406838,NA,71,bleeding due to thrombocytopenia,NA,NA,NA,NA
30406838,NA,71,adverse events,4-Mar,NA,NA,NA
30406838,NA,71,"diarrhea, vomiting or nausea",>=3,NA,NA,NA
30406838,NA,71,moderate to severe symptoms of early cholinergic syndrome or other adverse reactions leading to treatment delay for more than 2Â weeks,4,NA,NA,NA
27920527,NA,72,Neutropenia,NA,NA,NA,NA
23921573,NCT00925015,73,neutropenia,4,lasting >5 days;,NA,NA
23921573,NCT00925015,73,neutropenia,3 or 4,NA,NA,NA
23921573,NCT00925015,73,thrombocytopenia,4,NA,NA,NA
23921573,NCT00925015,73,nonhematological toxicity,3 or 4,NA,FALSE,NA
26429709,NCT01009073,74,thrombocytopenia,4,NA,NA,NA
26429709,NCT01009073,74,bleeding,>=2,NA,NA,NA
26429709,NCT01009073,74,reatment-emergent AEs,3 or 4,NA,FALSE,NA
30859690,C000000314,76,NA,NA,NA,NA,NA
30167847,18606,77,neutropenia,4,lasting > 7 days,NA,NA
30167847,18606,77,thrombocytopenia,4,NA,NA,NA
30167847,18606,77,febrile neutropenia,NA,NA,NA,NA
30167847,18606,77,hypertension,4,NA,NA,NA
30167847,18606,77,non-hematological adverse effects,3 or 4,NA,NA,NA
30167847,18606,77,treatment discontinuation due to adverse events,NA,NA,NA,NA
30167847,18606,77,delay in starting the second cycle for > 14 days,NA,NA,NA,NA
30167847,18606,77,treatment-related death,NA,NA,NA,NA
30042150,NCT02188264,78,neutropenia,4,>= 7 days,NA,NA
30042150,NCT02188264,78,neutropenia,3 or 4,NA,NA,NA
30042150,NCT02188264,78,thrombocytopenia,3,NA,NA,NA
30042150,NCT02188264,78,thrombocytopenia,4,NA,NA,NA
30042150,NCT02188264,78,nausea or vomiting,>=3,NA,NA,NA
30042150,NCT02188264,78,diarrhea,>=3,NA,NA,NA
30042150,NCT02188264,78,"hyponatremia, hypokalemia, hypomagnesemia, and hypophosphatemia",>=3,NA,NA,NA
30042150,NCT02188264,78,any intolerable adverse event regardless of grade that did not resolve within 7 days despite maximal medical management,4,NA,NA,NA
30042150,NCT02188264,78,nonhematologic toxicities,>=3,NA,FALSE,NA
34031756,NCT04088604,79,neutropenia,4,lasting for at least 3Â days,NA,NA
34031756,NCT04088604,79,febrile neutropenia,3,NA,NA,NA
34031756,NCT04088604,79,thrombocytopenia,3,NA,NA,NA
34031756,NCT04088604,79,hematologic,4,NA,NA,NA
34031756,NCT04088604,79,non-hematologic toxicities,3,NA,NA,NA
34031756,NCT04088604,79,"diarrhea, nausea, vomiting, or electrolyte disorders",3,NA,NA,NA
22415148,NA,80,NA,NA,NA,NA,NA
33993383,NCT01923337,81,non-hematologic toxicity,3,NA,NA,NA
33993383,NCT01923337,81,toxicity,4,NA,NA,NA
33993383,NCT01923337,81,diarrhea,3,NA,NA,NA
33993383,NCT01923337,81,neutropenia,4,NA,NA,NA
34383370,NCT01518413,82,neutropenia,4,NA,NA,NA
34383370,NCT01518413,82,hrombocytopenia,4,NA,NA,NA
34383370,NCT01518413,82,nonhematologic toxicity,>=3,NA,FALSE,NA
24249672,NA,83,neutropenia,4,>7 days,NA,NA
24249672,NA,83,thrombocytopenia,4,NA,NA,NA
24249672,NA,83,requiring a platelet transfusion on two separate days within a 7-day period,NA,NA,NA,NA
24249672,NA,83,myelosuppression that caused a delay of >14 days between treatment cycles,NA,NA,NA,NA
24249672,NA,83,nonhematologic toxicity,4-Mar,NA,FALSE,NA
24691674,NCT00838578,84,hematologic toxicity,4,â‰¥5 days duration,NA,NA
24691674,NCT00838578,84,febrile neutropenia,NA,NA,NA,NA
24691674,NCT00838578,84,diarrhea or vomiting,4,NA,NA,NA
24691674,NCT00838578,84,diarrhea,3,NA,NA,NA
24691674,NCT00838578,84,non-hematologic toxicity,>=3,NA,FALSE,NA
31857431,NA,86,neutropenia,4,reater than 7 days,NA,NA
31857431,NA,86,"platelet counts less than 20,000/mm3 on two separate measurements at least 48 hours apart",NA,NA,NA,NA
31857431,NA,86,requiring two or more platelet transfusions within 7 days,4,NA,NA,NA
31857431,NA,86,nonhematologic toxicity,4-Mar,NA,FALSE,NA
31857431,NA,86,any toxicity that required treatment interruption for > 14 days was considered dose limiting.,NA,NA,NA,NA
22615057,NCT00134069,87,nonhematological toxicity,>=3,NA,NA,NA
22615057,NCT00134069,87,hematological toxicity,>=4,NA,NA,NA
22615057,NCT00134069,87,"persistent nausea, vomiting and diarrhea in spite of adequate supportive care",NA,NA,NA,NA
26842236,NCT00576654,88,Nonhematologic toxicity,>=3,NA,NA,NA
26842236,NCT00576654,88,"nausea, vomiting, or diarrhea",>=3,NA,NA,NA
26842236,NCT00576654,88,granulocytopenia,4,lasting >= 5 days,NA,NA
26842236,NCT00576654,88,thrombocytopenia or febrile neutropenia,4,NA,NA,NA
26842236,NCT00576654,88,inability to begin cycle 2 of treatment (at full dose) within 2 weeks of the scheduled date of administration due to unresolved toxicity,NA,NA,NA,NA
26842236,NCT00576654,88,nonhematologic toxicity persisting beyond the first 42 days,>=2,NA,NA,NA
26842236,NCT00576654,88,the occurrence of grade 2 toxicities,NA,NA,NA,NA
26842236,NCT00576654,88,electrolyte imbalance secondary to another toxicity,>=3,NA,NA,NA
22701615,NCT00436072,89,hematological toxicity,4,.>7 days,NA,NA
22701615,NCT00436072,89,fever and neutropenia,NA,NA,NA,NA
22701615,NCT00436072,89,diarrhea,3,NA,NA,NA
22701615,NCT00436072,89,diarrhea,4,NA,NA,NA
22701615,NCT00436072,89,vomiting,4,NA,NA,NA
22701615,NCT00436072,89,nonhematological toxicity,>=3,lasting >1 week,FALSE,NA
22701615,NCT00436072,89,skin toxicity,4,NA,NA,NA
22701615,NCT00436072,89,cardiac toxicities or death from any cause,>=3,NA,NA,NA
25577133,NA,90,hematological toxicity,4,lasting for longer than 3 days,NA,NA
25577133,NA,90,febrile neutropenia,4,NA,NA,NA
25577133,NA,90,non-hematological toxicity,>3,nausea and vomiting,NA,NA
20943763,NA,91,neutropenia,4,â‰¥5 days,NA,NA
20943763,NA,91,thrombocytopenia,4,NA,NA,NA
20943763,NA,91,toxicity,>=3,NA,FALSE,NA
32537847,NCT02745769,92,hematologic toxicity,4,>5 days,NA,NA
32537847,NCT02745769,92,febrile neutropenia,>=3,NA,NA,NA
32537847,NCT02745769,92,thrombocytopenia,4,NA,NA,NA
32537847,NCT02745769,92,thrombocytopenia,3,NA,NA,NA
32537847,NCT02745769,92,nonhematologic toxicity,3,NA,NA,NA
32537847,NCT02745769,92,any other clinically significant toxicity deemed by the investigator and the sponsorâ€™s clinical research physician to be dose limiting (such as grade 2 seizures or severe tremors).,NA,NA,NA,NA
8708712,NA,93,toxicity,4-Mar,NA,NA,NA
26884555,NA,94,neutropenia,4,more than 7 days,NA,NA
26884555,NA,94,"need for platelet transfusion for a platelet count of less than 20,000/mL twice within a 7-day period",NA,NA,NA,NA
26884555,NA,94,greater than 14day delay in the start of a subsequent course because of neutropenia or thrombocytopenia,NA,NA,NA,NA
26884555,NA,94,any nonhematologic toxicity that delayed the start of a subsequent cycle by more than 14 days,NA,NA,NA,NA
26884555,NA,94,toxicity,>=3,NA,FALSE,NA
23170896,EU-CTR2006-001345-33,95,thrombocytopenia,4,NA,NA,NA
23170896,EU-CTR2006-001345-33,95,febrile neutropenia,NA,NA,NA,NA
23170896,EU-CTR2006-001345-33,95,neutropenia,4,NA,FALSE,NA
23170896,EU-CTR2006-001345-33,95,gastro-intestinal toxicities,>=3,NA,NA,NA
23170896,EU-CTR2006-001345-33,95,not reduced to grade 1 within 2 days of appropriate therapy,NA,NA,NA,NA
23170896,EU-CTR2006-001345-33,95,nonhaematologic toxicities,>=3,NA,FALSE,NA
22421195,NA,96,ANC less than 500/mm3 28 days after PBSC infusion;,NA,NA,NA,NA
22421195,NA,96,"platelets less than 20,000/mm3 56 days after PBSC infusion",NA,NA,NA,NA
22421195,NA,96,need for a second PBSC infusion,NA,NA,NA,NA
22421195,NA,96,hemolysis,NA,NA,NA,NA
22421195,NA,96,refractory to platelet transfusions with lifethreatening bleeding,NA,NA,NA,NA
22421195,NA,96,life-threatening anemia,NA,NA,NA,NA
22421195,NA,96,toxicity,>=3,NA,FALSE,NA
34559360,NCT02124148,97,nonhematologic toxicity,>=3,NA,FALSE,NA
34559360,NCT02124148,97,thrombocytopenia,>=3,NA,NA,NA
34559360,NCT02124148,97,neutropenia,4,>Â 5 days,NA,NA
34559360,NCT02124148,97,any febrile neutropenia,NA,NA,NA,NA
34559360,NCT02124148,97,any other significant toxicity deemed by the primary investigator and the studyâ€™s clinical research physician or scientist to be dose-limiting.,NA,NA,NA,NA
34559360,NCT02124148,98,nonhematologic toxicity,>=3,NA,FALSE,NA
34559360,NCT02124148,98,thrombocytopenia,>=3,NA,NA,NA
34559360,NCT02124148,98,neutropenia,4,>Â 5 days,NA,NA
34559360,NCT02124148,98,any febrile neutropenia,NA,NA,NA,NA
34559360,NCT02124148,98,any other significant toxicity deemed by the primary investigator and the studyâ€™s clinical research physician or scientist to be dose-limiting.,NA,NA,NA,NA
34559360,NCT02124148,99,nonhematologic toxicity,>=3,NA,FALSE,NA
34559360,NCT02124148,99,thrombocytopenia,>=3,NA,NA,NA
34559360,NCT02124148,99,neutropenia,4,>Â 5 days,NA,NA
34559360,NCT02124148,99,any febrile neutropenia,NA,NA,NA,NA
34559360,NCT02124148,99,any other significant toxicity deemed by the primary investigator and the studyâ€™s clinical research physician or scientist to be dose-limiting.,NA,NA,NA,NA
34559360,NCT02124148,100,nonhematologic toxicity,>=3,NA,FALSE,NA
34559360,NCT02124148,100,thrombocytopenia,>=3,NA,NA,NA
34559360,NCT02124148,100,neutropenia,4,>Â 5 days,NA,NA
34559360,NCT02124148,100,any febrile neutropenia,NA,NA,NA,NA
34559360,NCT02124148,100,any other significant toxicity deemed by the primary investigator and the studyâ€™s clinical research physician or scientist to be dose-limiting.,NA,NA,NA,NA
27871319,NCT02884128,101,non-hematological toxicity,4-Mar,NA,FALSE,NA
27871319,NCT02884128,101,hematologic toxicity,4,lasting for â‰¥3 days,NA,NA
27871319,NCT02884128,101,hematologic toxicity,3,NA,NA,NA
27871319,NCT02884128,101,dose delay of more than 2 weeks owing to drug-related toxicity,NA,NA,NA,NA
28573606,UMIN000004313,102,hematologic toxicity,4,NA,NA,NA
28573606,UMIN000004313,102,febrile (C38.5 Â°C) neutropenia,3,NA,NA,NA
28573606,UMIN000004313,102,thrombocytopenia,3,NA,NA,NA
28573606,UMIN000004313,102,non-hematologic event,3,NA,NA,NA
27189323,NA,103,neutropenia,4,persisted for at least 3 days,NA,NA
27189323,NA,103,febrile neutropenia,NA,NA,NA,NA
27189323,NA,103,hematotoxicity,4,NA,NA,NA
27189323,NA,103,nonhematological toxicity,>=3,NA,NA,NA
27189323,NA,103,treatment-related adverse event leading to a delay of 8 days or more in the start of the second cycle,4,NA,NA,NA
27189323,NA,103,treatment-related adverse event leading to skipping of the nab-paclitaxel dose on day 8 specified in schedule B,NA,NA,NA,NA
27189323,NA,104,neutropenia,4,persisted for at least 3 days,NA,NA
27189323,NA,104,febrile neutropenia,NA,NA,NA,NA
27189323,NA,104,hematotoxicity,4,NA,NA,NA
27189323,NA,104,nonhematological toxicity,>=3,NA,NA,NA
27189323,NA,104,treatment-related adverse event leading to a delay of 8 days or more in the start of the second cycle,4,NA,NA,NA
27189323,NA,104,treatment-related adverse event leading to skipping of the nab-paclitaxel dose on day 8 specified in schedule B,NA,NA,NA,NA
26490655,NCT01571024,105,hyperglycemia,3,NA,NA,NA
26490655,NCT01571024,105,hyperglycemia,2,NA,NA,NA
26490655,NCT01571024,105,hyperglycemia,4,NA,NA,NA
34050586,UMIN000017002,106,leucopenia or neutropenia,4,NA,NA,NA
34050586,UMIN000017002,106,thrombocytopenia,>=3,NA,NA,NA
34050586,UMIN000017002,106,anemia,>=3,NA,NA,NA
34050586,UMIN000017002,106,febrile neutropenia,>=3,NA,NA,NA
34050586,UMIN000017002,106,nonhematological toxicities,>=3,NA,NA,NA
26220846,NA,107,neutropenia,4,continuing for more than 3 days,NA,NA
26220846,NA,107,febrile neutropenia,4,NA,NA,NA
26220846,NA,107,thrombocytopenia,4,NA,NA,NA
26220846,NA,107,non-hematological toxicity,4-Mar,NA,NA,NA
26220846,NA,107,any toxicity that necessitated a treatment delay of more than 15 days,NA,NA,NA,NA
32669374,NCT01489865,108,neutropenia,4,lasting greater than 5 days or complicated by fever or infection.,NA,NA
32669374,NCT01489865,108,anemia or thrombocytopenia,4,NA,NA,NA
32669374,NCT01489865,108,hrombocytopenia,3,NA,NA,NA
32669374,NCT01489865,108,nonhematologic toxicity,4-Mar,NA,NA,NA
32669374,NCT01489865,108,"Any toxicity, regardless of grade, which resulted in withholding of therapy for greater than 3 weeks.",NA,NA,NA,NA
33386556,UMIN000015620,109,neutropenia,4,lasting for â‰¥ 5Â days,NA,NA
33386556,UMIN000015620,109,febrile neutropenia,4,NA,NA,NA
33386556,UMIN000015620,109,thrombocytopenia,4,NA,NA,NA
33386556,UMIN000015620,109,thrombocytopenia complicated by a bleeding risk,NA,NA,NA,NA
33386556,UMIN000015620,109,"clinically significant grade 3 or more non-hematologic toxicities [grading excludes nausea, vomiting, fatigue, and transient metabolic toxicities",NA,NA,NA,NA
33386556,UMIN000015620,109,acne-like rash,4,NA,NA,NA
33386556,UMIN000015620,109,any drug-related toxicity resulting in a > 2-week delay in the initiation of cycle 2 or 3,NA,NA,NA,NA
29691300,NA,110,neutropenia,4,for >7 days,NA,NA
29691300,NA,110,febrile neutropenia,NA,NA,NA,NA
29691300,NA,110,thrombocytopenia,4,NA,NA,NA
29691300,NA,110,thrombocytopenia with bleeding,3,NA,NA,NA
29691300,NA,110,nonhematologic toxicity,4-Mar,NA,FALSE,NA
29691300,NA,110,treatment delay of 14 days due to unresolved toxicity and nonhematologic toxicity of grade 2 that was dose-limiting,NA,NA,NA,NA
31185328,NA,112,febrile neutropenia,NA,NA,NA,NA
31185328,NA,112,neutropenic infection,NA,NA,NA,NA
31185328,NA,112,neutropenia,4,lasting >=7 days,NA,NA
31185328,NA,112,thrombocytopenia,>=3,lasting >= 7 days,NA,NA
31185328,NA,112,nausea,3,NA,NA,NA
31185328,NA,112,vomiting and diarrhoea despite appropriate concomitant treatment,NA,NA,NA,NA
31185328,NA,112,fatigue,>=3,lasting >= 7 days,NA,NA
31185328,NA,112,skin toxicity,>=3,NA,NA,NA
31185328,NA,112,any other grade 3 toxicity,NA,NA,FALSE,NA
31185328,NA,112,ncomplete first CRT period (patient received <75% of planned doses),NA,NA,NA,NA
31185328,NA,112,CT or RT delayed for 7 days due to toxicities.,NA,NA,NA,NA
31558477,NA,113,Nonhematologic,>=3,NA,FALSE,NA
31558477,NA,113,elevated amylase or lipase in the absence of clinical signs or symptoms of pancreatitis,NA,NA,NA,NA
31558477,NA,113,hyperglycemia,3,NA,NA,NA
31558477,NA,113,abnormalities of liver function tests clearly related to malignant biliary obstruction,NA,NA,NA,NA
31558477,NA,113,other grade 3 AEs deemed clinically insignificant,NA,NA,NA,NA
31558477,NA,113,neutropenia,4,>= 5 days,NA,NA
31558477,NA,113,neutropenia,4-Mar,NA,NA,NA
31558477,NA,113,thrombocytopenia,4,NA,NA,NA
31558477,NA,113,thrombocytopenia,3,NA,NA,NA
31558477,NA,113,Delay of cycle 1 day 15 dose of mFOLFIRINOX by more than 14 days constituted a DLT if the reason was attributable to study treatment.,NA,NA,NA,NA
33985455,ChiCTR1900027833,114,hematologic toxicity,4,NA,NA,NA
33985455,ChiCTR1900027833,114,thrombocytopenia,3,NA,NA,NA
33985455,ChiCTR1900027833,114,"nausea, vomiting, or diarrhea",>=3,NA,NA,NA
33985455,ChiCTR1900027833,114,reatment-related nonhematologic toxicity,>=3,NA,FALSE,NA
28489753,UMIN000005808,115,neutropenia,4,asting longer than 5 days,NA,NA
28489753,UMIN000005808,115,febrile neutropenia,NA,NA,NA,NA
28489753,UMIN000005808,115,thrombocytopenia,4,NA,NA,NA
28489753,UMIN000005808,115,toxicity,4-Mar,NA,NA,NA
28489753,UMIN000005808,115,delay of recovery from treatment-related toxicity for more than 2 weeks.,NA,NA,NA,NA
30511200,NA,116,onhematologic toxicity,>=3,NA,NA,NA
30511200,NA,116,nausea/vomiting/diarrhea,>=3,lasting >48 h and uncontrolled by aggressive medications,NA,NA
30511200,NA,116,neutropenia,4,lasting >7 days,NA,NA
30511200,NA,116,febrile neutropenia,NA,NA,NA,NA
30511200,NA,116,thrombocytopenia,4,NA,NA,NA
30511200,NA,116,thrombocytopenia,3,NA,NA,NA
30511200,NA,116,any TRAE that prevented completion of Cycle 1 (< 80% of planned cumulative dose),NA,NA,NA,NA
30511200,NA,116,any TRAE resulting in a > 14-day delay in the initiation of Cycle 2,NA,NA,NA,NA
33957442,NA,117,diarrhoea,>=3,NA,NA,NA
33957442,NA,117,febrile neutropenia,NA,NA,NA,NA
33957442,NA,117,neutropenic sepsis,NA,NA,NA,NA
33957442,NA,117,neutropenia,>=3,NA,NA,NA
33957442,NA,117,thrombo-embolic events,NA,NA,NA,NA
33957442,NA,117,peripheral neuropathy,>=3,NA,NA,NA
27979915,NCT01172964,118,toxicities,4-Mar,NA,NA,NA
28058527,NA,119,leukopenia,4,NA,NA,NA
28058527,NA,119,neutropenia,4,NA,NA,NA
28058527,NA,119,thrombocytopenia,4,NA,NA,NA
28058527,NA,119,any nonhematological toxicity,>=3,NA,NA,NA
32877909,NA,120,"febrile neutropenia,",>=3,NA,NA,NA
32877909,NA,120,"thrombocytopenia,",4,NA,NA,NA
32877909,NA,120,neutropenia,4,"over 7 days,",NA,NA
32877909,NA,120,nonhematological toxicities,>=3,NA,FALSE,NA
32877909,NA,120,delay of starting cycle 2 longer than 15 days due to adverse event.,NA,NA,NA,NA
27155613,UMIN000006396,121,febrile neutropenia,NA,NA,NA,NA
27155613,UMIN000006396,121,white blood cell decreased or neutropenia,4,NA,NA,NA
27155613,UMIN000006396,121,platelet count decreased,>=3,NA,NA,NA
27155613,UMIN000006396,121,non-hematologic toxicity,>=3,NA,NA,NA
27155613,UMIN000006396,121,peripheral neuropathy which was not recovered in the next course,>=3,NA,NA,NA
27155613,UMIN000006396,121,a treatment delay longer than 2 week due to drug-related toxicity,NA,NA,NA,NA
27155613,UMIN000006396,121,NA,4,NA,NA,NA
27745984,NCT00188266,122,acute toxicity related to study treatment and requiring intervention,>=3,NA,NA,NA
32642753,UMIN000012135,123,hematological toxicities,4,NA,NA,NA
32642753,UMIN000012135,123,oral mucositis or dermatitis,NA,NA,NA,NA
32642753,UMIN000012135,123,neutropenia;,3,NA,NA,NA
32642753,UMIN000012135,123,non-hematologic toxicities,3,NA,FALSE,NA
32642753,UMIN000012135,123,reduction of S-1 doses to less than two-thirds of the planned dose;,NA,NA,NA,NA
32642753,UMIN000012135,123,suspension of carbon-ion RT for at least 2 weeks.,NA,NA,NA,NA
30191522,NCT02319018,124,non-hematologic toxicity,>=3,NA,FALSE,NA
30191522,NCT02319018,124,hematologic toxicity,>=4,NA,NA,NA
30191522,NCT02319018,124,"Nausea, vomiting, or diarrhea",3,NA,NA,NA
30191522,NCT02319018,124,A treatment delay of >21 days due to a treatment-related toxicity was also dose limiting.,NA,NA,NA,NA
26597443,NCT01621217.,125,neutrophil count <0.5 x 10^9/l for more than 5 d,NA,NA,NA,NA
26597443,NCT01621217.,125,febrile neutropenia,4,NA,NA,NA
26597443,NCT01621217.,125,"platelets <25 x 10^9/l,",NA,NA,NA,NA
26597443,NCT01621217.,125,diarrhoea,>=3,NA,NA,NA
26597443,NCT01621217.,125,other adverse event >G3 thought to be treatment-related,4,NA,FALSE,NA
26597443,NCT01621217.,125,in-field radiation dermatitis,4,NA,NA,NA
26597443,NCT01621217.,125,dose intensity <70% of any delivered treatment component due to intolerance,NA,NA,NA,NA
25989270,NA,126,non-haematological toxicity,>=3,NA,FALSE,NA
25989270,NA,126,neutropenia,4,more than 5 days duration,NA,NA
25989270,NA,126,febrile neutropenia,NA,lasting more than 1 day;,NA,NA
25989270,NA,126,thrombocytopenia,4,NA,NA,NA
25989270,NA,126,thrombocytopenia,3,NA,NA,NA
25989270,NA,126,any treatment delay of more than 2 weeks owing to trial treatmentrelated adverse events (AEs),4,NA,NA,NA
26025485,NA,127,non-hematologic toxicity,>=3,NA,NA,NA
26025485,NA,127,leukopenia or neutropenia,4,NA,NA,NA
26025485,NA,127,anemia or thrombocytopenia,4-Mar,NA,NA,NA
26025485,NA,127,febrile neutropenia,NA,NA,NA,NA
26025485,NA,127,severe infection,NA,NA,NA,NA
26025485,NA,127,any treatmentrelated toxicity that required treatment (S-1 or radiation) interruption for more than 7 days or inability to deliver S-1 beyond 7 days,NA,NA,NA,NA
26861740,NCT01376453,128,NA,NA,NA,NA,NA
29995287,"apicCTI-152,864",129,thrombocytopenia,4,NA,NA,NA
29995287,"apicCTI-152,864",129,neutropenia,4,persisting for â‰¥8 days;,NA,NA
29995287,"apicCTI-152,864",129,febrile neutropenia,NA,NA,NA,NA
29995287,"apicCTI-152,864",129,non-hematologic toxicities,>=3,NA,NA,NA
30121935,NA,130,febrile neutropenia,4,NA,NA,NA
30121935,NA,130,neutropenia,4,NA,NA,NA
30121935,NA,130,leukopenia,4,â‰¥3 days,NA,NA
30121935,NA,130,"hrombocytopenia,",4,NA,NA,NA
30121935,NA,130,neuropathy,>=3,NA,NA,NA
30121935,NA,130,nonhematological adverse events,>=3,NA,FALSE,NA
30121935,NA,130,"delay in paclitaxel infusion on day 8,",NA,NA,NA,NA
30121935,NA,130,elay of >2 weeks in the administration of the next course of treatment.,NA,NA,NA,NA
26163340,JapicCTI-132099,131,non-haematological toxicities,>=3,NA,FALSE,NA
26163340,JapicCTI-132099,131,"nausea, vomiting or diarrhoea",>=3,NA,NA,NA
26163340,JapicCTI-132099,131,febrile neutropenia,>=3,NA,NA,NA
26163340,JapicCTI-132099,131,neutropenia,4,NA,NA,NA
26163340,JapicCTI-132099,131,thrombocytopenia,4,NA,NA,NA
26163340,JapicCTI-132099,131,other non-haematological toxicities,4,NA,NA,NA
26163340,JapicCTI-132099,131,delay of starting Cycle 2 longer than 14 days due to adverse drug reaction.,NA,NA,NA,NA
8120556,NA,132,NA,NA,NA,NA,NA
27919976,UMIN 000016377,133,decrease in platelet count,4,NA,NA,NA
27919976,UMIN 000016377,133,decrease in platelet count that required blood transfusion,3,NA,NA,NA
27919976,UMIN 000016377,133,febrile neutropenia with a neutrophil count of <500/mm3 and pyrexia of â‰¥38.5 ÌŠC;,NA,NA,NA,NA
27919976,UMIN 000016377,133,decrease in grade 4 neutrophil count,4,NA,FALSE,NA
27919976,UMIN 000016377,133,nonhematological toxicities.,>=3,NA,NA,NA
26019463,NA,134,"leucopenia, neutropenia, or anemia",4,NA,NA,NA
26019463,NA,134,neutropenia,4,NA,NA,NA
26019463,NA,134,thrombocytopenia,3,NA,NA,NA
26019463,NA,134,nonhematologic toxicity,4-Mar,NA,FALSE,NA
26019463,NA,134,a delay of more than 2 wk in starting the second cycle of chemotherapy,NA,NA,NA,NA
26019463,NA,134,a delay of more than 2 wk in the administering the cytotoxic agents scheduled to be given on day 15,NA,NA,NA,NA
26275531,NA,135,hematological toxicity,>=3,lasting for>7 days,NA,NA
26275531,NA,135,Febrile neutropenia,4,NA,NA,NA
26275531,NA,135,non-hematologic,>=3,NA,FALSE,NA
26275531,NA,135,hyperglycemia,3,NA,NA,NA
32253228,NA,136,neutropenia,4,NA,NA,NA
32253228,NA,136,"thrombocytopenia,",5-Mar,NA,NA,NA
32253228,NA,136,any nonhematologic toxicity,5-Mar,NA,NA,NA
26117830,JapicCTI-090973,137,hematological toxicity,>=4,NA,NA,NA
26117830,JapicCTI-090973,137,febrile neutropenia,>=3,NA,NA,NA
26117830,JapicCTI-090973,137,nonhematological toxicity,>=3,NA,FALSE,NA
26117830,JapicCTI-090973,137,drug-related pancreatitis associated with a grade 4 increase in pancreatic enzymes,NA,NA,NA,NA
26117830,JapicCTI-090973,137,Es requiring suspension of treatment of no <15 consecutive days and AEs requiring discontinuation of treatment,NA,NA,NA,NA
32977220,NCT02504333,138,neutropenia,4,>7d,NA,NA
32977220,NCT02504333,138,febrile neutropenia,>=3,NA,NA,NA
32977220,NCT02504333,138,thrombocytopenia,4,NA,NA,NA
32977220,NCT02504333,138,thrombocytopenia,3,NA,FALSE,NA
32977220,NCT02504333,138,delayed treatment for >2 weeks.,NA,NA,NA,NA
32710148,UMIN000023277,139,neutropenia,4,lasting 8Â days or more,NA,NA
32710148,UMIN000023277,139,febrile neutropenia,4,NA,NA,NA
32710148,UMIN000023277,139,thrombocytopenia,4,NA,NA,NA
32710148,UMIN000023277,139,non-hematological toxicity,>=3,NA,FALSE,NA
32710148,UMIN000023277,139,toxicity resulting in delay in starting the second cycle for 15Â days or more.,NA,NA,NA,NA
32694153,NA,140,nonhematologic toxicity,>=3,NA,NA,NA
32694153,NA,140,thrombocytopenia or neutropenia,4,lasting more than 7 days,NA,NA
32694153,NA,140,febrile neutropenia,>=3,NA,NA,NA
32694153,NA,140,total bilirubin or hepatic transaminases elevation,>=3,NA,NA,NA